,level_0,Unnamed: 0,index,Unnamed: 0.1,text,drug1,drug2,ddi,type,label,smile1,smile2,pos1,pos2
0,0,0,1,1,"Population pharmacokinetic analyses revealed that DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER did not influence DRUGOTHER clearance.",MTX,corticosteroids,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,5,7
1,1,1,2,2,"Population pharmacokinetic analyses revealed that DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2 did not influence DRUGOTHER clearance.",MTX,TNF blocking agents,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,5,9
2,3,3,4,4,"The majority of patients in RA clinical studies received one or more of the following concomitant medications with DRUGOTHER: DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, hydroxyDRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",MTX,corticosteroids,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,19,21
3,4,4,5,5,"The majority of patients in RA clinical studies received one or more of the following concomitant medications with DRUGOTHER: DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, hydroxyDRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",MTX,TNF blocking agents,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,19,22
4,5,5,6,6,"The majority of patients in RA clinical studies received one or more of the following concomitant medications with DRUGOTHER: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, hydroxyDRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",MTX,azathioprine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],19,23
5,6,6,7,7,"The majority of patients in RA clinical studies received one or more of the following concomitant medications with DRUGOTHER: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, hydroxyDRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",MTX,chloroquine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCN(CC)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1,19,24
6,7,7,8,8,"The majority of patients in RA clinical studies received one or more of the following concomitant medications with DRUGOTHER: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",MTX,hydroxychloroquine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCN(CCO)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1,19,26
7,8,8,9,9,"The majority of patients in RA clinical studies received one or more of the following concomitant medications with DRUGOTHER: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, hydroxyDRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",MTX,leflunomide,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F,19,27
8,9,9,10,10,"The majority of patients in RA clinical studies received one or more of the following concomitant medications with DRUGOTHER: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, hydroxyDRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",MTX,sulfasalazine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,19,28
9,46,46,47,47,"DRUG1, other DRUGOTHER, DRUGOTHER, and DRUG2 are associated with an increase in bleeding.",Heparin,anti platelet agents,False,Neg,0,[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,0,5
10,49,49,50,50,"These drugs include the DRUG1 and other DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",thiazides,diuretics,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,4,7
11,50,50,51,51,"These drugs include the DRUG1 and other DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",thiazides,corticosteroids,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,4,8
12,51,51,52,52,"These drugs include the DRUG1 and other DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",thiazides,phenothiazines,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,N1C2=CC=CC=C2SC2=CC=CC=C12,4,9
13,52,52,53,53,"These drugs include the DRUG1 and other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",thiazides,estrogens,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)OS(=O)(=O)[O-])[C@@H]1CCC2=O.[Na+],4,11
14,53,53,54,54,"These drugs include the DRUG1 and other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",thiazides,contraceptives,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,4,13
15,55,55,56,56,"These drugs include the DRUG1 and other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",thiazides,nicotinic acid,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1,4,15
16,56,56,57,57,"These drugs include the DRUG1 and other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",thiazides,isoniazid,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O,4,19
17,61,61,62,62,"These drugs include the DRUGOTHER and other DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",diuretics,phenytoin,False,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,7,14
18,67,67,68,68,"These drugs include the DRUGOTHER and other DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",corticosteroids,phenytoin,False,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,8,14
19,72,72,73,73,"These drugs include the DRUGOTHER and other DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",phenothiazines,phenytoin,False,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,9,14
20,76,76,77,77,"These drugs include the DRUGOTHER and other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, oral DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",estrogens,phenytoin,False,Neg,0,C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)OS(=O)(=O)[O-])[C@@H]1CCC2=O.[Na+],C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,11,14
21,79,79,80,80,"These drugs include the DRUGOTHER and other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",contraceptives,phenytoin,False,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,13,14
22,82,82,83,83,"These drugs include the DRUGOTHER and other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",phenytoin,nicotinic acid,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1,14,15
23,83,83,84,84,"These drugs include the DRUGOTHER and other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",phenytoin,isoniazid,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O,14,19
24,106,106,107,107,"No significant interactions with DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUGOTHER, or DRUGOTHER have been observed.",digoxin,hydrochlorothiazide,False,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,4,5
25,107,107,108,108,"No significant interactions with DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, oral DRUGOTHER, DRUGOTHER, or DRUGOTHER have been observed.",digoxin,hydralazine,False,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C1=CC=C2C(=C1)C=NN=C2NN,4,6
26,113,113,114,114,"No significant interactions with DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, oral DRUGOTHER, DRUGOTHER, or DRUGOTHER have been observed.",hydrochlorothiazide,sulfinpyrazone,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4,5,7
27,114,114,115,115,"No significant interactions with DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, oral DRUG2, DRUGOTHER, or DRUGOTHER have been observed.",hydrochlorothiazide,contraceptives,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,5,9
28,115,115,116,116,"No significant interactions with DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUG2, or DRUGOTHER have been observed.",hydrochlorothiazide,tolbutamide,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,5,10
29,116,116,117,117,"No significant interactions with DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUGOTHER, or DRUG2 have been observed.",hydrochlorothiazide,warfarin,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,5,12
30,117,117,118,118,"No significant interactions with DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, oral DRUGOTHER, DRUGOTHER, or DRUGOTHER have been observed.",hydralazine,sulfinpyrazone,False,Neg,0,C1=CC=C2C(=C1)C=NN=C2NN,C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4,6,7
31,118,118,119,119,"No significant interactions with DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, oral DRUG2, DRUGOTHER, or DRUGOTHER have been observed.",hydralazine,contraceptives,False,Neg,0,C1=CC=C2C(=C1)C=NN=C2NN,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,6,9
32,119,119,120,120,"No significant interactions with DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, oral DRUGOTHER, DRUG2, or DRUGOTHER have been observed.",hydralazine,tolbutamide,False,Neg,0,C1=CC=C2C(=C1)C=NN=C2NN,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,6,10
33,120,120,121,121,"No significant interactions with DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, oral DRUGOTHER, DRUGOTHER, or DRUG2 have been observed.",hydralazine,warfarin,False,Neg,0,C1=CC=C2C(=C1)C=NN=C2NN,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,6,12
34,127,127,128,128,DRUG1 modifies DRUG2 metabolism with increased serum levels of DRUG2.,DIAMOX,phenytoin,True,mechanism,4,CC(=O)NC1=NN=C(S1)S(N)(=O)=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,2
35,128,128,129,129,DRUG1 modifies DRUG2 metabolism with increased serum levels of DRUG2.,DIAMOX,phenytoin,True,mechanism,4,CC(=O)NC1=NN=C(S1)S(N)(=O)=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,2
36,155,155,157,157,DRUG1: DRUGOTHER has been studied in rheumatoid arthritis patients taking concomitant DRUG2.,Methotrexate,MTX,False,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,0,11
37,156,156,158,158,DRUGOTHER: DRUG1 has been studied in rheumatoid arthritis patients taking concomitant DRUG2.,HUMIRA,MTX,False,Neg,0,CC(C)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,1,11
38,157,157,159,159,The data do not suggest the need for dose adjustment of either DRUG1 or DRUG2.,HUMIRA,MTX,False,Neg,0,CC(C)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,12,14
39,166,166,168,168,"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: DRUG1 (e.g., DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER drugs (e.g., DRUGOTHER), DRUGOTHER, DRUG2.",aminoglycosides,vancomycin,False,Neg,0,OC(=O)CCCCCCCC(O)=O,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,20,31
40,172,172,174,174,"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: DRUGOTHER (e.g., DRUG1, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER drugs (e.g., DRUGOTHER), DRUGOTHER, DRUG2.",gentamicin,vancomycin,False,Neg,0,CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,22,31
41,177,177,179,179,"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: DRUGOTHER (e.g., DRUGOTHER, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER drugs (e.g., DRUGOTHER), DRUGOTHER, DRUG2.",amikacin,vancomycin,False,Neg,0,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@H](CCN)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,23,31
42,181,181,183,183,"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER drugs (e.g., DRUGOTHER), DRUGOTHER, DRUG2.",amphotericin B,vancomycin,False,Neg,0,C[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,24,31
43,184,184,186,186,"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER drugs (e.g., DRUGOTHER), DRUGOTHER, DRUG2.",cyclosporine,vancomycin,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,25,31
44,186,186,188,188,"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER drugs (e.g., DRUG1), DRUGOTHER, DRUG2.",ibuprofen,vancomycin,False,Neg,0,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,29,31
45,187,187,189,189,"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER drugs (e.g., DRUGOTHER), DRUG1, DRUG2.",tacrolimus,vancomycin,False,Neg,0,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,30,31
46,195,195,197,197,The effects of DRUG1 are antagonized by DRUG2 such as DRUGOTHER and DRUGOTHER.,adenosine,methylxanthines,True,effect,2,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1,O=C1NC2=C(NC=N2)C(=O)N1,3,7
47,196,196,198,198,The effects of DRUG1 are antagonized by DRUGOTHER such as DRUG2 and DRUGOTHER.,adenosine,caffeine,True,effect,2,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,3,10
48,197,197,199,199,The effects of DRUG1 are antagonized by DRUGOTHER such as DRUGOTHER and DRUG2.,adenosine,theophylline,True,effect,2,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,3,12
49,201,201,203,203,"In the presence of these DRUG1, larger doses of DRUG2 may be required or DRUG2 may not be effective.",methylxanthines,adenosine,True,advise,1,O=C1NC2=C(NC=N2)C(=O)N1,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1,5,9
50,202,202,204,204,"In the presence of these DRUG1, larger doses of DRUG2 may be required or DRUG2 may not be effective.",methylxanthines,adenosine,True,advise,1,O=C1NC2=C(NC=N2)C(=O)N1,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1,5,9
51,246,246,248,248,DRUG1: The pharmacokinetics of DRUGOTHER (DRUG2 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of DRUGOTHER (400 mg) in 6 healthy subjects.,Theophylline,aminophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,0,5
52,247,247,249,249,DRUG1: The pharmacokinetics of DRUGOTHER (DRUGOTHER 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of DRUG2 (400 mg) in 6 healthy subjects.,Theophylline,albendazole,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CCCS(=O)C1=CC2=C(C=C1)N=C(N2)N=C(O)OC,0,20
53,248,248,250,250,DRUGOTHER: The pharmacokinetics of DRUG1 (DRUG2 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of DRUGOTHER (400 mg) in 6 healthy subjects.,theophylline,aminophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,4,5
54,249,249,251,251,DRUGOTHER: The pharmacokinetics of DRUG1 (DRUGOTHER 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of DRUG2 (400 mg) in 6 healthy subjects.,theophylline,albendazole,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CCCS(=O)C1=CC2=C(C=C1)N=C(N2)N=C(O)OC,4,20
55,268,268,272,272,"Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when DRUG1 is administered in combination with other DRUG2 such as DRUGOTHER, DRUGOTHER, DRUGOTHER, or inhalation general DRUGOTHER.",ALFENTA,CNS depressants,True,effect,2,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,16,23
56,273,273,277,277,"Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when DRUGOTHER is administered in combination with other DRUG1 such as DRUG2, DRUGOTHER, DRUGOTHER, or inhalation general DRUGOTHER.",CNS depressants,barbiturates,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O,23,26
57,274,274,278,278,"Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when DRUGOTHER is administered in combination with other DRUG1 such as DRUGOTHER, DRUG2, DRUGOTHER, or inhalation general DRUGOTHER.",CNS depressants,tranquilizers,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,23,27
58,275,275,279,279,"Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when DRUGOTHER is administered in combination with other DRUG1 such as DRUGOTHER, DRUGOTHER, DRUG2, or inhalation general DRUGOTHER.",CNS depressants,opioids,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3.CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2.CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,23,28
59,276,276,280,280,"Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when DRUGOTHER is administered in combination with other DRUG1 such as DRUGOTHER, DRUGOTHER, DRUGOTHER, or inhalation general DRUG2.",CNS depressants,anesthetics,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCOC(=O)C1=CC=C(N)C=C1,23,32
60,298,298,302,302,"Co-administration of DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER did not result in clinically significant increases in DRUGOTHER exposure.",lovastatin,furosemide,False,Neg,0,CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,2,5
61,301,301,305,305,"Co-administration of DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER did not result in clinically significant increases in DRUGOTHER exposure.",lovastatin,hydrochlorothiazide,False,Neg,0,CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,2,8
62,308,308,312,312,"Co-administration of DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER did not result in clinically significant increases in DRUGOTHER exposure.",atenolol,furosemide,False,Neg,0,CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,3,5
63,311,311,315,315,"Co-administration of DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER did not result in clinically significant increases in DRUGOTHER exposure.",atenolol,hydrochlorothiazide,False,Neg,0,CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,3,8
64,317,317,321,321,"Co-administration of DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER did not result in clinically significant increases in DRUGOTHER exposure.",warfarin,furosemide,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,4,5
65,320,320,324,324,"Co-administration of DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER did not result in clinically significant increases in DRUGOTHER exposure.",warfarin,hydrochlorothiazide,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,4,8
66,326,326,330,330,"Co-administration of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER did not result in clinically significant increases in DRUGOTHER exposure.",furosemide,digoxin,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,5,6
67,327,327,331,331,"Co-administration of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER did not result in clinically significant increases in DRUGOTHER exposure.",furosemide,celecoxib,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,5,7
68,329,329,333,333,"Co-administration of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER did not result in clinically significant increases in DRUGOTHER exposure.",furosemide,ramipril,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(O)=O,5,9
69,330,330,334,334,"Co-administration of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER did not result in clinically significant increases in DRUGOTHER exposure.",furosemide,valsartan,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O,5,10
70,331,331,335,335,"Co-administration of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER did not result in clinically significant increases in DRUGOTHER exposure.",furosemide,metformin,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CN(C)C(=N)N=C(N)N,5,11
71,332,332,336,336,"Co-administration of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2 did not result in clinically significant increases in DRUGOTHER exposure.",furosemide,amlodipine,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN,5,13
72,333,333,337,337,"Co-administration of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER did not result in clinically significant increases in DRUG2 exposure.",furosemide,aliskiren,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,5,22
73,335,335,339,339,"Co-administration of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER did not result in clinically significant increases in DRUGOTHER exposure.",digoxin,hydrochlorothiazide,False,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,6,8
74,341,341,345,345,"Co-administration of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER did not result in clinically significant increases in DRUGOTHER exposure.",celecoxib,hydrochlorothiazide,False,Neg,0,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,7,8
75,347,347,351,351,"Co-administration of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER did not result in clinically significant increases in DRUGOTHER exposure.",hydrochlorothiazide,ramipril,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(O)=O,8,9
76,348,348,352,352,"Co-administration of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER did not result in clinically significant increases in DRUGOTHER exposure.",hydrochlorothiazide,valsartan,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O,8,10
77,349,349,353,353,"Co-administration of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER did not result in clinically significant increases in DRUGOTHER exposure.",hydrochlorothiazide,metformin,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,CN(C)C(=N)N=C(N)N,8,11
78,350,350,354,354,"Co-administration of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2 did not result in clinically significant increases in DRUGOTHER exposure.",hydrochlorothiazide,amlodipine,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN,8,13
79,351,351,355,355,"Co-administration of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER did not result in clinically significant increases in DRUG2 exposure.",hydrochlorothiazide,aliskiren,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,8,22
80,380,380,384,384,"Co-administration of DRUG1 did not significantly affect the pharmacokinetics of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2.",aliskiren,hydrochlorothiazide,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,2,20
81,389,389,393,393,"Co-administration of DRUGOTHER did not significantly affect the pharmacokinetics of DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2.",lovastatin,hydrochlorothiazide,False,Neg,0,CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,10,20
82,397,397,401,401,"Co-administration of DRUGOTHER did not significantly affect the pharmacokinetics of DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2.",digoxin,hydrochlorothiazide,False,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,11,20
83,404,404,408,408,"Co-administration of DRUGOTHER did not significantly affect the pharmacokinetics of DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2.",valsartan,hydrochlorothiazide,False,Neg,0,CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,12,20
84,410,410,414,414,"Co-administration of DRUGOTHER did not significantly affect the pharmacokinetics of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2.",amlodipine,hydrochlorothiazide,False,Neg,0,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,13,20
85,415,415,419,419,"Co-administration of DRUGOTHER did not significantly affect the pharmacokinetics of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2.",metformin,hydrochlorothiazide,False,Neg,0,CN(C)C(=N)N=C(N)N,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,14,20
86,419,419,423,423,"Co-administration of DRUGOTHER did not significantly affect the pharmacokinetics of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2.",celecoxib,hydrochlorothiazide,False,Neg,0,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,15,20
87,422,422,426,426,"Co-administration of DRUGOTHER did not significantly affect the pharmacokinetics of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER or DRUG2.",atenolol,hydrochlorothiazide,False,Neg,0,CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,16,20
88,424,424,428,428,"Co-administration of DRUGOTHER did not significantly affect the pharmacokinetics of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER or DRUG2.",atorvastatin,hydrochlorothiazide,False,Neg,0,CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,17,20
89,425,425,429,429,"Co-administration of DRUGOTHER did not significantly affect the pharmacokinetics of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 or DRUG2.",ramipril,hydrochlorothiazide,False,Neg,0,[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(O)=O,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,18,20
90,429,429,433,433,"DRUG1: When DRUG2 was co-administered with DRUGOTHER, the AUC and Cmax of DRUGOTHER were reduced by about 30% and 50%, respectively.",Furosemide,aliskiren,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,0,2
91,432,432,436,436,"DRUGOTHER: When DRUG1 was co-administered with DRUG2, the AUC and Cmax of DRUG2 were reduced by about 30% and 50%, respectively.",aliskiren,furosemide,True,mechanism,4,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,2,6
92,433,433,437,437,"DRUGOTHER: When DRUG1 was co-administered with DRUG2, the AUC and Cmax of DRUG2 were reduced by about 30% and 50%, respectively.",aliskiren,furosemide,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,2,6
93,491,491,505,505,"DRUG1: Enhanced bone marrow suppression by DRUG2 and other DRUGOTHER has been reported among patients with neoplastic disease, except leukemia, in the presence of DRUGOTHER.",Cytotoxic Agents,cyclophosphamide,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,ClCCN(CCCl)P1(=O)NCCCO1,0,6
94,494,494,508,508,"DRUGOTHER: Enhanced bone marrow suppression by DRUG1 and other DRUG2 has been reported among patients with neoplastic disease, except leukemia, in the presence of DRUGOTHER.",cyclophosphamide,cytotoxic agents,False,Neg,0,ClCCN(CCCl)P1(=O)NCCCO1,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,6,9
95,495,495,509,509,"DRUGOTHER: Enhanced bone marrow suppression by DRUG1 and other DRUGOTHER has been reported among patients with neoplastic disease, except leukemia, in the presence of DRUG2.",cyclophosphamide,allopurinol,True,effect,2,ClCCN(CCCl)P1(=O)NCCCO1,O=C1N=CN=C2NNC=C12,6,24
96,497,497,511,511,"However, in a well-controlled study of patients with lymphoma on combination therapy, DRUG1 did not increase the marrow toxicity of patients treated with DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER and/or DRUGOTHER.",allopurinol,cyclophosphamide,False,Neg,0,O=C1N=CN=C2NNC=C12,ClCCN(CCCl)P1(=O)NCCCO1,12,23
97,501,501,515,515,"However, in a well-controlled study of patients with lymphoma on combination therapy, DRUGOTHER did not increase the marrow toxicity of patients treated with DRUG1, DRUG2, DRUGOTHER, DRUGOTHER and/or DRUGOTHER.",cyclophosphamide,doxorubicin,False,Neg,0,ClCCN(CCCl)P1(=O)NCCCO1,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,23,24
98,502,502,516,516,"However, in a well-controlled study of patients with lymphoma on combination therapy, DRUGOTHER did not increase the marrow toxicity of patients treated with DRUG1, DRUGOTHER, DRUGOTHER, DRUG2 and/or DRUGOTHER.",cyclophosphamide,procarbazine,False,Neg,0,ClCCN(CCCl)P1(=O)NCCCO1,CNNCC1=CC=C(C=C1)C(=O)NC(C)C,23,26
99,503,503,517,517,"However, in a well-controlled study of patients with lymphoma on combination therapy, DRUGOTHER did not increase the marrow toxicity of patients treated with DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER and/or DRUG2.",cyclophosphamide,mechlorethamine,False,Neg,0,ClCCN(CCCl)P1(=O)NCCCO1,CN(CCCl)CCCl,23,28
100,523,523,537,537,"Because there is a theoretical basis that these effects may be additive, use of DRUG1-containing or DRUGOTHER (like dihydroDRUG1 or DRUG2) and DRUGOTHER within 24 hours of each other should be avoided.",ergotamine,methysergide,False,Neg,0,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C,14,20
101,525,525,539,539,"Because there is a theoretical basis that these effects may be additive, use of DRUGOTHER-containing or DRUGOTHER (like DRUG1 or DRUG2) and DRUGOTHER within 24 hours of each other should be avoided.",dihydroergotamine,methysergide,False,Neg,0,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C,18,20
102,527,527,541,541,"Because there is a theoretical basis that these effects may be additive, use of DRUGOTHER-containing or DRUGOTHER (like dihydroDRUGOTHER or DRUG1) and DRUG2 within 24 hours of each other should be avoided.",methysergide,AXERT,True,advise,1,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C,O.[OH-].[OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[Cl-],20,22
103,532,532,548,548,"DRUG1 (DRUGOTHER): DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER.",Selective Serotonin Reuptake Inhibitors,fluoxetine,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,0,4
104,533,533,549,549,"DRUG1 (DRUGOTHER): DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER.",Selective Serotonin Reuptake Inhibitors,fluvoxamine,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,0,5
105,534,534,550,550,"DRUG1 (DRUGOTHER): DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER.",Selective Serotonin Reuptake Inhibitors,paroxetine,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,0,6
106,535,535,551,551,"DRUG1 (DRUGOTHER): DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER.",Selective Serotonin Reuptake Inhibitors,sertraline,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,0,7
107,552,552,568,568,"Although the interaction between DRUG1 and other potent CYP3A4 inhibitors (e.g., DRUGOTHER, DRUG2, and DRUGOTHER) has not been studied, increased exposures to DRUG1 may be expected when DRUG1 is used concomitantly with these medications.",almotriptan,ritonavir,False,Neg,0,CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,4,12
108,556,556,572,572,"Although the interaction between DRUGOTHER and other potent CYP3A4 inhibitors (e.g., DRUG1, DRUG2, and DRUGOTHER) has not been studied, increased exposures to DRUGOTHER may be expected when DRUGOTHER is used concomitantly with these medications.",itraconazole,ritonavir,False,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,11,12
109,560,560,576,576,"Although the interaction between DRUGOTHER and other potent CYP3A4 inhibitors (e.g., DRUGOTHER, DRUG1, and DRUG2) has not been studied, increased exposures to DRUGOTHER may be expected when DRUGOTHER is used concomitantly with these medications.",ritonavir,erythromycin,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,12,14
110,561,561,577,577,"Although the interaction between DRUG2 and other potent CYP3A4 inhibitors (e.g., DRUGOTHER, DRUG1, and DRUGOTHER) has not been studied, increased exposures to DRUG2 may be expected when DRUG2 is used concomitantly with these medications.",ritonavir,almotriptan,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2,12,4
111,562,562,578,578,"Although the interaction between DRUG2 and other potent CYP3A4 inhibitors (e.g., DRUGOTHER, DRUG1, and DRUGOTHER) has not been studied, increased exposures to DRUG2 may be expected when DRUG2 is used concomitantly with these medications.",ritonavir,almotriptan,True,advise,1,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2,12,4
112,577,577,593,593,"Coadministration of DRUG1 and strong CYP3A4 inhibitors, such as DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",alosetron,telithromycin,True,advise,1,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,2,10
113,580,580,596,596,"Coadministration of DRUGOTHER and strong CYP3A4 inhibitors, such as DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",clarithromycin,telithromycin,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,9,10
114,583,583,599,599,"Coadministration of DRUGOTHER and strong CYP3A4 inhibitors, such as DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",telithromycin,voriconazole,False,Neg,0,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,10,12
115,584,584,600,600,"Coadministration of DRUGOTHER and strong CYP3A4 inhibitors, such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2 has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",telithromycin,itraconazole,False,Neg,0,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,10,14
116,588,588,604,604,"Although not studied with DRUG1, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as DRUGOTHER, DRUGOTHER, and DRUG2.",alosetron,hydralazine,True,effect,2,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,C1=CC=C2C(=C1)C=NN=C2NN,4,20
117,590,590,606,606,"Although not studied with DRUGOTHER, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as DRUG1, DRUGOTHER, and DRUG2.",isoniazid,hydralazine,False,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O,C1=CC=C2C(=C1)C=NN=C2NN,17,20
118,591,591,607,607,"Although not studied with DRUGOTHER, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as DRUGOTHER, DRUG1, and DRUG2.",procainamide,hydralazine,False,Neg,0,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,C1=CC=C2C(=C1)C=NN=C2NN,18,20
119,733,733,749,749,"DRUG1, such as DRUG2 and DRUGOTHER;",vasopressors,dopamine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1,0,3
120,734,734,750,750,"DRUG1, such as DRUGOTHER and DRUG2;",vasopressors,isoproterenol,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)O,0,5
121,736,736,752,752,"and DRUG1, such as DRUG2.",diuretics,furosemide,False,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,1,4
122,776,776,794,794,"Renal clearance measurements of DRUG1 cannot be made with any significant accuracy in patients receiving DRUG2, DRUGOTHER, or DRUGOTHER.",PAH,sulfonamides,True,effect,2,CCOC(=O)C1=CC=C(N)C=C1,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,4,15
123,779,779,797,797,"Renal clearance measurements of DRUGOTHER cannot be made with any significant accuracy in patients receiving DRUG1, DRUG2, or DRUGOTHER.",sulfonamides,procaine,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,15,16
124,780,780,798,798,"Renal clearance measurements of DRUGOTHER cannot be made with any significant accuracy in patients receiving DRUG1, DRUGOTHER, or DRUG2.",sulfonamides,thiazolesulfone,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,CC(=O)NC1=NN=C(S1)S(N)(=O)=O,15,18
125,787,787,805,805,"It is, however, possible that concomitant use of other known DRUG1 such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER might increase the photosensitivity reaction of actinic keratoses treated with the DRUGOTHER for Topical Solution.",photosensitizing agents,sulfonamides,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,10,17
126,792,792,810,810,"It is, however, possible that concomitant use of other known DRUGOTHER such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER might increase the photosensitivity reaction of actinic keratoses treated with the DRUGOTHER for Topical Solution.",griseofulvin,sulfonamides,False,Neg,0,C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,13,17
127,796,796,814,814,"It is, however, possible that concomitant use of other known DRUGOTHER such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2 and DRUGOTHER might increase the photosensitivity reaction of actinic keratoses treated with the DRUGOTHER for Topical Solution.",sulfonylureas,sulfonamides,False,Neg,0,NC(N)=O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,15,17
128,799,799,817,817,"It is, however, possible that concomitant use of other known DRUGOTHER such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2 and DRUGOTHER might increase the photosensitivity reaction of actinic keratoses treated with the DRUGOTHER for Topical Solution.",phenothiazines,sulfonamides,False,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,16,17
129,802,802,820,820,"It is, however, possible that concomitant use of other known DRUGOTHER such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 and DRUG2 might increase the photosensitivity reaction of actinic keratoses treated with the DRUGOTHER for Topical Solution.",sulfonamides,tetracyclines,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O,17,19
130,803,803,821,821,"It is, however, possible that concomitant use of other known DRUGOTHER such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 and DRUGOTHER might increase the photosensitivity reaction of actinic keratoses treated with the DRUG2 for Topical Solution.",sulfonamides,LEVULAN KERASTICK,True,effect,2,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,NCC(=O)CCC(O)=O,17,31
131,821,821,839,839,"Reported examples of this interaction include the following: DRUG1s: DRUG2 (DRUGOTHER substrate) administered in combination with oral DRUGOTHER has been reported to produce persistently elevated plasma concentrations of DRUGOTHER resulting in elevated creatinine, despite reduction in dose of DRUGOTHER.",Immunosuppressive,Cyclosporine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,8,9
132,822,822,840,840,"Reported examples of this interaction include the following: DRUG1s: DRUGOTHER (DRUGOTHER substrate) administered in combination with oral DRUG2 has been reported to produce persistently elevated plasma concentrations of DRUGOTHER resulting in elevated creatinine, despite reduction in dose of DRUGOTHER.",Immunosuppressive,amiodarone,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2,8,17
133,823,823,841,841,"Reported examples of this interaction include the following: DRUG1s: DRUGOTHER (DRUGOTHER substrate) administered in combination with oral DRUGOTHER has been reported to produce persistently elevated plasma concentrations of DRUG2 resulting in elevated creatinine, despite reduction in dose of DRUG2.",Immunosuppressive,cyclosporine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,8,28
134,824,824,842,842,"Reported examples of this interaction include the following: DRUG1s: DRUGOTHER (DRUGOTHER substrate) administered in combination with oral DRUGOTHER has been reported to produce persistently elevated plasma concentrations of DRUG2 resulting in elevated creatinine, despite reduction in dose of DRUG2.",Immunosuppressive,cyclosporine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,8,28
135,841,841,859,859,"DRUGOTHER: Other DRUGOTHER drugs, such as DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2, have been used concurrently with DRUGOTHER.",quinidine,phenytoin,False,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,6,10
136,844,844,862,862,"DRUGOTHER: Other DRUGOTHER drugs, such as DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2, have been used concurrently with DRUGOTHER.",procainamide,phenytoin,False,Neg,0,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,7,10
137,846,846,864,864,"DRUGOTHER: Other DRUGOTHER drugs, such as DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2, have been used concurrently with DRUGOTHER.",disopyramide,phenytoin,False,Neg,0,OC(=O)CCCCCCCC(O)=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,8,10
138,848,848,866,866,"DRUGOTHER: Other DRUGOTHER drugs, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1, have been used concurrently with DRUG2.",phenytoin,amiodarone,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2,10,16
139,850,850,868,868,"There have been case reports of increased steady-state levels of DRUG1, DRUGOTHER, and DRUG2 during concomitant therapy with DRUGOTHER.",quinidine,phenytoin,False,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,10,13
140,852,852,870,870,"There have been case reports of increased steady-state levels of DRUGOTHER, DRUG1, and DRUG2 during concomitant therapy with DRUGOTHER.",procainamide,phenytoin,False,Neg,0,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,11,13
141,854,854,872,872,"There have been case reports of increased steady-state levels of DRUGOTHER, DRUGOTHER, and DRUG1 during concomitant therapy with DRUG2.",phenytoin,amiodarone,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2,13,18
142,908,908,929,929,"In addition to the interactions noted above, chronic (  2 weeks) oral DRUGOTHER administration impairs metabolism of DRUG1, DRUGOTHER, and DRUG2.",phenytoin,methotrexate,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,18,21
143,909,909,930,930,"In addition to the interactions noted above, chronic (  2 weeks) oral DRUGOTHER administration impairs metabolism of DRUGOTHER, DRUG1, and DRUG2.",dextromethorphan,methotrexate,False,Neg,0,[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,19,21
144,920,920,941,941,"While all the selective DRUG1 (DRUGOTHER), e.g., DRUG2, DRUGOTHER, and DRUGOTHER, inhibit P450 2D6, they may vary in the extent of inhibition.",serotonin reuptake inhibitors,fluoxetine,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,4,7
145,921,921,942,942,"While all the selective DRUG1 (DRUGOTHER), e.g., DRUGOTHER, DRUG2, and DRUGOTHER, inhibit P450 2D6, they may vary in the extent of inhibition.",serotonin reuptake inhibitors,sertraline,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,4,8
146,922,922,943,943,"While all the selective DRUG1 (DRUGOTHER), e.g., DRUGOTHER, DRUGOTHER, and DRUG2, inhibit P450 2D6, they may vary in the extent of inhibition.",serotonin reuptake inhibitors,paroxetine,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,4,10
147,928,928,949,949,DRUG1: DRUG2 or similarly acting compounds;,Monoamine Oxidase Inhibitors,Guanethidine,False,Neg,0,OC(=O)CCCCCCCC(O)=O,C1CCCN(CCC1)CCN=C(N)N,0,1
148,930,930,951,951,"DRUG1, DRUGOTHER and other DRUG2;",alcohol,CNS depressants,False,Neg,0,CCO,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,0,4
149,931,931,952,952,"DRUGOTHER, DRUG1 and other DRUG2;",barbiturates,CNS depressants,False,Neg,0,CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,1,4
150,946,946,967,967,"Increases in plasma levels of DRUG1, and in the frequency and severity of side effects, particularly DRUGOTHER, have been reported when DRUGOTHER was added to the DRUG2 regimen.",tricyclic antidepressants,drug,False,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CN1C=NC2=C1C(=O)N(C)C(=O)N2C,5,26
151,948,948,969,969,"Increases in plasma levels of DRUGOTHER, and in the frequency and severity of side effects, particularly DRUG1, have been reported when DRUGOTHER was added to the DRUG2 regimen.",anticholinergic,drug,False,Neg,0,C[N+](C)(C)CCO,CN1C=NC2=C1C(=O)N(C)C(=O)N2C,16,26
152,949,949,970,970,"Increases in plasma levels of DRUGOTHER, and in the frequency and severity of side effects, particularly DRUGOTHER, have been reported when DRUG1 was added to the DRUG2 regimen.",cimetidine,drug,False,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CN1C=NC2=C1C(=O)N(C)C(=O)N2C,21,26
153,1010,1010,1034,1034,"DRUG1: DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER may interfere with the bactericidal effect of DRUGOTHER.",Bacteriostatic Antibiotics,sulfonamides,False,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,0,3
154,1014,1014,1038,1038,"DRUGOTHER: DRUG1, DRUGOTHER, DRUG2, or DRUGOTHER may interfere with the bactericidal effect of DRUGOTHER.",Chloramphenicol,sulfonamides,False,Neg,0,CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,1,3
155,1017,1017,1041,1041,"DRUGOTHER: DRUGOTHER, DRUG1, DRUG2, or DRUGOTHER may interfere with the bactericidal effect of DRUGOTHER.",erythromycins,sulfonamides,False,Neg,0,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,2,3
156,1020,1020,1044,1044,"DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUG1, or DRUG2 may interfere with the bactericidal effect of DRUGOTHER.",sulfonamides,tetracyclines,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O,3,5
157,1021,1021,1045,1045,"DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUG1, or DRUGOTHER may interfere with the bactericidal effect of DRUG2.",sulfonamides,penicillins,True,effect,2,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,3,13
158,1028,1028,1052,1052,"DRUG1 steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant DRUG2.",Saquinavir,amprenavir,True,mechanism,4,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1,0,17
159,1039,1039,1063,1063,"Laboratory Tests: The combination of DRUG1 and low-dose DRUG2 has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.",Amprenavir,ritonavir,True,effect,2,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,5,8
160,1040,1040,1064,1064,Appropriate laboratory testing should be considered prior to initiating combination therapy with DRUG1 and DRUG2 and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.,Amprenavir,ritonavir,True,advise,1,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,12,14
161,1061,1061,1085,1085,"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with DRUG1 in clinical trials were DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",anagrelide,furosemide,False,Neg,0,ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,16,23
162,1066,1066,1090,1090,"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with DRUGOTHER in clinical trials were DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",aspirin,furosemide,False,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,21,23
163,1070,1070,1094,1094,"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with DRUGOTHER in clinical trials were DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",acetaminophen,furosemide,False,Neg,0,CC(=O)NC1=CC=C(C=C1)O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,22,23
164,1074,1074,1098,1098,"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with DRUGOTHER in clinical trials were DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",furosemide,ranitidine,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,23,25
165,1075,1075,1099,1099,"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with DRUGOTHER in clinical trials were DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",furosemide,hydroxyurea,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,NC(=O)NO,23,26
166,1076,1076,1100,1100,"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with DRUGOTHER in clinical trials were DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",furosemide,allopurinol,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,O=C1N=CN=C2NNC=C12,23,28
167,1121,1121,1157,1157,"Drugs that have been reported to diminish oral DRUG1 response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",anticoagulant,haloperidol,True,effect,2,[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,8,22
168,1122,1122,1158,1158,"Drugs that have been reported to diminish oral DRUG1 response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",anticoagulant,meprobamate,True,effect,2,[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,8,22
169,1142,1142,1178,1178,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUG1;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",adrenocortical steroids,haloperidol,False,Neg,0,COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,19,22
170,1143,1143,1179,1179,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUG1;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",adrenocortical steroids,meprobamate,False,Neg,0,COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,19,22
171,1162,1162,1198,1198,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUG1*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",alcohol,haloperidol,False,Neg,0,CCO,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,19,22
172,1163,1163,1199,1199,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUG1*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",alcohol,meprobamate,False,Neg,0,CCO,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,19,22
173,1181,1181,1217,1217,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",antihistamines,haloperidol,False,Neg,0,NCCC1=CNC=N1,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,19,22
174,1182,1182,1218,1218,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",antihistamines,meprobamate,False,Neg,0,NCCC1=CNC=N1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,19,22
175,1199,1199,1235,1235,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",barbiturates,haloperidol,False,Neg,0,CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,19,22
176,1200,1200,1236,1236,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",barbiturates,meprobamate,False,Neg,0,CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,19,22
177,1216,1216,1252,1252,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",carbamazepine,haloperidol,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,19,22
178,1217,1217,1253,1253,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",carbamazepine,meprobamate,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,19,22
179,1232,1232,1268,1268,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",chloral hydrate,haloperidol,False,Neg,0,C(C(Cl)(Cl)Cl)(O)O,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,19,22
180,1233,1233,1269,1269,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",chloral hydrate,meprobamate,False,Neg,0,C(C(Cl)(Cl)Cl)(O)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,19,22
181,1247,1247,1283,1283,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUG1;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",chlordiazepoxide,haloperidol,False,Neg,0,CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,19,22
182,1248,1248,1284,1284,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUG1;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",chlordiazepoxide,meprobamate,False,Neg,0,CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,19,22
183,1261,1261,1297,1297,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUG1;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",cholestyramine,haloperidol,False,Neg,0,CCC1=CC=C(C=C1)C(C)CCC2=CC=C(C=C2)[N+](C)(C)C,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,19,22
184,1262,1262,1298,1298,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUG1;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",cholestyramine,meprobamate,False,Neg,0,CCC1=CC=C(C=C1)C(C)CCC2=CC=C(C=C2)[N+](C)(C)C,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,19,22
185,1274,1274,1310,1310,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUG1;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",vitamin K,haloperidol,False,Neg,0,CC1=C(C(=O)C2=CC=CC=C2C1=O)C/C=C(\C)/CCCC(C)CCCC(C)CCCC(C)C,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,22,22
186,1275,1275,1311,1311,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUG1;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",vitamin K,meprobamate,False,Neg,0,CC1=C(C(=O)C2=CC=CC=C2C1=O)C/C=C(\C)/CCCC(C)CCCC(C)CCCC(C)C,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,22,22
187,1286,1286,1322,1322,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUG1*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",diuretics,haloperidol,False,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,22,22
188,1287,1287,1323,1323,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUG1*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",diuretics,meprobamate,False,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,22,22
189,1297,1297,1333,1333,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUG1;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",ethchlorvynol,haloperidol,False,Neg,0,[H]C(Cl)=CC(O)(CC)C#C,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,22,22
190,1298,1298,1334,1334,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",ethchlorvynol,meprobamate,False,Neg,0,[H]C(Cl)=CC(O)(CC)C#C,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,22,22
191,1307,1307,1343,1343,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUG1;DRUGOTHER;DRUG2;DRUGOTHER;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",glutethimide,haloperidol,False,Neg,0,CCC1(CCC(=O)NC1=O)C1=CC=CC=C1,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,22,22
192,1308,1308,1344,1344,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUG2;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",glutethimide,meprobamate,False,Neg,0,CCC1(CCC(=O)NC1=O)C1=CC=CC=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,22,22
193,1316,1316,1352,1352,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG1;DRUG2;DRUGOTHER;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",griseofulvin,haloperidol,False,Neg,0,C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,22,22
194,1317,1317,1353,1353,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUG2;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",griseofulvin,meprobamate,False,Neg,0,C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,22,22
195,1326,1326,1362,1362,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;oral DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",haloperidol,contraceptives,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,22,23
196,1327,1327,1363,1363,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;oral DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",haloperidol,paraldehyde,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,OCC(O)CO,22,23
197,1328,1328,1364,1364,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;oral DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",haloperidol,primidone,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,22,23
198,1329,1329,1365,1365,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",haloperidol,ranitidine,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,22,23
199,1330,1330,1366,1366,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUG2;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",haloperidol,rifampin,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,22,23
200,1331,1331,1367,1367,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUG2;DRUGOTHER under-dosage.",haloperidol,vitamin C,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,[Na+].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO,22,26
201,1332,1332,1368,1368,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUG2 under-dosage.",haloperidol,warfarin sodium,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2,22,26
202,1333,1333,1369,1369,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;oral DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",meprobamate,contraceptives,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,22,23
203,1334,1334,1370,1370,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;oral DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",meprobamate,paraldehyde,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,OCC(O)CO,22,23
204,1335,1335,1371,1371,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;oral DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",meprobamate,primidone,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,22,23
205,1336,1336,1372,1372,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",meprobamate,ranitidine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,22,23
206,1337,1337,1373,1373,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUG2;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",meprobamate,rifampin,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,22,23
207,1338,1338,1374,1374,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUG2;DRUGOTHER under-dosage.",meprobamate,vitamin C,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,[Na+].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO,22,26
208,1339,1339,1375,1375,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUG2 under-dosage.",meprobamate,warfarin sodium,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2,22,26
209,1392,1392,1428,1428,"Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",anticoagulant,pentoxifylline,True,effect,2,[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,6,20
210,1395,1395,1431,1431,"Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",anticoagulant,phenytoin,True,effect,2,[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,6,20
211,1403,1403,1439,1439,"Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",anticoagulant,sulfonamides,True,effect,2,[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,6,22
212,1436,1436,1472,1472,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUG1*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",alcohol,pentoxifylline,False,Neg,0,CCO,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,14,20
213,1439,1439,1475,1475,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUG1*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",alcohol,phenytoin,False,Neg,0,CCO,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,14,20
214,1447,1447,1483,1483,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUG1*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",alcohol,sulfonamides,False,Neg,0,CCO,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,14,22
215,1479,1479,1515,1515,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",allopurinol,pentoxifylline,False,Neg,0,O=C1N=CN=C2NNC=C12,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,14,20
216,1482,1482,1518,1518,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",allopurinol,phenytoin,False,Neg,0,O=C1N=CN=C2NNC=C12,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,14,20
217,1490,1490,1526,1526,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",allopurinol,sulfonamides,False,Neg,0,O=C1N=CN=C2NNC=C12,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,14,22
218,1521,1521,1557,1557,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",aminosalicylic acid,pentoxifylline,False,Neg,0,NC1=CC(O)=C(C=C1)C(O)=O,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,14,20
219,1524,1524,1560,1560,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",aminosalicylic acid,phenytoin,False,Neg,0,NC1=CC(O)=C(C=C1)C(O)=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,14,20
220,1532,1532,1568,1568,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",aminosalicylic acid,sulfonamides,False,Neg,0,NC1=CC(O)=C(C=C1)C(O)=O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,14,22
221,1562,1562,1598,1598,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",amiodarone,pentoxifylline,False,Neg,0,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,14,20
222,1565,1565,1601,1601,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",amiodarone,phenytoin,False,Neg,0,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,14,20
223,1573,1573,1609,1609,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",amiodarone,sulfonamides,False,Neg,0,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,14,22
224,1602,1602,1638,1638,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",antibiotics,pentoxifylline,False,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,14,20
225,1605,1605,1641,1641,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",antibiotics,phenytoin,False,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,14,20
226,1613,1613,1649,1649,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",antibiotics,sulfonamides,False,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,14,22
227,1641,1641,1677,1677,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",chloral hydrate,pentoxifylline,False,Neg,0,C(C(Cl)(Cl)Cl)(O)O,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,14,20
228,1644,1644,1680,1680,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",chloral hydrate,phenytoin,False,Neg,0,C(C(Cl)(Cl)Cl)(O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,14,20
229,1652,1652,1688,1688,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",chloral hydrate,sulfonamides,False,Neg,0,C(C(Cl)(Cl)Cl)(O)O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,14,22
230,1679,1679,1715,1715,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",chlorpropamide,pentoxifylline,False,Neg,0,CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,14,20
231,1682,1682,1718,1718,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",chlorpropamide,phenytoin,False,Neg,0,CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,14,20
232,1690,1690,1726,1726,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",chlorpropamide,sulfonamides,False,Neg,0,CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,14,22
233,1716,1716,1752,1752,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",cimetidine,pentoxifylline,False,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,14,20
234,1719,1719,1755,1755,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",cimetidine,phenytoin,False,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,14,20
235,1727,1727,1763,1763,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",cimetidine,sulfonamides,False,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,14,22
236,1752,1752,1788,1788,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",cinchophen,pentoxifylline,False,Neg,0,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,14,20
237,1755,1755,1791,1791,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",cinchophen,phenytoin,False,Neg,0,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,14,20
238,1763,1763,1799,1799,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",cinchophen,sulfonamides,False,Neg,0,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,14,22
239,1787,1787,1823,1823,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",clofibrate,pentoxifylline,False,Neg,0,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,14,20
240,1790,1790,1826,1826,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",clofibrate,phenytoin,False,Neg,0,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,14,20
241,1798,1798,1834,1834,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",clofibrate,sulfonamides,False,Neg,0,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,14,22
242,1821,1821,1857,1857,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",dextrothyroxine,pentoxifylline,False,Neg,0,N[C@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,14,20
243,1824,1824,1860,1860,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",dextrothyroxine,phenytoin,False,Neg,0,N[C@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,14,20
244,1832,1832,1868,1868,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",dextrothyroxine,sulfonamides,False,Neg,0,N[C@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,14,22
245,1854,1854,1890,1890,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",diazoxide,pentoxifylline,False,Neg,0,CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,14,20
246,1857,1857,1893,1893,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",diazoxide,phenytoin,False,Neg,0,CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,14,20
247,1865,1865,1901,1901,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",diazoxide,sulfonamides,False,Neg,0,CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,14,22
248,1886,1886,1922,1922,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUG1;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",diflunisal,pentoxifylline,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,15,20
249,1889,1889,1925,1925,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUG1;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",diflunisal,phenytoin,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,15,20
250,1897,1897,1933,1933,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUG1;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",diflunisal,sulfonamides,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,15,22
251,1917,1917,1953,1953,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUG1;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",disulfiram,pentoxifylline,False,Neg,0,CCN(CC)C(=S)SSC(=S)N(CC)CC,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,15,20
252,1920,1920,1956,1956,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUG1;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",disulfiram,phenytoin,False,Neg,0,CCN(CC)C(=S)SSC(=S)N(CC)CC,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,15,20
253,1928,1928,1964,1964,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUG1;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",disulfiram,sulfonamides,False,Neg,0,CCN(CC)C(=S)SSC(=S)N(CC)CC,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,15,22
254,1947,1947,1983,1983,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUG1;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",ethacrynic acid,pentoxifylline,False,Neg,0,CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,18,20
255,1950,1950,1986,1986,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUG1;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",ethacrynic acid,phenytoin,False,Neg,0,CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,18,20
256,1958,1958,1994,1994,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUG1;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",ethacrynic acid,sulfonamides,False,Neg,0,CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,18,22
257,1976,1976,2012,2012,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUG1;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",ibuprofen,pentoxifylline,False,Neg,0,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,19,20
258,1979,1979,2015,2015,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUG1;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",ibuprofen,phenytoin,False,Neg,0,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,19,20
259,1987,1987,2023,2023,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUG1;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",ibuprofen,sulfonamides,False,Neg,0,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,19,22
260,2004,2004,2040,2040,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUG1;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",indomethacin,pentoxifylline,False,Neg,0,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,19,20
261,2007,2007,2043,2043,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUG1;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",indomethacin,phenytoin,False,Neg,0,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,19,20
262,2015,2015,2051,2051,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUG1;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",indomethacin,sulfonamides,False,Neg,0,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,19,22
263,2031,2031,2067,2067,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUG1;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",influenza virus vaccine,pentoxifylline,False,Neg,0,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,19,20
264,2034,2034,2070,2070,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUG1;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",influenza virus vaccine,phenytoin,False,Neg,0,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,19,20
265,2042,2042,2078,2078,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUG1;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",influenza virus vaccine,sulfonamides,False,Neg,0,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,19,22
266,2057,2057,2093,2093,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",anesthetics,pentoxifylline,False,Neg,0,CCOC(=O)C1=CC=C(N)C=C1,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,20,20
267,2060,2060,2096,2096,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",anesthetics,phenytoin,False,Neg,0,CCOC(=O)C1=CC=C(N)C=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,20,20
268,2068,2068,2104,2104,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",anesthetics,sulfonamides,False,Neg,0,CCOC(=O)C1=CC=C(N)C=C1,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,20,22
269,2082,2082,2118,2118,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",mefenamic acid,pentoxifylline,False,Neg,0,CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,20,20
270,2085,2085,2121,2121,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",mefenamic acid,phenytoin,False,Neg,0,CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,20,20
271,2093,2093,2129,2129,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",mefenamic acid,sulfonamides,False,Neg,0,CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,20,22
272,2106,2106,2142,2142,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",methyldopa,pentoxifylline,False,Neg,0,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,20,20
273,2109,2109,2145,2145,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",methyldopa,phenytoin,False,Neg,0,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,20,20
274,2117,2117,2153,2153,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",methyldopa,sulfonamides,False,Neg,0,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,20,22
275,2129,2129,2165,2165,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",methylphenidate,pentoxifylline,False,Neg,0,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,20,20
276,2132,2132,2168,2168,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",methylphenidate,phenytoin,False,Neg,0,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,20,20
277,2140,2140,2176,2176,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",methylphenidate,sulfonamides,False,Neg,0,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,20,22
278,2151,2151,2187,2187,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",metronidazole,pentoxifylline,False,Neg,0,CC1=NC=C(N1CCO)[N+](=O)[O-],CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,20,20
279,2154,2154,2190,2190,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",metronidazole,phenytoin,False,Neg,0,CC1=NC=C(N1CCO)[N+](=O)[O-],C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,20,20
280,2162,2162,2198,2198,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",metronidazole,sulfonamides,False,Neg,0,CC1=NC=C(N1CCO)[N+](=O)[O-],CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,20,22
281,2172,2172,2208,2208,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",miconazole,pentoxifylline,False,Neg,0,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,20,20
282,2175,2175,2211,2211,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",miconazole,phenytoin,False,Neg,0,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,20,20
283,2183,2183,2219,2219,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",miconazole,sulfonamides,False,Neg,0,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,20,22
284,2192,2192,2228,2228,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",monoamine oxidase inhibitors,pentoxifylline,False,Neg,0,OC(=O)CCCCCCCC(O)=O,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,20,20
285,2195,2195,2231,2231,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",monoamine oxidase inhibitors,phenytoin,False,Neg,0,OC(=O)CCCCCCCC(O)=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,20,20
286,2203,2203,2239,2239,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",monoamine oxidase inhibitors,sulfonamides,False,Neg,0,OC(=O)CCCCCCCC(O)=O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,20,22
287,2211,2211,2247,2247,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",nalidixic acid,pentoxifylline,False,Neg,0,CCN1C=C(C(O)=O)C(=O)C2=C1N=C(C)C=C2,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,20,20
288,2214,2214,2250,2250,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",nalidixic acid,phenytoin,False,Neg,0,CCN1C=C(C(O)=O)C(=O)C2=C1N=C(C)C=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,20,20
289,2222,2222,2258,2258,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",nalidixic acid,sulfonamides,False,Neg,0,CCN1C=C(C(O)=O)C(=O)C2=C1N=C(C)C=C2,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,20,22
290,2229,2229,2265,2265,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",naproxen,pentoxifylline,False,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,20,20
291,2232,2232,2268,2268,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",naproxen,phenytoin,False,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,20,20
292,2240,2240,2276,2276,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",naproxen,sulfonamides,False,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,20,22
293,2246,2246,2282,2282,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",oxolinic acid,pentoxifylline,False,Neg,0,CCN1C=C(C(O)=O)C(=O)C2=CC3=C(OCO3)C=C12,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,20,20
294,2249,2249,2285,2285,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",oxolinic acid,phenytoin,False,Neg,0,CCN1C=C(C(O)=O)C(=O)C2=CC3=C(OCO3)C=C12,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,20,20
295,2257,2257,2293,2293,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",oxolinic acid,sulfonamides,False,Neg,0,CCN1C=C(C(O)=O)C(=O)C2=CC3=C(OCO3)C=C12,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,20,22
296,2263,2263,2299,2299,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUG2;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",pentoxifylline,phenylbutazone,False,Neg,0,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,20,20
297,2264,2264,2300,2300,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUG2;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",pentoxifylline,phenyramidol,False,Neg,0,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,COC1=CC=C(CN(CCN(C)C)C2=NC=CC=C2)C=C1,20,20
298,2266,2266,2302,2302,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",pentoxifylline,prolonged narcotics,False,Neg,0,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,CCOC(=O)C1=CC=C(N)C=C1,20,22
299,2267,2267,2303,2303,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",pentoxifylline,pyrazolones,False,Neg,0,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,CC(=O)NC1=NN=C(S1)S(N)(=O)=O,20,22
300,2268,2268,2304,2304,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",pentoxifylline,quinidine,False,Neg,0,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,20,22
301,2269,2269,2305,2305,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",pentoxifylline,quinine,False,Neg,0,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,20,22
302,2270,2270,2306,2306,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",pentoxifylline,ranitidine,False,Neg,0,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,20,22
303,2271,2271,2307,2307,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUG2;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",pentoxifylline,salicylates,False,Neg,0,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1,20,22
304,2272,2272,2308,2308,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUG2;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",pentoxifylline,sulfinpyrazone,False,Neg,0,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4,20,22
305,2274,2274,2310,2310,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",pentoxifylline,sulindac,False,Neg,0,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(C=C1)S(C)=O,20,24
306,2275,2275,2311,2311,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",pentoxifylline,tolbutamide,False,Neg,0,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,20,24
307,2276,2276,2312,2312,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",pentoxifylline,trimethoprim,False,Neg,0,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1,20,24
308,2277,2277,2313,2313,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUG2;unreliable prothrombin time determinations;DRUGOTHER overdosage.",pentoxifylline,sulfamethoxazole,False,Neg,0,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N,20,24
309,2278,2278,2314,2314,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUG2 overdosage.",pentoxifylline,warfarin sodium,False,Neg,0,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2,20,27
310,2280,2280,2316,2316,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",phenylbutazone,phenytoin,False,Neg,0,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,20,20
311,2288,2288,2324,2324,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",phenylbutazone,sulfonamides,False,Neg,0,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,20,22
312,2294,2294,2330,2330,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",phenyramidol,phenytoin,False,Neg,0,COC1=CC=C(CN(CCN(C)C)C2=NC=CC=C2)C=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,20,20
313,2302,2302,2338,2338,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",phenyramidol,sulfonamides,False,Neg,0,COC1=CC=C(CN(CCN(C)C)C2=NC=CC=C2)C=C1,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,20,22
314,2308,2308,2344,2344,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;prolonged hot weather;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",phenytoin,prolonged narcotics,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCOC(=O)C1=CC=C(N)C=C1,20,22
315,2309,2309,2345,2345,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;prolonged hot weather;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",phenytoin,pyrazolones,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(=O)NC1=NN=C(S1)S(N)(=O)=O,20,22
316,2310,2310,2346,2346,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",phenytoin,quinidine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,20,22
317,2311,2311,2347,2347,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",phenytoin,quinine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,20,22
318,2312,2312,2348,2348,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",phenytoin,ranitidine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,20,22
319,2313,2313,2349,2349,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUG2;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",phenytoin,salicylates,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1,20,22
320,2314,2314,2350,2350,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUG2;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",phenytoin,sulfinpyrazone,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4,20,22
321,2316,2316,2352,2352,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",phenytoin,sulindac,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(C=C1)S(C)=O,20,24
322,2317,2317,2353,2353,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",phenytoin,tolbutamide,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,20,24
323,2318,2318,2354,2354,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",phenytoin,trimethoprim,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1,20,24
324,2319,2319,2355,2355,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUG2;unreliable prothrombin time determinations;DRUGOTHER overdosage.",phenytoin,sulfamethoxazole,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N,20,24
325,2320,2320,2356,2356,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUG2 overdosage.",phenytoin,warfarin sodium,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2,20,27
326,2327,2327,2363,2363,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",prolonged narcotics,sulfonamides,False,Neg,0,CCOC(=O)C1=CC=C(N)C=C1,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,22,22
327,2338,2338,2374,2374,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",pyrazolones,sulfonamides,False,Neg,0,CC(=O)NC1=NN=C(S1)S(N)(=O)=O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,22,22
328,2348,2348,2384,2384,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",quinidine,sulfonamides,False,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,22,22
329,2357,2357,2393,2393,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",quinine,sulfonamides,False,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,22,22
330,2365,2365,2401,2401,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",ranitidine,sulfonamides,False,Neg,0,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,22,22
331,2372,2372,2408,2408,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUG1;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",salicylates,sulfonamides,False,Neg,0,CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,22,22
332,2378,2378,2414,2414,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUG1;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",sulfinpyrazone,sulfonamides,False,Neg,0,C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,22,22
333,2384,2384,2420,2420,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG1, long acting;DRUG2;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",sulfonamides,sulindac,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(C=C1)S(C)=O,22,24
334,2385,2385,2421,2421,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG1, long acting;DRUGOTHER;DRUGOTHER;DRUG2;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",sulfonamides,tolbutamide,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,22,24
335,2386,2386,2422,2422,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG1, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG2/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",sulfonamides,trimethoprim,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1,22,24
336,2387,2387,2423,2423,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG1, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUG2;unreliable prothrombin time determinations;DRUGOTHER overdosage.",sulfonamides,sulfamethoxazole,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N,22,24
337,2388,2388,2424,2424,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG1, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUG2 overdosage.",sulfonamides,warfarin sodium,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2,22,27
338,2402,2402,2438,2438,"Because oral DRUGOTHER may interfere with the hepatic metabolism of DRUG1, toxic levels of the DRUG2 may occur when an oral DRUGOTHER and DRUG1 are administered concurrently.",phenytoin,anticonvulsant,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,10,15
339,2403,2403,2439,2439,"Because oral DRUG2s may interfere with the hepatic metabolism of DRUG1, toxic levels of the DRUGOTHER may occur when an oral DRUG2 and DRUG1 are administered concurrently.",phenytoin,anticoagulant,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,10,2
340,2406,2406,2442,2442,"Because oral DRUGOTHER may interfere with the hepatic metabolism of DRUG2, toxic levels of the DRUG1 may occur when an oral DRUGOTHER and DRUG2 are administered concurrently.",anticonvulsant,phenytoin,False,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,15,10
341,2407,2407,2443,2443,"Because oral DRUG1s may interfere with the hepatic metabolism of DRUG2, toxic levels of the DRUGOTHER may occur when an oral DRUG1 and DRUG2 are administered concurrently.",anticoagulant,phenytoin,True,mechanism,4,[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,2,10
342,2468,2468,2511,2511,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of DRUG1 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with DRUG2 (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) should be considered.",IOPIDINE,CNS depressants,True,advise,1,NC1=CC(Cl)=C(NC2=NCCN2)C(Cl)=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,18,31
343,2472,2472,2515,2515,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of DRUGOTHER 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with DRUG1 (DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) should be considered.",CNS depressants,alcohol,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCO,31,32
344,2473,2473,2516,2516,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of DRUGOTHER 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with DRUG1 (DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) should be considered.",CNS depressants,barbiturates,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O,31,33
345,2474,2474,2517,2517,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of DRUGOTHER 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) should be considered.",CNS depressants,anesthetics,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCOC(=O)C1=CC=C(N)C=C1,31,36
346,2483,2483,2526,2526,"Coadministration of DRUG1 with these drugs or other drugs that are known to be metabolized by CYP2C9, such as DRUG2, may result in lower plasma concentrations of these drugs.",Aprepitant,phenytoin,True,mechanism,4,C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,2,19
347,2611,2611,2654,2654,"Consequently, concomitant administration of DRUG1 with strong CYP3A4 inhibitors (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) should be approached with caution.",Aprepitant,nefazodone,True,advise,1,C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,4,12
348,2614,2614,2657,2657,"Consequently, concomitant administration of DRUG1 with strong CYP3A4 inhibitors (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) should be approached with caution.",Aprepitant,ritonavir,True,advise,1,C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,4,15
349,2617,2617,2660,2660,"Consequently, concomitant administration of DRUGOTHER with strong CYP3A4 inhibitors (e.g., DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) should be approached with caution.",ketoconazole,nefazodone,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,10,12
350,2620,2620,2663,2663,"Consequently, concomitant administration of DRUGOTHER with strong CYP3A4 inhibitors (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) should be approached with caution.",ketoconazole,ritonavir,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,10,15
351,2622,2622,2665,2665,"Consequently, concomitant administration of DRUGOTHER with strong CYP3A4 inhibitors (e.g., DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) should be approached with caution.",itraconazole,nefazodone,False,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,11,12
352,2625,2625,2668,2668,"Consequently, concomitant administration of DRUGOTHER with strong CYP3A4 inhibitors (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) should be approached with caution.",itraconazole,ritonavir,False,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,11,15
353,2627,2627,2670,2670,"Consequently, concomitant administration of DRUGOTHER with strong CYP3A4 inhibitors (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) should be approached with caution.",nefazodone,troleandomycin,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,12,13
354,2628,2628,2671,2671,"Consequently, concomitant administration of DRUGOTHER with strong CYP3A4 inhibitors (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) should be approached with caution.",nefazodone,clarithromycin,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,12,14
355,2630,2630,2673,2673,"Consequently, concomitant administration of DRUGOTHER with strong CYP3A4 inhibitors (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) should be approached with caution.",nefazodone,nelfinavir,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,12,16
356,2632,2632,2675,2675,"Consequently, concomitant administration of DRUGOTHER with strong CYP3A4 inhibitors (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER) should be approached with caution.",troleandomycin,ritonavir,False,Neg,0,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,13,15
357,2634,2634,2677,2677,"Consequently, concomitant administration of DRUGOTHER with strong CYP3A4 inhibitors (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER) should be approached with caution.",clarithromycin,ritonavir,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,14,15
358,2636,2636,2679,2679,"Consequently, concomitant administration of DRUGOTHER with strong CYP3A4 inhibitors (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2) should be approached with caution.",ritonavir,nelfinavir,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,15,16
359,2640,2640,2683,2683,"therefore, coadministration of DRUG1 with drugs that strongly induce CYP3A4 activity (e.g., DRUGOTHER, DRUGOTHER, DRUG2) may result in reduced plasma concentrations of DRUGOTHER that may result in decreased efficacy of DRUG1.",Aprepitant,phenytoin,True,mechanism,4,C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,3,14
360,2644,2644,2687,2687,"therefore, coadministration of DRUGOTHER with drugs that strongly induce CYP3A4 activity (e.g., DRUG1, DRUGOTHER, DRUG2) may result in reduced plasma concentrations of DRUGOTHER that may result in decreased efficacy of DRUGOTHER.",rifampin,phenytoin,False,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,12,14
361,2647,2647,2690,2690,"therefore, coadministration of DRUGOTHER with drugs that strongly induce CYP3A4 activity (e.g., DRUGOTHER, DRUG1, DRUG2) may result in reduced plasma concentrations of DRUGOTHER that may result in decreased efficacy of DRUGOTHER.",carbamazepine,phenytoin,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,13,14
362,2650,2650,2693,2693,"therefore, coadministration of DRUGOTHER with drugs that strongly induce CYP3A4 activity (e.g., DRUGOTHER, DRUGOTHER, DRUG1) may result in reduced plasma concentrations of DRUG2 that may result in decreased efficacy of DRUGOTHER.",phenytoin,aprepitant,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F,14,22
363,2651,2651,2694,2694,"therefore, coadministration of DRUG2 with drugs that strongly induce CYP3A4 activity (e.g., DRUGOTHER, DRUGOTHER, DRUG1) may result in reduced plasma concentrations of DRUGOTHER that may result in decreased efficacy of DRUG2.",phenytoin,Aprepitant,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F,14,3
364,2708,2708,2751,2751,"Concomitant treatment with DRUG1 (DRUG2, DRUGOTHER), DRUGOTHER, or DRUGOTHER may potentiate any hypokalemic effect of DRUGOTHER.",methylxanthines,aminophylline,False,Neg,0,O=C1NC2=C(NC=N2)C(=O)N1,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,3,4
365,2710,2710,2753,2753,"Concomitant treatment with DRUG1 (DRUGOTHER, DRUGOTHER), DRUG2, or DRUGOTHER may potentiate any hypokalemic effect of DRUGOTHER.",methylxanthines,steroids,False,Neg,0,O=C1NC2=C(NC=N2)C(=O)N1,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,3,6
366,2711,2711,2754,2754,"Concomitant treatment with DRUG1 (DRUGOTHER, DRUGOTHER), DRUGOTHER, or DRUG2 may potentiate any hypokalemic effect of DRUGOTHER.",methylxanthines,diuretics,False,Neg,0,O=C1NC2=C(NC=N2)C(=O)N1,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,3,8
367,2712,2712,2755,2755,"Concomitant treatment with DRUG1 (DRUGOTHER, DRUGOTHER), DRUGOTHER, or DRUGOTHER may potentiate any hypokalemic effect of DRUG2.",methylxanthines,adrenergic agonists,True,effect,2,O=C1NC2=C(NC=N2)C(=O)N1,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,3,15
368,2713,2713,2756,2756,"Concomitant treatment with DRUGOTHER (DRUG1, DRUG2), DRUGOTHER, or DRUGOTHER may potentiate any hypokalemic effect of DRUGOTHER.",aminophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,4,5
369,2717,2717,2760,2760,"Concomitant treatment with DRUGOTHER (DRUGOTHER, DRUG1), DRUG2, or DRUGOTHER may potentiate any hypokalemic effect of DRUGOTHER.",theophylline,steroids,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,5,6
370,2718,2718,2761,2761,"Concomitant treatment with DRUGOTHER (DRUGOTHER, DRUG1), DRUGOTHER, or DRUG2 may potentiate any hypokalemic effect of DRUGOTHER.",theophylline,diuretics,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,5,8
371,2719,2719,2762,2762,"Concomitant treatment with DRUGOTHER (DRUGOTHER, DRUG1), DRUGOTHER, or DRUGOTHER may potentiate any hypokalemic effect of DRUG2.",theophylline,adrenergic agonists,True,effect,2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,5,15
372,2729,2729,2772,2772,"The concurrent use of intravenously or orally administered DRUG1 (e.g., DRUG2, DRUGOTHER) by patients receiving DRUGOTHER has not been completely evaluated.",methylxanthines,aminophylline,False,Neg,0,O=C1NC2=C(NC=N2)C(=O)N1,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,8,10
373,2731,2731,2774,2774,"The concurrent use of intravenously or orally administered DRUG1 (e.g., DRUGOTHER, DRUGOTHER) by patients receiving DRUG2 has not been completely evaluated.",methylxanthines,BROVANA,False,Neg,0,O=C1NC2=C(NC=N2)C(=O)N1,COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC(NC=O)=C(O)C=C2)C=C1,8,15
374,2732,2732,2775,2775,"The concurrent use of intravenously or orally administered DRUGOTHER (e.g., DRUG1, DRUG2) by patients receiving DRUGOTHER has not been completely evaluated.",aminophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,10,11
375,2734,2734,2777,2777,"The concurrent use of intravenously or orally administered DRUGOTHER (e.g., DRUGOTHER, DRUG1) by patients receiving DRUG2 has not been completely evaluated.",theophylline,BROVANA,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC(NC=O)=C(O)C=C2)C=C1,11,15
376,2736,2736,2779,2779,"In two combined 12-week placebo controlled trials that included DRUG1 doses of 15 mcg twice daily, 25 mcg twice daily, and 50 mcg once daily, 54 of 873 DRUG1 -treated subjects received concomitant DRUG2 at study entry.",BROVANA,theophylline,False,Neg,0,COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC(NC=O)=C(O)C=C2)C=C1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,9,33
377,2737,2737,2780,2780,"In two combined 12-week placebo controlled trials that included DRUG1 doses of 15 mcg twice daily, 25 mcg twice daily, and 50 mcg once daily, 54 of 873 DRUG1 -treated subjects received concomitant DRUG2 at study entry.",BROVANA,theophylline,False,Neg,0,COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC(NC=O)=C(O)C=C2)C=C1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,9,33
378,2739,2739,2782,2782,"In a 12-month controlled trial that included a 50 mcg once daily DRUG1 dose, 30 of the 528 DRUG1 -treated subjects received concomitant DRUG2 at study entry.",BROVANA,theophylline,False,Neg,0,COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC(NC=O)=C(O)C=C2)C=C1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,12,23
379,2740,2740,2783,2783,"In a 12-month controlled trial that included a 50 mcg once daily DRUG1 dose, 30 of the 528 DRUG1 -treated subjects received concomitant DRUG2 at study entry.",BROVANA,theophylline,False,Neg,0,COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC(NC=O)=C(O)C=C2)C=C1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,12,23
380,2742,2742,2785,2785,"DRUG1: Since DRUG2 is contraindicated in patients with DRUG2-induced thrombocytopenia, the co-administration of DRUGOTHER and DRUG2 is unlikely for this indication.",Heparin,heparin,False,Neg,0,[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,0,2
381,2743,2743,2786,2786,"DRUG1: Since DRUG2 is contraindicated in patients with DRUG2-induced thrombocytopenia, the co-administration of DRUGOTHER and DRUG2 is unlikely for this indication.",Heparin,heparin,False,Neg,0,[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,0,2
382,2744,2744,2787,2787,"DRUG1: Since DRUGOTHER is contraindicated in patients with DRUGOTHER-induced thrombocytopenia, the co-administration of DRUG2 and DRUGOTHER is unlikely for this indication.",Heparin,Argatroban,False,Neg,0,[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O,C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)C1=CC=CC2=C1NCC(C)C2,0,13
383,2745,2745,2788,2788,"DRUG1: Since DRUG2 is contraindicated in patients with DRUG2-induced thrombocytopenia, the co-administration of DRUGOTHER and DRUG2 is unlikely for this indication.",Heparin,heparin,False,Neg,0,[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,0,2
384,2843,2843,2886,2886,"In in vivo studies, 10- to 30-mg/day doses of DRUG1 had no significant effect on metabolism by CYP2D6 (DRUG2), CYP2C9 (DRUGOTHER), CYP2C19 (DRUGOTHER, DRUGOTHER), and CYP3A4 (DRUG2) substrates.",aripiprazole,dextromethorphan,False,Neg,0,CC(=O)NC1=NN=C(S1)S(N)(=O)=O,[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C,9,18
385,2847,2847,2890,2890,"In in vivo studies, 10- to 30-mg/day doses of DRUG1 had no significant effect on metabolism by CYP2D6 (DRUG2), CYP2C9 (DRUGOTHER), CYP2C19 (DRUGOTHER, DRUGOTHER), and CYP3A4 (DRUG2) substrates.",aripiprazole,dextromethorphan,False,Neg,0,CC(=O)NC1=NN=C(S1)S(N)(=O)=O,[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C,9,18
386,2848,2848,2891,2891,"In in vivo studies, 10- to 30-mg/day doses of DRUGOTHER had no significant effect on metabolism by CYP2D6 (DRUG1), CYP2C9 (DRUG2), CYP2C19 (DRUGOTHER, DRUG2), and CYP3A4 (DRUG1) substrates.",dextromethorphan,warfarin,False,Neg,0,[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,18,20
387,2849,2849,2892,2892,"In in vivo studies, 10- to 30-mg/day doses of DRUGOTHER had no significant effect on metabolism by CYP2D6 (DRUG1), CYP2C9 (DRUGOTHER), CYP2C19 (DRUG2, DRUGOTHER), and CYP3A4 (DRUG1) substrates.",dextromethorphan,omeprazole,False,Neg,0,[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,18,22
388,2850,2850,2893,2893,"In in vivo studies, 10- to 30-mg/day doses of DRUGOTHER had no significant effect on metabolism by CYP2D6 (DRUG1), CYP2C9 (DRUG2), CYP2C19 (DRUGOTHER, DRUG2), and CYP3A4 (DRUG1) substrates.",dextromethorphan,warfarin,False,Neg,0,[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,18,20
389,2854,2854,2897,2897,"In in vivo studies, 10- to 30-mg/day doses of DRUGOTHER had no significant effect on metabolism by CYP2D6 (DRUG2), CYP2C9 (DRUG1), CYP2C19 (DRUGOTHER, DRUG1), and CYP3A4 (DRUG2) substrates.",warfarin,dextromethorphan,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C,20,18
390,2856,2856,2899,2899,"In in vivo studies, 10- to 30-mg/day doses of DRUGOTHER had no significant effect on metabolism by CYP2D6 (DRUG2), CYP2C9 (DRUGOTHER), CYP2C19 (DRUG1, DRUGOTHER), and CYP3A4 (DRUG2) substrates.",omeprazole,dextromethorphan,False,Neg,0,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C,22,18
391,2857,2857,2900,2900,"In in vivo studies, 10- to 30-mg/day doses of DRUGOTHER had no significant effect on metabolism by CYP2D6 (DRUG2), CYP2C9 (DRUG1), CYP2C19 (DRUGOTHER, DRUG1), and CYP3A4 (DRUG2) substrates.",warfarin,dextromethorphan,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C,20,18
392,2865,2865,2908,2908,Caution is advised when DRUG1 is coadministered with other medications that can prolong the QT interval (e.g. certain DRUGOTHER or DRUG2) or lead to electrolyte abnormalities (such as DRUGOTHER or DRUGOTHER).,TRISENOX,thioridazine,True,advise,1,O=[As]O[As]=O,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,4,20
393,2868,2868,2911,2911,Caution is advised when DRUGOTHER is coadministered with other medications that can prolong the QT interval (e.g. certain DRUGOTHER or DRUG1) or lead to electrolyte abnormalities (such as DRUG2 or DRUGOTHER).,thioridazine,diuretics,False,Neg,0,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,20,28
394,2869,2869,2912,2912,Caution is advised when DRUGOTHER is coadministered with other medications that can prolong the QT interval (e.g. certain DRUGOTHER or DRUG1) or lead to electrolyte abnormalities (such as DRUGOTHER or DRUG2).,thioridazine,amphotericin B,False,Neg,0,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,C[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O,20,30
395,2893,2893,2936,2936,DRUG1: Serum DRUGOTHER levels may be increased by DRUG2.,Phenytoin,aspirin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(=O)OC1=CC=CC=C1C(=O)O,0,8
396,2894,2894,2937,2937,DRUGOTHER: Serum DRUG1 levels may be increased by DRUG2.,phenytoin,aspirin,True,effect,2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(=O)OC1=CC=CC=C1C(=O)O,2,8
397,2975,2975,3018,3018,"Caution should be exercised if an DRUGOTHER is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as DRUG1, DRUG2, and DRUGOTHER.",ketoconazole,spironolactone,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,25,26
398,2977,2977,3020,3020,"Caution should be exercised if an DRUGOTHER is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as DRUGOTHER, DRUG1, and DRUG2.",spironolactone,cimetidine,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,CC1=C(N=CN1)CSCCNC(=NC)NC#N,26,28
399,2980,2980,3028,3028,DRUG1: Coadministration of DRUGOTHER and DRUG2 Suspension results in a significant decrease in average steady- state plasma DRUGOTHER concentrations.,Rifampin,MEPRON,False,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,0,5
400,2981,2981,3030,3030,DRUGOTHER: Coadministration of DRUG1 and DRUG2 Suspension results in a significant decrease in average steady- state plasma DRUGOTHER concentrations.,rifampin,MEPRON,True,mechanism,4,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,3,5
401,2982,2982,3033,3033,Alternatives to DRUG1 should be considered during the course of PCP treatment with DRUG2.,rifampin,MEPRON,True,advise,1,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,2,13
402,2989,2989,3040,3040,No interaction trials have been conducted with DRUG1 and DRUG2.,MEPRON,rifabutin,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,7,9
403,3088,3088,3142,3142,"When used in therapeutic doses, DRUG1 had a modest effect on the pharmacokinetics of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 (intravenous and oral), DRUGOTHER, DRUGOTHER/DRUGOTHER or DRUGOTHER.",azithromycin,theophylline,True,mechanism,4,CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,5,24
404,3102,3102,3156,3156,"When used in therapeutic doses, DRUGOTHER had a modest effect on the pharmacokinetics of DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 (intravenous and oral), DRUGOTHER, DRUGOTHER/DRUGOTHER or DRUGOTHER.",atorvastatin,theophylline,False,Neg,0,CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,CN1C2=C(C(=O)N(C1=O)C)NC=N2,14,24
405,3115,3115,3169,3169,"When used in therapeutic doses, DRUGOTHER had a modest effect on the pharmacokinetics of DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 (intravenous and oral), DRUGOTHER, DRUGOTHER/DRUGOTHER or DRUGOTHER.",carbamazepine,theophylline,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,15,24
406,3127,3127,3181,3181,"When used in therapeutic doses, DRUGOTHER had a modest effect on the pharmacokinetics of DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 (intravenous and oral), DRUGOTHER, DRUGOTHER/DRUGOTHER or DRUGOTHER.",cetirizine,theophylline,False,Neg,0,CN[C@@H](C)[C@@H](O)C1=CC=CC=C1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,16,24
407,3138,3138,3192,3192,"When used in therapeutic doses, DRUGOTHER had a modest effect on the pharmacokinetics of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 (intravenous and oral), DRUGOTHER, DRUGOTHER/DRUGOTHER or DRUGOTHER.",didanosine,theophylline,False,Neg,0,OC[C@@H]1CC[C@@H](O1)N1C=NC2=C1NC=NC2=O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,17,24
408,3148,3148,3202,3202,"When used in therapeutic doses, DRUGOTHER had a modest effect on the pharmacokinetics of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 (intravenous and oral), DRUGOTHER, DRUGOTHER/DRUGOTHER or DRUGOTHER.",efavirenz,theophylline,False,Neg,0,FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,18,24
409,3157,3157,3211,3211,"When used in therapeutic doses, DRUGOTHER had a modest effect on the pharmacokinetics of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 (intravenous and oral), DRUGOTHER, DRUGOTHER/DRUGOTHER or DRUGOTHER.",fluconazole,theophylline,False,Neg,0,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,19,24
410,3165,3165,3219,3219,"When used in therapeutic doses, DRUGOTHER had a modest effect on the pharmacokinetics of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 (intravenous and oral), DRUGOTHER, DRUGOTHER/DRUGOTHER or DRUGOTHER.",indinavir,theophylline,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CN1C2=C(C(=O)N(C1=O)C)NC=N2,20,24
411,3172,3172,3226,3226,"When used in therapeutic doses, DRUGOTHER had a modest effect on the pharmacokinetics of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2 (intravenous and oral), DRUGOTHER, DRUGOTHER/DRUGOTHER or DRUGOTHER.",midazolam,theophylline,False,Neg,0,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,CN1C2=C(C(=O)N(C1=O)C)NC=N2,21,24
412,3178,3178,3232,3232,"When used in therapeutic doses, DRUGOTHER had a modest effect on the pharmacokinetics of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2 (intravenous and oral), DRUGOTHER, DRUGOTHER/DRUGOTHER or DRUGOTHER.",rifabutin,theophylline,False,Neg,0,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,CN1C2=C(C(=O)N(C1=O)C)NC=N2,22,24
413,3183,3183,3237,3237,"When used in therapeutic doses, DRUGOTHER had a modest effect on the pharmacokinetics of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2 (intravenous and oral), DRUGOTHER, DRUGOTHER/DRUGOTHER or DRUGOTHER.",sildenafil,theophylline,False,Neg,0,CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,23,24
414,3188,3188,3242,3242,"When used in therapeutic doses, DRUGOTHER had a modest effect on the pharmacokinetics of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (intravenous and oral), DRUG2, DRUGOTHER/DRUGOTHER or DRUGOTHER.",theophylline,triazolam,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1,24,28
415,3189,3189,3243,3243,"When used in therapeutic doses, DRUGOTHER had a modest effect on the pharmacokinetics of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (intravenous and oral), DRUGOTHER, DRUG2/DRUGOTHER or DRUGOTHER.",theophylline,trimethoprim,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1,24,29
416,3190,3190,3244,3244,"When used in therapeutic doses, DRUGOTHER had a modest effect on the pharmacokinetics of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (intravenous and oral), DRUGOTHER, DRUGOTHER/DRUG2 or DRUGOTHER.",theophylline,sulfamethoxazole,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N,24,29
417,3191,3191,3245,3245,"When used in therapeutic doses, DRUGOTHER had a modest effect on the pharmacokinetics of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (intravenous and oral), DRUGOTHER, DRUGOTHER/DRUGOTHER or DRUG2.",theophylline,zidovudine,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],24,31
418,3206,3206,3260,3260,"DRUG1, DRUGOTHER and DRUG2 concentrations.",Cyclosporine,phenytoin,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,3
419,3207,3207,3261,3261,"DRUGOTHER, DRUG1 and DRUG2 concentrations.",hexobarbital,phenytoin,False,Neg,0,CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,1,3
420,3253,3253,3314,3314,"DRUGOTHER (DRUG1, DRUG2, DRUGOTHER, and others) or DRUGOTHER supplements can increase the risk of hyperkalemia.",spironolactone,amiloride,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N,1,2
421,3254,3254,3315,3315,"DRUGOTHER (DRUG1, DRUGOTHER, DRUG2, and others) or DRUGOTHER supplements can increase the risk of hyperkalemia.",spironolactone,triamterene,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,1,3
422,3257,3257,3318,3318,"Other No clinically important pharmacokinetic interactions occurred when DRUG1 was administered concomitantly with DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER.",Lotensin,hydrochlorothiazide,False,Neg,0,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,8,13
423,3259,3259,3320,3320,"Other No clinically important pharmacokinetic interactions occurred when DRUG1 was administered concomitantly with DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER.",Lotensin,furosemide,False,Neg,0,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,8,15
424,3265,3265,3326,3326,"Other No clinically important pharmacokinetic interactions occurred when DRUGOTHER was administered concomitantly with DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER.",hydrochlorothiazide,chlorthalidone,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,NS(=O)(=O)C1=C(Cl)C=CC(=C1)C1(O)NC(=O)C2=CC=CC=C12,13,14
425,3267,3267,3328,3328,"Other No clinically important pharmacokinetic interactions occurred when DRUGOTHER was administered concomitantly with DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER.",hydrochlorothiazide,digoxin,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,13,16
426,3268,3268,3329,3329,"Other No clinically important pharmacokinetic interactions occurred when DRUGOTHER was administered concomitantly with DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER.",hydrochlorothiazide,propranolol,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,13,17
427,3269,3269,3330,3330,"Other No clinically important pharmacokinetic interactions occurred when DRUGOTHER was administered concomitantly with DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER.",hydrochlorothiazide,atenolol,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1,13,18
428,3270,3270,3331,3331,"Other No clinically important pharmacokinetic interactions occurred when DRUGOTHER was administered concomitantly with DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER.",hydrochlorothiazide,naproxen,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,13,19
429,3271,3271,3332,3332,"Other No clinically important pharmacokinetic interactions occurred when DRUGOTHER was administered concomitantly with DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2.",hydrochlorothiazide,cimetidine,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,CC1=C(N=CN1)CSCCNC(=NC)NC#N,13,21
430,3272,3272,3333,3333,"Other No clinically important pharmacokinetic interactions occurred when DRUGOTHER was administered concomitantly with DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER.",chlorthalidone,furosemide,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=CC(=C1)C1(O)NC(=O)C2=CC=CC=C12,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,14,15
431,3278,3278,3339,3339,"Other No clinically important pharmacokinetic interactions occurred when DRUGOTHER was administered concomitantly with DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER.",furosemide,digoxin,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,15,16
432,3279,3279,3340,3340,"Other No clinically important pharmacokinetic interactions occurred when DRUGOTHER was administered concomitantly with DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER.",furosemide,propranolol,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,15,17
433,3280,3280,3341,3341,"Other No clinically important pharmacokinetic interactions occurred when DRUGOTHER was administered concomitantly with DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER.",furosemide,atenolol,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1,15,18
434,3281,3281,3342,3342,"Other No clinically important pharmacokinetic interactions occurred when DRUGOTHER was administered concomitantly with DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER.",furosemide,naproxen,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,15,19
435,3282,3282,3343,3343,"Other No clinically important pharmacokinetic interactions occurred when DRUGOTHER was administered concomitantly with DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2.",furosemide,cimetidine,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC1=C(N=CN1)CSCCNC(=NC)NC#N,15,21
436,3296,3296,3357,3357,"DRUG1 has been used concomitantly with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2, without evidence of clinically important adverse interactions.",Lotensin,hydralazine,False,Neg,0,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC,C1=CC=C2C(=C1)C=NN=C2NN,0,11
437,3299,3299,3360,3360,"DRUGOTHER has been used concomitantly with DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2, without evidence of clinically important adverse interactions.",beta-adrenergic-blocking agents,hydralazine,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,C1=CC=C2C(=C1)C=NN=C2NN,6,11
438,3301,3301,3362,3362,"DRUGOTHER has been used concomitantly with DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2, without evidence of clinically important adverse interactions.",diuretics,hydralazine,False,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,C1=CC=C2C(=C1)C=NN=C2NN,8,11
439,3302,3302,3363,3363,"DRUGOTHER has been used concomitantly with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2, without evidence of clinically important adverse interactions.",digoxin,hydralazine,False,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C1=CC=C2C(=C1)C=NN=C2NN,9,11
440,3308,3308,3376,3376,"DRUGOTHER may interact with DRUG1 (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), local DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER), DRUGOTHER (DRUGOTHER)-containing preparations (e.g., sunscreens and some DRUGOTHER), DRUGOTHER (e.g., DRUG2), DRUGOTHER (sulfa medicines), DRUGOTHER (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).",acetaminophen,Pronestyl,False,Neg,0,CC(=O)NC1=CC=C(C=C1)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,4,26
441,3309,3309,3377,3377,"DRUGOTHER may interact with DRUG1 (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), local DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER), DRUGOTHER (DRUGOTHER)-containing preparations (e.g., sunscreens and some DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUG2 (sulfa medicines), DRUGOTHER (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).",acetaminophen,sulfonamides,False,Neg,0,CC(=O)NC1=CC=C(C=C1)O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,4,27
442,3313,3313,3381,3381,"DRUGOTHER may interact with DRUGOTHER (e.g., DRUGOTHER), DRUG1 (e.g., DRUGOTHER), local DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER), DRUGOTHER (DRUGOTHER)-containing preparations (e.g., sunscreens and some DRUGOTHER), DRUGOTHER (e.g., DRUG2), DRUGOTHER (sulfa medicines), DRUGOTHER (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).",chloramphenicol,Pronestyl,False,Neg,0,CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,7,26
443,3314,3314,3382,3382,"DRUGOTHER may interact with DRUGOTHER (e.g., DRUGOTHER), DRUG1 (e.g., DRUGOTHER), local DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER), DRUGOTHER (DRUGOTHER)-containing preparations (e.g., sunscreens and some DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUG2 (sulfa medicines), DRUGOTHER (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).",chloramphenicol,sulfonamides,False,Neg,0,CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,7,27
444,3317,3317,3385,3385,"DRUGOTHER may interact with DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), local DRUG1 (e.g., DRUGOTHER and DRUGOTHER), DRUGOTHER (DRUGOTHER)-containing preparations (e.g., sunscreens and some DRUGOTHER), DRUGOTHER (e.g., DRUG2), DRUGOTHER (sulfa medicines), DRUGOTHER (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).",anesthetics,Pronestyl,False,Neg,0,CCOC(=O)C1=CC=C(N)C=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,11,26
445,3318,3318,3386,3386,"DRUGOTHER may interact with DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), local DRUG1 (e.g., DRUGOTHER and DRUGOTHER), DRUGOTHER (DRUGOTHER)-containing preparations (e.g., sunscreens and some DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUG2 (sulfa medicines), DRUGOTHER (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).",anesthetics,sulfonamides,False,Neg,0,CCOC(=O)C1=CC=C(N)C=C1,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,11,27
446,3320,3320,3388,3388,"DRUGOTHER may interact with DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), local DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER), DRUGOTHER (DRUGOTHER)-containing preparations (e.g., sunscreens and some DRUG1), DRUGOTHER (e.g., DRUG2), DRUGOTHER (sulfa medicines), DRUGOTHER (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).",multivitamins,Pronestyl,False,Neg,0,NC(=O)C1=CC=CN=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,23,26
447,3321,3321,3389,3389,"DRUGOTHER may interact with DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), local DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER), DRUGOTHER (DRUGOTHER)-containing preparations (e.g., sunscreens and some DRUG1), DRUGOTHER (e.g., DRUGOTHER), DRUG2 (sulfa medicines), DRUGOTHER (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).",multivitamins,sulfonamides,False,Neg,0,NC(=O)C1=CC=CN=C1,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,23,27
448,3322,3322,3390,3390,"DRUGOTHER may interact with DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), local DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER), DRUGOTHER (DRUGOTHER)-containing preparations (e.g., sunscreens and some DRUGOTHER), DRUG1 (e.g., DRUG2), DRUGOTHER (sulfa medicines), DRUGOTHER (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).",procainamide,Pronestyl,False,Neg,0,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,24,26
449,3323,3323,3391,3391,"DRUGOTHER may interact with DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), local DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER), DRUGOTHER (DRUGOTHER)-containing preparations (e.g., sunscreens and some DRUGOTHER), DRUG1 (e.g., DRUGOTHER), DRUG2 (sulfa medicines), DRUGOTHER (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).",procainamide,sulfonamides,False,Neg,0,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,24,27
450,3334,3334,3402,3402,DRUGOTHER such as DRUG1 or DRUG2;,phenothiazines,haloperidol,False,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,3,5
451,3335,3335,3403,3403,DRUG1: The concomitant use of DRUG2 with long- and short-acting DRUGOTHER has been safely tolerated in patients with stable angina pectoris.,Nitrates,Bepridil,False,Neg,0,[O-]N(=O)=O,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,0,5
452,3337,3337,3405,3405,DRUGOTHER: The concomitant use of DRUG1 with long- and short-acting DRUG2 has been safely tolerated in patients with stable angina pectoris.,Bepridil,nitrates,False,Neg,0,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,[N+](=O)([O-])[O-],5,10
453,3338,3338,3406,3406,Sublingual DRUG1 may be taken if necessary for the control of acute angina attacks during DRUG2 therapy.,nitroglycerin,Bepridil,False,Neg,0,OCC(O)CO,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,1,15
454,3339,3339,3407,3407,DRUG1: The concomitant use of DRUG2 and DRUGOTHER has been well tolerated in patients with stable angina.,Beta-blocking Agents,Bepridil,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,0,5
455,3341,3341,3409,3409,DRUGOTHER: The concomitant use of DRUG1 and DRUG2 has been well tolerated in patients with stable angina.,Bepridil,beta-blocking agents,False,Neg,0,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,5,7
456,3342,3342,3410,3410,"DRUG1: In controlled studies in healthy volunteers, DRUG2 either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum DRUGOTHER concentrations.",Digoxin,bepridil hydrochloride,False,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,0,7
457,3344,3344,3412,3412,"DRUGOTHER: In controlled studies in healthy volunteers, DRUG1 either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum DRUG2 concentrations.",bepridil hydrochloride,digoxin,True,mechanism,4,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,7,27
458,3345,3345,3413,3413,Limited clinical data in angina patients receiving concomitant DRUG1 and DRUG2 therapy indicate no discernible changes in serum DRUG2 levels.,bepridil hydrochloride,digoxin,False,Neg,0,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,8,10
459,3346,3346,3414,3414,Oral DRUGOTHER: DRUG1 has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for DRUG2 or oral DRUGOTHER.,Bepridil,insulin,False,Neg,0,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CN=CN2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN,2,22
460,3347,3347,3415,3415,Oral DRUGOTHER: DRUG1 has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for DRUGOTHER or oral DRUG2.,Bepridil,hypoglycemic agents,False,Neg,0,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,2,25
461,3349,3349,3417,3417,"In general, these are drugs that have one or more pharmacologic activities similar to DRUG1, including DRUG2 such as DRUGOTHER and DRUGOTHER, DRUGOTHER and DRUGOTHER.",bepridil hydrochloride,anti-arrhythmic agents,False,Neg,0,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,14,16
462,3350,3350,3418,3418,"In general, these are drugs that have one or more pharmacologic activities similar to DRUG1, including DRUGOTHER such as DRUG2 and DRUGOTHER, DRUGOTHER and DRUGOTHER.",bepridil hydrochloride,quinidine,False,Neg,0,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,14,19
463,3351,3351,3419,3419,"In general, these are drugs that have one or more pharmacologic activities similar to DRUG1, including DRUGOTHER such as DRUGOTHER and DRUG2, DRUGOTHER and DRUGOTHER.",bepridil hydrochloride,procainamide,False,Neg,0,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,14,21
464,3355,3355,3423,3423,"In general, these are drugs that have one or more pharmacologic activities similar to DRUGOTHER, including DRUG1 such as DRUGOTHER and DRUGOTHER, DRUGOTHER and DRUG2.",anti-arrhythmic agents,tricyclic anti-depressants,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,16,24
465,3357,3357,3425,3425,"In general, these are drugs that have one or more pharmacologic activities similar to DRUGOTHER, including DRUGOTHER such as DRUG1 and DRUGOTHER, DRUGOTHER and DRUG2.",quinidine,tricyclic anti-depressants,False,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,19,24
466,3358,3358,3426,3426,"In general, these are drugs that have one or more pharmacologic activities similar to DRUGOTHER, including DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER and DRUG2.",procainamide,tricyclic anti-depressants,False,Neg,0,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,21,24
467,3362,3362,3434,3434,"The following drugs have been coadministered with DRUGOTHER and have not altered its pharmacokinetics: DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2.",cimetidine,hydrochlorothiazide,False,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,14,18
468,3364,3364,3436,3436,"The following drugs have been coadministered with DRUGOTHER and have not altered its pharmacokinetics: DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2.",nifedipine,hydrochlorothiazide,False,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,15,18
469,3365,3365,3437,3437,"The following drugs have been coadministered with DRUGOTHER and have not altered its pharmacokinetics: DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2.",chlorthalidone,hydrochlorothiazide,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=CC(=C1)C1(O)NC(=O)C2=CC=CC=C12,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,16,18
470,3391,3391,3469,3469,"Furthermore, DRUG1, DRUG2, DRUGOTHER, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma DRUGOTHER concentrations.",rifampin,phenytoin,False,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,1,2
471,3394,3394,3472,3472,"Furthermore, DRUGOTHER, DRUG1, DRUG2, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma DRUGOTHER concentrations.",phenytoin,phenobarbital,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,2,3
472,3395,3395,3473,3473,"Furthermore, DRUGOTHER, DRUG1, DRUGOTHER, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma DRUG2 concentrations.",phenytoin,bexarotene,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=CC2=C(C=C1C(=C)C1=CC=C(C=C1)C(O)=O)C(C)(C)CCC2(C)C,2,17
473,3410,3410,3492,3492,"Drug Interactions: The central DRUG1 syndrome can occur when DRUG1 agents such as DRUGOTHER are administered concomitantly with drugs that have secondary DRUG1 actions, e.g., certain DRUGOTHER such as DRUG2, the DRUGOTHER and other DRUGOTHER, DRUGOTHER, certain DRUGOTHER such as the DRUGOTHER salts, and DRUGOTHER.",anticholinergic,meperidine,True,effect,2,C[N+](C)(C)CCO,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,4,29
474,3416,3416,3498,3498,"Drug Interactions: The central DRUGOTHER syndrome can occur when DRUGOTHER agents such as DRUG1 are administered concomitantly with drugs that have secondary DRUGOTHER actions, e.g., certain DRUGOTHER such as DRUG2, the DRUGOTHER and other DRUGOTHER, DRUGOTHER, certain DRUGOTHER such as the DRUGOTHER salts, and DRUGOTHER.",AKINETON,meperidine,True,effect,2,CCC1=NC=CC(=C1)C(N)=S,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,13,29
475,3421,3421,3503,3503,"Drug Interactions: The central DRUGOTHER syndrome can occur when DRUGOTHER agents such as DRUGOTHER are administered concomitantly with drugs that have secondary DRUGOTHER actions, e.g., certain DRUG1 such as DRUG2, the DRUGOTHER and other DRUGOTHER, DRUGOTHER, certain DRUGOTHER such as the DRUGOTHER salts, and DRUGOTHER.",narcotic analgesics,meperidine,False,Neg,0,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,26,29
476,3426,3426,3508,3508,"Drug Interactions: The central DRUGOTHER syndrome can occur when DRUGOTHER agents such as DRUGOTHER are administered concomitantly with drugs that have secondary DRUGOTHER actions, e.g., certain DRUGOTHER such as DRUG1, the DRUG2 and other DRUGOTHER, DRUGOTHER, certain DRUGOTHER such as the DRUGOTHER salts, and DRUGOTHER.",meperidine,phenothiazines,False,Neg,0,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,N1C2=CC=CC=C2SC2=CC=CC=C12,29,31
477,3427,3427,3509,3509,"Drug Interactions: The central DRUGOTHER syndrome can occur when DRUGOTHER agents such as DRUGOTHER are administered concomitantly with drugs that have secondary DRUGOTHER actions, e.g., certain DRUGOTHER such as DRUG1, the DRUGOTHER and other DRUGOTHER, DRUG2, certain DRUGOTHER such as the DRUGOTHER salts, and DRUGOTHER.",meperidine,tricyclic antidepressants,False,Neg,0,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,29,35
478,3428,3428,3510,3510,"Drug Interactions: The central DRUGOTHER syndrome can occur when DRUGOTHER agents such as DRUGOTHER are administered concomitantly with drugs that have secondary DRUGOTHER actions, e.g., certain DRUGOTHER such as DRUG1, the DRUGOTHER and other DRUGOTHER, DRUGOTHER, certain DRUGOTHER such as the DRUG2 salts, and DRUGOTHER.",meperidine,quinidine,False,Neg,0,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,29,41
479,3429,3429,3511,3511,"Drug Interactions: The central DRUGOTHER syndrome can occur when DRUGOTHER agents such as DRUGOTHER are administered concomitantly with drugs that have secondary DRUGOTHER actions, e.g., certain DRUGOTHER such as DRUG1, the DRUGOTHER and other DRUGOTHER, DRUGOTHER, certain DRUGOTHER such as the DRUGOTHER salts, and DRUG2.",meperidine,antihistamines,False,Neg,0,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,NCCC1=CNC=N1,29,44
480,3437,3437,3519,3519,"Patients receiving catecholamine-depleting drugs, such as DRUG1 or DRUG2, should be closely monitored, because the added beta-adrenergic blocking action of DRUGOTHER may produce excessive reduction of sympathetic activity.",reserpine,guanethidine,False,Neg,0,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,C1CCCN(CCC1)CCN=C(N)N,6,8
481,3439,3439,3521,3521,"Patients receiving catecholamine-depleting drugs, such as DRUGOTHER or DRUG1, should be closely monitored, because the added beta-adrenergic blocking action of DRUG2 may produce excessive reduction of sympathetic activity.",guanethidine,ZEBETA,True,effect,2,C1CCCN(CCC1)CCN=C(N)N,CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1,8,20
482,3585,3585,3673,3673,"Co-administration of DRUGOTHER and DRUG1 or other agents interfering with neuromuscular transmission (e.g., DRUGOTHER) should only be performed with caution as the effect of the DRUG2 may be potentiated.",aminoglycosides,toxin,False,Neg,0,OC(=O)CCCCCCCC(O)=O,CCC1(C)CC(=O)NC1=O,4,25
483,3586,3586,3674,3674,"Co-administration of DRUGOTHER and DRUG1 or other agents interfering with neuromuscular transmission (e.g., DRUGOTHER) should only be performed with caution as the effect of the DRUG2 may be potentiated.",aminoglycosides,toxin,False,Neg,0,OC(=O)CCCCCCCC(O)=O,CCC1(C)CC(=O)NC1=O,4,25
484,3590,3590,3682,3682,"Although specific drug interaction studies have not been conducted with DRUGOTHER, the possibility of an additive or potentiating effect with DRUG1 (DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER) should be considered.",CNS depressants,alcohol,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCO,20,21
485,3591,3591,3683,3683,"Although specific drug interaction studies have not been conducted with DRUGOTHER, the possibility of an additive or potentiating effect with DRUG1 (DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER) should be considered.",CNS depressants,barbiturates,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O,20,22
486,3592,3592,3684,3684,"Although specific drug interaction studies have not been conducted with DRUGOTHER, the possibility of an additive or potentiating effect with DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2) should be considered.",CNS depressants,anesthetics,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCOC(=O)C1=CC=C(N)C=C1,20,26
487,3598,3598,3696,3696,"Compounds in these categories result in a decreased efficacy of DRUGOTHER: DRUG1, DRUG2, DRUGOTHER, DRUGOTHER.",phenothiazines,haloperidol,False,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,11,12
488,3601,3601,3699,3699,"Compounds in these categories result in a decreased efficacy of DRUGOTHER: DRUGOTHER, DRUG1, DRUG2, DRUGOTHER.",haloperidol,metoclopramide,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,12,13
489,3602,3602,3700,3700,"Compounds in these categories result in a decreased efficacy of DRUGOTHER: DRUGOTHER, DRUG1, DRUGOTHER, DRUG2.",haloperidol,pimozide,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,12,14
490,3605,3605,3703,3703,"DRUG1 can interact with DRUGOTHER or other DRUG2 (may potentiate the CNS depressant effects of either these medications or DRUGOTHER), DRUGOTHER or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with DRUGOTHER), and DRUGOTHER (concurrent use with DRUGOTHER may prolong and intensify the anticholinergic and CNS depressant effects of DRUGOTHER).",Dexbrompheniramine,CNS depressants,True,effect,2,CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C1=CC=CC=N1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,0,7
491,3612,3612,3710,3710,"DRUGOTHER can interact with DRUG1 or other DRUG2 (may potentiate the CNS depressant effects of either these medications or DRUGOTHER), DRUGOTHER or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with DRUGOTHER), and DRUGOTHER (concurrent use with DRUGOTHER may prolong and intensify the anticholinergic and CNS depressant effects of DRUGOTHER).",alcohol,CNS depressants,False,Neg,0,CCO,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,4,7
492,3619,3619,3717,3717,"DRUGOTHER can interact with DRUGOTHER or other DRUG1 (may potentiate the CNS depressant effects of either these medications or DRUG2), DRUGOTHER or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with DRUG2), and DRUGOTHER (concurrent use with DRUG2 may prolong and intensify the anticholinergic and CNS depressant effects of DRUG2).",CNS depressants,antihistamines,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,NCCC1=CNC=N1,7,19
493,3620,3620,3718,3718,"DRUGOTHER can interact with DRUGOTHER or other DRUG1 (may potentiate the CNS depressant effects of either these medications or DRUGOTHER), DRUG2 or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with DRUGOTHER), and DRUGOTHER (concurrent use with DRUGOTHER may prolong and intensify the anticholinergic and CNS depressant effects of DRUGOTHER).",CNS depressants,anticholinergics,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C[N+](C)(C)CCO,7,20
494,3621,3621,3719,3719,"DRUGOTHER can interact with DRUGOTHER or other DRUG1 (may potentiate the CNS depressant effects of either these medications or DRUG2), DRUGOTHER or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with DRUG2), and DRUGOTHER (concurrent use with DRUG2 may prolong and intensify the anticholinergic and CNS depressant effects of DRUG2).",CNS depressants,antihistamines,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,NCCC1=CNC=N1,7,19
495,3622,3622,3720,3720,"DRUGOTHER can interact with DRUGOTHER or other DRUG1 (may potentiate the CNS depressant effects of either these medications or DRUGOTHER), DRUGOTHER or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with DRUGOTHER), and DRUG2 (concurrent use with DRUGOTHER may prolong and intensify the anticholinergic and CNS depressant effects of DRUGOTHER).",CNS depressants,monoamine oxidase (MAO) inhibitors,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,OC(=O)CCCCCCCC(O)=O,7,41
496,3623,3623,3721,3721,"DRUGOTHER can interact with DRUGOTHER or other DRUG1 (may potentiate the CNS depressant effects of either these medications or DRUG2), DRUGOTHER or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with DRUG2), and DRUGOTHER (concurrent use with DRUG2 may prolong and intensify the anticholinergic and CNS depressant effects of DRUG2).",CNS depressants,antihistamines,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,NCCC1=CNC=N1,7,19
497,3624,3624,3722,3722,"DRUGOTHER can interact with DRUGOTHER or other DRUG1 (may potentiate the CNS depressant effects of either these medications or DRUG2), DRUGOTHER or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with DRUG2), and DRUGOTHER (concurrent use with DRUG2 may prolong and intensify the anticholinergic and CNS depressant effects of DRUG2).",CNS depressants,antihistamines,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,NCCC1=CNC=N1,7,19
498,3640,3640,3738,3738,"This drug may interact with DRUG1 or other DRUG2 (may potentiate the CNS depressant effects of either these medications or DRUGOTHER), DRUGOTHER or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with DRUGOTHER), and DRUGOTHER (concurrent use with DRUGOTHER may prolong and intensify the anticholinergic and CNS depressant effects of DRUGOTHER).",alcohol,CNS depressants,False,Neg,0,CCO,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,5,8
499,3647,3647,3745,3745,"This drug may interact with DRUGOTHER or other DRUG1 (may potentiate the CNS depressant effects of either these medications or DRUG2), DRUGOTHER or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with DRUG2), and DRUGOTHER (concurrent use with DRUG2 may prolong and intensify the anticholinergic and CNS depressant effects of DRUG2).",CNS depressants,antihistamines,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,NCCC1=CNC=N1,8,20
500,3648,3648,3746,3746,"This drug may interact with DRUGOTHER or other DRUG1 (may potentiate the CNS depressant effects of either these medications or DRUGOTHER), DRUG2 or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with DRUGOTHER), and DRUGOTHER (concurrent use with DRUGOTHER may prolong and intensify the anticholinergic and CNS depressant effects of DRUGOTHER).",CNS depressants,anticholinergics,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C[N+](C)(C)CCO,8,21
501,3649,3649,3747,3747,"This drug may interact with DRUGOTHER or other DRUG1 (may potentiate the CNS depressant effects of either these medications or DRUG2), DRUGOTHER or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with DRUG2), and DRUGOTHER (concurrent use with DRUG2 may prolong and intensify the anticholinergic and CNS depressant effects of DRUG2).",CNS depressants,antihistamines,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,NCCC1=CNC=N1,8,20
502,3650,3650,3748,3748,"This drug may interact with DRUGOTHER or other DRUG1 (may potentiate the CNS depressant effects of either these medications or DRUGOTHER), DRUGOTHER or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with DRUGOTHER), and DRUG2 (concurrent use with DRUGOTHER may prolong and intensify the anticholinergic and CNS depressant effects of DRUGOTHER).",CNS depressants,monoamine oxidase (MAO) inhibitors,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,OC(=O)CCCCCCCC(O)=O,8,42
503,3651,3651,3749,3749,"This drug may interact with DRUGOTHER or other DRUG1 (may potentiate the CNS depressant effects of either these medications or DRUG2), DRUGOTHER or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with DRUG2), and DRUGOTHER (concurrent use with DRUG2 may prolong and intensify the anticholinergic and CNS depressant effects of DRUG2).",CNS depressants,antihistamines,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,NCCC1=CNC=N1,8,20
504,3652,3652,3750,3750,"This drug may interact with DRUGOTHER or other DRUG1 (may potentiate the CNS depressant effects of either these medications or DRUG2), DRUGOTHER or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with DRUG2), and DRUGOTHER (concurrent use with DRUG2 may prolong and intensify the anticholinergic and CNS depressant effects of DRUG2).",CNS depressants,antihistamines,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,NCCC1=CNC=N1,8,20
505,3670,3670,3768,3768,"If treatment with inhibitors of CYP3A4 activity (such as DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, etc.) is indicated, reduction of the DRUGOTHER dose should be considered.",ketoconazole,ritonavir,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,9,11
506,3672,3672,3770,3770,"If treatment with inhibitors of CYP3A4 activity (such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, etc.) is indicated, reduction of the DRUGOTHER dose should be considered.",ketoconazole,saquinavir,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,9,13
507,3675,3675,3773,3773,"If treatment with inhibitors of CYP3A4 activity (such as DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, etc.) is indicated, reduction of the DRUGOTHER dose should be considered.",intraconazole,ritonavir,False,Neg,0,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,10,11
508,3677,3677,3775,3775,"If treatment with inhibitors of CYP3A4 activity (such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, etc.) is indicated, reduction of the DRUGOTHER dose should be considered.",intraconazole,saquinavir,False,Neg,0,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,10,13
509,3680,3680,3778,3778,"If treatment with inhibitors of CYP3A4 activity (such as DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, etc.) is indicated, reduction of the DRUGOTHER dose should be considered.",ritonavir,indinavir,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,11,12
510,3682,3682,3780,3780,"If treatment with inhibitors of CYP3A4 activity (such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, etc.) is indicated, reduction of the DRUGOTHER dose should be considered.",ritonavir,erythromycin,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,11,14
511,3683,3683,3781,3781,"If treatment with inhibitors of CYP3A4 activity (such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, etc.) is indicated, reduction of the DRUG2 dose should be considered.",ritonavir,budesonide,True,advise,1,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,11,21
512,3684,3684,3782,3782,"If treatment with inhibitors of CYP3A4 activity (such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, etc.) is indicated, reduction of the DRUGOTHER dose should be considered.",indinavir,saquinavir,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,12,13
513,3687,3687,3785,3785,"If treatment with inhibitors of CYP3A4 activity (such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, etc.) is indicated, reduction of the DRUGOTHER dose should be considered.",saquinavir,erythromycin,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,13,14
514,3688,3688,3786,3786,"If treatment with inhibitors of CYP3A4 activity (such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, etc.) is indicated, reduction of the DRUG2 dose should be considered.",saquinavir,budesonide,True,advise,1,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,13,21
515,3700,3700,3798,3798,"Because CYP 3A4 inhibitors may increase plasma concentrations of DRUG1, patients already on CYP 3A4 inhibitors such as DRUG2 (e.g.",buprenorphine,azole antifungals,False,Neg,0,C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O,OC(=O)CCCCCCCCC=C,9,18
516,3703,3703,3801,3801,"DRUG1), DRUGOTHER (e.g. DRUGOTHER), and DRUGOTHER (e.g. DRUG2, DRUGOTHER and DRUGOTHER) should have their dose of DRUGOTHER or DRUGOTHER adjusted.",ketoconazole,ritonavir,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,0,7
517,3705,3705,3803,3803,"DRUG1), DRUGOTHER (e.g. DRUGOTHER), and DRUGOTHER (e.g. DRUGOTHER, DRUGOTHER and DRUG2) should have their dose of DRUGOTHER or DRUGOTHER adjusted.",ketoconazole,saquinavir,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,0,10
518,3706,3706,3804,3804,"DRUG1), DRUGOTHER (e.g. DRUGOTHER), and DRUGOTHER (e.g. DRUGOTHER, DRUGOTHER and DRUGOTHER) should have their dose of DRUG2 or DRUGOTHER adjusted.",ketoconazole,SUBUTEX,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4,0,16
519,3709,3709,3807,3807,"DRUGOTHER), DRUG1 (e.g. DRUGOTHER), and DRUGOTHER (e.g. DRUG2, DRUGOTHER and DRUGOTHER) should have their dose of DRUGOTHER or DRUGOTHER adjusted.",macrolide antibiotics,ritonavir,False,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1,7
520,3711,3711,3809,3809,"DRUGOTHER), DRUG1 (e.g. DRUGOTHER), and DRUGOTHER (e.g. DRUGOTHER, DRUGOTHER and DRUG2) should have their dose of DRUGOTHER or DRUGOTHER adjusted.",macrolide antibiotics,saquinavir,False,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1,10
521,3712,3712,3810,3810,"DRUGOTHER), DRUG1 (e.g. DRUGOTHER), and DRUGOTHER (e.g. DRUGOTHER, DRUGOTHER and DRUGOTHER) should have their dose of DRUG2 or DRUGOTHER adjusted.",macrolide antibiotics,SUBUTEX,False,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4,1,16
522,3714,3714,3812,3812,"DRUGOTHER), DRUGOTHER (e.g. DRUG1), and DRUGOTHER (e.g. DRUG2, DRUGOTHER and DRUGOTHER) should have their dose of DRUGOTHER or DRUGOTHER adjusted.",erythromycin,ritonavir,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,3,7
523,3716,3716,3814,3814,"DRUGOTHER), DRUGOTHER (e.g. DRUG1), and DRUGOTHER (e.g. DRUGOTHER, DRUGOTHER and DRUG2) should have their dose of DRUGOTHER or DRUGOTHER adjusted.",erythromycin,saquinavir,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,3,10
524,3717,3717,3815,3815,"DRUGOTHER), DRUGOTHER (e.g. DRUG1), and DRUGOTHER (e.g. DRUGOTHER, DRUGOTHER and DRUGOTHER) should have their dose of DRUG2 or DRUGOTHER adjusted.",erythromycin,SUBUTEX,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4,3,16
525,3719,3719,3817,3817,"DRUGOTHER), DRUGOTHER (e.g. DRUGOTHER), and DRUGOTHER (e.g. DRUG1, DRUG2 and DRUGOTHER) should have their dose of DRUGOTHER or DRUGOTHER adjusted.",ritonavir,indinavir,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,7,8
526,3722,3722,3820,3820,"DRUGOTHER), DRUGOTHER (e.g. DRUGOTHER), and DRUGOTHER (e.g. DRUG1, DRUGOTHER and DRUGOTHER) should have their dose of DRUGOTHER or DRUG2 adjusted.",ritonavir,SUBOXONE,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O,7,18
527,3723,3723,3821,3821,"DRUGOTHER), DRUGOTHER (e.g. DRUGOTHER), and DRUGOTHER (e.g. DRUGOTHER, DRUG1 and DRUG2) should have their dose of DRUGOTHER or DRUGOTHER adjusted.",indinavir,saquinavir,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,8,10
528,3724,3724,3822,3822,"DRUGOTHER), DRUGOTHER (e.g. DRUGOTHER), and DRUGOTHER (e.g. DRUGOTHER, DRUG1 and DRUGOTHER) should have their dose of DRUG2 or DRUGOTHER adjusted.",indinavir,SUBUTEX,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4,8,16
529,3727,3727,3825,3825,"DRUGOTHER), DRUGOTHER (e.g. DRUGOTHER), and DRUGOTHER (e.g. DRUGOTHER, DRUGOTHER and DRUG1) should have their dose of DRUGOTHER or DRUG2 adjusted.",saquinavir,SUBOXONE,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O,10,18
530,3728,3728,3826,3826,"DRUGOTHER), DRUGOTHER (e.g. DRUGOTHER), and DRUGOTHER (e.g. DRUGOTHER, DRUGOTHER and DRUGOTHER) should have their dose of DRUG1 or DRUG2 adjusted.",SUBUTEX,SUBOXONE,False,Neg,0,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4,OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O,16,18
531,3729,3729,3827,3827,"Based on anecdotal reports, there may be an interaction between DRUG1 and DRUG2.",buprenorphine,benzodiazepines,True,int,3,C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O,N1N=CC=CC2=CC=CC=C12,10,12
532,3730,3730,3828,3828,There have been a number of reports in the post-marketing experience of coma and death associated with the concomitant intravenous misuse of DRUG1 and DRUG2 by addicts.,buprenorphine,benzodiazepines,True,effect,2,C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O,N1N=CC=CC2=CC=CC=C12,22,24
533,3732,3732,3830,3830,"DRUG1 and DRUG2 should be prescribed with caution to patients on DRUGOTHER or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse.",SUBUTEX,SUBOXONE,False,Neg,0,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4,OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O,0,2
534,3733,3733,3831,3831,"DRUG1 and DRUGOTHER should be prescribed with caution to patients on DRUG2 or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse.",SUBUTEX,benzodiazepines,True,advise,1,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4,N1N=CC=CC2=CC=CC=C12,0,11
535,3736,3736,3834,3834,Patients should be warned of the potential danger of the intravenous self-administration of DRUG1 while under treatment with DRUGOTHER or DRUG2.,benzodiazepines,SUBUTEX,True,advise,1,N1N=CC=CC2=CC=CC=C12,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4,13,20
536,3737,3737,3835,3835,Patients should be warned of the potential danger of the intravenous self-administration of DRUGOTHER while under treatment with DRUG1 or DRUG2.,SUBOXONE,SUBUTEX,False,Neg,0,OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4,18,20
537,3739,3739,3837,3837,In vitro studies indicate that DRUG1 is primarily metabolized to hydroxyDRUG1 by the CYP2B6 isoenzyme.,bupropion,hydroxybupropion,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1,5,-1
538,3741,3741,3839,3839,"Therefore, the potential exists for a drug interaction between DRUG1 and drugs that affect the CYP2B6 isoenzyme (e.g., DRUGOTHER and DRUG2).",WELLBUTRIN,cyclophosphamide,True,int,3,CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1,ClCCN(CCCl)P1(=O)NCCCO1,9,20
539,3742,3742,3840,3840,"Therefore, the potential exists for a drug interaction between DRUGOTHER and drugs that affect the CYP2B6 isoenzyme (e.g., DRUG1 and DRUG2).",orphenadrine,cyclophosphamide,False,Neg,0,CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C,ClCCN(CCCl)P1(=O)NCCCO1,18,20
540,3743,3743,3841,3841,The DRUG1 metabolite of DRUG2 does not appear to be produced by the cytochrome P450 isoenzymes.,threohydrobupropion,bupropion,False,Neg,0,CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,1,4
541,3744,3744,3842,3842,The effects of concomitant administration of DRUG1 on the pharmacokinetics of DRUG2 and its active metabolites were studied in 24 healthy young male volunteers.,cimetidine,bupropion,False,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,6,11
542,3745,3745,3843,3843,"Following oral administration of two 150-mg sustained-release tablets with and without 800 mg of DRUG1, the pharmacokinetics of DRUG2 and hydroxyDRUG2 were unaffected.",cimetidine,bupropion,False,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,14,18
543,3747,3747,3845,3845,"Following oral administration of two 150-mg sustained-release tablets with and without 800 mg of DRUGOTHER, the pharmacokinetics of DRUG1 and hydroxyDRUG1 were unaffected.",bupropion,hydroxybupropion,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1,18,-1
544,3749,3749,3847,3847,"While not systematically studied, certain drugs may induce the metabolism of DRUG1 (e.g., DRUG2, DRUGOTHER, DRUGOTHER).",bupropion,carbamazepine,True,mechanism,4,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,11,13
545,3750,3750,3848,3848,"While not systematically studied, certain drugs may induce the metabolism of DRUG1 (e.g., DRUGOTHER, DRUG2, DRUGOTHER).",bupropion,phenobarbital,True,mechanism,4,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,11,14
546,3753,3753,3851,3851,"While not systematically studied, certain drugs may induce the metabolism of DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUG2).",carbamazepine,phenytoin,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,13,15
547,3754,3754,3852,3852,"While not systematically studied, certain drugs may induce the metabolism of DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUG2).",phenobarbital,phenytoin,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,14,15
548,3756,3756,3854,3854,"Although DRUG1 is not metabolized by this isoenzyme, DRUG1 and hydroxyDRUG1 are inhibitors of the CYP2D6 isoenzyme in vitro.",bupropion,hydroxybupropion,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1,1,-1
549,3757,3757,3855,3855,"Although DRUG1 is not metabolized by this isoenzyme, DRUG1 and hydroxyDRUG1 are inhibitors of the CYP2D6 isoenzyme in vitro.",bupropion,hydroxybupropion,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1,1,-1
550,3758,3758,3856,3856,"In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of DRUG1 given as 150 mg twice daily followed by a single dose of 50 mg DRUG2 increased the Cmax, AUC, and t1/2 of DRUG2 by an average of approximately 2-, 5- and 2-fold, respectively.",bupropion,desipramine,True,mechanism,4,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,23,38
551,3759,3759,3857,3857,"In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of DRUG1 given as 150 mg twice daily followed by a single dose of 50 mg DRUG2 increased the Cmax, AUC, and t1/2 of DRUG2 by an average of approximately 2-, 5- and 2-fold, respectively.",bupropion,desipramine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,23,38
552,3761,3761,3859,3859,"Therefore, co-administration of DRUG1 with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUG2 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,antidepressants,True,advise,1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,3,14
553,3762,3762,3860,3860,"Therefore, co-administration of DRUG1 with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,nortriptyline,True,advise,1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,3,16
554,3763,3763,3861,3861,"Therefore, co-administration of DRUG1 with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,imipramine,True,advise,1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,3,17
555,3764,3764,3862,3862,"Therefore, co-administration of DRUG1 with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,desipramine,True,advise,1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,3,18
556,3765,3765,3863,3863,"Therefore, co-administration of DRUG1 with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,paroxetine,True,advise,1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,3,19
557,3766,3766,3864,3864,"Therefore, co-administration of DRUG1 with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,fluoxetine,True,advise,1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,3,20
558,3767,3767,3865,3865,"Therefore, co-administration of DRUG1 with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,sertraline,True,advise,1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,3,21
559,3769,3769,3867,3867,"Therefore, co-administration of DRUG1 with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,risperidone,True,advise,1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,3,25
560,3771,3771,3869,3869,"Therefore, co-administration of DRUG1 with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUG2), and DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,metoprolol,True,advise,1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,3,29
561,3772,3772,3870,3870,"Therefore, co-administration of DRUG1 with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUG2, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,propafenone,True,advise,1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O,3,33
562,3773,3773,3871,3871,"Therefore, co-administration of DRUG1 with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER, DRUG2), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,flecainide,True,advise,1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,3,34
563,3780,3780,3878,3878,"Therefore, co-administration of DRUGOTHER with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",antidepressants,haloperidol,False,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,14,24
564,3782,3782,3880,3880,"Therefore, co-administration of DRUGOTHER with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",antidepressants,thioridazine,False,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,14,26
565,3791,3791,3889,3889,"Therefore, co-administration of DRUGOTHER with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",nortriptyline,haloperidol,False,Neg,0,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,16,24
566,3793,3793,3891,3891,"Therefore, co-administration of DRUGOTHER with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",nortriptyline,thioridazine,False,Neg,0,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,16,26
567,3801,3801,3899,3899,"Therefore, co-administration of DRUGOTHER with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",imipramine,haloperidol,False,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,17,24
568,3803,3803,3901,3901,"Therefore, co-administration of DRUGOTHER with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",imipramine,thioridazine,False,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,17,26
569,3810,3810,3908,3908,"Therefore, co-administration of DRUGOTHER with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",desipramine,haloperidol,False,Neg,0,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,18,24
570,3812,3812,3910,3910,"Therefore, co-administration of DRUGOTHER with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",desipramine,thioridazine,False,Neg,0,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,18,26
571,3818,3818,3916,3916,"Therefore, co-administration of DRUGOTHER with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",paroxetine,haloperidol,False,Neg,0,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,19,24
572,3820,3820,3918,3918,"Therefore, co-administration of DRUGOTHER with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",paroxetine,thioridazine,False,Neg,0,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,19,26
573,3825,3825,3923,3923,"Therefore, co-administration of DRUGOTHER with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",fluoxetine,haloperidol,False,Neg,0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,20,24
574,3827,3827,3925,3925,"Therefore, co-administration of DRUGOTHER with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",fluoxetine,thioridazine,False,Neg,0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,20,26
575,3831,3831,3929,3929,"Therefore, co-administration of DRUGOTHER with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",sertraline,haloperidol,False,Neg,0,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,21,24
576,3833,3833,3931,3931,"Therefore, co-administration of DRUGOTHER with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",sertraline,thioridazine,False,Neg,0,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,21,26
577,3837,3837,3935,3935,"Therefore, co-administration of DRUGOTHER with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUG1, DRUG2, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",haloperidol,risperidone,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,24,25
578,3839,3839,3937,3937,"Therefore, co-administration of DRUGOTHER with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUG2), and DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",haloperidol,metoprolol,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,24,29
579,3840,3840,3938,3938,"Therefore, co-administration of DRUGOTHER with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUG2, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",haloperidol,propafenone,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O,24,33
580,3841,3841,3939,3939,"Therefore, co-administration of DRUGOTHER with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER, DRUG2), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",haloperidol,flecainide,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,24,34
581,3842,3842,3940,3940,"Therefore, co-administration of DRUGOTHER with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUG2), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",risperidone,thioridazine,False,Neg,0,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,25,26
582,3846,3846,3944,3944,"Therefore, co-administration of DRUGOTHER with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER (e.g., DRUG2), and DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",thioridazine,metoprolol,False,Neg,0,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,26,29
583,3847,3847,3945,3945,"Therefore, co-administration of DRUGOTHER with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUG2, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",thioridazine,propafenone,False,Neg,0,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O,26,33
584,3848,3848,3946,3946,"Therefore, co-administration of DRUGOTHER with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER, DRUG2), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",thioridazine,flecainide,False,Neg,0,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,26,34
585,3852,3852,3950,3950,DRUG1: Studies in animals demonstrate that the acute toxicity of DRUG2 is enhanced by the DRUGOTHER DRUGOTHER .,MAO Inhibitors,bupropion,False,Neg,0,CN(CC#C)CC1=CC=CC=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,0,10
586,3855,3855,3953,3953,DRUGOTHER: Studies in animals demonstrate that the acute toxicity of DRUG1 is enhanced by the DRUG2 DRUGOTHER .,bupropion,MAO inhibitor,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN(CC#C)CC1=CC=CC=C1,10,15
587,3856,3856,3954,3954,DRUGOTHER: Studies in animals demonstrate that the acute toxicity of DRUG1 is enhanced by the DRUGOTHER DRUG2 .,bupropion,phenelzine,True,effect,2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C1=CC=C(C=C1)CCNN,10,16
588,3859,3859,3957,3957,DRUG1 and DRUGOTHER: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving DRUG2 concurrently with either DRUGOTHER or DRUGOTHER.,Levodopa,bupropion,False,Neg,0,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,0,16
589,3862,3862,3960,3960,DRUGOTHER and DRUG1: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving DRUG2 concurrently with either DRUGOTHER or DRUGOTHER.,Amantadine,bupropion,False,Neg,0,C1C2CC3CC1CC(C2)(C3)N,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,2,16
590,3865,3865,3963,3963,DRUGOTHER and DRUGOTHER: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving DRUG1 concurrently with either DRUG2 or DRUGOTHER.,bupropion,levodopa,True,effect,2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O,16,20
591,3866,3866,3964,3964,DRUGOTHER and DRUGOTHER: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving DRUG1 concurrently with either DRUGOTHER or DRUG2.,bupropion,amantadine,True,effect,2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C1C2CC3CC1CC(C2)(C3)N,16,22
592,3872,3872,3970,3970,"Drugs that Lower Seizure Threshold: Concurrent administration of DRUG1 and agents (e.g., DRUGOTHER, other DRUGOTHER, DRUG2, systemic DRUGOTHER, etc.) that lower seizure threshold should be undertaken only with extreme caution.",WELLBUTRIN,theophylline,True,advise,1,CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,8,15
593,3874,3874,3972,3972,"Drugs that Lower Seizure Threshold: Concurrent administration of DRUGOTHER and agents (e.g., DRUGOTHER, other DRUG1, DRUG2, systemic DRUGOTHER, etc.) that lower seizure threshold should be undertaken only with extreme caution.",antidepressants,theophylline,False,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CN1C2=C(C(=O)N(C1=O)C)NC=N2,14,15
594,3876,3876,3974,3974,"Drugs that Lower Seizure Threshold: Concurrent administration of DRUGOTHER and agents (e.g., DRUGOTHER, other DRUGOTHER, DRUG1, systemic DRUG2, etc.) that lower seizure threshold should be undertaken only with extreme caution.",theophylline,steroids,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,15,17
595,3893,3893,3991,3991,"In a study in normal volunteers, concomitant administration of DRUG1 and DRUG2 resulted in increased serum DRUG2 concentrations.",buspirone HCl,haloperidol,True,mechanism,4,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,9,11
596,3894,3894,3992,3992,"In a study in normal volunteers, concomitant administration of DRUG1 and DRUG2 resulted in increased serum DRUG2 concentrations.",buspirone HCl,haloperidol,False,Neg,0,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,9,11
597,3896,3896,3994,3994,"In vitro, DRUGOTHER does not displace tightly bound drugs like DRUG1, DRUG2, and DRUGOTHER from serum proteins.",phenytoin,propranolol,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,10,11
598,3897,3897,3995,3995,"In vitro, DRUGOTHER does not displace tightly bound drugs like DRUG1, DRUGOTHER, and DRUG2 from serum proteins.",phenytoin,warfarin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,10,13
599,3899,3899,3997,3997,"The patient was also chronically receiving DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER.",phenytoin,phenobarbital,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,6,7
600,3900,3900,3998,3998,"The patient was also chronically receiving DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER.",phenytoin,digoxin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,6,8
601,3901,3901,3999,3999,"The patient was also chronically receiving DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2.",phenytoin,levothyroxine sodium,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)[O-])N.[Na+],6,10
602,3921,3921,4019,4019,"DRUG1 increases the clearance of DRUG2 by 15% or more, possibly due to the induction of glutathione-S-transferase.",Phenytoin,busulfan,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1,0,5
603,3922,3922,4020,4020,"Since the pharmacokinetics of DRUG1 were studied in patients treated with DRUG2, the clearance of DRUG1 at the recommended dose may be lower and exposure (AUC) higher in patients not treated with DRUG2.",BUSULFEX,phenytoin,True,mechanism,4,CS(=O)(=O)OCCCCOS(C)(=O)=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,4,11
604,3924,3924,4022,4022,"Since the pharmacokinetics of DRUG1 were studied in patients treated with DRUG2, the clearance of DRUG1 at the recommended dose may be lower and exposure (AUC) higher in patients not treated with DRUG2.",BUSULFEX,phenytoin,False,Neg,0,CS(=O)(=O)OCCCCOS(C)(=O)=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,4,11
605,3925,3925,4023,4023,"Since the pharmacokinetics of DRUG2 were studied in patients treated with DRUG1, the clearance of DRUG2 at the recommended dose may be lower and exposure (AUC) higher in patients not treated with DRUG1.",phenytoin,BUSULFEX,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CS(=O)(=O)OCCCCOS(C)(=O)=O,11,4
606,3927,3927,4025,4025,"Since the pharmacokinetics of DRUG1 were studied in patients treated with DRUG2, the clearance of DRUG1 at the recommended dose may be lower and exposure (AUC) higher in patients not treated with DRUG2.",BUSULFEX,phenytoin,False,Neg,0,CS(=O)(=O)OCCCCOS(C)(=O)=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,4,11
607,3995,3995,4093,4093,"DRUG1, DRUGOTHER and DRUG2 may enhance the effects of: other DRUGOTHERs, DRUGOTHER, general DRUGOTHER, DRUGOTHER such as DRUGOTHER, DRUGOTHER, or other DRUGOTHER, causing increased CNS depression.",Butalbital,caffeine,False,Neg,0,CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,0,3
608,4001,4001,4099,4099,"DRUG1, DRUGOTHER and DRUGOTHER may enhance the effects of: other DRUGOTHERs, DRUGOTHER, general DRUGOTHER, DRUGOTHER such as DRUGOTHER, DRUGOTHER, or other DRUG2, causing increased CNS depression.",Butalbital,CNS depressants,True,effect,2,CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,0,21
609,4002,4002,4100,4100,"DRUGOTHER, DRUG1 and DRUG2 may enhance the effects of: other DRUGOTHERs, DRUGOTHER, general DRUGOTHER, DRUGOTHER such as DRUGOTHER, DRUGOTHER, or other DRUGOTHER, causing increased CNS depression.",acetaminophen,caffeine,False,Neg,0,CC(=O)NC1=CC=C(C=C1)O,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,1,3
610,4008,4008,4106,4106,"DRUGOTHER, DRUG1 and DRUGOTHER may enhance the effects of: other DRUGOTHERs, DRUGOTHER, general DRUGOTHER, DRUGOTHER such as DRUGOTHER, DRUGOTHER, or other DRUG2, causing increased CNS depression.",acetaminophen,CNS depressants,True,effect,2,CC(=O)NC1=CC=C(C=C1)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,1,21
611,4009,4009,4107,4107,"DRUGOTHER, DRUGOTHER and DRUG1 may enhance the effects of: other DRUG2s, DRUGOTHER, general DRUGOTHER, DRUGOTHER such as DRUGOTHER, DRUGOTHER, or other DRUGOTHER, causing increased CNS depression.",caffeine,narcotic analgesic,True,effect,2,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,3,10
612,4010,4010,4108,4108,"DRUGOTHER, DRUGOTHER and DRUG1 may enhance the effects of: other DRUGOTHERs, DRUG2, general DRUGOTHER, DRUGOTHER such as DRUGOTHER, DRUGOTHER, or other DRUGOTHER, causing increased CNS depression.",caffeine,alcohol,True,effect,2,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CCO,3,11
613,4011,4011,4109,4109,"DRUGOTHER, DRUGOTHER and DRUG1 may enhance the effects of: other DRUGOTHERs, DRUGOTHER, general DRUG2, DRUGOTHER such as DRUGOTHER, DRUGOTHER, or other DRUGOTHER, causing increased CNS depression.",caffeine,anesthetics,True,effect,2,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CCOC(=O)C1=CC=C(N)C=C1,3,13
614,4012,4012,4110,4110,"DRUGOTHER, DRUGOTHER and DRUG1 may enhance the effects of: other DRUGOTHERs, DRUGOTHER, general DRUGOTHER, DRUG2 such as DRUGOTHER, DRUGOTHER, or other DRUGOTHER, causing increased CNS depression.",caffeine,tranquilizers,True,effect,2,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,3,14
615,4013,4013,4111,4111,"DRUGOTHER, DRUGOTHER and DRUG1 may enhance the effects of: other DRUGOTHERs, DRUGOTHER, general DRUGOTHER, DRUGOTHER such as DRUG2, DRUGOTHER, or other DRUGOTHER, causing increased CNS depression.",caffeine,chlordiazepoxide,True,effect,2,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1,3,17
616,4019,4019,4117,4117,"DRUGOTHER, DRUGOTHER and DRUGOTHER may enhance the effects of: other DRUG1s, DRUGOTHER, general DRUGOTHER, DRUGOTHER such as DRUGOTHER, DRUGOTHER, or other DRUG2, causing increased CNS depression.",narcotic analgesic,CNS depressants,False,Neg,0,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,10,21
617,4023,4023,4121,4121,"DRUGOTHER, DRUGOTHER and DRUGOTHER may enhance the effects of: other DRUGOTHERs, DRUG1, general DRUGOTHER, DRUGOTHER such as DRUGOTHER, DRUGOTHER, or other DRUG2, causing increased CNS depression.",alcohol,CNS depressants,False,Neg,0,CCO,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,11,21
618,4026,4026,4124,4124,"DRUGOTHER, DRUGOTHER and DRUGOTHER may enhance the effects of: other DRUGOTHERs, DRUGOTHER, general DRUG1, DRUGOTHER such as DRUGOTHER, DRUGOTHER, or other DRUG2, causing increased CNS depression.",anesthetics,CNS depressants,False,Neg,0,CCOC(=O)C1=CC=C(N)C=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,13,21
619,4028,4028,4126,4126,"DRUGOTHER, DRUGOTHER and DRUGOTHER may enhance the effects of: other DRUGOTHERs, DRUGOTHER, general DRUGOTHER, DRUG1 such as DRUGOTHER, DRUGOTHER, or other DRUG2, causing increased CNS depression.",tranquilizers,CNS depressants,False,Neg,0,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,14,21
620,4029,4029,4127,4127,"DRUGOTHER, DRUGOTHER and DRUGOTHER may enhance the effects of: other DRUGOTHERs, DRUGOTHER, general DRUGOTHER, DRUGOTHER such as DRUG1, DRUGOTHER, or other DRUG2, causing increased CNS depression.",chlordiazepoxide,CNS depressants,False,Neg,0,CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,17,21
621,4053,4053,4152,4152,"In healthy volunteers, the pharmacokinetics of a 1-mg dose of DRUG1 administered as DRUGOTHER were not affected by the coadministration of a single 6-mg subcutaneous dose of DRUG2.",butorphanol,sumatriptan,False,Neg,0,C1CC[C@]2([C@H]3CC4=C([C@]2(C1)CCN3CC5CCC5)C=C(C=C4)O)O,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,10,27
622,4054,4054,4153,4153,"In healthy volunteers, the pharmacokinetics of a 1-mg dose of DRUGOTHER administered as DRUG1 were not affected by the coadministration of a single 6-mg subcutaneous dose of DRUG2.",STADOL NS,sumatriptan,False,Neg,0,[H][C@@]12CC3=C(C=C(O)C=C3)[C@]3(CCCC[C@@]13O)CCN2CC1CCC1,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,13,27
623,4056,4056,4155,4155,"However, in another study in healthy volunteers, the pharmacokinetics of DRUG1 were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of DRUGOTHER was administered 1 minute after a 20-mg dose of DRUG2 nasal spray.",butorphanol,sumatriptan,False,Neg,0,C1CC[C@]2([C@H]3CC4=C([C@]2(C1)CCN3CC5CCC5)C=C(C=C4)O)O,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,10,38
624,4057,4057,4156,4156,"However, in another study in healthy volunteers, the pharmacokinetics of DRUGOTHER were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of DRUG1 was administered 1 minute after a 20-mg dose of DRUG2 nasal spray.",STADOL NS,sumatriptan,True,mechanism,4,[H][C@@]12CC3=C(C=C(O)C=C3)[C@]3(CCCC[C@@]13O)CCN2CC1CCC1,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,28,38
625,4058,4058,4157,4157,"When the DRUG1 was administered 30 minutes after the DRUG2 nasal spray, the AUC of DRUGOTHER increased 11% and Cmax decreased 18%.",STADOL NS,sumatriptan,True,mechanism,4,[H][C@@]12CC3=C(C=C(O)C=C3)[C@]3(CCCC[C@@]13O)CCN2CC1CCC1,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,2,9
626,4060,4060,4159,4159,"When the DRUGOTHER was administered 30 minutes after the DRUG1 nasal spray, the AUC of DRUG2 increased 11% and Cmax decreased 18%.",sumatriptan,butorphanol,False,Neg,0,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,C1CC[C@]2([C@H]3CC4=C([C@]2(C1)CCN3CC5CCC5)C=C(C=C4)O)O,9,15
627,4061,4061,4160,4160,In neither case were the pharmacokinetics of DRUG1 affected by coadministration with DRUG2.,sumatriptan,STADOL NS,False,Neg,0,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,[H][C@@]12CC3=C(C=C(O)C=C3)[C@]3(CCCC[C@@]13O)CCN2CC1CCC1,7,12
628,4062,4062,4161,4161,"These results suggest that the analgesic effect of DRUG1 may be diminished when it is administered shortly after DRUG2 nasal spray, but by 30 minutes any such reduction in effect should be minimal.",STADOL NS,sumatriptan,True,effect,2,[H][C@@]12CC3=C(C=C(O)C=C3)[C@]3(CCCC[C@@]13O)CCN2CC1CCC1,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,8,18
629,4063,4063,4162,4162,The safety of using DRUG1 and DRUG2 (DRUGOTHER) Nasal Spray during the same episode of migraine has not been established.,STADOL NS,IMITREX,False,Neg,0,[H][C@@]12CC3=C(C=C(O)C=C3)[C@]3(CCCC[C@@]13O)CCN2CC1CCC1,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1,4,6
630,4064,4064,4163,4163,The safety of using DRUG1 and DRUGOTHER (DRUG2) Nasal Spray during the same episode of migraine has not been established.,STADOL NS,sumatriptan,False,Neg,0,[H][C@@]12CC3=C(C=C(O)C=C3)[C@]3(CCCC[C@@]13O)CCN2CC1CCC1,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,4,7
631,4076,4076,4177,4177,"DRUG1 should not be administered concurrently with D2-antagonists, such as DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER.",DOSTINEX,phenothiazines,True,advise,1,[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC,N1C2=CC=CC=C2SC2=CC=CC=C12,0,10
632,4078,4078,4179,4179,"DRUG1 should not be administered concurrently with D2-antagonists, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2.",DOSTINEX,metoclopramide,True,advise,1,[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,0,14
633,4079,4079,4180,4180,"DRUGOTHER should not be administered concurrently with D2-antagonists, such as DRUG1, DRUGOTHER, DRUG2, or DRUGOTHER.",phenothiazines,thioxanthines,False,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,O=C1NC2=C(NC=N2)C(=O)N1,10,12
634,4081,4081,4182,4182,"DRUGOTHER should not be administered concurrently with D2-antagonists, such as DRUGOTHER, DRUGOTHER, DRUG1, or DRUG2.",thioxanthines,metoclopramide,False,Neg,0,O=C1NC2=C(NC=N2)C(=O)N1,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,12,14
635,4083,4083,4184,4184,"Based on adult data, lower doses of DRUG1 may be needed following coadministration of drugs which are reported to decrease DRUG1 elimination (e.g., DRUG2 and DRUGOTHER) and higher DRUG1 doses may be needed following coadministration of drugs that increase DRUG1 elimination (e.g., DRUGOTHER and DRUGOTHER).",caffeine,cimetidine,True,advise,1,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC1=C(N=CN1)CSCCNC(=NC)NC#N,7,23
636,4084,4084,4185,4185,"Based on adult data, lower doses of DRUG1 may be needed following coadministration of drugs which are reported to decrease DRUG1 elimination (e.g., DRUGOTHER and DRUG2) and higher DRUG1 doses may be needed following coadministration of drugs that increase DRUG1 elimination (e.g., DRUGOTHER and DRUGOTHER).",caffeine,ketoconazole,True,advise,1,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,7,25
637,4087,4087,4188,4188,"Based on adult data, lower doses of DRUG1 may be needed following coadministration of drugs which are reported to decrease DRUG1 elimination (e.g., DRUGOTHER and DRUGOTHER) and higher DRUG1 doses may be needed following coadministration of drugs that increase DRUG1 elimination (e.g., DRUG2 and DRUGOTHER).",caffeine,phenobarbital,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,7,42
638,4089,4089,4190,4190,"Based on adult data, lower doses of DRUG1 may be needed following coadministration of drugs which are reported to decrease DRUG1 elimination (e.g., DRUG2 and DRUGOTHER) and higher DRUG1 doses may be needed following coadministration of drugs that increase DRUG1 elimination (e.g., DRUGOTHER and DRUGOTHER).",caffeine,cimetidine,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC1=C(N=CN1)CSCCNC(=NC)NC#N,7,23
639,4090,4090,4191,4191,"Based on adult data, lower doses of DRUG1 may be needed following coadministration of drugs which are reported to decrease DRUG1 elimination (e.g., DRUGOTHER and DRUG2) and higher DRUG1 doses may be needed following coadministration of drugs that increase DRUG1 elimination (e.g., DRUGOTHER and DRUGOTHER).",caffeine,ketoconazole,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,7,25
640,4093,4093,4194,4194,"Based on adult data, lower doses of DRUG1 may be needed following coadministration of drugs which are reported to decrease DRUG1 elimination (e.g., DRUGOTHER and DRUGOTHER) and higher DRUG1 doses may be needed following coadministration of drugs that increase DRUG1 elimination (e.g., DRUG2 and DRUGOTHER).",caffeine,phenobarbital,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,7,42
641,4096,4096,4197,4197,"Based on adult data, lower doses of DRUG2 may be needed following coadministration of drugs which are reported to decrease DRUG2 elimination (e.g., DRUG1 and DRUGOTHER) and higher DRUG2 doses may be needed following coadministration of drugs that increase DRUG2 elimination (e.g., DRUGOTHER and DRUGOTHER).",cimetidine,caffeine,False,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,23,7
642,4097,4097,4198,4198,"Based on adult data, lower doses of DRUG2 may be needed following coadministration of drugs which are reported to decrease DRUG2 elimination (e.g., DRUG1 and DRUGOTHER) and higher DRUG2 doses may be needed following coadministration of drugs that increase DRUG2 elimination (e.g., DRUGOTHER and DRUGOTHER).",cimetidine,caffeine,False,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,23,7
643,4099,4099,4200,4200,"Based on adult data, lower doses of DRUGOTHER may be needed following coadministration of drugs which are reported to decrease DRUGOTHER elimination (e.g., DRUG1 and DRUGOTHER) and higher DRUGOTHER doses may be needed following coadministration of drugs that increase DRUGOTHER elimination (e.g., DRUGOTHER and DRUG2).",cimetidine,phenytoin,False,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,23,44
644,4100,4100,4201,4201,"Based on adult data, lower doses of DRUG2 may be needed following coadministration of drugs which are reported to decrease DRUG2 elimination (e.g., DRUGOTHER and DRUG1) and higher DRUG2 doses may be needed following coadministration of drugs that increase DRUG2 elimination (e.g., DRUGOTHER and DRUGOTHER).",ketoconazole,caffeine,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,25,7
645,4101,4101,4202,4202,"Based on adult data, lower doses of DRUG2 may be needed following coadministration of drugs which are reported to decrease DRUG2 elimination (e.g., DRUGOTHER and DRUG1) and higher DRUG2 doses may be needed following coadministration of drugs that increase DRUG2 elimination (e.g., DRUGOTHER and DRUGOTHER).",ketoconazole,caffeine,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,25,7
646,4103,4103,4204,4204,"Based on adult data, lower doses of DRUGOTHER may be needed following coadministration of drugs which are reported to decrease DRUGOTHER elimination (e.g., DRUGOTHER and DRUG1) and higher DRUGOTHER doses may be needed following coadministration of drugs that increase DRUGOTHER elimination (e.g., DRUGOTHER and DRUG2).",ketoconazole,phenytoin,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,25,44
647,4105,4105,4206,4206,"Based on adult data, lower doses of DRUG1 may be needed following coadministration of drugs which are reported to decrease DRUG1 elimination (e.g., DRUGOTHER and DRUGOTHER) and higher DRUG1 doses may be needed following coadministration of drugs that increase DRUG1 elimination (e.g., DRUG2 and DRUGOTHER).",caffeine,phenobarbital,True,advise,1,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,7,42
648,4107,4107,4208,4208,"Based on adult data, lower doses of DRUG1 may be needed following coadministration of drugs which are reported to decrease DRUG1 elimination (e.g., DRUGOTHER and DRUGOTHER) and higher DRUG1 doses may be needed following coadministration of drugs that increase DRUG1 elimination (e.g., DRUG2 and DRUGOTHER).",caffeine,phenobarbital,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,7,42
649,4109,4109,4210,4210,"Based on adult data, lower doses of DRUGOTHER may be needed following coadministration of drugs which are reported to decrease DRUGOTHER elimination (e.g., DRUGOTHER and DRUGOTHER) and higher DRUGOTHER doses may be needed following coadministration of drugs that increase DRUGOTHER elimination (e.g., DRUG1 and DRUG2).",phenobarbital,phenytoin,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,42,44
650,4110,4110,4211,4211,DRUG1 administered concurrently with DRUG2 reduced the urine volume in 4 healthy volunteers.,Caffeine,ketoprofen,True,effect,2,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1,0,4
651,4122,4122,4223,4223,"DRUG1/DRUG2: The coadministration of DRUGOTHER or DRUGOTHER will not affect plasma concentrations of DRUGOTHER, but may reduce endogenous plasma levels of DRUGOTHER/ergoDRUGOTHER by accelerating metabolism.",Phenytoin,Phenobarbital,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,0,0
652,4124,4124,4225,4225,"DRUG1/DRUGOTHER: The coadministration of DRUGOTHER or DRUG2 will not affect plasma concentrations of DRUGOTHER, but may reduce endogenous plasma levels of DRUGOTHER/ergoDRUGOTHER by accelerating metabolism.",Phenytoin,phenobarbital,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,0,6
653,4125,4125,4226,4226,"DRUG1/DRUGOTHER: The coadministration of DRUGOTHER or DRUGOTHER will not affect plasma concentrations of DRUG2, but may reduce endogenous plasma levels of DRUGOTHER/ergoDRUGOTHER by accelerating metabolism.",Phenytoin,vitamin D,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,OC(=O)CCCCCCCC(O)=O,0,13
654,4126,4126,4227,4227,"DRUG1/DRUGOTHER: The coadministration of DRUGOTHER or DRUGOTHER will not affect plasma concentrations of DRUGOTHER, but may reduce endogenous plasma levels of DRUG2/ergoDRUG2 by accelerating metabolism.",Phenytoin,calcitriol,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,0,21
655,4127,4127,4228,4228,"DRUGOTHER/DRUG1: The coadministration of DRUG2 or DRUGOTHER will not affect plasma concentrations of DRUGOTHER, but may reduce endogenous plasma levels of DRUGOTHER/ergoDRUGOTHER by accelerating metabolism.",Phenobarbital,phenytoin,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,4
656,4131,4131,4232,4232,"DRUGOTHER/DRUGOTHER: The coadministration of DRUG1 or DRUG2 will not affect plasma concentrations of DRUGOTHER, but may reduce endogenous plasma levels of DRUGOTHER/ergoDRUGOTHER by accelerating metabolism.",phenytoin,phenobarbital,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,4,6
657,4132,4132,4233,4233,"DRUGOTHER/DRUGOTHER: The coadministration of DRUG1 or DRUGOTHER will not affect plasma concentrations of DRUG2, but may reduce endogenous plasma levels of DRUGOTHER/ergoDRUGOTHER by accelerating metabolism.",phenytoin,vitamin D,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,OC(=O)CCCCCCCC(O)=O,4,13
658,4133,4133,4234,4234,"DRUGOTHER/DRUGOTHER: The coadministration of DRUG1 or DRUGOTHER will not affect plasma concentrations of DRUGOTHER, but may reduce endogenous plasma levels of DRUG2/ergoDRUG2 by accelerating metabolism.",phenytoin,calcitriol,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,4,21
659,4138,4138,4239,4239,Some reports have shown that the concomitant administration of DRUG1 with DRUG2 causes hypercalcemia.,thiazides,vitamin D,True,effect,2,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,OC(=O)CCCCCCCC(O)=O,9,11
660,4157,4157,4258,4258,"DRUG1/DRUG2: The coadministration of DRUGOTHER or DRUGOTHER will not affect plasma concentrations of DRUGOTHER, but may reduce endogenous plasma levels of DRUGOTHER/ergoDRUGOTHER by accelerating metabolism.",Phenytoin,Phenobarbital,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,0,0
661,4159,4159,4260,4260,"DRUG1/DRUGOTHER: The coadministration of DRUGOTHER or DRUG2 will not affect plasma concentrations of DRUGOTHER, but may reduce endogenous plasma levels of DRUGOTHER/ergoDRUGOTHER by accelerating metabolism.",Phenytoin,phenobarbital,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,0,6
662,4160,4160,4261,4261,"DRUG1/DRUGOTHER: The coadministration of DRUGOTHER or DRUGOTHER will not affect plasma concentrations of DRUG2, but may reduce endogenous plasma levels of DRUGOTHER/ergoDRUGOTHER by accelerating metabolism.",Phenytoin,vitamin D,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,OC(=O)CCCCCCCC(O)=O,0,13
663,4161,4161,4262,4262,"DRUG1/DRUGOTHER: The coadministration of DRUGOTHER or DRUGOTHER will not affect plasma concentrations of DRUGOTHER, but may reduce endogenous plasma levels of DRUG2/ergoDRUG2 by accelerating metabolism.",Phenytoin,calcitriol,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,0,21
664,4162,4162,4263,4263,"DRUGOTHER/DRUG1: The coadministration of DRUG2 or DRUGOTHER will not affect plasma concentrations of DRUGOTHER, but may reduce endogenous plasma levels of DRUGOTHER/ergoDRUGOTHER by accelerating metabolism.",Phenobarbital,phenytoin,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,4
665,4166,4166,4267,4267,"DRUGOTHER/DRUGOTHER: The coadministration of DRUG1 or DRUG2 will not affect plasma concentrations of DRUGOTHER, but may reduce endogenous plasma levels of DRUGOTHER/ergoDRUGOTHER by accelerating metabolism.",phenytoin,phenobarbital,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,4,6
666,4167,4167,4268,4268,"DRUGOTHER/DRUGOTHER: The coadministration of DRUG1 or DRUGOTHER will not affect plasma concentrations of DRUG2, but may reduce endogenous plasma levels of DRUGOTHER/ergoDRUGOTHER by accelerating metabolism.",phenytoin,vitamin D,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,OC(=O)CCCCCCCC(O)=O,4,13
667,4168,4168,4269,4269,"DRUGOTHER/DRUGOTHER: The coadministration of DRUG1 or DRUGOTHER will not affect plasma concentrations of DRUGOTHER, but may reduce endogenous plasma levels of DRUG2/ergoDRUG2 by accelerating metabolism.",phenytoin,calcitriol,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,4,21
668,4173,4173,4274,4274,Some reports have shown that the concomitant administration of DRUG1 with DRUG2 causes hypercalcemia.,thiazides,vitamin D,True,effect,2,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,OC(=O)CCCCCCCC(O)=O,9,11
669,4191,4191,4292,4292,"No significant drug interactions have been reported in studies of DRUGOTHER given with other drugs such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and oral DRUGOTHER in healthy volunteers, or given with DRUGOTHER to patients with heart failure (NYHA class II and III).",glyburide,hydrochlorothiazide,False,Neg,0,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,17,21
670,4196,4196,4297,4297,"No significant drug interactions have been reported in studies of DRUGOTHER given with other drugs such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and oral DRUGOTHER in healthy volunteers, or given with DRUGOTHER to patients with heart failure (NYHA class II and III).",nifedipine,hydrochlorothiazide,False,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,18,21
671,4200,4200,4301,4301,"No significant drug interactions have been reported in studies of DRUGOTHER given with other drugs such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and oral DRUGOTHER in healthy volunteers, or given with DRUGOTHER to patients with heart failure (NYHA class II and III).",digoxin,hydrochlorothiazide,False,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,19,21
672,4203,4203,4304,4304,"No significant drug interactions have been reported in studies of DRUGOTHER given with other drugs such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and oral DRUGOTHER in healthy volunteers, or given with DRUGOTHER to patients with heart failure (NYHA class II and III).",warfarin,hydrochlorothiazide,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,20,21
673,4206,4206,4307,4307,"No significant drug interactions have been reported in studies of DRUGOTHER given with other drugs such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and oral DRUG2 in healthy volunteers, or given with DRUGOTHER to patients with heart failure (NYHA class II and III).",hydrochlorothiazide,contraceptives,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,21,24
674,4207,4207,4308,4308,"No significant drug interactions have been reported in studies of DRUGOTHER given with other drugs such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and oral DRUGOTHER in healthy volunteers, or given with DRUG2 to patients with heart failure (NYHA class II and III).",hydrochlorothiazide,enalapril,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,21,31
675,4238,4238,4343,4343,"Hypotension   Patients on DRUG1 Therapy: Patients on DRUGOTHER and especially those in whom DRUGOTHER therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of DRUG2.",Diuretic,captopril,False,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,5,51
676,4240,4240,4345,4345,"Hypotension   Patients on DRUGOTHER Therapy: Patients on DRUG1 and especially those in whom DRUGOTHER therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of DRUG2.",diuretics,captopril,True,effect,2,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,9,51
677,4241,4241,4346,4346,"Hypotension   Patients on DRUGOTHER Therapy: Patients on DRUG1s and especially those in whom DRUG1 therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of DRUG2.",diuretic,captopril,False,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,9,51
678,4242,4242,4347,4347,"The possibility of hypotensive effects with DRUG1 can be minimized by either discontinuing the DRUG2 or increasing the salt intake approximately one week prior to initiation of treatment with DRUG1 (DRUG1 tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).",captopril,diuretic,True,effect,2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,6,14
679,4245,4245,4350,4350,"The possibility of hypotensive effects with DRUG2 can be minimized by either discontinuing the DRUG1 or increasing the salt intake approximately one week prior to initiation of treatment with DRUG2 (DRUG2 tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).",diuretic,captopril,False,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,14,6
680,4246,4246,4351,4351,"The possibility of hypotensive effects with DRUG2 can be minimized by either discontinuing the DRUG1 or increasing the salt intake approximately one week prior to initiation of treatment with DRUG2 (DRUG2 tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).",diuretic,captopril,False,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,14,6
681,4249,4249,4354,4354,"therefore, DRUG1 or other DRUGOTHER (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting DRUG2.",nitroglycerin,captopril,True,advise,1,OCC(O)CO,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,1,24
682,4250,4250,4355,4355,"therefore, DRUGOTHER or other DRUG1 (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting DRUG2.",nitrates,captopril,True,advise,1,[N+](=O)([O-])[O-],CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,4,24
683,4251,4251,4356,4356,Agents Causing Renin Release DRUG1's effect will be augmented by DRUG2 that cause renin release.,Captopril,antihypertensive agents,True,effect,2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,4,10
684,4252,4252,4357,4357,"For example, DRUG1 (e.g., DRUG2) may activate the renin-angiotensin-aldosterone system.",diuretics,thiazides,False,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,2,4
685,4253,4253,4358,4358,Agents Affecting Sympathetic Activity The sympathetic nervous system may be especially important in supporting blood pressure in patients receiving DRUG1 alone or with DRUG2.,captopril,diuretics,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,19,23
686,4255,4255,4360,4360,"DRUGOTHER such as DRUG1, DRUG2, or DRUGOTHER, or DRUGOTHER supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum DRUGOTHER.",spironolactone,triamterene,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,3,4
687,4256,4256,4361,4361,"DRUGOTHER such as DRUG1, DRUGOTHER, or DRUG2, or DRUGOTHER supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum DRUGOTHER.",spironolactone,amiloride,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N,3,6
688,4258,4258,4363,4363,"Inhibitors Of Endogenous Prostaglandin Synthesis It has been reported that DRUG1 may reduce the antihypertensive effect of DRUG2, especially in cases of low renin hypertension.",indomethacin,captopril,True,effect,2,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,10,17
689,4260,4260,4365,4365,DRUGOTHER: In a study of young healthy male subjects no evidence of a direct pharmacokinetic DRUG1-DRUG2 interaction could be found.,captopril,digoxin,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,15,15
690,4264,4264,4369,4369,DRUG1: In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when DRUG2 and DRUGOTHER were administered concomitantly for 6 days.,Allopurinol,captopril,False,Neg,0,O=C1N=CN=C2NNC=C12,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,0,14
691,4266,4266,4371,4371,DRUGOTHER: In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when DRUG1 and DRUG2 were administered concomitantly for 6 days.,captopril,allopurinol,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,O=C1N=CN=C2NNC=C12,14,16
692,4282,4282,4387,4387,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of DRUG1 are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER.",EQUETROTM,nefazodone,True,mechanism,4,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,17,38
693,4305,4305,4410,4410,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of DRUGOTHER are the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER.",Acetazolamide,nefazodone,False,Neg,0,CC(=O)NC1=NN=C(S1)S(=O)(=O)N,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,21,38
694,4327,4327,4432,4432,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER.",azole antifungals,nefazodone,False,Neg,0,OC(=O)CCCCCCCCC=C,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,22,38
695,4348,4348,4453,4453,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER.",cimetidine,nefazodone,False,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,23,38
696,4368,4368,4473,4473,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1(1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER.",clarithromycin,nefazodone,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,24,38
697,4387,4387,4492,4492,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER.",danazol,nefazodone,False,Neg,0,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,26,38
698,4405,4405,4510,4510,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER.",delavirdine,nefazodone,False,Neg,0,CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,27,38
699,4422,4422,4527,4527,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER.",diltiazem,nefazodone,False,Neg,0,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,28,38
700,4438,4438,4543,4543,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1(1), DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER.",erythromycin,nefazodone,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,29,38
701,4453,4453,4558,4558,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUG1, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER.",fluoxetine,nefazodone,False,Neg,0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,30,38
702,4467,4467,4572,4572,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUG1, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER.",fluvoxamine,nefazodone,False,Neg,0,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,31,38
703,4480,4480,4585,4585,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, grapefruit juice, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER.",isoniazid,nefazodone,False,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,34,38
704,4492,4492,4597,4597,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER.",itraconazole,nefazodone,False,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,35,38
705,4503,4503,4608,4608,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER.",ketoconazole,nefazodone,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,36,38
706,4513,4513,4618,4618,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER.",loratadine,nefazodone,False,Neg,0,CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,37,38
707,4523,4523,4628,4628,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER.",nefazodone,niacinamide,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,OC(=O)C1=CN=CC=C1,38,39
708,4524,4524,4629,4629,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER.",nefazodone,nicotinamide,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,NC(=O)C1=CC=CN=C1,38,40
709,4525,4525,4630,4630,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER.",nefazodone,propoxyphene,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CCC(=O)O[C@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@H](C)CN(C)C,38,42
710,4526,4526,4631,4631,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER.",nefazodone,quinine,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,38,43
711,4527,4527,4632,4632,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER.",nefazodone,quinupristin,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1,38,44
712,4528,4528,4633,4633,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER(1), DRUGOTHER, DRUGOTHER.",nefazodone,troleandomycin,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,38,45
713,4529,4529,4634,4634,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2(1), DRUGOTHER, DRUGOTHER.",nefazodone,valproate,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CCCC(CCC)C(=O)O,38,46
714,4530,4530,4635,4635,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUG2, DRUGOTHER.",nefazodone,verapamil,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,38,47
715,4531,4531,4636,4636,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(1), DRUGOTHER, DRUG2.",nefazodone,zileuton,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,38,48
716,4572,4572,4677,4677,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of DRUG1 are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2(2), DRUGOTHER, DRUGOTHER, and DRUGOTHER Thus, if a patient has been titrated to a stable dosage on DRUG1, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for DRUG1 may be necessary.",EQUETROTM,Phenytoin,True,mechanism,4,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,17,26
717,4575,4575,4680,4680,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of DRUG1 are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(2), DRUGOTHER, DRUGOTHER, and DRUG2 Thus, if a patient has been titrated to a stable dosage on DRUG1, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for DRUG1 may be necessary.",EQUETROTM,theophylline,True,mechanism,4,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,CN1C2=C(C(=O)N(C1=O)C)NC=N2,17,30
718,4580,4580,4685,4685,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2(2), DRUGOTHER, DRUGOTHER, and DRUGOTHER Thus, if a patient has been titrated to a stable dosage on DRUGOTHER, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for DRUGOTHER may be necessary.",felbamate,Phenytoin,False,Neg,0,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,23,26
719,4583,4583,4688,4688,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER(2), DRUGOTHER, DRUGOTHER, and DRUG2 Thus, if a patient has been titrated to a stable dosage on DRUGOTHER, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for DRUGOTHER may be necessary.",felbamate,theophylline,False,Neg,0,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,23,30
720,4587,4587,4692,4692,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2(2), DRUGOTHER, DRUGOTHER, and DRUGOTHER Thus, if a patient has been titrated to a stable dosage on DRUGOTHER, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for DRUGOTHER may be necessary.",rifampin,Phenytoin,False,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,24,26
721,4590,4590,4695,4695,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER(2), DRUGOTHER, DRUGOTHER, and DRUG2 Thus, if a patient has been titrated to a stable dosage on DRUGOTHER, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for DRUGOTHER may be necessary.",rifampin,theophylline,False,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CN1C2=C(C(=O)N(C1=O)C)NC=N2,24,30
722,4593,4593,4698,4698,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2(2), DRUGOTHER, DRUGOTHER, and DRUGOTHER Thus, if a patient has been titrated to a stable dosage on DRUGOTHER, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for DRUGOTHER may be necessary.",phenobarbital,Phenytoin,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,25,26
723,4596,4596,4701,4701,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER(2), DRUGOTHER, DRUGOTHER, and DRUG2 Thus, if a patient has been titrated to a stable dosage on DRUGOTHER, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for DRUGOTHER may be necessary.",phenobarbital,theophylline,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,25,30
724,4599,4599,4704,4704,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1(2), DRUG2, DRUGOTHER, and DRUGOTHER Thus, if a patient has been titrated to a stable dosage on DRUGOTHER, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for DRUGOTHER may be necessary.",Phenytoin,primidone,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,26,27
725,4600,4600,4705,4705,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1(2), DRUGOTHER, DRUG2, and DRUGOTHER Thus, if a patient has been titrated to a stable dosage on DRUGOTHER, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for DRUGOTHER may be necessary.",Phenytoin,methsuximide,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1(CC(=O)N(C1=O)C)C2=CC=CC=C2,26,28
726,4602,4602,4707,4707,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of DRUG2 are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1(2), DRUGOTHER, DRUGOTHER, and DRUGOTHER Thus, if a patient has been titrated to a stable dosage on DRUG2, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for DRUG2 may be necessary.",Phenytoin,EQUETROTM,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,26,17
727,4603,4603,4708,4708,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of DRUG2 are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1(2), DRUGOTHER, DRUGOTHER, and DRUGOTHER Thus, if a patient has been titrated to a stable dosage on DRUG2, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for DRUG2 may be necessary.",Phenytoin,EQUETROTM,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,26,17
728,4605,4605,4710,4710,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(2), DRUG1, DRUGOTHER, and DRUG2 Thus, if a patient has been titrated to a stable dosage on DRUGOTHER, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for DRUGOTHER may be necessary.",primidone,theophylline,False,Neg,0,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,27,30
729,4608,4608,4713,4713,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(2), DRUGOTHER, DRUG1, and DRUG2 Thus, if a patient has been titrated to a stable dosage on DRUGOTHER, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for DRUGOTHER may be necessary.",methsuximide,theophylline,False,Neg,0,CC1(CC(=O)N(C1=O)C)C2=CC=CC=C2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,28,30
730,4611,4611,4716,4716,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of DRUG2 are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(2), DRUGOTHER, DRUGOTHER, and DRUG1 Thus, if a patient has been titrated to a stable dosage on DRUG2, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for DRUG2 may be necessary.",theophylline,EQUETROTM,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,30,17
731,4612,4612,4717,4717,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of DRUG2 are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(2), DRUGOTHER, DRUGOTHER, and DRUG1 Thus, if a patient has been titrated to a stable dosage on DRUG2, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for DRUG2 may be necessary.",theophylline,EQUETROTM,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,30,17
732,4618,4618,4723,4723,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUG1 due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",EQUETROTM,bupropion,True,mechanism,4,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,17,30
733,4628,4628,4733,4733,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUG1 due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",EQUETROTM,doxycycline,True,mechanism,4,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,17,41
734,4629,4629,4734,4734,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUG1 due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",EQUETROTM,ethosuximide,True,mechanism,4,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,CCC1(C)CC(=O)NC1=O,17,42
735,4633,4633,4738,4738,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUG1 due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",EQUETROTM,haloperidol,True,mechanism,4,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,17,46
736,4645,4645,4750,4750,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUG1 due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG2(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",EQUETROTM,Phenytoin,True,mechanism,4,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,17,59
737,4649,4649,4754,4754,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUG1 due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",EQUETROTM,theophylline,True,mechanism,4,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,CN1C2=C(C(=O)N(C1=O)C)NC=N2,17,64
738,4650,4650,4755,4755,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUG1 due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",EQUETROTM,topiramate,True,mechanism,4,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,17,65
739,4656,4656,4761,4761,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUG1 due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",EQUETROTM,ziprasidone,True,mechanism,4,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,17,72
740,4660,4660,4765,4765,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",Acetaminophen,bupropion,False,Neg,0,CC(=O)NC1=CC=C(C=C1)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,27,30
741,4670,4670,4775,4775,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",Acetaminophen,doxycycline,False,Neg,0,CC(=O)NC1=CC=C(C=C1)O,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,27,41
742,4671,4671,4776,4776,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",Acetaminophen,ethosuximide,False,Neg,0,CC(=O)NC1=CC=C(C=C1)O,CCC1(C)CC(=O)NC1=O,27,42
743,4675,4675,4780,4780,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",Acetaminophen,haloperidol,False,Neg,0,CC(=O)NC1=CC=C(C=C1)O,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,27,46
744,4687,4687,4792,4792,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG2(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",Acetaminophen,Phenytoin,False,Neg,0,CC(=O)NC1=CC=C(C=C1)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,27,59
745,4691,4691,4796,4796,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",Acetaminophen,theophylline,False,Neg,0,CC(=O)NC1=CC=C(C=C1)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,27,64
746,4692,4692,4797,4797,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",Acetaminophen,topiramate,False,Neg,0,CC(=O)NC1=CC=C(C=C1)O,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,27,65
747,4698,4698,4803,4803,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",Acetaminophen,ziprasidone,False,Neg,0,CC(=O)NC1=CC=C(C=C1)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,27,72
748,4701,4701,4806,4806,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",alprazolam,bupropion,False,Neg,0,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,28,30
749,4711,4711,4816,4816,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",alprazolam,doxycycline,False,Neg,0,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,28,41
750,4712,4712,4817,4817,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",alprazolam,ethosuximide,False,Neg,0,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12,CCC1(C)CC(=O)NC1=O,28,42
751,4716,4716,4821,4821,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",alprazolam,haloperidol,False,Neg,0,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,28,46
752,4728,4728,4833,4833,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG2(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",alprazolam,Phenytoin,False,Neg,0,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,28,59
753,4732,4732,4837,4837,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",alprazolam,theophylline,False,Neg,0,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12,CN1C2=C(C(=O)N(C1=O)C)NC=N2,28,64
754,4733,4733,4838,4838,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",alprazolam,topiramate,False,Neg,0,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,28,65
755,4739,4739,4844,4844,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",alprazolam,ziprasidone,False,Neg,0,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,28,72
756,4741,4741,4846,4846,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",amitriptyline,bupropion,False,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,29,30
757,4751,4751,4856,4856,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",amitriptyline,doxycycline,False,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,29,41
758,4752,4752,4857,4857,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",amitriptyline,ethosuximide,False,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CCC1(C)CC(=O)NC1=O,29,42
759,4756,4756,4861,4861,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",amitriptyline,haloperidol,False,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,29,46
760,4768,4768,4873,4873,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG2(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",amitriptyline,Phenytoin,False,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,29,59
761,4772,4772,4877,4877,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",amitriptyline,theophylline,False,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN1C2=C(C(=O)N(C1=O)C)NC=N2,29,64
762,4773,4773,4878,4878,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",amitriptyline,topiramate,False,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,29,65
763,4779,4779,4884,4884,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",amitriptyline,ziprasidone,False,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,29,72
764,4781,4781,4886,4886,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,citalopram,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,30,32
765,4782,4782,4887,4887,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,clobazam,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O,30,33
766,4783,4783,4888,4888,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,clonazepam,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,30,34
767,4784,4784,4889,4889,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,clozapine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1,30,35
768,4785,4785,4890,4890,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,cyclosporin,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,30,36
769,4786,4786,4891,4891,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,delavirdine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C,30,37
770,4787,4787,4892,4892,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,desipramine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,30,38
771,4788,4788,4893,4893,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,diazepam,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,30,39
772,4789,4789,4894,4894,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,dicumarol,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2,30,40
773,4792,4792,4897,4897,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,felbamate,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,30,43
774,4793,4793,4898,4898,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,felodipine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,30,44
775,4794,4794,4899,4899,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,glucocorticoids,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1,30,45
776,4796,4796,4901,4901,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,itraconazole,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,30,47
777,4797,4797,4902,4902,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,lamotrigine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,30,48
778,4798,4798,4903,4903,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,levothyroxine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)O)N,30,49
779,4799,4799,4904,4904,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,lorazepam,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,30,50
780,4800,4800,4905,4905,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,methadone,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,30,51
781,4801,4801,4906,4906,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,midazolam,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,30,52
782,4802,4802,4907,4907,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,mirtazapine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,30,53
783,4803,4803,4908,4908,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,nortriptyline,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,30,54
784,4804,4804,4909,4909,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,olanzapine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12,30,55
785,4805,4805,4910,4910,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUG2(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,contraceptives,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,30,57
786,4806,4806,4911,4911,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUG2, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,oxcarbazepine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2,30,58
787,4808,4808,4913,4913,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,praziquantel,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,O=C(C1CCCCC1)N1CC2N(CCC3=CC=CC=C23)C(=O)C1,30,60
788,4809,4809,4914,4914,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,quetiapine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12,30,62
789,4810,4810,4915,4915,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,risperidone,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,30,63
790,4813,4813,4918,4918,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,tiagabine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F,30,66
791,4814,4814,4919,4919,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,tramadol,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,30,67
792,4815,4815,4920,4920,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,triazolam,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1,30,68
793,4816,4816,4921,4921,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,valproate,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCCC(CCC)C(=O)O,30,69
794,4817,4817,4922,4922,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2(5) , DRUGOTHER, and DRUGOTHER.",bupropion,warfarin,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,30,70
795,4819,4819,4924,4924,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUG2.",bupropion,zonisamide,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,NS(=O)(=O)CC1=NOC2=CC=CC=C12,30,74
796,4828,4828,4933,4933,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",citalopram,doxycycline,False,Neg,0,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,32,41
797,4829,4829,4934,4934,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",citalopram,ethosuximide,False,Neg,0,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CCC1(C)CC(=O)NC1=O,32,42
798,4833,4833,4938,4938,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",citalopram,haloperidol,False,Neg,0,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,32,46
799,4845,4845,4950,4950,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG2(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",citalopram,Phenytoin,False,Neg,0,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,32,59
800,4849,4849,4954,4954,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",citalopram,theophylline,False,Neg,0,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CN1C2=C(C(=O)N(C1=O)C)NC=N2,32,64
801,4850,4850,4955,4955,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",citalopram,topiramate,False,Neg,0,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,32,65
802,4856,4856,4961,4961,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",citalopram,ziprasidone,False,Neg,0,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,32,72
803,4865,4865,4970,4970,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",clobazam,doxycycline,False,Neg,0,CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,33,41
804,4866,4866,4971,4971,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",clobazam,ethosuximide,False,Neg,0,CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O,CCC1(C)CC(=O)NC1=O,33,42
805,4870,4870,4975,4975,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",clobazam,haloperidol,False,Neg,0,CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,33,46
806,4882,4882,4987,4987,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG2(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",clobazam,Phenytoin,False,Neg,0,CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,33,59
807,4886,4886,4991,4991,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",clobazam,theophylline,False,Neg,0,CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,33,64
808,4887,4887,4992,4992,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",clobazam,topiramate,False,Neg,0,CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,33,65
809,4893,4893,4998,4998,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",clobazam,ziprasidone,False,Neg,0,CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,33,72
810,4901,4901,5006,5006,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",clonazepam,doxycycline,False,Neg,0,[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,34,41
811,4902,4902,5007,5007,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",clonazepam,ethosuximide,False,Neg,0,[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,CCC1(C)CC(=O)NC1=O,34,42
812,4906,4906,5011,5011,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",clonazepam,haloperidol,False,Neg,0,[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,34,46
813,4918,4918,5023,5023,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG2(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",clonazepam,Phenytoin,False,Neg,0,[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,34,59
814,4922,4922,5027,5027,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",clonazepam,theophylline,False,Neg,0,[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,34,64
815,4923,4923,5028,5028,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",clonazepam,topiramate,False,Neg,0,[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,34,65
816,4929,4929,5034,5034,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",clonazepam,ziprasidone,False,Neg,0,[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,34,72
817,4936,4936,5041,5041,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",clozapine,doxycycline,False,Neg,0,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,35,41
818,4937,4937,5042,5042,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",clozapine,ethosuximide,False,Neg,0,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1,CCC1(C)CC(=O)NC1=O,35,42
819,4941,4941,5046,5046,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",clozapine,haloperidol,False,Neg,0,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,35,46
820,4953,4953,5058,5058,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG2(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",clozapine,Phenytoin,False,Neg,0,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,35,59
821,4957,4957,5062,5062,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",clozapine,theophylline,False,Neg,0,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,35,64
822,4958,4958,5063,5063,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",clozapine,topiramate,False,Neg,0,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,35,65
823,4964,4964,5069,5069,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",clozapine,ziprasidone,False,Neg,0,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,35,72
824,4970,4970,5075,5075,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",cyclosporin,doxycycline,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,36,41
825,4971,4971,5076,5076,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",cyclosporin,ethosuximide,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CCC1(C)CC(=O)NC1=O,36,42
826,4975,4975,5080,5080,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",cyclosporin,haloperidol,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,36,46
827,4987,4987,5092,5092,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG2(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",cyclosporin,Phenytoin,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,36,59
828,4991,4991,5096,5096,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",cyclosporin,theophylline,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CN1C2=C(C(=O)N(C1=O)C)NC=N2,36,64
829,4992,4992,5097,5097,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",cyclosporin,topiramate,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,36,65
830,4998,4998,5103,5103,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",cyclosporin,ziprasidone,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,36,72
831,5003,5003,5108,5108,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",delavirdine,doxycycline,False,Neg,0,CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,37,41
832,5004,5004,5109,5109,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",delavirdine,ethosuximide,False,Neg,0,CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C,CCC1(C)CC(=O)NC1=O,37,42
833,5008,5008,5113,5113,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",delavirdine,haloperidol,False,Neg,0,CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,37,46
834,5020,5020,5125,5125,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG2(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",delavirdine,Phenytoin,False,Neg,0,CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,37,59
835,5024,5024,5129,5129,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",delavirdine,theophylline,False,Neg,0,CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C,CN1C2=C(C(=O)N(C1=O)C)NC=N2,37,64
836,5025,5025,5130,5130,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",delavirdine,topiramate,False,Neg,0,CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,37,65
837,5031,5031,5136,5136,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",delavirdine,ziprasidone,False,Neg,0,CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,37,72
838,5035,5035,5140,5140,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",desipramine,doxycycline,False,Neg,0,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,38,41
839,5036,5036,5141,5141,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",desipramine,ethosuximide,False,Neg,0,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CCC1(C)CC(=O)NC1=O,38,42
840,5040,5040,5145,5145,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",desipramine,haloperidol,False,Neg,0,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,38,46
841,5052,5052,5157,5157,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG2(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",desipramine,Phenytoin,False,Neg,0,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,38,59
842,5056,5056,5161,5161,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",desipramine,theophylline,False,Neg,0,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CN1C2=C(C(=O)N(C1=O)C)NC=N2,38,64
843,5057,5057,5162,5162,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",desipramine,topiramate,False,Neg,0,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,38,65
844,5063,5063,5168,5168,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",desipramine,ziprasidone,False,Neg,0,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,38,72
845,5066,5066,5171,5171,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",diazepam,doxycycline,False,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,39,41
846,5067,5067,5172,5172,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",diazepam,ethosuximide,False,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,CCC1(C)CC(=O)NC1=O,39,42
847,5071,5071,5176,5176,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",diazepam,haloperidol,False,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,39,46
848,5083,5083,5188,5188,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG2(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",diazepam,Phenytoin,False,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,39,59
849,5087,5087,5192,5192,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",diazepam,theophylline,False,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,CN1C2=C(C(=O)N(C1=O)C)NC=N2,39,64
850,5088,5088,5193,5193,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",diazepam,topiramate,False,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,39,65
851,5094,5094,5199,5199,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",diazepam,ziprasidone,False,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,39,72
852,5096,5096,5201,5201,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",dicumarol,doxycycline,False,Neg,0,OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,40,41
853,5097,5097,5202,5202,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",dicumarol,ethosuximide,False,Neg,0,OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2,CCC1(C)CC(=O)NC1=O,40,42
854,5101,5101,5206,5206,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",dicumarol,haloperidol,False,Neg,0,OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,40,46
855,5113,5113,5218,5218,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG2(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",dicumarol,Phenytoin,False,Neg,0,OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,40,59
856,5117,5117,5222,5222,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",dicumarol,theophylline,False,Neg,0,OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,40,64
857,5118,5118,5223,5223,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",dicumarol,topiramate,False,Neg,0,OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,40,65
858,5124,5124,5229,5229,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",dicumarol,ziprasidone,False,Neg,0,OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,40,72
859,5127,5127,5232,5232,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",doxycycline,felbamate,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,41,43
860,5128,5128,5233,5233,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",doxycycline,felodipine,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,41,44
861,5129,5129,5234,5234,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",doxycycline,glucocorticoids,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1,41,45
862,5131,5131,5236,5236,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",doxycycline,itraconazole,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,41,47
863,5132,5132,5237,5237,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",doxycycline,lamotrigine,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,41,48
864,5133,5133,5238,5238,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",doxycycline,levothyroxine,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)O)N,41,49
865,5134,5134,5239,5239,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",doxycycline,lorazepam,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,41,50
866,5135,5135,5240,5240,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",doxycycline,methadone,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,41,51
867,5136,5136,5241,5241,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",doxycycline,midazolam,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,41,52
868,5137,5137,5242,5242,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",doxycycline,mirtazapine,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,41,53
869,5138,5138,5243,5243,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",doxycycline,nortriptyline,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,41,54
870,5139,5139,5244,5244,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",doxycycline,olanzapine,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12,41,55
871,5140,5140,5245,5245,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUG2(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",doxycycline,contraceptives,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,41,57
872,5141,5141,5246,5246,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUG2, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",doxycycline,oxcarbazepine,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2,41,58
873,5143,5143,5248,5248,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",doxycycline,praziquantel,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,O=C(C1CCCCC1)N1CC2N(CCC3=CC=CC=C23)C(=O)C1,41,60
874,5144,5144,5249,5249,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",doxycycline,quetiapine,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12,41,62
875,5145,5145,5250,5250,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",doxycycline,risperidone,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,41,63
876,5148,5148,5253,5253,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",doxycycline,tiagabine,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F,41,66
877,5149,5149,5254,5254,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",doxycycline,tramadol,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,41,67
878,5150,5150,5255,5255,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",doxycycline,triazolam,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1,41,68
879,5151,5151,5256,5256,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",doxycycline,valproate,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CCCC(CCC)C(=O)O,41,69
880,5152,5152,5257,5257,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2(5) , DRUGOTHER, and DRUGOTHER.",doxycycline,warfarin,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,41,70
881,5154,5154,5259,5259,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUG2.",doxycycline,zonisamide,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,NS(=O)(=O)CC1=NOC2=CC=CC=C12,41,74
882,5155,5155,5260,5260,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",ethosuximide,felbamate,False,Neg,0,CCC1(C)CC(=O)NC1=O,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,42,43
883,5156,5156,5261,5261,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",ethosuximide,felodipine,False,Neg,0,CCC1(C)CC(=O)NC1=O,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,42,44
884,5157,5157,5262,5262,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",ethosuximide,glucocorticoids,False,Neg,0,CCC1(C)CC(=O)NC1=O,COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1,42,45
885,5159,5159,5264,5264,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",ethosuximide,itraconazole,False,Neg,0,CCC1(C)CC(=O)NC1=O,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,42,47
886,5160,5160,5265,5265,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",ethosuximide,lamotrigine,False,Neg,0,CCC1(C)CC(=O)NC1=O,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,42,48
887,5161,5161,5266,5266,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",ethosuximide,levothyroxine,False,Neg,0,CCC1(C)CC(=O)NC1=O,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)O)N,42,49
888,5162,5162,5267,5267,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",ethosuximide,lorazepam,False,Neg,0,CCC1(C)CC(=O)NC1=O,C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,42,50
889,5163,5163,5268,5268,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",ethosuximide,methadone,False,Neg,0,CCC1(C)CC(=O)NC1=O,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,42,51
890,5164,5164,5269,5269,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",ethosuximide,midazolam,False,Neg,0,CCC1(C)CC(=O)NC1=O,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,42,52
891,5165,5165,5270,5270,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",ethosuximide,mirtazapine,False,Neg,0,CCC1(C)CC(=O)NC1=O,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,42,53
892,5166,5166,5271,5271,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",ethosuximide,nortriptyline,False,Neg,0,CCC1(C)CC(=O)NC1=O,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,42,54
893,5167,5167,5272,5272,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",ethosuximide,olanzapine,False,Neg,0,CCC1(C)CC(=O)NC1=O,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12,42,55
894,5168,5168,5273,5273,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUG2(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",ethosuximide,contraceptives,False,Neg,0,CCC1(C)CC(=O)NC1=O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,42,57
895,5169,5169,5274,5274,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUG2, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",ethosuximide,oxcarbazepine,False,Neg,0,CCC1(C)CC(=O)NC1=O,NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2,42,58
896,5171,5171,5276,5276,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",ethosuximide,praziquantel,False,Neg,0,CCC1(C)CC(=O)NC1=O,O=C(C1CCCCC1)N1CC2N(CCC3=CC=CC=C23)C(=O)C1,42,60
897,5172,5172,5277,5277,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",ethosuximide,quetiapine,False,Neg,0,CCC1(C)CC(=O)NC1=O,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12,42,62
898,5173,5173,5278,5278,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",ethosuximide,risperidone,False,Neg,0,CCC1(C)CC(=O)NC1=O,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,42,63
899,5176,5176,5281,5281,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",ethosuximide,tiagabine,False,Neg,0,CCC1(C)CC(=O)NC1=O,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F,42,66
900,5177,5177,5282,5282,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",ethosuximide,tramadol,False,Neg,0,CCC1(C)CC(=O)NC1=O,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,42,67
901,5178,5178,5283,5283,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",ethosuximide,triazolam,False,Neg,0,CCC1(C)CC(=O)NC1=O,O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1,42,68
902,5179,5179,5284,5284,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",ethosuximide,valproate,False,Neg,0,CCC1(C)CC(=O)NC1=O,CCCC(CCC)C(=O)O,42,69
903,5180,5180,5285,5285,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2(5) , DRUGOTHER, and DRUGOTHER.",ethosuximide,warfarin,False,Neg,0,CCC1(C)CC(=O)NC1=O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,42,70
904,5182,5182,5287,5287,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUG2.",ethosuximide,zonisamide,False,Neg,0,CCC1(C)CC(=O)NC1=O,NS(=O)(=O)CC1=NOC2=CC=CC=C12,42,74
905,5185,5185,5290,5290,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",felbamate,haloperidol,False,Neg,0,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,43,46
906,5197,5197,5302,5302,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG2(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",felbamate,Phenytoin,False,Neg,0,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,43,59
907,5201,5201,5306,5306,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",felbamate,theophylline,False,Neg,0,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,43,64
908,5202,5202,5307,5307,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",felbamate,topiramate,False,Neg,0,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,43,65
909,5208,5208,5313,5313,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",felbamate,ziprasidone,False,Neg,0,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,43,72
910,5211,5211,5316,5316,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",felodipine,haloperidol,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,44,46
911,5223,5223,5328,5328,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG2(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",felodipine,Phenytoin,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,44,59
912,5227,5227,5332,5332,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",felodipine,theophylline,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,CN1C2=C(C(=O)N(C1=O)C)NC=N2,44,64
913,5228,5228,5333,5333,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",felodipine,topiramate,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,44,65
914,5234,5234,5339,5339,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",felodipine,ziprasidone,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,44,72
915,5236,5236,5341,5341,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",glucocorticoids,haloperidol,False,Neg,0,COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,45,46
916,5248,5248,5353,5353,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG2(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",glucocorticoids,Phenytoin,False,Neg,0,COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,45,59
917,5252,5252,5357,5357,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",glucocorticoids,theophylline,False,Neg,0,COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,45,64
918,5253,5253,5358,5358,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",glucocorticoids,topiramate,False,Neg,0,COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,45,65
919,5259,5259,5364,5364,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",glucocorticoids,ziprasidone,False,Neg,0,COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,45,72
920,5261,5261,5366,5366,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",haloperidol,itraconazole,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,46,47
921,5262,5262,5367,5367,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",haloperidol,lamotrigine,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,46,48
922,5263,5263,5368,5368,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",haloperidol,levothyroxine,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)O)N,46,49
923,5264,5264,5369,5369,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",haloperidol,lorazepam,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,46,50
924,5265,5265,5370,5370,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",haloperidol,methadone,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,46,51
925,5266,5266,5371,5371,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",haloperidol,midazolam,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,46,52
926,5267,5267,5372,5372,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",haloperidol,mirtazapine,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,46,53
927,5268,5268,5373,5373,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",haloperidol,nortriptyline,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,46,54
928,5269,5269,5374,5374,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",haloperidol,olanzapine,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12,46,55
929,5270,5270,5375,5375,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUG2(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",haloperidol,contraceptives,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,46,57
930,5271,5271,5376,5376,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUG2, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",haloperidol,oxcarbazepine,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2,46,58
931,5273,5273,5378,5378,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",haloperidol,praziquantel,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,O=C(C1CCCCC1)N1CC2N(CCC3=CC=CC=C23)C(=O)C1,46,60
932,5274,5274,5379,5379,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",haloperidol,quetiapine,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12,46,62
933,5275,5275,5380,5380,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",haloperidol,risperidone,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,46,63
934,5278,5278,5383,5383,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",haloperidol,tiagabine,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F,46,66
935,5279,5279,5384,5384,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",haloperidol,tramadol,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,46,67
936,5280,5280,5385,5385,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",haloperidol,triazolam,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1,46,68
937,5281,5281,5386,5386,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",haloperidol,valproate,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CCCC(CCC)C(=O)O,46,69
938,5282,5282,5387,5387,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2(5) , DRUGOTHER, and DRUGOTHER.",haloperidol,warfarin,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,46,70
939,5284,5284,5389,5389,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUG2.",haloperidol,zonisamide,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,NS(=O)(=O)CC1=NOC2=CC=CC=C12,46,74
940,5295,5295,5400,5400,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG2(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",itraconazole,Phenytoin,False,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,47,59
941,5299,5299,5404,5404,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",itraconazole,theophylline,False,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CN1C2=C(C(=O)N(C1=O)C)NC=N2,47,64
942,5300,5300,5405,5405,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",itraconazole,topiramate,False,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,47,65
943,5306,5306,5411,5411,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",itraconazole,ziprasidone,False,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,47,72
944,5317,5317,5422,5422,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG2(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",lamotrigine,Phenytoin,False,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,48,59
945,5321,5321,5426,5426,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",lamotrigine,theophylline,False,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,48,64
946,5322,5322,5427,5427,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",lamotrigine,topiramate,False,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,48,65
947,5328,5328,5433,5433,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",lamotrigine,ziprasidone,False,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,48,72
948,5338,5338,5443,5443,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG2(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",levothyroxine,Phenytoin,False,Neg,0,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)O)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,49,59
949,5342,5342,5447,5447,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",levothyroxine,theophylline,False,Neg,0,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)O)N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,49,64
950,5343,5343,5448,5448,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",levothyroxine,topiramate,False,Neg,0,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)O)N,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,49,65
951,5349,5349,5454,5454,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",levothyroxine,ziprasidone,False,Neg,0,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)O)N,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,49,72
952,5358,5358,5463,5463,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG2(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",lorazepam,Phenytoin,False,Neg,0,C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,50,59
953,5362,5362,5467,5467,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",lorazepam,theophylline,False,Neg,0,C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,CN1C2=C(C(=O)N(C1=O)C)NC=N2,50,64
954,5363,5363,5468,5468,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",lorazepam,topiramate,False,Neg,0,C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,50,65
955,5369,5369,5474,5474,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",lorazepam,ziprasidone,False,Neg,0,C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,50,72
956,5377,5377,5482,5482,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG2(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",methadone,Phenytoin,False,Neg,0,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,51,59
957,5381,5381,5486,5486,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",methadone,theophylline,False,Neg,0,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,51,64
958,5382,5382,5487,5487,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",methadone,topiramate,False,Neg,0,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,51,65
959,5388,5388,5493,5493,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",methadone,ziprasidone,False,Neg,0,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,51,72
960,5395,5395,5500,5500,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG2(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",midazolam,Phenytoin,False,Neg,0,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,52,59
961,5399,5399,5504,5504,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",midazolam,theophylline,False,Neg,0,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,CN1C2=C(C(=O)N(C1=O)C)NC=N2,52,64
962,5400,5400,5505,5505,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",midazolam,topiramate,False,Neg,0,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,52,65
963,5406,5406,5511,5511,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",midazolam,ziprasidone,False,Neg,0,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,52,72
964,5412,5412,5517,5517,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG2(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",mirtazapine,Phenytoin,False,Neg,0,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,53,59
965,5416,5416,5521,5521,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",mirtazapine,theophylline,False,Neg,0,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,CN1C2=C(C(=O)N(C1=O)C)NC=N2,53,64
966,5417,5417,5522,5522,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",mirtazapine,topiramate,False,Neg,0,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,53,65
967,5423,5423,5528,5528,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",mirtazapine,ziprasidone,False,Neg,0,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,53,72
968,5428,5428,5533,5533,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG2(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",nortriptyline,Phenytoin,False,Neg,0,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,54,59
969,5432,5432,5537,5537,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",nortriptyline,theophylline,False,Neg,0,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN1C2=C(C(=O)N(C1=O)C)NC=N2,54,64
970,5433,5433,5538,5538,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",nortriptyline,topiramate,False,Neg,0,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,54,65
971,5439,5439,5544,5544,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",nortriptyline,ziprasidone,False,Neg,0,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,54,72
972,5443,5443,5548,5548,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, oral DRUGOTHER(3), DRUGOTHER, DRUG2(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",olanzapine,Phenytoin,False,Neg,0,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,55,59
973,5447,5447,5552,5552,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",olanzapine,theophylline,False,Neg,0,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12,CN1C2=C(C(=O)N(C1=O)C)NC=N2,55,64
974,5448,5448,5553,5553,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",olanzapine,topiramate,False,Neg,0,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,55,65
975,5454,5454,5559,5559,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",olanzapine,ziprasidone,False,Neg,0,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,55,72
976,5457,5457,5562,5562,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUG1(3), DRUGOTHER, DRUG2(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",contraceptives,Phenytoin,False,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,57,59
977,5461,5461,5566,5566,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUG1(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",contraceptives,theophylline,False,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,CN1C2=C(C(=O)N(C1=O)C)NC=N2,57,64
978,5462,5462,5567,5567,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUG1(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",contraceptives,topiramate,False,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,57,65
979,5468,5468,5573,5573,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUG1(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",contraceptives,ziprasidone,False,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,57,72
980,5470,5470,5575,5575,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUG1, DRUG2(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",oxcarbazepine,Phenytoin,False,Neg,0,NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,58,59
981,5474,5474,5579,5579,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUG1, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",oxcarbazepine,theophylline,False,Neg,0,NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,58,64
982,5475,5475,5580,5580,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUG1, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",oxcarbazepine,topiramate,False,Neg,0,NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,58,65
983,5481,5481,5586,5586,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUG1, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",oxcarbazepine,ziprasidone,False,Neg,0,NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,58,72
984,5483,5483,5588,5588,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG1(4), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",Phenytoin,praziquantel,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,O=C(C1CCCCC1)N1CC2N(CCC3=CC=CC=C23)C(=O)C1,59,60
985,5484,5484,5589,5589,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG1(4), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",Phenytoin,quetiapine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12,59,62
986,5485,5485,5590,5590,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG1(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",Phenytoin,risperidone,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,59,63
987,5488,5488,5593,5593,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG1(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",Phenytoin,tiagabine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F,59,66
988,5489,5489,5594,5594,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG1(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",Phenytoin,tramadol,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,59,67
989,5490,5490,5595,5595,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG1(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",Phenytoin,triazolam,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1,59,68
990,5491,5491,5596,5596,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG1(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",Phenytoin,valproate,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCCC(CCC)C(=O)O,59,69
991,5492,5492,5597,5597,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG1(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2(5) , DRUGOTHER, and DRUGOTHER.",Phenytoin,warfarin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,59,70
992,5494,5494,5599,5599,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG1(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUG2.",Phenytoin,zonisamide,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NS(=O)(=O)CC1=NOC2=CC=CC=C12,59,74
993,5497,5497,5602,5602,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",praziquantel,theophylline,False,Neg,0,O=C(C1CCCCC1)N1CC2N(CCC3=CC=CC=C23)C(=O)C1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,60,64
994,5498,5498,5603,5603,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",praziquantel,topiramate,False,Neg,0,O=C(C1CCCCC1)N1CC2N(CCC3=CC=CC=C23)C(=O)C1,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,60,65
995,5504,5504,5609,5609,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",praziquantel,ziprasidone,False,Neg,0,O=C(C1CCCCC1)N1CC2N(CCC3=CC=CC=C23)C(=O)C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,60,72
996,5507,5507,5612,5612,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",quetiapine,theophylline,False,Neg,0,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12,CN1C2=C(C(=O)N(C1=O)C)NC=N2,62,64
997,5508,5508,5613,5613,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",quetiapine,topiramate,False,Neg,0,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,62,65
998,5514,5514,5619,5619,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",quetiapine,ziprasidone,False,Neg,0,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,62,72
999,5516,5516,5621,5621,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",risperidone,theophylline,False,Neg,0,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,63,64
1000,5517,5517,5622,5622,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",risperidone,topiramate,False,Neg,0,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,63,65
1001,5523,5523,5628,5628,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",risperidone,ziprasidone,False,Neg,0,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,63,72
1002,5526,5526,5631,5631,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",theophylline,tiagabine,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F,64,66
1003,5527,5527,5632,5632,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",theophylline,tramadol,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,64,67
1004,5528,5528,5633,5633,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",theophylline,triazolam,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1,64,68
1005,5529,5529,5634,5634,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",theophylline,valproate,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CCCC(CCC)C(=O)O,64,69
1006,5530,5530,5635,5635,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2(5) , DRUGOTHER, and DRUGOTHER.",theophylline,warfarin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,64,70
1007,5532,5532,5637,5637,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUG2.",theophylline,zonisamide,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,NS(=O)(=O)CC1=NOC2=CC=CC=C12,64,74
1008,5533,5533,5638,5638,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",topiramate,tiagabine,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F,65,66
1009,5534,5534,5639,5639,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",topiramate,tramadol,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,65,67
1010,5535,5535,5640,5640,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",topiramate,triazolam,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1,65,68
1011,5536,5536,5641,5641,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",topiramate,valproate,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,CCCC(CCC)C(=O)O,65,69
1012,5537,5537,5642,5642,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2(5) , DRUGOTHER, and DRUGOTHER.",topiramate,warfarin,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,65,70
1013,5539,5539,5644,5644,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUG2.",topiramate,zonisamide,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,NS(=O)(=O)CC1=NOC2=CC=CC=C12,65,74
1014,5544,5544,5649,5649,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",tiagabine,ziprasidone,False,Neg,0,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,66,72
1015,5549,5549,5654,5654,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",tramadol,ziprasidone,False,Neg,0,CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,67,72
1016,5553,5553,5658,5658,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",triazolam,ziprasidone,False,Neg,0,O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,68,72
1017,5556,5556,5661,5661,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",valproate,ziprasidone,False,Neg,0,CCCC(CCC)C(=O)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,69,72
1018,5558,5558,5663,5663,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1(5) , DRUG2, and DRUGOTHER.",warfarin,ziprasidone,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,70,72
1019,5560,5560,5665,5665,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG1, and DRUG2.",ziprasidone,zonisamide,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,NS(=O)(=O)CC1=NOC2=CC=CC=C12,72,74
1020,5562,5562,5667,5667,"Agents with Increased Levels in the Presence of DRUG1: DRUGOTHER increases the plasma levels of the following agents: DRUGOTHER, DRUG2(6), and DRUGOTHER Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with DRUGOTHER, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.",Carbamazepine,Phenytoin,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,8,19
1021,5565,5565,5670,5670,"Agents with Increased Levels in the Presence of DRUGOTHER: DRUG1 increases the plasma levels of the following agents: DRUGOTHER, DRUG2(6), and DRUGOTHER Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with DRUG1, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.",EQUETROTM,Phenytoin,True,mechanism,4,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,9,19
1022,5568,5568,5673,5673,"Agents with Increased Levels in the Presence of DRUGOTHER: DRUGOTHER increases the plasma levels of the following agents: DRUGOTHER, DRUG1(6), and DRUG2 Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with DRUGOTHER, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.",Phenytoin,primidone,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,19,21
1023,5569,5569,5674,5674,"Agents with Increased Levels in the Presence of DRUGOTHER: DRUG2 increases the plasma levels of the following agents: DRUGOTHER, DRUG1(6), and DRUGOTHER Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with DRUG2, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.",Phenytoin,EQUETROTM,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,19,9
1024,5601,5601,5709,5709,"In addition, the beneficial effects of DRUG1 in Parkinsons disease have been reported to be reversed by DRUG2 and DRUGOTHER.",levodopa,phenytoin,True,effect,2,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,6,17
1025,5619,5619,5736,5736,"DRUG1 may enhance the effects of DRUGOTHER, DRUGOTHER, DRUGOTHER, and other DRUG2.",Antihistamines,CNS depressants,True,effect,2,NCCC1=CNC=N1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,0,11
1026,5622,5622,5739,5739,"DRUGOTHER may enhance the effects of DRUG1, DRUGOTHER, DRUGOTHER, and other DRUG2.",tricyclic antidepressants,CNS depressants,False,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,6,11
1027,5624,5624,5741,5741,"DRUGOTHER may enhance the effects of DRUGOTHER, DRUG1, DRUGOTHER, and other DRUG2.",barbiturates,CNS depressants,False,Neg,0,CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,7,11
1028,5625,5625,5742,5742,"DRUGOTHER may enhance the effects of DRUGOTHER, DRUGOTHER, DRUG1, and other DRUG2.",alcohol,CNS depressants,False,Neg,0,CCO,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,8,11
1029,5691,5691,5809,5809,"Clinical studies in healthy volunteers show that the pharmacokinetics of DRUG1 are not altered by DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER.",CANCIDAS,itraconazole,False,Neg,0,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,10,15
1030,5692,5692,5810,5810,"Clinical studies in healthy volunteers show that the pharmacokinetics of DRUG1 are not altered by DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER.",CANCIDAS,amphotericin B,False,Neg,0,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,C[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O,10,16
1031,5693,5693,5811,5811,"Clinical studies in healthy volunteers show that the pharmacokinetics of DRUG1 are not altered by DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER.",CANCIDAS,mycophenolate,False,Neg,0,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,COC1=C(C\C=C(/C)CCC(=O)OCCN2CCOCC2)C(O)=C2C(=O)OCC2=C1C,10,17
1032,5694,5694,5812,5812,"Clinical studies in healthy volunteers show that the pharmacokinetics of DRUG1 are not altered by DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER.",CANCIDAS,nelfinavir,False,Neg,0,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,10,18
1033,5695,5695,5813,5813,"Clinical studies in healthy volunteers show that the pharmacokinetics of DRUG1 are not altered by DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2.",CANCIDAS,tacrolimus,False,Neg,0,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,10,20
1034,5706,5706,5824,5824,"DRUG1 has no effect on the pharmacokinetics of DRUG2, DRUGOTHER, or the active metabolite of mycophenolate.",CANCIDAS,itraconazole,False,Neg,0,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,0,8
1035,5707,5707,5825,5825,"DRUG1 has no effect on the pharmacokinetics of DRUGOTHER, DRUG2, or the active metabolite of mycophenolate.",CANCIDAS,amphotericin B,False,Neg,0,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,C[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O,0,9
1036,5709,5709,5827,5827,"DRUG1 reduced the blood AUC0-12 of DRUG2 by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when DRUG2 (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of DRUG1 70 mg daily, as compared to results from a control period in which DRUG2 was administered alone.",CANCIDAS,tacrolimus,True,mechanism,4,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,0,6
1037,5710,5710,5828,5828,"DRUG1 reduced the blood AUC0-12 of DRUG2 by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when DRUG2 (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of DRUG1 70 mg daily, as compared to results from a control period in which DRUG2 was administered alone.",CANCIDAS,tacrolimus,False,Neg,0,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,0,6
1038,5712,5712,5830,5830,"DRUG1 reduced the blood AUC0-12 of DRUG2 by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when DRUG2 (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of DRUG1 70 mg daily, as compared to results from a control period in which DRUG2 was administered alone.",CANCIDAS,tacrolimus,False,Neg,0,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,0,6
1039,5714,5714,5832,5832,"DRUG2 reduced the blood AUC0-12 of DRUG1 by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when DRUG1 (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of DRUG2 70 mg daily, as compared to results from a control period in which DRUG1 was administered alone.",tacrolimus,CANCIDAS,False,Neg,0,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,6,0
1040,5716,5716,5834,5834,"DRUG2 reduced the blood AUC0-12 of DRUG1 by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when DRUG1 (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of DRUG2 70 mg daily, as compared to results from a control period in which DRUG1 was administered alone.",tacrolimus,CANCIDAS,False,Neg,0,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,6,0
1041,5718,5718,5836,5836,"DRUG1 reduced the blood AUC0-12 of DRUG2 by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when DRUG2 (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of DRUG1 70 mg daily, as compared to results from a control period in which DRUG2 was administered alone.",CANCIDAS,tacrolimus,False,Neg,0,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,0,6
1042,5720,5720,5838,5838,"In two clinical studies, DRUG1 (one 4 mg/kg dose or two 3 mg/kg doses) increased the AUC of DRUG2 by approximately 35%.",cyclosporine,caspofungin,True,mechanism,4,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,4,18
1043,5721,5721,5839,5839,DRUG1 did not increase the plasma levels of DRUG2.,CANCIDAS,cyclosporine,False,Neg,0,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,0,8
1044,5722,5722,5840,5840,There were transient increases in liver ALT and AST when DRUG1 and DRUG2 were co-administered.,CANCIDAS,cyclosporine,True,effect,2,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,10,12
1045,5723,5723,5841,5841,A drug-drug interaction study with DRUG1 in healthy volunteers has shown a 30% decrease in DRUG2 trough concentrations.,rifampin,caspofungin,True,mechanism,4,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,5,15
1046,5724,5724,5842,5842,Patients on DRUG1 should receive 70 mg of DRUG2 daily.,rifampin,CANCIDAS,True,advise,1,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,2,8
1047,5726,5726,5844,5844,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER) with DRUGOTHER may result in clinically meaningful reductions in DRUGOTHER concentrations.",efavirenz,phenytoin,False,Neg,0,FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,19,21
1048,5729,5729,5847,5847,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER) with DRUG2 may result in clinically meaningful reductions in DRUGOTHER concentrations.",efavirenz,CANCIDAS,True,mechanism,4,FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,19,26
1049,5730,5730,5848,5848,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER) with DRUGOTHER may result in clinically meaningful reductions in DRUG2 concentrations.",efavirenz,caspofungin,False,Neg,0,FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,19,34
1050,5731,5731,5849,5849,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, or DRUGOTHER) with DRUGOTHER may result in clinically meaningful reductions in DRUGOTHER concentrations.",nevirapine,phenytoin,False,Neg,0,CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,20,21
1051,5734,5734,5852,5852,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, or DRUGOTHER) with DRUG2 may result in clinically meaningful reductions in DRUGOTHER concentrations.",nevirapine,CANCIDAS,True,mechanism,4,CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,20,26
1052,5735,5735,5853,5853,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, or DRUGOTHER) with DRUGOTHER may result in clinically meaningful reductions in DRUG2 concentrations.",nevirapine,caspofungin,False,Neg,0,CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,20,34
1053,5736,5736,5854,5854,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, or DRUGOTHER) with DRUGOTHER may result in clinically meaningful reductions in DRUGOTHER concentrations.",phenytoin,dexamethasone,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,21,22
1054,5737,5737,5855,5855,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, or DRUG2) with DRUGOTHER may result in clinically meaningful reductions in DRUGOTHER concentrations.",phenytoin,carbamazepine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,21,24
1055,5741,5741,5859,5859,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, or DRUGOTHER) with DRUG2 may result in clinically meaningful reductions in DRUGOTHER concentrations.",dexamethasone,CANCIDAS,True,mechanism,4,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,22,26
1056,5742,5742,5860,5860,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, or DRUGOTHER) with DRUGOTHER may result in clinically meaningful reductions in DRUG2 concentrations.",dexamethasone,caspofungin,False,Neg,0,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,22,34
1057,5743,5743,5861,5861,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG1) with DRUG2 may result in clinically meaningful reductions in DRUGOTHER concentrations.",carbamazepine,CANCIDAS,True,mechanism,4,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,24,26
1058,5744,5744,5862,5862,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG1) with DRUGOTHER may result in clinically meaningful reductions in DRUG2 concentrations.",carbamazepine,caspofungin,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,24,34
1059,5746,5746,5864,5864,"When DRUG1 is co-administered with inducers of drug clearance, such as DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER, use of a daily dose of 70 mg of DRUG1 should be considered",CANCIDAS,efavirenz,True,advise,1,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1,1,11
1060,5747,5747,5865,5865,"When DRUG1 is co-administered with inducers of drug clearance, such as DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER, use of a daily dose of 70 mg of DRUG1 should be considered",CANCIDAS,nevirapine,True,advise,1,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1,1,12
1061,5749,5749,5867,5867,"When DRUG1 is co-administered with inducers of drug clearance, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER, use of a daily dose of 70 mg of DRUG1 should be considered",CANCIDAS,dexamethasone,True,advise,1,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,1,14
1062,5750,5750,5868,5868,"When DRUG1 is co-administered with inducers of drug clearance, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2, use of a daily dose of 70 mg of DRUG1 should be considered",CANCIDAS,carbamazepine,True,advise,1,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1,16
1063,5753,5753,5871,5871,"When DRUGOTHER is co-administered with inducers of drug clearance, such as DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER, use of a daily dose of 70 mg of DRUGOTHER should be considered",efavirenz,phenytoin,False,Neg,0,FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,11,13
1064,5756,5756,5874,5874,"When DRUG2 is co-administered with inducers of drug clearance, such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER, use of a daily dose of 70 mg of DRUG2 should be considered",efavirenz,CANCIDAS,False,Neg,0,FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,11,1
1065,5757,5757,5875,5875,"When DRUGOTHER is co-administered with inducers of drug clearance, such as DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, or DRUGOTHER, use of a daily dose of 70 mg of DRUGOTHER should be considered",nevirapine,phenytoin,False,Neg,0,CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,12,13
1066,5760,5760,5878,5878,"When DRUG2 is co-administered with inducers of drug clearance, such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, or DRUGOTHER, use of a daily dose of 70 mg of DRUG2 should be considered",nevirapine,CANCIDAS,False,Neg,0,CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,12,1
1067,5761,5761,5879,5879,"When DRUGOTHER is co-administered with inducers of drug clearance, such as DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, or DRUGOTHER, use of a daily dose of 70 mg of DRUGOTHER should be considered",phenytoin,dexamethasone,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,13,14
1068,5762,5762,5880,5880,"When DRUGOTHER is co-administered with inducers of drug clearance, such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, or DRUG2, use of a daily dose of 70 mg of DRUGOTHER should be considered",phenytoin,carbamazepine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,13,16
1069,5765,5765,5883,5883,"When DRUG2 is co-administered with inducers of drug clearance, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, or DRUGOTHER, use of a daily dose of 70 mg of DRUG2 should be considered",dexamethasone,CANCIDAS,False,Neg,0,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,14,1
1070,5766,5766,5884,5884,"When DRUG2 is co-administered with inducers of drug clearance, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG1, use of a daily dose of 70 mg of DRUG2 should be considered",carbamazepine,CANCIDAS,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,16,1
1071,5789,5789,5907,5907,"Drug/Laboratory Test Interactions A false-positive reaction for ketones in the urine may occur with tests using DRUG1, but not with those using DRUG2.",nitroprusside,nitroferricyanide,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,O=N[Fe--](C#N)(C#N)(C#N)(C#N)C#N,16,22
1072,5809,5809,5927,5927,Nephrotoxicity has been reported following concomitant administration of other DRUG1 with potent DRUGOTHER such as DRUG2.,cephalosporins,furosemide,True,effect,2,CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CCC[C@H](C(=O)O)N)SC1)C(=O)O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,9,15
1073,5810,5810,5928,5928,Nephrotoxicity has been reported following concomitant administration of other DRUGOTHER with potent DRUG1 such as DRUG2.,diuretics,furosemide,False,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,12,15
1074,5812,5812,5930,5930,Drug/Laboratory Test Interactions A false-positive reaction for ketones in the urine may occur with tests using DRUG1 but not with those using DRUG2.,nitroprusside,nitroferricyanide,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,O=N[Fe--](C#N)(C#N)(C#N)(C#N)C#N,16,22
1075,5817,5817,5938,5938,Concomitant administration of DRUG1 doubled the AUC for DRUG2.,probenecid,cefprozil,True,mechanism,4,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,3,8
1076,5818,5818,5939,5939,The bioavailability of the capsule formulation of DRUG1 was not affected when administered 5 minutes following an DRUG2.,cefprozil,antacid,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O,7,17
1077,5821,5821,5942,5942,Nephrotoxicity has been reported following concomitant administration of DRUG1 with DRUGOTHER or potent DRUGOTHER such as DRUG2.,cephalosporins,furosemide,True,effect,2,CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CCC[C@H](C(=O)O)N)SC1)C(=O)O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,8,16
1078,5823,5823,5944,5944,Nephrotoxicity has been reported following concomitant administration of DRUGOTHER with DRUG1 or potent DRUGOTHER such as DRUG2.,aminoglycoside antibiotics,furosemide,False,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,10,16
1079,5824,5824,5945,5945,Nephrotoxicity has been reported following concomitant administration of DRUGOTHER with DRUGOTHER or potent DRUG1 such as DRUG2.,diuretics,furosemide,False,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,13,16
1080,5829,5829,5950,5950,DRUG1: Twelve healthy male volunteers were administered one 200-mg DRUG2 capsule twice daily for 6 days.,Theophylline,ceftibuten,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=C/CC(O)=O)\C1=CSC(N)=N1)C(O)=O,0,9
1081,5830,5830,5951,5951,"With the morning dose of DRUG1 on day 6, each volunteer received a single intravenous infusion of DRUG2 (4 mg/kg).",ceftibuten,theophylline,False,Neg,0,[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=C/CC(O)=O)\C1=CSC(N)=N1)C(O)=O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,5,17
1082,5831,5831,5952,5952,The effect of DRUG1 on the pharmacokinetics of DRUG2 administered orally has not been investigated.,ceftibuten,theophylline,False,Neg,0,[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=C/CC(O)=O)\C1=CSC(N)=N1)C(O)=O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,3,8
1083,5839,5839,5960,5960,Experience with DRUG1 (DRUGOTHER) suggests the potential for interactions with DRUG2 and DRUGOTHER.,nonsteroidal anti-inflammatory drugs,furosemide,True,int,3,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,2,10
1084,5843,5843,5964,5964,"The effects DRUG1 on the pharmacokinetics and/or pharmacodynamics of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER have been studied in vivo and clinically important interactions have not been found.",celecoxib,phenytoin,False,Neg,0,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,2,12
1085,5848,5848,5969,5969,"The effects DRUGOTHER on the pharmacokinetics and/or pharmacodynamics of DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER have been studied in vivo and clinically important interactions have not been found.",glyburide,phenytoin,False,Neg,0,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,9,12
1086,5852,5852,5973,5973,"The effects DRUGOTHER on the pharmacokinetics and/or pharmacodynamics of DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER have been studied in vivo and clinically important interactions have not been found.",ketoconazole,phenytoin,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,10,12
1087,5855,5855,5976,5976,"The effects DRUGOTHER on the pharmacokinetics and/or pharmacodynamics of DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER have been studied in vivo and clinically important interactions have not been found.",methotrexate,phenytoin,False,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,11,12
1088,5858,5858,5979,5979,"The effects DRUGOTHER on the pharmacokinetics and/or pharmacodynamics of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER have been studied in vivo and clinically important interactions have not been found.",phenytoin,tolbutamide,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,12,13
1089,5859,5859,5980,5980,"The effects DRUGOTHER on the pharmacokinetics and/or pharmacodynamics of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2 have been studied in vivo and clinically important interactions have not been found.",phenytoin,warfarin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,12,15
1090,5911,5911,6032,6032,"DRUG1, DRUGOTHER, DRUG2 (DRUGOTHER, DRUGOTHER, DRUGOTHER: Skeletal Muscle.",Immunosuppressive Drugs,Niacin,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,NC(=O)C1=CN=CC=C1.[H]C(O)(CO)[C@@]1([H])OC(=O)C(O)=C1O,0,2
1091,5912,5912,6033,6033,"DRUG1, DRUGOTHER, DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER: Skeletal Muscle.",Immunosuppressive Drugs,Nicotinic Acid,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1,0,3
1092,5913,5913,6034,6034,"DRUG1, DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER: Skeletal Muscle.",Immunosuppressive Drugs,Erythromycin,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,0,4
1093,5914,5914,6035,6035,"DRUG1, DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2: Skeletal Muscle.",Immunosuppressive Drugs,Azole Antifungals,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,OC(=O)CCCCCCCCC=C,0,5
1094,5986,5986,6107,6107,"In a multiple dose study of DRUG1 (400 mg once daily for 3 days) and DRUG2 (20 mg once daily for 3 days), a 16% decrease in the clearance of DRUG2 was observed.",theophylline,cetirizine,True,mechanism,4,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN[C@@H](C)[C@@H](O)C1=CC=CC=C1,6,15
1095,5987,5987,6108,6108,"In a multiple dose study of DRUG1 (400 mg once daily for 3 days) and DRUG2 (20 mg once daily for 3 days), a 16% decrease in the clearance of DRUG2 was observed.",theophylline,cetirizine,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN[C@@H](C)[C@@H](O)C1=CC=CC=C1,6,15
1096,5989,5989,6110,6110,The disposition of DRUG1 was not altered by concomitant DRUG2 administration.,theophylline,cetirizine,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN[C@@H](C)[C@@H](O)C1=CC=CC=C1,3,9
1097,5990,5990,6111,6111,"Drug-Drug Interactions: No clinically significant drug interactions have been found with DRUG1 at a low dose, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER.",theophylline,azithromycin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,11,16
1098,5991,5991,6112,6112,"Drug-Drug Interactions: No clinically significant drug interactions have been found with DRUG1 at a low dose, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER.",theophylline,pseudoephedrine,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C[C@@H]([C@H](C1=CC=CC=C1)O)NC,11,17
1099,5992,5992,6113,6113,"Drug-Drug Interactions: No clinically significant drug interactions have been found with DRUG1 at a low dose, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER.",theophylline,ketoconazole,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,11,18
1100,5993,5993,6114,6114,"Drug-Drug Interactions: No clinically significant drug interactions have been found with DRUG1 at a low dose, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2.",theophylline,erythromycin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,11,20
1101,6000,6000,6121,6121,There was a small decrease in the clearance of DRUG1 caused by a 400-mg dose of DRUG2;,cetirizine,theophylline,True,mechanism,4,CN[C@@H](C)[C@@H](O)C1=CC=CC=C1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,9,16
1102,6092,6092,6214,6214,"Increased toxicity (CNS depression): DRUG1, DRUG2, DRUGOTHER, DRUGOTHER.",CNS depressants,MAO inhibitors,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN(CC#C)CC1=CC=CC=C1,4,5
1103,6093,6093,6215,6215,"Increased toxicity (CNS depression): DRUG1, DRUGOTHER, DRUG2, DRUGOTHER.",CNS depressants,tricyclic antidepressants,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,4,6
1104,6094,6094,6216,6216,"Increased toxicity (CNS depression): DRUG1, DRUGOTHER, DRUGOTHER, DRUG2.",CNS depressants,phenothiazines,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,N1C2=CC=CC=C2SC2=CC=CC=C12,4,7
1105,6101,6101,6223,6223,"Example inhibitors include DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",azole antifungals,doxycycline,False,Neg,0,OC(=O)CCCCCCCCC=C,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,3,7
1106,6103,6103,6225,6225,"Example inhibitors include DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",azole antifungals,imatinib,False,Neg,0,OC(=O)CCCCCCCCC=C,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,3,9
1107,6105,6105,6227,6227,"Example inhibitors include DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",azole antifungals,nefazodone,False,Neg,0,OC(=O)CCCCCCCCC=C,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,3,11
1108,6112,6112,6234,6234,"Example inhibitors include DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",ciprofloxacin,doxycycline,False,Neg,0,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,4,7
1109,6114,6114,6236,6236,"Example inhibitors include DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",ciprofloxacin,imatinib,False,Neg,0,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,4,9
1110,6116,6116,6238,6238,"Example inhibitors include DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",ciprofloxacin,nefazodone,False,Neg,0,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,4,11
1111,6122,6122,6244,6244,"Example inhibitors include DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",clarithromycin,doxycycline,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,5,7
1112,6124,6124,6246,6246,"Example inhibitors include DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",clarithromycin,imatinib,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,5,9
1113,6126,6126,6248,6248,"Example inhibitors include DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",clarithromycin,nefazodone,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,5,11
1114,6131,6131,6253,6253,"Example inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",diclofenac,doxycycline,False,Neg,0,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,6,7
1115,6133,6133,6255,6255,"Example inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",diclofenac,imatinib,False,Neg,0,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,6,9
1116,6135,6135,6257,6257,"Example inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",diclofenac,nefazodone,False,Neg,0,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,6,11
1117,6140,6140,6262,6262,"Example inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",doxycycline,erythromycin,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,7,8
1118,6142,6142,6264,6264,"Example inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",doxycycline,isoniazid,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O,7,10
1119,6144,6144,6266,6266,"Example inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",doxycycline,nicardipine,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1,7,12
1120,6145,6145,6267,6267,"Example inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",doxycycline,propofol,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CC(C)C1=C(C(=CC=C1)C(C)C)O,7,13
1121,6146,6146,6268,6268,"Example inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",doxycycline,quinidine,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,7,15
1122,6147,6147,6269,6269,"Example inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",doxycycline,verapamil,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,7,17
1123,6148,6148,6270,6270,"Example inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",erythromycin,imatinib,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,8,9
1124,6150,6150,6272,6272,"Example inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",erythromycin,nefazodone,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,8,11
1125,6155,6155,6277,6277,"Example inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",imatinib,isoniazid,False,Neg,0,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O,9,10
1126,6157,6157,6279,6279,"Example inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",imatinib,nicardipine,False,Neg,0,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1,9,12
1127,6158,6158,6280,6280,"Example inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",imatinib,propofol,False,Neg,0,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,CC(C)C1=C(C(=CC=C1)C(C)C)O,9,13
1128,6159,6159,6281,6281,"Example inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",imatinib,quinidine,False,Neg,0,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,9,15
1129,6160,6160,6282,6282,"Example inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",imatinib,verapamil,False,Neg,0,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,9,17
1130,6161,6161,6283,6283,"Example inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",isoniazid,nefazodone,False,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,10,11
1131,6166,6166,6288,6288,"Example inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",nefazodone,nicardipine,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1,11,12
1132,6167,6167,6289,6289,"Example inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",nefazodone,propofol,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC(C)C1=C(C(=CC=C1)C(C)C)O,11,13
1133,6168,6168,6290,6290,"Example inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",nefazodone,quinidine,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,11,15
1134,6169,6169,6291,6291,"Example inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",nefazodone,verapamil,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,11,17
1135,6186,6186,6308,6308,"Interactions may also occur with the following: DRUG1/DRUGOTHER, drugs used to treat an overactive thyroid, DRUGOTHER (e.g., DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER pain medication (e.g., DRUGOTHER), drugs used to aid sleep, drowsiness-causing DRUGOTHER (e.g., DRUGOTHER), any other drugs that may make you drowsy.",anti-depressants,propranolol,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,7,17
1136,6187,6187,6309,6309,"Interactions may also occur with the following: DRUG1/DRUGOTHER, drugs used to treat an overactive thyroid, DRUGOTHER (e.g., DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER pain medication (e.g., DRUGOTHER), drugs used to aid sleep, drowsiness-causing DRUGOTHER (e.g., DRUGOTHER), any other drugs that may make you drowsy.",anti-depressants,sparfloxacin,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C[C@H]1CN(C[C@@H](C)N1)C1=C(F)C(N)=C2C(=O)C(=CN(C3CC3)C2=C1F)C(O)=O,7,18
1137,6188,6188,6310,6310,"Interactions may also occur with the following: DRUG1/DRUGOTHER, drugs used to treat an overactive thyroid, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER pain medication (e.g., DRUGOTHER), drugs used to aid sleep, drowsiness-causing DRUGOTHER (e.g., DRUGOTHER), any other drugs that may make you drowsy.",anti-depressants,grepafloxacin,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O,7,19
1138,6190,6190,6312,6312,"Interactions may also occur with the following: DRUG1/DRUGOTHER, drugs used to treat an overactive thyroid, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER pain medication (e.g., DRUGOTHER), drugs used to aid sleep, drowsiness-causing DRUGOTHER (e.g., DRUGOTHER), any other drugs that may make you drowsy.",anti-depressants,guanadrel,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,NC(N)=NCC1COC2(CCCCC2)O1,7,21
1139,6191,6191,6313,6313,"Interactions may also occur with the following: DRUG1/DRUGOTHER, drugs used to treat an overactive thyroid, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER pain medication (e.g., DRUGOTHER), drugs used to aid sleep, drowsiness-causing DRUGOTHER (e.g., DRUGOTHER), any other drugs that may make you drowsy.",anti-depressants,metrizamide,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@]([H])(C=O)N=C(O)C1=C(I)C(N=C(C)O)=C(I)C(N(C)C(C)=O)=C1I,7,22
1140,6193,6193,6315,6315,"Interactions may also occur with the following: DRUG1/DRUGOTHER, drugs used to treat an overactive thyroid, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 pain medication (e.g., DRUGOTHER), drugs used to aid sleep, drowsiness-causing DRUGOTHER (e.g., DRUGOTHER), any other drugs that may make you drowsy.",anti-depressants,narcotic,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCO,7,25
1141,6194,6194,6316,6316,"Interactions may also occur with the following: DRUG1/DRUGOTHER, drugs used to treat an overactive thyroid, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER pain medication (e.g., DRUGOTHER), drugs used to aid sleep, drowsiness-causing DRUG2 (e.g., DRUGOTHER), any other drugs that may make you drowsy.",anti-depressants,antihistamines,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,NCCC1=CNC=N1,7,36
1142,6195,6195,6317,6317,"Interactions may also occur with the following: DRUG1/DRUGOTHER, drugs used to treat an overactive thyroid, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER pain medication (e.g., DRUGOTHER), drugs used to aid sleep, drowsiness-causing DRUGOTHER (e.g., DRUG2), any other drugs that may make you drowsy.",anti-depressants,diphenhydramine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,7,38
1143,6198,6198,6320,6320,"Interactions may also occur with the following: DRUGOTHER/DRUGOTHER, drugs used to treat an overactive thyroid, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER pain medication (e.g., DRUGOTHER), drugs used to aid sleep, drowsiness-causing DRUGOTHER (e.g., DRUGOTHER), any other drugs that may make you drowsy.",propranolol,guanethidine,False,Neg,0,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,C1CCCN(CCC1)CCN=C(N)N,17,20
1144,6201,6201,6323,6323,"Interactions may also occur with the following: DRUGOTHER/DRUGOTHER, drugs used to treat an overactive thyroid, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER pain medication (e.g., DRUGOTHER), drugs used to aid sleep, drowsiness-causing DRUGOTHER (e.g., DRUGOTHER), any other drugs that may make you drowsy.",propranolol,cabergoline,False,Neg,0,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC,17,23
1145,6206,6206,6328,6328,"Interactions may also occur with the following: DRUGOTHER/DRUGOTHER, drugs used to treat an overactive thyroid, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER pain medication (e.g., DRUGOTHER), drugs used to aid sleep, drowsiness-causing DRUGOTHER (e.g., DRUGOTHER), any other drugs that may make you drowsy.",sparfloxacin,guanethidine,False,Neg,0,C[C@H]1CN(C[C@@H](C)N1)C1=C(F)C(N)=C2C(=O)C(=CN(C3CC3)C2=C1F)C(O)=O,C1CCCN(CCC1)CCN=C(N)N,18,20
1146,6209,6209,6331,6331,"Interactions may also occur with the following: DRUGOTHER/DRUGOTHER, drugs used to treat an overactive thyroid, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER pain medication (e.g., DRUGOTHER), drugs used to aid sleep, drowsiness-causing DRUGOTHER (e.g., DRUGOTHER), any other drugs that may make you drowsy.",sparfloxacin,cabergoline,False,Neg,0,C[C@H]1CN(C[C@@H](C)N1)C1=C(F)C(N)=C2C(=O)C(=CN(C3CC3)C2=C1F)C(O)=O,[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC,18,23
1147,6213,6213,6335,6335,"Interactions may also occur with the following: DRUGOTHER/DRUGOTHER, drugs used to treat an overactive thyroid, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER pain medication (e.g., DRUGOTHER), drugs used to aid sleep, drowsiness-causing DRUGOTHER (e.g., DRUGOTHER), any other drugs that may make you drowsy.",grepafloxacin,guanethidine,False,Neg,0,CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O,C1CCCN(CCC1)CCN=C(N)N,19,20
1148,6216,6216,6338,6338,"Interactions may also occur with the following: DRUGOTHER/DRUGOTHER, drugs used to treat an overactive thyroid, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER pain medication (e.g., DRUGOTHER), drugs used to aid sleep, drowsiness-causing DRUGOTHER (e.g., DRUGOTHER), any other drugs that may make you drowsy.",grepafloxacin,cabergoline,False,Neg,0,CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O,[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC,19,23
1149,6220,6220,6342,6342,"Interactions may also occur with the following: DRUGOTHER/DRUGOTHER, drugs used to treat an overactive thyroid, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER pain medication (e.g., DRUGOTHER), drugs used to aid sleep, drowsiness-causing DRUGOTHER (e.g., DRUGOTHER), any other drugs that may make you drowsy.",guanethidine,guanadrel,False,Neg,0,C1CCCN(CCC1)CCN=C(N)N,NC(N)=NCC1COC2(CCCCC2)O1,20,21
1150,6221,6221,6343,6343,"Interactions may also occur with the following: DRUGOTHER/DRUGOTHER, drugs used to treat an overactive thyroid, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER pain medication (e.g., DRUGOTHER), drugs used to aid sleep, drowsiness-causing DRUGOTHER (e.g., DRUGOTHER), any other drugs that may make you drowsy.",guanethidine,metrizamide,False,Neg,0,C1CCCN(CCC1)CCN=C(N)N,[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@]([H])(C=O)N=C(O)C1=C(I)C(N=C(C)O)=C(I)C(N(C)C(C)=O)=C1I,20,22
1151,6223,6223,6345,6345,"Interactions may also occur with the following: DRUGOTHER/DRUGOTHER, drugs used to treat an overactive thyroid, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 pain medication (e.g., DRUGOTHER), drugs used to aid sleep, drowsiness-causing DRUGOTHER (e.g., DRUGOTHER), any other drugs that may make you drowsy.",guanethidine,narcotic,False,Neg,0,C1CCCN(CCC1)CCN=C(N)N,CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCO,20,25
1152,6224,6224,6346,6346,"Interactions may also occur with the following: DRUGOTHER/DRUGOTHER, drugs used to treat an overactive thyroid, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER pain medication (e.g., DRUGOTHER), drugs used to aid sleep, drowsiness-causing DRUG2 (e.g., DRUGOTHER), any other drugs that may make you drowsy.",guanethidine,antihistamines,False,Neg,0,C1CCCN(CCC1)CCN=C(N)N,NCCC1=CNC=N1,20,36
1153,6225,6225,6347,6347,"Interactions may also occur with the following: DRUGOTHER/DRUGOTHER, drugs used to treat an overactive thyroid, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER pain medication (e.g., DRUGOTHER), drugs used to aid sleep, drowsiness-causing DRUGOTHER (e.g., DRUG2), any other drugs that may make you drowsy.",guanethidine,diphenhydramine,False,Neg,0,C1CCCN(CCC1)CCN=C(N)N,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,20,38
1154,6227,6227,6349,6349,"Interactions may also occur with the following: DRUGOTHER/DRUGOTHER, drugs used to treat an overactive thyroid, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER pain medication (e.g., DRUGOTHER), drugs used to aid sleep, drowsiness-causing DRUGOTHER (e.g., DRUGOTHER), any other drugs that may make you drowsy.",guanadrel,cabergoline,False,Neg,0,NC(N)=NCC1COC2(CCCCC2)O1,[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC,21,23
1155,6231,6231,6353,6353,"Interactions may also occur with the following: DRUGOTHER/DRUGOTHER, drugs used to treat an overactive thyroid, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER pain medication (e.g., DRUGOTHER), drugs used to aid sleep, drowsiness-causing DRUGOTHER (e.g., DRUGOTHER), any other drugs that may make you drowsy.",metrizamide,cabergoline,False,Neg,0,[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@]([H])(C=O)N=C(O)C1=C(I)C(N=C(C)O)=C(I)C(N(C)C(C)=O)=C1I,[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC,22,23
1156,6235,6235,6357,6357,"Interactions may also occur with the following: DRUGOTHER/DRUGOTHER, drugs used to treat an overactive thyroid, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2 pain medication (e.g., DRUGOTHER), drugs used to aid sleep, drowsiness-causing DRUGOTHER (e.g., DRUGOTHER), any other drugs that may make you drowsy.",cabergoline,narcotic,False,Neg,0,[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC,CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCO,23,25
1157,6236,6236,6358,6358,"Interactions may also occur with the following: DRUGOTHER/DRUGOTHER, drugs used to treat an overactive thyroid, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER pain medication (e.g., DRUGOTHER), drugs used to aid sleep, drowsiness-causing DRUG2 (e.g., DRUGOTHER), any other drugs that may make you drowsy.",cabergoline,antihistamines,False,Neg,0,[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC,NCCC1=CNC=N1,23,36
1158,6237,6237,6359,6359,"Interactions may also occur with the following: DRUGOTHER/DRUGOTHER, drugs used to treat an overactive thyroid, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER pain medication (e.g., DRUGOTHER), drugs used to aid sleep, drowsiness-causing DRUGOTHER (e.g., DRUG2), any other drugs that may make you drowsy.",cabergoline,diphenhydramine,False,Neg,0,[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,23,38
1159,6243,6243,6365,6365,"The hypoglycemic action of DRUG1 may be potentiated by certain drugs including DRUGOTHER and other drugs that are highly protein bound, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",sulfonylurea,sulfonamides,True,effect,2,C(=O)(N)N=S(=O)=O.C(=O)(N)N=S(=O)=O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,4,22
1160,6250,6250,6372,6372,"The hypoglycemic action of DRUGOTHER may be potentiated by certain drugs including DRUG1 and other drugs that are highly protein bound, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",nonsteroidal anti-inflammatory agents,sulfonamides,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,12,22
1161,6256,6256,6378,6378,"The hypoglycemic action of DRUGOTHER may be potentiated by certain drugs including DRUGOTHER and other drugs that are highly protein bound, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",salicylates,sulfonamides,False,Neg,0,CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,21,22
1162,6262,6262,6384,6384,"The hypoglycemic action of DRUGOTHER may be potentiated by certain drugs including DRUGOTHER and other drugs that are highly protein bound, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",sulfonamides,chloramphenicol,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O,22,23
1163,6263,6263,6385,6385,"The hypoglycemic action of DRUGOTHER may be potentiated by certain drugs including DRUGOTHER and other drugs that are highly protein bound, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",sulfonamides,probenecid,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,22,24
1164,6264,6264,6386,6386,"The hypoglycemic action of DRUGOTHER may be potentiated by certain drugs including DRUGOTHER and other drugs that are highly protein bound, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",sulfonamides,coumarins,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,O=C1OC2=CC=CC=C2C=C1,22,25
1165,6265,6265,6387,6387,"The hypoglycemic action of DRUGOTHER may be potentiated by certain drugs including DRUGOTHER and other drugs that are highly protein bound, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",sulfonamides,monoamine oxidase inhibitors,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,OC(=O)CCCCCCCC(O)=O,22,26
1166,6266,6266,6388,6388,"The hypoglycemic action of DRUGOTHER may be potentiated by certain drugs including DRUGOTHER and other drugs that are highly protein bound, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",sulfonamides,beta adrenergic blocking agents,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,22,28
1167,6277,6277,6399,6399,"These drugs include the DRUG1 and other DRUG2, DRUGOTHER, DRUGOTHER, thyroid products, DRUGOTHER, oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",thiazides,diuretics,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,4,7
1168,6278,6278,6400,6400,"These drugs include the DRUG1 and other DRUGOTHER, DRUG2, DRUGOTHER, thyroid products, DRUGOTHER, oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",thiazides,corticosteroids,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,4,8
1169,6279,6279,6401,6401,"These drugs include the DRUG1 and other DRUGOTHER, DRUGOTHER, DRUG2, thyroid products, DRUGOTHER, oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",thiazides,phenothiazines,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,N1C2=CC=CC=C2SC2=CC=CC=C12,4,9
1170,6280,6280,6402,6402,"These drugs include the DRUG1 and other DRUGOTHER, DRUGOTHER, DRUGOTHER, thyroid products, DRUG2, oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",thiazides,estrogens,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)OS(=O)(=O)[O-])[C@@H]1CCC2=O.[Na+],4,12
1171,6281,6281,6403,6403,"These drugs include the DRUG1 and other DRUGOTHER, DRUGOTHER, DRUGOTHER, thyroid products, DRUGOTHER, oral DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",thiazides,contraceptives,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,4,14
1172,6283,6283,6405,6405,"These drugs include the DRUG1 and other DRUGOTHER, DRUGOTHER, DRUGOTHER, thyroid products, DRUGOTHER, oral DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",thiazides,nicotinic acid,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1,4,16
1173,6284,6284,6406,6406,"These drugs include the DRUG1 and other DRUGOTHER, DRUGOTHER, DRUGOTHER, thyroid products, DRUGOTHER, oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",thiazides,isoniazid,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O,4,20
1174,6289,6289,6411,6411,"These drugs include the DRUGOTHER and other DRUG1, DRUGOTHER, DRUGOTHER, thyroid products, DRUGOTHER, oral DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",diuretics,phenytoin,False,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,7,15
1175,6295,6295,6417,6417,"These drugs include the DRUGOTHER and other DRUGOTHER, DRUG1, DRUGOTHER, thyroid products, DRUGOTHER, oral DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",corticosteroids,phenytoin,False,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,8,15
1176,6300,6300,6422,6422,"These drugs include the DRUGOTHER and other DRUGOTHER, DRUGOTHER, DRUG1, thyroid products, DRUGOTHER, oral DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",phenothiazines,phenytoin,False,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,9,15
1177,6304,6304,6426,6426,"These drugs include the DRUGOTHER and other DRUGOTHER, DRUGOTHER, DRUGOTHER, thyroid products, DRUG1, oral DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",estrogens,phenytoin,False,Neg,0,C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)OS(=O)(=O)[O-])[C@@H]1CCC2=O.[Na+],C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,12,15
1178,6307,6307,6429,6429,"These drugs include the DRUGOTHER and other DRUGOTHER, DRUGOTHER, DRUGOTHER, thyroid products, DRUGOTHER, oral DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",contraceptives,phenytoin,False,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,14,15
1179,6310,6310,6432,6432,"These drugs include the DRUGOTHER and other DRUGOTHER, DRUGOTHER, DRUGOTHER, thyroid products, DRUGOTHER, oral DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",phenytoin,nicotinic acid,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1,15,16
1180,6311,6311,6433,6433,"These drugs include the DRUGOTHER and other DRUGOTHER, DRUGOTHER, DRUGOTHER, thyroid products, DRUGOTHER, oral DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",phenytoin,isoniazid,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O,15,20
1181,6353,6353,6475,6475,"DRUG1/DRUG2: The coadministration of DRUGOTHER or DRUGOTHER will not affect plasma concentrations of DRUGOTHER, but may reduce endogenous plasma levels of DRUGOTHER/ergoDRUGOTHER by accelerating metabolism.",Phenytoin,Phenobarbital,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,0,0
1182,6355,6355,6477,6477,"DRUG1/DRUGOTHER: The coadministration of DRUGOTHER or DRUG2 will not affect plasma concentrations of DRUGOTHER, but may reduce endogenous plasma levels of DRUGOTHER/ergoDRUGOTHER by accelerating metabolism.",Phenytoin,phenobarbital,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,0,6
1183,6356,6356,6478,6478,"DRUG1/DRUGOTHER: The coadministration of DRUGOTHER or DRUGOTHER will not affect plasma concentrations of DRUG2, but may reduce endogenous plasma levels of DRUGOTHER/ergoDRUGOTHER by accelerating metabolism.",Phenytoin,vitamin D,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,OC(=O)CCCCCCCC(O)=O,0,13
1184,6357,6357,6479,6479,"DRUG1/DRUGOTHER: The coadministration of DRUGOTHER or DRUGOTHER will not affect plasma concentrations of DRUGOTHER, but may reduce endogenous plasma levels of DRUG2/ergoDRUG2 by accelerating metabolism.",Phenytoin,calcitriol,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,0,21
1185,6358,6358,6480,6480,"DRUGOTHER/DRUG1: The coadministration of DRUG2 or DRUGOTHER will not affect plasma concentrations of DRUGOTHER, but may reduce endogenous plasma levels of DRUGOTHER/ergoDRUGOTHER by accelerating metabolism.",Phenobarbital,phenytoin,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,4
1186,6362,6362,6484,6484,"DRUGOTHER/DRUGOTHER: The coadministration of DRUG1 or DRUG2 will not affect plasma concentrations of DRUGOTHER, but may reduce endogenous plasma levels of DRUGOTHER/ergoDRUGOTHER by accelerating metabolism.",phenytoin,phenobarbital,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,4,6
1187,6363,6363,6485,6485,"DRUGOTHER/DRUGOTHER: The coadministration of DRUG1 or DRUGOTHER will not affect plasma concentrations of DRUG2, but may reduce endogenous plasma levels of DRUGOTHER/ergoDRUGOTHER by accelerating metabolism.",phenytoin,vitamin D,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,OC(=O)CCCCCCCC(O)=O,4,13
1188,6364,6364,6486,6486,"DRUGOTHER/DRUGOTHER: The coadministration of DRUG1 or DRUGOTHER will not affect plasma concentrations of DRUGOTHER, but may reduce endogenous plasma levels of DRUG2/ergoDRUG2 by accelerating metabolism.",phenytoin,calcitriol,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,4,21
1189,6369,6369,6491,6491,Some reports have shown that the concomitant administration of DRUG1 with DRUG2 causes hypercalcemia.,thiazides,vitamin D,True,effect,2,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,OC(=O)CCCCCCCC(O)=O,9,11
1190,6385,6385,6507,6507,"DRUG1 DRUGOTHER may delay or reduce the absorption of concomitant oral medication such as DRUGOTHER, DRUGOTHER, DRUGOTHER (acidic) or DRUGOTHER (basic), as well as DRUG2 DRUGOTHER, DRUGOTHER, thyroid and DRUGOTHER preparations, DRUGOTHER and DRUGOTHER, and DRUGOTHER.",Cholestyramine,tetracycline,True,mechanism,4,CCC1=CC=C(C=C1)C(C)CCC2=CC=C(C=C2)[N+](C)(C)C,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,0,24
1191,6395,6395,6517,6517,"DRUGOTHER DRUG1 may delay or reduce the absorption of concomitant oral medication such as DRUGOTHER, DRUGOTHER, DRUGOTHER (acidic) or DRUGOTHER (basic), as well as DRUG2 DRUGOTHER, DRUGOTHER, thyroid and DRUGOTHER preparations, DRUGOTHER and DRUGOTHER, and DRUGOTHER.",resin,tetracycline,False,Neg,0,OC1=CC(O)=CC=C1,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,1,24
1192,6404,6404,6526,6526,"DRUGOTHER DRUGOTHER may delay or reduce the absorption of concomitant oral medication such as DRUG1, DRUGOTHER, DRUGOTHER (acidic) or DRUGOTHER (basic), as well as DRUG2 DRUGOTHER, DRUGOTHER, thyroid and DRUGOTHER preparations, DRUGOTHER and DRUGOTHER, and DRUGOTHER.",phenylbutazone,tetracycline,False,Neg,0,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,14,24
1193,6412,6412,6534,6534,"DRUGOTHER DRUGOTHER may delay or reduce the absorption of concomitant oral medication such as DRUGOTHER, DRUG1, DRUGOTHER (acidic) or DRUGOTHER (basic), as well as DRUG2 DRUGOTHER, DRUGOTHER, thyroid and DRUGOTHER preparations, DRUGOTHER and DRUGOTHER, and DRUGOTHER.",warfarin,tetracycline,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,15,24
1194,6419,6419,6541,6541,"DRUGOTHER DRUGOTHER may delay or reduce the absorption of concomitant oral medication such as DRUGOTHER, DRUGOTHER, DRUGOTHER (acidic) or DRUG1 (basic), as well as DRUG2 DRUGOTHER, DRUGOTHER, thyroid and DRUGOTHER preparations, DRUGOTHER and DRUGOTHER, and DRUGOTHER.",propranolol,tetracycline,False,Neg,0,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,19,24
1195,6426,6426,6548,6548,"DRUGOTHER DRUGOTHER may delay or reduce the absorption of concomitant oral medication such as DRUGOTHER, DRUGOTHER, DRUGOTHER (acidic) or DRUGOTHER (basic), as well as DRUG1 DRUG2, DRUGOTHER, thyroid and DRUGOTHER preparations, DRUGOTHER and DRUGOTHER, and DRUGOTHER.",tetracycline,penicillin G,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O,24,25
1196,6427,6427,6549,6549,"DRUGOTHER DRUGOTHER may delay or reduce the absorption of concomitant oral medication such as DRUGOTHER, DRUGOTHER, DRUGOTHER (acidic) or DRUGOTHER (basic), as well as DRUG1 DRUGOTHER, DRUG2, thyroid and DRUGOTHER preparations, DRUGOTHER and DRUGOTHER, and DRUGOTHER.",tetracycline,phenobarbital,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,24,26
1197,6428,6428,6550,6550,"DRUGOTHER DRUGOTHER may delay or reduce the absorption of concomitant oral medication such as DRUGOTHER, DRUGOTHER, DRUGOTHER (acidic) or DRUGOTHER (basic), as well as DRUG1 DRUGOTHER, DRUGOTHER, thyroid and DRUG2 preparations, DRUGOTHER and DRUGOTHER, and DRUGOTHER.",tetracycline,thyroxine,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)O)N,24,29
1198,6429,6429,6551,6551,"DRUGOTHER DRUGOTHER may delay or reduce the absorption of concomitant oral medication such as DRUGOTHER, DRUGOTHER, DRUGOTHER (acidic) or DRUGOTHER (basic), as well as DRUG1 DRUGOTHER, DRUGOTHER, thyroid and DRUGOTHER preparations, DRUG2 and DRUGOTHER, and DRUGOTHER.",tetracycline,estrogens,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)OS(=O)(=O)[O-])[C@@H]1CCC2=O.[Na+],24,31
1199,6430,6430,6552,6552,"DRUGOTHER DRUGOTHER may delay or reduce the absorption of concomitant oral medication such as DRUGOTHER, DRUGOTHER, DRUGOTHER (acidic) or DRUGOTHER (basic), as well as DRUG1 DRUGOTHER, DRUGOTHER, thyroid and DRUGOTHER preparations, DRUGOTHER and DRUG2, and DRUGOTHER.",tetracycline,progestins,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,[H][C@@]12CC[C@@](O)(CC=C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H],24,33
1200,6431,6431,6553,6553,"DRUGOTHER DRUGOTHER may delay or reduce the absorption of concomitant oral medication such as DRUGOTHER, DRUGOTHER, DRUGOTHER (acidic) or DRUGOTHER (basic), as well as DRUG1 DRUGOTHER, DRUGOTHER, thyroid and DRUGOTHER preparations, DRUGOTHER and DRUGOTHER, and DRUG2.",tetracycline,digitalis,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,24,35
1201,6508,6508,6630,6630,"DRUG1 : DRUG1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER agents, DRUGOTHER, and DRUGOTHER).",Probenecid,furosemide,False,Neg,0,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,0,28
1202,6510,6510,6632,6632,"DRUG1 : DRUG1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER agents, DRUG2, and DRUGOTHER).",Probenecid,theophylline,False,Neg,0,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,31
1203,6520,6520,6642,6642,"DRUG1 : DRUG1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER agents, DRUGOTHER, and DRUGOTHER).",Probenecid,furosemide,True,mechanism,4,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,0,28
1204,6522,6522,6644,6644,"DRUG1 : DRUG1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER agents, DRUG2, and DRUGOTHER).",Probenecid,theophylline,True,mechanism,4,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,31
1205,6531,6531,6653,6653,"DRUGOTHER : DRUGOTHER is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER agents, DRUGOTHER, and DRUGOTHER).",acetaminophen,furosemide,False,Neg,0,CC(=O)NC1=CC=C(C=C1)O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,18,28
1206,6533,6533,6655,6655,"DRUGOTHER : DRUGOTHER is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER agents, DRUG2, and DRUGOTHER).",acetaminophen,theophylline,False,Neg,0,CC(=O)NC1=CC=C(C=C1)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,18,31
1207,6541,6541,6663,6663,"DRUGOTHER : DRUGOTHER is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER agents, DRUGOTHER, and DRUGOTHER).",acyclovir,furosemide,False,Neg,0,C1=NC2=C(N1COCCO)N=C(NC2=O)N,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,19,28
1208,6543,6543,6665,6665,"DRUGOTHER : DRUGOTHER is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER agents, DRUG2, and DRUGOTHER).",acyclovir,theophylline,False,Neg,0,C1=NC2=C(N1COCCO)N=C(NC2=O)N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,19,31
1209,6550,6550,6672,6672,"DRUGOTHER : DRUGOTHER is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER agents, DRUGOTHER, and DRUGOTHER).",aminosalicylic acid,furosemide,False,Neg,0,NC1=CC(O)=C(C=C1)C(O)=O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,21,28
1210,6552,6552,6674,6674,"DRUGOTHER : DRUGOTHER is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER agents, DRUG2, and DRUGOTHER).",aminosalicylic acid,theophylline,False,Neg,0,NC1=CC(O)=C(C=C1)C(O)=O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,21,31
1211,6558,6558,6680,6680,"DRUGOTHER : DRUGOTHER is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER agents, DRUGOTHER, and DRUGOTHER).",barbiturates,furosemide,False,Neg,0,CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,22,28
1212,6560,6560,6682,6682,"DRUGOTHER : DRUGOTHER is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER agents, DRUG2, and DRUGOTHER).",barbiturates,theophylline,False,Neg,0,CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,22,31
1213,6565,6565,6687,6687,"DRUGOTHER : DRUGOTHER is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER agents, DRUGOTHER, and DRUGOTHER).",benzodiazepines,furosemide,False,Neg,0,N1N=CC=CC2=CC=CC=C12,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,23,28
1214,6567,6567,6689,6689,"DRUGOTHER : DRUGOTHER is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER agents, DRUG2, and DRUGOTHER).",benzodiazepines,theophylline,False,Neg,0,N1N=CC=CC2=CC=CC=C12,CN1C2=C(C(=O)N(C1=O)C)NC=N2,23,31
1215,6571,6571,6693,6693,"DRUGOTHER : DRUGOTHER is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER agents, DRUGOTHER, and DRUGOTHER).",clofibrate,furosemide,False,Neg,0,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,25,28
1216,6573,6573,6695,6695,"DRUGOTHER : DRUGOTHER is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER agents, DRUG2, and DRUGOTHER).",clofibrate,theophylline,False,Neg,0,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,CN1C2=C(C(=O)N(C1=O)C)NC=N2,25,31
1217,6576,6576,6698,6698,"DRUGOTHER : DRUGOTHER is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER agents, DRUGOTHER, and DRUGOTHER).",methotrexate,furosemide,False,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,26,28
1218,6578,6578,6700,6700,"DRUGOTHER : DRUGOTHER is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER agents, DRUG2, and DRUGOTHER).",methotrexate,theophylline,False,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,26,31
1219,6580,6580,6702,6702,"DRUGOTHER : DRUGOTHER is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER agents, DRUGOTHER, and DRUGOTHER).",famotidine,furosemide,False,Neg,0,OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,27,28
1220,6582,6582,6704,6704,"DRUGOTHER : DRUGOTHER is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER agents, DRUG2, and DRUGOTHER).",famotidine,theophylline,False,Neg,0,OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,27,31
1221,6584,6584,6706,6706,"DRUGOTHER : DRUGOTHER is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2 agents, DRUGOTHER, and DRUGOTHER).",furosemide,nonsteroidal anti-inflammatory,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,28,29
1222,6586,6586,6708,6708,"DRUGOTHER : DRUGOTHER is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER agents, DRUGOTHER, and DRUG2).",furosemide,zidovudine,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],28,33
1223,6587,6587,6709,6709,"DRUGOTHER : DRUGOTHER is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 agents, DRUG2, and DRUGOTHER).",nonsteroidal anti-inflammatory,theophylline,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,29,31
1224,6589,6589,6711,6711,"DRUGOTHER : DRUGOTHER is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER agents, DRUG1, and DRUG2).",theophylline,zidovudine,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],31,33
1225,6597,6597,6719,6719,"Nephrotoxic agents : Concomitant administration of DRUGOTHER and agents with nephrotoxic potential [e.g., intravenous DRUG1 (e.g., DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER, DRUGOTHER, intravenous DRUGOTHER, DRUG2, and DRUGOTHER] is contraindicated.",aminoglycosides,vancomycin,False,Neg,0,OC(=O)CCCCCCCC(O)=O,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,14,24
1226,6604,6604,6726,6726,"Nephrotoxic agents : Concomitant administration of DRUGOTHER and agents with nephrotoxic potential [e.g., intravenous DRUGOTHER (e.g., DRUG1, DRUGOTHER, and DRUGOTHER), DRUGOTHER, DRUGOTHER, intravenous DRUGOTHER, DRUG2, and DRUGOTHER] is contraindicated.",tobramycin,vancomycin,False,Neg,0,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,16,24
1227,6610,6610,6732,6732,"Nephrotoxic agents : Concomitant administration of DRUGOTHER and agents with nephrotoxic potential [e.g., intravenous DRUGOTHER (e.g., DRUGOTHER, DRUG1, and DRUGOTHER), DRUGOTHER, DRUGOTHER, intravenous DRUGOTHER, DRUG2, and DRUGOTHER] is contraindicated.",gentamicin,vancomycin,False,Neg,0,CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,17,24
1228,6615,6615,6737,6737,"Nephrotoxic agents : Concomitant administration of DRUGOTHER and agents with nephrotoxic potential [e.g., intravenous DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, and DRUG1), DRUGOTHER, DRUGOTHER, intravenous DRUGOTHER, DRUG2, and DRUGOTHER] is contraindicated.",amikacin,vancomycin,False,Neg,0,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@H](CCN)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,19,24
1229,6619,6619,6741,6741,"Nephrotoxic agents : Concomitant administration of DRUGOTHER and agents with nephrotoxic potential [e.g., intravenous DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUG1, DRUGOTHER, intravenous DRUGOTHER, DRUG2, and DRUGOTHER] is contraindicated.",amphotericin B,vancomycin,False,Neg,0,C[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,20,24
1230,6622,6622,6744,6744,"Nephrotoxic agents : Concomitant administration of DRUGOTHER and agents with nephrotoxic potential [e.g., intravenous DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER, DRUG1, intravenous DRUGOTHER, DRUG2, and DRUGOTHER] is contraindicated.",foscarnet,vancomycin,False,Neg,0,NC(=O)NC1NC(=O)NC1=O,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,21,24
1231,6624,6624,6746,6746,"Nephrotoxic agents : Concomitant administration of DRUGOTHER and agents with nephrotoxic potential [e.g., intravenous DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER, DRUGOTHER, intravenous DRUG1, DRUG2, and DRUGOTHER] is contraindicated.",pentamidine,vancomycin,False,Neg,0,OC(=O)CCCCCCCC(O)=O,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,23,24
1232,6626,6626,6748,6748,"Nephrotoxic agents : Concomitant administration of DRUGOTHER and agents with nephrotoxic potential [e.g., intravenous DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER, DRUGOTHER, intravenous DRUGOTHER, DRUG1, and DRUG2] is contraindicated.",vancomycin,non-steroidal anti-inflammatory agents,False,Neg,0,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,24,26
1233,6632,6632,6757,6757,"DRUG1, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, certain DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,phenytoin,True,mechanism,4,CN\C(NCCSCC1=C(C)NC=N1)=N\C#N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,20
1234,6638,6638,6763,6763,"DRUG1, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, certain DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,theophylline,True,mechanism,4,CN\C(NCCSCC1=C(C)NC=N1)=N\C#N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,28
1235,6640,6640,6765,6765,"DRUGOTHER, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, certain DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER, thereby delaying elimination and increasing blood levels of these drugs.",warfarin-type anticoagulants,phenytoin,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,19,20
1236,6646,6646,6771,6771,"DRUGOTHER, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, certain DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER, thereby delaying elimination and increasing blood levels of these drugs.",warfarin-type anticoagulants,theophylline,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,19,28
1237,6648,6648,6773,6773,"DRUGOTHER, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, certain DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER, thereby delaying elimination and increasing blood levels of these drugs.",phenytoin,propranolol,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,20,21
1238,6649,6649,6774,6774,"DRUGOTHER, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, certain DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER, thereby delaying elimination and increasing blood levels of these drugs.",phenytoin,nifedipine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,20,22
1239,6650,6650,6775,6775,"DRUGOTHER, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, certain DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER, thereby delaying elimination and increasing blood levels of these drugs.",phenytoin,chlordiazepoxide,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1,20,23
1240,6651,6651,6776,6776,"DRUGOTHER, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, certain DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER, thereby delaying elimination and increasing blood levels of these drugs.",phenytoin,diazepam,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,20,24
1241,6652,6652,6777,6777,"DRUGOTHER, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, certain DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER, thereby delaying elimination and increasing blood levels of these drugs.",phenytoin,tricyclic antidepressants,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,20,26
1242,6654,6654,6779,6779,"DRUGOTHER, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, certain DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2, thereby delaying elimination and increasing blood levels of these drugs.",phenytoin,metronidazole,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=NC=C(N1CCO)[N+](=O)[O-],20,30
1243,6659,6659,6784,6784,"DRUGOTHER, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, certain DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER, thereby delaying elimination and increasing blood levels of these drugs.",propranolol,theophylline,False,Neg,0,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,21,28
1244,6664,6664,6789,6789,"DRUGOTHER, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, certain DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER, thereby delaying elimination and increasing blood levels of these drugs.",nifedipine,theophylline,False,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,CN1C2=C(C(=O)N(C1=O)C)NC=N2,22,28
1245,6668,6668,6793,6793,"DRUGOTHER, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, certain DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER, thereby delaying elimination and increasing blood levels of these drugs.",chlordiazepoxide,theophylline,False,Neg,0,CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,23,28
1246,6671,6671,6796,6796,"DRUGOTHER, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, certain DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER, thereby delaying elimination and increasing blood levels of these drugs.",diazepam,theophylline,False,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,CN1C2=C(C(=O)N(C1=O)C)NC=N2,24,28
1247,6673,6673,6798,6798,"DRUGOTHER, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, certain DRUG1, DRUGOTHER, DRUG2 and DRUGOTHER, thereby delaying elimination and increasing blood levels of these drugs.",tricyclic antidepressants,theophylline,False,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CN1C2=C(C(=O)N(C1=O)C)NC=N2,26,28
1248,6675,6675,6800,6800,"DRUGOTHER, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, certain DRUGOTHER, DRUGOTHER, DRUG1 and DRUG2, thereby delaying elimination and increasing blood levels of these drugs.",theophylline,metronidazole,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1=NC=C(N1CCO)[N+](=O)[O-],28,30
1249,6678,6678,6803,6803,"However, a crossover study in healthy subjects receiving either DRUG1 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of DRUG2 (DRUGOTHER , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state DRUG2 peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.",Tagamet,theophylline,True,mechanism,4,CN\C(NCCSCC1=C(C)NC=N1)=N\C#N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,9,25
1250,6679,6679,6804,6804,"However, a crossover study in healthy subjects receiving either DRUG1 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of DRUGOTHER (DRUG2 , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state DRUGOTHER peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.",Tagamet,Theo-Dur,True,mechanism,4,CN\C(NCCSCC1=C(C)NC=N1)=N\C#N,CN1C2=C(NC=N2)C(=O)N(C)C1=O,9,26
1251,6680,6680,6805,6805,"However, a crossover study in healthy subjects receiving either DRUG1 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of DRUG2 (DRUGOTHER , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state DRUG2 peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.",Tagamet,theophylline,False,Neg,0,CN\C(NCCSCC1=C(C)NC=N1)=N\C#N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,9,25
1252,6685,6685,6810,6810,"Therefore, dose adjustments of concomitant medications that are predominantly metabolized by CYP2D6 and have a narrow therapeutic index (e.g., DRUG1, DRUGOTHER, DRUG2 and most DRUGOTHER) may be required.",flecainide,thioridazine,False,Neg,0,C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,19,21
1253,6687,6687,6812,6812,"Therefore, dose adjustments of concomitant medications that are predominantly metabolized by CYP2D6 and have a narrow therapeutic index (e.g., DRUGOTHER, DRUG1, DRUG2 and most DRUGOTHER) may be required.",vinblastine,thioridazine,False,Neg,0,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,20,21
1254,6689,6689,6814,6814,"Therefore, dose adjustments of concomitant medications that are predominantly metabolized by CYP2D6 and have a narrow therapeutic index (e.g., DRUGOTHER, DRUGOTHER, DRUG1 and most DRUG2) may be required.",thioridazine,tricyclic antidepressants,False,Neg,0,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,21,24
1255,6697,6697,6826,6826,There have been reports of DRUG1-related side-effects in patients on concomitant DRUG1-DRUG2 therapy.,theophylline,quinolone,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C(=O)C=CC2=CC=CC=C12,5,11
1256,6698,6698,6827,6827,There have been reports of DRUG1-related side-effects in patients on concomitant DRUG1-DRUG2 therapy.,theophylline,quinolone,True,effect,2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C(=O)C=CC2=CC=CC=C12,5,11
1257,6710,6710,6844,6844,"Some DRUGOTHER, including DRUG1, have also been shown to interfere with the metabolism of DRUG2.",ciprofloxacin,caffeine,True,mechanism,4,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,3,14
1258,6756,6756,6890,6890,DRUG1: Altered serum levels of DRUGOTHER (increased and decreased) have been reported in patients receiving concomitant DRUG2.,Phenytoin,ciprofloxacin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O,0,16
1259,6757,6757,6891,6891,DRUGOTHER: Altered serum levels of DRUG1 (increased and decreased) have been reported in patients receiving concomitant DRUG2.,phenytoin,ciprofloxacin,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O,5,16
1260,6764,6764,6898,6898,"DRUG1: As with some other DRUGOTHER, concurrent administration of DRUG2 with DRUGOTHER may lead to elevated serum concentrations of DRUGOTHER and prolongation of its elimination half-life.",Theophylline,ciprofloxacin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O,0,9
1261,6767,6767,6901,6901,"DRUGOTHER: As with some other DRUGOTHER, concurrent administration of DRUG1 with DRUG2 may lead to elevated serum concentrations of DRUG2 and prolongation of its elimination half-life.",ciprofloxacin,theophylline,True,mechanism,4,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,9,11
1262,6768,6768,6902,6902,"DRUGOTHER: As with some other DRUGOTHER, concurrent administration of DRUG1 with DRUG2 may lead to elevated serum concentrations of DRUG2 and prolongation of its elimination half-life.",ciprofloxacin,theophylline,False,Neg,0,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,9,11
1263,6793,6793,6934,6934,"DRUG1: In vitro data indicate that DRUG2 inhibits the metabolism of DRUGOTHER, which can result in an increase in plasma DRUGOTHER levels and prolongation of the QT interval on the ECG.",Antidepressants,nefazodone,False,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,0,6
1264,6796,6796,6937,6937,"DRUGOTHER: In vitro data indicate that DRUG1 inhibits the metabolism of DRUG2, which can result in an increase in plasma DRUG2 levels and prolongation of the QT interval on the ECG.",nefazodone,cisapride,True,mechanism,4,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,6,11
1265,6797,6797,6938,6938,"DRUGOTHER: In vitro data indicate that DRUG1 inhibits the metabolism of DRUG2, which can result in an increase in plasma DRUG2 levels and prolongation of the QT interval on the ECG.",nefazodone,cisapride,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,6,11
1266,6827,6827,6968,6968,DRUGOTHER: In vitro data indicate that DRUG1 and DRUG2 markedly inhibit the metabolism of DRUGOTHER which can result in an increase in plasma DRUGOTHER levels and prolongation of the QT interval on the ECG.,indinavir,ritonavir,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,6,8
1267,6830,6830,6971,6971,DRUGOTHER: In vitro data indicate that DRUGOTHER and DRUG1 markedly inhibit the metabolism of DRUG2 which can result in an increase in plasma DRUG2 levels and prolongation of the QT interval on the ECG.,ritonavir,cisapride,True,mechanism,4,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,8,14
1268,6831,6831,6972,6972,DRUGOTHER: In vitro data indicate that DRUGOTHER and DRUG1 markedly inhibit the metabolism of DRUG2 which can result in an increase in plasma DRUG2 levels and prolongation of the QT interval on the ECG.,ritonavir,cisapride,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,8,14
1269,6841,6841,6983,6983,"DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER.",astemizole,bepridil,False,Neg,0,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,0,1
1270,6843,6843,6985,6985,"DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER.",bepridil,sparfloxacin,False,Neg,0,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,C[C@H]1CN(C[C@@H](C)N1)C1=C(F)C(N)=C2C(=O)C(=CN(C3CC3)C2=C1F)C(O)=O,1,2
1271,6948,6948,7092,7092,Resistance to the neuromuscular blocking action of DRUG1 has been demonstrated in patients chronically administered DRUG2 or DRUGOTHER.,nondepolarizing neuromuscular blocking agents,phenytoin,True,effect,2,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,7,15
1272,6950,6950,7094,7094,Resistance to the neuromuscular blocking action of DRUGOTHER has been demonstrated in patients chronically administered DRUG1 or DRUG2.,phenytoin,carbamazepine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,15,17
1273,6951,6951,7095,7095,"While the effects of chronic DRUG1 or DRUG2 therapy on the action of DRUGOTHER are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.",phenytoin,carbamazepine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,5,7
1274,6952,6952,7096,7096,"While the effects of chronic DRUG1 or DRUGOTHER therapy on the action of DRUG2 are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.",phenytoin,NIMBEX,True,effect,2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,COC1=CC2=C(C=C1OC)[C@@H](CC1=CC(OC)=C(OC)C=C1)[N@@+](C)(CCC(=O)OCCCCCOC(=O)CC[N@@+]1(C)CCC3=C(C=C(OC)C(OC)=C3)[C@H]1CC1=CC(OC)=C(OC)C=C1)CC2,5,13
1275,6987,6987,7131,7131,"Additive CNS depression may occur when DRUG1 are administered concomitantly with other DRUG2 including DRUGOTHER, DRUGOTHER, and DRUGOTHER.",antihistamines,CNS depressants,True,effect,2,NCCC1=CNC=N1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,6,12
1276,6991,6991,7135,7135,"Additive CNS depression may occur when DRUGOTHER are administered concomitantly with other DRUG1 including DRUG2, DRUGOTHER, and DRUGOTHER.",CNS depressants,barbiturates,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O,12,14
1277,6992,6992,7136,7136,"Additive CNS depression may occur when DRUGOTHER are administered concomitantly with other DRUG1 including DRUGOTHER, DRUG2, and DRUGOTHER.",CNS depressants,tranquilizers,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,12,15
1278,6993,6993,7137,7137,"Additive CNS depression may occur when DRUGOTHER are administered concomitantly with other DRUG1 including DRUGOTHER, DRUGOTHER, and DRUG2.",CNS depressants,alcohol,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCO,12,17
1279,6997,6997,7141,7141,Patients receiving DRUG1 should be advised against the concurrent use of other DRUG2.,antihistamines,CNS depressant drugs,True,advise,1,NCCC1=CNC=N1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,2,12
1280,7006,7006,7155,7155,DRUG1 may displace acidic drugs such as DRUG2 or DRUGOTHER from their binding sites.,Atromid-S,phenytoin,True,mechanism,4,CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,7
1281,7008,7008,7157,7157,DRUGOTHER may displace acidic drugs such as DRUG1 or DRUG2 from their binding sites.,phenytoin,tolbutamide,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,7,9
1282,7013,7013,7164,7164,"Several DRUG1 have been reported to block the pharmacologic effects of DRUG2, DRUGOTHER, or similar agents, and such an effect may be anticipated with DRUGOTHER because of its structural similarity to other DRUG1.",tricyclic antidepressants,guanethidine,True,effect,2,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,C1CCCN(CCC1)CCN=C(N)N,1,11
1283,7016,7016,7167,7167,"Several DRUGOTHER have been reported to block the pharmacologic effects of DRUG1, DRUG2, or similar agents, and such an effect may be anticipated with DRUGOTHER because of its structural similarity to other DRUGOTHER.",guanethidine,clonidine,False,Neg,0,C1CCCN(CCC1)CCN=C(N)N,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl,11,12
1284,7017,7017,7168,7168,"Several DRUG2 have been reported to block the pharmacologic effects of DRUG1, DRUGOTHER, or similar agents, and such an effect may be anticipated with DRUGOTHER because of its structural similarity to other DRUG2.",guanethidine,tricyclic antidepressants,False,Neg,0,C1CCCN(CCC1)CCN=C(N)N,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,11,1
1285,7023,7023,7174,7174,"plasma levels of several closely related DRUG1 have been reported to be increased by the concomitant administration of DRUGOTHER or hepatic enzyme inhibitors (e.g., DRUGOTHER, DRUGOTHER) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., DRUGOTHER, DRUG2), and such an effect may be anticipated with DRUGOTHER as well.",tricyclic antidepressants,phenytoin,True,mechanism,4,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,6,38
1286,7027,7027,7178,7178,"plasma levels of several closely related DRUGOTHER have been reported to be increased by the concomitant administration of DRUG1 or hepatic enzyme inhibitors (e.g., DRUGOTHER, DRUGOTHER) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., DRUGOTHER, DRUG2), and such an effect may be anticipated with DRUGOTHER as well.",methylphenidate,phenytoin,False,Neg,0,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,18,38
1287,7030,7030,7181,7181,"plasma levels of several closely related DRUGOTHER have been reported to be increased by the concomitant administration of DRUGOTHER or hepatic enzyme inhibitors (e.g., DRUG1, DRUGOTHER) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., DRUGOTHER, DRUG2), and such an effect may be anticipated with DRUGOTHER as well.",cimetidine,phenytoin,False,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,24,38
1288,7032,7032,7183,7183,"plasma levels of several closely related DRUGOTHER have been reported to be increased by the concomitant administration of DRUGOTHER or hepatic enzyme inhibitors (e.g., DRUGOTHER, DRUG1) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., DRUGOTHER, DRUG2), and such an effect may be anticipated with DRUGOTHER as well.",fluoxetine,phenytoin,False,Neg,0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,25,38
1289,7033,7033,7184,7184,"plasma levels of several closely related DRUGOTHER have been reported to be increased by the concomitant administration of DRUGOTHER or hepatic enzyme inhibitors (e.g., DRUGOTHER, DRUGOTHER) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., DRUG1, DRUG2), and such an effect may be anticipated with DRUGOTHER as well.",barbiturates,phenytoin,False,Neg,0,CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,37,38
1290,7044,7044,7195,7195,"While all the DRUG1 (DRUGOTHER), e.g., DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER, inhibit P450 2D6, they may vary in the extent of inhibition.",selective serotonin reuptake inhibitors,fluoxetine,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,3,6
1291,7045,7045,7196,7196,"While all the DRUG1 (DRUGOTHER), e.g., DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER, inhibit P450 2D6, they may vary in the extent of inhibition.",selective serotonin reuptake inhibitors,sertraline,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,3,7
1292,7046,7046,7197,7197,"While all the DRUG1 (DRUGOTHER), e.g., DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER, inhibit P450 2D6, they may vary in the extent of inhibition.",selective serotonin reuptake inhibitors,paroxetine,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,3,8
1293,7047,7047,7198,7198,"While all the DRUG1 (DRUGOTHER), e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2, inhibit P450 2D6, they may vary in the extent of inhibition.",selective serotonin reuptake inhibitors,fluvoxamine,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,3,10
1294,7064,7064,7215,7215,"Effect of DRUG1 on the Pharmacokinetics of Other Drugs: DRUG1 does not appear to alter the pharmacokinetics of DRUG2, DRUGOTHER, or DRUGOTHER.",Clonazepam,phenytoin,False,Neg,0,[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,2,18
1295,7067,7067,7218,7218,"Effect of DRUG1 on the Pharmacokinetics of Other Drugs: DRUG1 does not appear to alter the pharmacokinetics of DRUG2, DRUGOTHER, or DRUGOTHER.",Clonazepam,phenytoin,False,Neg,0,[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,2,18
1296,7070,7070,7221,7221,"Effect of DRUGOTHER on the Pharmacokinetics of Other Drugs: DRUGOTHER does not appear to alter the pharmacokinetics of DRUG1, DRUG2, or DRUGOTHER.",phenytoin,carbamazepine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,18,19
1297,7071,7071,7222,7222,"Effect of DRUGOTHER on the Pharmacokinetics of Other Drugs: DRUGOTHER does not appear to alter the pharmacokinetics of DRUG1, DRUGOTHER, or DRUG2.",phenytoin,phenobarbital,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,18,21
1298,7092,7092,7243,7243,"Cytochrome P-450 inducers, such as DRUG1, DRUG2 and DRUGOTHER, induce DRUGOTHER metabolism, causing an approximately 30% decrease in plasma DRUGOTHER levels.",phenytoin,carbamazepine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,5,6
1299,7093,7093,7244,7244,"Cytochrome P-450 inducers, such as DRUG1, DRUGOTHER and DRUG2, induce DRUGOTHER metabolism, causing an approximately 30% decrease in plasma DRUGOTHER levels.",phenytoin,phenobarbital,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,5,8
1300,7094,7094,7245,7245,"Cytochrome P-450 inducers, such as DRUG1, DRUGOTHER and DRUGOTHER, induce DRUG2 metabolism, causing an approximately 30% decrease in plasma DRUG2 levels.",phenytoin,clonazepam,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,5,10
1301,7095,7095,7246,7246,"Cytochrome P-450 inducers, such as DRUG1, DRUGOTHER and DRUGOTHER, induce DRUG2 metabolism, causing an approximately 30% decrease in plasma DRUG2 levels.",phenytoin,clonazepam,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,5,10
1302,7205,7205,7356,7356,"DRUG1, DRUG2, and DRUGOTHER may decrease DRUGOTHER plasma levels, resulting in a decrease in effectiveness of a previously effective DRUGOTHER dose.",Phenytoin,nicotine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN1CCC[C@H]1C2=CN=CC=C2,0,1
1303,7206,7206,7357,7357,"DRUG1, DRUGOTHER, and DRUG2 may decrease DRUGOTHER plasma levels, resulting in a decrease in effectiveness of a previously effective DRUGOTHER dose.",Phenytoin,rifampin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,0,3
1304,7207,7207,7358,7358,"DRUG1, DRUGOTHER, and DRUGOTHER may decrease DRUG2 plasma levels, resulting in a decrease in effectiveness of a previously effective DRUG2 dose.",Phenytoin,Clozapine,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1,0,6
1305,7208,7208,7359,7359,"DRUG1, DRUGOTHER, and DRUGOTHER may decrease DRUG2 plasma levels, resulting in a decrease in effectiveness of a previously effective DRUG2 dose.",Phenytoin,Clozapine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1,0,6
1306,7215,7215,7366,7366,"DRUG1, DRUG2, and DRUGOTHER may increase plasma levels of DRUGOTHER, potentially resulting in adverse effects.",Cimetidine,caffeine,False,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,0,1
1307,7218,7218,7369,7369,"DRUGOTHER, DRUG1, and DRUG2 may increase plasma levels of DRUGOTHER, potentially resulting in adverse effects.",caffeine,erythromycin,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1,3
1308,7219,7219,7370,7370,"DRUGOTHER, DRUG1, and DRUGOTHER may increase plasma levels of DRUG2, potentially resulting in adverse effects.",caffeine,Clozapine,True,mechanism,4,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1,1,9
1309,7248,7248,7399,7399,"Such individuals are referred to as poor metabolizers of drugs such as DRUG1, DRUG2, the DRUGOTHER, and DRUGOTHER.",debrisoquin,dextromethorphan,False,Neg,0,NC(=N)N1CCC2=CC=CC=C2C1,[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C,12,13
1310,7251,7251,7402,7402,"Such individuals are referred to as poor metabolizers of drugs such as DRUGOTHER, DRUG1, the DRUG2, and DRUGOTHER.",dextromethorphan,tricyclic antidepressants,False,Neg,0,[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,13,15
1311,7252,7252,7403,7403,"Such individuals are referred to as poor metabolizers of drugs such as DRUGOTHER, DRUG1, the DRUGOTHER, and DRUG2.",dextromethorphan,clozapine,False,Neg,0,[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1,13,17
1312,7255,7255,7406,7406,"In addition, certain drugs that are metabolized by this isozyme, including many DRUG1 (DRUGOTHER, DRUG2, and others), may inhibit the activity of this isozyme, and thus may make normal metabolizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interaction.",antidepressants,selective serotonin reuptake inhibitors,False,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,NCCC1=CNC2=CC=C(O)C=C12,12,14
1313,7256,7256,7407,7407,"In addition, certain drugs that are metabolized by this isozyme, including many DRUGOTHER (DRUG1, DRUG2, and others), may inhibit the activity of this isozyme, and thus may make normal metabolizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interaction.",clozapine,selective serotonin reuptake inhibitors,False,Neg,0,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1,NCCC1=CNC2=CC=C(O)C=C12,13,14
1314,7286,7286,7437,7437,"Although the specific drug interaction was not studied in a clinical trial, there have been more than 50 episodes of concomitant use of antifibrinolytic therapies (i.e., DRUG1, DRUG2) and DRUGOTHER.",tranexamic acid,aminocaproic acid,False,Neg,0,NC[C@H]1CC[C@@H](CC1)C(O)=O,NCCCCCC(O)=O,26,27
1315,7290,7290,7441,7441,"DRUGOTHER in combination with other DRUG1, general DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or other DRUG2 (including DRUGOTHER) has additive depressant effects.",narcotic analgesics,CNS depressants,False,Neg,0,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,5,13
1316,7294,7294,7445,7445,"DRUGOTHER in combination with other DRUGOTHER, general DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, or other DRUG2 (including DRUGOTHER) has additive depressant effects.",anesthetics,CNS depressants,False,Neg,0,CCOC(=O)C1=CC=C(N)C=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,7,13
1317,7297,7297,7448,7448,"DRUGOTHER in combination with other DRUGOTHER, general DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, or other DRUG2 (including DRUGOTHER) has additive depressant effects.",phenothiazines,CNS depressants,False,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,8,13
1318,7299,7299,7450,7450,"DRUGOTHER in combination with other DRUGOTHER, general DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, or other DRUG2 (including DRUGOTHER) has additive depressant effects.",tranquilizers,CNS depressants,False,Neg,0,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,9,13
1319,7301,7301,7452,7452,"DRUGOTHER in combination with other DRUGOTHER, general DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or other DRUG1 (including DRUG2) has additive depressant effects.",CNS depressants,alcohol,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCO,13,15
1320,7324,7324,7477,7477,"The absorption of DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER was significantly decreased when given simultaneously with DRUGOTHER;",tetracycline,penicillin G,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O,3,5
1321,7326,7326,7479,7479,"The absorption of DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2 was significantly decreased when given simultaneously with DRUGOTHER;",tetracycline,gemfibrozil,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O,3,8
1322,7327,7327,7480,7480,"The absorption of DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER was significantly decreased when given simultaneously with DRUGOTHER;",furosemide,penicillin G,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O,4,5
1323,7329,7329,7482,7482,"The absorption of DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2 was significantly decreased when given simultaneously with DRUGOTHER;",furosemide,gemfibrozil,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O,4,8
1324,7330,7330,7483,7483,"The absorption of DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER was significantly decreased when given simultaneously with DRUGOTHER;",penicillin G,hydrochlorothiazide,False,Neg,0,CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,5,6
1325,7332,7332,7485,7485,"The absorption of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2 was significantly decreased when given simultaneously with DRUGOTHER;",hydrochlorothiazide,gemfibrozil,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O,6,8
1326,7339,7339,7492,7492,"No depressant effect on blood levels in humans was noted when DRUGOTHER was administered with any of the following drugs: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER, DRUG2 or DRUGOTHER.",aspirin,phenytoin,False,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,20,27
1327,7346,7346,7499,7499,"No depressant effect on blood levels in humans was noted when DRUGOTHER was administered with any of the following drugs: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER, DRUG2 or DRUGOTHER.",clindamycin,phenytoin,False,Neg,0,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@H](C)Cl,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,21,27
1328,7352,7352,7505,7505,"No depressant effect on blood levels in humans was noted when DRUGOTHER was administered with any of the following drugs: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER, DRUG2 or DRUGOTHER.",clofibrate,phenytoin,False,Neg,0,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,22,27
1329,7357,7357,7510,7510,"No depressant effect on blood levels in humans was noted when DRUGOTHER was administered with any of the following drugs: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (DRUGOTHER), DRUGOTHER, DRUG2 or DRUGOTHER.",methyldopa,phenytoin,False,Neg,0,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,23,27
1330,7361,7361,7514,7514,"No depressant effect on blood levels in humans was noted when DRUGOTHER was administered with any of the following drugs: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (DRUGOTHER), DRUGOTHER, DRUG2 or DRUGOTHER.",nicotinic acid,phenytoin,False,Neg,0,OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,24,27
1331,7364,7364,7517,7517,"No depressant effect on blood levels in humans was noted when DRUGOTHER was administered with any of the following drugs: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (DRUG1), DRUGOTHER, DRUG2 or DRUGOTHER.",niacin,phenytoin,False,Neg,0,NC(=O)C1=CN=CC=C1.[H]C(O)(CO)[C@@]1([H])OC(=O)C(O)=C1O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,25,27
1332,7366,7366,7519,7519,"No depressant effect on blood levels in humans was noted when DRUGOTHER was administered with any of the following drugs: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUG1, DRUG2 or DRUGOTHER.",tolbutamide,phenytoin,False,Neg,0,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,26,27
1333,7368,7368,7521,7521,"No depressant effect on blood levels in humans was noted when DRUGOTHER was administered with any of the following drugs: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER, DRUG1 or DRUG2.",phenytoin,warfarin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,27,29
1334,7391,7391,7555,7555,"Drugs that induce hepatic enzymes such as DRUG1, DRUG2 and DRUGOTHER may increase the clearance of DRUGOTHER and may require increases in DRUGOTHER dose to achieve the desired response.",phenobarbital,phenytoin,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,7,8
1335,7395,7395,7559,7559,"Drugs that induce hepatic enzymes such as DRUGOTHER, DRUG1 and DRUG2 may increase the clearance of DRUGOTHER and may require increases in DRUGOTHER dose to achieve the desired response.",phenytoin,rifampin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,8,10
1336,7396,7396,7560,7560,"Drugs that induce hepatic enzymes such as DRUGOTHER, DRUG1 and DRUGOTHER may increase the clearance of DRUG2 and may require increases in DRUGOTHER dose to achieve the desired response.",phenytoin,corticosteroids,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,8,16
1337,7397,7397,7561,7561,"Drugs that induce hepatic enzymes such as DRUGOTHER, DRUG1 and DRUGOTHER may increase the clearance of DRUG2s and may require increases in DRUG2 dose to achieve the desired response.",phenytoin,corticosteroid,True,advise,1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,8,16
1338,7423,7423,7596,7596,"DRUGOTHER may enhance the effects of DRUG1, DRUGOTHER, and other DRUG2.",alcohol,CNS depressants,False,Neg,0,CCO,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,6,10
1339,7424,7424,7597,7597,"DRUGOTHER may enhance the effects of DRUGOTHER, DRUG1, and other DRUG2.",barbiturates,CNS depressants,False,Neg,0,CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,7,10
1340,7425,7425,7598,7598,DRUG1 may block the antihypertensive action of DRUG2 and similarly acting compounds.,Tricyclic antidepressants,guanethidine,True,effect,2,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,C1CCCN(CCC1)CCN=C(N)N,0,7
1341,7427,7427,7600,7600,The rate of metabolism and the leukopenic activity of DRUG1 reportedly are increased by chronic administration of high doses of DRUG2.,cyclophosphamide,phenobarbital,True,mechanism,4,ClCCN(CCCl)P1(=O)NCCCO1,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,9,20
1342,7429,7429,7602,7602,"DRUG1 treatment, which causes a marked and persistent inhibition of cholinesterase activity, potentiates the effect of DRUG2.",Cyclophosphamide,succinylcholine chloride,True,effect,2,ClCCN(CCCl)P1(=O)NCCCO1,C[N+](C)(C)CCO,0,16
1343,7435,7435,7608,7608,"DRUG1 may have additive effects with DRUGOTHER and other DRUG2, e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",Antihistamines,CNS depressants,True,effect,2,NCCC1=CNC=N1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,0,9
1344,7438,7438,7611,7611,"DRUGOTHER may have additive effects with DRUG1 and other DRUG2, e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",alcohol,CNS depressants,False,Neg,0,CCO,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,6,9
1345,7441,7441,7614,7614,"DRUGOTHER may have additive effects with DRUGOTHER and other DRUG1, e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER.",CNS depressants,tranquilizers,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,9,13
1346,7442,7442,7615,7615,"DRUGOTHER may have additive effects with DRUGOTHER and other DRUG1, e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2.",CNS depressants,antianxiety agents,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,9,14
1347,7445,7445,7621,7621,"Binding to plasma protein is not significantly altered by DRUG1, DRUG2, or DRUGOTHER.",diazepam,diphenylhydantoin,False,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,9,10
1348,7447,7447,7623,7623,"Binding to plasma protein is not significantly altered by DRUGOTHER, DRUG1, or DRUG2.",diphenylhydantoin,phenylbutazone,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,10,12
1349,7465,7465,7650,7650,"The daily dose of DRUGOTHER should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER and nefazadone) .",ketoconazole,ritonavir,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,17,19
1350,7468,7468,7653,7653,"The daily dose of DRUGOTHER should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER and nefazadone) .",itraconazole,ritonavir,False,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,18,19
1351,7471,7471,7656,7656,"The daily dose of DRUGOTHER should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER and nefazadone) .",ritonavir,nelfinavir,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,19,20
1352,7472,7472,7657,7657,"The daily dose of DRUGOTHER should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2 and nefazadone) .",ritonavir,clarithromycin,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,19,21
1353,7474,7474,7659,7659,"Caution should be taken when DRUGOTHER is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as DRUG1, DRUG2 and DRUGOTHER (see CLINICAL PHARMACOLOGY).",flecainide,thioridazine,False,Neg,0,C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,26,27
1354,7476,7476,7661,7661,"Caution should be taken when DRUGOTHER is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as DRUGOTHER, DRUG1 and DRUG2 (see CLINICAL PHARMACOLOGY).",thioridazine,tricyclic antidepressants,False,Neg,0,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,27,29
1355,7478,7478,7663,7663,"Concomitant use of DRUG1 and drugs that inhibit CYP3A4 (eg, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",SPRYCEL,ketoconazole,True,mechanism,4,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,3,10
1356,7479,7479,7664,7664,"Concomitant use of DRUG1 and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",SPRYCEL,itraconazole,True,mechanism,4,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,3,11
1357,7480,7480,7665,7665,"Concomitant use of DRUG1 and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",SPRYCEL,erythromycin,True,mechanism,4,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,3,12
1358,7481,7481,7666,7666,"Concomitant use of DRUG1 and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",SPRYCEL,clarithromycin,True,mechanism,4,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,3,13
1359,7483,7483,7668,7668,"Concomitant use of DRUG1 and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",SPRYCEL,atazanavir,True,mechanism,4,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,3,15
1360,7484,7484,7669,7669,"Concomitant use of DRUG1 and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",SPRYCEL,indinavir,True,mechanism,4,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,3,16
1361,7486,7486,7671,7671,"Concomitant use of DRUG1 and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",SPRYCEL,nelfinavir,True,mechanism,4,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,3,18
1362,7493,7493,7678,7678,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",ketoconazole,ritonavir,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,10,14
1363,7496,7496,7681,7681,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",ketoconazole,nefazodone,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,10,17
1364,7498,7498,7683,7683,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",ketoconazole,saquinavir,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,10,19
1365,7499,7499,7684,7684,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) may increase exposure to DRUGOTHER and should be avoided.",ketoconazole,telithromycin,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,10,20
1366,7500,7500,7685,7685,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increase exposure to DRUG2 and should be avoided.",ketoconazole,dasatinib,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,10,25
1367,7503,7503,7688,7688,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",itraconazole,ritonavir,False,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,11,14
1368,7506,7506,7691,7691,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",itraconazole,nefazodone,False,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,11,17
1369,7508,7508,7693,7693,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",itraconazole,saquinavir,False,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,11,19
1370,7509,7509,7694,7694,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) may increase exposure to DRUGOTHER and should be avoided.",itraconazole,telithromycin,False,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,11,20
1371,7510,7510,7695,7695,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increase exposure to DRUG2 and should be avoided.",itraconazole,dasatinib,False,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,11,25
1372,7512,7512,7697,7697,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",erythromycin,ritonavir,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,12,14
1373,7515,7515,7700,7700,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",erythromycin,nefazodone,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,12,17
1374,7517,7517,7702,7702,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",erythromycin,saquinavir,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,12,19
1375,7518,7518,7703,7703,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) may increase exposure to DRUGOTHER and should be avoided.",erythromycin,telithromycin,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,12,20
1376,7519,7519,7704,7704,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increase exposure to DRUG2 and should be avoided.",erythromycin,dasatinib,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,12,25
1377,7520,7520,7705,7705,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",clarithromycin,ritonavir,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,13,14
1378,7523,7523,7708,7708,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",clarithromycin,nefazodone,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,13,17
1379,7525,7525,7710,7710,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",clarithromycin,saquinavir,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,13,19
1380,7526,7526,7711,7711,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) may increase exposure to DRUGOTHER and should be avoided.",clarithromycin,telithromycin,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,13,20
1381,7527,7527,7712,7712,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increase exposure to DRUG2 and should be avoided.",clarithromycin,dasatinib,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,13,25
1382,7528,7528,7713,7713,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",ritonavir,atazanavir,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,14,15
1383,7529,7529,7714,7714,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",ritonavir,indinavir,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,14,16
1384,7531,7531,7716,7716,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",ritonavir,nelfinavir,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,14,18
1385,7536,7536,7721,7721,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",atazanavir,nefazodone,False,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,15,17
1386,7538,7538,7723,7723,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",atazanavir,saquinavir,False,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,15,19
1387,7539,7539,7724,7724,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) may increase exposure to DRUGOTHER and should be avoided.",atazanavir,telithromycin,False,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,15,20
1388,7540,7540,7725,7725,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increase exposure to DRUG2 and should be avoided.",atazanavir,dasatinib,False,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,15,25
1389,7541,7541,7726,7726,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",indinavir,nefazodone,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,16,17
1390,7543,7543,7728,7728,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",indinavir,saquinavir,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,16,19
1391,7544,7544,7729,7729,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) may increase exposure to DRUGOTHER and should be avoided.",indinavir,telithromycin,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,16,20
1392,7545,7545,7730,7730,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increase exposure to DRUG2 and should be avoided.",indinavir,dasatinib,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,16,25
1393,7546,7546,7731,7731,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",nefazodone,nelfinavir,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,17,18
1394,7550,7550,7735,7735,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",nelfinavir,saquinavir,False,Neg,0,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,18,19
1395,7551,7551,7736,7736,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2) may increase exposure to DRUGOTHER and should be avoided.",nelfinavir,telithromycin,False,Neg,0,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,18,20
1396,7552,7552,7737,7737,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER) may increase exposure to DRUG2 and should be avoided.",nelfinavir,dasatinib,False,Neg,0,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,18,25
1397,7558,7558,7743,7743,"In patients in whom CYP3A4 inducers (eg, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) are indicated, alternative agents with less enzyme induction potential should be used.",dexamethasone,phenytoin,False,Neg,0,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,7,8
1398,7562,7562,7747,7747,"In patients in whom CYP3A4 inducers (eg, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER) are indicated, alternative agents with less enzyme induction potential should be used.",phenytoin,carbamazepine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,8,9
1399,7563,7563,7748,7748,"In patients in whom CYP3A4 inducers (eg, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER) are indicated, alternative agents with less enzyme induction potential should be used.",phenytoin,rifampicin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,8,10
1400,7564,7564,7749,7749,"In patients in whom CYP3A4 inducers (eg, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2) are indicated, alternative agents with less enzyme induction potential should be used.",phenytoin,phenobarbital,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,8,11
1401,7569,7569,7754,7754,"If DRUG1 therapy is needed, the DRUG1 dose should be administered at least 2 hours prior to or 2 hours after the dose of DRUG2.",antacid,SPRYCEL,True,advise,1,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,1,24
1402,7571,7571,7756,7756,"DRUGOTHER/DRUG1: Long-term suppression of gastric acid secretion by DRUGOTHER or DRUGOTHER (eg, DRUG2 and DRUGOTHER) is likely to reduce DRUGOTHER exposure.",Proton Pump Inhibitors,famotidine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1,0,12
1403,7572,7572,7757,7757,"DRUGOTHER/DRUG1: Long-term suppression of gastric acid secretion by DRUGOTHER or DRUGOTHER (eg, DRUGOTHER and DRUG2) is likely to reduce DRUGOTHER exposure.",Proton Pump Inhibitors,omeprazole,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,0,14
1404,7574,7574,7759,7759,"DRUGOTHER/DRUGOTHER: Long-term suppression of gastric acid secretion by DRUGOTHER or DRUG1 (eg, DRUG2 and DRUGOTHER) is likely to reduce DRUGOTHER exposure.",proton pump inhibitors,famotidine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1,10,12
1405,7575,7575,7760,7760,"DRUGOTHER/DRUGOTHER: Long-term suppression of gastric acid secretion by DRUGOTHER or DRUG1 (eg, DRUGOTHER and DRUG2) is likely to reduce DRUGOTHER exposure.",proton pump inhibitors,omeprazole,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,10,14
1406,7578,7578,7763,7763,"DRUGOTHER/DRUGOTHER: Long-term suppression of gastric acid secretion by DRUGOTHER or DRUGOTHER (eg, DRUG1 and DRUGOTHER) is likely to reduce DRUG2 exposure.",famotidine,dasatinib,True,effect,2,OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,12,19
1407,7579,7579,7764,7764,"DRUGOTHER/DRUGOTHER: Long-term suppression of gastric acid secretion by DRUGOTHER or DRUGOTHER (eg, DRUGOTHER and DRUG1) is likely to reduce DRUG2 exposure.",omeprazole,dasatinib,True,effect,2,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,14,19
1408,7587,7587,7772,7772,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER (DRUGOTHER, dihydroDRUGOTHER) should be administered with caution in patients receiving DRUGOTHER.",alfentanil,fentanyl,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,12,17
1409,7590,7590,7775,7775,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER (DRUGOTHER, dihydroDRUGOTHER) should be administered with caution in patients receiving DRUGOTHER.",alfentanil,sirolimus,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,12,20
1410,7595,7595,7780,7780,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER (DRUGOTHER, dihydroDRUGOTHER) should be administered with caution in patients receiving DRUG2.",alfentanil,SPRYCEL,True,advise,1,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,12,34
1411,7599,7599,7784,7784,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER (DRUGOTHER, dihydroDRUGOTHER) should be administered with caution in patients receiving DRUGOTHER.",astemizole,fentanyl,False,Neg,0,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,13,17
1412,7602,7602,7787,7787,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER (DRUGOTHER, dihydroDRUGOTHER) should be administered with caution in patients receiving DRUGOTHER.",astemizole,sirolimus,False,Neg,0,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,13,20
1413,7607,7607,7792,7792,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER (DRUGOTHER, dihydroDRUGOTHER) should be administered with caution in patients receiving DRUG2.",astemizole,SPRYCEL,True,advise,1,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,13,34
1414,7610,7610,7795,7795,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER (DRUGOTHER, dihydroDRUGOTHER) should be administered with caution in patients receiving DRUGOTHER.",terfenadine,fentanyl,False,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,14,17
1415,7613,7613,7798,7798,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER (DRUGOTHER, dihydroDRUGOTHER) should be administered with caution in patients receiving DRUGOTHER.",terfenadine,sirolimus,False,Neg,0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,14,20
1416,7618,7618,7803,7803,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER (DRUGOTHER, dihydroDRUGOTHER) should be administered with caution in patients receiving DRUG2.",terfenadine,SPRYCEL,True,advise,1,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,14,34
1417,7620,7620,7805,7805,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER (DRUGOTHER, dihydroDRUGOTHER) should be administered with caution in patients receiving DRUGOTHER.",cisapride,fentanyl,False,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,15,17
1418,7623,7623,7808,7808,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER (DRUGOTHER, dihydroDRUGOTHER) should be administered with caution in patients receiving DRUGOTHER.",cisapride,sirolimus,False,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,15,20
1419,7628,7628,7813,7813,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER (DRUGOTHER, dihydroDRUGOTHER) should be administered with caution in patients receiving DRUG2.",cisapride,SPRYCEL,True,advise,1,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,15,34
1420,7629,7629,7814,7814,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER (DRUGOTHER, dihydroDRUGOTHER) should be administered with caution in patients receiving DRUGOTHER.",cyclosporine,fentanyl,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,16,17
1421,7632,7632,7817,7817,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER (DRUGOTHER, dihydroDRUGOTHER) should be administered with caution in patients receiving DRUGOTHER.",cyclosporine,sirolimus,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,16,20
1422,7637,7637,7822,7822,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER (DRUGOTHER, dihydroDRUGOTHER) should be administered with caution in patients receiving DRUG2.",cyclosporine,SPRYCEL,True,advise,1,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,16,34
1423,7638,7638,7823,7823,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER (DRUGOTHER, dihydroDRUGOTHER) should be administered with caution in patients receiving DRUGOTHER.",fentanyl,pimozide,False,Neg,0,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,17,18
1424,7639,7639,7824,7824,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER (DRUGOTHER, dihydroDRUGOTHER) should be administered with caution in patients receiving DRUGOTHER.",fentanyl,quinidine,False,Neg,0,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,17,19
1425,7641,7641,7826,7826,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER (DRUGOTHER, dihydroDRUGOTHER) should be administered with caution in patients receiving DRUGOTHER.",fentanyl,tacrolimus,False,Neg,0,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,17,21
1426,7642,7642,7827,7827,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2 (DRUGOTHER, dihydroDRUGOTHER) should be administered with caution in patients receiving DRUGOTHER.",fentanyl,ergot alkaloids,False,Neg,0,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,17,23
1427,7643,7643,7828,7828,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER (DRUG2, dihydroDRUG2) should be administered with caution in patients receiving DRUGOTHER.",fentanyl,ergotamine,False,Neg,0,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C,17,24
1428,7644,7644,7829,7829,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER (DRUGOTHER, DRUG2) should be administered with caution in patients receiving DRUGOTHER.",fentanyl,dihydroergotamine,False,Neg,0,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,17,25
1429,7647,7647,7832,7832,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER (DRUGOTHER, dihydroDRUGOTHER) should be administered with caution in patients receiving DRUGOTHER.",pimozide,sirolimus,False,Neg,0,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,18,20
1430,7652,7652,7837,7837,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER (DRUGOTHER, dihydroDRUGOTHER) should be administered with caution in patients receiving DRUG2.",pimozide,SPRYCEL,True,advise,1,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,18,34
1431,7653,7653,7838,7838,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, or DRUGOTHER (DRUGOTHER, dihydroDRUGOTHER) should be administered with caution in patients receiving DRUGOTHER.",quinidine,sirolimus,False,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,19,20
1432,7658,7658,7843,7843,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, or DRUGOTHER (DRUGOTHER, dihydroDRUGOTHER) should be administered with caution in patients receiving DRUG2.",quinidine,SPRYCEL,True,advise,1,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,19,34
1433,7659,7659,7844,7844,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, or DRUGOTHER (DRUGOTHER, dihydroDRUGOTHER) should be administered with caution in patients receiving DRUGOTHER.",sirolimus,tacrolimus,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,20,21
1434,7660,7660,7845,7845,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, or DRUG2 (DRUGOTHER, dihydroDRUGOTHER) should be administered with caution in patients receiving DRUGOTHER.",sirolimus,ergot alkaloids,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,20,23
1435,7661,7661,7846,7846,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, or DRUGOTHER (DRUG2, dihydroDRUG2) should be administered with caution in patients receiving DRUGOTHER.",sirolimus,ergotamine,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C,20,24
1436,7662,7662,7847,7847,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, or DRUGOTHER (DRUGOTHER, DRUG2) should be administered with caution in patients receiving DRUGOTHER.",sirolimus,dihydroergotamine,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,20,25
1437,7667,7667,7852,7852,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, or DRUGOTHER (DRUGOTHER, dihydroDRUGOTHER) should be administered with caution in patients receiving DRUG2.",tacrolimus,SPRYCEL,True,advise,1,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,21,34
1438,7670,7670,7855,7855,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG1 (DRUGOTHER, dihydroDRUGOTHER) should be administered with caution in patients receiving DRUG2.",ergot alkaloids,SPRYCEL,True,advise,1,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,23,34
1439,7672,7672,7857,7857,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER (DRUG1, dihydroDRUG1) should be administered with caution in patients receiving DRUG2.",ergotamine,SPRYCEL,True,advise,1,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,24,34
1440,7673,7673,7858,7858,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER (DRUGOTHER, DRUG1) should be administered with caution in patients receiving DRUG2.",dihydroergotamine,SPRYCEL,True,advise,1,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,25,34
1441,7678,7678,7863,7863,DRUG1 used concurrently with DRUG2 may also result in increased cardiotoxicity.,Cyclophosphamide,Cerubidine,True,effect,2,ClCCN(CCCl)P1(=O)NCCCO1,COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O,0,4
1442,7699,7699,7894,7894,"Antiacid, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, Indanavir, DRUGOTHER, DRUG2, Phenobarbitol, DRUGOTHER, DRUGOTHER, DRUGOTHER, Ritanovir, DRUGOTHER.",clarithromycin,Phenytoin,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,1,7
1443,7703,7703,7898,7898,"Antiacid, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, Indanavir, DRUGOTHER, DRUGOTHER, Phenobarbitol, DRUGOTHER, DRUGOTHER, DRUGOTHER, Ritanovir, DRUG2.",clarithromycin,Saquinavir,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,1,13
1444,7707,7707,7902,7902,"Antiacid, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, Indanavir, DRUGOTHER, DRUG2, Phenobarbitol, DRUGOTHER, DRUGOTHER, DRUGOTHER, Ritanovir, DRUGOTHER.",Didanosine,Phenytoin,False,Neg,0,OC[C@@H]1CC[C@@H](O1)N1C=NC2=C1NC=NC2=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,2,7
1445,7711,7711,7906,7906,"Antiacid, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, Indanavir, DRUGOTHER, DRUGOTHER, Phenobarbitol, DRUGOTHER, DRUGOTHER, DRUGOTHER, Ritanovir, DRUG2.",Didanosine,Saquinavir,False,Neg,0,OC[C@@H]1CC[C@@H](O1)N1C=NC2=C1NC=NC2=O,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,2,13
1446,7714,7714,7909,7909,"Antiacid, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, Indanavir, DRUGOTHER, DRUG2, Phenobarbitol, DRUGOTHER, DRUGOTHER, DRUGOTHER, Ritanovir, DRUGOTHER.",Fluconazole,Phenytoin,False,Neg,0,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,3,7
1447,7718,7718,7913,7913,"Antiacid, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, Indanavir, DRUGOTHER, DRUGOTHER, Phenobarbitol, DRUGOTHER, DRUGOTHER, DRUGOTHER, Ritanovir, DRUG2.",Fluconazole,Saquinavir,False,Neg,0,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,3,13
1448,7720,7720,7915,7915,"Antiacid, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, Indanavir, DRUGOTHER, DRUG2, Phenobarbitol, DRUGOTHER, DRUGOTHER, DRUGOTHER, Ritanovir, DRUGOTHER.",Fluoxetine,Phenytoin,False,Neg,0,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,4,7
1449,7724,7724,7919,7919,"Antiacid, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, Indanavir, DRUGOTHER, DRUGOTHER, Phenobarbitol, DRUGOTHER, DRUGOTHER, DRUGOTHER, Ritanovir, DRUG2.",Fluoxetine,Saquinavir,False,Neg,0,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,4,13
1450,7725,7725,7920,7920,"Antiacid, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Indanavir, DRUG1, DRUG2, Phenobarbitol, DRUGOTHER, DRUGOTHER, DRUGOTHER, Ritanovir, DRUGOTHER.",Ketoconazole,Phenytoin,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,6,7
1451,7729,7729,7924,7924,"Antiacid, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Indanavir, DRUG1, DRUGOTHER, Phenobarbitol, DRUGOTHER, DRUGOTHER, DRUGOTHER, Ritanovir, DRUG2.",Ketoconazole,Saquinavir,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,6,13
1452,7730,7730,7925,7925,"Antiacid, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Indanavir, DRUGOTHER, DRUG1, Phenobarbitol, DRUG2, DRUGOTHER, DRUGOTHER, Ritanovir, DRUGOTHER.",Phenytoin,carbamazepine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,7,9
1453,7731,7731,7926,7926,"Antiacid, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Indanavir, DRUGOTHER, DRUG1, Phenobarbitol, DRUGOTHER, DRUG2, DRUGOTHER, Ritanovir, DRUGOTHER.",Phenytoin,Rifabutin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,7,10
1454,7732,7732,7927,7927,"Antiacid, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Indanavir, DRUGOTHER, DRUG1, Phenobarbitol, DRUGOTHER, DRUGOTHER, DRUG2, Ritanovir, DRUGOTHER.",Phenytoin,Rifampin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,7,11
1455,7736,7736,7931,7931,"Antiacid, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Indanavir, DRUGOTHER, DRUGOTHER, Phenobarbitol, DRUG1, DRUGOTHER, DRUGOTHER, Ritanovir, DRUG2.",carbamazepine,Saquinavir,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,9,13
1456,7738,7738,7933,7933,"Antiacid, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Indanavir, DRUGOTHER, DRUGOTHER, Phenobarbitol, DRUGOTHER, DRUG1, DRUGOTHER, Ritanovir, DRUG2.",Rifabutin,Saquinavir,False,Neg,0,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,10,13
1457,7739,7739,7934,7934,"Antiacid, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Indanavir, DRUGOTHER, DRUGOTHER, Phenobarbitol, DRUGOTHER, DRUGOTHER, DRUG1, Ritanovir, DRUG2.",Rifampin,Saquinavir,False,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,11,13
1458,7757,7757,7954,7954,"While all the DRUG1 (DRUGOTHER), e.g., DRUG2, seriraline, and DRUGOTHER, inhibit P450 2D6, they may vary in the extent of inhibition.",selective serotonin reuptake inhibitors,fluoxetine,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,3,6
1459,7758,7758,7955,7955,"While all the DRUG1 (DRUGOTHER), e.g., DRUGOTHER, seriraline, and DRUG2, inhibit P450 2D6, they may vary in the extent of inhibition.",selective serotonin reuptake inhibitors,paroxetine,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,3,9
1460,7797,7797,7994,7994,"A similar association, though less marked, has been suggested with DRUG1, phenyl-butazone, DRUG2, DRUGOTHER and possibly with DRUGOTHER, DRUGOTHER, and DRUGOTHER (72)",barbiturates,phenytoin sodium,False,Neg,0,CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,10,12
1461,7802,7802,7999,7999,"A similar association, though less marked, has been suggested with DRUGOTHER, phenyl-butazone, DRUG1, DRUG2 and possibly with DRUGOTHER, DRUGOTHER, and DRUGOTHER (72)",phenytoin sodium,carbamazepine,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,12,13
1462,7803,7803,8000,8000,"A similar association, though less marked, has been suggested with DRUGOTHER, phenyl-butazone, DRUG1, DRUGOTHER and possibly with DRUG2, DRUGOTHER, and DRUGOTHER (72)",phenytoin sodium,griseofulvin,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC,12,17
1463,7804,7804,8001,8001,"A similar association, though less marked, has been suggested with DRUGOTHER, phenyl-butazone, DRUG1, DRUGOTHER and possibly with DRUGOTHER, DRUG2, and DRUGOTHER (72)",phenytoin sodium,ampicillin,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C,12,18
1464,7805,7805,8002,8002,"A similar association, though less marked, has been suggested with DRUGOTHER, phenyl-butazone, DRUG1, DRUGOTHER and possibly with DRUGOTHER, DRUGOTHER, and DRUG2 (72)",phenytoin sodium,tetracyclines,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O,12,20
1465,7851,7851,8049,8049,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., DRUG1, DRUG2, DRUGOTHER, DRUGOTHER) may enhance the metabolism of DRUGOTHER and require that the dosage of the DRUGOTHER be increased.",barbiturates,phenytoin,False,Neg,0,CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,17,18
1466,7856,7856,8054,8054,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., DRUGOTHER, DRUG1, DRUG2, DRUGOTHER) may enhance the metabolism of DRUGOTHER and require that the dosage of the DRUGOTHER be increased.",phenytoin,carbamazepine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,18,19
1467,7857,7857,8055,8055,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUG2) may enhance the metabolism of DRUGOTHER and require that the dosage of the DRUGOTHER be increased.",phenytoin,rifampin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,18,20
1468,7858,7858,8056,8056,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER) may enhance the metabolism of DRUG2 and require that the dosage of the DRUGOTHER be increased.",phenytoin,corticosteroids,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,18,26
1469,7859,7859,8057,8057,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER) may enhance the metabolism of DRUG2s and require that the dosage of the DRUG2 be increased.",phenytoin,corticosteroid,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,18,26
1470,7886,7886,8084,8084,"DRUG1: In post-marketing experience, there have been reports of both increases and decreases in DRUGOTHER levels with DRUG2 co-administration, leading to alterations in seizure control.",Phenytoin,dexamethasone,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,0,17
1471,7887,7887,8085,8085,"DRUGOTHER: In post-marketing experience, there have been reports of both increases and decreases in DRUG1 levels with DRUG2 co-administration, leading to alterations in seizure control.",phenytoin,dexamethasone,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,14,17
1472,7889,7889,8087,8087,"DRUG1 can interact with DRUGOTHER or other DRUG2 (may potentiate the CNS depressant effects of either these medications or DRUGOTHER), DRUGOTHER or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with DRUGOTHER), and DRUGOTHER (concurrent use with DRUGOTHER may prolong and intensify the anticholinergic and CNS depressant effects of DRUGOTHER).",Dexbrompheniramine,CNS depressants,True,int,3,CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C1=CC=CC=N1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,0,7
1473,7896,7896,8094,8094,"DRUGOTHER can interact with DRUG1 or other DRUG2 (may potentiate the CNS depressant effects of either these medications or DRUGOTHER), DRUGOTHER or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with DRUGOTHER), and DRUGOTHER (concurrent use with DRUGOTHER may prolong and intensify the anticholinergic and CNS depressant effects of DRUGOTHER).",alcohol,CNS depressants,False,Neg,0,CCO,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,4,7
1474,7903,7903,8101,8101,"DRUGOTHER can interact with DRUGOTHER or other DRUG1 (may potentiate the CNS depressant effects of either these medications or DRUG2), DRUGOTHER or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with DRUG2), and DRUGOTHER (concurrent use with DRUG2 may prolong and intensify the anticholinergic and CNS depressant effects of DRUG2).",CNS depressants,antihistamines,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,NCCC1=CNC=N1,7,19
1475,7904,7904,8102,8102,"DRUGOTHER can interact with DRUGOTHER or other DRUG1 (may potentiate the CNS depressant effects of either these medications or DRUGOTHER), DRUG2 or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with DRUGOTHER), and DRUGOTHER (concurrent use with DRUGOTHER may prolong and intensify the anticholinergic and CNS depressant effects of DRUGOTHER).",CNS depressants,anticholinergics,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C[N+](C)(C)CCO,7,20
1476,7905,7905,8103,8103,"DRUGOTHER can interact with DRUGOTHER or other DRUG1 (may potentiate the CNS depressant effects of either these medications or DRUG2), DRUGOTHER or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with DRUG2), and DRUGOTHER (concurrent use with DRUG2 may prolong and intensify the anticholinergic and CNS depressant effects of DRUG2).",CNS depressants,antihistamines,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,NCCC1=CNC=N1,7,19
1477,7906,7906,8104,8104,"DRUGOTHER can interact with DRUGOTHER or other DRUG1 (may potentiate the CNS depressant effects of either these medications or DRUGOTHER), DRUGOTHER or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with DRUGOTHER), and DRUG2 (concurrent use with DRUGOTHER may prolong and intensify the anticholinergic and CNS depressant effects of DRUGOTHER).",CNS depressants,monoamine oxidase (MAO) inhibitors,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,OC(=O)CCCCCCCC(O)=O,7,41
1478,7907,7907,8105,8105,"DRUGOTHER can interact with DRUGOTHER or other DRUG1 (may potentiate the CNS depressant effects of either these medications or DRUG2), DRUGOTHER or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with DRUG2), and DRUGOTHER (concurrent use with DRUG2 may prolong and intensify the anticholinergic and CNS depressant effects of DRUG2).",CNS depressants,antihistamines,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,NCCC1=CNC=N1,7,19
1479,7908,7908,8106,8106,"DRUGOTHER can interact with DRUGOTHER or other DRUG1 (may potentiate the CNS depressant effects of either these medications or DRUG2), DRUGOTHER or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with DRUG2), and DRUGOTHER (concurrent use with DRUG2 may prolong and intensify the anticholinergic and CNS depressant effects of DRUG2).",CNS depressants,antihistamines,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,NCCC1=CNC=N1,7,19
1480,7940,7940,8138,8138,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of DRUG1 (DRUGOTHER) and agents for migraine therapy, such as DRUGOTHER (DRUGOTHER) and DRUG2.",selective serotonin reuptake inhibitors,dihydroergotamine,True,effect,2,NCCC1=CNC2=CC=C(O)C=C12,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,18,30
1481,7941,7941,8139,8139,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of DRUGOTHER (DRUGOTHER) and agents for migraine therapy, such as DRUGOTHER (DRUG1) and DRUG2.",sumatriptan succinate,dihydroergotamine,False,Neg,0,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C.C(CC(=O)O)C(=O)O,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,28,30
1482,7962,7962,8167,8167,"DRUG1: DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, fruit juices, etc.) lower absorption of DRUGOTHER.",Acidifying agents,guanethidine,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,C1CCCN(CCC1)CCN=C(N)N,0,2
1483,7967,7967,8172,8172,"DRUGOTHER: DRUG1 (DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, fruit juices, etc.) lower absorption of DRUGOTHER.",Gastrointestinal acidifying agents,guanethidine,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,C1CCCN(CCC1)CCN=C(N)N,1,2
1484,7972,7972,8177,8177,"DRUGOTHER: DRUGOTHER (DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, fruit juices, etc.) lower absorption of DRUGOTHER.",guanethidine,reserpine,False,Neg,0,C1CCCN(CCC1)CCN=C(N)N,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,2,3
1485,7973,7973,8178,8178,"DRUGOTHER: DRUGOTHER (DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, fruit juices, etc.) lower absorption of DRUGOTHER.",guanethidine,glutamic acid HCl,False,Neg,0,C1CCCN(CCC1)CCN=C(N)N,N[C@@H](CCC(O)=O)C(O)=O,2,4
1486,7974,7974,8179,8179,"DRUGOTHER: DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, fruit juices, etc.) lower absorption of DRUGOTHER.",guanethidine,ascorbic acid,False,Neg,0,C1CCCN(CCC1)CCN=C(N)N,C([C@@H]([C@@H]1C(=C(C(=O)O1)O)O)O)O,2,5
1487,7975,7975,8180,8180,"DRUGOTHER: DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, fruit juices, etc.) lower absorption of DRUG2.",guanethidine,amphetamines,True,mechanism,4,C1CCCN(CCC1)CCN=C(N)N,CC(N)CC1=CC=CC=C1,2,12
1488,7986,7986,8191,8191,"Urinary alkalinizing agents (DRUG1, some DRUG2) increase the concentration of the non-ionized species of the DRUGOTHER molecule, thereby decreasing urinary excretion.",acetazolamide,thiazides,False,Neg,0,CC(=O)NC1=NN=C(S1)S(=O)(=O)N,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,3,5
1489,7988,7988,8193,8193,"Urinary alkalinizing agents (DRUGOTHER, some DRUG1) increase the concentration of the non-ionized species of the DRUG2 molecule, thereby decreasing urinary excretion.",thiazides,amphetamine,True,mechanism,4,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,CC(CC1=CC=CC=C1)N,5,15
1490,8016,8016,8221,8221,DRUG1: DRUG2 may delay intestinal absorption of DRUGOTHER.,Ethosuximide,Amphetamines,False,Neg,0,CCC1(C)CC(=O)NC1=O,CC(N)CC1=CC=CC=C1,0,1
1491,8018,8018,8223,8223,DRUGOTHER: DRUG1 may delay intestinal absorption of DRUG2.,Amphetamines,ethosuximide,True,mechanism,4,CC(N)CC1=CC=CC=C1,CCC1(C)CC(=O)NC1=O,1,7
1492,8020,8020,8225,8225,"DRUG1: DRUG1 blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of DRUG2.",Haloperidol,amphetamines,False,Neg,0,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1,CC(N)CC1=CC=CC=C1,0,14
1493,8021,8021,8226,8226,"DRUG1: DRUG1 blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of DRUG2.",Haloperidol,amphetamines,True,effect,2,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1,CC(N)CC1=CC=CC=C1,0,14
1494,8025,8025,8230,8230,DRUG1: DRUG2 potentiate the analgesic effect of DRUGOTHER.,Meperidine,Amphetamines,False,Neg,0,CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1,CC(N)CC1=CC=CC=C1,0,1
1495,8027,8027,8232,8232,DRUGOTHER: DRUG1 potentiate the analgesic effect of DRUG2.,Amphetamines,meperidine,True,effect,2,CC(N)CC1=CC=CC=C1,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,1,7
1496,8037,8037,8245,8245,DRUG1: DRUG2 may delay intestinal absorption of DRUGOTHER;,Phenytoin,Amphetamines,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(N)CC1=CC=CC=C1,0,1
1497,8039,8039,8247,8247,DRUGOTHER: DRUG1 may delay intestinal absorption of DRUG2;,Amphetamines,phenytoin,True,mechanism,4,CC(N)CC1=CC=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,1,7
1498,8053,8053,8261,8261,"May interact with thyroid medication (e.g., DRUG1), DRUGOTHER-containing products, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), and DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",levothyroxine,proton pump inhibitors,False,Neg,0,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)O)N,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,6,15
1499,8058,8058,8266,8266,"May interact with thyroid medication (e.g., DRUGOTHER), DRUG1-containing products, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), and DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",iodine,proton pump inhibitors,False,Neg,0,II,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,7,15
1500,8062,8062,8270,8270,"May interact with thyroid medication (e.g., DRUGOTHER), DRUGOTHER-containing products, DRUGOTHER, DRUGOTHER (e.g., DRUG1, DRUGOTHER), and DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",famotidine,proton pump inhibitors,False,Neg,0,OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,12,15
1501,8065,8065,8273,8273,"May interact with thyroid medication (e.g., DRUGOTHER), DRUGOTHER-containing products, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER, DRUG1), and DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",ranitidine,proton pump inhibitors,False,Neg,0,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,13,15
1502,8068,8068,8276,8276,"May interact with thyroid medication (e.g., DRUGOTHER), DRUGOTHER-containing products, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), and DRUG1 (e.g., DRUG2, DRUGOTHER).",proton pump inhibitors,lansoprazole,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1,15,17
1503,8069,8069,8277,8277,"May interact with thyroid medication (e.g., DRUGOTHER), DRUGOTHER-containing products, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), and DRUG1 (e.g., DRUGOTHER, DRUG2).",proton pump inhibitors,omeprazole,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,15,18
1504,8124,8124,8332,8332,"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER did not significantly affect the peak levels and AUC values of DRUGOTHER.",azathioprine,doxycycline,False,Neg,0,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,13,18
1505,8128,8128,8336,8336,"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER did not significantly affect the peak levels and AUC values of DRUGOTHER.",chloroquine,doxycycline,False,Neg,0,CCN(CC)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,15,18
1506,8131,8131,8339,8339,"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, or DRUGOTHER did not significantly affect the peak levels and AUC values of DRUGOTHER.",prednisolone,doxycycline,False,Neg,0,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,17,18
1507,8134,8134,8342,8342,"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, or DRUG2 did not significantly affect the peak levels and AUC values of DRUGOTHER.",doxycycline,digitoxin,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)C1=CC(=O)OC1,18,20
1508,8135,8135,8343,8343,"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, or DRUGOTHER did not significantly affect the peak levels and AUC values of DRUG2.",doxycycline,diclofenac,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,18,32
1509,8150,8150,8358,8358,"DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER have no influence in vitro on the protein binding of DRUGOTHER in human serum.",ampicillin,doxycycline,False,Neg,0,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,1,4
1510,8154,8154,8364,8364,"DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER have no influence in vitro on the protein binding of DRUGOTHER in human serum.",doxycycline,erythromycin,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,4,6
1511,8155,8155,8365,8365,"DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2 have no influence in vitro on the protein binding of DRUGOTHER in human serum.",doxycycline,sulfamethoxazole,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N,4,8
1512,8156,8156,8366,8366,"DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER have no influence in vitro on the protein binding of DRUG2 in human serum.",doxycycline,diclofenac,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,4,19
1513,8160,8160,8373,8373,"DRUG1, a DRUG2, may antagonize the bactercidal effect of DRUGOTHER and concurrent use of these drugs should be avoided.",Tetracycline,bacteriostatic antibiotic,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,0,2
1514,8161,8161,8374,8374,"DRUG1, a DRUGOTHER, may antagonize the bactercidal effect of DRUG2 and concurrent use of these drugs should be avoided.",Tetracycline,penicillin,True,effect,2,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,0,9
1515,8192,8192,8405,8405,"DRUG1, DRUGOTHER (e.g., DRUG2), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity.",MAO inhibitors,meperidine,False,Neg,0,CN(CC#C)CC1=CC=CC=C1,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,0,3
1516,8197,8197,8410,8410,"DRUGOTHER, DRUG1 (e.g., DRUG2), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity.",narcotic analgesics,meperidine,False,Neg,0,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,1,3
1517,8202,8202,8415,8415,"DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUG2 and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity.",meperidine,nitrates,False,Neg,0,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,[N+](=O)([O-])[O-],3,4
1518,8203,8203,8416,8416,"DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER and DRUG2, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity.",meperidine,nitrites,False,Neg,0,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,N(=O)[O-],3,6
1519,8204,8204,8417,8417,"DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER and DRUGOTHER, DRUG2, DRUGOTHER, and other drugs having anticholinergic activity.",meperidine,sympathomimetic agents,False,Neg,0,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,3,7
1520,8205,8205,8418,8418,"DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG2, and other drugs having anticholinergic activity.",meperidine,tricyclic antidepressants,False,Neg,0,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,3,8
1521,8262,8262,8475,8475,"conversely, DRUG1 may interfere with DRUG2 (i.e., DRUGOTHER, DRUGOTHER).",diethylpropion,antihypertensive drugs,True,int,3,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,1,5
1522,8264,8264,8477,8477,"conversely, DRUG1 may interfere with DRUGOTHER (i.e., DRUGOTHER, DRUG2).",diethylpropion,a-methyldopa,True,int,3,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O,1,8
1523,8265,8265,8478,8478,"conversely, DRUGOTHER may interfere with DRUG1 (i.e., DRUG2, DRUGOTHER).",antihypertensive drugs,guanethidine,False,Neg,0,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,C1CCCN(CCC1)CCN=C(N)N,5,7
1524,8267,8267,8480,8480,"conversely, DRUGOTHER may interfere with DRUGOTHER (i.e., DRUG1, DRUG2).",guanethidine,a-methyldopa,False,Neg,0,C1CCCN(CCC1)CCN=C(N)N,C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O,7,8
1525,8268,8268,8481,8481,Concurrent use of DRUG1 may antagonize the anorectic effect of DRUG2.,phenothiazines,diethylpropion,True,effect,2,N1C2=CC=CC=C2SC2=CC=CC=C12,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,3,10
1526,8285,8285,8502,8502,"DRUG1: In normal volunteers, concomitant administration of DRUG2 and DRUGOTHER resulted in significantly increased plasma levels of DRUGOTHER.",Hydrochlorothiazide,diflunisal,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,0,7
1527,8288,8288,8505,8505,"DRUGOTHER: In normal volunteers, concomitant administration of DRUG1 and DRUG2 resulted in significantly increased plasma levels of DRUG2.",diflunisal,hydrochlorothiazide,True,mechanism,4,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,7,9
1528,8289,8289,8506,8506,"DRUGOTHER: In normal volunteers, concomitant administration of DRUG1 and DRUG2 resulted in significantly increased plasma levels of DRUG2.",diflunisal,hydrochlorothiazide,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,7,9
1529,8291,8291,8508,8508,DRUG1 decreased the hyperuricemic effect of DRUG2.,Diflunisal,hydrochlorothiazide,True,effect,2,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,0,6
1530,8292,8292,8509,8509,"DRUG1: In normal volunteers, the concomitant administration of DRUG2 and DRUGOTHER had no effect on the diuretic activity of DRUGOTHER.",Furosemide,diflunisal,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,0,8
1531,8295,8295,8512,8512,"DRUGOTHER: In normal volunteers, the concomitant administration of DRUG1 and DRUG2 had no effect on the diuretic activity of DRUG2.",diflunisal,furosemide,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,8,10
1532,8296,8296,8513,8513,"DRUGOTHER: In normal volunteers, the concomitant administration of DRUG1 and DRUG2 had no effect on the diuretic activity of DRUG2.",diflunisal,furosemide,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,8,10
1533,8298,8298,8515,8515,DRUG1 decreased the hyperuricemic effect of DRUG2.,Diflunisal,furosemide,True,effect,2,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,0,6
1534,8359,8359,8576,8576,"DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2 raise the serum DRUGOTHER concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that DRUGOTHER intoxication may result.",Quinidine,spironolactone,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,0,8
1535,8367,8367,8584,8584,"DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2 raise the serum DRUGOTHER concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that DRUGOTHER intoxication may result.",verapamil,spironolactone,False,Neg,0,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,1,8
1536,8374,8374,8591,8591,"DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2 raise the serum DRUGOTHER concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that DRUGOTHER intoxication may result.",amiodarone,spironolactone,False,Neg,0,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,2,8
1537,8380,8380,8597,8597,"DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2 raise the serum DRUGOTHER concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that DRUGOTHER intoxication may result.",propafenone,spironolactone,False,Neg,0,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,3,8
1538,8385,8385,8602,8602,"DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2 raise the serum DRUGOTHER concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that DRUGOTHER intoxication may result.",indomethacin,spironolactone,False,Neg,0,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,4,8
1539,8389,8389,8606,8606,"DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2 raise the serum DRUGOTHER concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that DRUGOTHER intoxication may result.",itraconazole,spironolactone,False,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,5,8
1540,8392,8392,8609,8609,"DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2 raise the serum DRUGOTHER concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that DRUGOTHER intoxication may result.",alprazolam,spironolactone,False,Neg,0,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,6,8
1541,8395,8395,8612,8612,"DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1 raise the serum DRUG2 concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that DRUGOTHER intoxication may result.",spironolactone,digoxin,True,mechanism,4,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,8,12
1542,8396,8396,8613,8613,"DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1 raise the serum DRUGOTHER concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that DRUG2 intoxication may result.",spironolactone,digitalis,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,8,32
1543,8400,8400,8617,8617,"DRUG1 and DRUGOTHER (and possibly other DRUGOTHER) and DRUG2 may increase DRUGOTHER absorption in patients who inactivate DRUGOTHER by bacterial metabolism in the lower intestine, so that DRUGOTHER intoxication may result.",Erythromycin,tetracycline,False,Neg,0,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,0,8
1544,8405,8405,8622,8622,"DRUGOTHER and DRUG1 (and possibly other DRUGOTHER) and DRUG2 may increase DRUGOTHER absorption in patients who inactivate DRUGOTHER by bacterial metabolism in the lower intestine, so that DRUGOTHER intoxication may result.",clarithromycin,tetracycline,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,2,8
1545,8409,8409,8626,8626,"DRUGOTHER and DRUGOTHER (and possibly other DRUG1) and DRUG2 may increase DRUGOTHER absorption in patients who inactivate DRUGOTHER by bacterial metabolism in the lower intestine, so that DRUGOTHER intoxication may result.",macrolide antibiotics,tetracycline,False,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,6,8
1546,8413,8413,8630,8630,"DRUGOTHER and DRUGOTHER (and possibly other DRUGOTHER) and DRUG1 may increase DRUG2 absorption in patients who inactivate DRUG2 by bacterial metabolism in the lower intestine, so that DRUGOTHER intoxication may result.",tetracycline,digoxin,True,mechanism,4,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,8,11
1547,8414,8414,8631,8631,"DRUGOTHER and DRUGOTHER (and possibly other DRUGOTHER) and DRUG1 may increase DRUG2 absorption in patients who inactivate DRUG2 by bacterial metabolism in the lower intestine, so that DRUGOTHER intoxication may result.",tetracycline,digoxin,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,8,11
1548,8415,8415,8632,8632,"DRUGOTHER and DRUGOTHER (and possibly other DRUGOTHER) and DRUG1 may increase DRUGOTHER absorption in patients who inactivate DRUGOTHER by bacterial metabolism in the lower intestine, so that DRUG2 intoxication may result.",tetracycline,digitalis,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,8,27
1549,8443,8443,8660,8660,"DRUG1: DRUG1 has been reported to cause coronary artery vasospasm, and its effect could be additive with DRUG2  (DRUGOTHER) Injection, USP.",Sumatriptan,D.H.E. 45,False,Neg,0,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1,[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O,0,17
1550,8444,8444,8661,8661,"DRUG1: DRUG1 has been reported to cause coronary artery vasospasm, and its effect could be additive with DRUGOTHER  (DRUG2) Injection, USP.",Sumatriptan,dihydroergotamine mesylate,False,Neg,0,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1,[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O,0,19
1551,8445,8445,8662,8662,"DRUG1: DRUG1 has been reported to cause coronary artery vasospasm, and its effect could be additive with DRUG2  (DRUGOTHER) Injection, USP.",Sumatriptan,D.H.E. 45,True,effect,2,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1,[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O,0,17
1552,8446,8446,8663,8663,"DRUG1: DRUG1 has been reported to cause coronary artery vasospasm, and its effect could be additive with DRUGOTHER  (DRUG2) Injection, USP.",Sumatriptan,dihydroergotamine mesylate,True,effect,2,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1,[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O,0,19
1553,8448,8448,8665,8665,"DRUG1 and DRUG2  (DRUGOTHER) Injection, USP should not be taken within 24 hours of each other..",Sumatriptan,D.H.E. 45,True,advise,1,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1,[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O,0,2
1554,8449,8449,8666,8666,"DRUG1 and DRUGOTHER  (DRUG2) Injection, USP should not be taken within 24 hours of each other..",Sumatriptan,dihydroergotamine mesylate,True,advise,1,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1,[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O,0,4
1555,8548,8548,8767,8767,no change in DRUG1 AUC and Cmax was observed during DRUG2 coadministration.,pravastatin,diltiazem,False,Neg,0,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,3,10
1556,8549,8549,8768,8768,DRUGOTHER plasma levels were not significantly affected by DRUG1 or DRUG2.,lovastatin,pravastatin,False,Neg,0,CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,8,10
1557,8556,8556,8777,8777,"DRUG1 has additive effects with DRUGOTHER and other DRUG2 (DRUGOTHER, DRUGOTHER, DRUGOTHER, etc).",Diphenhydramine hydrochloride,CNS depressants,True,effect,2,[Zn++].CC([O-])=O.CC([O-])=O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,0,8
1558,8558,8558,8779,8779,"DRUGOTHER has additive effects with DRUG1 and other DRUG2 (DRUGOTHER, DRUGOTHER, DRUGOTHER, etc).",alcohol,CNS depressants,False,Neg,0,CCO,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,5,8
1559,8560,8560,8781,8781,"DRUGOTHER has additive effects with DRUGOTHER and other DRUG1 (DRUGOTHER, DRUGOTHER, DRUG2, etc).",CNS depressants,tranquilizers,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,8,11
1560,8567,8567,8799,8799,"This drug may interact with DRUG1 or other DRUG2 (may potentiate the CNS depressant effects of either these medications or DRUGOTHER), DRUGOTHER or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with DRUGOTHER), and DRUGOTHER (concurrent use with DRUGOTHER may prolong and intensify the anticholinergic and CNS depressant effects of DRUGOTHER).",alcohol,CNS depressants,False,Neg,0,CCO,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,5,8
1561,8574,8574,8806,8806,"This drug may interact with DRUGOTHER or other DRUG1 (may potentiate the CNS depressant effects of either these medications or DRUG2), DRUGOTHER or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with DRUG2), and DRUGOTHER (concurrent use with DRUG2 may prolong and intensify the anticholinergic and CNS depressant effects of DRUG2).",CNS depressants,antihistamines,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,NCCC1=CNC=N1,8,20
1562,8575,8575,8807,8807,"This drug may interact with DRUGOTHER or other DRUG1 (may potentiate the CNS depressant effects of either these medications or DRUGOTHER), DRUG2 or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with DRUGOTHER), and DRUGOTHER (concurrent use with DRUGOTHER may prolong and intensify the anticholinergic and CNS depressant effects of DRUGOTHER).",CNS depressants,anticholinergics,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C[N+](C)(C)CCO,8,21
1563,8576,8576,8808,8808,"This drug may interact with DRUGOTHER or other DRUG1 (may potentiate the CNS depressant effects of either these medications or DRUG2), DRUGOTHER or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with DRUG2), and DRUGOTHER (concurrent use with DRUG2 may prolong and intensify the anticholinergic and CNS depressant effects of DRUG2).",CNS depressants,antihistamines,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,NCCC1=CNC=N1,8,20
1564,8577,8577,8809,8809,"This drug may interact with DRUGOTHER or other DRUG1 (may potentiate the CNS depressant effects of either these medications or DRUGOTHER), DRUGOTHER or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with DRUGOTHER), and DRUG2 (concurrent use with DRUGOTHER may prolong and intensify the anticholinergic and CNS depressant effects of DRUGOTHER).",CNS depressants,monoamine oxidase (MAO) inhibitors,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,OC(=O)CCCCCCCC(O)=O,8,42
1565,8578,8578,8810,8810,"This drug may interact with DRUGOTHER or other DRUG1 (may potentiate the CNS depressant effects of either these medications or DRUG2), DRUGOTHER or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with DRUG2), and DRUGOTHER (concurrent use with DRUG2 may prolong and intensify the anticholinergic and CNS depressant effects of DRUG2).",CNS depressants,antihistamines,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,NCCC1=CNC=N1,8,20
1566,8579,8579,8811,8811,"This drug may interact with DRUGOTHER or other DRUG1 (may potentiate the CNS depressant effects of either these medications or DRUG2), DRUGOTHER or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with DRUG2), and DRUGOTHER (concurrent use with DRUG2 may prolong and intensify the anticholinergic and CNS depressant effects of DRUG2).",CNS depressants,antihistamines,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,NCCC1=CNC=N1,8,20
1567,8629,8629,8861,8861,"DRUG1: Following co-administration of two 250-mg DRUG2 tablets administered once daily with 200-mg DRUGOTHER tablets administered twice daily for 10 days to 14 healthy subjects, the steady-state plasma concentration of DRUGOTHER was not significantly altered.",Theophylline,dirithromycin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O,0,6
1568,8632,8632,8864,8864,"DRUGOTHER: Following co-administration of two 250-mg DRUG1 tablets administered once daily with 200-mg DRUG2 tablets administered twice daily for 10 days to 14 healthy subjects, the steady-state plasma concentration of DRUG2 was not significantly altered.",dirithromycin,theophylline,False,Neg,0,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,6,13
1569,8633,8633,8865,8865,"DRUGOTHER: Following co-administration of two 250-mg DRUG1 tablets administered once daily with 200-mg DRUG2 tablets administered twice daily for 10 days to 14 healthy subjects, the steady-state plasma concentration of DRUG2 was not significantly altered.",dirithromycin,theophylline,False,Neg,0,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,6,13
1570,8635,8635,8867,8867,"In general, most patients treated with DRUG1 who are receiving concomitant DRUG2 therapy may not require empiric adjustment of DRUG2 dosage or monitoring of DRUG2 plasma concentrations.",dirithromycin,theophylline,False,Neg,0,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,6,11
1571,8636,8636,8868,8868,"In general, most patients treated with DRUG1 who are receiving concomitant DRUG2 therapy may not require empiric adjustment of DRUG2 dosage or monitoring of DRUG2 plasma concentrations.",dirithromycin,theophylline,False,Neg,0,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,6,11
1572,8637,8637,8869,8869,"In general, most patients treated with DRUG1 who are receiving concomitant DRUG2 therapy may not require empiric adjustment of DRUG2 dosage or monitoring of DRUG2 plasma concentrations.",dirithromycin,theophylline,False,Neg,0,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,6,11
1573,8668,8668,8900,8900,"Other drugs Drug interactions have been reported with concomitant administration of DRUG1 and other medications, including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",erythromycin,phenytoin,True,int,3,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,11,21
1574,8677,8677,8909,8909,"Other drugs Drug interactions have been reported with concomitant administration of DRUGOTHER and other medications, including DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",cyclosporine,phenytoin,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,16,21
1575,8685,8685,8917,8917,"Other drugs Drug interactions have been reported with concomitant administration of DRUGOTHER and other medications, including DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",hexobarbital,phenytoin,False,Neg,0,CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,17,21
1576,8692,8692,8924,8924,"Other drugs Drug interactions have been reported with concomitant administration of DRUGOTHER and other medications, including DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",carbamazepine,phenytoin,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,18,21
1577,8698,8698,8930,8930,"Other drugs Drug interactions have been reported with concomitant administration of DRUGOTHER and other medications, including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",alfentanil,phenytoin,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,19,21
1578,8703,8703,8935,8935,"Other drugs Drug interactions have been reported with concomitant administration of DRUGOTHER and other medications, including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",disopyramide,phenytoin,False,Neg,0,OC(=O)CCCCCCCC(O)=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,20,21
1579,8708,8708,8940,8940,"Other drugs Drug interactions have been reported with concomitant administration of DRUGOTHER and other medications, including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",phenytoin,bromocriptine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C,21,22
1580,8709,8709,8941,8941,"Other drugs Drug interactions have been reported with concomitant administration of DRUGOTHER and other medications, including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",phenytoin,valproate,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCCC(CCC)C(=O)O,21,23
1581,8710,8710,8942,8942,"Other drugs Drug interactions have been reported with concomitant administration of DRUGOTHER and other medications, including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",phenytoin,astemizole,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,21,24
1582,8711,8711,8943,8943,"Other drugs Drug interactions have been reported with concomitant administration of DRUGOTHER and other medications, including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",phenytoin,lovastatin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,21,26
1583,8718,8718,8950,8950,"If DRUG1 or other hepatic enzyme inducers are taken concurrently with DRUG2 or DRUG2 CR, lower plasma levels of DRUGOTHER may occur.",phenytoin,Norpace,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C1=NC=CC=C1)C(C)C,1,11
1584,8719,8719,8951,8951,"If DRUG1 or other hepatic enzyme inducers are taken concurrently with DRUGOTHER or DRUG2, lower plasma levels of DRUGOTHER may occur.",phenytoin,Norpace CR,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C1=NC=CC=C1)C(C)C,1,13
1585,8720,8720,8952,8952,"If DRUG1 or other hepatic enzyme inducers are taken concurrently with DRUGOTHER or DRUGOTHER CR, lower plasma levels of DRUG2 may occur.",phenytoin,disopyramide,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,OC(=O)CCCCCCCC(O)=O,1,19
1586,8764,8764,8996,8996,"Preliminary studies indicate that the concomitant use of DRUG1 and DRUG2 results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone.",dobutamine,nitroprusside,True,effect,2,CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,8,10
1587,8766,8766,8998,8998,"There was no evidence of drug interactions in clinical studies in which DRUG1 was administered concurrently with other drugs, including DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",dobutamine,furosemide,False,Neg,0,CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,12,21
1588,8767,8767,8999,8999,"There was no evidence of drug interactions in clinical studies in which DRUG1 was administered concurrently with other drugs, including DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",dobutamine,spironolactone,False,Neg,0,CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,12,22
1589,8776,8776,9008,9008,"There was no evidence of drug interactions in clinical studies in which DRUGOTHER was administered concurrently with other drugs, including DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",digitalis preparations,furosemide,False,Neg,0,O=[Fe]O[Fe]=O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,20,21
1590,8777,8777,9009,9009,"There was no evidence of drug interactions in clinical studies in which DRUGOTHER was administered concurrently with other drugs, including DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",digitalis preparations,spironolactone,False,Neg,0,O=[Fe]O[Fe]=O,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,20,22
1591,8787,8787,9019,9019,"There was no evidence of drug interactions in clinical studies in which DRUGOTHER was administered concurrently with other drugs, including DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",furosemide,glyceryl trinitrate,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,[O-]N(=O)=O,21,24
1592,8788,8788,9020,9020,"There was no evidence of drug interactions in clinical studies in which DRUGOTHER was administered concurrently with other drugs, including DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",furosemide,isosorbide dinitrate,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,[H][C@]12OC[C@H](O[N+]([O-])=O)[C@@]1([H])OC[C@H]2O[N+]([O-])=O,21,25
1593,8789,8789,9021,9021,"There was no evidence of drug interactions in clinical studies in which DRUGOTHER was administered concurrently with other drugs, including DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",furosemide,morphine,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,21,26
1594,8790,8790,9022,9022,"There was no evidence of drug interactions in clinical studies in which DRUGOTHER was administered concurrently with other drugs, including DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",furosemide,atropine,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3,21,27
1595,8791,8791,9023,9023,"There was no evidence of drug interactions in clinical studies in which DRUGOTHER was administered concurrently with other drugs, including DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",furosemide,heparin,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,21,28
1596,8792,8792,9024,9024,"There was no evidence of drug interactions in clinical studies in which DRUGOTHER was administered concurrently with other drugs, including DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",furosemide,potassium chloride,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,[Cl-].[K+],21,30
1597,8793,8793,9025,9025,"There was no evidence of drug interactions in clinical studies in which DRUGOTHER was administered concurrently with other drugs, including DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",furosemide,folic acid,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,21,31
1598,8794,8794,9026,9026,"There was no evidence of drug interactions in clinical studies in which DRUGOTHER was administered concurrently with other drugs, including DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",furosemide,acetaminophen,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC(=O)NC1=CC=C(C=C1)O,21,33
1599,8795,8795,9027,9027,"There was no evidence of drug interactions in clinical studies in which DRUGOTHER was administered concurrently with other drugs, including DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",spironolactone,glyceryl trinitrate,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,[O-]N(=O)=O,22,24
1600,8796,8796,9028,9028,"There was no evidence of drug interactions in clinical studies in which DRUGOTHER was administered concurrently with other drugs, including DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",spironolactone,isosorbide dinitrate,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,[H][C@]12OC[C@H](O[N+]([O-])=O)[C@@]1([H])OC[C@H]2O[N+]([O-])=O,22,25
1601,8797,8797,9029,9029,"There was no evidence of drug interactions in clinical studies in which DRUGOTHER was administered concurrently with other drugs, including DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",spironolactone,morphine,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,22,26
1602,8798,8798,9030,9030,"There was no evidence of drug interactions in clinical studies in which DRUGOTHER was administered concurrently with other drugs, including DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",spironolactone,atropine,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3,22,27
1603,8799,8799,9031,9031,"There was no evidence of drug interactions in clinical studies in which DRUGOTHER was administered concurrently with other drugs, including DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",spironolactone,heparin,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,22,28
1604,8800,8800,9032,9032,"There was no evidence of drug interactions in clinical studies in which DRUGOTHER was administered concurrently with other drugs, including DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",spironolactone,potassium chloride,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,[Cl-].[K+],22,30
1605,8801,8801,9033,9033,"There was no evidence of drug interactions in clinical studies in which DRUGOTHER was administered concurrently with other drugs, including DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",spironolactone,folic acid,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,22,31
1606,8802,8802,9034,9034,"There was no evidence of drug interactions in clinical studies in which DRUGOTHER was administered concurrently with other drugs, including DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",spironolactone,acetaminophen,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,CC(=O)NC1=CC=C(C=C1)O,22,33
1607,8887,8887,9122,9122,DRUG1 (DRUG2) Alone or in Combination with DRUGOTHER: Concomitant use of DRUG2 alone or in combination with DRUGOTHER is contraindicated.,Hydrochlorothiazide,HCTZ,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1,0,1
1608,8888,8888,9123,9123,DRUG1 (DRUGOTHER) Alone or in Combination with DRUG2: Concomitant use of DRUGOTHER alone or in combination with DRUGOTHER is contraindicated.,Hydrochlorothiazide,Triamterene,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1,0,7
1609,8889,8889,9124,9124,DRUG1 (DRUG2) Alone or in Combination with DRUGOTHER: Concomitant use of DRUG2 alone or in combination with DRUGOTHER is contraindicated.,Hydrochlorothiazide,HCTZ,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1,0,1
1610,8890,8890,9125,9125,DRUG1 (DRUGOTHER) Alone or in Combination with DRUGOTHER: Concomitant use of DRUGOTHER alone or in combination with DRUG2 is contraindicated.,Hydrochlorothiazide,triamterene,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,0,17
1611,8918,8918,9153,9153,"Inhibitors of this isoenzyme (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) should be cautiously coadministered with DRUGOTHER as they can potentially increase DRUGOTHER levels.",macrolide antibiotics,serotonin reuptake inhibitors,False,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,NCCC1=CNC2=CC=C(O)C=C12,5,8
1612,8927,8927,9162,9162,"Inhibitors of this isoenzyme (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) should be cautiously coadministered with DRUGOTHER as they can potentially increase DRUGOTHER levels.",azole antifungal agents,serotonin reuptake inhibitors,False,Neg,0,OC(=O)CCCCCCCCC=C,NCCC1=CNC2=CC=C(O)C=C12,6,8
1613,8936,8936,9171,9171,"Inhibitors of this isoenzyme (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) should be cautiously coadministered with DRUGOTHER as they can potentially increase DRUGOTHER levels.",serotonin reuptake inhibitors,amiodarone,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2,8,9
1614,8937,8937,9172,9172,"Inhibitors of this isoenzyme (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) should be cautiously coadministered with DRUGOTHER as they can potentially increase DRUGOTHER levels.",serotonin reuptake inhibitors,diltiazem,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,8,11
1615,8938,8938,9173,9173,"Inhibitors of this isoenzyme (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) should be cautiously coadministered with DRUGOTHER as they can potentially increase DRUGOTHER levels.",serotonin reuptake inhibitors,nefazadone,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1,8,14
1616,8939,8939,9174,9174,"Inhibitors of this isoenzyme (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) should be cautiously coadministered with DRUGOTHER as they can potentially increase DRUGOTHER levels.",serotonin reuptake inhibitors,norfloxacin,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C,8,15
1617,8940,8940,9175,9175,"Inhibitors of this isoenzyme (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) should be cautiously coadministered with DRUGOTHER as they can potentially increase DRUGOTHER levels.",serotonin reuptake inhibitors,quinine,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,8,16
1618,8941,8941,9176,9176,"Inhibitors of this isoenzyme (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) should be cautiously coadministered with DRUGOTHER as they can potentially increase DRUGOTHER levels.",serotonin reuptake inhibitors,zafirlukast,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,COC1=CC(=CC=C1CC1=CN(C)C2=C1C=C(NC(=O)OC1CCCC1)C=C2)C(=O)NS(=O)(=O)C1=CC=CC=C1C,8,17
1619,8942,8942,9177,9177,"Inhibitors of this isoenzyme (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) should be cautiously coadministered with DRUG2 as they can potentially increase DRUGOTHER levels.",serotonin reuptake inhibitors,TIKOSYN,True,advise,1,NCCC1=CNC2=CC=C(O)C=C12,CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC1=CC=C(NS(C)(=O)=O)C=C1,8,23
1620,8943,8943,9178,9178,"Inhibitors of this isoenzyme (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) should be cautiously coadministered with DRUGOTHER as they can potentially increase DRUG2 levels.",serotonin reuptake inhibitors,dofetilide,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC1=CC=C(NS(C)(=O)=O)C=C1,8,29
1621,8977,8977,9212,9212,"Other Drugs: In healthy volunteers, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, hormone replacement therapy (a combination of conjugated DRUGOTHER and DRUGOTHER), DRUGOTHER (aluminum and DRUGOTHERs) and DRUGOTHER did not affect the pharmacokinetics of DRUGOTHER.",amlodipine,phenytoin,False,Neg,0,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,5,6
1622,8986,8986,9221,9221,"Other Drugs: In healthy volunteers, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, hormone replacement therapy (a combination of conjugated DRUGOTHER and DRUGOTHER), DRUGOTHER (aluminum and DRUGOTHERs) and DRUG2 did not affect the pharmacokinetics of DRUGOTHER.",amlodipine,theophylline,False,Neg,0,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN,CN1C2=C(C(=O)N(C1=O)C)NC=N2,5,25
1623,8988,8988,9223,9223,"Other Drugs: In healthy volunteers, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, hormone replacement therapy (a combination of conjugated DRUGOTHER and DRUGOTHER), DRUGOTHER (aluminum and DRUGOTHERs) and DRUGOTHER did not affect the pharmacokinetics of DRUGOTHER.",phenytoin,glyburide,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,6,7
1624,8989,8989,9224,9224,"Other Drugs: In healthy volunteers, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, hormone replacement therapy (a combination of conjugated DRUGOTHER and DRUGOTHER), DRUGOTHER (aluminum and DRUGOTHERs) and DRUGOTHER did not affect the pharmacokinetics of DRUGOTHER.",phenytoin,ranitidine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,6,8
1625,8990,8990,9225,9225,"Other Drugs: In healthy volunteers, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, hormone replacement therapy (a combination of conjugated DRUGOTHER and DRUGOTHER), DRUGOTHER (aluminum and DRUGOTHERs) and DRUGOTHER did not affect the pharmacokinetics of DRUGOTHER.",phenytoin,omeprazole,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,6,9
1626,8991,8991,9226,9226,"Other Drugs: In healthy volunteers, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, hormone replacement therapy (a combination of conjugated DRUG2 and DRUGOTHER), DRUGOTHER (aluminum and DRUGOTHERs) and DRUGOTHER did not affect the pharmacokinetics of DRUGOTHER.",phenytoin,estrogens,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)OS(=O)(=O)[O-])[C@@H]1CCC2=O.[Na+],6,17
1627,8992,8992,9227,9227,"Other Drugs: In healthy volunteers, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, hormone replacement therapy (a combination of conjugated DRUGOTHER and DRUG2), DRUGOTHER (aluminum and DRUGOTHERs) and DRUGOTHER did not affect the pharmacokinetics of DRUGOTHER.",phenytoin,medroxyprogesterone,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C,6,19
1628,8993,8993,9228,9228,"Other Drugs: In healthy volunteers, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, hormone replacement therapy (a combination of conjugated DRUGOTHER and DRUGOTHER), DRUG2 (aluminum and DRUGOTHERs) and DRUGOTHER did not affect the pharmacokinetics of DRUGOTHER.",phenytoin,antacid,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O,6,20
1629,8994,8994,9229,9229,"Other Drugs: In healthy volunteers, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, hormone replacement therapy (a combination of conjugated DRUGOTHER and DRUGOTHER), DRUGOTHER (aluminum and DRUGOTHERs) and DRUGOTHER did not affect the pharmacokinetics of DRUGOTHER.",phenytoin,aluminum hydroxide,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[OH-].[OH-].[OH-].[Al+3],6,-1
1630,8995,8995,9230,9230,"Other Drugs: In healthy volunteers, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, hormone replacement therapy (a combination of conjugated DRUGOTHER and DRUGOTHER), DRUGOTHER (aluminum and DRUG2s) and DRUGOTHER did not affect the pharmacokinetics of DRUGOTHER.",phenytoin,magnesium hydroxide,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[OH-].[OH-].[Mg+2],6,23
1631,8997,8997,9232,9232,"Other Drugs: In healthy volunteers, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, hormone replacement therapy (a combination of conjugated DRUGOTHER and DRUGOTHER), DRUGOTHER (aluminum and DRUGOTHERs) and DRUGOTHER did not affect the pharmacokinetics of DRUG2.",phenytoin,TIKOSYN,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC1=CC=C(NS(C)(=O)=O)C=C1,6,32
1632,9005,9005,9240,9240,"Other Drugs: In healthy volunteers, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, hormone replacement therapy (a combination of conjugated DRUGOTHER and DRUGOTHER), DRUGOTHER (aluminum and DRUGOTHERs) and DRUG2 did not affect the pharmacokinetics of DRUGOTHER.",glyburide,theophylline,False,Neg,0,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,CN1C2=C(C(=O)N(C1=O)C)NC=N2,7,25
1633,9013,9013,9248,9248,"Other Drugs: In healthy volunteers, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, hormone replacement therapy (a combination of conjugated DRUGOTHER and DRUGOTHER), DRUGOTHER (aluminum and DRUGOTHERs) and DRUG2 did not affect the pharmacokinetics of DRUGOTHER.",ranitidine,theophylline,False,Neg,0,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,CN1C2=C(C(=O)N(C1=O)C)NC=N2,8,25
1634,9020,9020,9255,9255,"Other Drugs: In healthy volunteers, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, hormone replacement therapy (a combination of conjugated DRUGOTHER and DRUGOTHER), DRUGOTHER (aluminum and DRUGOTHERs) and DRUG2 did not affect the pharmacokinetics of DRUGOTHER.",omeprazole,theophylline,False,Neg,0,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,CN1C2=C(C(=O)N(C1=O)C)NC=N2,9,25
1635,9026,9026,9261,9261,"Other Drugs: In healthy volunteers, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, hormone replacement therapy (a combination of conjugated DRUG1 and DRUGOTHER), DRUGOTHER (aluminum and DRUGOTHERs) and DRUG2 did not affect the pharmacokinetics of DRUGOTHER.",estrogens,theophylline,False,Neg,0,C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)OS(=O)(=O)[O-])[C@@H]1CCC2=O.[Na+],CN1C2=C(C(=O)N(C1=O)C)NC=N2,17,25
1636,9031,9031,9266,9266,"Other Drugs: In healthy volunteers, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, hormone replacement therapy (a combination of conjugated DRUGOTHER and DRUG1), DRUGOTHER (aluminum and DRUGOTHERs) and DRUG2 did not affect the pharmacokinetics of DRUGOTHER.",medroxyprogesterone,theophylline,False,Neg,0,[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C,CN1C2=C(C(=O)N(C1=O)C)NC=N2,19,25
1637,9035,9035,9270,9270,"Other Drugs: In healthy volunteers, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, hormone replacement therapy (a combination of conjugated DRUGOTHER and DRUGOTHER), DRUG1 (aluminum and DRUGOTHERs) and DRUG2 did not affect the pharmacokinetics of DRUGOTHER.",antacid,theophylline,False,Neg,0,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,20,25
1638,9038,9038,9273,9273,"Other Drugs: In healthy volunteers, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, hormone replacement therapy (a combination of conjugated DRUGOTHER and DRUGOTHER), DRUGOTHER (aluminum and DRUGOTHERs) and DRUG2 did not affect the pharmacokinetics of DRUGOTHER.",aluminum hydroxide,theophylline,False,Neg,0,[OH-].[OH-].[OH-].[Al+3],CN1C2=C(C(=O)N(C1=O)C)NC=N2,-1,25
1639,9040,9040,9275,9275,"Other Drugs: In healthy volunteers, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, hormone replacement therapy (a combination of conjugated DRUGOTHER and DRUGOTHER), DRUGOTHER (aluminum and DRUG1s) and DRUG2 did not affect the pharmacokinetics of DRUGOTHER.",magnesium hydroxide,theophylline,False,Neg,0,[OH-].[OH-].[Mg+2],CN1C2=C(C(=O)N(C1=O)C)NC=N2,23,25
1640,9042,9042,9277,9277,"Other Drugs: In healthy volunteers, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, hormone replacement therapy (a combination of conjugated DRUGOTHER and DRUGOTHER), DRUGOTHER (aluminum and DRUGOTHERs) and DRUG1 did not affect the pharmacokinetics of DRUG2.",theophylline,TIKOSYN,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC1=CC=C(NS(C)(=O)=O)C=C1,25,32
1641,9045,9045,9280,9280,"In addition, studies in healthy volunteers have shown that DRUG1 does not affect the pharmacokinetics or pharmacodynamics of DRUGOTHER, or the pharmacokinetics of DRUGOTHER (40 mg twice daily), DRUG2, DRUGOTHER, or oral DRUGOTHER.",TIKOSYN,phenytoin,False,Neg,0,CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC1=CC=C(NS(C)(=O)=O)C=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,9,28
1642,9046,9046,9281,9281,"In addition, studies in healthy volunteers have shown that DRUG1 does not affect the pharmacokinetics or pharmacodynamics of DRUGOTHER, or the pharmacokinetics of DRUGOTHER (40 mg twice daily), DRUGOTHER, DRUG2, or oral DRUGOTHER.",TIKOSYN,theophylline,False,Neg,0,CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC1=CC=C(NS(C)(=O)=O)C=C1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,9,29
1643,9049,9049,9284,9284,"In addition, studies in healthy volunteers have shown that DRUGOTHER does not affect the pharmacokinetics or pharmacodynamics of DRUG1, or the pharmacokinetics of DRUGOTHER (40 mg twice daily), DRUG2, DRUGOTHER, or oral DRUGOTHER.",warfarin,phenytoin,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,18,28
1644,9050,9050,9285,9285,"In addition, studies in healthy volunteers have shown that DRUGOTHER does not affect the pharmacokinetics or pharmacodynamics of DRUG1, or the pharmacokinetics of DRUGOTHER (40 mg twice daily), DRUGOTHER, DRUG2, or oral DRUGOTHER.",warfarin,theophylline,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,18,29
1645,9052,9052,9287,9287,"In addition, studies in healthy volunteers have shown that DRUGOTHER does not affect the pharmacokinetics or pharmacodynamics of DRUGOTHER, or the pharmacokinetics of DRUG1 (40 mg twice daily), DRUG2, DRUGOTHER, or oral DRUGOTHER.",propranolol,phenytoin,False,Neg,0,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,23,28
1646,9053,9053,9288,9288,"In addition, studies in healthy volunteers have shown that DRUGOTHER does not affect the pharmacokinetics or pharmacodynamics of DRUGOTHER, or the pharmacokinetics of DRUG1 (40 mg twice daily), DRUGOTHER, DRUG2, or oral DRUGOTHER.",propranolol,theophylline,False,Neg,0,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,23,29
1647,9056,9056,9291,9291,"In addition, studies in healthy volunteers have shown that DRUGOTHER does not affect the pharmacokinetics or pharmacodynamics of DRUGOTHER, or the pharmacokinetics of DRUGOTHER (40 mg twice daily), DRUG1, DRUGOTHER, or oral DRUG2.",phenytoin,contraceptives,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,28,32
1648,9057,9057,9292,9292,"In addition, studies in healthy volunteers have shown that DRUGOTHER does not affect the pharmacokinetics or pharmacodynamics of DRUGOTHER, or the pharmacokinetics of DRUGOTHER (40 mg twice daily), DRUGOTHER, DRUG1, or oral DRUG2.",theophylline,contraceptives,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,29,32
1649,9060,9060,9297,9297,"In patients taking DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and various chemotherapy agents, no effect was shown on the clearance of DRUGOTHER.",furosemide,nifedipine,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,3,4
1650,9061,9061,9298,9298,"In patients taking DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and various chemotherapy agents, no effect was shown on the clearance of DRUGOTHER.",furosemide,diltiazem,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,3,5
1651,9062,9062,9299,9299,"In patients taking DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and various chemotherapy agents, no effect was shown on the clearance of DRUGOTHER.",furosemide,verapamil,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,3,7
1652,9063,9063,9300,9300,"In patients taking DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and various chemotherapy agents, no effect was shown on the clearance of DRUGOTHER.",furosemide,glyburide,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,3,8
1653,9064,9064,9301,9301,"In patients taking DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and various chemotherapy agents, no effect was shown on the clearance of DRUGOTHER.",furosemide,propranolol,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,3,9
1654,9077,9077,9314,9314,"DRUGOTHER did not inhibit the antitumor activity of four DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUG2) in four murine models.",cisplatin,cyclophosphamide,False,Neg,0,N.N.Cl[Pt]Cl,ClCCN(CCCl)P1(=O)NCCCO1,10,13
1655,9079,9079,9316,9316,"DRUGOTHER did not inhibit the antitumor activity of four DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER, DRUG2) in four murine models.",5-fluorouracil,cyclophosphamide,False,Neg,0,FC1=CNC(=O)NC1=O,ClCCN(CCCl)P1(=O)NCCCO1,11,13
1656,9080,9080,9317,9317,"DRUGOTHER did not inhibit the antitumor activity of four DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1, DRUG2) in four murine models.",doxorubicin,cyclophosphamide,False,Neg,0,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,ClCCN(CCCl)P1(=O)NCCCO1,12,13
1657,9096,9096,9333,9333,DRUGOTHER (such as DRUG1) and DRUG2 can suppress the DRUGOTHERrgic renal and mesenteric vasodilation induced with low dose DRUGOTHER infusion.,haloperidol,phenothiazines,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,N1C2=CC=CC=C2SC2=CC=CC=C12,3,5
1658,9097,9097,9334,9334,DRUGOTHER (such as DRUG1) and DRUGOTHER can suppress the DRUG2rgic renal and mesenteric vasodilation induced with low dose DRUG2 infusion.,haloperidol,dopamine,True,effect,2,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1,3,9
1659,9105,9105,9347,9347,Administration of DRUG1 to patients receiving DRUG2 has been reported to lead to hypotension and bradycardia.,phenytoin,dopamine HCl,True,effect,2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1,2,6
1660,9106,9106,9348,9348,"It is suggested that in patients receiving DRUG1, alternatives to DRUG2 should be used if DRUGOTHER therapy is needed.",dopamine HCl,phenytoin,True,advise,1,[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,7,10
1661,9108,9108,9350,9350,"It is suggested that in patients receiving DRUGOTHER, alternatives to DRUG1 should be used if DRUG2 therapy is needed.",phenytoin,anticonvulsant,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,10,15
1662,9194,9194,9436,9436,"As with some other DRUG1, the time of onset of neuromuscular block induced by DRUGOTHER is lengthened and the duration of block is shortened in patients receiving DRUG2 or DRUGOTHER.",nondepolarizing neuromuscular blocking agents,phenytoin,True,effect,2,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,4,27
1663,9196,9196,9438,9438,"As with some other DRUGOTHER, the time of onset of neuromuscular block induced by DRUG1 is lengthened and the duration of block is shortened in patients receiving DRUG2 or DRUGOTHER.",NUROMAX,phenytoin,True,effect,2,COC1=CC(CC2C3=C(OC)C(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C(OC)=C3C2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,14,27
1664,9198,9198,9440,9440,"As with some other DRUGOTHER, the time of onset of neuromuscular block induced by DRUGOTHER is lengthened and the duration of block is shortened in patients receiving DRUG1 or DRUG2.",phenytoin,carbamazepine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,27,29
1665,9200,9200,9442,9442,"In vitro data in human plasma indicate that DRUGOTHER has no effect on protein binding of DRUG1, DRUGOTHER, DRUG2 or DRUGOTHER.",digoxin,phenytoin,False,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,16,18
1666,9202,9202,9444,9444,"In vitro data in human plasma indicate that DRUGOTHER has no effect on protein binding of DRUGOTHER, DRUG1, DRUG2 or DRUGOTHER.",warfarin,phenytoin,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,17,18
1667,9204,9204,9446,9446,"In vitro data in human plasma indicate that DRUGOTHER has no effect on protein binding of DRUGOTHER, DRUGOTHER, DRUG1 or DRUG2.",phenytoin,indomethacin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,18,20
1668,9227,9227,9469,9469,"Cardiovascular agents (e.g., DRUG1, DRUG2, DRUGOTHER).",atenolol,hydrochlorothiazide,False,Neg,0,CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,3,4
1669,9229,9229,9471,9471,"Cardiovascular agents (e.g., DRUGOTHER, DRUG1, DRUG2).",hydrochlorothiazide,propranolol,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,4,5
1670,9241,9241,9483,9483,"While all the DRUG1 (DRUGOTHER), e.g., DRUG2, esDRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER, inhibit P450 2D6, they may vary in the extent of inhibition.",selective serotonin reuptake inhibitors,citalopram,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,3,6
1671,9242,9242,9484,9484,"While all the DRUG1 (DRUGOTHER), e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER, inhibit P450 2D6, they may vary in the extent of inhibition.",selective serotonin reuptake inhibitors,escitalopram,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,3,7
1672,9243,9243,9485,9485,"While all the DRUG1 (DRUGOTHER), e.g., DRUGOTHER, esDRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER, inhibit P450 2D6, they may vary in the extent of inhibition.",selective serotonin reuptake inhibitors,fluoxetine,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,3,8
1673,9244,9244,9486,9486,"While all the DRUG1 (DRUGOTHER), e.g., DRUGOTHER, esDRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER, inhibit P450 2D6, they may vary in the extent of inhibition.",selective serotonin reuptake inhibitors,sertraline,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,3,9
1674,9245,9245,9487,9487,"While all the DRUG1 (DRUGOTHER), e.g., DRUGOTHER, esDRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2, inhibit P450 2D6, they may vary in the extent of inhibition.",selective serotonin reuptake inhibitors,paroxetine,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,3,11
1675,9258,9258,9500,9500,"Inhibitors or substrates of CYP2D6 (i.e., DRUG1, DRUG2 [DRUGOTHER]) may increase the plasma concentration of DRUGOTHER when administered concomitantly.",quinidine,selective serotonin reuptake inhibitors,False,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,NCCC1=CNC2=CC=C(O)C=C12,6,7
1676,9259,9259,9501,9501,"Inhibitors or substrates of CYP2D6 (i.e., DRUG1, DRUGOTHER [DRUGOTHER]) may increase the plasma concentration of DRUG2 when administered concomitantly.",quinidine,doxepin,True,mechanism,4,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,6,15
1677,9281,9281,9523,9523,Absorption of DRUG1 is impaired by DRUG2.,tetracycline,bismuth subsalicylate,True,mechanism,4,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1,2,6
1678,9283,9283,9525,9525,"DRUG1, DRUGOTHER, and DRUG2 decrease the half-life of DRUGOTHER.",Barbiturates,phenytoin,False,Neg,0,CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,3
1679,9284,9284,9526,9526,"DRUG1, DRUGOTHER, and DRUGOTHER decrease the half-life of DRUG2.",Barbiturates,doxycycline,True,mechanism,4,CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,0,8
1680,9285,9285,9527,9527,"DRUGOTHER, DRUG1, and DRUG2 decrease the half-life of DRUGOTHER.",carbamazepine,phenytoin,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,1,3
1681,9286,9286,9528,9528,"DRUGOTHER, DRUG1, and DRUGOTHER decrease the half-life of DRUG2.",carbamazepine,doxycycline,True,mechanism,4,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,1,8
1682,9288,9288,9530,9530,The concurrent use of DRUG1 and DRUG2 (DRUGOTHER) has been reported to result in fatal renal toxicity.,tetracycline,Penthrane,True,effect,2,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,COC(F)(F)C(Cl)Cl,4,6
1683,9289,9289,9531,9531,The concurrent use of DRUG1 and DRUGOTHER (DRUG2) has been reported to result in fatal renal toxicity.,tetracycline,methoxyflurane,True,effect,2,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,COC(C(Cl)Cl)(F)F,4,7
1684,9291,9291,9533,9533,Concurrent use of DRUG1 may render oral DRUG2 less effective.,tetracycline,contraceptives,True,effect,2,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,3,7
1685,9293,9293,9535,9535,"Potential drug interactions for DRUG1 include, increased sedation if DRUG1 is combined with other DRUG2.",doxylamine,CNS depressant drugs,False,Neg,0,CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=CC=N1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,4,14
1686,9294,9294,9536,9536,"Potential drug interactions for DRUG1 include, increased sedation if DRUG1 is combined with other DRUG2.",doxylamine,CNS depressant drugs,True,effect,2,CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=CC=N1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,4,14
1687,9299,9299,9541,9541,"Other DRUG1 (e.g. DRUG2, DRUGOTHER, DRUGOTHER and general DRUGOTHER) have additive or potentiating effects with DRUGOTHER.",CNS depressant drugs,barbiturates,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O,1,3
1688,9300,9300,9542,9542,"Other DRUG1 (e.g. DRUGOTHER, DRUG2, DRUGOTHER and general DRUGOTHER) have additive or potentiating effects with DRUGOTHER.",CNS depressant drugs,tranquilizers,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,1,4
1689,9301,9301,9543,9543,"Other DRUG1 (e.g. DRUGOTHER, DRUGOTHER, DRUG2 and general DRUGOTHER) have additive or potentiating effects with DRUGOTHER.",CNS depressant drugs,opioids,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3.CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2.CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,1,5
1690,9302,9302,9544,9544,"Other DRUG1 (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER and general DRUG2) have additive or potentiating effects with DRUGOTHER.",CNS depressant drugs,anesthetics,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCOC(=O)C1=CC=C(N)C=C1,1,8
1691,9303,9303,9545,9545,"Other DRUG1 (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER and general DRUGOTHER) have additive or potentiating effects with DRUG2.",CNS depressant drugs,INAPSINE,True,effect,2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=CC=CC=C12,1,15
1692,9314,9314,9556,9556,"Following the administration of DRUG1, the dose of other DRUG2 should be reduced.",INAPSINE,CNS depressant drugs,True,advise,1,FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=CC=CC=C12,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,4,9
1693,9372,9372,9614,9614,"Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of DRUG1, DRUG2 and DRUG1 should not be co-administered.",thioridazine,Duloxetine,False,Neg,0,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,CNCC[C@H](OC1=CC=CC2=CC=CC=C12)C1=CC=CS1,18,19
1694,9374,9374,9616,9616,"Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of DRUG2, DRUG1 and DRUG2 should not be co-administered.",Duloxetine,thioridazine,True,advise,1,CNCC[C@H](OC1=CC=CC2=CC=CC=C12)C1=CC=CS1,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,19,18
1695,9397,9397,9639,9639,It is unknown whether the concomitant administration of DRUG1 affects DRUG2 absorption.,proton pump inhibitors,duloxetine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CNCC[C@H](OC1=CC=CC2=CC=CC=C12)C1=CC=CS1,8,10
1696,9399,9399,9641,9641,"Synergism between DRUG1 (e.g., DRUGOTHER), DRUG2, and other DRUGOTHER has been reported.",xanthine bronchodilators,ephedrine,False,Neg,0,O=C1NC2=C(NC=N2)C(=O)N1,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC,2,5
1697,9400,9400,9642,9642,"Synergism between DRUGOTHER (e.g., DRUG1), DRUG2, and other DRUGOTHER has been reported.",theophylline,ephedrine,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC,4,5
1698,9401,9401,9643,9643,"Concurrent administration of DRUG1 and DRUG2, which competes for tubular secretion, has been shown to increase the plasma half-life of DRUG1 .",dyphylline,probenecid,True,mechanism,4,CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,3,5
1699,9403,9403,9645,9645,"Concurrent administration of DRUG2 and DRUG1, which competes for tubular secretion, has been shown to increase the plasma half-life of DRUG2 .",probenecid,dyphylline,False,Neg,0,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O,5,3
1700,9429,9429,9671,9671,"When coadministered with DRUG1 in treatment-naive patients, the recommended dose of DRUGOTHER is 300 mg with DRUG2 100 mg and DRUG1 600 mg (all once daily).",SUSTIVA,ritonavir,False,Neg,0,FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,3,16
1701,9431,9431,9673,9673,"When coadministered with DRUGOTHER in treatment-naive patients, the recommended dose of DRUG1 is 300 mg with DRUG2 100 mg and DRUGOTHER 600 mg (all once daily).",atazanavir,ritonavir,False,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,11,16
1702,9433,9433,9675,9675,"When coadministered with DRUG2 in treatment-naive patients, the recommended dose of DRUGOTHER is 300 mg with DRUG1 100 mg and DRUG2 600 mg (all once daily).",ritonavir,SUSTIVA,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1,16,3
1703,9451,9451,9693,9693,DRUG1/DRUG2,Lopinavir,ritonavir,False,Neg,0,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,0,0
1704,9452,9452,9694,9694,A dose increase of DRUG1/DRUG2 to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with DRUGOTHER.,lopinavir,ritonavir,False,Neg,0,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,4,4
1705,9454,9454,9696,9696,A dose increase of DRUGOTHER/DRUG1 to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with DRUG2.,ritonavir,SUSTIVA,True,advise,1,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1,4,25
1706,9461,9461,9703,9703,Monitoring of liver enzymes is recommended when DRUG1 is used in combination with DRUG2.,SUSTIVA,ritonavir,True,advise,1,FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,7,13
1707,9462,9462,9704,9704,DRUG1: DRUG2 DRUGOTHER DRUGOTHER,Anticonvulsants,Phenytoin,False,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,1
1708,9465,9465,9707,9707,DRUGOTHER: DRUG1 DRUG2 DRUGOTHER,Phenytoin,Phenobarbital,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,1,2
1709,9466,9466,9708,9708,DRUGOTHER: DRUG1 DRUGOTHER DRUG2,Phenytoin,Carbamazepine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1,3
1710,9575,9575,9817,9817,"Other Cardiovascular Agents: DRUGOTHER and DRUG1 IV have been used concomitantly with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER without evidence of clinically significant adverse interactions.",enalapril,hydralazine,False,Neg,0,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,C1=CC=C2C(=C1)C=NN=C2NN,5,16
1711,9579,9579,9821,9821,"Other Cardiovascular Agents: DRUGOTHER and DRUGOTHER IV have been used concomitantly with DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER without evidence of clinically significant adverse interactions.",methyldopa,hydralazine,False,Neg,0,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N,C1=CC=C2C(=C1)C=NN=C2NN,13,16
1712,9582,9582,9824,9824,"Other Cardiovascular Agents: DRUGOTHER and DRUGOTHER IV have been used concomitantly with DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER without evidence of clinically significant adverse interactions.",nitrates,hydralazine,False,Neg,0,[N+](=O)([O-])[O-],C1=CC=C2C(=C1)C=NN=C2NN,14,16
1713,9585,9585,9827,9827,"Other Cardiovascular Agents: DRUGOTHER and DRUGOTHER IV have been used concomitantly with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2 and DRUGOTHER without evidence of clinically significant adverse interactions.",hydralazine,prazosin,False,Neg,0,C1=CC=C2C(=C1)C=NN=C2NN,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC,16,17
1714,9586,9586,9828,9828,"Other Cardiovascular Agents: DRUGOTHER and DRUGOTHER IV have been used concomitantly with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER and DRUG2 without evidence of clinically significant adverse interactions.",hydralazine,digoxin,False,Neg,0,C1=CC=C2C(=C1)C=NN=C2NN,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,16,19
1715,9588,9588,9830,9830,"DRUGOTHER (e.g., DRUG1, DRUG2, or DRUGOTHER), DRUGOTHER supplements, or DRUGOTHER-containing salt substitutes may lead to significant increases in serum DRUGOTHER.",spironolactone,triamterene,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,2,3
1716,9589,9589,9831,9831,"DRUGOTHER (e.g., DRUG1, DRUGOTHER, or DRUG2), DRUGOTHER supplements, or DRUGOTHER-containing salt substitutes may lead to significant increases in serum DRUGOTHER.",spironolactone,amiloride,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N,2,5
1717,9604,9604,9846,9846,DRUG1: DRUG2 is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of DRUGOTHER.,Caffeine,Enoxacin,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1,0,1
1718,9606,9606,9848,9848,DRUGOTHER: DRUG1 is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of DRUG2.,Enoxacin,methylxanthines,True,mechanism,4,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1,O=C1NC2=C(NC=N2)C(=O)N1,1,16
1719,9607,9607,9849,9849,"In a multiple-dose study, DRUG1 caused a dose-related increase in the mean elimination half-life of DRUG2, thereby decreasing the clearance of DRUG2 by up to 80% and leading to a five-fold increase in the AUC and the half-life of DRUG2.",enoxacin,caffeine,True,mechanism,4,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,4,15
1720,9608,9608,9850,9850,"In a multiple-dose study, DRUG1 caused a dose-related increase in the mean elimination half-life of DRUG2, thereby decreasing the clearance of DRUG2 by up to 80% and leading to a five-fold increase in the AUC and the half-life of DRUG2.",enoxacin,caffeine,False,Neg,0,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,4,15
1721,9609,9609,9851,9851,"In a multiple-dose study, DRUG1 caused a dose-related increase in the mean elimination half-life of DRUG2, thereby decreasing the clearance of DRUG2 by up to 80% and leading to a five-fold increase in the AUC and the half-life of DRUG2.",enoxacin,caffeine,False,Neg,0,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,4,15
1722,9613,9613,9855,9855,Trough plasma DRUG1 levels were also 20% higher when DRUG2 and DRUG1 were administered concomitantly.,enoxacin,caffeine,False,Neg,0,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,2,9
1723,9615,9615,9857,9857,Trough plasma DRUG2 levels were also 20% higher when DRUG1 and DRUG2 were administered concomitantly.,caffeine,enoxacin,True,mechanism,4,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1,9,2
1724,9617,9617,9859,9859,DRUG1-related adverse effects have occurred in patients consuming DRUGOTHER while on therapy with DRUG2.,Caffeine,enoxacin,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1,0,13
1725,9618,9618,9860,9860,DRUGOTHER-related adverse effects have occurred in patients consuming DRUG1 while on therapy with DRUG2.,caffeine,enoxacin,True,effect,2,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1,8,13
1726,9648,9648,9890,9890,DRUG1: DRUG2 is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of DRUGOTHER.,Theophylline,Enoxacin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1,0,1
1727,9650,9650,9892,9892,DRUGOTHER: DRUG1 is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of DRUG2.,Enoxacin,methylxanthines,True,mechanism,4,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1,O=C1NC2=C(NC=N2)C(=O)N1,1,16
1728,9651,9651,9893,9893,DRUG1 interferes with the metabolism of DRUG2 resulting in a 42% to 74% dose-related decrease in DRUG2 clearance and a subsequent 260% to 350% increase in serum DRUG2 levels.,Enoxacin,theophylline,True,mechanism,4,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,6
1729,9652,9652,9894,9894,DRUG1 interferes with the metabolism of DRUG2 resulting in a 42% to 74% dose-related decrease in DRUG2 clearance and a subsequent 260% to 350% increase in serum DRUG2 levels.,Enoxacin,theophylline,False,Neg,0,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,6
1730,9655,9655,9897,9897,DRUG1-related adverse effects have occurred in patients when DRUGOTHER and DRUG2 were coadministered.,Theophylline,enoxacin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1,0,10
1731,9656,9656,9898,9898,DRUGOTHER-related adverse effects have occurred in patients when DRUG1 and DRUG2 were coadministered.,theophylline,enoxacin,True,effect,2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1,8,10
1732,9667,9667,9909,9909,"These agents include medications such as: DRUGOTHER, DRUGOTHER including DRUG1, sali-cylates, DRUGOTHER (including DRUG2), DRUGOTHER, or DRUGOTHER.",acetylsalicylic acid,ketorolac tromethamine,False,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,9,13
1733,9670,9670,9912,9912,"These agents include medications such as: DRUGOTHER, DRUGOTHER including DRUGOTHER, sali-cylates, DRUGOTHER (including DRUG1), DRUG2, or DRUGOTHER.",ketorolac tromethamine,dipyridamole,False,Neg,0,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO,13,14
1734,9671,9671,9913,9913,"These agents include medications such as: DRUGOTHER, DRUGOTHER including DRUGOTHER, sali-cylates, DRUGOTHER (including DRUG1), DRUGOTHER, or DRUG2.",ketorolac tromethamine,sulfinpyrazone,False,Neg,0,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4,13,16
1735,9725,9725,9967,9967,All DRUG1 should be used cautiously in patients taking DRUG2.,vasopressors,monoamine oxidase (MAO) inhibitors,True,advise,1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,OC(=O)CCCCCCCC(O)=O,1,9
1736,9736,9736,9979,9979,"Administration of DRUG1 with other CYP3A4 inhibitors (e.g., DRUGOTHER 500 mg BID, DRUGOTHER 240 mg QD, DRUG2 1200 mg TID, DRUGOTHER 200 mg QD) resulted in increases in Cmax of DRUG1 ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",eplerenone,saquinavir,True,mechanism,4,[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[C@H]1O[C@@]11[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)C(=O)OC,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,2,16
1737,9740,9740,9983,9983,"Administration of DRUGOTHER with other CYP3A4 inhibitors (e.g., DRUG1 500 mg BID, DRUGOTHER 240 mg QD, DRUG2 1200 mg TID, DRUGOTHER 200 mg QD) resulted in increases in Cmax of DRUGOTHER ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",erythromycin,saquinavir,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,8,16
1738,9743,9743,9986,9986,"Administration of DRUGOTHER with other CYP3A4 inhibitors (e.g., DRUGOTHER 500 mg BID, DRUG1 240 mg QD, DRUG2 1200 mg TID, DRUGOTHER 200 mg QD) resulted in increases in Cmax of DRUGOTHER ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",verapamil,saquinavir,False,Neg,0,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,12,16
1739,9746,9746,9989,9989,"Administration of DRUGOTHER with other CYP3A4 inhibitors (e.g., DRUGOTHER 500 mg BID, DRUGOTHER 240 mg QD, DRUG1 1200 mg TID, DRUG2 200 mg QD) resulted in increases in Cmax of DRUGOTHER ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",saquinavir,fluconazole,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,16,20
1740,9747,9747,9990,9990,"Administration of DRUG2 with other CYP3A4 inhibitors (e.g., DRUGOTHER 500 mg BID, DRUGOTHER 240 mg QD, DRUG1 1200 mg TID, DRUGOTHER 200 mg QD) resulted in increases in Cmax of DRUG2 ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",saquinavir,eplerenone,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[C@H]1O[C@@]11[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)C(=O)OC,16,2
1741,9776,9776,10019,10019,"In clinical trials, DRUG1 was used with DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, and supplemental DRUGOTHER.In a pharmacokinetic substudy in patients with congestive heart failure receiving DRUG2 or DRUGOTHER in whom therapy with DRUG1 was initiated, apparent oral clearance values for DRUG2 (n = 23) and DRUGOTHER (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.",FLOLAN,furosemide,False,Neg,0,[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,3,25
1742,9779,9779,10022,10022,"In clinical trials, DRUG1 was used with DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, and supplemental DRUGOTHER.In a pharmacokinetic substudy in patients with congestive heart failure receiving DRUG2 or DRUGOTHER in whom therapy with DRUG1 was initiated, apparent oral clearance values for DRUG2 (n = 23) and DRUGOTHER (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.",FLOLAN,furosemide,False,Neg,0,[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,3,25
1743,9783,9783,10026,10026,"In clinical trials, DRUGOTHER was used with DRUG1, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, and supplemental DRUGOTHER.In a pharmacokinetic substudy in patients with congestive heart failure receiving DRUG2 or DRUG1 in whom therapy with DRUGOTHER was initiated, apparent oral clearance values for DRUG2 (n = 23) and DRUG1 (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.",digoxin,furosemide,False,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,7,25
1744,9786,9786,10029,10029,"In clinical trials, DRUGOTHER was used with DRUG1, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, and supplemental DRUGOTHER.In a pharmacokinetic substudy in patients with congestive heart failure receiving DRUG2 or DRUG1 in whom therapy with DRUGOTHER was initiated, apparent oral clearance values for DRUG2 (n = 23) and DRUG1 (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.",digoxin,furosemide,False,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,7,25
1745,9789,9789,10032,10032,"In clinical trials, DRUGOTHER was used with DRUGOTHER, DRUG1, DRUGOTHER, oral DRUGOTHER, and supplemental DRUGOTHER.In a pharmacokinetic substudy in patients with congestive heart failure receiving DRUG2 or DRUGOTHER in whom therapy with DRUGOTHER was initiated, apparent oral clearance values for DRUG2 (n = 23) and DRUGOTHER (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.",diuretics,furosemide,False,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,8,25
1746,9792,9792,10035,10035,"In clinical trials, DRUGOTHER was used with DRUGOTHER, DRUG1, DRUGOTHER, oral DRUGOTHER, and supplemental DRUGOTHER.In a pharmacokinetic substudy in patients with congestive heart failure receiving DRUG2 or DRUGOTHER in whom therapy with DRUGOTHER was initiated, apparent oral clearance values for DRUG2 (n = 23) and DRUGOTHER (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.",diuretics,furosemide,False,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,8,25
1747,9794,9794,10037,10037,"In clinical trials, DRUGOTHER was used with DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, and supplemental DRUG1.In a pharmacokinetic substudy in patients with congestive heart failure receiving DRUG2 or DRUGOTHER in whom therapy with DRUGOTHER was initiated, apparent oral clearance values for DRUG2 (n = 23) and DRUGOTHER (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.",oxygen,furosemide,False,Neg,0,O=O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,14,25
1748,9797,9797,10040,10040,"In clinical trials, DRUGOTHER was used with DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, and supplemental DRUG1.In a pharmacokinetic substudy in patients with congestive heart failure receiving DRUG2 or DRUGOTHER in whom therapy with DRUGOTHER was initiated, apparent oral clearance values for DRUG2 (n = 23) and DRUGOTHER (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.",oxygen,furosemide,False,Neg,0,O=O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,14,25
1749,9799,9799,10042,10042,"In clinical trials, DRUGOTHER was used with DRUG2, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, and supplemental DRUGOTHER.In a pharmacokinetic substudy in patients with congestive heart failure receiving DRUG1 or DRUG2 in whom therapy with DRUGOTHER was initiated, apparent oral clearance values for DRUG1 (n = 23) and DRUG2 (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.",furosemide,digoxin,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,25,7
1750,9800,9800,10043,10043,"In clinical trials, DRUG2 was used with DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, and supplemental DRUGOTHER.In a pharmacokinetic substudy in patients with congestive heart failure receiving DRUG1 or DRUGOTHER in whom therapy with DRUG2 was initiated, apparent oral clearance values for DRUG1 (n = 23) and DRUGOTHER (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.",furosemide,FLOLAN,True,mechanism,4,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O,25,3
1751,9802,9802,10045,10045,"In clinical trials, DRUGOTHER was used with DRUG2, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, and supplemental DRUGOTHER.In a pharmacokinetic substudy in patients with congestive heart failure receiving DRUG1 or DRUG2 in whom therapy with DRUGOTHER was initiated, apparent oral clearance values for DRUG1 (n = 23) and DRUG2 (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.",furosemide,digoxin,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,25,7
1752,9804,9804,10047,10047,"In clinical trials, DRUGOTHER was used with DRUG1, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, and supplemental DRUGOTHER.In a pharmacokinetic substudy in patients with congestive heart failure receiving DRUG2 or DRUG1 in whom therapy with DRUGOTHER was initiated, apparent oral clearance values for DRUG2 (n = 23) and DRUG1 (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.",digoxin,furosemide,False,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,7,25
1753,9806,9806,10049,10049,"In clinical trials, DRUG1 was used with DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, and supplemental DRUGOTHER.In a pharmacokinetic substudy in patients with congestive heart failure receiving DRUG2 or DRUGOTHER in whom therapy with DRUG1 was initiated, apparent oral clearance values for DRUG2 (n = 23) and DRUGOTHER (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.",FLOLAN,furosemide,False,Neg,0,[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,3,25
1754,9808,9808,10051,10051,"In clinical trials, DRUGOTHER was used with DRUG2, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, and supplemental DRUGOTHER.In a pharmacokinetic substudy in patients with congestive heart failure receiving DRUG1 or DRUG2 in whom therapy with DRUGOTHER was initiated, apparent oral clearance values for DRUG1 (n = 23) and DRUG2 (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.",furosemide,digoxin,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,25,7
1755,9815,9815,10058,10058,DRUG1 has been shown to have no effect on the pharmacokinetics of DRUG2 and the pharmacodynamics of DRUGOTHER and DRUGOTHER.,Eprosartan,digoxin,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,0,12
1756,9816,9816,10059,10059,DRUG1 has been shown to have no effect on the pharmacokinetics of DRUGOTHER and the pharmacodynamics of DRUG2 and DRUGOTHER.,Eprosartan,warfarin,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,0,17
1757,9817,9817,10060,10060,DRUG1 has been shown to have no effect on the pharmacokinetics of DRUGOTHER and the pharmacodynamics of DRUGOTHER and DRUG2.,Eprosartan,glyburide,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,0,19
1758,9821,9821,10064,10064,"Because DRUG1 is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and DRUG2 and DRUGOTHER, potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on DRUG1 pharmacokinetics.",eprosartan,ketoconazole,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,1,23
1759,9822,9822,10065,10065,"Because DRUG1 is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and DRUGOTHER and DRUG2, potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on DRUG1 pharmacokinetics.",eprosartan,fluconazole,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,1,25
1760,9825,9825,10068,10068,"Because DRUG2 is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and DRUG1 and DRUGOTHER, potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on DRUG2 pharmacokinetics.",ketoconazole,eprosartan,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,23,1
1761,9826,9826,10069,10069,"Because DRUG2 is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and DRUGOTHER and DRUG1, potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on DRUG2 pharmacokinetics.",fluconazole,eprosartan,False,Neg,0,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,25,1
1762,9827,9827,10070,10070,DRUG1 also has no effect on DRUG2 pharmacokinetics.,Ranitidine,eprosartan,False,Neg,0,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,0,6
1763,9829,9829,10072,10072,DRUG1 doses of up to 300 mg b.i.d. have been safely used concomitantly with sustained-release DRUGOTHER (sustained-release DRUG2) with no clinically significant adverse interactions.,Eprosartan,nifedipine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,0,17
1764,9840,9840,10083,10083,"Caution should be used when administering or taking DRUG1 with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",TARCEVA,nefazodone,True,advise,1,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,8,26
1765,9842,9842,10085,10085,"Caution should be used when administering or taking DRUG1 with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",TARCEVA,ritonavir,True,advise,1,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,8,28
1766,9843,9843,10086,10086,"Caution should be used when administering or taking DRUG1 with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",TARCEVA,saquinavir,True,advise,1,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,8,29
1767,9844,9844,10087,10087,"Caution should be used when administering or taking DRUG1 with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",TARCEVA,telithromycin,True,advise,1,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,8,30
1768,9852,9852,10095,10095,"Caution should be used when administering or taking DRUGOTHER with DRUG1 and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",ketoconazole,nefazodone,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,10,26
1769,9854,9854,10097,10097,"Caution should be used when administering or taking DRUGOTHER with DRUG1 and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",ketoconazole,ritonavir,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,10,28
1770,9855,9855,10098,10098,"Caution should be used when administering or taking DRUGOTHER with DRUG1 and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",ketoconazole,saquinavir,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,10,29
1771,9856,9856,10099,10099,"Caution should be used when administering or taking DRUGOTHER with DRUG1 and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",ketoconazole,telithromycin,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,10,30
1772,9863,9863,10106,10106,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",atazanavir,nefazodone,False,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,22,26
1773,9865,9865,10108,10108,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",atazanavir,ritonavir,False,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,22,28
1774,9866,9866,10109,10109,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",atazanavir,saquinavir,False,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,22,29
1775,9867,9867,10110,10110,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",atazanavir,telithromycin,False,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,22,30
1776,9873,9873,10116,10116,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",clarithromycin,nefazodone,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,23,26
1777,9875,9875,10118,10118,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",clarithromycin,ritonavir,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,23,28
1778,9876,9876,10119,10119,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",clarithromycin,saquinavir,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,23,29
1779,9877,9877,10120,10120,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",clarithromycin,telithromycin,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,23,30
1780,9882,9882,10125,10125,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",indinavir,nefazodone,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,24,26
1781,9884,9884,10127,10127,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",indinavir,ritonavir,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,24,28
1782,9885,9885,10128,10128,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",indinavir,saquinavir,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,24,29
1783,9886,9886,10129,10129,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",indinavir,telithromycin,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,24,30
1784,9890,9890,10133,10133,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",itraconazole,nefazodone,False,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,25,26
1785,9892,9892,10135,10135,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",itraconazole,ritonavir,False,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,25,28
1786,9893,9893,10136,10136,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",itraconazole,saquinavir,False,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,25,29
1787,9894,9894,10137,10137,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",itraconazole,telithromycin,False,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,25,30
1788,9898,9898,10141,10141,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",nefazodone,nelfinavir,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,26,27
1789,9902,9902,10145,10145,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER .",nefazodone,troleandomycin,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,26,31
1790,9903,9903,10146,10146,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER .",nefazodone,TAO,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O,26,32
1791,9904,9904,10147,10147,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUG2 .",nefazodone,voriconazole,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,26,34
1792,9905,9905,10148,10148,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",nelfinavir,ritonavir,False,Neg,0,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,27,28
1793,9906,9906,10149,10149,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",nelfinavir,saquinavir,False,Neg,0,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,27,29
1794,9907,9907,10150,10150,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",nelfinavir,telithromycin,False,Neg,0,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,27,30
1795,9913,9913,10156,10156,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER .",ritonavir,troleandomycin,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,28,31
1796,9914,9914,10157,10157,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER .",ritonavir,TAO,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O,28,32
1797,9915,9915,10158,10158,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUG2 .",ritonavir,voriconazole,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,28,34
1798,9917,9917,10160,10160,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER .",saquinavir,troleandomycin,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,29,31
1799,9918,9918,10161,10161,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER .",saquinavir,TAO,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O,29,32
1800,9919,9919,10162,10162,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUG2 .",saquinavir,voriconazole,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,29,34
1801,9920,9920,10163,10163,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2 (DRUGOTHER), and DRUGOTHER .",telithromycin,troleandomycin,False,Neg,0,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,30,31
1802,9921,9921,10164,10164,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (DRUG2), and DRUGOTHER .",telithromycin,TAO,False,Neg,0,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O,30,32
1803,9922,9922,10165,10165,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (DRUGOTHER), and DRUG2 .",telithromycin,voriconazole,False,Neg,0,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,30,34
1804,9929,9929,10172,10172,"Other CYP3A4 inducers include, but are not limited to, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER and St. Johns Wort.",rifabutin,phenytoin,False,Neg,0,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,9,11
1805,9932,9932,10175,10175,"Other CYP3A4 inducers include, but are not limited to, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER and St. Johns Wort.",rifapentine,phenytoin,False,Neg,0,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\C=N\N1CCN(CC1)C1CCCC1)=C2O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,10,11
1806,9935,9935,10178,10178,"Other CYP3A4 inducers include, but are not limited to, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER and St. Johns Wort.",phenytoin,carbamazepine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,11,12
1807,9936,9936,10179,10179,"Other CYP3A4 inducers include, but are not limited to, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2 and St. Johns Wort.",phenytoin,phenobarbital,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,11,13
1808,9953,9953,10196,10196,DRUG1 use in patients who are receiving high doses of DRUG2 may be associated with an increase in serum DRUG2 levels and potential DRUG2 toxicity.,Erythromycin,theophylline,True,effect,2,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,10
1809,9954,9954,10197,10197,DRUG1 use in patients who are receiving high doses of DRUG2 may be associated with an increase in serum DRUG2 levels and potential DRUG2 toxicity.,Erythromycin,theophylline,False,Neg,0,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,10
1810,9955,9955,10198,10198,DRUG1 use in patients who are receiving high doses of DRUG2 may be associated with an increase in serum DRUG2 levels and potential DRUG2 toxicity.,Erythromycin,theophylline,False,Neg,0,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,10
1811,9961,9961,10204,10204,"In case of DRUG1 toxicity and/or elevated serum DRUG1 levels, the dose of DRUG1 should be reduced while the patient is receiving concomitant DRUG2 therapy.",theophylline,erythromycin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,3,23
1812,9963,9963,10206,10206,"In case of DRUG1 toxicity and/or elevated serum DRUG1 levels, the dose of DRUG1 should be reduced while the patient is receiving concomitant DRUG2 therapy.",theophylline,erythromycin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,3,23
1813,9964,9964,10207,10207,"In case of DRUG1 toxicity and/or elevated serum DRUG1 levels, the dose of DRUG1 should be reduced while the patient is receiving concomitant DRUG2 therapy.",theophylline,erythromycin,True,advise,1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,3,23
1814,9981,9981,10224,10224,"There have been reports of interactions of DRUG1 with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",erythromycin,phenytoin,True,int,3,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,7,13
1815,9993,9993,10236,10236,"There have been reports of interactions of DRUGOTHER with DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",carbamazepine,phenytoin,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,9,13
1816,10004,10004,10247,10247,"There have been reports of interactions of DRUGOTHER with DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",cyclosporine,phenytoin,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,10,13
1817,10014,10014,10257,10257,"There have been reports of interactions of DRUGOTHER with DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",tacrolimus,phenytoin,False,Neg,0,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,11,13
1818,10023,10023,10266,10266,"There have been reports of interactions of DRUGOTHER with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",hexobarbital,phenytoin,False,Neg,0,CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,12,13
1819,10032,10032,10275,10275,"There have been reports of interactions of DRUGOTHER with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",phenytoin,alfentanil,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,13,14
1820,10033,10033,10276,10276,"There have been reports of interactions of DRUGOTHER with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",phenytoin,cisapride,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,13,15
1821,10034,10034,10277,10277,"There have been reports of interactions of DRUGOTHER with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",phenytoin,disopyramide,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,OC(=O)CCCCCCCC(O)=O,13,16
1822,10035,10035,10278,10278,"There have been reports of interactions of DRUGOTHER with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",phenytoin,lovastatin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,13,17
1823,10036,10036,10279,10279,"There have been reports of interactions of DRUGOTHER with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",phenytoin,bromocriptine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C,13,18
1824,10037,10037,10280,10280,"There have been reports of interactions of DRUGOTHER with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",phenytoin,valproate,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCCC(CCC)C(=O)O,13,19
1825,10038,10038,10281,10281,"There have been reports of interactions of DRUGOTHER with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",phenytoin,terfenadine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,13,20
1826,10039,10039,10282,10282,"There have been reports of interactions of DRUGOTHER with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",phenytoin,astemizole,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,13,22
1827,10131,10131,10374,10374,"If concomitant treatment with DRUG1 and an DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, esDRUGOTHER) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,fluoxetine,True,advise,1,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,4,9
1828,10132,10132,10375,10375,"If concomitant treatment with DRUG1 and an DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, esDRUGOTHER) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,fluvoxamine,True,advise,1,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,4,10
1829,10133,10133,10376,10376,"If concomitant treatment with DRUG1 and an DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, esDRUGOTHER) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,paroxetine,True,advise,1,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,4,11
1830,10134,10134,10377,10377,"If concomitant treatment with DRUG1 and an DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, esDRUGOTHER) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,sertraline,True,advise,1,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,4,12
1831,10135,10135,10378,10378,"If concomitant treatment with DRUG1 and an DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, esDRUG2) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,citalopram,True,advise,1,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,4,13
1832,10136,10136,10379,10379,"If concomitant treatment with DRUG1 and an DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,escitalopram,True,advise,1,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,4,14
1833,10152,10152,10395,10395,DRUG1 - Combined administration of racemic DRUG2 (40 mg/day for 21 days) and the CYP1A2 substrate DRUGOTHER (single dose of 300 mg) did not affect the pharmacokinetics of DRUGOTHER.,Theophylline,citalopram,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,0,6
1834,10155,10155,10398,10398,DRUGOTHER - Combined administration of racemic DRUG1 (40 mg/day for 21 days) and the CYP1A2 substrate DRUG2 (single dose of 300 mg) did not affect the pharmacokinetics of DRUG2.,citalopram,theophylline,False,Neg,0,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CN1C2=C(C(=O)N(C1=O)C)NC=N2,6,16
1835,10156,10156,10399,10399,DRUGOTHER - Combined administration of racemic DRUG1 (40 mg/day for 21 days) and the CYP1A2 substrate DRUG2 (single dose of 300 mg) did not affect the pharmacokinetics of DRUG2.,citalopram,theophylline,False,Neg,0,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CN1C2=C(C(=O)N(C1=O)C)NC=N2,6,16
1836,10158,10158,10401,10401,The effect of DRUG1 on the pharmacokinetics of DRUG2 was not evaluated.,theophylline,citalopram,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,3,8
1837,10195,10195,10438,10438,"DRUG1 - Combined administration of a single dose of DRUGOTHER (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and DRUG2 (20 mg) did not affect the pharmacokinetics of either DRUGOTHER or DRUG2.",Ritonavir,escitalopram,False,Neg,0,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,0,23
1838,10197,10197,10440,10440,"DRUG1 - Combined administration of a single dose of DRUGOTHER (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and DRUG2 (20 mg) did not affect the pharmacokinetics of either DRUGOTHER or DRUG2.",Ritonavir,escitalopram,False,Neg,0,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,0,23
1839,10198,10198,10441,10441,"DRUGOTHER - Combined administration of a single dose of DRUG1 (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and DRUG2 (20 mg) did not affect the pharmacokinetics of either DRUG1 or DRUG2.",ritonavir,escitalopram,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,9,23
1840,10200,10200,10443,10443,"DRUGOTHER - Combined administration of a single dose of DRUG1 (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and DRUG2 (20 mg) did not affect the pharmacokinetics of either DRUG1 or DRUG2.",ritonavir,escitalopram,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,9,23
1841,10201,10201,10444,10444,"DRUGOTHER - Combined administration of a single dose of DRUG2 (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and DRUG1 (20 mg) did not affect the pharmacokinetics of either DRUG2 or DRUG1.",escitalopram,ritonavir,False,Neg,0,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,23,9
1842,10203,10203,10446,10446,"DRUGOTHER - Combined administration of a single dose of DRUG1 (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and DRUG2 (20 mg) did not affect the pharmacokinetics of either DRUG1 or DRUG2.",ritonavir,escitalopram,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,9,23
1843,10204,10204,10447,10447,"However, coadministration of DRUG1 (20 mg) and DRUG2 (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of DRUG1.",escitalopram,ritonavir,False,Neg,0,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,3,7
1844,10206,10206,10449,10449,"However, coadministration of DRUG2 (20 mg) and DRUG1 (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of DRUG2.",ritonavir,escitalopram,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,7,3
1845,10253,10253,10496,10496,"Drug interaction studies have shown that DRUG1 does not have any clinically significant interactions with DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER.",esomeprazole,phenytoin,False,Neg,0,CC1=CN=C(C(=C1OC)C)C[S@](=O)C2=NC3=C(N2)C=C(C=C3)OC,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,6,15
1846,10258,10258,10501,10501,"Drug interaction studies have shown that DRUGOTHER does not have any clinically significant interactions with DRUG1, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER.",phenytoin,warfarin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,15,16
1847,10259,10259,10502,10502,"Drug interaction studies have shown that DRUGOTHER does not have any clinically significant interactions with DRUG1, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER.",phenytoin,quinidine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,15,17
1848,10260,10260,10503,10503,"Drug interaction studies have shown that DRUGOTHER does not have any clinically significant interactions with DRUG1, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER.",phenytoin,clarithromycin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,15,18
1849,10261,10261,10504,10504,"Drug interaction studies have shown that DRUGOTHER does not have any clinically significant interactions with DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2.",phenytoin,amoxicillin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,15,20
1850,10269,10269,10512,10512,Patients treated with DRUG1 and DRUG2 concomitantly may need to be monitored for increases in INR and prothrombin time.,proton pump inhibitors,warfarin,True,effect,2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,3,5
1851,10278,10278,10521,10521,"Coadministration of oral DRUG1, DRUGOTHER, DRUG2, or DRUGOTHER did not seem to change the pharmacokinetic profile of DRUGOTHER.",contraceptives,phenytoin,False,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,3,5
1852,10281,10281,10524,10524,"Coadministration of oral DRUGOTHER, DRUG1, DRUG2, or DRUGOTHER did not seem to change the pharmacokinetic profile of DRUGOTHER.",diazepam,phenytoin,False,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,4,5
1853,10284,10284,10527,10527,"Coadministration of oral DRUGOTHER, DRUGOTHER, DRUG1, or DRUG2 did not seem to change the pharmacokinetic profile of DRUGOTHER.",phenytoin,quinidine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,5,7
1854,10285,10285,10528,10528,"Coadministration of oral DRUGOTHER, DRUGOTHER, DRUG1, or DRUGOTHER did not seem to change the pharmacokinetic profile of DRUG2.",phenytoin,esomeprazole,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=CN=C(C(=C1OC)C)C[S@](=O)C2=NC3=C(N2)C=C(C=C3)OC,5,17
1855,10317,10317,10560,10560,"While no in vivo drug-drug interaction studies were conducted between DRUG1 and inducers of CYP3A, compounds that are potent CYP3A inducers (such as DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) would be expected to decrease DRUG1 concentrations.",estazolam,phenytoin,True,mechanism,4,ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,10,24
1856,10321,10321,10564,10564,"While no in vivo drug-drug interaction studies were conducted between DRUGOTHER and inducers of CYP3A, compounds that are potent CYP3A inducers (such as DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER) would be expected to decrease DRUGOTHER concentrations.",carbamazepine,phenytoin,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,23,24
1857,10325,10325,10568,10568,"While no in vivo drug-drug interaction studies were conducted between DRUGOTHER and inducers of CYP3A, compounds that are potent CYP3A inducers (such as DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER) would be expected to decrease DRUGOTHER concentrations.",phenytoin,rifampin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,24,25
1858,10326,10326,10569,10569,"While no in vivo drug-drug interaction studies were conducted between DRUGOTHER and inducers of CYP3A, compounds that are potent CYP3A inducers (such as DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2) would be expected to decrease DRUGOTHER concentrations.",phenytoin,barbiturates,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O,24,27
1859,10327,10327,10570,10570,"While no in vivo drug-drug interaction studies were conducted between DRUG2 and inducers of CYP3A, compounds that are potent CYP3A inducers (such as DRUGOTHER, DRUG1, DRUGOTHER, and DRUGOTHER) would be expected to decrease DRUG2 concentrations.",phenytoin,estazolam,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1,24,10
1860,10340,10340,10583,10583,"The following are examples of drugs known to inhibit the metabolism of other related DRUG1, presumably through inhibition of CYP3A: DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and some DRUGOTHER.",benzodiazepines,nefazodone,True,mechanism,4,N1N=CC=CC2=CC=CC=C12,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,14,20
1861,10346,10346,10589,10589,"The following are examples of drugs known to inhibit the metabolism of other related DRUGOTHER, presumably through inhibition of CYP3A: DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and some DRUGOTHER.",nefazodone,fluvoxamine,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,20,21
1862,10347,10347,10590,10590,"The following are examples of drugs known to inhibit the metabolism of other related DRUGOTHER, presumably through inhibition of CYP3A: DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and some DRUGOTHER.",nefazodone,cimetidine,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC1=C(N=CN1)CSCCNC(=NC)NC#N,20,22
1863,10348,10348,10591,10591,"The following are examples of drugs known to inhibit the metabolism of other related DRUGOTHER, presumably through inhibition of CYP3A: DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and some DRUGOTHER.",nefazodone,diltiazem,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,20,23
1864,10349,10349,10592,10592,"The following are examples of drugs known to inhibit the metabolism of other related DRUGOTHER, presumably through inhibition of CYP3A: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and some DRUGOTHER.",nefazodone,isoniazide,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O,20,24
1865,10350,10350,10593,10593,"The following are examples of drugs known to inhibit the metabolism of other related DRUGOTHER, presumably through inhibition of CYP3A: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and some DRUG2.",nefazodone,macrolide antibiotics,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,20,27
1866,10384,10384,10627,10627,"Other strong inhibitors of CYP3A4 (e.g., DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) would be expected to behave similarly.",itraconazole,nefazodone,False,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,6,8
1867,10386,10386,10629,10629,"Other strong inhibitors of CYP3A4 (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) would be expected to behave similarly.",itraconazole,ritonavir,False,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,6,10
1868,10388,10388,10631,10631,"Other strong inhibitors of CYP3A4 (e.g., DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) would be expected to behave similarly.",clarithromycin,nefazodone,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,7,8
1869,10390,10390,10633,10633,"Other strong inhibitors of CYP3A4 (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) would be expected to behave similarly.",clarithromycin,ritonavir,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,7,10
1870,10392,10392,10635,10635,"Other strong inhibitors of CYP3A4 (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER) would be expected to behave similarly.",nefazodone,troleandomycin,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,8,9
1871,10394,10394,10637,10637,"Other strong inhibitors of CYP3A4 (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2) would be expected to behave similarly.",nefazodone,nelfinavir,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,8,11
1872,10395,10395,10638,10638,"Other strong inhibitors of CYP3A4 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER) would be expected to behave similarly.",troleandomycin,ritonavir,False,Neg,0,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,9,10
1873,10397,10397,10640,10640,"Other strong inhibitors of CYP3A4 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2) would be expected to behave similarly.",ritonavir,nelfinavir,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,10,11
1874,10435,10435,10678,10678,"May interact with addictive medications, especially DRUG1 with habituating potential (prolonged concurrent use may increase the risk of habituation), DRUGOTHER or CNS depression producing medications (concurrent use may increase the CNS depressant effects of either these medications or DRUG2).",central nervous system (CNS) depressants,ethinamate,False,Neg,0,C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1,NC(=O)OC1(CCCCC1)C#C,6,38
1875,10436,10436,10679,10679,"May interact with addictive medications, especially DRUGOTHER with habituating potential (prolonged concurrent use may increase the risk of habituation), DRUG1 or CNS depression producing medications (concurrent use may increase the CNS depressant effects of either these medications or DRUG2).",alcohol,ethinamate,False,Neg,0,CCO,NC(=O)OC1(CCCCC1)C#C,19,38
1876,10438,10438,10681,10681,"DRUG1 may interact with DRUGOTHER or other DRUG2, causing increased sedative effects.",Ethopropazine,CNS depressants,True,effect,2,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,0,7
1877,10439,10439,10682,10682,"DRUGOTHER may interact with DRUG1 or other DRUG2, causing increased sedative effects.",alcohol,CNS depressants,False,Neg,0,CCO,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,4,7
1878,10446,10446,10689,10689,"Since DRUGOTHER (DRUG1) may interact with concurrently administered DRUGOTHER, periodic serum level determinations of these drugs may be necessary (eg, DRUG1 may elevate DRUGOTHER serum levels and DRUG2 has been reported to both increase and decrease DRUG1 levels).",ethosuximide,valproic acid,False,Neg,0,CCC1(C)CC(=O)NC1=O,CCCC(CCC)C(=O)O,2,27
1879,10449,10449,10692,10692,"Since DRUGOTHER (DRUG1) may interact with concurrently administered DRUGOTHER, periodic serum level determinations of these drugs may be necessary (eg, DRUG1 may elevate DRUGOTHER serum levels and DRUG2 has been reported to both increase and decrease DRUG1 levels).",ethosuximide,valproic acid,False,Neg,0,CCC1(C)CC(=O)NC1=O,CCCC(CCC)C(=O)O,2,27
1880,10451,10451,10694,10694,"Since DRUGOTHER (DRUGOTHER) may interact with concurrently administered DRUGOTHER, periodic serum level determinations of these drugs may be necessary (eg, DRUGOTHER may elevate DRUG1 serum levels and DRUG2 has been reported to both increase and decrease DRUGOTHER levels).",phenytoin,valproic acid,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCCC(CCC)C(=O)O,23,27
1881,10453,10453,10696,10696,"Since DRUGOTHER (DRUG2) may interact with concurrently administered DRUGOTHER, periodic serum level determinations of these drugs may be necessary (eg, DRUG2 may elevate DRUGOTHER serum levels and DRUG1 has been reported to both increase and decrease DRUG2 levels).",valproic acid,ethosuximide,True,mechanism,4,CCCC(CCC)C(=O)O,CCC1(C)CC(=O)NC1=O,27,2
1882,10457,10457,10700,10700,"A two-way interaction between the DRUGOTHER, DRUG1, and the DRUG2s has been suggested.",phenytoin,coumarin anticoagulant,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,O=C1OC2=CC=CC=C2C=C1,6,9
1883,10458,10458,10701,10701,"Presumably, DRUG1 acts as a stimulator of DRUG2 metabolism and has been reported to cause decreased serum levels of the DRUG2 anticoagulants and increased prothrombin-proconvertin concentrations.",phenytoin,coumarin,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC(=O)O2,1,7
1884,10459,10459,10702,10702,"Presumably, DRUG1 acts as a stimulator of DRUGOTHER metabolism and has been reported to cause decreased serum levels of the DRUG2 and increased prothrombin-proconvertin concentrations.",phenytoin,coumarin anticoagulants,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,O=C1OC2=CC=CC=C2C=C1,1,20
1885,10461,10461,10704,10704,"Conversely, the DRUG1 have been reported to increase the serum levels and prolong the serum half-life of DRUG2 by inhibiting its metabolism.",coumarin anticoagulants,phenytoin,True,mechanism,4,O=C1OC2=CC=CC=C2C=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,2,17
1886,10475,10475,10726,10726,"DRUG1 (DRUGOTHER, DRUG2): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these DRUGOTHER on plasma concentrations of DRUGOTHER.",Antibiotics,tetracycline,False,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,0,2
1887,10477,10477,10728,10728,"DRUGOTHER (DRUG1, DRUG2): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these DRUGOTHER on plasma concentrations of DRUGOTHER.",ampicillin,tetracycline,False,Neg,0,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,1,2
1888,10479,10479,10730,10730,"DRUGOTHER (DRUGOTHER, DRUG1): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these DRUG2 on plasma concentrations of DRUGOTHER.",tetracycline,antibiotics,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,2,20
1889,10484,10484,10735,10735,"DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER): Increase the metabolism of DRUGOTHER and/or some DRUGOTHER, leading to possible decrease in contraceptive effectiveness.",Anticonvulsants,phenytoin,False,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,4
1890,10485,10485,10736,10736,"DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2): Increase the metabolism of DRUGOTHER and/or some DRUGOTHER, leading to possible decrease in contraceptive effectiveness.",Anticonvulsants,topiramate,False,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,0,5
1891,10490,10490,10741,10741,"DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER): Increase the metabolism of DRUGOTHER and/or some DRUGOTHER, leading to possible decrease in contraceptive effectiveness.",carbamazepine,phenytoin,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,1,4
1892,10491,10491,10742,10742,"DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2): Increase the metabolism of DRUGOTHER and/or some DRUGOTHER, leading to possible decrease in contraceptive effectiveness.",carbamazepine,topiramate,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,1,5
1893,10495,10495,10746,10746,"DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER): Increase the metabolism of DRUGOTHER and/or some DRUGOTHER, leading to possible decrease in contraceptive effectiveness.",felbamate,phenytoin,False,Neg,0,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,2,4
1894,10496,10496,10747,10747,"DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2): Increase the metabolism of DRUGOTHER and/or some DRUGOTHER, leading to possible decrease in contraceptive effectiveness.",felbamate,topiramate,False,Neg,0,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,2,5
1895,10499,10499,10750,10750,"DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER): Increase the metabolism of DRUGOTHER and/or some DRUGOTHER, leading to possible decrease in contraceptive effectiveness.",phenobarbital,phenytoin,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,3,4
1896,10500,10500,10751,10751,"DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2): Increase the metabolism of DRUGOTHER and/or some DRUGOTHER, leading to possible decrease in contraceptive effectiveness.",phenobarbital,topiramate,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,3,5
1897,10504,10504,10755,10755,"DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER): Increase the metabolism of DRUG2 and/or some DRUGOTHER, leading to possible decrease in contraceptive effectiveness.",phenytoin,ethinyl estradiol,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,4,10
1898,10505,10505,10756,10756,"DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER): Increase the metabolism of DRUGOTHER and/or some DRUG2, leading to possible decrease in contraceptive effectiveness.",phenytoin,progestins,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[H][C@@]12CC[C@@](O)(CC=C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H],4,13
1899,10506,10506,10757,10757,"DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1): Increase the metabolism of DRUG2 and/or some DRUGOTHER, leading to possible decrease in contraceptive effectiveness.",topiramate,ethinyl estradiol,True,mechanism,4,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,5,10
1900,10507,10507,10758,10758,"DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1): Increase the metabolism of DRUGOTHER and/or some DRUG2, leading to possible decrease in contraceptive effectiveness.",topiramate,progestins,True,mechanism,4,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,[H][C@@]12CC[C@@](O)(CC=C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H],5,13
1901,10560,10560,10815,10815,"Example inducers include DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",aminoglutethimide,phenytoin,False,Neg,0,CCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,3,8
1902,10564,10564,10820,10820,"Example inducers include DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",carbamazepine,phenytoin,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,4,8
1903,10567,10567,10827,10827,"Example inducers include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER.",nevirapine,phenytoin,False,Neg,0,CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,6,8
1904,10569,10569,10829,10829,"Example inducers include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER.",phenobarbital,phenytoin,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,7,8
1905,10571,10571,10831,10831,"Example inducers include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2.",phenytoin,rifamycins,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C=C2O,8,10
1906,10586,10586,10846,10846,"DRUGOTHER: DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2 have been shown to decrease plasma levels of DRUGOTHER;",Amprenavir,ritonavir,False,Neg,0,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1,5
1907,10589,10589,10849,10849,"DRUGOTHER: DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2 have been shown to decrease plasma levels of DRUGOTHER;",lopinavir,ritonavir,False,Neg,0,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,2,5
1908,10591,10591,10851,10851,"DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2 have been shown to decrease plasma levels of DRUGOTHER;",nelfinavir,ritonavir,False,Neg,0,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,3,5
1909,10593,10593,10853,10853,"DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1 have been shown to decrease plasma levels of DRUG2;",ritonavir,combination hormonal contraceptives,True,mechanism,4,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,5,14
1910,10611,10611,10871,10871,"DRUG1: DRUG2 may inhibit the metabolism of DRUGOTHER, leading to increased plasma concentrations.",Theophylline,Ethinyl estradiol,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,0,1
1911,10613,10613,10873,10873,"DRUGOTHER: DRUG1 may inhibit the metabolism of DRUG2, leading to increased plasma concentrations.",Ethinyl estradiol,theophylline,True,mechanism,4,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,CN1C2=C(C(=O)N(C1=O)C)NC=N2,1,7
1912,10629,10629,10889,10889,DRUG1 / NUTRITION / HERB INTERACTIONS: Food: CNS effects of DRUG2 may be enhanced if DRUGOTHER are used concurrently with DRUG2.,ETHANOL,caffeine,False,Neg,0,OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,0,10
1913,10631,10631,10891,10891,DRUG1 / NUTRITION / HERB INTERACTIONS: Food: CNS effects of DRUG2 may be enhanced if DRUGOTHER are used concurrently with DRUG2.,ETHANOL,caffeine,False,Neg,0,OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,0,10
1914,10632,10632,10892,10892,DRUGOTHER / NUTRITION / HERB INTERACTIONS: Food: CNS effects of DRUG1 may be enhanced if DRUG2 are used concurrently with DRUG1.,caffeine,combination hormonal contraceptives,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,10,15
1915,10634,10634,10894,10894,DRUGOTHER / NUTRITION / HERB INTERACTIONS: Food: CNS effects of DRUG2 may be enhanced if DRUG1 are used concurrently with DRUG2.,combination hormonal contraceptives,caffeine,True,effect,2,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,15,10
1916,10650,10650,10910,10910,DRUG1: Etodolac has no apparent pharmacokinetic interaction when administered with DRUG2 or DRUGOTHER.,Diuretics,furosemide,False,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,0,10
1917,10651,10651,10911,10911,DRUG1: Etodolac has no apparent pharmacokinetic interaction when administered with DRUGOTHER or DRUG2.,Diuretics,hydrochlorothiazide,False,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,0,12
1918,10653,10653,10913,10913,"Nevertheless, clinical studies, as well as postmarketing observations have shown that DRUG1 can reduce the natriuretic effect of DRUG2 and DRUGOTHER in some patients.",Lodine,furosemide,True,effect,2,CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,11,18
1919,10654,10654,10914,10914,"Nevertheless, clinical studies, as well as postmarketing observations have shown that DRUG1 can reduce the natriuretic effect of DRUGOTHER and DRUG2 in some patients.",Lodine,thiazides,True,effect,2,CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,11,20
1920,10663,10663,10923,10923,DRUG1: DRUG2 has no apparent pharmacokinetic interaction when administered with DRUGOTHER.,Phenytoin,Etodolac,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1,0,1
1921,10665,10665,10925,10925,DRUGOTHER: DRUG1 has no apparent pharmacokinetic interaction when administered with DRUG2.,Etodolac,phenytoin,False,Neg,0,CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,1,10
1922,10686,10686,10949,10949,"DRUG1 may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG2, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Etonogestrel,tetracycline,True,int,3,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,0,14
1923,10688,10688,10951,10951,"DRUG1 may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Etonogestrel,Dilantin,True,int,3,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,0,16
1924,10692,10692,10955,10955,"DRUG1 may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Etonogestrel,Topamax,True,int,3,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,0,20
1925,10707,10707,10970,10970,"DRUG1 may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Etonogestrel,Fortovase,True,int,3,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,0,40
1926,10708,10708,10971,10971,"DRUG1 may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Etonogestrel,Invirase,True,int,3,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,0,41
1927,10710,10710,10973,10973,"DRUG1 may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Etonogestrel,Norvir,True,int,3,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,0,43
1928,10722,10722,10985,10985,"DRUG1 may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",Etonogestrel,theophylline,True,int,3,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,58
1929,10723,10723,10986,10986,"DRUG1 may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",Etonogestrel,Theo-Dur,True,int,3,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],CN1C2=C(NC=N2)C(=O)N(C)C1=O,0,59
1930,10727,10727,10990,10990,"DRUGOTHER may interact with the following medications: DRUG1 (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG2, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",acetaminophen,tetracycline,False,Neg,0,CC(=O)NC1=CC=C(C=C1)O,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,7,14
1931,10729,10729,10992,10992,"DRUGOTHER may interact with the following medications: DRUG1 (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",acetaminophen,Dilantin,False,Neg,0,CC(=O)NC1=CC=C(C=C1)O,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,7,16
1932,10733,10733,10996,10996,"DRUGOTHER may interact with the following medications: DRUG1 (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",acetaminophen,Topamax,False,Neg,0,CC(=O)NC1=CC=C(C=C1)O,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,7,20
1933,10748,10748,11011,11011,"DRUGOTHER may interact with the following medications: DRUG1 (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",acetaminophen,Fortovase,False,Neg,0,CC(=O)NC1=CC=C(C=C1)O,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,7,40
1934,10749,10749,11012,11012,"DRUGOTHER may interact with the following medications: DRUG1 (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",acetaminophen,Invirase,False,Neg,0,CC(=O)NC1=CC=C(C=C1)O,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,7,41
1935,10751,10751,11014,11014,"DRUGOTHER may interact with the following medications: DRUG1 (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",acetaminophen,Norvir,False,Neg,0,CC(=O)NC1=CC=C(C=C1)O,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,7,43
1936,10763,10763,11026,11026,"DRUGOTHER may interact with the following medications: DRUG1 (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",acetaminophen,theophylline,False,Neg,0,CC(=O)NC1=CC=C(C=C1)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,7,58
1937,10764,10764,11027,11027,"DRUGOTHER may interact with the following medications: DRUG1 (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",acetaminophen,Theo-Dur,False,Neg,0,CC(=O)NC1=CC=C(C=C1)O,CN1C2=C(NC=N2)C(=O)N(C)C1=O,7,59
1938,10767,10767,11030,11030,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUG1 such as DRUGOTHER and DRUG2, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",antibiotics,tetracycline,False,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,9,14
1939,10769,10769,11032,11032,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUG1 such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",antibiotics,Dilantin,False,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,9,16
1940,10773,10773,11036,11036,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUG1 such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",antibiotics,Topamax,False,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,9,20
1941,10788,10788,11051,11051,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUG1 such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",antibiotics,Fortovase,False,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,9,40
1942,10789,10789,11052,11052,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUG1 such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",antibiotics,Invirase,False,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,9,41
1943,10791,10791,11054,11054,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUG1 such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",antibiotics,Norvir,False,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,9,43
1944,10803,10803,11066,11066,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUG1 such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",antibiotics,theophylline,False,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,9,58
1945,10804,10804,11067,11067,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUG1 such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",antibiotics,Theo-Dur,False,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CN1C2=C(NC=N2)C(=O)N(C)C1=O,9,59
1946,10806,10806,11069,11069,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUG1 and DRUG2, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",ampicillin,tetracycline,False,Neg,0,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,12,14
1947,10808,10808,11071,11071,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUG1 and DRUGOTHER, DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",ampicillin,Dilantin,False,Neg,0,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,12,16
1948,10812,10812,11075,11075,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUG1 and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",ampicillin,Topamax,False,Neg,0,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,12,20
1949,10827,10827,11090,11090,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUG1 and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",ampicillin,Fortovase,False,Neg,0,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,12,40
1950,10828,10828,11091,11091,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUG1 and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",ampicillin,Invirase,False,Neg,0,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,12,41
1951,10830,10830,11093,11093,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUG1 and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",ampicillin,Norvir,False,Neg,0,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,12,43
1952,10842,10842,11105,11105,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUG1 and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",ampicillin,theophylline,False,Neg,0,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C,CN1C2=C(C(=O)N(C1=O)C)NC=N2,12,58
1953,10843,10843,11106,11106,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUG1 and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",ampicillin,Theo-Dur,False,Neg,0,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C,CN1C2=C(NC=N2)C(=O)N(C)C1=O,12,59
1954,10845,10845,11108,11108,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUG2 (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,anticonvulsants,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,14,15
1955,10847,10847,11110,11110,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,Phenobarbital,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,14,17
1956,10848,10848,11111,11111,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,Tegretol,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,14,18
1957,10849,10849,11112,11112,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,Trileptal,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,14,19
1958,10851,10851,11114,11114,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,Felbatol,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,14,21
1959,10852,10852,11115,11115,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2 (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,antifungals,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,OC(=O)CCCCCCCCC=C,14,22
1960,10853,10853,11116,11116,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,Gris-PEG,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]1(O2)[C@H](C)CC(=O)C=C1OC,14,23
1961,10854,10854,11117,11117,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,Nizoral,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,14,24
1962,10855,10855,11118,11118,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,Sporanox,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,[Na+].[Cl-],14,25
1963,10856,10856,11119,11119,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,atorvastatin,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,14,26
1964,10857,10857,11120,11120,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,Lipitor,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1,14,27
1965,10858,10858,11121,11121,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,clofibrate,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,14,28
1966,10859,10859,11122,11122,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,Atromid-S,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1,14,29
1967,10860,10860,11123,11123,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,cyclosporine,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,14,30
1968,10861,10861,11124,11124,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,Neoral,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,14,31
1969,10862,10862,11125,11125,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUG2), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,Sandimmune,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,14,32
1970,10863,10863,11126,11126,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,Agenerase,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1,14,38
1971,10864,10864,11127,11127,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,Crixivan,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12,14,39
1972,10867,10867,11130,11130,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,Kaletra,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1,14,42
1973,10869,10869,11132,11132,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,Viracept,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C,14,44
1974,10870,10870,11133,11133,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2 (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,morphine,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,14,45
1975,10871,10871,11134,11134,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,Astramorph,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,14,46
1976,10872,10872,11135,11135,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,Kadian,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,14,47
1977,10873,10873,11136,11136,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,MS Contin,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,14,48
1978,10874,10874,11137,11137,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,phenylbutazone,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,14,49
1979,10875,10875,11138,11138,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,prednisolone,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,14,50
1980,10876,10876,11139,11139,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,Prelone,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,14,51
1981,10877,10877,11140,11140,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,rifadin,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1,14,52
1982,10878,10878,11141,11141,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,rifampin,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,14,53
1983,10879,10879,11142,11142,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUG2, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,temazepam,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1,14,57
1984,10882,10882,11145,11145,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUG2.",tetracycline,vitamin C,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,[Na+].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO,14,61
1985,10883,10883,11146,11146,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUG1 (DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",anticonvulsants,Dilantin,False,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,15,16
1986,10887,10887,11150,11150,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",anticonvulsants,Topamax,False,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,15,20
1987,10902,10902,11165,11165,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",anticonvulsants,Fortovase,False,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,15,40
1988,10903,10903,11166,11166,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",anticonvulsants,Invirase,False,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,15,41
1989,10905,10905,11168,11168,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",anticonvulsants,Norvir,False,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,15,43
1990,10917,10917,11180,11180,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",anticonvulsants,theophylline,False,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,15,58
1991,10918,10918,11181,11181,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",anticonvulsants,Theo-Dur,False,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,CN1C2=C(NC=N2)C(=O)N(C)C1=O,15,59
1992,10920,10920,11183,11183,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,Phenobarbital,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,16,17
1993,10921,10921,11184,11184,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,Tegretol,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,16,18
1994,10922,10922,11185,11185,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,Trileptal,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,16,19
1995,10924,10924,11187,11187,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,Felbatol,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,16,21
1996,10925,10925,11188,11188,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2 (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,antifungals,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,OC(=O)CCCCCCCCC=C,16,22
1997,10926,10926,11189,11189,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,Gris-PEG,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]1(O2)[C@H](C)CC(=O)C=C1OC,16,23
1998,10927,10927,11190,11190,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,Nizoral,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,16,24
1999,10928,10928,11191,11191,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,Sporanox,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,[Na+].[Cl-],16,25
2000,10929,10929,11192,11192,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,atorvastatin,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,16,26
2001,10930,10930,11193,11193,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,Lipitor,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1,16,27
2002,10931,10931,11194,11194,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,clofibrate,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,16,28
2003,10932,10932,11195,11195,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,Atromid-S,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1,16,29
2004,10933,10933,11196,11196,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,cyclosporine,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,16,30
2005,10934,10934,11197,11197,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,Neoral,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,16,31
2006,10935,10935,11198,11198,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUG2), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,Sandimmune,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,16,32
2007,10936,10936,11199,11199,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,Agenerase,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1,16,38
2008,10937,10937,11200,11200,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,Crixivan,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12,16,39
2009,10940,10940,11203,11203,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,Kaletra,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1,16,42
2010,10942,10942,11205,11205,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,Viracept,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C,16,44
2011,10943,10943,11206,11206,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2 (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,morphine,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,16,45
2012,10944,10944,11207,11207,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,Astramorph,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,16,46
2013,10945,10945,11208,11208,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,Kadian,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,16,47
2014,10946,10946,11209,11209,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,MS Contin,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,16,48
2015,10947,10947,11210,11210,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,phenylbutazone,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,16,49
2016,10948,10948,11211,11211,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,prednisolone,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,16,50
2017,10949,10949,11212,11212,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,Prelone,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,16,51
2018,10950,10950,11213,11213,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,rifadin,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1,16,52
2019,10951,10951,11214,11214,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,rifampin,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,16,53
2020,10952,10952,11215,11215,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUG2, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,temazepam,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1,16,57
2021,10955,10955,11218,11218,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUG2.",Dilantin,vitamin C,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,[Na+].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO,16,61
2022,10958,10958,11221,11221,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Phenobarbital,Topamax,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,17,20
2023,10973,10973,11236,11236,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Phenobarbital,Fortovase,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,17,40
2024,10974,10974,11237,11237,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Phenobarbital,Invirase,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,17,41
2025,10976,10976,11239,11239,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Phenobarbital,Norvir,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,17,43
2026,10988,10988,11251,11251,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",Phenobarbital,theophylline,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,17,58
2027,10989,10989,11252,11252,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",Phenobarbital,Theo-Dur,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CN1C2=C(NC=N2)C(=O)N(C)C1=O,17,59
2028,10992,10992,11255,11255,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Tegretol,Topamax,False,Neg,0,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,18,20
2029,11007,11007,11270,11270,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Tegretol,Fortovase,False,Neg,0,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,18,40
2030,11008,11008,11271,11271,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Tegretol,Invirase,False,Neg,0,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,18,41
2031,11010,11010,11273,11273,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Tegretol,Norvir,False,Neg,0,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,18,43
2032,11022,11022,11285,11285,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",Tegretol,theophylline,False,Neg,0,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,CN1C2=C(C(=O)N(C1=O)C)NC=N2,18,58
2033,11023,11023,11286,11286,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",Tegretol,Theo-Dur,False,Neg,0,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,CN1C2=C(NC=N2)C(=O)N(C)C1=O,18,59
2034,11025,11025,11288,11288,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Trileptal,Topamax,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,19,20
2035,11040,11040,11303,11303,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Trileptal,Fortovase,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,19,40
2036,11041,11041,11304,11304,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Trileptal,Invirase,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,19,41
2037,11043,11043,11306,11306,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Trileptal,Norvir,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,19,43
2038,11055,11055,11318,11318,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",Trileptal,theophylline,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,19,58
2039,11056,11056,11319,11319,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",Trileptal,Theo-Dur,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CN1C2=C(NC=N2)C(=O)N(C)C1=O,19,59
2040,11058,11058,11321,11321,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Topamax,Felbatol,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,20,21
2041,11059,11059,11322,11322,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUG2 (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Topamax,antifungals,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,OC(=O)CCCCCCCCC=C,20,22
2042,11060,11060,11323,11323,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Topamax,Gris-PEG,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]1(O2)[C@H](C)CC(=O)C=C1OC,20,23
2043,11061,11061,11324,11324,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Topamax,Nizoral,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,20,24
2044,11062,11062,11325,11325,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Topamax,Sporanox,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,[Na+].[Cl-],20,25
2045,11063,11063,11326,11326,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Topamax,atorvastatin,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,20,26
2046,11064,11064,11327,11327,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Topamax,Lipitor,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1,20,27
2047,11065,11065,11328,11328,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Topamax,clofibrate,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,20,28
2048,11066,11066,11329,11329,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Topamax,Atromid-S,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1,20,29
2049,11067,11067,11330,11330,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Topamax,cyclosporine,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,20,30
2050,11068,11068,11331,11331,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Topamax,Neoral,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,20,31
2051,11069,11069,11332,11332,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUG2), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Topamax,Sandimmune,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,20,32
2052,11070,11070,11333,11333,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Topamax,Agenerase,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1,20,38
2053,11071,11071,11334,11334,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Topamax,Crixivan,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12,20,39
2054,11074,11074,11337,11337,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Topamax,Kaletra,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1,20,42
2055,11076,11076,11339,11339,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Topamax,Viracept,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C,20,44
2056,11077,11077,11340,11340,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2 (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Topamax,morphine,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,20,45
2057,11078,11078,11341,11341,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Topamax,Astramorph,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,20,46
2058,11079,11079,11342,11342,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Topamax,Kadian,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,20,47
2059,11080,11080,11343,11343,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Topamax,MS Contin,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,20,48
2060,11081,11081,11344,11344,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Topamax,phenylbutazone,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,20,49
2061,11082,11082,11345,11345,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Topamax,prednisolone,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,20,50
2062,11083,11083,11346,11346,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Topamax,Prelone,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,20,51
2063,11084,11084,11347,11347,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Topamax,rifadin,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1,20,52
2064,11085,11085,11348,11348,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Topamax,rifampin,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,20,53
2065,11086,11086,11349,11349,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUG2, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Topamax,temazepam,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1,20,57
2066,11089,11089,11352,11352,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUG2.",Topamax,vitamin C,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,[Na+].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO,20,61
2067,11103,11103,11366,11366,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Felbatol,Fortovase,False,Neg,0,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,21,40
2068,11104,11104,11367,11367,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Felbatol,Invirase,False,Neg,0,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,21,41
2069,11106,11106,11369,11369,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Felbatol,Norvir,False,Neg,0,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,21,43
2070,11118,11118,11381,11381,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",Felbatol,theophylline,False,Neg,0,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,21,58
2071,11119,11119,11382,11382,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",Felbatol,Theo-Dur,False,Neg,0,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,CN1C2=C(NC=N2)C(=O)N(C)C1=O,21,59
2072,11133,11133,11396,11396,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",antifungals,Fortovase,False,Neg,0,OC(=O)CCCCCCCCC=C,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,22,40
2073,11134,11134,11397,11397,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",antifungals,Invirase,False,Neg,0,OC(=O)CCCCCCCCC=C,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,22,41
2074,11136,11136,11399,11399,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",antifungals,Norvir,False,Neg,0,OC(=O)CCCCCCCCC=C,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,22,43
2075,11148,11148,11411,11411,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",antifungals,theophylline,False,Neg,0,OC(=O)CCCCCCCCC=C,CN1C2=C(C(=O)N(C1=O)C)NC=N2,22,58
2076,11149,11149,11412,11412,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",antifungals,Theo-Dur,False,Neg,0,OC(=O)CCCCCCCCC=C,CN1C2=C(NC=N2)C(=O)N(C)C1=O,22,59
2077,11162,11162,11425,11425,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Gris-PEG,Fortovase,False,Neg,0,COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]1(O2)[C@H](C)CC(=O)C=C1OC,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,23,40
2078,11163,11163,11426,11426,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Gris-PEG,Invirase,False,Neg,0,COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]1(O2)[C@H](C)CC(=O)C=C1OC,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,23,41
2079,11165,11165,11428,11428,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Gris-PEG,Norvir,False,Neg,0,COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]1(O2)[C@H](C)CC(=O)C=C1OC,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,23,43
2080,11177,11177,11440,11440,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",Gris-PEG,theophylline,False,Neg,0,COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]1(O2)[C@H](C)CC(=O)C=C1OC,CN1C2=C(C(=O)N(C1=O)C)NC=N2,23,58
2081,11178,11178,11441,11441,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",Gris-PEG,Theo-Dur,False,Neg,0,COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]1(O2)[C@H](C)CC(=O)C=C1OC,CN1C2=C(NC=N2)C(=O)N(C)C1=O,23,59
2082,11190,11190,11453,11453,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Nizoral,Fortovase,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,24,40
2083,11191,11191,11454,11454,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Nizoral,Invirase,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,24,41
2084,11193,11193,11456,11456,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Nizoral,Norvir,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,24,43
2085,11205,11205,11468,11468,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",Nizoral,theophylline,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,24,58
2086,11206,11206,11469,11469,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",Nizoral,Theo-Dur,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CN1C2=C(NC=N2)C(=O)N(C)C1=O,24,59
2087,11217,11217,11480,11480,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Sporanox,Fortovase,False,Neg,0,[Na+].[Cl-],[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,25,40
2088,11218,11218,11481,11481,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Sporanox,Invirase,False,Neg,0,[Na+].[Cl-],[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,25,41
2089,11220,11220,11483,11483,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Sporanox,Norvir,False,Neg,0,[Na+].[Cl-],CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,25,43
2090,11232,11232,11495,11495,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",Sporanox,theophylline,False,Neg,0,[Na+].[Cl-],CN1C2=C(C(=O)N(C1=O)C)NC=N2,25,58
2091,11233,11233,11496,11496,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",Sporanox,Theo-Dur,False,Neg,0,[Na+].[Cl-],CN1C2=C(NC=N2)C(=O)N(C)C1=O,25,59
2092,11243,11243,11506,11506,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",atorvastatin,Fortovase,False,Neg,0,CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,26,40
2093,11244,11244,11507,11507,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",atorvastatin,Invirase,False,Neg,0,CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,26,41
2094,11246,11246,11509,11509,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",atorvastatin,Norvir,False,Neg,0,CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,26,43
2095,11258,11258,11521,11521,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",atorvastatin,theophylline,False,Neg,0,CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,CN1C2=C(C(=O)N(C1=O)C)NC=N2,26,58
2096,11259,11259,11522,11522,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",atorvastatin,Theo-Dur,False,Neg,0,CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,CN1C2=C(NC=N2)C(=O)N(C)C1=O,26,59
2097,11268,11268,11531,11531,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Lipitor,Fortovase,False,Neg,0,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,27,40
2098,11269,11269,11532,11532,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Lipitor,Invirase,False,Neg,0,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,27,41
2099,11271,11271,11534,11534,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Lipitor,Norvir,False,Neg,0,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,27,43
2100,11283,11283,11546,11546,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",Lipitor,theophylline,False,Neg,0,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,27,58
2101,11284,11284,11547,11547,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",Lipitor,Theo-Dur,False,Neg,0,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1,CN1C2=C(NC=N2)C(=O)N(C)C1=O,27,59
2102,11292,11292,11555,11555,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",clofibrate,Fortovase,False,Neg,0,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,28,40
2103,11293,11293,11556,11556,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",clofibrate,Invirase,False,Neg,0,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,28,41
2104,11295,11295,11558,11558,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",clofibrate,Norvir,False,Neg,0,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,28,43
2105,11307,11307,11570,11570,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",clofibrate,theophylline,False,Neg,0,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,CN1C2=C(C(=O)N(C1=O)C)NC=N2,28,58
2106,11308,11308,11571,11571,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",clofibrate,Theo-Dur,False,Neg,0,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,CN1C2=C(NC=N2)C(=O)N(C)C1=O,28,59
2107,11315,11315,11578,11578,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Atromid-S,Fortovase,False,Neg,0,CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,29,40
2108,11316,11316,11579,11579,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Atromid-S,Invirase,False,Neg,0,CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,29,41
2109,11318,11318,11581,11581,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Atromid-S,Norvir,False,Neg,0,CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,29,43
2110,11330,11330,11593,11593,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",Atromid-S,theophylline,False,Neg,0,CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,29,58
2111,11331,11331,11594,11594,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",Atromid-S,Theo-Dur,False,Neg,0,CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1,CN1C2=C(NC=N2)C(=O)N(C)C1=O,29,59
2112,11337,11337,11600,11600,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",cyclosporine,Fortovase,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,30,40
2113,11338,11338,11601,11601,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",cyclosporine,Invirase,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,30,41
2114,11340,11340,11603,11603,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",cyclosporine,Norvir,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,30,43
2115,11352,11352,11615,11615,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",cyclosporine,theophylline,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CN1C2=C(C(=O)N(C1=O)C)NC=N2,30,58
2116,11353,11353,11616,11616,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",cyclosporine,Theo-Dur,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CN1C2=C(NC=N2)C(=O)N(C)C1=O,30,59
2117,11358,11358,11621,11621,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Neoral,Fortovase,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,31,40
2118,11359,11359,11622,11622,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Neoral,Invirase,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,31,41
2119,11361,11361,11624,11624,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Neoral,Norvir,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,31,43
2120,11373,11373,11636,11636,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",Neoral,theophylline,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,31,58
2121,11374,11374,11637,11637,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",Neoral,Theo-Dur,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CN1C2=C(NC=N2)C(=O)N(C)C1=O,31,59
2122,11378,11378,11641,11641,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUG1), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Sandimmune,Fortovase,False,Neg,0,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,32,40
2123,11379,11379,11642,11642,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUG1), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Sandimmune,Invirase,False,Neg,0,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,32,41
2124,11381,11381,11644,11644,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUG1), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Sandimmune,Norvir,False,Neg,0,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,32,43
2125,11393,11393,11656,11656,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUG1), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",Sandimmune,theophylline,False,Neg,0,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,CN1C2=C(C(=O)N(C1=O)C)NC=N2,32,58
2126,11394,11394,11657,11657,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUG1), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",Sandimmune,Theo-Dur,False,Neg,0,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,CN1C2=C(NC=N2)C(=O)N(C)C1=O,32,59
2127,11397,11397,11660,11660,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Agenerase,Fortovase,False,Neg,0,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,38,40
2128,11398,11398,11661,11661,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Agenerase,Invirase,False,Neg,0,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,38,41
2129,11400,11400,11663,11663,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Agenerase,Norvir,False,Neg,0,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,38,43
2130,11412,11412,11675,11675,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",Agenerase,theophylline,False,Neg,0,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,38,58
2131,11413,11413,11676,11676,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",Agenerase,Theo-Dur,False,Neg,0,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1,CN1C2=C(NC=N2)C(=O)N(C)C1=O,38,59
2132,11415,11415,11678,11678,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Crixivan,Fortovase,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,39,40
2133,11416,11416,11679,11679,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Crixivan,Invirase,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,39,41
2134,11418,11418,11681,11681,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Crixivan,Norvir,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,39,43
2135,11430,11430,11693,11693,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",Crixivan,theophylline,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12,CN1C2=C(C(=O)N(C1=O)C)NC=N2,39,58
2136,11431,11431,11694,11694,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",Crixivan,Theo-Dur,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12,CN1C2=C(NC=N2)C(=O)N(C)C1=O,39,59
2137,11434,11434,11697,11697,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Fortovase,Kaletra,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1,40,42
2138,11436,11436,11699,11699,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Fortovase,Viracept,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C,40,44
2139,11437,11437,11700,11700,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2 (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Fortovase,morphine,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,40,45
2140,11438,11438,11701,11701,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Fortovase,Astramorph,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,40,46
2141,11439,11439,11702,11702,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Fortovase,Kadian,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,40,47
2142,11440,11440,11703,11703,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Fortovase,MS Contin,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,40,48
2143,11441,11441,11704,11704,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Fortovase,phenylbutazone,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,40,49
2144,11442,11442,11705,11705,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Fortovase,prednisolone,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,40,50
2145,11443,11443,11706,11706,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Fortovase,Prelone,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,40,51
2146,11444,11444,11707,11707,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Fortovase,rifadin,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1,40,52
2147,11445,11445,11708,11708,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Fortovase,rifampin,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,40,53
2148,11446,11446,11709,11709,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUG2, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Fortovase,temazepam,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1,40,57
2149,11449,11449,11712,11712,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUG2.",Fortovase,vitamin C,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,[Na+].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO,40,61
2150,11450,11450,11713,11713,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Invirase,Kaletra,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1,41,42
2151,11452,11452,11715,11715,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Invirase,Viracept,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C,41,44
2152,11453,11453,11716,11716,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2 (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Invirase,morphine,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,41,45
2153,11454,11454,11717,11717,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Invirase,Astramorph,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,41,46
2154,11455,11455,11718,11718,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Invirase,Kadian,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,41,47
2155,11456,11456,11719,11719,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Invirase,MS Contin,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,41,48
2156,11457,11457,11720,11720,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Invirase,phenylbutazone,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,41,49
2157,11458,11458,11721,11721,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Invirase,prednisolone,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,41,50
2158,11459,11459,11722,11722,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Invirase,Prelone,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,41,51
2159,11460,11460,11723,11723,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Invirase,rifadin,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1,41,52
2160,11461,11461,11724,11724,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Invirase,rifampin,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,41,53
2161,11462,11462,11725,11725,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUG2, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Invirase,temazepam,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1,41,57
2162,11465,11465,11728,11728,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUG2.",Invirase,vitamin C,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,[Na+].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO,41,61
2163,11466,11466,11729,11729,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Kaletra,Norvir,False,Neg,0,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,42,43
2164,11478,11478,11741,11741,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",Kaletra,theophylline,False,Neg,0,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,42,58
2165,11479,11479,11742,11742,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",Kaletra,Theo-Dur,False,Neg,0,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1,CN1C2=C(NC=N2)C(=O)N(C)C1=O,42,59
2166,11481,11481,11744,11744,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Norvir,Viracept,False,Neg,0,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C,43,44
2167,11482,11482,11745,11745,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUG2 (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Norvir,morphine,False,Neg,0,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,43,45
2168,11483,11483,11746,11746,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Norvir,Astramorph,False,Neg,0,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,43,46
2169,11484,11484,11747,11747,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Norvir,Kadian,False,Neg,0,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,43,47
2170,11485,11485,11748,11748,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Norvir,MS Contin,False,Neg,0,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,43,48
2171,11486,11486,11749,11749,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Norvir,phenylbutazone,False,Neg,0,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,43,49
2172,11487,11487,11750,11750,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Norvir,prednisolone,False,Neg,0,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,43,50
2173,11488,11488,11751,11751,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Norvir,Prelone,False,Neg,0,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,43,51
2174,11489,11489,11752,11752,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Norvir,rifadin,False,Neg,0,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1,43,52
2175,11490,11490,11753,11753,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Norvir,rifampin,False,Neg,0,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,43,53
2176,11491,11491,11754,11754,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUG2, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Norvir,temazepam,False,Neg,0,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1,43,57
2177,11494,11494,11757,11757,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUG2.",Norvir,vitamin C,False,Neg,0,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,[Na+].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO,43,61
2178,11505,11505,11768,11768,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",Viracept,theophylline,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C,CN1C2=C(C(=O)N(C1=O)C)NC=N2,44,58
2179,11506,11506,11769,11769,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",Viracept,Theo-Dur,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C,CN1C2=C(NC=N2)C(=O)N(C)C1=O,44,59
2180,11517,11517,11780,11780,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",morphine,theophylline,False,Neg,0,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,45,58
2181,11518,11518,11781,11781,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",morphine,Theo-Dur,False,Neg,0,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,CN1C2=C(NC=N2)C(=O)N(C)C1=O,45,59
2182,11528,11528,11791,11791,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",Astramorph,theophylline,False,Neg,0,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,46,58
2183,11529,11529,11792,11792,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",Astramorph,Theo-Dur,False,Neg,0,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,CN1C2=C(NC=N2)C(=O)N(C)C1=O,46,59
2184,11538,11538,11801,11801,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",Kadian,theophylline,False,Neg,0,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,47,58
2185,11539,11539,11802,11802,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",Kadian,Theo-Dur,False,Neg,0,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,CN1C2=C(NC=N2)C(=O)N(C)C1=O,47,59
2186,11547,11547,11810,11810,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",MS Contin,theophylline,False,Neg,0,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,48,58
2187,11548,11548,11811,11811,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",MS Contin,Theo-Dur,False,Neg,0,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,CN1C2=C(NC=N2)C(=O)N(C)C1=O,48,59
2188,11555,11555,11818,11818,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",phenylbutazone,theophylline,False,Neg,0,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,CN1C2=C(C(=O)N(C1=O)C)NC=N2,49,58
2189,11556,11556,11819,11819,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",phenylbutazone,Theo-Dur,False,Neg,0,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,CN1C2=C(NC=N2)C(=O)N(C)C1=O,49,59
2190,11562,11562,11825,11825,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",prednisolone,theophylline,False,Neg,0,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,50,58
2191,11563,11563,11826,11826,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",prednisolone,Theo-Dur,False,Neg,0,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,CN1C2=C(NC=N2)C(=O)N(C)C1=O,50,59
2192,11568,11568,11831,11831,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",Prelone,theophylline,False,Neg,0,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,CN1C2=C(C(=O)N(C1=O)C)NC=N2,51,58
2193,11569,11569,11832,11832,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",Prelone,Theo-Dur,False,Neg,0,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,CN1C2=C(NC=N2)C(=O)N(C)C1=O,51,59
2194,11573,11573,11836,11836,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",rifadin,theophylline,False,Neg,0,OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,52,58
2195,11574,11574,11837,11837,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",rifadin,Theo-Dur,False,Neg,0,OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1,CN1C2=C(NC=N2)C(=O)N(C)C1=O,52,59
2196,11577,11577,11840,11840,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",rifampin,theophylline,False,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CN1C2=C(C(=O)N(C1=O)C)NC=N2,53,58
2197,11578,11578,11841,11841,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",rifampin,Theo-Dur,False,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CN1C2=C(NC=N2)C(=O)N(C)C1=O,53,59
2198,11580,11580,11843,11843,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUG1, DRUG2 (DRUGOTHER), and DRUGOTHER.",temazepam,theophylline,False,Neg,0,CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,57,58
2199,11581,11581,11844,11844,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUG1, DRUGOTHER (DRUG2), and DRUGOTHER.",temazepam,Theo-Dur,False,Neg,0,CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1,CN1C2=C(NC=N2)C(=O)N(C)C1=O,57,59
2200,11584,11584,11847,11847,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG1 (DRUGOTHER), and DRUG2.",theophylline,vitamin C,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,[Na+].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO,58,61
2201,11585,11585,11848,11848,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG1), and DRUG2.",Theo-Dur,vitamin C,False,Neg,0,CN1C2=C(NC=N2)C(=O)N(C)C1=O,[Na+].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO,59,61
2202,11596,11596,11863,11863,"Co-medications that induce CYP 3A4 (e.g., DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, or St. John s wort) may significantly decrease exposure to DRUGOTHER.",rifampicin,phenytoin,False,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,6,7
2203,11599,11599,11867,11867,"Co-medications that induce CYP 3A4 (e.g., DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, or St. John s wort) may significantly decrease exposure to DRUGOTHER.",phenytoin,carbamazepine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,7,8
2204,11600,11600,11868,11868,"Co-medications that induce CYP 3A4 (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, or St. John s wort) may significantly decrease exposure to DRUGOTHER.",phenytoin,phenobarbital,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,7,9
2205,11602,11602,11875,11875,"Compounds tested in man include DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER.",warfarin,theophylline,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,5,6
2206,11603,11603,11876,11876,"Compounds tested in man include DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER.",warfarin,phenytoin,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,5,7
2207,11608,11608,11881,11881,"Compounds tested in man include DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER.",theophylline,diazepam,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,6,8
2208,11609,11609,11882,11882,"Compounds tested in man include DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER.",theophylline,aminopyrine,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,OC(=O)CCCCCCCC(O)=O,6,9
2209,11610,11610,11883,11883,"Compounds tested in man include DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2.",theophylline,antipyrine,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1=CC(=O)N(N1C)C2=CC=CC=C2,6,11
2210,11611,11611,11884,11884,"Compounds tested in man include DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER and DRUGOTHER.",phenytoin,diazepam,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,7,8
2211,11612,11612,11885,11885,"Compounds tested in man include DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2 and DRUGOTHER.",phenytoin,aminopyrine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,OC(=O)CCCCCCCC(O)=O,7,9
2212,11613,11613,11886,11886,"Compounds tested in man include DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER and DRUG2.",phenytoin,antipyrine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=CC(=O)N(N1C)C2=CC=CC=C2,7,11
2213,11620,11620,11893,11893,Specific Effects of DRUG1  on Other DRUGOTHER DRUG2: DRUG1  causes an increase in steady-state DRUGOTHER plasma concentrations.,Felbatol,Phenytoin,False,Neg,0,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,3,8
2214,11622,11622,11895,11895,Specific Effects of DRUG1  on Other DRUGOTHER DRUGOTHER: DRUG1  causes an increase in steady-state DRUG2 plasma concentrations.,Felbatol,phenytoin,False,Neg,0,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,3,16
2215,11623,11623,11896,11896,Specific Effects of DRUG2  on Other DRUGOTHER DRUG1: DRUG2  causes an increase in steady-state DRUGOTHER plasma concentrations.,Phenytoin,Felbatol,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,8,3
2216,11625,11625,11898,11898,Specific Effects of DRUG1  on Other DRUGOTHER DRUGOTHER: DRUG1  causes an increase in steady-state DRUG2 plasma concentrations.,Felbatol,phenytoin,True,mechanism,4,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,3,16
2217,11627,11627,11900,11900,Increasing the DRUG1 dose to 1800 mg/day in six of these subjects increased the steady-state DRUG2 Cmin to 25 7 micrograms/mL.,felbamate,phenytoin,True,mechanism,4,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,2,15
2218,11628,11628,11901,11901,"In order to maintain DRUG1 levels, limit adverse experiences, and achieve the DRUG2 dose of 3600 mg/day, a DRUG1 dose reduction of approximately 40% was necessary for eight of these 10 subjects.",phenytoin,felbamate,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,4,12
2219,11630,11630,11903,11903,"In order to maintain DRUG2 levels, limit adverse experiences, and achieve the DRUG1 dose of 3600 mg/day, a DRUG2 dose reduction of approximately 40% was necessary for eight of these 10 subjects.",felbamate,phenytoin,True,advise,1,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,12,4
2220,11631,11631,11904,11904,"In a controlled clinical trial, a 20% reduction of the DRUG1 dose at the initiation of DRUG2  therapy resulted in DRUG1 levels comparable to those prior to DRUG2  administration.",phenytoin,Felbatol,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,10,16
2221,11633,11633,11906,11906,"In a controlled clinical trial, a 20% reduction of the DRUG1 dose at the initiation of DRUG2  therapy resulted in DRUG1 levels comparable to those prior to DRUG2  administration.",phenytoin,Felbatol,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,10,16
2222,11634,11634,11907,11907,"In a controlled clinical trial, a 20% reduction of the DRUG2 dose at the initiation of DRUG1  therapy resulted in DRUG2 levels comparable to those prior to DRUG1  administration.",Felbatol,phenytoin,False,Neg,0,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,16,10
2223,11636,11636,11909,11909,"In a controlled clinical trial, a 20% reduction of the DRUG1 dose at the initiation of DRUG2  therapy resulted in DRUG1 levels comparable to those prior to DRUG2  administration.",phenytoin,Felbatol,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,10,16
2224,11664,11664,11937,11937,"Effects of Other DRUGOTHER on DRUG1  DRUG2: DRUG2 causes an approximate doubling of the clearance of DRUG1  (DRUGOTHER) at steady state and, therefore, the addition of DRUGOTHER causes an approximate 45% decrease in the steady-state trough concentrations of DRUG1  as compared to the same dose of DRUG1  given as monotherapy.",Felbatol,Phenytoin,False,Neg,0,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,5,7
2225,11665,11665,11938,11938,"Effects of Other DRUGOTHER on DRUG1  DRUG2: DRUG2 causes an approximate doubling of the clearance of DRUG1  (DRUGOTHER) at steady state and, therefore, the addition of DRUGOTHER causes an approximate 45% decrease in the steady-state trough concentrations of DRUG1  as compared to the same dose of DRUG1  given as monotherapy.",Felbatol,Phenytoin,False,Neg,0,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,5,7
2226,11668,11668,11941,11941,"Effects of Other DRUGOTHER on DRUG1  DRUGOTHER: DRUGOTHER causes an approximate doubling of the clearance of DRUG1  (DRUGOTHER) at steady state and, therefore, the addition of DRUG2 causes an approximate 45% decrease in the steady-state trough concentrations of DRUG1  as compared to the same dose of DRUG1  given as monotherapy.",Felbatol,phenytoin,False,Neg,0,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,5,28
2227,11672,11672,11945,11945,"Effects of Other DRUGOTHER on DRUG2  DRUG1: DRUG1 causes an approximate doubling of the clearance of DRUG2  (DRUGOTHER) at steady state and, therefore, the addition of DRUGOTHER causes an approximate 45% decrease in the steady-state trough concentrations of DRUG2  as compared to the same dose of DRUG2  given as monotherapy.",Phenytoin,Felbatol,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,7,5
2228,11673,11673,11946,11946,"Effects of Other DRUGOTHER on DRUGOTHER  DRUG1: DRUG1 causes an approximate doubling of the clearance of DRUGOTHER  (DRUG2) at steady state and, therefore, the addition of DRUGOTHER causes an approximate 45% decrease in the steady-state trough concentrations of DRUGOTHER  as compared to the same dose of DRUGOTHER  given as monotherapy.",Phenytoin,felbamate,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,7,19
2229,11675,11675,11948,11948,"Effects of Other DRUGOTHER on DRUG2  DRUG1: DRUG1 causes an approximate doubling of the clearance of DRUG2  (DRUGOTHER) at steady state and, therefore, the addition of DRUGOTHER causes an approximate 45% decrease in the steady-state trough concentrations of DRUG2  as compared to the same dose of DRUG2  given as monotherapy.",Phenytoin,Felbatol,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,7,5
2230,11676,11676,11949,11949,"Effects of Other DRUGOTHER on DRUG2  DRUG1: DRUG1 causes an approximate doubling of the clearance of DRUG2  (DRUGOTHER) at steady state and, therefore, the addition of DRUGOTHER causes an approximate 45% decrease in the steady-state trough concentrations of DRUG2  as compared to the same dose of DRUG2  given as monotherapy.",Phenytoin,Felbatol,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,7,5
2231,11677,11677,11950,11950,"Effects of Other DRUGOTHER on DRUG2  DRUG1: DRUG1 causes an approximate doubling of the clearance of DRUG2  (DRUGOTHER) at steady state and, therefore, the addition of DRUGOTHER causes an approximate 45% decrease in the steady-state trough concentrations of DRUG2  as compared to the same dose of DRUG2  given as monotherapy.",Phenytoin,Felbatol,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,7,5
2232,11678,11678,11951,11951,"Effects of Other DRUGOTHER on DRUGOTHER  DRUG1: DRUG1 causes an approximate doubling of the clearance of DRUGOTHER  (DRUG2) at steady state and, therefore, the addition of DRUGOTHER causes an approximate 45% decrease in the steady-state trough concentrations of DRUGOTHER  as compared to the same dose of DRUGOTHER  given as monotherapy.",Phenytoin,felbamate,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,7,19
2233,11680,11680,11953,11953,"Effects of Other DRUGOTHER on DRUG2  DRUG1: DRUG1 causes an approximate doubling of the clearance of DRUG2  (DRUGOTHER) at steady state and, therefore, the addition of DRUGOTHER causes an approximate 45% decrease in the steady-state trough concentrations of DRUG2  as compared to the same dose of DRUG2  given as monotherapy.",Phenytoin,Felbatol,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,7,5
2234,11681,11681,11954,11954,"Effects of Other DRUGOTHER on DRUG2  DRUG1: DRUG1 causes an approximate doubling of the clearance of DRUG2  (DRUGOTHER) at steady state and, therefore, the addition of DRUGOTHER causes an approximate 45% decrease in the steady-state trough concentrations of DRUG2  as compared to the same dose of DRUG2  given as monotherapy.",Phenytoin,Felbatol,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,7,5
2235,11683,11683,11956,11956,"Effects of Other DRUGOTHER on DRUG1  DRUGOTHER: DRUGOTHER causes an approximate doubling of the clearance of DRUG1  (DRUGOTHER) at steady state and, therefore, the addition of DRUG2 causes an approximate 45% decrease in the steady-state trough concentrations of DRUG1  as compared to the same dose of DRUG1  given as monotherapy.",Felbatol,phenytoin,False,Neg,0,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,5,28
2236,11686,11686,11959,11959,"Effects of Other DRUGOTHER on DRUGOTHER  DRUGOTHER: DRUGOTHER causes an approximate doubling of the clearance of DRUGOTHER  (DRUG1) at steady state and, therefore, the addition of DRUG2 causes an approximate 45% decrease in the steady-state trough concentrations of DRUGOTHER  as compared to the same dose of DRUGOTHER  given as monotherapy.",felbamate,phenytoin,False,Neg,0,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,19,28
2237,11689,11689,11962,11962,"Effects of Other DRUGOTHER on DRUG2  DRUGOTHER: DRUGOTHER causes an approximate doubling of the clearance of DRUG2  (DRUGOTHER) at steady state and, therefore, the addition of DRUG1 causes an approximate 45% decrease in the steady-state trough concentrations of DRUG2  as compared to the same dose of DRUG2  given as monotherapy.",phenytoin,Felbatol,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,28,5
2238,11690,11690,11963,11963,"Effects of Other DRUGOTHER on DRUG2  DRUGOTHER: DRUGOTHER causes an approximate doubling of the clearance of DRUG2  (DRUGOTHER) at steady state and, therefore, the addition of DRUG1 causes an approximate 45% decrease in the steady-state trough concentrations of DRUG2  as compared to the same dose of DRUG2  given as monotherapy.",phenytoin,Felbatol,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,28,5
2239,11773,11773,12046,12046,"DRUG1: In a pharmacokinetic study, maximum plasma concentrations of DRUGOTHER were considerably lower in epileptic patients on long-term DRUGOTHER therapy (eg, DRUG2, DRUGOTHER, or DRUGOTHER) than in healthy volunteers.",Anticonvulsants,phenytoin,False,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,21
2240,11777,11777,12050,12050,"DRUGOTHER: In a pharmacokinetic study, maximum plasma concentrations of DRUG1 were considerably lower in epileptic patients on long-term DRUGOTHER therapy (eg, DRUG2, DRUGOTHER, or DRUGOTHER) than in healthy volunteers.",felodipine,phenytoin,True,mechanism,4,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,9,21
2241,11780,11780,12053,12053,"DRUGOTHER: In a pharmacokinetic study, maximum plasma concentrations of DRUGOTHER were considerably lower in epileptic patients on long-term DRUG1 therapy (eg, DRUG2, DRUGOTHER, or DRUGOTHER) than in healthy volunteers.",anticonvulsant,phenytoin,False,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,18,21
2242,11783,11783,12056,12056,"DRUGOTHER: In a pharmacokinetic study, maximum plasma concentrations of DRUGOTHER were considerably lower in epileptic patients on long-term DRUGOTHER therapy (eg, DRUG1, DRUG2, or DRUGOTHER) than in healthy volunteers.",phenytoin,carbamazepine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,21,22
2243,11784,11784,12057,12057,"DRUGOTHER: In a pharmacokinetic study, maximum plasma concentrations of DRUGOTHER were considerably lower in epileptic patients on long-term DRUGOTHER therapy (eg, DRUG1, DRUGOTHER, or DRUG2) than in healthy volunteers.",phenytoin,phenobarbital,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,21,24
2244,11789,11789,12062,12062,Other Concomitant Therapy  In healthy subjects there were no clinically significant interactions when DRUG1 was given concomitantly with DRUGOTHER or DRUG2.,felodipine,spironolactone,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,14,21
2245,11790,11790,12063,12063,Other Concomitant Therapy  In healthy subjects there were no clinically significant interactions when DRUGOTHER was given concomitantly with DRUG1 or DRUG2.,indomethacin,spironolactone,False,Neg,0,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,19,21
2246,11792,11792,12065,12065,"DRUG1 may increase slightly the effect of DRUGOTHER, e.g., DRUG2, DRUGOTHER, DRUGOTHER.",Fenfluramine,guanethidine,True,effect,2,CCNC(C)CC1=CC(=CC=C1)C(F)(F)F,C1CCCN(CCC1)CCN=C(N)N,0,9
2247,11795,11795,12068,12068,"DRUGOTHER may increase slightly the effect of DRUG1, e.g., DRUG2, DRUGOTHER, DRUGOTHER.",antihypertensive drugs,guanethidine,False,Neg,0,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,C1CCCN(CCC1)CCN=C(N)N,7,9
2248,11798,11798,12071,12071,"DRUGOTHER may increase slightly the effect of DRUGOTHER, e.g., DRUG1, DRUG2, DRUGOTHER.",guanethidine,methyldopa,False,Neg,0,C1CCCN(CCC1)CCN=C(N)N,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N,9,10
2249,11799,11799,12072,12072,"DRUGOTHER may increase slightly the effect of DRUGOTHER, e.g., DRUG1, DRUGOTHER, DRUG2.",guanethidine,reserpine,False,Neg,0,C1CCCN(CCC1)CCN=C(N)N,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,9,11
2250,11801,11801,12074,12074,"Other DRUG1 should be used with caution in patients taking DRUG2, since the effects may be additive.",CNS depressant drugs,fenfluramine,True,advise,1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCNC(C)CC1=CC(=CC=C1)C(F)(F)F,1,10
2251,11806,11806,12079,12079,"The benefits and risks of using DRUG1 with DRUG2 and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed",TRICOR,immunosuppressants,True,advise,1,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,6,8
2252,11808,11808,12081,12081,"Concomitant administration of DRUG1 (equivalent to 145mg DRUGOTHER) with DRUG2 (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for DRUG2 by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-DRUG2 by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.",fenofibrate,pravastatin,True,mechanism,4,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,3,9
2253,11809,11809,12082,12082,"Concomitant administration of DRUG1 (equivalent to 145mg DRUGOTHER) with DRUG2 (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for DRUG2 by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-DRUG2 by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.",fenofibrate,pravastatin,False,Neg,0,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,3,9
2254,11810,11810,12083,12083,"Concomitant administration of DRUGOTHER (equivalent to 145mg DRUG1) with DRUG2 (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for DRUG2 by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-DRUG2 by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.",TRICOR,pravastatin,True,mechanism,4,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,7,9
2255,11811,11811,12084,12084,"Concomitant administration of DRUGOTHER (equivalent to 145mg DRUG1) with DRUG2 (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for DRUG2 by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-DRUG2 by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.",TRICOR,pravastatin,False,Neg,0,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,7,9
2256,11825,11825,12100,12100,"Patients receiving DRUGOTHER, DRUG1, or DRUG2 should be observed for increased activity of these drugs and, therefore, signs of toxicity from these drugs.",sulfonamides,sulfonylureas,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,NC(N)=O,3,5
2257,11829,11829,12104,12104,"Agents Affecting Cytochrome P450 3A4 Isoenzyme System DRUG1 is metabolized mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4), therefore potential interactions may occur when DRUG2  is given concurrently with agents that affect CYP3A4 activity.",Fentanyl,DURAGESIC,False,Neg,0,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,7,26
2258,11831,11831,12106,12106,"The concomitant use of transdermal DRUG1 with DRUGOTHER or other potent 3A4 inhibitors such as DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and nefazadone may result in an increase in DRUG1 plasma concentrations.",fentanyl,ketoconazole,True,mechanism,4,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,5,15
2259,11832,11832,12107,12107,"The concomitant use of transdermal DRUG1 with DRUGOTHER or other potent 3A4 inhibitors such as DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and nefazadone may result in an increase in DRUG1 plasma concentrations.",fentanyl,itraconazole,True,mechanism,4,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,5,16
2260,11833,11833,12108,12108,"The concomitant use of transdermal DRUG1 with DRUGOTHER or other potent 3A4 inhibitors such as DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and nefazadone may result in an increase in DRUG1 plasma concentrations.",fentanyl,troleandomycin,True,mechanism,4,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,5,17
2261,11834,11834,12109,12109,"The concomitant use of transdermal DRUG1 with DRUGOTHER or other potent 3A4 inhibitors such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and nefazadone may result in an increase in DRUG1 plasma concentrations.",fentanyl,clarithromycin,True,mechanism,4,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,5,18
2262,11835,11835,12110,12110,"The concomitant use of transdermal DRUG1 with DRUGOTHER or other potent 3A4 inhibitors such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and nefazadone may result in an increase in DRUG1 plasma concentrations.",fentanyl,nelfinavir,True,mechanism,4,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,5,19
2263,11837,11837,12112,12112,"The concomitant use of transdermal DRUGOTHER with DRUG1 or other potent 3A4 inhibitors such as DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and nefazadone may result in an increase in DRUGOTHER plasma concentrations.",ritonavir,ketoconazole,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,7,15
2264,11838,11838,12113,12113,"The concomitant use of transdermal DRUGOTHER with DRUG1 or other potent 3A4 inhibitors such as DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and nefazadone may result in an increase in DRUGOTHER plasma concentrations.",ritonavir,itraconazole,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,7,16
2265,11839,11839,12114,12114,"The concomitant use of transdermal DRUGOTHER with DRUG1 or other potent 3A4 inhibitors such as DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and nefazadone may result in an increase in DRUGOTHER plasma concentrations.",ritonavir,troleandomycin,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,7,17
2266,11840,11840,12115,12115,"The concomitant use of transdermal DRUGOTHER with DRUG1 or other potent 3A4 inhibitors such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and nefazadone may result in an increase in DRUGOTHER plasma concentrations.",ritonavir,clarithromycin,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,7,18
2267,11841,11841,12116,12116,"The concomitant use of transdermal DRUGOTHER with DRUG1 or other potent 3A4 inhibitors such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and nefazadone may result in an increase in DRUGOTHER plasma concentrations.",ritonavir,nelfinavir,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,7,19
2268,11847,11847,12122,12122,"The concomitant use of transdermal DRUG2 with DRUGOTHER or other potent 3A4 inhibitors such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and nefazadone may result in an increase in DRUG2 plasma concentrations.",ketoconazole,fentanyl,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,15,5
2269,11851,11851,12126,12126,"The concomitant use of transdermal DRUG2 with DRUGOTHER or other potent 3A4 inhibitors such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and nefazadone may result in an increase in DRUG2 plasma concentrations.",itraconazole,fentanyl,False,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,16,5
2270,11854,11854,12129,12129,"The concomitant use of transdermal DRUG2 with DRUGOTHER or other potent 3A4 inhibitors such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and nefazadone may result in an increase in DRUG2 plasma concentrations.",troleandomycin,fentanyl,False,Neg,0,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,17,5
2271,11856,11856,12131,12131,"The concomitant use of transdermal DRUG2 with DRUGOTHER or other potent 3A4 inhibitors such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and nefazadone may result in an increase in DRUG2 plasma concentrations.",clarithromycin,fentanyl,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,18,5
2272,11857,11857,12132,12132,"The concomitant use of transdermal DRUG2 with DRUGOTHER or other potent 3A4 inhibitors such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and nefazadone may result in an increase in DRUG2 plasma concentrations.",nelfinavir,fentanyl,False,Neg,0,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,19,5
2273,11859,11859,12134,12134,"The concomitant use of other CYP3A4 inhibitors such as DRUG1 and DRUGOTHER with transdermal DRUG2 may also result in an increase in DRUG2 plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.",diltiazem,fentanyl,True,mechanism,4,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,9,14
2274,11860,11860,12135,12135,"The concomitant use of other CYP3A4 inhibitors such as DRUG1 and DRUGOTHER with transdermal DRUG2 may also result in an increase in DRUG2 plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.",diltiazem,fentanyl,False,Neg,0,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,9,14
2275,11861,11861,12136,12136,"The concomitant use of other CYP3A4 inhibitors such as DRUGOTHER and DRUG1 with transdermal DRUG2 may also result in an increase in DRUG2 plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.",erythromycin,fentanyl,True,mechanism,4,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,11,14
2276,11862,11862,12137,12137,"The concomitant use of other CYP3A4 inhibitors such as DRUGOTHER and DRUG1 with transdermal DRUG2 may also result in an increase in DRUG2 plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.",erythromycin,fentanyl,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,11,14
2277,11864,11864,12139,12139,"DRUG1: The concomitant use of DRUG2  (DRUGOTHER transdermal system) with other DRUGOTHER, including but not limited to other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), general DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",Central Nervous System Depressants,DURAGESIC,False,Neg,0,C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,0,5
2278,11865,11865,12140,12140,"DRUG1: The concomitant use of DRUGOTHER  (DRUG2 transdermal system) with other DRUGOTHER, including but not limited to other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), general DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",Central Nervous System Depressants,fentanyl,False,Neg,0,C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,0,7
2279,11874,11874,12149,12149,"DRUGOTHER: The concomitant use of DRUG1  (DRUGOTHER transdermal system) with other DRUG2, including but not limited to other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), general DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,central nervous system depressants,True,effect,2,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1,5,12
2280,11875,11875,12150,12150,"DRUGOTHER: The concomitant use of DRUG1  (DRUGOTHER transdermal system) with other DRUGOTHER, including but not limited to other DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), general DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,opioids,True,effect,2,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3.CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2.CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,5,19
2281,11876,11876,12151,12151,"DRUGOTHER: The concomitant use of DRUG1  (DRUGOTHER transdermal system) with other DRUGOTHER, including but not limited to other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 (e.g., DRUGOTHER), general DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,tranquilizers,True,effect,2,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,5,22
2282,11877,11877,12152,12152,"DRUGOTHER: The concomitant use of DRUG1  (DRUGOTHER transdermal system) with other DRUGOTHER, including but not limited to other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG2), general DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,benzodiazepines,True,effect,2,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,N1N=CC=CC2=CC=CC=C12,5,24
2283,11878,11878,12153,12153,"DRUGOTHER: The concomitant use of DRUG1  (DRUGOTHER transdermal system) with other DRUGOTHER, including but not limited to other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), general DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,anesthetics,True,effect,2,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,CCOC(=O)C1=CC=C(N)C=C1,5,26
2284,11879,11879,12154,12154,"DRUGOTHER: The concomitant use of DRUG1  (DRUGOTHER transdermal system) with other DRUGOTHER, including but not limited to other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), general DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,phenothiazines,True,effect,2,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,N1C2=CC=CC=C2SC2=CC=CC=C12,5,27
2285,11880,11880,12155,12155,"DRUGOTHER: The concomitant use of DRUG1  (DRUGOTHER transdermal system) with other DRUGOTHER, including but not limited to other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), general DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,alcohol,True,effect,2,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,CCO,5,30
2286,11881,11881,12156,12156,"DRUGOTHER: The concomitant use of DRUGOTHER  (DRUG1 transdermal system) with other DRUG2, including but not limited to other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), general DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,central nervous system depressants,True,effect,2,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1,7,12
2287,11882,11882,12157,12157,"DRUGOTHER: The concomitant use of DRUGOTHER  (DRUG1 transdermal system) with other DRUGOTHER, including but not limited to other DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), general DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,opioids,True,effect,2,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3.CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2.CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,7,19
2288,11883,11883,12158,12158,"DRUGOTHER: The concomitant use of DRUGOTHER  (DRUG1 transdermal system) with other DRUGOTHER, including but not limited to other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 (e.g., DRUGOTHER), general DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,tranquilizers,True,effect,2,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,7,22
2289,11884,11884,12159,12159,"DRUGOTHER: The concomitant use of DRUGOTHER  (DRUG1 transdermal system) with other DRUGOTHER, including but not limited to other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG2), general DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,benzodiazepines,True,effect,2,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,N1N=CC=CC2=CC=CC=C12,7,24
2290,11885,11885,12160,12160,"DRUGOTHER: The concomitant use of DRUGOTHER  (DRUG1 transdermal system) with other DRUGOTHER, including but not limited to other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), general DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,anesthetics,True,effect,2,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CCOC(=O)C1=CC=C(N)C=C1,7,26
2291,11886,11886,12161,12161,"DRUGOTHER: The concomitant use of DRUGOTHER  (DRUG1 transdermal system) with other DRUGOTHER, including but not limited to other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), general DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,phenothiazines,True,effect,2,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,N1C2=CC=CC=C2SC2=CC=CC=C12,7,27
2292,11887,11887,12162,12162,"DRUGOTHER: The concomitant use of DRUGOTHER  (DRUG1 transdermal system) with other DRUGOTHER, including but not limited to other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), general DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,alcohol,True,effect,2,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CCO,7,30
2293,11909,11909,12184,12184,DRUG1: DRUG2  is not recommended for use in patients who have received DRUGOTHER within 14 days because severe and unpredictable potentiation by DRUGOTHER has been reported with DRUGOTHER,MAO Inhibitors,DURAGESIC,False,Neg,0,CN(CC#C)CC1=CC=CC=C1,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,0,1
2294,11912,11912,12187,12187,DRUGOTHER: DRUG1  is not recommended for use in patients who have received DRUGOTHER within 14 days because severe and unpredictable potentiation by DRUG2 has been reported with DRUGOTHER,DURAGESIC,MAO inhibitors,False,Neg,0,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,CN(CC#C)CC1=CC=CC=C1,1,23
2295,11913,11913,12188,12188,DRUGOTHER: DRUG1  is not recommended for use in patients who have received DRUGOTHER within 14 days because severe and unpredictable potentiation by DRUGOTHER has been reported with DRUG2,DURAGESIC,opioid analgesics,False,Neg,0,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3.CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2.CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,1,28
2296,11952,11952,12227,12227,"Compounds that have been tested in man include DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER and no clinically meaningful interactions were found.",antipyrine,theophylline,False,Neg,0,CC1=CC(=O)N(N1C)C2=CC=CC=C2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,8,11
2297,11955,11955,12230,12230,"Compounds that have been tested in man include DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER and no clinically meaningful interactions were found.",digoxin,theophylline,False,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,9,11
2298,11957,11957,12232,12232,"Compounds that have been tested in man include DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER and no clinically meaningful interactions were found.",propranolol,theophylline,False,Neg,0,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,10,11
2299,11959,11959,12234,12234,"Compounds that have been tested in man include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2 and no clinically meaningful interactions were found.",theophylline,warfarin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,11,13
2300,11968,11968,12243,12243,"Other concomitant therapy Although specific interaction studies were not performed, DRUG1 doses of 1 mg or more were concomitantly used in clinical studies with DRUGOTHER, DRUGOTHER, a-blockers, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, cardiac DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 (also referred to as DRUGOTHER), and DRUGOTHER without evidence of clinically significant adverse interactions.",finasteride,prostaglandin synthetase inhibitors,False,Neg,0,[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=C(C=CC=C2)S1(=O)=O,10,38
2301,11976,11976,12251,12251,"Other concomitant therapy Although specific interaction studies were not performed, DRUGOTHER doses of 1 mg or more were concomitantly used in clinical studies with DRUG1, DRUGOTHER, a-blockers, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, cardiac DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 (also referred to as DRUGOTHER), and DRUGOTHER without evidence of clinically significant adverse interactions.",acetaminophen,prostaglandin synthetase inhibitors,False,Neg,0,CC(=O)NC1=CC=C(C=C1)O,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=C(C=CC=C2)S1(=O)=O,24,38
2302,11983,11983,12258,12258,"Other concomitant therapy Although specific interaction studies were not performed, DRUGOTHER doses of 1 mg or more were concomitantly used in clinical studies with DRUGOTHER, DRUG1, a-blockers, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, cardiac DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 (also referred to as DRUGOTHER), and DRUGOTHER without evidence of clinically significant adverse interactions.",acetylsalicylic acid,prostaglandin synthetase inhibitors,False,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=C(C=CC=C2)S1(=O)=O,25,38
2303,11989,11989,12264,12264,"Other concomitant therapy Although specific interaction studies were not performed, DRUGOTHER doses of 1 mg or more were concomitantly used in clinical studies with DRUGOTHER, DRUGOTHER, a-blockers, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, cardiac DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 (also referred to as DRUGOTHER), and DRUGOTHER without evidence of clinically significant adverse interactions.",analgesics,prostaglandin synthetase inhibitors,False,Neg,0,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=C(C=CC=C2)S1(=O)=O,27,38
2304,11994,11994,12269,12269,"Other concomitant therapy Although specific interaction studies were not performed, DRUGOTHER doses of 1 mg or more were concomitantly used in clinical studies with DRUGOTHER, DRUGOTHER, a-blockers, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, cardiac DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 (also referred to as DRUGOTHER), and DRUGOTHER without evidence of clinically significant adverse interactions.",angiotensin-converting enzyme (ACE) inhibitors,prostaglandin synthetase inhibitors,False,Neg,0,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=C(C=CC=C2)S1(=O)=O,28,38
2305,11998,11998,12273,12273,"Other concomitant therapy Although specific interaction studies were not performed, DRUGOTHER doses of 1 mg or more were concomitantly used in clinical studies with DRUGOTHER, DRUGOTHER, a-blockers, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, cardiac DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 (also referred to as DRUGOTHER), and DRUGOTHER without evidence of clinically significant adverse interactions.",anticonvulsants,prostaglandin synthetase inhibitors,False,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=C(C=CC=C2)S1(=O)=O,29,38
2306,12001,12001,12276,12276,"Other concomitant therapy Although specific interaction studies were not performed, DRUGOTHER doses of 1 mg or more were concomitantly used in clinical studies with DRUGOTHER, DRUGOTHER, a-blockers, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, cardiac DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 (also referred to as DRUGOTHER), and DRUGOTHER without evidence of clinically significant adverse interactions.",benzodiazepines,prostaglandin synthetase inhibitors,False,Neg,0,N1N=CC=CC2=CC=CC=C12,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=C(C=CC=C2)S1(=O)=O,30,38
2307,12003,12003,12278,12278,"Other concomitant therapy Although specific interaction studies were not performed, DRUGOTHER doses of 1 mg or more were concomitantly used in clinical studies with DRUGOTHER, DRUGOTHER, a-blockers, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, cardiac DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 (also referred to as DRUGOTHER), and DRUGOTHER without evidence of clinically significant adverse interactions.",nitrates,prostaglandin synthetase inhibitors,False,Neg,0,[N+](=O)([O-])[O-],CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=C(C=CC=C2)S1(=O)=O,34,38
2308,12004,12004,12279,12279,"Other concomitant therapy Although specific interaction studies were not performed, DRUGOTHER doses of 1 mg or more were concomitantly used in clinical studies with DRUGOTHER, DRUGOTHER, a-blockers, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, cardiac DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2 (also referred to as DRUGOTHER), and DRUGOTHER without evidence of clinically significant adverse interactions.",diuretics,prostaglandin synthetase inhibitors,False,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=C(C=CC=C2)S1(=O)=O,35,38
2309,12012,12012,12287,12287,"Limited data in patients receiving known enzyme inducers ( DRUG1, DRUG2, DRUGOTHER ) indicate only a 30% increase in the rate of DRUGOTHER elimination.",phenytoin,phenobarbital,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,9,10
2310,12013,12013,12288,12288,"Limited data in patients receiving known enzyme inducers ( DRUG1, DRUGOTHER, DRUG2 ) indicate only a 30% increase in the rate of DRUGOTHER elimination.",phenytoin,carbamazepine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,9,11
2311,12014,12014,12289,12289,"Limited data in patients receiving known enzyme inducers ( DRUG1, DRUGOTHER, DRUGOTHER ) indicate only a 30% increase in the rate of DRUG2 elimination.",phenytoin,flecainide,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,9,22
2312,12033,12033,12312,12312,"DRUG1 or DRUGOTHER (DRUGOTHER and related drugs, DRUGOTHER and DRUG2) enhanced hypokalemia.",Amphotericin B,furosemide,False,Neg,0,CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,0,9
2313,12034,12034,12315,12315,"DRUGOTHER or DRUGOTHER (DRUGOTHER and related drugs, DRUG1 and DRUG2) enhanced hypokalemia.",ethacrynic acid,furosemide,False,Neg,0,CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,7,9
2314,12040,12040,12321,12321,"DRUG1, DRUG2, or DRUGOTHER increased metabolic clearance of DRUGOTHER because of the induction of hepatic enzymes.",Barbiturates,phenytoin,False,Neg,0,CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,1
2315,12043,12043,12324,12324,"DRUGOTHER, DRUG1, or DRUG2 increased metabolic clearance of DRUGOTHER because of the induction of hepatic enzymes.",phenytoin,rifampin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,1,3
2316,12044,12044,12325,12325,"DRUGOTHER, DRUG1, or DRUGOTHER increased metabolic clearance of DRUG2 because of the induction of hepatic enzymes.",phenytoin,fludrocortisone acetate,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)CC[C@@]43C)F)O)C)O,1,8
2317,12103,12103,12384,12384,Tell your doctor if you are taking any of the following drugs: DRUGOTHERs (DRUG1) other DRUGOTHER DRUGOTHER DRUGOTHER DRUGOTHER (DRUGOTHER) DRUGOTHER (DRUGOTHER) DRUGOTHER DRUGOTHER (DRUG2) intraconazole (DRUGOTHER) DRUGOTHER (DRUGOTHER) DRUGOTHER DRUGOTHER DRUGOTHER birth control pills sleeping pills thyroid medications,Coumadin,Prozac,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,13,24
2318,12116,12116,12397,12397,Tell your doctor if you are taking any of the following drugs: DRUGOTHERs (DRUGOTHER) other DRUG1 DRUGOTHER DRUGOTHER DRUGOTHER (DRUGOTHER) DRUGOTHER (DRUGOTHER) DRUGOTHER DRUGOTHER (DRUG2) intraconazole (DRUGOTHER) DRUGOTHER (DRUGOTHER) DRUGOTHER DRUGOTHER DRUGOTHER birth control pills sleeping pills thyroid medications,antidepressants,Prozac,False,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,15,24
2319,12128,12128,12409,12409,Tell your doctor if you are taking any of the following drugs: DRUGOTHERs (DRUGOTHER) other DRUGOTHER DRUG1 DRUGOTHER DRUGOTHER (DRUGOTHER) DRUGOTHER (DRUGOTHER) DRUGOTHER DRUGOTHER (DRUG2) intraconazole (DRUGOTHER) DRUGOTHER (DRUGOTHER) DRUGOTHER DRUGOTHER DRUGOTHER birth control pills sleeping pills thyroid medications,metoprolol,Prozac,False,Neg,0,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,16,24
2320,12139,12139,12420,12420,Tell your doctor if you are taking any of the following drugs: DRUGOTHERs (DRUGOTHER) other DRUGOTHER DRUGOTHER DRUG1 DRUGOTHER (DRUGOTHER) DRUGOTHER (DRUGOTHER) DRUGOTHER DRUGOTHER (DRUG2) intraconazole (DRUGOTHER) DRUGOTHER (DRUGOTHER) DRUGOTHER DRUGOTHER DRUGOTHER birth control pills sleeping pills thyroid medications,antihistamines,Prozac,False,Neg,0,NCCC1=CNC=N1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,17,24
2321,12149,12149,12430,12430,Tell your doctor if you are taking any of the following drugs: DRUGOTHERs (DRUGOTHER) other DRUGOTHER DRUGOTHER DRUGOTHER DRUG1 (DRUGOTHER) DRUGOTHER (DRUGOTHER) DRUGOTHER DRUGOTHER (DRUG2) intraconazole (DRUGOTHER) DRUGOTHER (DRUGOTHER) DRUGOTHER DRUGOTHER DRUGOTHER birth control pills sleeping pills thyroid medications,carbamazepine,Prozac,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,18,24
2322,12158,12158,12439,12439,Tell your doctor if you are taking any of the following drugs: DRUGOTHERs (DRUGOTHER) other DRUGOTHER DRUGOTHER DRUGOTHER DRUGOTHER (DRUG1) DRUGOTHER (DRUGOTHER) DRUGOTHER DRUGOTHER (DRUG2) intraconazole (DRUGOTHER) DRUGOTHER (DRUGOTHER) DRUGOTHER DRUGOTHER DRUGOTHER birth control pills sleeping pills thyroid medications,Tegretol,Prozac,False,Neg,0,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,19,24
2323,12166,12166,12447,12447,Tell your doctor if you are taking any of the following drugs: DRUGOTHERs (DRUGOTHER) other DRUGOTHER DRUGOTHER DRUGOTHER DRUGOTHER (DRUGOTHER) DRUG1 (DRUGOTHER) DRUGOTHER DRUGOTHER (DRUG2) intraconazole (DRUGOTHER) DRUGOTHER (DRUGOTHER) DRUGOTHER DRUGOTHER DRUGOTHER birth control pills sleeping pills thyroid medications,cimetidine,Prozac,False,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,20,24
2324,12173,12173,12454,12454,Tell your doctor if you are taking any of the following drugs: DRUGOTHERs (DRUGOTHER) other DRUGOTHER DRUGOTHER DRUGOTHER DRUGOTHER (DRUGOTHER) DRUGOTHER (DRUG1) DRUGOTHER DRUGOTHER (DRUG2) intraconazole (DRUGOTHER) DRUGOTHER (DRUGOTHER) DRUGOTHER DRUGOTHER DRUGOTHER birth control pills sleeping pills thyroid medications,Tagamet,Prozac,False,Neg,0,CN\C(NCCSCC1=C(C)NC=N1)=N\C#N,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,21,24
2325,12179,12179,12460,12460,Tell your doctor if you are taking any of the following drugs: DRUGOTHERs (DRUGOTHER) other DRUGOTHER DRUGOTHER DRUGOTHER DRUGOTHER (DRUGOTHER) DRUGOTHER (DRUGOTHER) DRUG1 DRUGOTHER (DRUG2) intraconazole (DRUGOTHER) DRUGOTHER (DRUGOTHER) DRUGOTHER DRUGOTHER DRUGOTHER birth control pills sleeping pills thyroid medications,estrogens,Prozac,False,Neg,0,C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)OS(=O)(=O)[O-])[C@@H]1CCC2=O.[Na+],CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,22,24
2326,12184,12184,12465,12465,Tell your doctor if you are taking any of the following drugs: DRUGOTHERs (DRUGOTHER) other DRUGOTHER DRUGOTHER DRUGOTHER DRUGOTHER (DRUGOTHER) DRUGOTHER (DRUGOTHER) DRUGOTHER DRUG1 (DRUG2) intraconazole (DRUGOTHER) DRUGOTHER (DRUGOTHER) DRUGOTHER DRUGOTHER DRUGOTHER birth control pills sleeping pills thyroid medications,fluoxetine,Prozac,False,Neg,0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,23,24
2327,12189,12189,12470,12470,Tell your doctor if you are taking any of the following drugs: DRUGOTHERs (DRUGOTHER) other DRUGOTHER DRUGOTHER DRUGOTHER DRUGOTHER (DRUGOTHER) DRUGOTHER (DRUGOTHER) DRUGOTHER DRUGOTHER (DRUG1) intraconazole (DRUG2) DRUGOTHER (DRUGOTHER) DRUGOTHER DRUGOTHER DRUGOTHER birth control pills sleeping pills thyroid medications,Prozac,Sporanox,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,[Na+].[Cl-],24,26
2328,12190,12190,12471,12471,Tell your doctor if you are taking any of the following drugs: DRUGOTHERs (DRUGOTHER) other DRUGOTHER DRUGOTHER DRUGOTHER DRUGOTHER (DRUGOTHER) DRUGOTHER (DRUGOTHER) DRUGOTHER DRUGOTHER (DRUG1) intraconazole (DRUGOTHER) DRUG2 (DRUGOTHER) DRUGOTHER DRUGOTHER DRUGOTHER birth control pills sleeping pills thyroid medications,Prozac,ketoconazole,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,24,27
2329,12191,12191,12472,12472,Tell your doctor if you are taking any of the following drugs: DRUGOTHERs (DRUGOTHER) other DRUGOTHER DRUGOTHER DRUGOTHER DRUGOTHER (DRUGOTHER) DRUGOTHER (DRUGOTHER) DRUGOTHER DRUGOTHER (DRUG1) intraconazole (DRUGOTHER) DRUGOTHER (DRUG2) DRUGOTHER DRUGOTHER DRUGOTHER birth control pills sleeping pills thyroid medications,Prozac,Nizoral,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,24,28
2330,12192,12192,12473,12473,Tell your doctor if you are taking any of the following drugs: DRUGOTHERs (DRUGOTHER) other DRUGOTHER DRUGOTHER DRUGOTHER DRUGOTHER (DRUGOTHER) DRUGOTHER (DRUGOTHER) DRUGOTHER DRUGOTHER (DRUG1) intraconazole (DRUGOTHER) DRUGOTHER (DRUGOTHER) DRUG2 DRUGOTHER DRUGOTHER birth control pills sleeping pills thyroid medications,Prozac,levodopa,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O,24,29
2331,12254,12254,12535,12535,"DRUG1: Studies in normal volunteers have shown that DRUGOTHER like other DRUGOTHER, can interfere with the effects of DRUG2.",Diuretics,furosemide,False,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,0,18
2332,12256,12256,12537,12537,"DRUGOTHER: Studies in normal volunteers have shown that DRUG1 like other DRUGOTHER, can interfere with the effects of DRUG2.",flurbiprofen,furosemide,True,effect,2,CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,8,18
2333,12257,12257,12538,12538,"DRUGOTHER: Studies in normal volunteers have shown that DRUGOTHER like other DRUG1, can interfere with the effects of DRUG2.",nonsteroidal anti-inflammatory drugs,furosemide,True,effect,2,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,11,18
2334,12258,12258,12539,12539,Patients receiving DRUG1 and DRUG2 or other DRUGOTHER should be observed closely to determine if the desired effect is obtained.,flurbiprofen,furosemide,True,advise,1,CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,2,4
2335,12260,12260,12541,12541,Patients receiving DRUGOTHER and DRUG1 or other DRUG2 should be observed closely to determine if the desired effect is obtained.,furosemide,diuretics,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,4,7
2336,12294,12294,12575,12575,"In patients receiving another DRUG1 in combination with DRUG2 (DRUGOTHER), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.",serotonin reuptake inhibitor drug,monoamine oxidase inhibitors,True,effect,2,NCCC1=CNC2=CC=C(O)C=C12,OC(=O)CCCCCCCC(O)=O,4,8
2337,12377,12377,12658,12658,"DRUG1: The effect of steady-state DRUG2 l50 mg bid on the pharmacokinetics of a single dose of DRUG1 (375 mg) as 442 mg DRUGOTHER was evaluated in 12 healthy non-smoking, male volunteers.",Theophylline,fluvoxamine,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,0,5
2338,12379,12379,12660,12660,"DRUG1: The effect of steady-state DRUGOTHER l50 mg bid on the pharmacokinetics of a single dose of DRUG1 (375 mg) as 442 mg DRUG2 was evaluated in 12 healthy non-smoking, male volunteers.",Theophylline,aminophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,0,23
2339,12380,12380,12661,12661,"DRUG2: The effect of steady-state DRUG1 l50 mg bid on the pharmacokinetics of a single dose of DRUG2 (375 mg) as 442 mg DRUGOTHER was evaluated in 12 healthy non-smoking, male volunteers.",fluvoxamine,Theophylline,False,Neg,0,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,CN1C2=C(C(=O)N(C1=O)C)NC=N2,5,0
2340,12382,12382,12663,12663,"DRUG1: The effect of steady-state DRUGOTHER l50 mg bid on the pharmacokinetics of a single dose of DRUG1 (375 mg) as 442 mg DRUG2 was evaluated in 12 healthy non-smoking, male volunteers.",Theophylline,aminophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,0,23
2341,12383,12383,12664,12664,"Therefore, if DRUG1 is co-administered with DRUG2, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of DRUG1 should to monitored.",theophylline,fluvoxamine maleate,True,advise,1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1,2,6
2342,12385,12385,12666,12666,"Therefore, if DRUG2 is co-administered with DRUG1, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of DRUG2 should to monitored.",fluvoxamine maleate,theophylline,False,Neg,0,ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,6,2
2343,12393,12393,12674,12674,"Medications can interfere with folate utilization, including: DRUG1 (such as DRUG2, and DRUGOTHER) DRUGOTHER (sometimes prescribed to control blood sugar in type 2 diabetes) DRUGOTHER (used to control inflammation associated with Crohns disease and ulcerative colitis) DRUGOTHER (a DRUGOTHER) DRUGOTHER There has been concern about the interaction between DRUGOTHER and DRUGOTHER.",anticonvulsant medications,phenytoin,False,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,7,10
2344,12402,12402,12683,12683,"Medications can interfere with folate utilization, including: DRUGOTHER (such as DRUG1, and DRUG2) DRUGOTHER (sometimes prescribed to control blood sugar in type 2 diabetes) DRUGOTHER (used to control inflammation associated with Crohns disease and ulcerative colitis) DRUGOTHER (a DRUGOTHER) DRUGOTHER There has been concern about the interaction between DRUGOTHER and DRUGOTHER.",phenytoin,primidone,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,10,12
2345,12403,12403,12684,12684,"Medications can interfere with folate utilization, including: DRUGOTHER (such as DRUG1, and DRUGOTHER) DRUG2 (sometimes prescribed to control blood sugar in type 2 diabetes) DRUGOTHER (used to control inflammation associated with Crohns disease and ulcerative colitis) DRUGOTHER (a DRUGOTHER) DRUGOTHER There has been concern about the interaction between DRUGOTHER and DRUGOTHER.",phenytoin,metformin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN(C)C(=N)N=C(N)N,10,13
2346,12404,12404,12685,12685,"Medications can interfere with folate utilization, including: DRUGOTHER (such as DRUG1, and DRUGOTHER) DRUGOTHER (sometimes prescribed to control blood sugar in type 2 diabetes) DRUG2 (used to control inflammation associated with Crohns disease and ulcerative colitis) DRUGOTHER (a DRUGOTHER) DRUGOTHER There has been concern about the interaction between DRUGOTHER and DRUGOTHER.",phenytoin,sulfasalazine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,10,24
2347,12405,12405,12686,12686,"Medications can interfere with folate utilization, including: DRUGOTHER (such as DRUG1, and DRUGOTHER) DRUGOTHER (sometimes prescribed to control blood sugar in type 2 diabetes) DRUGOTHER (used to control inflammation associated with Crohns disease and ulcerative colitis) DRUG2 (a DRUGOTHER) DRUGOTHER There has been concern about the interaction between DRUGOTHER and DRUGOTHER.",phenytoin,triamterene,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,10,36
2348,12406,12406,12687,12687,"Medications can interfere with folate utilization, including: DRUGOTHER (such as DRUG1, and DRUGOTHER) DRUGOTHER (sometimes prescribed to control blood sugar in type 2 diabetes) DRUGOTHER (used to control inflammation associated with Crohns disease and ulcerative colitis) DRUGOTHER (a DRUG2) DRUGOTHER There has been concern about the interaction between DRUGOTHER and DRUGOTHER.",phenytoin,diuretic,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,10,38
2349,12407,12407,12688,12688,"Medications can interfere with folate utilization, including: DRUGOTHER (such as DRUG1, and DRUGOTHER) DRUGOTHER (sometimes prescribed to control blood sugar in type 2 diabetes) DRUGOTHER (used to control inflammation associated with Crohns disease and ulcerative colitis) DRUGOTHER (a DRUGOTHER) DRUG2 There has been concern about the interaction between DRUGOTHER and DRUGOTHER.",phenytoin,Methotrexate,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,10,39
2350,12408,12408,12689,12689,"Medications can interfere with folate utilization, including: DRUGOTHER (such as DRUG1, and DRUGOTHER) DRUGOTHER (sometimes prescribed to control blood sugar in type 2 diabetes) DRUGOTHER (used to control inflammation associated with Crohns disease and ulcerative colitis) DRUGOTHER (a DRUGOTHER) DRUGOTHER There has been concern about the interaction between DRUG2 and DRUGOTHER.",phenytoin,vitamin B12,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N,10,48
2351,12409,12409,12690,12690,"Medications can interfere with folate utilization, including: DRUGOTHER (such as DRUG1, and DRUGOTHER) DRUGOTHER (sometimes prescribed to control blood sugar in type 2 diabetes) DRUGOTHER (used to control inflammation associated with Crohns disease and ulcerative colitis) DRUGOTHER (a DRUGOTHER) DRUGOTHER There has been concern about the interaction between DRUGOTHER and DRUG2.",phenytoin,folic acid,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,10,50
2352,12442,12442,12723,12723,"Reciprocal interactions may occur with concomitant use of DRUG1 and drugs that increase or inhibit the cytochrome P450 system (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), though this has not been studied",Antizol,phenytoin,True,mechanism,4,CC1=CNN=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,8,20
2353,12446,12446,12727,12727,"Reciprocal interactions may occur with concomitant use of DRUGOTHER and drugs that increase or inhibit the cytochrome P450 system (e.g., DRUG1, DRUG2, DRUGOTHER, DRUGOTHER), though this has not been studied",phenytoin,carbamazepine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,20,21
2354,12447,12447,12728,12728,"Reciprocal interactions may occur with concomitant use of DRUGOTHER and drugs that increase or inhibit the cytochrome P450 system (e.g., DRUG1, DRUGOTHER, DRUG2, DRUGOTHER), though this has not been studied",phenytoin,cimetidine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=C(N=CN1)CSCCNC(=NC)NC#N,20,22
2355,12448,12448,12729,12729,"Reciprocal interactions may occur with concomitant use of DRUGOTHER and drugs that increase or inhibit the cytochrome P450 system (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUG2), though this has not been studied",phenytoin,ketoconazole,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,20,23
2356,12485,12485,12766,12766,"DRUG1, DRUG2 and DRUGOTHER: Concomitant treatment with DRUGOTHER, DRUGOTHER, or DRUGOTHER may potentiate a possible hypokalemic effect of  DRUGOTHER",Corticosteroids,Methylxanthines,False,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,O=C1NC2=C(NC=N2)C(=O)N1,0,1
2357,12487,12487,12768,12768,"DRUG1, DRUGOTHER and DRUGOTHER: Concomitant treatment with DRUG2, DRUGOTHER, or DRUGOTHER may potentiate a possible hypokalemic effect of  DRUGOTHER",Corticosteroids,xanthine derivatives,False,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,O=C1NC2=C(NC=N2)C(=O)N1,0,7
2358,12490,12490,12771,12771,"DRUGOTHER, DRUG1 and DRUG2: Concomitant treatment with DRUGOTHER, DRUGOTHER, or DRUGOTHER may potentiate a possible hypokalemic effect of  DRUGOTHER",Methylxanthines,Diuretics,False,Neg,0,O=C1NC2=C(NC=N2)C(=O)N1,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,1,3
2359,12492,12492,12773,12773,"CorticoDRUG2, DRUG1 and DRUGOTHER: Concomitant treatment with DRUGOTHER, DRUG2, or DRUGOTHER may potentiate a possible hypokalemic effect of  DRUGOTHER",Methylxanthines,steroids,False,Neg,0,O=C1NC2=C(NC=N2)C(=O)N1,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,1,0
2360,12493,12493,12774,12774,"DRUGOTHER, DRUG1 and DRUGOTHER: Concomitant treatment with DRUGOTHER, DRUGOTHER, or DRUG2 may potentiate a possible hypokalemic effect of  DRUGOTHER",Methylxanthines,diuretics,False,Neg,0,O=C1NC2=C(NC=N2)C(=O)N1,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,1,10
2361,12494,12494,12775,12775,"DRUGOTHER, DRUGOTHER and DRUG1: Concomitant treatment with DRUG2, DRUGOTHER, or DRUGOTHER may potentiate a possible hypokalemic effect of  DRUGOTHER",Diuretics,xanthine derivatives,False,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,O=C1NC2=C(NC=N2)C(=O)N1,3,7
2362,12497,12497,12778,12778,"CorticoDRUG2, DRUGOTHER and DRUGOTHER: Concomitant treatment with DRUG1, DRUG2, or DRUGOTHER may potentiate a possible hypokalemic effect of  DRUGOTHER",xanthine derivatives,steroids,False,Neg,0,O=C1NC2=C(NC=N2)C(=O)N1,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,7,0
2363,12498,12498,12779,12779,"DRUGOTHER, DRUGOTHER and DRUGOTHER: Concomitant treatment with DRUG1, DRUGOTHER, or DRUG2 may potentiate a possible hypokalemic effect of  DRUGOTHER",xanthine derivatives,diuretics,False,Neg,0,O=C1NC2=C(NC=N2)C(=O)N1,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,7,10
2364,12549,12549,12830,12830,"DRUGOTHER (DRUG1, DRUG2,DRUGOTHER, and others) or DRUGOTHER supplements can increase the risk of hyperkalemia.",spironolactone,amiloride,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N,1,2
2365,12550,12550,12831,12831,"DRUGOTHER (DRUG1, DRUGOTHER,DRUG2, and others) or DRUGOTHER supplements can increase the risk of hyperkalemia.",spironolactone,triamterene,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,1,2
2366,12582,12582,12863,12863,"In separate single or multiple dose pharmacokinetic interaction studies with DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER, the bioavailability of DRUGOTHER was not altered by coadministration of DRUGOTHER with any one of these drugs.",chlorthalidone,hydrochlorothiazide,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=CC(=C1)C1(O)NC(=O)C2=CC=CC=C12,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,10,13
2367,12591,12591,12872,12872,"In separate single or multiple dose pharmacokinetic interaction studies with DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER, the bioavailability of DRUGOTHER was not altered by coadministration of DRUGOTHER with any one of these drugs.",nifedipine,hydrochlorothiazide,False,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,11,13
2368,12599,12599,12880,12880,"In separate single or multiple dose pharmacokinetic interaction studies with DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER, the bioavailability of DRUGOTHER was not altered by coadministration of DRUGOTHER with any one of these drugs.",propanolol,hydrochlorothiazide,False,Neg,0,OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,12,13
2369,12607,12607,12888,12888,"In separate single or multiple dose pharmacokinetic interaction studies with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER, the bioavailability of DRUGOTHER was not altered by coadministration of DRUGOTHER with any one of these drugs.",hydrochlorothiazide,cimetidine,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,CC1=C(N=CN1)CSCCNC(=NC)NC#N,13,14
2370,12608,12608,12889,12889,"In separate single or multiple dose pharmacokinetic interaction studies with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER, the bioavailability of DRUGOTHER was not altered by coadministration of DRUGOTHER with any one of these drugs.",hydrochlorothiazide,metoclopramide,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,13,15
2371,12609,12609,12890,12890,"In separate single or multiple dose pharmacokinetic interaction studies with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER, the bioavailability of DRUGOTHER was not altered by coadministration of DRUGOTHER with any one of these drugs.",hydrochlorothiazide,propantheline,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC2=CC3=C(OCO3)C=C2C)=C1Cl,13,16
2372,12610,12610,12891,12891,"In separate single or multiple dose pharmacokinetic interaction studies with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER, the bioavailability of DRUGOTHER was not altered by coadministration of DRUGOTHER with any one of these drugs.",hydrochlorothiazide,digoxin,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,13,17
2373,12611,12611,12892,12892,"In separate single or multiple dose pharmacokinetic interaction studies with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2, the bioavailability of DRUGOTHER was not altered by coadministration of DRUGOTHER with any one of these drugs.",hydrochlorothiazide,warfarin,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,13,19
2374,12612,12612,12893,12893,"In separate single or multiple dose pharmacokinetic interaction studies with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER, the bioavailability of DRUG2 was not altered by coadministration of DRUGOTHER with any one of these drugs.",hydrochlorothiazide,fosinoprilat,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,[H][C@]1(C[C@H](N(C1)C(=O)CP(O)(=O)CCCCC1=CC=CC=C1)C(O)=O)C1CCCCC1,13,23
2375,12613,12613,12894,12894,"In separate single or multiple dose pharmacokinetic interaction studies with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER, the bioavailability of DRUG2at was not altered by coadministration of DRUG2 with any one of these drugs.",hydrochlorothiazide,fosinopril,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O,13,23
2376,12645,12645,12926,12926,"The pharmacokinetics and protein binding of DRUG1, DRUGOTHER, and DRUG2 were not altered when DRUG2 and DRUGOTHER were concurrently administered in single submaximal doses.",fosphenytoin,diazepam,False,Neg,0,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,6,9
2377,12646,12646,12927,12927,"The pharmacokinetics and protein binding of DRUG1, DRUGOTHER, and DRUG2 were not altered when DRUG2 and DRUGOTHER were concurrently administered in single submaximal doses.",fosphenytoin,diazepam,False,Neg,0,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,6,9
2378,12648,12648,12929,12929,"The pharmacokinetics and protein binding of fosDRUG1, DRUG1, and DRUG2 were not altered when DRUG2 and DRUGOTHER were concurrently administered in single submaximal doses.",phenytoin,diazepam,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,6,9
2379,12649,12649,12930,12930,"The pharmacokinetics and protein binding of fosDRUG1, DRUG1, and DRUG2 were not altered when DRUG2 and DRUGOTHER were concurrently administered in single submaximal doses.",phenytoin,diazepam,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,6,9
2380,12652,12652,12933,12933,"The pharmacokinetics and protein binding of DRUGOTHER, DRUGOTHER, and DRUG1 were not altered when DRUG1 and DRUG2 were concurrently administered in single submaximal doses.",diazepam,Cerebyx,False,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,9,16
2381,12653,12653,12934,12934,"The pharmacokinetics and protein binding of DRUGOTHER, DRUGOTHER, and DRUG1 were not altered when DRUG1 and DRUG2 were concurrently administered in single submaximal doses.",diazepam,Cerebyx,False,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,9,16
2382,12655,12655,12936,12936,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUG1 concentrations include: acute DRUG2 intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER",phenytoin,alcohol,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCO,15,19
2383,12656,12656,12937,12937,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUG1 concentrations include: acute DRUGOTHER intake, DRUG2, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER",phenytoin,amiodarone,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2,15,21
2384,12657,12657,12938,12938,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUG1 concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER",phenytoin,chlordiazepoxide,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1,15,23
2385,12658,12658,12939,12939,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUG1 concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER",phenytoin,cimetidine,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=C(N=CN1)CSCCNC(=NC)NC#N,15,24
2386,12659,12659,12940,12940,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUG1 concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER",phenytoin,diazepam,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,15,25
2387,12660,12660,12941,12941,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUG1 concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER",phenytoin,dicumarol,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2,15,26
2388,12661,12661,12942,12942,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUG1 concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER",phenytoin,disulfiram,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCN(CC)C(=S)SSC(=S)N(CC)CC,15,27
2389,12662,12662,12943,12943,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUG1 concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER",phenytoin,estrogens,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)OS(=O)(=O)[O-])[C@@H]1CCC2=O.[Na+],15,28
2390,12664,12664,12945,12945,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUG1 concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER",phenytoin,fluoxetine,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,15,30
2391,12665,12665,12946,12946,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUG1 concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER",phenytoin,halothane,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C(C(F)(F)F)(Cl)Br,15,32
2392,12666,12666,12947,12947,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUG1 concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER",phenytoin,isoniazid,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O,15,33
2393,12667,12667,12948,12948,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUG1 concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER",phenytoin,methylphenidate,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,15,34
2394,12668,12668,12949,12949,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUG1 concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER",phenytoin,phenothiazines,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,N1C2=CC=CC=C2SC2=CC=CC=C12,15,35
2395,12669,12669,12950,12950,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUG1 concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER",phenytoin,phenylbutazone,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,15,36
2396,12670,12670,12951,12951,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUG1 concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER",phenytoin,salicylates,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1,15,37
2397,12672,12672,12953,12953,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUG1 concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER",phenytoin,tolbutamide,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,15,40
2398,12673,12673,12954,12954,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUG1 concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2",phenytoin,trazodone,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1,15,41
2399,12681,12681,12962,12962,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUG1 intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER",alcohol,ethosuximide,False,Neg,0,CCO,CCC1(C)CC(=O)NC1=O,19,29
2400,12689,12689,12970,12970,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUG1 intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER",alcohol,sulfonamides,False,Neg,0,CCO,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,19,39
2401,12698,12698,12979,12979,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUG1, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER",amiodarone,ethosuximide,False,Neg,0,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2,CCC1(C)CC(=O)NC1=O,21,29
2402,12706,12706,12987,12987,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUG1, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER",amiodarone,sulfonamides,False,Neg,0,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,21,39
2403,12714,12714,12995,12995,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER",chlordiazepoxide,ethosuximide,False,Neg,0,CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1,CCC1(C)CC(=O)NC1=O,23,29
2404,12722,12722,13003,13003,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER",chlordiazepoxide,sulfonamides,False,Neg,0,CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,23,39
2405,12729,12729,13010,13010,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER",cimetidine,ethosuximide,False,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CCC1(C)CC(=O)NC1=O,24,29
2406,12737,12737,13018,13018,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER",cimetidine,sulfonamides,False,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,24,39
2407,12743,12743,13024,13024,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER",diazepam,ethosuximide,False,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,CCC1(C)CC(=O)NC1=O,25,29
2408,12751,12751,13032,13032,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER",diazepam,sulfonamides,False,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,25,39
2409,12756,12756,13037,13037,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER",dicumarol,ethosuximide,False,Neg,0,OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2,CCC1(C)CC(=O)NC1=O,26,29
2410,12764,12764,13045,13045,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER",dicumarol,sulfonamides,False,Neg,0,OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,26,39
2411,12768,12768,13049,13049,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER",disulfiram,ethosuximide,False,Neg,0,CCN(CC)C(=S)SSC(=S)N(CC)CC,CCC1(C)CC(=O)NC1=O,27,29
2412,12776,12776,13057,13057,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER",disulfiram,sulfonamides,False,Neg,0,CCN(CC)C(=S)SSC(=S)N(CC)CC,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,27,39
2413,12779,12779,13060,13060,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER",estrogens,ethosuximide,False,Neg,0,C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)OS(=O)(=O)[O-])[C@@H]1CCC2=O.[Na+],CCC1(C)CC(=O)NC1=O,28,29
2414,12787,12787,13068,13068,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER",estrogens,sulfonamides,False,Neg,0,C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)OS(=O)(=O)[O-])[C@@H]1CCC2=O.[Na+],CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,28,39
2415,12790,12790,13071,13071,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER",ethosuximide,fluoxetine,False,Neg,0,CCC1(C)CC(=O)NC1=O,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,29,30
2416,12791,12791,13072,13072,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER",ethosuximide,halothane,False,Neg,0,CCC1(C)CC(=O)NC1=O,C(C(F)(F)F)(Cl)Br,29,32
2417,12792,12792,13073,13073,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER",ethosuximide,isoniazid,False,Neg,0,CCC1(C)CC(=O)NC1=O,CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O,29,33
2418,12793,12793,13074,13074,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER",ethosuximide,methylphenidate,False,Neg,0,CCC1(C)CC(=O)NC1=O,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,29,34
2419,12794,12794,13075,13075,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER",ethosuximide,phenothiazines,False,Neg,0,CCC1(C)CC(=O)NC1=O,N1C2=CC=CC=C2SC2=CC=CC=C12,29,35
2420,12795,12795,13076,13076,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER",ethosuximide,phenylbutazone,False,Neg,0,CCC1(C)CC(=O)NC1=O,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,29,36
2421,12796,12796,13077,13077,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER",ethosuximide,salicylates,False,Neg,0,CCC1(C)CC(=O)NC1=O,CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1,29,37
2422,12798,12798,13079,13079,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER",ethosuximide,tolbutamide,False,Neg,0,CCC1(C)CC(=O)NC1=O,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,29,40
2423,12799,12799,13080,13080,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2",ethosuximide,trazodone,False,Neg,0,CCC1(C)CC(=O)NC1=O,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1,29,41
2424,12806,12806,13087,13087,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER",fluoxetine,sulfonamides,False,Neg,0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,30,39
2425,12814,12814,13095,13095,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER",halothane,sulfonamides,False,Neg,0,C(C(F)(F)F)(Cl)Br,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,32,39
2426,12821,12821,13102,13102,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER",isoniazid,sulfonamides,False,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,33,39
2427,12827,12827,13108,13108,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER",methylphenidate,sulfonamides,False,Neg,0,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,34,39
2428,12832,12832,13113,13113,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER",phenothiazines,sulfonamides,False,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,35,39
2429,12836,12836,13117,13117,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER",phenylbutazone,sulfonamides,False,Neg,0,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,36,39
2430,12839,12839,13120,13120,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER",salicylates,sulfonamides,False,Neg,0,CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,37,39
2431,12842,12842,13123,13123,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER",sulfonamides,tolbutamide,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,39,40
2432,12843,12843,13124,13124,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2",sulfonamides,trazodone,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1,39,41
2433,12845,12845,13126,13126," Drugs that may decrease plasma DRUG1 concentrations include: DRUG2, chronic DRUGOTHER abuse, DRUGOTHER",phenytoin,carbamazepine,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,6,9
2434,12846,12846,13127,13127," Drugs that may decrease plasma DRUG1 concentrations include: DRUGOTHER, chronic DRUG2 abuse, DRUGOTHER",phenytoin,alcohol,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCO,6,11
2435,12847,12847,13128,13128," Drugs that may decrease plasma DRUG1 concentrations include: DRUGOTHER, chronic DRUGOTHER abuse, DRUG2",phenytoin,reserpine,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,6,13
2436,12851,12851,13132,13132," Drugs that may either increase or decrease plasma DRUG1 concentrations include: DRUG2, vaiproic acid, and DRUGOTHER.",phenytoin,phenobarbital,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,9,12
2437,12852,12852,13133,13133,"Similarly, the effects of DRUG1 on DRUG2, DRUGOTHER and sodium plasma DRUGOTHER concentrations are unpredictable",phenytoin,phenobarbital,True,effect,2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,4,6
2438,12853,12853,13134,13134,"Similarly, the effects of DRUG1 on DRUGOTHER, DRUG2 and sodium plasma DRUGOTHER concentrations are unpredictable",phenytoin,valproic acid,True,effect,2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCCC(CCC)C(=O)O,4,7
2439,12854,12854,13135,13135,"Similarly, the effects of DRUG1 on DRUGOTHER, DRUGOTHER and sodium plasma DRUG2 concentrations are unpredictable",phenytoin,valproate,True,effect,2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCCC(CCC)C(=O)O,4,11
2440,12858,12858,13139,13139,"- Although not a true drug interaction, DRUG1 may precipitate seizures in susceptible patients and DRUG2 dosage may need to be adjusted",tricyclic antidepressants,Cerebyx,True,effect,2,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,7,15
2441,12859,12859,13140,13140," Drugs whose efficacy is impaired by DRUG1 include: DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",phenytoin,corticosteroids,True,effect,2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,7,10
2442,12860,12860,13141,13141," Drugs whose efficacy is impaired by DRUG1 include: DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",phenytoin,coumarin,True,effect,2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC(=O)O2,7,11
2443,12861,12861,13142,13142," Drugs whose efficacy is impaired by DRUG1 include: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",phenytoin,digitoxin,True,effect,2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)C1=CC(=O)OC1,7,12
2444,12863,12863,13144,13144," Drugs whose efficacy is impaired by DRUG1 include: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",phenytoin,estrogens,True,effect,2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)OS(=O)(=O)[O-])[C@@H]1CCC2=O.[Na+],7,14
2445,12865,12865,13146,13146," Drugs whose efficacy is impaired by DRUG1 include: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Oral DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",phenytoin,contraceptives,True,effect,2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,7,17
2446,12866,12866,13147,13147," Drugs whose efficacy is impaired by DRUG1 include: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Oral DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER.",phenytoin,rifampin,True,effect,2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,7,18
2447,12867,12867,13148,13148," Drugs whose efficacy is impaired by DRUG1 include: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Oral DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",phenytoin,quinidine,True,effect,2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,7,19
2448,12869,12869,13150,13150," Drugs whose efficacy is impaired by DRUG1 include: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2.",phenytoin,vitamin D,True,effect,2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,OC(=O)CCCCCCCC(O)=O,7,21
2449,12872,12872,13153,13153," Drugs whose efficacy is impaired by DRUGOTHER include: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",corticosteroids,doxycycline,False,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,10,13
2450,12874,12874,13155,13155," Drugs whose efficacy is impaired by DRUGOTHER include: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",corticosteroids,furosemide,False,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,10,15
2451,12878,12878,13159,13159," Drugs whose efficacy is impaired by DRUGOTHER include: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER.",corticosteroids,theophylline,False,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,10,20
2452,12881,12881,13162,13162," Drugs whose efficacy is impaired by DRUGOTHER include: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",coumarin,doxycycline,False,Neg,0,C1=CC=C2C(=C1)C=CC(=O)O2,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,11,13
2453,12883,12883,13164,13164," Drugs whose efficacy is impaired by DRUGOTHER include: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",coumarin,furosemide,False,Neg,0,C1=CC=C2C(=C1)C=CC(=O)O2,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,11,15
2454,12887,12887,13168,13168," Drugs whose efficacy is impaired by DRUGOTHER include: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER.",coumarin,theophylline,False,Neg,0,C1=CC=C2C(=C1)C=CC(=O)O2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,11,20
2455,12889,12889,13170,13170," Drugs whose efficacy is impaired by DRUGOTHER include: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",digitoxin,doxycycline,False,Neg,0,[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)C1=CC(=O)OC1,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,12,13
2456,12891,12891,13172,13172," Drugs whose efficacy is impaired by DRUGOTHER include: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",digitoxin,furosemide,False,Neg,0,[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)C1=CC(=O)OC1,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,12,15
2457,12895,12895,13176,13176," Drugs whose efficacy is impaired by DRUGOTHER include: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER.",digitoxin,theophylline,False,Neg,0,[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)C1=CC(=O)OC1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,12,20
2458,12897,12897,13178,13178," Drugs whose efficacy is impaired by DRUGOTHER include: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",doxycycline,estrogens,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)OS(=O)(=O)[O-])[C@@H]1CCC2=O.[Na+],13,14
2459,12899,12899,13180,13180," Drugs whose efficacy is impaired by DRUGOTHER include: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, Oral DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",doxycycline,contraceptives,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,13,17
2460,12900,12900,13181,13181," Drugs whose efficacy is impaired by DRUGOTHER include: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, Oral DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER.",doxycycline,rifampin,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,13,18
2461,12901,12901,13182,13182," Drugs whose efficacy is impaired by DRUGOTHER include: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, Oral DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",doxycycline,quinidine,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,13,19
2462,12903,12903,13184,13184," Drugs whose efficacy is impaired by DRUGOTHER include: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2.",doxycycline,vitamin D,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,OC(=O)CCCCCCCC(O)=O,13,21
2463,12904,12904,13185,13185," Drugs whose efficacy is impaired by DRUGOTHER include: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",estrogens,furosemide,False,Neg,0,C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)OS(=O)(=O)[O-])[C@@H]1CCC2=O.[Na+],C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,14,15
2464,12908,12908,13189,13189," Drugs whose efficacy is impaired by DRUGOTHER include: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER.",estrogens,theophylline,False,Neg,0,C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)OS(=O)(=O)[O-])[C@@H]1CCC2=O.[Na+],CN1C2=C(C(=O)N(C1=O)C)NC=N2,14,20
2465,12910,12910,13191,13191," Drugs whose efficacy is impaired by DRUGOTHER include: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, Oral DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",furosemide,contraceptives,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,15,17
2466,12911,12911,13192,13192," Drugs whose efficacy is impaired by DRUGOTHER include: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, Oral DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER.",furosemide,rifampin,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,15,18
2467,12912,12912,13193,13193," Drugs whose efficacy is impaired by DRUGOTHER include: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, Oral DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",furosemide,quinidine,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,15,19
2468,12914,12914,13195,13195," Drugs whose efficacy is impaired by DRUGOTHER include: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2.",furosemide,vitamin D,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,OC(=O)CCCCCCCC(O)=O,15,21
2469,12917,12917,13198,13198," Drugs whose efficacy is impaired by DRUGOTHER include: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Oral DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER.",contraceptives,theophylline,False,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,CN1C2=C(C(=O)N(C1=O)C)NC=N2,17,20
2470,12920,12920,13201,13201," Drugs whose efficacy is impaired by DRUGOTHER include: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Oral DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER.",rifampin,theophylline,False,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CN1C2=C(C(=O)N(C1=O)C)NC=N2,18,20
2471,12922,12922,13203,13203," Drugs whose efficacy is impaired by DRUGOTHER include: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Oral DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER.",quinidine,theophylline,False,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,19,20
2472,12924,12924,13205,13205," Drugs whose efficacy is impaired by DRUGOTHER include: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2.",theophylline,vitamin D,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,OC(=O)CCCCCCCC(O)=O,20,21
2473,12927,12927,13208,13208,"Due to a theoretical risk of a pharmacodynamic interaction, use of DRUG1-containing or DRUGOTHER (like dihydroDRUG1 or DRUG2) and DRUGOTHER within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",ergotamine,methysergide,False,Neg,0,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C,11,17
2474,12928,12928,13210,13210,"Due to a theoretical risk of a pharmacodynamic interaction, use of DRUGOTHER-containing or DRUGOTHER (like DRUG1 or DRUG2) and DRUGOTHER within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",dihydroergotamine,methysergide,False,Neg,0,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C,15,17
2475,12929,12929,13213,13213,"DRUG1 (DRUGOTHER) (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER.",Selective serotonin reuptake inhibitors,fluoxetine,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,0,3
2476,12930,12930,13214,13214,"DRUG1 (DRUGOTHER) (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER.",Selective serotonin reuptake inhibitors,fluvoxamine,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,0,4
2477,12931,12931,13215,13215,"DRUG1 (DRUGOTHER) (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER.",Selective serotonin reuptake inhibitors,paroxetine,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,0,5
2478,12932,12932,13216,13216,"DRUG1 (DRUGOTHER) (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER.",Selective serotonin reuptake inhibitors,sertraline,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,0,6
2479,12940,12940,13224,13224,"DRUG1 may increase the ototoxic potential of DRUG2, especially in the presence of impaired renal function.",Furosemide,aminoglycoside antibiotics,True,effect,2,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,0,7
2480,12941,12941,13225,13225,DRUG1 should not be used concomitantly with DRUG2 because of the possibility of ototoxicity.,Furosemide,ethacrynic acid,True,advise,1,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl,0,7
2481,12942,12942,13226,13226,"Patients receiving high doses of DRUG1 concomitantly with DRUG2, as in rheumatic disease, may experience DRUGOTHER toxicity at lower doses because of competitive renal excretory sites.",salicylates,furosemide,True,effect,2,CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,5,8
2482,12944,12944,13228,13228,"Patients receiving high doses of DRUG2s concomitantly with DRUG1, as in rheumatic disease, may experience DRUG2 toxicity at lower doses because of competitive renal excretory sites.",furosemide,salicylate,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C1=CC=C(C(=C1)C(=O)O)[O-],8,5
2483,12945,12945,13229,13229,DRUG1 has a tendency to antagonize the skeletal muscle relaxing effect of DRUG2 and may potentiate the action of DRUGOTHER.,Furosemide,tubocurarine,True,effect,2,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)O)O3)[N+](CCC6=CC(=C5O)OC)(C)C)OC,0,12
2484,12946,12946,13230,13230,DRUG1 has a tendency to antagonize the skeletal muscle relaxing effect of DRUGOTHER and may potentiate the action of DRUG2.,Furosemide,succinylcholine,True,effect,2,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,0,19
2485,12948,12948,13232,13232,DRUG1 may add to or potentiate the therapeutic effect of other DRUG2.,Furosemide,antihypertensive drugs,True,effect,2,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,0,11
2486,12949,12949,13233,13233,DRUG1 may decrease arterial responsiveness to DRUG2.,Furosemide,norepinephrine,True,effect,2,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C1=CC(=C(C=C1[C@H](CN)O)O)O,0,6
2487,12950,12950,13234,13234,Tablets Simultaneous administration of DRUG1 and DRUG2 tablets may reduce the natriuretic and antihypertensive effects of DRUG2.,sucralfate,furosemide,True,effect,2,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al].O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Al],C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,4,6
2488,12951,12951,13235,13235,Tablets Simultaneous administration of DRUG1 and DRUG2 tablets may reduce the natriuretic and antihypertensive effects of DRUG2.,sucralfate,furosemide,False,Neg,0,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al].O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Al],C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,4,6
2489,12953,12953,13237,13237,The intake of DRUG1 and DRUG2 should be separated by at least two hours.,furosemide,sucralfate,True,advise,1,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al].O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Al],3,5
2490,12954,12954,13238,13238,"Tablets, Injection, and Oral Solution One study in six subjects demonstrated that the combination of DRUG1 and DRUG2 temporarily reduced creatinine clearance in patients with chronic renal insufficiency.",furosemide,acetylsalicylic acid,True,effect,2,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC(=O)OC1=CC=CC=C1C(=O)O,15,17
2491,12955,12955,13239,13239,Literature reports indicate that coadministration of DRUG1 may reduce the natriuretic and antihypertensive effects of DRUG2 in some patients by inhibiting prostaglandin synthesis.,indomethacin,furosemide,True,effect,2,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,6,15
2492,12956,12956,13240,13240,Patients receiving both DRUG1 and DRUG2 should be observed closely to determine if the desired diuretic and/or antihypertensive effect of DRUG2 is achieved.,indomethacin,furosemide,True,advise,1,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,3,5
2493,12957,12957,13241,13241,Patients receiving both DRUG1 and DRUG2 should be observed closely to determine if the desired diuretic and/or antihypertensive effect of DRUG2 is achieved.,indomethacin,furosemide,False,Neg,0,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,3,5
2494,12975,12975,13259,13259,"DRUG1: Steady-state trough plasma DRUGOTHER and DRUGOTHER 10, 11 epoxide concentrations were not affected by concomitant DRUG2 (400 mg TID;",Carbamazepine,gabapentin,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,NCC1(CC(O)=O)CCCCC1,0,16
2495,12976,12976,13260,13260,"DRUGOTHER: Steady-state trough plasma DRUG1 and DRUG1 10, 11 epoxide concentrations were not affected by concomitant DRUG2 (400 mg TID;",carbamazepine,gabapentin,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,NCC1(CC(O)=O)CCCCC1,4,16
2496,12977,12977,13261,13261,"Likewise, DRUG1 pharmacokinetics were unaltered by DRUG2 administration.",gabapentin,carbamazepine,False,Neg,0,NCC1(CC(O)=O)CCCCC1,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,1,6
2497,12978,12978,13262,13262,DRUGOTHER: The mean steady-state trough serum DRUG1 concentrations prior to and during concomitant DRUG2 administration (400 mg TID;,valproic acid,gabapentin,False,Neg,0,CCCC(CCC)C(=O)O,NCC1(CC(O)=O)CCCCC1,6,13
2498,12979,12979,13263,13263,N=17) were not different and neither were DRUG1 pharmacokinetic parameters affected by DRUG2.,gabapentin,valproic acid,False,Neg,0,NCC1(CC(O)=O)CCCCC1,CCCC(CCC)C(=O)O,7,12
2499,12981,12981,13265,13265,DRUG1: Estimates of steady-state pharmacokinetic parameters for DRUGOTHER or DRUG2 (300 mg TID;,Phenobarbital,gabapentin,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,NCC1(CC(O)=O)CCCCC1,0,9
2500,12982,12982,13266,13266,DRUGOTHER: Estimates of steady-state pharmacokinetic parameters for DRUG1 or DRUG2 (300 mg TID;,phenobarbital,gabapentin,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,NCC1(CC(O)=O)CCCCC1,7,9
2501,12984,12984,13268,13268,DRUG1: Coadministration (N=18) of DRUGOTHER capsules (250 mg) with DRUGOTHER (125 mg) appears to increase the amount of DRUG2 absorbed by 12% to 15%.,Naproxen,gabapentin,False,Neg,0,COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1,NCC1(CC(O)=O)CCCCC1,0,18
2502,12985,12985,13269,13269,DRUGOTHER: Coadministration (N=18) of DRUG1 capsules (250 mg) with DRUGOTHER (125 mg) appears to increase the amount of DRUG2 absorbed by 12% to 15%.,naproxen sodium,gabapentin,False,Neg,0,CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1,NCC1(CC(O)=O)CCCCC1,4,18
2503,12987,12987,13271,13271,"DRUG1: A literature article reported that when a 60-mg controlled-release DRUGOTHER capsule was administered 2 hours prior to a 600-mg DRUGOTHER  capsule (N=12), mean DRUG2 AUC increased by 44% compared to DRUG2 administered without DRUGOTHER.",Morphine,gabapentin,False,Neg,0,[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23,NCC1(CC(O)=O)CCCCC1,0,25
2504,12988,12988,13272,13272,"DRUG1: A literature article reported that when a 60-mg controlled-release DRUGOTHER capsule was administered 2 hours prior to a 600-mg DRUGOTHER  capsule (N=12), mean DRUG2 AUC increased by 44% compared to DRUG2 administered without DRUGOTHER.",Morphine,gabapentin,False,Neg,0,[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23,NCC1(CC(O)=O)CCCCC1,0,25
2505,12990,12990,13274,13274,"DRUGOTHER: A literature article reported that when a 60-mg controlled-release DRUG1 capsule was administered 2 hours prior to a 600-mg DRUGOTHER  capsule (N=12), mean DRUG2 AUC increased by 44% compared to DRUG2 administered without DRUG1.",morphine,gabapentin,False,Neg,0,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,NCC1(CC(O)=O)CCCCC1,10,25
2506,12991,12991,13275,13275,"DRUGOTHER: A literature article reported that when a 60-mg controlled-release DRUG1 capsule was administered 2 hours prior to a 600-mg DRUGOTHER  capsule (N=12), mean DRUG2 AUC increased by 44% compared to DRUG2 administered without DRUG1.",morphine,gabapentin,False,Neg,0,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,NCC1(CC(O)=O)CCCCC1,10,25
2507,12994,12994,13278,13278,"DRUGOTHER: A literature article reported that when a 60-mg controlled-release DRUG2 capsule was administered 2 hours prior to a 600-mg DRUGOTHER  capsule (N=12), mean DRUG1 AUC increased by 44% compared to DRUG1 administered without DRUG2.",gabapentin,morphine,False,Neg,0,NCC1(CC(O)=O)CCCCC1,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,25,10
2508,12995,12995,13279,13279,"DRUGOTHER: A literature article reported that when a 60-mg controlled-release DRUG2 capsule was administered 2 hours prior to a 600-mg DRUGOTHER  capsule (N=12), mean DRUG1 AUC increased by 44% compared to DRUG1 administered without DRUG2.",gabapentin,morphine,False,Neg,0,NCC1(CC(O)=O)CCCCC1,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,25,10
2509,12998,12998,13282,13282,DRUG1: In the presence of DRUGOTHER at 300 mg QID (N=12) the mean apparent oral clearance of DRUG2 fell by 14% and creatinine clearance fell by 10%.,Cimetidine,gabapentin,False,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,NCC1(CC(O)=O)CCCCC1,0,17
2510,12999,12999,13283,13283,DRUGOTHER: In the presence of DRUG1 at 300 mg QID (N=12) the mean apparent oral clearance of DRUG2 fell by 14% and creatinine clearance fell by 10%.,cimetidine,gabapentin,True,mechanism,4,CC1=C(N=CN1)CSCCNC(=NC)NC#N,NCC1(CC(O)=O)CCCCC1,5,17
2511,13000,13000,13284,13284,"Thus DRUG1 appeared to alter the renal excretion of both DRUG2 and creatinine, an endogenous marker of renal function.",cimetidine,gabapentin,True,mechanism,4,CC1=C(N=CN1)CSCCNC(=NC)NC#N,NCC1(CC(O)=O)CCCCC1,1,10
2512,13001,13001,13285,13285,This small decrease in excretion of DRUG1 by DRUG2 is not expected to be of clinical importance.,gabapentin,cimetidine,True,mechanism,4,NCC1(CC(O)=O)CCCCC1,CC1=C(N=CN1)CSCCNC(=NC)NC#N,6,8
2513,13002,13002,13286,13286,The effect of DRUG1 on DRUG2 was not evaluated.,gabapentin,cimetidine,False,Neg,0,NCC1(CC(O)=O)CCCCC1,CC1=C(N=CN1)CSCCNC(=NC)NC#N,3,5
2514,13006,13006,13290,13290,"Oral DRUGOTHER: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of DRUG1 and DRUGOTHER following administration of tablets containing 2.5 mg of DRUG1 acetate and 50 mcg of DRUGOTHER were similar with and without coadministration of DRUG2 (400 mg TID;",norethindrone,gabapentin,False,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,NCC1(CC(O)=O)CCCCC1,11,36
2515,13009,13009,13293,13293,"Oral DRUGOTHER: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of DRUGOTHER and DRUG1 following administration of tablets containing 2.5 mg of DRUGOTHER acetate and 50 mcg of DRUG1 were similar with and without coadministration of DRUG2 (400 mg TID;",ethinyl estradiol,gabapentin,False,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,NCC1(CC(O)=O)CCCCC1,13,36
2516,13011,13011,13295,13295,"Oral DRUGOTHER: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of DRUGOTHER and DRUGOTHER following administration of tablets containing 2.5 mg of DRUG1 and 50 mcg of DRUGOTHER were similar with and without coadministration of DRUG2 (400 mg TID;",norethindrone acetate,gabapentin,False,Neg,0,CC(=O)O[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C)C#C,NCC1(CC(O)=O)CCCCC1,22,35
2517,13012,13012,13296,13296,"Oral DRUGOTHER: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of DRUGOTHER and DRUG1 following administration of tablets containing 2.5 mg of DRUGOTHER acetate and 50 mcg of DRUG1 were similar with and without coadministration of DRUG2 (400 mg TID;",ethinyl estradiol,gabapentin,False,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,NCC1(CC(O)=O)CCCCC1,13,36
2518,13013,13013,13297,13297,The Cmax of DRUG1 was 13% higher when it was coadministered with DRUG2;,norethindrone,gabapentin,True,mechanism,4,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,NCC1(CC(O)=O)CCCCC1,3,12
2519,13016,13016,13300,13300,DRUG1 (DRUGOTHER ): DRUGOTHER reduced the bioavailability of DRUG2 (N=16) by about 20%.,Antacid,gabapentin,False,Neg,0,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O,NCC1(CC(O)=O)CCCCC1,0,8
2520,13018,13018,13302,13302,DRUGOTHER (DRUG1 ): DRUG1 reduced the bioavailability of DRUG2 (N=16) by about 20%.,Maalox,gabapentin,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,NCC1(CC(O)=O)CCCCC1,1,8
2521,13019,13019,13303,13303,DRUGOTHER (DRUG1 ): DRUG1 reduced the bioavailability of DRUG2 (N=16) by about 20%.,Maalox,gabapentin,True,mechanism,4,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,NCC1(CC(O)=O)CCCCC1,1,8
2522,13020,13020,13304,13304,This decrease in bioavailability was about 5% when DRUG1 was administered 2 hours after DRUG2.,gabapentin,Maalox,True,mechanism,4,NCC1(CC(O)=O)CCCCC1,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,8,14
2523,13021,13021,13305,13305,It is recommended that DRUG1 be taken at least 2 hours following DRUG2 administration.,gabapentin,Maalox,True,advise,1,NCC1(CC(O)=O)CCCCC1,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,4,12
2524,13023,13023,13307,13307,This indicates that DRUG1 does not undergo renal tubular secretion by the pathway that is blocked by DRUG2.,gabapentin,probenecid,False,Neg,0,NCC1(CC(O)=O)CCCCC1,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,3,17
2525,13024,13024,13308,13308,"In patients receiving a potent CYP3A4 inducer such as DRUG1 or DRUG2, a dose increase to 500 mg daily should be considered in the absence of severe adverse drug reaction, and clinical response and adverse events should be carefully monitored (see CLINICAL PHARMACOLOGY-Pharmacokinetics-Drug-Drug Interactions and DOSAGE AND ADMINISTRATION-Dosage Adjustment sections).",rifampicin,phenytoin,False,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,9,11
2526,13028,13028,13312,13312,"Administration of repeat doses of DRUG1 had no effect on the repeat dose pharmacokinetics of DRUG2, DRUGOTHER or an DRUGOTHER/levonorgestrol oral DRUGOTHER in healthy subjects.",FACTIVE,theophylline,False,Neg,0,CO\N=C1/CN(CC1CN)C1=NC2=C(C=C1F)C(=O)C(=CN2C1CC1)C(O)=O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,5,15
2527,13031,13031,13315,13315,"Administration of repeat doses of DRUG1 had no effect on the repeat dose pharmacokinetics of DRUGOTHER, DRUGOTHER or an DRUGOTHER/levonorgestrol oral DRUG2 in healthy subjects.",FACTIVE,contraceptive product,False,Neg,0,CO\N=C1/CN(CC1CN)C1=NC2=C(C=C1F)C(=O)C(=CN2C1CC1)C(O)=O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,5,21
2528,13032,13032,13316,13316,"Administration of repeat doses of DRUGOTHER had no effect on the repeat dose pharmacokinetics of DRUG1, DRUG2 or an DRUGOTHER/levonorgestrol oral DRUGOTHER in healthy subjects.",theophylline,digoxin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,15,16
2529,13033,13033,13317,13317,"Administration of repeat doses of DRUGOTHER had no effect on the repeat dose pharmacokinetics of DRUG1, DRUGOTHER or an DRUG2/levonorgestrol oral DRUGOTHER in healthy subjects.",theophylline,ethinylestradiol,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,15,19
2530,13036,13036,13320,13320,"Administration of repeat doses of DRUGOTHER had no effect on the repeat dose pharmacokinetics of DRUGOTHER, DRUG1 or an DRUGOTHER/levonorgestrol oral DRUG2 in healthy subjects.",digoxin,contraceptive product,False,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,16,21
2531,13037,13037,13321,13321,"Administration of repeat doses of DRUGOTHER had no effect on the repeat dose pharmacokinetics of DRUGOTHER, DRUGOTHER or an DRUG1/levonorgestrol oral DRUG2 in healthy subjects.",ethinylestradiol,contraceptive product,False,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,19,21
2532,13081,13081,13365,13365,"The hypoglycemic action of DRUG1 may be potentiated by certain drugs including DRUGOTHER and other drugs that are highly protein bound, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",sulfonylureas,sulfonamides,True,effect,2,NC(N)=O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,4,22
2533,13088,13088,13372,13372,"The hypoglycemic action of DRUGOTHER may be potentiated by certain drugs including DRUG1 and other drugs that are highly protein bound, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",nonsteroidal anti-inflammatory agents,sulfonamides,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,12,22
2534,13094,13094,13378,13378,"The hypoglycemic action of DRUGOTHER may be potentiated by certain drugs including DRUGOTHER and other drugs that are highly protein bound, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",salicylates,sulfonamides,False,Neg,0,CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,21,22
2535,13100,13100,13384,13384,"The hypoglycemic action of DRUGOTHER may be potentiated by certain drugs including DRUGOTHER and other drugs that are highly protein bound, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",sulfonamides,chloramphenicol,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O,22,23
2536,13101,13101,13385,13385,"The hypoglycemic action of DRUGOTHER may be potentiated by certain drugs including DRUGOTHER and other drugs that are highly protein bound, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",sulfonamides,probenecid,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,22,24
2537,13102,13102,13386,13386,"The hypoglycemic action of DRUGOTHER may be potentiated by certain drugs including DRUGOTHER and other drugs that are highly protein bound, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",sulfonamides,coumarins,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,O=C1OC2=CC=CC=C2C=C1,22,25
2538,13103,13103,13387,13387,"The hypoglycemic action of DRUGOTHER may be potentiated by certain drugs including DRUGOTHER and other drugs that are highly protein bound, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",sulfonamides,monoamine oxidase inhibitors,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,OC(=O)CCCCCCCC(O)=O,22,26
2539,13104,13104,13388,13388,"The hypoglycemic action of DRUGOTHER may be potentiated by certain drugs including DRUGOTHER and other drugs that are highly protein bound, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",sulfonamides,beta adrenergic blocking agents,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,22,28
2540,13115,13115,13399,13399,"These drugs include the DRUG1 and other DRUG2, DRUGOTHER, phe-nothiazines, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUGOTHER, DRUGOTHER, sympathomimet-ics, DRUGOTHER, and DRUGOTHER.",thiazides,diuretics,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,4,7
2541,13116,13116,13400,13400,"These drugs include the DRUG1 and other DRUGOTHER, DRUG2, phe-nothiazines, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUGOTHER, DRUGOTHER, sympathomimet-ics, DRUGOTHER, and DRUGOTHER.",thiazides,corticosteroids,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,4,8
2542,13117,13117,13401,13401,"These drugs include the DRUG1 and other DRUGOTHER, DRUGOTHER, phe-nothiazines, DRUGOTHER, DRUG2, oral DRUGOTHER, DRUGOTHER, DRUGOTHER, sympathomimet-ics, DRUGOTHER, and DRUGOTHER.",thiazides,estrogens,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)OS(=O)(=O)[O-])[C@@H]1CCC2=O.[Na+],4,11
2543,13118,13118,13402,13402,"These drugs include the DRUG1 and other DRUGOTHER, DRUGOTHER, phe-nothiazines, DRUGOTHER, DRUGOTHER, oral DRUG2, DRUGOTHER, DRUGOTHER, sympathomimet-ics, DRUGOTHER, and DRUGOTHER.",thiazides,contraceptives,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,4,13
2544,13120,13120,13404,13404,"These drugs include the DRUG1 and other DRUGOTHER, DRUGOTHER, phe-nothiazines, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUGOTHER, DRUG2, sympathomimet-ics, DRUGOTHER, and DRUGOTHER.",thiazides,nicotinic acid,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1,4,15
2545,13121,13121,13405,13405,"These drugs include the DRUG1 and other DRUGOTHER, DRUGOTHER, phe-nothiazines, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUGOTHER, DRUGOTHER, sympathomimet-ics, DRUGOTHER, and DRUG2.",thiazides,isoniazid,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O,4,19
2546,13125,13125,13409,13409,"These drugs include the DRUGOTHER and other DRUG1, DRUGOTHER, phe-nothiazines, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUG2, DRUGOTHER, sympathomimet-ics, DRUGOTHER, and DRUGOTHER.",diuretics,phenytoin,False,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,7,14
2547,13130,13130,13414,13414,"These drugs include the DRUGOTHER and other DRUGOTHER, DRUG1, phe-nothiazines, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUG2, DRUGOTHER, sympathomimet-ics, DRUGOTHER, and DRUGOTHER.",corticosteroids,phenytoin,False,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,8,14
2548,13134,13134,13418,13418,"These drugs include the DRUGOTHER and other DRUGOTHER, DRUGOTHER, phe-nothiazines, DRUGOTHER, DRUG1, oral DRUGOTHER, DRUG2, DRUGOTHER, sympathomimet-ics, DRUGOTHER, and DRUGOTHER.",estrogens,phenytoin,False,Neg,0,C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)OS(=O)(=O)[O-])[C@@H]1CCC2=O.[Na+],C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,11,14
2549,13137,13137,13421,13421,"These drugs include the DRUGOTHER and other DRUGOTHER, DRUGOTHER, phe-nothiazines, DRUGOTHER, DRUGOTHER, oral DRUG1, DRUG2, DRUGOTHER, sympathomimet-ics, DRUGOTHER, and DRUGOTHER.",contraceptives,phenytoin,False,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,13,14
2550,13140,13140,13424,13424,"These drugs include the DRUGOTHER and other DRUGOTHER, DRUGOTHER, phe-nothiazines, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUG1, DRUG2, sympathomimet-ics, DRUGOTHER, and DRUGOTHER.",phenytoin,nicotinic acid,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1,14,15
2551,13141,13141,13425,13425,"These drugs include the DRUGOTHER and other DRUGOTHER, DRUGOTHER, phe-nothiazines, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUG1, DRUGOTHER, sympathomimet-ics, DRUGOTHER, and DRUG2.",phenytoin,isoniazid,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O,14,19
2552,13166,13166,13450,13450,"- a DRUG1 (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER);",nonsteroidal anti-inflammatory drug,oxaprozin,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,2,25
2553,13167,13167,13451,13451,"- a DRUG1 (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER);",nonsteroidal anti-inflammatory drug,Daypro,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,2,26
2554,13169,13169,13453,13453,"- a DRUG1 (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), and DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER);",nonsteroidal anti-inflammatory drug,Anaprox,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,2,29
2555,13170,13170,13454,13454,"- a DRUG1 (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), and DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER);",nonsteroidal anti-inflammatory drug,Naprosyn,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,2,30
2556,13182,13182,13466,13466,"- a DRUGOTHER (DRUG1) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER);",NSAID,oxaprozin,False,Neg,0,OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,3,25
2557,13183,13183,13467,13467,"- a DRUGOTHER (DRUG1) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER);",NSAID,Daypro,False,Neg,0,OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,3,26
2558,13185,13185,13469,13469,"- a DRUGOTHER (DRUG1) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), and DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER);",NSAID,Anaprox,False,Neg,0,OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,3,29
2559,13186,13186,13470,13470,"- a DRUGOTHER (DRUG1) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), and DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER);",NSAID,Naprosyn,False,Neg,0,OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,3,30
2560,13197,13197,13481,13481,"- a DRUGOTHER (DRUGOTHER) such as DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER);",ibuprofen,oxaprozin,False,Neg,0,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,6,25
2561,13198,13198,13482,13482,"- a DRUGOTHER (DRUGOTHER) such as DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER);",ibuprofen,Daypro,False,Neg,0,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,6,26
2562,13200,13200,13484,13484,"- a DRUGOTHER (DRUGOTHER) such as DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), and DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER);",ibuprofen,Anaprox,False,Neg,0,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,6,29
2563,13201,13201,13485,13485,"- a DRUGOTHER (DRUGOTHER) such as DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), and DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER);",ibuprofen,Naprosyn,False,Neg,0,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,6,30
2564,13211,13211,13495,13495,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUG1 (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER);",ketoprofen,oxaprozin,False,Neg,0,[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,11,25
2565,13212,13212,13496,13496,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUG1 (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER);",ketoprofen,Daypro,False,Neg,0,[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,11,26
2566,13214,13214,13498,13498,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUG1 (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), and DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER);",ketoprofen,Anaprox,False,Neg,0,[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,11,29
2567,13215,13215,13499,13499,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUG1 (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), and DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER);",ketoprofen,Naprosyn,False,Neg,0,[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,11,30
2568,13224,13224,13508,13508,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUG1, DRUG1 KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER);",Orudis,oxaprozin,False,Neg,0,CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,12,25
2569,13225,13225,13509,13509,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUG1, DRUG1 KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER);",Orudis,Daypro,False,Neg,0,CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,12,26
2570,13227,13227,13511,13511,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUG1, DRUG1 KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), and DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER);",Orudis,Anaprox,False,Neg,0,CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,12,29
2571,13228,13228,13512,13512,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUG1, DRUG1 KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), and DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER);",Orudis,Naprosyn,False,Neg,0,CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,12,30
2572,13236,13236,13520,13520,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUG1 (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER);",diclofenac,oxaprozin,False,Neg,0,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,16,25
2573,13237,13237,13521,13521,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUG1 (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER);",diclofenac,Daypro,False,Neg,0,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,16,26
2574,13239,13239,13523,13523,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUG1 (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), and DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER);",diclofenac,Anaprox,False,Neg,0,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,16,29
2575,13240,13240,13524,13524,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUG1 (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), and DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER);",diclofenac,Naprosyn,False,Neg,0,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,16,30
2576,13247,13247,13531,13531,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER);",etodolac,oxaprozin,False,Neg,0,CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,19,25
2577,13248,13248,13532,13532,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER);",etodolac,Daypro,False,Neg,0,CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,19,26
2578,13250,13250,13534,13534,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), and DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER);",etodolac,Anaprox,False,Neg,0,CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,19,29
2579,13251,13251,13535,13535,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), and DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER);",etodolac,Naprosyn,False,Neg,0,CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,19,30
2580,13257,13257,13541,13541,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER);",Lodine,oxaprozin,False,Neg,0,CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,20,25
2581,13258,13258,13542,13542,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER);",Lodine,Daypro,False,Neg,0,CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,20,26
2582,13260,13260,13544,13544,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), and DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER);",Lodine,Anaprox,False,Neg,0,CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,20,29
2583,13261,13261,13545,13545,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), and DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER);",Lodine,Naprosyn,False,Neg,0,CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,20,30
2584,13266,13266,13550,13550,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER);",indomethacin,oxaprozin,False,Neg,0,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,21,25
2585,13267,13267,13551,13551,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER);",indomethacin,Daypro,False,Neg,0,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,21,26
2586,13269,13269,13553,13553,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), and DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER);",indomethacin,Anaprox,False,Neg,0,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,21,29
2587,13270,13270,13554,13554,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), and DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER);",indomethacin,Naprosyn,False,Neg,0,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,21,30
2588,13274,13274,13558,13558,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER);",Indocin,oxaprozin,False,Neg,0,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,22,25
2589,13275,13275,13559,13559,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER);",Indocin,Daypro,False,Neg,0,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,22,26
2590,13277,13277,13561,13561,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), and DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER);",Indocin,Anaprox,False,Neg,0,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,22,29
2591,13278,13278,13562,13562,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), and DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER);",Indocin,Naprosyn,False,Neg,0,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,22,30
2592,13281,13281,13565,13565,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUG2 (DRUGOTHER), and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER);",nabumetone,oxaprozin,False,Neg,0,COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,23,25
2593,13282,13282,13566,13566,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUG2), and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER);",nabumetone,Daypro,False,Neg,0,COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,23,26
2594,13284,13284,13568,13568,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), and DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER);",nabumetone,Anaprox,False,Neg,0,COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,23,29
2595,13285,13285,13569,13569,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), and DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER);",nabumetone,Naprosyn,False,Neg,0,COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,23,30
2596,13287,13287,13571,13571,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUG2 (DRUGOTHER), and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER);",Relafen,oxaprozin,False,Neg,0,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,24,25
2597,13288,13288,13572,13572,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUG2), and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER);",Relafen,Daypro,False,Neg,0,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,24,26
2598,13290,13290,13574,13574,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), and DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER);",Relafen,Anaprox,False,Neg,0,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,24,29
2599,13291,13291,13575,13575,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), and DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER);",Relafen,Naprosyn,False,Neg,0,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,24,30
2600,13294,13294,13578,13578,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), and DRUG2 (DRUGOTHER, DRUGOTHER, DRUGOTHER);",oxaprozin,naproxen,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,25,28
2601,13297,13297,13581,13581,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2);",oxaprozin,Aleve,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O,25,31
2602,13298,13298,13582,13582,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), and DRUG2 (DRUGOTHER, DRUGOTHER, DRUGOTHER);",Daypro,naproxen,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,26,28
2603,13301,13301,13585,13585,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2);",Daypro,Aleve,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O,26,31
2604,13302,13302,13586,13586,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), and DRUG1 (DRUG2, DRUGOTHER, DRUGOTHER);",naproxen,Anaprox,False,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,28,29
2605,13303,13303,13587,13587,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), and DRUG1 (DRUGOTHER, DRUG2, DRUGOTHER);",naproxen,Naprosyn,False,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,28,30
2606,13306,13306,13590,13590,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), and DRUGOTHER (DRUG1, DRUGOTHER, DRUG2);",Anaprox,Aleve,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O,29,31
2607,13307,13307,13591,13591,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), and DRUGOTHER (DRUGOTHER, DRUG1, DRUG2);",Naprosyn,Aleve,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O,30,31
2608,13385,13385,13669,13669,"- a DRUG1 (water pill) such as DRUG2 (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), and others;",diuretic,hydrochlorothiazide,False,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,2,7
2609,13390,13390,13674,13674,"- a DRUGOTHER (water pill) such as DRUG1 (DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER), and others;",hydrochlorothiazide,HCTZ,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1,7,8
2610,13391,13391,13675,13675,"- a DRUGOTHER (water pill) such as DRUG1 (DRUGOTHER, DRUG2), DRUGOTHER (DRUGOTHER), and others;",hydrochlorothiazide,Hydrodiuril,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1,7,9
2611,13392,13392,13676,13676,"- a DRUGOTHER (water pill) such as DRUG1 (DRUGOTHER, DRUGOTHER), DRUG2 (DRUGOTHER), and others;",hydrochlorothiazide,chlorothiazide,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1,7,10
2612,13393,13393,13677,13677,"- a DRUGOTHER (water pill) such as DRUG1 (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUG2), and others;",hydrochlorothiazide,Diuril,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1,7,11
2613,13431,13431,13715,13715,"- a DRUG1 such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), and others;",phenothiazine,Prolixin,False,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,2,8
2614,13439,13439,13723,13723,"- a DRUGOTHER such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), and others;",chlorpromazine,Prolixin,False,Neg,0,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,5,8
2615,13446,13446,13730,13730,"- a DRUGOTHER such as DRUGOTHER (DRUG1), DRUGOTHER (DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), and others;",Thorazine,Prolixin,False,Neg,0,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,6,8
2616,13452,13452,13736,13736,"- a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), and others;",fluphenazine,Prolixin,False,Neg,0,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,7,8
2617,13458,13458,13742,13742,"- a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1, DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), and others;",Prolixin,Permitil,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1,8,9
2618,13459,13459,13743,13743,"- a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1, DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), and others;",Prolixin,prochlorperazine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1,8,10
2619,13460,13460,13744,13744,"- a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1, DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), and others;",Prolixin,Compazine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1,8,11
2620,13461,13461,13745,13745,"- a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), and others;",Prolixin,promethazine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,8,12
2621,13462,13462,13746,13746,"- a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), and others;",Prolixin,Phenergan,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,8,13
2622,13480,13480,13764,13764,"Immediate and Extended Release Tablets The hypoglycemic action of DRUG1 may be potentiated by certain drugs including DRUGOTHER, some DRUGOTHER and other drugs that are highly protein bound, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",sulfonylureas,sulfonamides,True,effect,2,NC(N)=O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,9,29
2623,13487,13487,13771,13771,"Immediate and Extended Release Tablets The hypoglycemic action of DRUGOTHER may be potentiated by certain drugs including DRUG1, some DRUGOTHER and other drugs that are highly protein bound, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",nonsteroidal anti-inflammatory agents,sulfonamides,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,17,29
2624,13493,13493,13777,13777,"Immediate and Extended Release Tablets The hypoglycemic action of DRUGOTHER may be potentiated by certain drugs including DRUGOTHER, some DRUGOTHER and other drugs that are highly protein bound, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",salicylates,sulfonamides,False,Neg,0,CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,28,29
2625,13499,13499,13783,13783,"Immediate and Extended Release Tablets The hypoglycemic action of DRUGOTHER may be potentiated by certain drugs including DRUGOTHER, some DRUGOTHER and other drugs that are highly protein bound, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",sulfonamides,chloramphenicol,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O,29,30
2626,13500,13500,13784,13784,"Immediate and Extended Release Tablets The hypoglycemic action of DRUGOTHER may be potentiated by certain drugs including DRUGOTHER, some DRUGOTHER and other drugs that are highly protein bound, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",sulfonamides,probenecid,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,29,31
2627,13501,13501,13785,13785,"Immediate and Extended Release Tablets The hypoglycemic action of DRUGOTHER may be potentiated by certain drugs including DRUGOTHER, some DRUGOTHER and other drugs that are highly protein bound, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",sulfonamides,coumarins,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,O=C1OC2=CC=CC=C2C=C1,29,32
2628,13502,13502,13786,13786,"Immediate and Extended Release Tablets The hypoglycemic action of DRUGOTHER may be potentiated by certain drugs including DRUGOTHER, some DRUGOTHER and other drugs that are highly protein bound, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",sulfonamides,monoamine oxidase inhibitors,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,OC(=O)CCCCCCCC(O)=O,29,33
2629,13503,13503,13787,13787,"Immediate and Extended Release Tablets The hypoglycemic action of DRUGOTHER may be potentiated by certain drugs including DRUGOTHER, some DRUGOTHER and other drugs that are highly protein bound, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",sulfonamides,beta adrenergic blocking agents,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,29,35
2630,13514,13514,13798,13798,In vitro binding studies with human serum proteins indicate that DRUG1 binds differently than DRUG2 and does not interact with DRUGOTHER or DRUGOTHER.,glipizide,tolbutamide,False,Neg,0,CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,10,14
2631,13515,13515,13799,13799,In vitro binding studies with human serum proteins indicate that DRUG1 binds differently than DRUGOTHER and does not interact with DRUG2 or DRUGOTHER.,glipizide,salicylate,False,Neg,0,CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,C1=CC=C(C(=C1)C(=O)O)[O-],10,20
2632,13516,13516,13800,13800,In vitro binding studies with human serum proteins indicate that DRUG1 binds differently than DRUGOTHER and does not interact with DRUGOTHER or DRUG2.,glipizide,dicumarol,False,Neg,0,CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2,10,22
2633,13520,13520,13804,13804,"These drugs include the DRUG1 and other DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",thiazides,diuretics,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,4,7
2634,13521,13521,13805,13805,"These drugs include the DRUG1 and other DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",thiazides,corticosteroids,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,4,8
2635,13522,13522,13806,13806,"These drugs include the DRUG1 and other DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",thiazides,phenothiazines,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,N1C2=CC=CC=C2SC2=CC=CC=C12,4,9
2636,13523,13523,13807,13807,"These drugs include the DRUG1 and other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",thiazides,estrogens,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)OS(=O)(=O)[O-])[C@@H]1CCC2=O.[Na+],4,11
2637,13524,13524,13808,13808,"These drugs include the DRUG1 and other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",thiazides,contraceptives,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,4,13
2638,13526,13526,13810,13810,"These drugs include the DRUG1 and other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",thiazides,nicotinic acid,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1,4,15
2639,13527,13527,13811,13811,"These drugs include the DRUG1 and other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",thiazides,isoniazid,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O,4,19
2640,13532,13532,13816,13816,"These drugs include the DRUGOTHER and other DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",diuretics,phenytoin,False,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,7,14
2641,13538,13538,13822,13822,"These drugs include the DRUGOTHER and other DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",corticosteroids,phenytoin,False,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,8,14
2642,13543,13543,13827,13827,"These drugs include the DRUGOTHER and other DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",phenothiazines,phenytoin,False,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,9,14
2643,13547,13547,13831,13831,"These drugs include the DRUGOTHER and other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, oral DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",estrogens,phenytoin,False,Neg,0,C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)OS(=O)(=O)[O-])[C@@H]1CCC2=O.[Na+],C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,11,14
2644,13550,13550,13834,13834,"These drugs include the DRUGOTHER and other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",contraceptives,phenytoin,False,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,13,14
2645,13553,13553,13837,13837,"These drugs include the DRUGOTHER and other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",phenytoin,nicotinic acid,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1,14,15
2646,13554,13554,13838,13838,"These drugs include the DRUGOTHER and other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",phenytoin,isoniazid,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O,14,19
2647,13557,13557,13841,13841,The effect of concomitant administration of DRUG1 and DRUG2 has been demonstrated in a placebo-controlled crossover study in normal volunteers.,fluconazole,glipizide,True,int,3,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,6,8
2648,13558,13558,13842,13842,All subjects received DRUG1 alone and following treatment with 100 mg of DRUG2 as a single daily oral dose for seven days.,glipizide,fluconazole,False,Neg,0,CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,3,12
2649,13559,13559,13843,13843,The mean percentage increase in the DRUG1 AUC after DRUG2 administration was 56.9% (range: 35 to 81).,glipizide,fluconazole,True,mechanism,4,CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,6,9
2650,13569,13569,13853,13853,"The gonadotropin levels may be transiently elevated by DRUG1, minimally elevated by DRUG2, and suppressed by oral DRUGOTHER and DRUGOTHER.",spironolactone,levodopa,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O,8,12
2651,13570,13570,13854,13854,"The gonadotropin levels may be transiently elevated by DRUG1, minimally elevated by DRUGOTHER, and suppressed by oral DRUG2 and DRUGOTHER.",spironolactone,contraceptives,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,8,17
2652,13571,13571,13855,13855,"The gonadotropin levels may be transiently elevated by DRUG1, minimally elevated by DRUGOTHER, and suppressed by oral DRUGOTHER and DRUG2.",spironolactone,digoxin,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,8,19
2653,13590,13590,13874,13874,"DRUG1 DRUGOTHER DRUG2, like other DRUGOTHER, may inhibit the metabolism of DRUGOTHER and DRUGOTHER.",Caffeine,Grepafloxacin,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O,0,2
2654,13593,13593,13877,13877,"DRUGOTHER DRUG1 DRUG2, like other DRUGOTHER, may inhibit the metabolism of DRUGOTHER and DRUGOTHER.",Theobromine,Grepafloxacin,False,Neg,0,CN1C=NC2=C1C(=O)NC(=O)N2C,CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O,1,2
2655,13596,13596,13880,13880,"DRUGOTHER DRUGOTHER DRUG1, like other DRUGOTHER, may inhibit the metabolism of DRUG2 and DRUGOTHER.",Grepafloxacin,caffeine,True,mechanism,4,CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,2,11
2656,13597,13597,13881,13881,"DRUGOTHER DRUGOTHER DRUG1, like other DRUGOTHER, may inhibit the metabolism of DRUGOTHER and DRUG2.",Grepafloxacin,theobromine,True,mechanism,4,CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O,CN1C=NC2=C1C(=O)NC(=O)N2C,2,13
2657,13600,13600,13884,13884,DRUG1: DRUG2 is a competitive inhibitor of the metabolism of DRUGOTHER.,Theophylline,Grepafloxacin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O,0,1
2658,13602,13602,13886,13886,DRUGOTHER: DRUG1 is a competitive inhibitor of the metabolism of DRUG2.,Grepafloxacin,theophylline,True,mechanism,4,CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,1,10
2659,13603,13603,13887,13887,Serum DRUG1 concentrations increase when DRUG2 is initiated in a patient maintained on DRUG1.,theophylline,grepafloxacin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O,1,5
2660,13605,13605,13889,13889,Serum DRUG2 concentrations increase when DRUG1 is initiated in a patient maintained on DRUG2.,grepafloxacin,theophylline,True,mechanism,4,CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,5,1
2661,13606,13606,13890,13890,"When initiating a multi-day course of DRUG1 in a patient maintained on DRUG2, the DRUG2 maintenance dose should be halved for the period of concurrent use of DRUG1 and monitoring of serum DRUG2 concentrations should be initiated as a guide to further dosage adjustments.",grepafloxacin,theophylline,False,Neg,0,CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,6,12
2662,13607,13607,13891,13891,"When initiating a multi-day course of DRUG1 in a patient maintained on DRUG2, the DRUG2 maintenance dose should be halved for the period of concurrent use of DRUG1 and monitoring of serum DRUG2 concentrations should be initiated as a guide to further dosage adjustments.",grepafloxacin,theophylline,False,Neg,0,CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,6,12
2663,13609,13609,13893,13893,"When initiating a multi-day course of DRUG1 in a patient maintained on DRUG2, the DRUG2 maintenance dose should be halved for the period of concurrent use of DRUG1 and monitoring of serum DRUG2 concentrations should be initiated as a guide to further dosage adjustments.",grepafloxacin,theophylline,False,Neg,0,CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,6,12
2664,13611,13611,13895,13895,"When initiating a multi-day course of DRUG2 in a patient maintained on DRUG1, the DRUG1 maintenance dose should be halved for the period of concurrent use of DRUG2 and monitoring of serum DRUG1 concentrations should be initiated as a guide to further dosage adjustments.",theophylline,grepafloxacin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O,12,6
2665,13613,13613,13897,13897,"When initiating a multi-day course of DRUG2 in a patient maintained on DRUG1, the DRUG1 maintenance dose should be halved for the period of concurrent use of DRUG2 and monitoring of serum DRUG1 concentrations should be initiated as a guide to further dosage adjustments.",theophylline,grepafloxacin,True,advise,1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O,12,6
2666,13615,13615,13899,13899,"When initiating a multi-day course of DRUG1 in a patient maintained on DRUG2, the DRUG2 maintenance dose should be halved for the period of concurrent use of DRUG1 and monitoring of serum DRUG2 concentrations should be initiated as a guide to further dosage adjustments.",grepafloxacin,theophylline,False,Neg,0,CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,6,12
2667,13622,13622,13906,13906,"Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of DRUG1 on DRUG2 indicates that DRUG1 inhibits DRUG2 metabolism, which is mediated by CYP1A2.",grepafloxacin,theophylline,False,Neg,0,CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,14,16
2668,13624,13624,13908,13908,"Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of DRUG1 on DRUG2 indicates that DRUG1 inhibits DRUG2 metabolism, which is mediated by CYP1A2.",grepafloxacin,theophylline,False,Neg,0,CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,14,16
2669,13625,13625,13909,13909,"Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of DRUG2 on DRUG1 indicates that DRUG2 inhibits DRUG1 metabolism, which is mediated by CYP1A2.",theophylline,grepafloxacin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O,16,14
2670,13627,13627,13911,13911,"Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of DRUG1 on DRUG2 indicates that DRUG1 inhibits DRUG2 metabolism, which is mediated by CYP1A2.",grepafloxacin,theophylline,True,mechanism,4,CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,14,16
2671,13628,13628,13912,13912,"substrates, in vitro data suggest similar effects of DRUG1 in CYP3A4 mediated metabolism and DRUG2 metabolism.",grepafloxacin,theophylline,False,Neg,0,CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,8,14
2672,13647,13647,13931,13931,Serious toxicity may result if DRUG1 is coadministered with DRUG2 (DRUGOTHER).,dextromethorphan,monoamine oxidase inhibitors,True,effect,2,[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C,OC(=O)CCCCCCCC(O)=O,5,9
2673,13648,13648,13932,13932,"The use of DRUG1 may result in additive CNS depressant effects when coadministered with DRUG2, DRUGOTHER, DRUGOTHER or other drugs that produce CNS depression.",dextromethorphan hydrobromide,alcohol,True,effect,2,[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C,CCO,3,14
2674,13649,13649,13933,13933,"The use of DRUG1 may result in additive CNS depressant effects when coadministered with DRUGOTHER, DRUG2, DRUGOTHER or other drugs that produce CNS depression.",dextromethorphan hydrobromide,antihistamines,True,effect,2,[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C,NCCC1=CNC=N1,3,15
2675,13651,13651,13935,13935,The potential for increased sedation when DRUG1 is given with other DRUG2 should be appreciated.,guanfacine,CNS-depressant drug,True,effect,2,OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,6,11
2676,13653,13653,13937,13937,The administration of DRUG1 concomitantly with known microsomal enzyme inducer (DRUGOTHER or DRUG2) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.,guanfacine,phenytoin,True,mechanism,4,OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,3,12
2677,13654,13654,13938,13938,The administration of DRUGOTHER concomitantly with known microsomal enzyme inducer (DRUG1 or DRUG2) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.,phenobarbital,phenytoin,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,10,12
2678,13660,13660,13947,13947,"As with other DRUG1, it should be noted that DRUGOTHER may be capable of potentiating DRUG2 such as DRUGOTHER, DRUGOTHER, and DRUGOTHER.",antipsychotic agents,CNS depressants,True,effect,2,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,3,15
2679,13663,13663,13950,13950,"As with other DRUGOTHER, it should be noted that DRUG1 may be capable of potentiating DRUG2 such as DRUGOTHER, DRUGOTHER, and DRUGOTHER.",HALDOL,CNS depressants,True,effect,2,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,9,15
2680,13666,13666,13953,13953,"As with other DRUGOTHER, it should be noted that DRUGOTHER may be capable of potentiating DRUG1 such as DRUG2, DRUGOTHER, and DRUGOTHER.",CNS depressants,anesthetics,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCOC(=O)C1=CC=C(N)C=C1,15,18
2681,13667,13667,13954,13954,"As with other DRUGOTHER, it should be noted that DRUGOTHER may be capable of potentiating DRUG1 such as DRUGOTHER, DRUGOTHER, and DRUG2.",CNS depressants,alcohol,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCO,15,21
2682,13669,13669,13956,13956,"In a study of 12 schizophrenic patients coadministered oral DRUG1 and DRUG2, plasma DRUG1 levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.",haloperidol,rifampin,True,mechanism,4,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,9,11
2683,13671,13671,13958,13958,"In a study of 12 schizophrenic patients coadministered oral DRUG2 and DRUG1, plasma DRUG2 levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.",rifampin,haloperidol,False,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,11,9
2684,13672,13672,13959,13959,"In 5 other schizophrenic patients treated with oral DRUG1 and DRUG2, discontinuation of DRUG2 produced a mean 3.3-fold increase in DRUG1 concentrations.",haloperidol,rifampin,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,8,10
2685,13673,13673,13960,13960,"In 5 other schizophrenic patients treated with oral DRUG1 and DRUG2, discontinuation of DRUG2 produced a mean 3.3-fold increase in DRUG1 concentrations.",haloperidol,rifampin,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,8,10
2686,13676,13676,13963,13963,"In 5 other schizophrenic patients treated with oral DRUG2 and DRUG1, discontinuation of DRUG1 produced a mean 3.3-fold increase in DRUG2 concentrations.",rifampin,haloperidol,False,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,10,8
2687,13677,13677,13964,13964,"In 5 other schizophrenic patients treated with oral DRUG2 and DRUG1, discontinuation of DRUG1 produced a mean 3.3-fold increase in DRUG2 concentrations.",rifampin,haloperidol,True,mechanism,4,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,10,8
2688,13678,13678,13965,13965,"Thus, careful monitoring of clinical status is warranted when DRUG1 is administered or discontinued in DRUG2-treated patients.",rifampin,haloperidol,True,advise,1,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,9,15
2689,13683,13683,13970,13970,"Caution should also be applied for other DRUGOTHER, and for DRUG1 and DRUG2 and DRUGOTHER, which may also precipitate arrhythmias.",aminophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,10,12
2690,13685,13685,13972,13972,"Caution should also be applied for other DRUGOTHER, and for DRUGOTHER and DRUG1 and DRUG2, which may also precipitate arrhythmias.",theophylline,tricyclic antidepressants,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,12,14
2691,13686,13686,13973,13973,Drug Interactions: a. Drugs Enhancing DRUG1 Effect: Oral DRUGOTHER: DRUG1 sodium may prolong the one-stage prothrombin time.,Heparin,Heparin sodium,False,Neg,0,[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O,[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C=O,5,-1
2692,13711,13711,13998,13998,"Drugs Decreasing DRUG1 Effect: DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER may partially counteract the anticoagulant action of DRUGOTHER.",Heparin,Digitalis,False,Neg,0,[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,2,4
2693,13712,13712,13999,13999,"Drugs Decreasing DRUG1 Effect: DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER may partially counteract the anticoagulant action of DRUGOTHER.",Heparin,tetracyclines,False,Neg,0,[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O,[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O,2,5
2694,13713,13713,14000,14000,"Drugs Decreasing DRUG1 Effect: DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER may partially counteract the anticoagulant action of DRUGOTHER.",Heparin,nicotine,False,Neg,0,[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O,CN1CCC[C@H]1C2=CN=CC=C2,2,6
2695,13714,13714,14001,14001,"Drugs Decreasing DRUG1 Effect: DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2 may partially counteract the anticoagulant action of DRUGOTHER.",Heparin,antihistamines,False,Neg,0,[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O,NCCC1=CNC=N1,2,8
2696,13715,13715,14002,14002,"Drugs Decreasing DRUG1 Effect: DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER may partially counteract the anticoagulant action of DRUG2.",Heparin,heparin sodium,False,Neg,0,[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O,[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C=O,2,16
2697,13768,13768,14055,14055,"DRUG1 may decrease the effectiveness of oral DRUGOTHER, certain DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",Barbiturates,theophylline,True,effect,2,CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,11
2698,13772,13772,14059,14059,"DRUGOTHER may decrease the effectiveness of oral DRUG1, certain DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",contraceptives,theophylline,False,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,CN1C2=C(C(=O)N(C1=O)C)NC=N2,7,11
2699,13775,13775,14062,14062,"DRUGOTHER may decrease the effectiveness of oral DRUGOTHER, certain DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",antibiotics,theophylline,False,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,9,11
2700,13777,13777,14064,14064,"DRUGOTHER may decrease the effectiveness of oral DRUGOTHER, certain DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",quinidine,theophylline,False,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,10,11
2701,13779,13779,14066,14066,"DRUGOTHER may decrease the effectiveness of oral DRUGOTHER, certain DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER.",theophylline,corticosteroids,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,11,12
2702,13780,13780,14067,14067,DRUG1 should be used with caution in patients receiving DRUG2.,MAO inhibitors,hydralazine,True,advise,1,CN(CC#C)CC1=CC=CC=C1,C1=CC=C2C(=C1)C=NN=C2NN,0,9
2703,13782,13782,14069,14069,"When other potent parental DRUG1, such as DRUGOTHER, are used in combination with DRUG2, patients should be continuously observed for several hours for any excessive fall in blood pressure.",antihypertensive drugs,hydralazine,True,effect,2,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,C1=CC=C2C(=C1)C=NN=C2NN,4,13
2704,13783,13783,14070,14070,"When other potent parental DRUGOTHER, such as DRUG1, are used in combination with DRUG2, patients should be continuously observed for several hours for any excessive fall in blood pressure.",diazoxide,hydralazine,False,Neg,0,CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl,C1=CC=C2C(=C1)C=NN=C2NN,7,13
2705,13784,13784,14071,14071,Profound hypotensive episodes may occur when DRUG1 infection and DRUG2 are used concomitantly.,diazoxide,hydralazine,True,effect,2,CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl,C1=CC=C2C(=C1)C=NN=C2NN,6,9
2706,13786,13786,14073,14073,DRUG1 increases DRUG2s serum concentrations.,Propranolol,hydralazine,True,mechanism,4,CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2,C1=CC=C2C(=C1)C=NN=C2NN,0,2
2707,13791,13791,14080,14080,DRUG1 and DRUGOTHER DRUGOTHER: Absorption of DRUG2 is impaired in the presence of anionic exchange DRUGOTHER.,Cholestyramine,hydrochlorothiazide,False,Neg,0,CCC1=CC=C(C=C1)C(C)CCC2=CC=C(C=C2)[N+](C)(C)C,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,0,6
2708,13792,13792,14081,14081,"Single doses of either DRUG1 or DRUGOTHER DRUGOTHER bind the DRUG2 and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.",cholestyramine,hydrochlorothiazide,True,mechanism,4,CCC1=CC=C(C=C1)C(C)CCC2=CC=C(C=C2)[N+](C)(C)C,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,4,10
2709,13795,13795,14084,14084,"Therefore, when DRUG1 and DRUG2 are used concomitantly, the patient should be observed closely to determine if the desired effect of the DRUGOTHER is obtained.",Hydrochlorothiazide,non-steroidal anti-inflammatory agents,True,advise,1,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,2,4
2710,13796,13796,14085,14085,"Therefore, when DRUG1 and DRUGOTHER are used concomitantly, the patient should be observed closely to determine if the desired effect of the DRUG2 is obtained.",Hydrochlorothiazide,diuretic,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,2,22
2711,13799,13799,14088,14088,"Patients receiving other DRUG1, DRUGOTHER, DRUGOTHER, or other DRUG2 (including DRUGOTHER) concomitantly with DRUGOTHER and DRUGOTHER tablets may exhibit an additive CNS depression.",narcotic analgesics,CNS depressants,False,Neg,0,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,3,8
2712,13803,13803,14092,14092,"Patients receiving other DRUGOTHER, DRUGOTHER, DRUG1, or other DRUG2 (including DRUGOTHER) concomitantly with DRUGOTHER and DRUGOTHER tablets may exhibit an additive CNS depression.",antianxiety agents,CNS depressants,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,5,8
2713,13807,13807,14096,14096,"Patients receiving other DRUGOTHER, DRUGOTHER, DRUGOTHER, or other DRUG1 (including DRUG2) concomitantly with DRUGOTHER and DRUGOTHER tablets may exhibit an additive CNS depression.",CNS depressants,alcohol,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCO,8,10
2714,13808,13808,14097,14097,"Patients receiving other DRUGOTHER, DRUGOTHER, DRUGOTHER, or other DRUG1 (including DRUGOTHER) concomitantly with DRUG2 and DRUGOTHER tablets may exhibit an additive CNS depression.",CNS depressants,hydrocodone,True,effect,2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O,8,13
2715,13809,13809,14098,14098,"Patients receiving other DRUGOTHER, DRUGOTHER, DRUGOTHER, or other DRUG1 (including DRUGOTHER) concomitantly with DRUGOTHER and DRUG2 tablets may exhibit an additive CNS depression.",CNS depressants,acetaminophen,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(=O)NC1=CC=C(C=C1)O,8,15
2716,13828,13828,14117,14117,(DRUG1 may decrease arterial responsiveness to DRUG2.,Thiazides,norepinephrine,True,effect,2,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,C1=CC(=C(C=C1[C@H](CN)O)O)O,0,6
2717,13833,13833,14122,14122,"Patients receiving other DRUG1s, general DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or other DRUG2 (including DRUGOTHER) concomitantly with DRUGOTHER may exhibit an additive CNS depression.",narcotic analgesic,CNS depressants,False,Neg,0,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,3,12
2718,13839,13839,14128,14128,"Patients receiving other DRUGOTHERs, general DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or other DRUG2 (including DRUGOTHER) concomitantly with DRUGOTHER may exhibit an additive CNS depression.",anesthetics,CNS depressants,False,Neg,0,CCOC(=O)C1=CC=C(N)C=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,5,12
2719,13844,13844,14133,14133,"Patients receiving other DRUGOTHERs, general DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER or other DRUG2 (including DRUGOTHER) concomitantly with DRUGOTHER may exhibit an additive CNS depression.",phenothiazines,CNS depressants,False,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,6,12
2720,13848,13848,14137,14137,"Patients receiving other DRUGOTHERs, general DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER or other DRUG2 (including DRUGOTHER) concomitantly with DRUGOTHER may exhibit an additive CNS depression.",tranquilizers,CNS depressants,False,Neg,0,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,7,12
2721,13851,13851,14140,14140,"Patients receiving other DRUGOTHERs, general DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 or other DRUG2 (including DRUGOTHER) concomitantly with DRUGOTHER may exhibit an additive CNS depression.",tricyclic antidepressants,CNS depressants,False,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,9,12
2722,13854,13854,14143,14143,"Patients receiving other DRUGOTHERs, general DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or other DRUG1 (including DRUG2) concomitantly with DRUGOTHER may exhibit an additive CNS depression.",CNS depressants,alcohol,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCO,12,14
2723,13855,13855,14144,14144,"Patients receiving other DRUGOTHERs, general DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or other DRUG1 (including DRUGOTHER) concomitantly with DRUG2 may exhibit an additive CNS depression.",CNS depressants,DILAUDID,True,effect,2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O,12,17
2724,13868,13868,14157,14157,"Patients should be advised against the simultaneous use of other DRUG1, and cautioned that the effect of DRUG2 may be increased.",CNS depressant drugs,alcohol,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCO,10,17
2725,13871,13871,14160,14160,"Additive adverse effects resulting from cholinergic blockade may occur when DRUG1 is administered concomitantly with other DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER or some DRUGOTHER.",LEVSIN,haloperidol,True,effect,2,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,10,18
2726,13877,13877,14166,14166,"Additive adverse effects resulting from cholinergic blockade may occur when DRUGOTHER is administered concomitantly with other DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER or some DRUGOTHER.",antimuscarinics,haloperidol,False,Neg,0,NC(=O)NC1NC(=O)NC1=O,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,16,18
2727,13882,13882,14171,14171,"Additive adverse effects resulting from cholinergic blockade may occur when DRUGOTHER is administered concomitantly with other DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER or some DRUGOTHER.",amantadine,haloperidol,False,Neg,0,C1C2CC3CC1CC(C2)(C3)N,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,17,18
2728,13887,13887,14176,14176,"Additive adverse effects resulting from cholinergic blockade may occur when DRUGOTHER is administered concomitantly with other DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER or some DRUGOTHER.",haloperidol,phenothiazines,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,N1C2=CC=CC=C2SC2=CC=CC=C12,18,19
2729,13888,13888,14177,14177,"Additive adverse effects resulting from cholinergic blockade may occur when DRUGOTHER is administered concomitantly with other DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER or some DRUGOTHER.",haloperidol,monoamine oxidase (MAO) inhibitors,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,OC(=O)CCCCCCCC(O)=O,18,20
2730,13889,13889,14178,14178,"Additive adverse effects resulting from cholinergic blockade may occur when DRUGOTHER is administered concomitantly with other DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2 or some DRUGOTHER.",haloperidol,tricyclic antidepressants,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,18,21
2731,13890,13890,14179,14179,"Additive adverse effects resulting from cholinergic blockade may occur when DRUGOTHER is administered concomitantly with other DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER or some DRUG2.",haloperidol,antihistamines,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,NCCC1=CNC=N1,18,24
2732,13933,13933,14222,14222,"DRUG1: Clinical studies, as well as random observations, have shown that DRUG2 can reduce the natriuretic effect of DRUGOTHER and DRUGOTHER in some patients.",Furosemide,ibuprofen,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,0,11
2733,13936,13936,14225,14225,"DRUGOTHER: Clinical studies, as well as random observations, have shown that DRUG1 can reduce the natriuretic effect of DRUG2 and DRUGOTHER in some patients.",ibuprofen,furosemide,True,effect,2,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,11,18
2734,13937,13937,14226,14226,"DRUGOTHER: Clinical studies, as well as random observations, have shown that DRUG1 can reduce the natriuretic effect of DRUGOTHER and DRUG2 in some patients.",ibuprofen,thiazides,True,effect,2,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,11,20
2735,13961,13961,14250,14250,DRUG1: No human drug interaction studies with DRUG2 were conducted.,Heparin,heparin,False,Neg,0,[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,0,7
2736,13964,13964,14253,14253,"In vitro studies evaluating the minimum inhibitory concentration (MIC) of DRUG1, DRUG2, DRUGOTHER, DRUGOTHER/flucoxacillin, DRUGOTHER, DRUGOTHER, and DRUGOTHER demonstrated no evidence of incompatibility of these DRUGOTHER with DRUGOTHER.",vancomycin,cefazolin,False,Neg,0,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,CC(=O)NC1=NN=C(S1)S(N)(=O)=O,10,11
2737,13965,13965,14254,14254,"In vitro studies evaluating the minimum inhibitory concentration (MIC) of DRUG1, DRUGOTHER, DRUG2, DRUG2/flucoxacillin, DRUGOTHER, DRUGOTHER, and DRUGOTHER demonstrated no evidence of incompatibility of these DRUGOTHER with DRUGOTHER.",vancomycin,ampicillin,False,Neg,0,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C,10,12
2738,13966,13966,14255,14255,"In vitro studies evaluating the minimum inhibitory concentration (MIC) of DRUG1, DRUGOTHER, DRUG2, DRUG2/flucoxacillin, DRUGOTHER, DRUGOTHER, and DRUGOTHER demonstrated no evidence of incompatibility of these DRUGOTHER with DRUGOTHER.",vancomycin,ampicillin,False,Neg,0,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C,10,12
2739,13967,13967,14256,14256,"In vitro studies evaluating the minimum inhibitory concentration (MIC) of DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER/flucoxacillin, DRUG2, DRUGOTHER, and DRUGOTHER demonstrated no evidence of incompatibility of these DRUGOTHER with DRUGOTHER.",vancomycin,ceftazidime,False,Neg,0,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,[H][C@](C=O)(N=C(O)C(=N/OC(C)(C)C(O)=O)\C1=CSC(=N)N1)[C@@]1([H])SCC(=C)C(=N1)C(O)=O,10,14
2740,13968,13968,14257,14257,"In vitro studies evaluating the minimum inhibitory concentration (MIC) of DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER/flucoxacillin, DRUGOTHER, DRUG2, and DRUGOTHER demonstrated no evidence of incompatibility of these DRUGOTHER with DRUGOTHER.",vancomycin,gentamicin,False,Neg,0,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC,10,15
2741,13969,13969,14258,14258,"In vitro studies evaluating the minimum inhibitory concentration (MIC) of DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER/flucoxacillin, DRUGOTHER, DRUGOTHER, and DRUG2 demonstrated no evidence of incompatibility of these DRUGOTHER with DRUGOTHER.",vancomycin,amphotericin,False,Neg,0,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1,10,17
2742,13970,13970,14259,14259,"In vitro studies evaluating the minimum inhibitory concentration (MIC) of DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER/flucoxacillin, DRUGOTHER, DRUGOTHER, and DRUGOTHER demonstrated no evidence of incompatibility of these DRUG2 with DRUGOTHER.",vancomycin,antibiotics,False,Neg,0,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,10,25
2743,13971,13971,14260,14260,"In vitro studies evaluating the minimum inhibitory concentration (MIC) of DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER/flucoxacillin, DRUGOTHER, DRUGOTHER, and DRUGOTHER demonstrated no evidence of incompatibility of these DRUGOTHER with DRUG2.",vancomycin,EXTRANEAL,False,Neg,0,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,[Mg++].[Cl-].[Cl-],10,27
2744,14007,14007,14301,14301,"In studies in normal volunteers, there was no pharmacodynamic interaction between intravenous DRUGOTHER and either DRUG1, DRUGOTHER, or DRUG2.",nifedipine,captopril,False,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,15,18
2745,14008,14008,14302,14302,"In studies in normal volunteers, there was no pharmacodynamic interaction between intravenous DRUGOTHER and either DRUGOTHER, DRUG1, or DRUG2.",diltiazem,captopril,False,Neg,0,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,16,18
2746,14014,14014,14308,14308,"Drugs that may alter DRUG1 plasma concentrations Drugs that may increase DRUG1 plasma concentrations: Caution is recommended when administering DRUGOTHER with inhibitors of the CYP3A4 family (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER).",imatinib,ketoconazole,False,Neg,0,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,4,27
2747,14015,14015,14309,14309,"Drugs that may alter DRUG1 plasma concentrations Drugs that may increase DRUG1 plasma concentrations: Caution is recommended when administering DRUGOTHER with inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER).",imatinib,itraconazole,False,Neg,0,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,4,28
2748,14016,14016,14310,14310,"Drugs that may alter DRUG1 plasma concentrations Drugs that may increase DRUG1 plasma concentrations: Caution is recommended when administering DRUGOTHER with inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER).",imatinib,erythromycin,False,Neg,0,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,4,29
2749,14017,14017,14311,14311,"Drugs that may alter DRUG1 plasma concentrations Drugs that may increase DRUG1 plasma concentrations: Caution is recommended when administering DRUGOTHER with inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2).",imatinib,clarithromycin,False,Neg,0,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,4,30
2750,14019,14019,14313,14313,"Drugs that may alter DRUG1 plasma concentrations Drugs that may increase DRUG1 plasma concentrations: Caution is recommended when administering DRUGOTHER with inhibitors of the CYP3A4 family (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER).",imatinib,ketoconazole,False,Neg,0,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,4,27
2751,14020,14020,14314,14314,"Drugs that may alter DRUG1 plasma concentrations Drugs that may increase DRUG1 plasma concentrations: Caution is recommended when administering DRUGOTHER with inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER).",imatinib,itraconazole,False,Neg,0,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,4,28
2752,14021,14021,14315,14315,"Drugs that may alter DRUG1 plasma concentrations Drugs that may increase DRUG1 plasma concentrations: Caution is recommended when administering DRUGOTHER with inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER).",imatinib,erythromycin,False,Neg,0,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,4,29
2753,14022,14022,14316,14316,"Drugs that may alter DRUG1 plasma concentrations Drugs that may increase DRUG1 plasma concentrations: Caution is recommended when administering DRUGOTHER with inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2).",imatinib,clarithromycin,False,Neg,0,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,4,30
2754,14023,14023,14317,14317,"Drugs that may alter DRUGOTHER plasma concentrations Drugs that may increase DRUGOTHER plasma concentrations: Caution is recommended when administering DRUG1 with inhibitors of the CYP3A4 family (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER).",Gleevec,ketoconazole,True,advise,1,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,19,27
2755,14024,14024,14318,14318,"Drugs that may alter DRUGOTHER plasma concentrations Drugs that may increase DRUGOTHER plasma concentrations: Caution is recommended when administering DRUG1 with inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER).",Gleevec,itraconazole,True,advise,1,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,19,28
2756,14025,14025,14319,14319,"Drugs that may alter DRUGOTHER plasma concentrations Drugs that may increase DRUGOTHER plasma concentrations: Caution is recommended when administering DRUG1 with inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER).",Gleevec,erythromycin,True,advise,1,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,19,29
2757,14026,14026,14320,14320,"Drugs that may alter DRUGOTHER plasma concentrations Drugs that may increase DRUGOTHER plasma concentrations: Caution is recommended when administering DRUG1 with inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2).",Gleevec,clarithromycin,True,advise,1,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,19,30
2758,14034,14034,14328,14328,There is a significant increase in exposure to DRUG1 when DRUGOTHER is coadministered with DRUG2 (CYP3A4 inhibitor).,imatinib,ketoconazole,False,Neg,0,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,8,14
2759,14035,14035,14329,14329,There is a significant increase in exposure to DRUGOTHER when DRUG1 is coadministered with DRUG2 (CYP3A4 inhibitor).,Gleevec,ketoconazole,True,mechanism,4,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,10,14
2760,14037,14037,14331,14331,"Co-medications that induce CYP3A4 (e.g., DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER or St.",dexamethasone,phenytoin,False,Neg,0,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,5,6
2761,14041,14041,14335,14335,"Co-medications that induce CYP3A4 (e.g., DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER or St.",phenytoin,carbamazepine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,6,7
2762,14042,14042,14336,14336,"Co-medications that induce CYP3A4 (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER or St.",phenytoin,rifampin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,6,8
2763,14043,14043,14337,14337,"Co-medications that induce CYP3A4 (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2 or St.",phenytoin,phenobarbital,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,6,9
2764,14047,14047,14341,14341,"Pretreatment of healthy volunteers with multiple doses of DRUG1 followed by a single dose of DRUG2, increased DRUG2 oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).",rifampin,Gleevec,True,mechanism,4,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,8,15
2765,14048,14048,14342,14342,"Pretreatment of healthy volunteers with multiple doses of DRUG1 followed by a single dose of DRUG2, increased DRUG2 oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).",rifampin,Gleevec,False,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,8,15
2766,14051,14051,14345,14345,"Drugs that may have their plasma concentration altered by DRUG1 DRUG1 increases the mean cmax and AUC of DRUG2 (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by DRUG1.",Gleevec,simvastatin,False,Neg,0,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,9,18
2767,14053,14053,14347,14347,"Drugs that may have their plasma concentration altered by DRUG1 DRUG1 increases the mean cmax and AUC of DRUG2 (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by DRUG1.",Gleevec,simvastatin,True,mechanism,4,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,9,18
2768,14055,14055,14349,14349,"Drugs that may have their plasma concentration altered by DRUG2 DRUG2 increases the mean cmax and AUC of DRUG1 (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by DRUG2.",simvastatin,Gleevec,False,Neg,0,CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,18,9
2769,14056,14056,14350,14350,"Particular caution is recommended when administering DRUG1 with CYP3A4 substrates that have a narrow therapeutic window (e.g., DRUG2 or DRUGOTHER).",Gleevec,cyclosporine,True,advise,1,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,6,17
2770,14057,14057,14351,14351,"Particular caution is recommended when administering DRUG1 with CYP3A4 substrates that have a narrow therapeutic window (e.g., DRUGOTHER or DRUG2).",Gleevec,pimozide,True,advise,1,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,6,19
2771,14059,14059,14353,14353,"DRUG1 will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-DRUG2, DRUGOTHER, certain DRUGOTHER, etc.).",Gleevec,benzodiazepines,True,mechanism,4,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,N1N=CC=CC2=CC=CC=C12,0,10
2772,14061,14061,14355,14355,Systemic exposure to DRUG1 is expected to be increased when coadministered with DRUG2.,acetaminophen,Gleevec,True,mechanism,4,CC(=O)NC1=CC=C(C=C1)O,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,3,12
2773,14068,14068,14362,14362,DRUG1 may potentiate the effects of DRUG2.,Imipramine hydrochloride,CNS depressant drugs,True,effect,2,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,0,6
2774,14072,14072,14366,14366,"The plasma concentration of DRUG1 may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., DRUGOTHER, DRUGOTHER) and decrease by concomitant administration of hepatic enzyme inducers (e.g., DRUGOTHER, DRUG2), and adjustment of the dosage of DRUG1 may therefore be necessary.",imipramine,phenytoin,True,mechanism,4,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,4,31
2775,14076,14076,14370,14370,"The plasma concentration of DRUGOTHER may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., DRUG1, DRUGOTHER) and decrease by concomitant administration of hepatic enzyme inducers (e.g., DRUGOTHER, DRUG2), and adjustment of the dosage of DRUGOTHER may therefore be necessary.",cimetidine,phenytoin,False,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,18,31
2776,14079,14079,14373,14373,"The plasma concentration of DRUGOTHER may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., DRUGOTHER, DRUG1) and decrease by concomitant administration of hepatic enzyme inducers (e.g., DRUGOTHER, DRUG2), and adjustment of the dosage of DRUGOTHER may therefore be necessary.",fluoxetine,phenytoin,False,Neg,0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,19,31
2777,14081,14081,14375,14375,"The plasma concentration of DRUGOTHER may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., DRUGOTHER, DRUGOTHER) and decrease by concomitant administration of hepatic enzyme inducers (e.g., DRUG1, DRUG2), and adjustment of the dosage of DRUGOTHER may therefore be necessary.",barbiturates,phenytoin,False,Neg,0,CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,30,31
2778,14083,14083,14377,14377,"The plasma concentration of DRUG2 may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., DRUGOTHER, DRUGOTHER) and decrease by concomitant administration of hepatic enzyme inducers (e.g., DRUGOTHER, DRUG1), and adjustment of the dosage of DRUG2 may therefore be necessary.",phenytoin,imipramine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,31,4
2779,14094,14094,14388,14388,"While all the DRUG1 (DRUGOTHER), e. g., DRUG2, DRUGOTHER, and DRUGOTHER, inhibit P450 2D6, they may vary in the extent of inhibition.",selective serotonin reuptake inhibitors,fluoxetine,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,3,7
2780,14095,14095,14389,14389,"While all the DRUG1 (DRUGOTHER), e. g., DRUGOTHER, DRUG2, and DRUGOTHER, inhibit P450 2D6, they may vary in the extent of inhibition.",selective serotonin reuptake inhibitors,sertraline,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,3,8
2781,14096,14096,14390,14390,"While all the DRUG1 (DRUGOTHER), e. g., DRUGOTHER, DRUGOTHER, and DRUG2, inhibit P450 2D6, they may vary in the extent of inhibition.",selective serotonin reuptake inhibitors,paroxetine,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,3,10
2782,14104,14104,14398,14398,"Ergot derivatives: DRUG1, DRUG2, DRUGOTHER, methylDRUG2",dihydroergotamine,ergonovine,False,Neg,0,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO,2,3
2783,14106,14106,14400,14400,"Ergot derivatives: DRUG1, DRUGOTHER, DRUGOTHER, DRUG2",dihydroergotamine,methylergonovine,False,Neg,0,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO,2,5
2784,14107,14107,14401,14401,"Ergot derivatives: dihydroDRUG2, DRUG1, DRUG2, methylDRUG1",ergonovine,ergotamine,False,Neg,0,[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C,3,2
2785,14109,14109,14403,14403,"Ergot derivatives: dihydroDRUG1, DRUGOTHER, DRUG1, DRUG2",ergotamine,methylergonovine,False,Neg,0,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C,[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO,2,5
2786,14118,14118,14412,14412,DRUG1 concentration   DRUG2 concentration,indinavir,ritonavir,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,0,4
2787,14119,14119,14413,14413,Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving DRUG1 in combination with DRUG2 than those receiving DRUGOTHER 800 mg q8h.,indinavir,ritonavir,True,effect,2,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,14,18
2788,14120,14120,14414,14414,"DRUGOTHER: DRUG1, DRUGOTHER (systemic) and DRUG2",bepridil,quinidine,False,Neg,0,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,1,5
2789,14123,14123,14417,14417,"DRUG1: DRUGOTHER, DRUGOTHER, DRUG2",Anticonvulsants,phenytoin,False,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,3
2790,14125,14125,14419,14419,"DRUGOTHER: DRUG1, DRUGOTHER, DRUG2",carbamazepine,phenytoin,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,1,3
2791,14126,14126,14420,14420,"DRUGOTHER: DRUGOTHER, DRUG1, DRUG2",phenobarbital,phenytoin,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,2,3
2792,14131,14131,14425,14425,"Use lowest possible dose of DRUG1 with careful monitoring, or consider DRUGOTHER that are not primarily metabolized by CYP3A4, such as DRUG2, DRUGOTHER, or DRUGOTHER in combination with DRUGOTHER.",atorvastatin,pravastatin,False,Neg,0,CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,5,21
2793,14133,14133,14427,14427,"Use lowest possible dose of DRUGOTHER with careful monitoring, or consider DRUGOTHER that are not primarily metabolized by CYP3A4, such as DRUG1, DRUG2, or DRUGOTHER in combination with DRUGOTHER.",pravastatin,fluvastatin,False,Neg,0,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@H](C[C@H](CC(=O)O)O)O)C3=CC=C(C=C3)F,21,22
2794,14135,14135,14429,14429,"DRUGOTHER: DRUG1, DRUGOTHER, DRUG2",cyclosporine,sirolimus,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,1,3
2795,14136,14136,14430,14430,"DRUGOTHER: DRUGOTHER, DRUG1, DRUG2",tacrolimus,sirolimus,False,Neg,0,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,2,3
2796,14154,14154,14448,14448,DRUGOTHER can reduce the antihypertensive effects of DRUG1 and DRUG2.,captopril,losartan,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1,7,9
2797,14155,14155,14449,14449,"In rheumatoid arthritis, concomitant medications besides DRUG1 were DRUG2, DRUGOTHER, DRUGOTHER and/or DRUGOTHER.",MTX,nonsteroidal anti-inflammatory agents,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,6,8
2798,14156,14156,14450,14450,"In rheumatoid arthritis, concomitant medications besides DRUG1 were DRUGOTHER, DRUG2, DRUGOTHER and/or DRUGOTHER.",MTX,folic acid,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,6,9
2799,14157,14157,14451,14451,"In rheumatoid arthritis, concomitant medications besides DRUG1 were DRUGOTHER, DRUGOTHER, DRUG2 and/or DRUGOTHER.",MTX,corticosteroids,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,6,10
2800,14158,14158,14452,14452,"In rheumatoid arthritis, concomitant medications besides DRUG1 were DRUGOTHER, DRUGOTHER, DRUGOTHER and/or DRUG2.",MTX,narcotics,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCO,6,12
2801,14175,14175,14469,14469,"In psoriatic arthritis clinical trials, concomitant medications included DRUG1 in approximately half of the patients as well as DRUG2, DRUGOTHER and DRUGOTHER.",MTX,nonsteroidal anti-inflammatory agents,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,8,18
2802,14176,14176,14470,14470,"In psoriatic arthritis clinical trials, concomitant medications included DRUG1 in approximately half of the patients as well as DRUGOTHER, DRUG2 and DRUGOTHER.",MTX,folic acid,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,8,19
2803,14177,14177,14471,14471,"In psoriatic arthritis clinical trials, concomitant medications included DRUG1 in approximately half of the patients as well as DRUGOTHER, DRUGOTHER and DRUG2.",MTX,corticosteroids,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,8,21
2804,14285,14285,14579,14579,"In addition, under the influence of sympatholytic medicinal products such as DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER, the signs of hypoglycemia may be reduced or absent.",clonidine,guanethidine,False,Neg,0,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl,C1CCCN(CCC1)CCN=C(N)N,12,13
2805,14287,14287,14581,14581,"In addition, under the influence of sympatholytic medicinal products such as DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2, the signs of hypoglycemia may be reduced or absent.",guanethidine,reserpine,False,Neg,0,C1CCCN(CCC1)CCN=C(N)N,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,13,15
2806,14288,14288,14582,14582,"The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER.",antidiabetic products,disopyramide,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,OC(=O)CCCCCCCC(O)=O,17,19
2807,14289,14289,14583,14583,"The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER.",antidiabetic products,fluoxetine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,17,21
2808,14290,14290,14584,14584,"The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER.",antidiabetic products,monoamine oxidase (MAO) inhibitors,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,OC(=O)CCCCCCCC(O)=O,17,22
2809,14291,14291,14585,14585,"The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER.",antidiabetic products,propoxyphene,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCC(=O)O[C@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@H](C)CN(C)C,17,23
2810,14292,14292,14586,14586,"The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER.",antidiabetic products,salicylates,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1,17,24
2811,14293,14293,14587,14587,"The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 (e.g., DRUGOTHER), DRUGOTHER.",antidiabetic products,somatostatin analog,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O,17,25
2812,14294,14294,14588,14588,"The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG2), DRUGOTHER.",antidiabetic products,octreotide,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,[H][C@]1(NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@H](CO)[C@@H](C)O)NC(=O)[C@H](N)CC1=CC=CC=C1)[C@@H](C)O,17,27
2813,14295,14295,14589,14589,"The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG2.",antidiabetic products,sulfonamide antibiotics,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,17,28
2814,14393,14393,14687,14687,"In addition, under the influence of sympatholytic medicinal products such as DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER, the signs of hypoglycemia may be reduced or absent.",clonidine,guanethidine,False,Neg,0,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl,C1CCCN(CCC1)CCN=C(N)N,12,13
2815,14395,14395,14689,14689,"In addition, under the influence of sympatholytic medicinal products such as DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2, the signs of hypoglycemia may be reduced or absent.",guanethidine,reserpine,False,Neg,0,C1CCCN(CCC1)CCN=C(N)N,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,13,15
2816,14398,14398,14694,14694,"DRUGOTHER Inhalation Aerosol has been used concomitantly with other drugs, including DRUGOTHER, DRUG1, and DRUG2, commonly used in the treatment of chronic obstructive pulmonary disease.",methylxanthines,steroids,False,Neg,0,O=C1NC2=C(NC=N2)C(=O)N1,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,12,14
2817,14400,14400,14700,14700,"No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER.",hydrochlorothiazide,digoxin,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,14,15
2818,14401,14401,14701,14701,"No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER.",hydrochlorothiazide,warfarin,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,14,16
2819,14402,14402,14702,14702,"No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2.",hydrochlorothiazide,nifedipine,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,14,18
2820,14410,14410,14710,14710,"In separate studies of patients receiving maintenance doses of DRUG1, DRUG2, or DRUGOTHER, DRUGOTHER administration for 7 days had no effect on the pharmacodynamics of DRUG1 (prothrombin time) or pharmacokinetics of DRUGOTHER.",warfarin,hydrochlorothiazide,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,9,10
2821,14415,14415,14715,14715,"In separate studies of patients receiving maintenance doses of DRUGOTHER, DRUG1, or DRUG2, DRUGOTHER administration for 7 days had no effect on the pharmacodynamics of DRUGOTHER (prothrombin time) or pharmacokinetics of DRUG2.",hydrochlorothiazide,digoxin,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,10,12
2822,14416,14416,14716,14716,"In separate studies of patients receiving maintenance doses of DRUGOTHER, DRUG1, or DRUGOTHER, DRUG2 administration for 7 days had no effect on the pharmacodynamics of DRUGOTHER (prothrombin time) or pharmacokinetics of DRUGOTHER.",hydrochlorothiazide,irbesartan,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1,10,13
2823,14417,14417,14717,14717,"In separate studies of patients receiving maintenance doses of DRUG2, DRUG1, or DRUGOTHER, DRUGOTHER administration for 7 days had no effect on the pharmacodynamics of DRUG2 (prothrombin time) or pharmacokinetics of DRUGOTHER.",hydrochlorothiazide,warfarin,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,10,9
2824,14418,14418,14718,14718,"In separate studies of patients receiving maintenance doses of DRUGOTHER, DRUG1, or DRUG2, DRUGOTHER administration for 7 days had no effect on the pharmacodynamics of DRUGOTHER (prothrombin time) or pharmacokinetics of DRUG2.",hydrochlorothiazide,digoxin,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,10,12
2825,14426,14426,14726,14726,The pharmacokinetics of DRUG1 were not affected by coadministration of DRUGOTHER or DRUG2,irbesartan,hydrochlorothiazide,False,Neg,0,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,3,12
2826,14427,14427,14727,14727,The pharmacokinetics of DRUGOTHER were not affected by coadministration of DRUG1 or DRUG2,nifedipine,hydrochlorothiazide,False,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,10,12
2827,14474,14474,14774,14774,DRUG1: DRUG2 may increase serum levels of DRUGOTHER.,Phenytoin,Isoniazid,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O,0,1
2828,14476,14476,14776,14776,DRUGOTHER: DRUG1 may increase serum levels of DRUG2.,Isoniazid,phenytoin,True,mechanism,4,CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,1,7
2829,14477,14477,14777,14777,"To avoid DRUG1 intoxication, appropriate adjustment of the DRUG2 should be made.",phenytoin,anticonvulsant,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,2,8
2830,14478,14478,14778,14778,"Therophylline: A recent study has shown that concomitan administration of DRUG1 and DRUG2 may cause elevated plasma levels of DRUG2, and in some instances a slight decrease in the elimination of DRUG1.",isoniazid,theophylline,True,mechanism,4,CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,10,12
2831,14479,14479,14779,14779,"Therophylline: A recent study has shown that concomitan administration of DRUG1 and DRUG2 may cause elevated plasma levels of DRUG2, and in some instances a slight decrease in the elimination of DRUG1.",isoniazid,theophylline,False,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,10,12
2832,14482,14482,14782,14782,"Therophylline: A recent study has shown that concomitan administration of DRUG2 and DRUG1 may cause elevated plasma levels of DRUG1, and in some instances a slight decrease in the elimination of DRUG2.",theophylline,isoniazid,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O,12,10
2833,14483,14483,14783,14783,"Therophylline: A recent study has shown that concomitan administration of DRUG2 and DRUG1 may cause elevated plasma levels of DRUG1, and in some instances a slight decrease in the elimination of DRUG2.",theophylline,isoniazid,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O,12,10
2834,14494,14494,14794,14794,"DRUG1 should be used with caution, if at all, when potent inhalational DRUG2 such as DRUGOTHER are employed because of potential to sensitize the myocardium to effects of DRUGOTHER.",ISUPREL,anesthetics,True,advise,1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCOC(=O)C1=CC=C(N)C=C1,0,12
2835,14495,14495,14795,14795,"DRUG1 should be used with caution, if at all, when potent inhalational DRUGOTHER such as DRUG2 are employed because of potential to sensitize the myocardium to effects of DRUGOTHER.",ISUPREL,halothane,True,advise,1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C(C(F)(F)F)(Cl)Br,0,15
2836,14496,14496,14796,14796,"DRUG1 should be used with caution, if at all, when potent inhalational DRUGOTHER such as DRUGOTHER are employed because of potential to sensitize the myocardium to effects of DRUG2.",ISUPREL,sympathomimetic amines,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,OC(=O)CCCCCCCC(O)=O,0,28
2837,14514,14514,14814,14814,DRUG1: A study in normal healthy volunteers has shown that concomitant administration of DRUG2  (DRUGOTHER) and DRUGOTHER does not result in altered pharmacoktnetics of either drug.,Hydrochlorothiazide,DynaCirc,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C,0,13
2838,14515,14515,14815,14815,DRUG1: A study in normal healthy volunteers has shown that concomitant administration of DRUGOTHER  (DRUG2) and DRUGOTHER does not result in altered pharmacoktnetics of either drug.,Hydrochlorothiazide,isradipine,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C,0,15
2839,14518,14518,14818,14818,DRUGOTHER: A study in normal healthy volunteers has shown that concomitant administration of DRUG1  (DRUGOTHER) and DRUG2 does not result in altered pharmacoktnetics of either drug.,DynaCirc,hydrochlorothiazide,False,Neg,0,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,13,17
2840,14519,14519,14819,14819,DRUGOTHER: A study in normal healthy volunteers has shown that concomitant administration of DRUGOTHER  (DRUG1) and DRUG2 does not result in altered pharmacoktnetics of either drug.,isradipine,hydrochlorothiazide,False,Neg,0,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,15,17
2841,14520,14520,14820,14820,"In a study in hypertensive patients, addition of DRUG1 to existing DRUG2 therapy did not result in any unexpected adverse effects, and DRUG1 had an additional antihypertensive effect.",isradipine,hydrochlorothiazide,False,Neg,0,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,8,11
2842,14522,14522,14822,14822,"In a study in hypertensive patients, addition of DRUG2 to existing DRUG1 therapy did not result in any unexpected adverse effects, and DRUG2 had an additional antihypertensive effect.",hydrochlorothiazide,isradipine,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C,11,8
2843,14573,14573,14873,14873,DRUG1 Anesthesia: Severe hypotension has been reported during DRUG2 anesthesia with concomitant use of a DRUGOTHER and a DRUGOTHER.,Fentanyl,fentanyl,False,Neg,0,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,0,8
2844,14615,14615,14915,14915,Rhabdomyolysis has been observed in patients receiving DRUGOTHER administered alone (at recommended dosages) or concomitantly with DRUG1 including DRUG2.,immunosuppressive drugs,cyclosporine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,16,18
2845,14616,14616,14916,14916,"When DRUG1 was coadministered with DRUG2, DRUGOTHER, or H2antagonists, reduced plasma concentrations of DRUGOTHER were reported.",Itraconazole,phenytoin,True,mechanism,4,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,1,5
2846,14619,14619,14919,14919,"When DRUGOTHER was coadministered with DRUG1, DRUG2, or H2antagonists, reduced plasma concentrations of DRUGOTHER were reported.",phenytoin,rifampin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,5,6
2847,14620,14620,14920,14920,"When DRUGOTHER was coadministered with DRUG1, DRUGOTHER, or H2antagonists, reduced plasma concentrations of DRUG2 were reported.",phenytoin,itraconazole,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,5,13
2848,14623,14623,14923,14923,"Although no studies have been conducted, concomitant administration of DRUG1 and DRUG2 may alter the metabolism of DRUG2;",Itraconazole,phenytoin,True,mechanism,4,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,9,11
2849,14624,14624,14924,14924,"Although no studies have been conducted, concomitant administration of DRUG1 and DRUG2 may alter the metabolism of DRUG2;",Itraconazole,phenytoin,False,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,9,11
2850,14626,14626,14926,14926,"therefore, plasma concentrations of DRUG1 should also be monitored when it is given concurrently with DRUG2.",phenytoin,Itraconazole,True,advise,1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,4,15
2851,14699,14699,14999,14999,Concomitant administration of DRUG1 tablets with DRUG2 may alter the metabolism of one or both of the drugs.,ketoconazole,phenytoin,True,mechanism,4,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,3,6
2852,14700,14700,15000,15000,It is suggested to monitor both DRUG1 and DRUG2.,ketoconazole,phenytoin,True,advise,1,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,6,8
2853,14730,14730,15030,15030,"DRUG1: DRUG2, given concomitantly with DRUGOTHER, produces a reduction in urinary potassium and chloride excretion compared to DRUGOTHER alone.",Diuretic,Hydrochlorothiazide,False,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,0,1
2854,14732,14732,15032,15032,"DRUG1: DRUGOTHER, given concomitantly with DRUGOTHER, produces a reduction in urinary potassium and chloride excretion compared to DRUG2 alone.",Diuretic,hydrochlorothiazide,False,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,0,17
2855,14733,14733,15033,15033,"DRUGOTHER: DRUG1, given concomitantly with DRUG2, produces a reduction in urinary potassium and chloride excretion compared to DRUGOTHER alone.",Hydrochlorothiazide,ketoprofen,True,effect,2,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1,1,5
2856,14735,14735,15035,15035,"DRUGOTHER: DRUGOTHER, given concomitantly with DRUG1, produces a reduction in urinary potassium and chloride excretion compared to DRUG2 alone.",ketoprofen,hydrochlorothiazide,False,Neg,0,[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,5,17
2857,14765,14765,15065,15065,"DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2 The in vitro binding of DRUGOTHER to plasma proteins is only slightly reduced by DRUGOTHER (99.5% control vs 99.3%) when DRUGOTHER plasma concentrations reach 5 to10 m g/mL.",Warfarin,Heparin,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O,0,4
2858,14767,14767,15067,15067,"DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER The in vitro binding of DRUGOTHER to plasma proteins is only slightly reduced by DRUG2 (99.5% control vs 99.3%) when DRUGOTHER plasma concentrations reach 5 to10 m g/mL.",Warfarin,ketorolac tromethamine,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,0,19
2859,14768,14768,15068,15068,"DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER The in vitro binding of DRUGOTHER to plasma proteins is only slightly reduced by DRUG2 tromethamine (99.5% control vs 99.3%) when DRUG2 plasma concentrations reach 5 to10 m g/mL.",Warfarin,ketorolac,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,0,19
2860,14770,14770,15070,15070,"DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2 The in vitro binding of DRUGOTHER to plasma proteins is only slightly reduced by DRUGOTHER (99.5% control vs 99.3%) when DRUGOTHER plasma concentrations reach 5 to10 m g/mL.",Digoxin,Heparin,False,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O,1,4
2861,14772,14772,15072,15072,"DRUGOTHER, DRUG1, DRUGOTHER, and DRUGOTHER The in vitro binding of DRUGOTHER to plasma proteins is only slightly reduced by DRUG2 (99.5% control vs 99.3%) when DRUGOTHER plasma concentrations reach 5 to10 m g/mL.",Digoxin,ketorolac tromethamine,False,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,1,19
2862,14773,14773,15073,15073,"DRUGOTHER, DRUG1, DRUGOTHER, and DRUGOTHER The in vitro binding of DRUGOTHER to plasma proteins is only slightly reduced by DRUG2 tromethamine (99.5% control vs 99.3%) when DRUG2 plasma concentrations reach 5 to10 m g/mL.",Digoxin,ketorolac,False,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,1,19
2863,14774,14774,15074,15074,"DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2 The in vitro binding of DRUGOTHER to plasma proteins is only slightly reduced by DRUGOTHER (99.5% control vs 99.3%) when DRUGOTHER plasma concentrations reach 5 to10 m g/mL.",Salicylate,Heparin,False,Neg,0,C1=CC=C(C(=C1)C(=O)O)[O-],[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O,2,4
2864,14776,14776,15076,15076,"DRUGOTHER, DRUGOTHER, DRUG1, and DRUGOTHER The in vitro binding of DRUGOTHER to plasma proteins is only slightly reduced by DRUG2 (99.5% control vs 99.3%) when DRUGOTHER plasma concentrations reach 5 to10 m g/mL.",Salicylate,ketorolac tromethamine,False,Neg,0,C1=CC=C(C(=C1)C(=O)O)[O-],OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,2,19
2865,14777,14777,15077,15077,"DRUGOTHER, DRUGOTHER, DRUG1, and DRUGOTHER The in vitro binding of DRUGOTHER to plasma proteins is only slightly reduced by DRUG2 tromethamine (99.5% control vs 99.3%) when DRUG2 plasma concentrations reach 5 to10 m g/mL.",Salicylate,ketorolac,False,Neg,0,C1=CC=C(C(=C1)C(=O)O)[O-],OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,2,19
2866,14778,14778,15078,15078,"DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1 The in vitro binding of DRUG2 to plasma proteins is only slightly reduced by DRUGOTHER (99.5% control vs 99.3%) when DRUGOTHER plasma concentrations reach 5 to10 m g/mL.",Heparin,warfarin,False,Neg,0,[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,4,10
2867,14781,14781,15081,15081,"DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER The in vitro binding of DRUG1 to plasma proteins is only slightly reduced by DRUG2 (99.5% control vs 99.3%) when DRUGOTHER plasma concentrations reach 5 to10 m g/mL.",warfarin,ketorolac tromethamine,True,mechanism,4,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,10,19
2868,14782,14782,15082,15082,"DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER The in vitro binding of DRUG1 to plasma proteins is only slightly reduced by DRUG2 tromethamine (99.5% control vs 99.3%) when DRUG2 plasma concentrations reach 5 to10 m g/mL.",warfarin,ketorolac,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,10,19
2869,14784,14784,15084,15084,DRUG1 does not alter DRUG2 protein binding.,Ketorolac,digoxin,False,Neg,0,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,0,4
2870,14785,14785,15085,15085,"In vitro studies indicate that, at therapeutic concentrations of DRUG1 (300 m g/mL), the binding of DRUG2 was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound DRUG2 plasma levels.",salicylate,ketorolac,True,mechanism,4,C1=CC=C(C(=C1)C(=O)O)[O-],OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,9,16
2871,14786,14786,15086,15086,"In vitro studies indicate that, at therapeutic concentrations of DRUG1 (300 m g/mL), the binding of DRUG2 was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound DRUG2 plasma levels.",salicylate,ketorolac,False,Neg,0,C1=CC=C(C(=C1)C(=O)O)[O-],OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,9,16
2872,14793,14793,15093,15093,"Therapeutic concentrations of DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 andtolbutamide did not alter DRUGOTHER protein binding.",digoxin,phenytoin,False,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,3,9
2873,14794,14794,15094,15094,"Therapeutic concentrations of DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER andtolbutamide did not alter DRUG2 protein binding.",digoxin,ketorolac tromethamine,False,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,3,14
2874,14799,14799,15099,15099,"Therapeutic concentrations of DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 andtolbutamide did not alter DRUGOTHER protein binding.",warfarin,phenytoin,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,4,9
2875,14800,14800,15100,15100,"Therapeutic concentrations of DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER andtolbutamide did not alter DRUG2 protein binding.",warfarin,ketorolac tromethamine,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,4,14
2876,14804,14804,15104,15104,"Therapeutic concentrations of DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 andtolbutamide did not alter DRUGOTHER protein binding.",ibuprofen,phenytoin,False,Neg,0,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,5,9
2877,14805,14805,15105,15105,"Therapeutic concentrations of DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER andtolbutamide did not alter DRUG2 protein binding.",ibuprofen,ketorolac tromethamine,False,Neg,0,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,5,14
2878,14808,14808,15108,15108,"Therapeutic concentrations of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2 andtolbutamide did not alter DRUGOTHER protein binding.",naproxen,phenytoin,False,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,6,9
2879,14809,14809,15109,15109,"Therapeutic concentrations of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER andtolbutamide did not alter DRUG2 protein binding.",naproxen,ketorolac tromethamine,False,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,6,14
2880,14811,14811,15111,15111,"Therapeutic concentrations of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2 andtolbutamide did not alter DRUGOTHER protein binding.",piroxicam,phenytoin,False,Neg,0,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,7,9
2881,14812,14812,15112,15112,"Therapeutic concentrations of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER andtolbutamide did not alter DRUG2 protein binding.",piroxicam,ketorolac tromethamine,False,Neg,0,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,7,14
2882,14813,14813,15113,15113,"Therapeutic concentrations of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2 andtolbutamide did not alter DRUGOTHER protein binding.",acetaminophen,phenytoin,False,Neg,0,CC(=O)NC1=CC=C(C=C1)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,8,9
2883,14814,14814,15114,15114,"Therapeutic concentrations of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER andtolbutamide did not alter DRUG2 protein binding.",acetaminophen,ketorolac tromethamine,False,Neg,0,CC(=O)NC1=CC=C(C=C1)O,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,8,14
2884,14818,14818,15118,15118,"Although these results do not indicate a significant interaction between DRUG1 and DRUG2 or DRUGOTHER, the administration of DRUG1 to patients taking DRUGOTHER should be done extremely cautiously, and patients should be closely monitored.",TORADOL,warfarin,False,Neg,0,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,10,12
2885,14819,14819,15119,15119,"Although these results do not indicate a significant interaction between DRUG1 and DRUGOTHER or DRUG2, the administration of DRUG1 to patients taking DRUGOTHER should be done extremely cautiously, and patients should be closely monitored.",TORADOL,heparin,False,Neg,0,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,10,14
2886,14822,14822,15122,15122,"Although these results do not indicate a significant interaction between DRUG2 and DRUG1 or DRUGOTHER, the administration of DRUG2 to patients taking DRUGOTHER should be done extremely cautiously, and patients should be closely monitored.",warfarin,TORADOL,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,12,10
2887,14823,14823,15123,15123,"Although these results do not indicate a significant interaction between DRUG2 and DRUGOTHER or DRUG1, the administration of DRUG2 to patients taking DRUGOTHER should be done extremely cautiously, and patients should be closely monitored.",heparin,TORADOL,False,Neg,0,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,14,10
2888,14825,14825,15125,15125,DRUG1: DRUGOTHER IV/IM reduced the DRUG2 response to DRUGOTHER in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).,Furosemide,diuretic,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,0,5
2889,14827,14827,15127,15127,DRUGOTHER: DRUG1 IV/IM reduced the DRUG2 response to DRUGOTHER in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).,TORADOL,diuretic,False,Neg,0,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,1,5
2890,14829,14829,15129,15129,DRUGOTHER: DRUGOTHER IV/IM reduced the DRUG1 response to DRUG2 in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).,diuretic,furosemide,False,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,5,8
2891,14830,14830,15130,15130,DRUG1: Concomitant administration of DRUG2 ORAL and DRUGOTHER resulted in decreased clearance of DRUGOTHER and significant increases in DRUGOTHER plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.,Probenecid,TORADOL,False,Neg,0,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,0,4
2892,14832,14832,15132,15132,DRUG1: Concomitant administration of DRUGOTHER ORAL and DRUGOTHER resulted in decreased clearance of DRUG2 and significant increases in DRUG2 plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.,Probenecid,ketorolac,False,Neg,0,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,0,13
2893,14833,14833,15133,15133,DRUG1: Concomitant administration of DRUGOTHER ORAL and DRUGOTHER resulted in decreased clearance of DRUG2 and significant increases in DRUG2 plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.,Probenecid,ketorolac,False,Neg,0,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,0,13
2894,14834,14834,15134,15134,DRUGOTHER: Concomitant administration of DRUG1 ORAL and DRUG2 resulted in decreased clearance of DRUGOTHER and significant increases in DRUGOTHER plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.,TORADOL,probenecid,True,mechanism,4,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,4,7
2895,14837,14837,15137,15137,DRUGOTHER: Concomitant administration of DRUGOTHER ORAL and DRUG1 resulted in decreased clearance of DRUG2 and significant increases in DRUG2 plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.,probenecid,ketorolac,False,Neg,0,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,7,13
2896,14838,14838,15138,15138,DRUGOTHER: Concomitant administration of DRUGOTHER ORAL and DRUG1 resulted in decreased clearance of DRUG2 and significant increases in DRUG2 plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.,probenecid,ketorolac,False,Neg,0,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,7,13
2897,14840,14840,15140,15140,"Therefore, concomitant use of DRUG1 and DRUG2 is contraindicated.",TORADOL,probenecid,True,advise,1,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,4,6
2898,14848,14848,15148,15148,The effect of DRUG1 on DRUG2 clearance has not been studied.,TORADOL,methotrexate,False,Neg,0,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,3,5
2899,14850,14850,15150,15150,"DRUGOTHER: Sporadic cases of seizures have been reported during concomitant use of DRUG1 and DRUGOTHER (DRUGOTHER, DRUG2).",TORADOL,carbamazepine,True,effect,2,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,12,16
2900,14851,14851,15151,15151,"DRUGOTHER: Sporadic cases of seizures have been reported during concomitant use of DRUGOTHER and DRUGOTHER (DRUG1, DRUG2).",phenytoin,carbamazepine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,15,16
2901,14852,14852,15152,15152,"DRUG1: Hallucinations have been reported when DRUG2 was used in patients taking DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER).",Psychoactive Drugs,TORADOL,False,Neg,0,OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,0,6
2902,14856,14856,15157,15157,"DRUGOTHER: Hallucinations have been reported when DRUG1 was used in patients taking DRUG2 (DRUGOTHER, DRUGOTHER, DRUGOTHER).",TORADOL,psychoactive drugs,True,effect,2,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1,6,12
2903,14857,14857,15158,15158,"DRUGOTHER: Hallucinations have been reported when DRUG1 was used in patients taking DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER).",TORADOL,fluoxetine,True,effect,2,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,6,13
2904,14858,14858,15160,15160,"DRUGOTHER: Hallucinations have been reported when DRUG1 was used in patients taking DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2).",TORADOL,alprazolam,True,effect,2,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12,6,15
2905,14863,14863,15168,15168,Do not mix DRUG1 and DRUG2 in the same syringe.,TORADOL,morphine,False,Neg,0,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,3,5
2906,14914,14914,15222,15222,"DRUG1 such as DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUG2), and DRUGOTHER (e.g., DRUGOTHER): Using these medicines with DRUGOTHER may increase the chance of side effects.",Monoamine oxidase (MAO) inhibitors,Eldepryl,False,Neg,0,OC(=O)CCCCCCCC(O)=O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,0,14
2907,14917,14917,15225,15225,"DRUG1 such as DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER): Using these medicines with DRUG2 may increase the chance of side effects.",Monoamine oxidase (MAO) inhibitors,L-tryptophan,False,Neg,0,OC(=O)CCCCCCCC(O)=O,N[C@@H](CC1=CNC2=CC=CC=C12)C(O)=O,0,23
2908,14924,14924,15232,15232,"DRUGOTHER such as DRUG1 (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUG2), and DRUGOTHER (e.g., DRUGOTHER): Using these medicines with DRUGOTHER may increase the chance of side effects.",isocarboxazid,Eldepryl,False,Neg,0,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,3,14
2909,14927,14927,15235,15235,"DRUGOTHER such as DRUG1 (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER): Using these medicines with DRUG2 may increase the chance of side effects.",isocarboxazid,L-tryptophan,False,Neg,0,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,N[C@@H](CC1=CNC2=CC=CC=C12)C(O)=O,3,23
2910,14933,14933,15241,15241,"DRUGOTHER such as DRUGOTHER (e.g., DRUG1), DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUG2), and DRUGOTHER (e.g., DRUGOTHER): Using these medicines with DRUGOTHER may increase the chance of side effects.",Marplan,Eldepryl,False,Neg,0,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,5,14
2911,14936,14936,15244,15244,"DRUGOTHER such as DRUGOTHER (e.g., DRUG1), DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER): Using these medicines with DRUG2 may increase the chance of side effects.",Marplan,L-tryptophan,False,Neg,0,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,N[C@@H](CC1=CNC2=CC=CC=C12)C(O)=O,5,23
2912,14941,14941,15249,15249,"DRUGOTHER such as DRUGOTHER (e.g., DRUGOTHER), DRUG1 (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUG2), and DRUGOTHER (e.g., DRUGOTHER): Using these medicines with DRUGOTHER may increase the chance of side effects.",phenelzine,Eldepryl,False,Neg,0,C1=CC=C(C=C1)CCNN,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,6,14
2913,14944,14944,15252,15252,"DRUGOTHER such as DRUGOTHER (e.g., DRUGOTHER), DRUG1 (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER): Using these medicines with DRUG2 may increase the chance of side effects.",phenelzine,L-tryptophan,False,Neg,0,C1=CC=C(C=C1)CCNN,N[C@@H](CC1=CNC2=CC=CC=C12)C(O)=O,6,23
2914,14948,14948,15256,15256,"DRUGOTHER such as DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUG1), DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUG2), and DRUGOTHER (e.g., DRUGOTHER): Using these medicines with DRUGOTHER may increase the chance of side effects.",Nardil,Eldepryl,False,Neg,0,C1=CC=C(C=C1)CCNN,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,8,14
2915,14951,14951,15259,15259,"DRUGOTHER such as DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUG1), DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER): Using these medicines with DRUG2 may increase the chance of side effects.",Nardil,L-tryptophan,False,Neg,0,C1=CC=C(C=C1)CCNN,N[C@@H](CC1=CNC2=CC=CC=C12)C(O)=O,8,23
2916,14954,14954,15262,15262,"DRUGOTHER such as DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUG1 (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUG2), and DRUGOTHER (e.g., DRUGOTHER): Using these medicines with DRUGOTHER may increase the chance of side effects.",procarbazine,Eldepryl,False,Neg,0,CNNCC1=CC=C(C=C1)C(=O)NC(C)C,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,9,14
2917,14957,14957,15265,15265,"DRUGOTHER such as DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUG1 (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER): Using these medicines with DRUG2 may increase the chance of side effects.",procarbazine,L-tryptophan,False,Neg,0,CNNCC1=CC=C(C=C1)C(=O)NC(C)C,N[C@@H](CC1=CNC2=CC=CC=C12)C(O)=O,9,23
2918,14959,14959,15267,15267,"DRUGOTHER such as DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUG1), DRUGOTHER (e.g., DRUG2), and DRUGOTHER (e.g., DRUGOTHER): Using these medicines with DRUGOTHER may increase the chance of side effects.",Matulane,Eldepryl,False,Neg,0,CC(C)NC(=O)C1=CC=C(C=C1)CNNC.Cl,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,11,14
2919,14962,14962,15270,15270,"DRUGOTHER such as DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUG1), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER): Using these medicines with DRUG2 may increase the chance of side effects.",Matulane,L-tryptophan,False,Neg,0,CC(C)NC(=O)C1=CC=C(C=C1)CNNC.Cl,N[C@@H](CC1=CNC2=CC=CC=C12)C(O)=O,11,23
2920,14963,14963,15271,15271,"DRUGOTHER such as DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUG1 (e.g., DRUG2), and DRUGOTHER (e.g., DRUGOTHER): Using these medicines with DRUGOTHER may increase the chance of side effects.",selegiline,Eldepryl,False,Neg,0,C[C@H](CC1=CC=CC=C1)N(C)CC#C,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,12,14
2921,14966,14966,15274,15274,"DRUGOTHER such as DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUG1 (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER): Using these medicines with DRUG2 may increase the chance of side effects.",selegiline,L-tryptophan,False,Neg,0,C[C@H](CC1=CC=CC=C1)N(C)CC#C,N[C@@H](CC1=CNC2=CC=CC=C12)C(O)=O,12,23
2922,14967,14967,15275,15275,"DRUGOTHER such as DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUG1), and DRUG2 (e.g., DRUGOTHER): Using these medicines with DRUGOTHER may increase the chance of side effects.",Eldepryl,tranylcypromine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C1[C@H]([C@@H]1N)C2=CC=CC=C2,14,16
2923,14968,14968,15276,15276,"DRUGOTHER such as DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUG1), and DRUGOTHER (e.g., DRUG2): Using these medicines with DRUGOTHER may increase the chance of side effects.",Eldepryl,Parnate,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C1[C@H]([C@@H]1N)C2=CC=CC=C2,14,18
2924,14971,14971,15279,15279,"DRUGOTHER such as DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), and DRUG1 (e.g., DRUGOTHER): Using these medicines with DRUG2 may increase the chance of side effects.",tranylcypromine,L-tryptophan,False,Neg,0,C1[C@H]([C@@H]1N)C2=CC=CC=C2,N[C@@H](CC1=CNC2=CC=CC=C12)C(O)=O,16,23
2925,14972,14972,15280,15280,"DRUGOTHER such as DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUG1): Using these medicines with DRUG2 may increase the chance of side effects.",Parnate,L-tryptophan,False,Neg,0,C1[C@H]([C@@H]1N)C2=CC=CC=C2,N[C@@H](CC1=CNC2=CC=CC=C12)C(O)=O,18,23
2926,15008,15008,15317,15317,"Studies have shown that DRUG1 does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER in healthy subjects.",lansoprazole,phenytoin,False,Neg,0,CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,4,26
2927,15017,15017,15326,15326,"Studies have shown that DRUGOTHER does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER in healthy subjects.",warfarin,phenytoin,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,22,26
2928,15025,15025,15334,15334,"Studies have shown that DRUGOTHER does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER in healthy subjects.",antipyrine,phenytoin,False,Neg,0,CC1=CC(=O)N(N1C)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,23,26
2929,15032,15032,15341,15341,"Studies have shown that DRUGOTHER does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER in healthy subjects.",indomethacin,phenytoin,False,Neg,0,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,24,26
2930,15038,15038,15347,15347,"Studies have shown that DRUGOTHER does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER in healthy subjects.",ibuprofen,phenytoin,False,Neg,0,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,25,26
2931,15044,15044,15353,15353,"Studies have shown that DRUGOTHER does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER in healthy subjects.",phenytoin,propranolol,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,26,27
2932,15045,15045,15354,15354,"Studies have shown that DRUGOTHER does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER in healthy subjects.",phenytoin,prednisone,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,26,28
2933,15046,15046,15355,15355,"Studies have shown that DRUGOTHER does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER in healthy subjects.",phenytoin,diazepam,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,26,29
2934,15047,15047,15356,15356,"Studies have shown that DRUGOTHER does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER in healthy subjects.",phenytoin,clarithromycin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,26,30
2935,15048,15048,15357,15357,"Studies have shown that DRUGOTHER does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2 in healthy subjects.",phenytoin,terfenadine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,26,32
2936,15059,15059,15368,15368,"When DRUG1 was administered concomitantly with DRUG2 (CYP1A2, CYP3A), a minor increase (10%) in the clearance of DRUG2 was seen.",lansoprazole,theophylline,True,mechanism,4,CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,1,6
2937,15060,15060,15369,15369,"When DRUG1 was administered concomitantly with DRUG2 (CYP1A2, CYP3A), a minor increase (10%) in the clearance of DRUG2 was seen.",lansoprazole,theophylline,False,Neg,0,CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,1,6
2938,15062,15062,15371,15371,"Nonetheless, individual patients may require additional titration of their DRUG1 dosage when DRUG2 is started or stopped to ensure clinically effective blood levels.",theophylline,lansoprazole,True,advise,1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1,9,12
2939,15066,15066,15375,15375,"In a single-dose crossover study examining DRUG1 30 mg and DRUGOTHER 20 mg each administered alone and concomitantly with DRUGOTHER 1 gram, absorption of the DRUG2 was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with DRUGOTHER.",lansoprazole,proton pump inhibitors,False,Neg,0,CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,6,25
2940,15069,15069,15378,15378,"In a single-dose crossover study examining DRUGOTHER 30 mg and DRUG1 20 mg each administered alone and concomitantly with DRUGOTHER 1 gram, absorption of the DRUG2 was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with DRUGOTHER.",omeprazole,proton pump inhibitors,False,Neg,0,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,10,25
2941,15071,15071,15380,15380,"In a single-dose crossover study examining DRUGOTHER 30 mg and DRUGOTHER 20 mg each administered alone and concomitantly with DRUG1 1 gram, absorption of the DRUG2 was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with DRUG1.",sucralfate,proton pump inhibitors,False,Neg,0,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al].O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Al],CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,19,25
2942,15073,15073,15382,15382,"In a single-dose crossover study examining DRUGOTHER 30 mg and DRUGOTHER 20 mg each administered alone and concomitantly with DRUG2 1 gram, absorption of the DRUG1 was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with DRUG2.",proton pump inhibitors,sucralfate,True,mechanism,4,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al].O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Al],25,19
2943,15074,15074,15383,15383,"Therefore, DRUG1 should be taken at least 30 minutes prior to DRUG2.",proton pump inhibitors,sucralfate,True,advise,1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al].O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Al],1,11
2944,15124,15124,15439,15439,"DRUG1 in large amounts may counteract the antiepileptic effect of DRUGOTHER, DRUG2 and DRUGOTHER, and increase the frequency of seizures in susceptible pediatric patients.",Folic acid,phenytoin,True,effect,2,[H]N([H])C(=O)[C@H](CS)N([H])C(C)=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,11
2945,15126,15126,15441,15441,"DRUGOTHER in large amounts may counteract the antiepileptic effect of DRUG1, DRUG2 and DRUGOTHER, and increase the frequency of seizures in susceptible pediatric patients.",phenobarbital,phenytoin,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,10,11
2946,15128,15128,15443,15443,"DRUGOTHER in large amounts may counteract the antiepileptic effect of DRUGOTHER, DRUG1 and DRUG2, and increase the frequency of seizures in susceptible pediatric patients.",phenytoin,primidone,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,11,13
2947,15134,15134,15457,15457,"Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (DRUG1, DRUG2, oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.",phenytoin,valproate,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCCC(CCC)C(=O)O,9,10
2948,15135,15135,15458,15458,"Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (DRUG1, DRUGOTHER, oral DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.",phenytoin,contraceptive,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,9,12
2949,15136,15136,15459,15459,"Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (DRUG1, DRUGOTHER, oral DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.",phenytoin,digoxin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,9,13
2950,15137,15137,15460,15460,"Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (DRUG1, DRUGOTHER, oral DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.",phenytoin,warfarin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,9,14
2951,15138,15138,15461,15461,"Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (DRUG1, DRUGOTHER, oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.",phenytoin,probenecid,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,9,15
2952,15149,15149,15472,15472,Drug-Drug Interactions Between DRUG1  And Other DRUGOTHER (DRUGOTHER) DRUG2 DRUG1  (3000 mg daily) had no effect on the pharmacokinetic disposition of DRUGOTHER in patients with refractory epilepsy.,Keppra,Phenytoin,False,Neg,0,CC[C@H](N1CCCC1=O)C(N)=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,3,9
2953,15151,15151,15474,15474,Drug-Drug Interactions Between DRUG1  And Other DRUGOTHER (DRUGOTHER) DRUGOTHER DRUG1  (3000 mg daily) had no effect on the pharmacokinetic disposition of DRUG2 in patients with refractory epilepsy.,Keppra,phenytoin,False,Neg,0,CC[C@H](N1CCCC1=O)C(N)=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,3,23
2954,15152,15152,15475,15475,Drug-Drug Interactions Between DRUG2  And Other DRUGOTHER (DRUGOTHER) DRUG1 DRUG2  (3000 mg daily) had no effect on the pharmacokinetic disposition of DRUGOTHER in patients with refractory epilepsy.,Phenytoin,Keppra,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC[C@H](N1CCCC1=O)C(N)=O,9,3
2955,15154,15154,15477,15477,Drug-Drug Interactions Between DRUG1  And Other DRUGOTHER (DRUGOTHER) DRUGOTHER DRUG1  (3000 mg daily) had no effect on the pharmacokinetic disposition of DRUG2 in patients with refractory epilepsy.,Keppra,phenytoin,False,Neg,0,CC[C@H](N1CCCC1=O)C(N)=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,3,23
2956,15155,15155,15478,15478,Pharmacokinetics of DRUG1 were also not affected by DRUG2.,levetiracetam,phenytoin,False,Neg,0,CCC(N1CCCC1=O)C(O)=N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,2,8
2957,15158,15158,15481,15481,"Potential drug interactions between DRUG1  and other DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER) were also assessed by evaluating the serum concentrations of DRUGOTHER and these DRUGOTHER during placebo-controlled clinical studies.",Keppra,gabapentin,False,Neg,0,CC[C@H](N1CCCC1=O)C(N)=O,NCC1(CC(O)=O)CCCCC1,4,10
2958,15161,15161,15484,15484,"Potential drug interactions between DRUG1  and other DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER) were also assessed by evaluating the serum concentrations of DRUGOTHER and these DRUGOTHER during placebo-controlled clinical studies.",Keppra,phenytoin,False,Neg,0,CC[C@H](N1CCCC1=O)C(N)=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,4,13
2959,15165,15165,15488,15488,"Potential drug interactions between DRUGOTHER  and other DRUGOTHER (DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER) were also assessed by evaluating the serum concentrations of DRUGOTHER and these DRUGOTHER during placebo-controlled clinical studies.",carbamazepine,gabapentin,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,NCC1(CC(O)=O)CCCCC1,9,10
2960,15168,15168,15491,15491,"Potential drug interactions between DRUGOTHER  and other DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER) were also assessed by evaluating the serum concentrations of DRUGOTHER and these DRUGOTHER during placebo-controlled clinical studies.",carbamazepine,phenytoin,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,9,13
2961,15172,15172,15495,15495,"Potential drug interactions between DRUGOTHER  and other DRUGOTHER (DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER) were also assessed by evaluating the serum concentrations of DRUGOTHER and these DRUGOTHER during placebo-controlled clinical studies.",gabapentin,lamotrigine,False,Neg,0,NCC1(CC(O)=O)CCCCC1,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,10,11
2962,15173,15173,15496,15496,"Potential drug interactions between DRUGOTHER  and other DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER) were also assessed by evaluating the serum concentrations of DRUGOTHER and these DRUGOTHER during placebo-controlled clinical studies.",gabapentin,phenobarbital,False,Neg,0,NCC1(CC(O)=O)CCCCC1,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,10,12
2963,15175,15175,15498,15498,"Potential drug interactions between DRUGOTHER  and other DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER) were also assessed by evaluating the serum concentrations of DRUGOTHER and these DRUGOTHER during placebo-controlled clinical studies.",gabapentin,primidone,False,Neg,0,NCC1(CC(O)=O)CCCCC1,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,10,14
2964,15176,15176,15499,15499,"Potential drug interactions between DRUGOTHER  and other DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2) were also assessed by evaluating the serum concentrations of DRUGOTHER and these DRUGOTHER during placebo-controlled clinical studies.",gabapentin,valproate,False,Neg,0,NCC1(CC(O)=O)CCCCC1,CCCC(CCC)C(=O)O,10,16
2965,15177,15177,15500,15500,"Potential drug interactions between DRUGOTHER  and other DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER) were also assessed by evaluating the serum concentrations of DRUG2 and these DRUGOTHER during placebo-controlled clinical studies.",gabapentin,levetiracetam,False,Neg,0,NCC1(CC(O)=O)CCCCC1,CCC(N1CCCC1=O)C(O)=N,10,26
2966,15179,15179,15502,15502,"Potential drug interactions between DRUGOTHER  and other DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER) were also assessed by evaluating the serum concentrations of DRUGOTHER and these DRUGOTHER during placebo-controlled clinical studies.",lamotrigine,phenytoin,False,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,11,13
2967,15183,15183,15506,15506,"Potential drug interactions between DRUGOTHER  and other DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER and DRUGOTHER) were also assessed by evaluating the serum concentrations of DRUGOTHER and these DRUGOTHER during placebo-controlled clinical studies.",phenobarbital,phenytoin,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,12,13
2968,15187,15187,15510,15510,"Potential drug interactions between DRUGOTHER  and other DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2 and DRUGOTHER) were also assessed by evaluating the serum concentrations of DRUGOTHER and these DRUGOTHER during placebo-controlled clinical studies.",phenytoin,primidone,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,13,14
2969,15188,15188,15511,15511,"Potential drug interactions between DRUGOTHER  and other DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER and DRUG2) were also assessed by evaluating the serum concentrations of DRUGOTHER and these DRUGOTHER during placebo-controlled clinical studies.",phenytoin,valproate,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCCC(CCC)C(=O)O,13,16
2970,15189,15189,15512,15512,"Potential drug interactions between DRUGOTHER  and other DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER and DRUGOTHER) were also assessed by evaluating the serum concentrations of DRUG2 and these DRUGOTHER during placebo-controlled clinical studies.",phenytoin,levetiracetam,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC(N1CCCC1=O)C(O)=N,13,26
2971,15196,15196,15519,15519,"Dose adjustment is not recommended.DRUG1 had no effect on plasma concentrations of DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER.",Levetiracetam,topiramate,False,Neg,0,CCC(N1CCCC1=O)C(O)=N,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,4,14
2972,15199,15199,15522,15522,"Dose adjustment is not recommended.DRUGOTHER had no effect on plasma concentrations of DRUG1, DRUGOTHER, DRUG2, or DRUGOTHER.",carbamazepine,topiramate,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,12,14
2973,15201,15201,15524,15524,"Dose adjustment is not recommended.DRUGOTHER had no effect on plasma concentrations of DRUGOTHER, DRUG1, DRUG2, or DRUGOTHER.",valproate,topiramate,False,Neg,0,CCCC(CCC)C(=O)O,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,13,14
2974,15203,15203,15526,15526,"Dose adjustment is not recommended.DRUGOTHER had no effect on plasma concentrations of DRUGOTHER, DRUGOTHER, DRUG1, or DRUG2.",topiramate,lamotrigine,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,14,16
2975,15237,15237,15561,15561,"Although no clinical studies have been conducted, it is likely that the metabolism of DRUG1 may be affected by the known CYP3A4 inducers (such as DRUG2, DRUGOTHER, DRUGOTHER), CYP3A4 inhibitors (azole antimycotics e.g., DRUGOTHER;",levobupivacaine,phenytoin,True,mechanism,4,CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,14,25
2976,15241,15241,15565,15565,"Although no clinical studies have been conducted, it is likely that the metabolism of DRUGOTHER may be affected by the known CYP3A4 inducers (such as DRUG1, DRUG2, DRUGOTHER), CYP3A4 inhibitors (azole antimycotics e.g., DRUGOTHER;",phenytoin,phenobarbital,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,25,26
2977,15242,15242,15566,15566,"Although no clinical studies have been conducted, it is likely that the metabolism of DRUGOTHER may be affected by the known CYP3A4 inducers (such as DRUG1, DRUGOTHER, DRUG2), CYP3A4 inhibitors (azole antimycotics e.g., DRUGOTHER;",phenytoin,rifampin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,25,27
2978,15243,15243,15567,15567,"Although no clinical studies have been conducted, it is likely that the metabolism of DRUGOTHER may be affected by the known CYP3A4 inducers (such as DRUG1, DRUGOTHER, DRUGOTHER), CYP3A4 inhibitors (azole antimycotics e.g., DRUG2;",phenytoin,ketoconazole,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,25,33
2979,15253,15253,15580,15580,"However, the systemic administration of some DRUGOTHER has been shown to elevate plasma concentrations of DRUG1, interfere with the metabolism of DRUGOTHER, and enhance the effects of the oral DRUG2 DRUGOTHER and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic DRUGOTHER concomitantly.",theophylline,anticoagulant,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,15,29
2980,15254,15254,15581,15581,"However, the systemic administration of some DRUGOTHER has been shown to elevate plasma concentrations of DRUG1, interfere with the metabolism of DRUGOTHER, and enhance the effects of the oral DRUGOTHER DRUG2 and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic DRUGOTHER concomitantly.",theophylline,warfarin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,15,30
2981,15255,15255,15582,15582,"However, the systemic administration of some DRUGOTHER has been shown to elevate plasma concentrations of DRUG1, interfere with the metabolism of DRUGOTHER, and enhance the effects of the oral DRUGOTHER DRUGOTHER and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic DRUG2 concomitantly.",theophylline,cyclosporine,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,15,48
2982,15256,15256,15583,15583,"However, the systemic administration of some DRUGOTHER has been shown to elevate plasma concentrations of DRUGOTHER, interfere with the metabolism of DRUG1, and enhance the effects of the oral DRUG2 DRUGOTHER and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic DRUGOTHER concomitantly.",caffeine,anticoagulant,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,21,29
2983,15257,15257,15584,15584,"However, the systemic administration of some DRUGOTHER has been shown to elevate plasma concentrations of DRUGOTHER, interfere with the metabolism of DRUG1, and enhance the effects of the oral DRUGOTHER DRUG2 and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic DRUGOTHER concomitantly.",caffeine,warfarin,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,21,30
2984,15258,15258,15585,15585,"However, the systemic administration of some DRUGOTHER has been shown to elevate plasma concentrations of DRUGOTHER, interfere with the metabolism of DRUG1, and enhance the effects of the oral DRUGOTHER DRUGOTHER and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic DRUG2 concomitantly.",caffeine,cyclosporine,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,21,48
2985,15262,15262,15589,15589,"Interactions with Other CNS Agents: Concurrent use of DRUG1 with all DRUG2 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, other DRUGOTHER, general DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER) may result in additive central nervous system depressant effects.",Levo-Dromoran,central nervous system depressants,True,effect,2,[H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2,C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1,8,11
2986,15263,15263,15590,15590,"Interactions with Other CNS Agents: Concurrent use of DRUG1 with all DRUGOTHER (eg, DRUG2, DRUGOTHER, DRUGOTHER, other DRUGOTHER, general DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER) may result in additive central nervous system depressant effects.",Levo-Dromoran,alcohol,True,effect,2,[H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2,CCO,8,13
2987,15264,15264,15591,15591,"Interactions with Other CNS Agents: Concurrent use of DRUG1 with all DRUGOTHER (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, other DRUG2, general DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER) may result in additive central nervous system depressant effects.",Levo-Dromoran,opioids,True,effect,2,[H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3.CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2.CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O,8,17
2988,15265,15265,15592,15592,"Interactions with Other CNS Agents: Concurrent use of DRUG1 with all DRUGOTHER (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, other DRUGOTHER, general DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER) may result in additive central nervous system depressant effects.",Levo-Dromoran,anesthetics,True,effect,2,[H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2,CCOC(=O)C1=CC=C(N)C=C1,8,19
2989,15266,15266,15593,15593,"Interactions with Other CNS Agents: Concurrent use of DRUG1 with all DRUGOTHER (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, other DRUGOTHER, general DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER) may result in additive central nervous system depressant effects.",Levo-Dromoran,barbiturates,True,effect,2,[H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2,CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O,8,20
2990,15267,15267,15594,15594,"Interactions with Other CNS Agents: Concurrent use of DRUG1 with all DRUGOTHER (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, other DRUGOTHER, general DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER) may result in additive central nervous system depressant effects.",Levo-Dromoran,tricyclic antidepressants,True,effect,2,[H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,8,21
2991,15268,15268,15595,15595,"Interactions with Other CNS Agents: Concurrent use of DRUG1 with all DRUGOTHER (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, other DRUGOTHER, general DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER) may result in additive central nervous system depressant effects.",Levo-Dromoran,phenothiazines,True,effect,2,[H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2,N1C2=CC=CC=C2SC2=CC=CC=C12,8,22
2992,15269,15269,15596,15596,"Interactions with Other CNS Agents: Concurrent use of DRUG1 with all DRUGOTHER (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, other DRUGOTHER, general DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER) may result in additive central nervous system depressant effects.",Levo-Dromoran,tranquilizers,True,effect,2,[H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,8,23
2993,15270,15270,15597,15597,"Interactions with Other CNS Agents: Concurrent use of DRUG1 with all DRUGOTHER (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, other DRUGOTHER, general DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2) may result in additive central nervous system depressant effects.",Levo-Dromoran,antihistamines,True,effect,2,[H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2,NCCC1=CNC=N1,8,26
2994,15307,15307,15634,15634,"Although no interaction between DRUG1 and DRUG2 has been observed, it is not recommended for use with DRUG1.",MAO inhibitors,Levo-Dromoran,False,Neg,0,CN(CC#C)CC1=CC=CC=C1,[H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2,4,6
2995,15309,15309,15636,15636,"Although no interaction between DRUG2 and DRUG1 has been observed, it is not recommended for use with DRUG2.",Levo-Dromoran,MAO inhibitors,True,advise,1,[H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2,CN(CC#C)CC1=CC=CC=C1,6,4
2996,15310,15310,15637,15637,"Most cases of serious or fatal adverse events involving DRUG1 reported to the manufacturer or the FDA have involved either the administration of large initial doses or too frequent doses of the drug to nonopioid tolerant patients, or the simultaneous administration of DRUG2 with other drugs affecting respiration.",Levo-Dromoran,levorphanol,False,Neg,0,[H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2,OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,9,42
2997,15315,15315,15643,15643,"Interactions with DRUG1: DRUGOTHER (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2) should NOT be administered to a patient who has received or is receiving a course of therapy with a DRUGOTHER such as DRUGOTHER.",Mixed Agonist/Antagonist Opioid Analgesics,buprenorphine,False,Neg,0,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O,2,10
2998,15317,15317,15645,15645,"Interactions with DRUG1: DRUGOTHER (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER) should NOT be administered to a patient who has received or is receiving a course of therapy with a DRUGOTHER such as DRUG2.",Mixed Agonist/Antagonist Opioid Analgesics,Levo-Dromoran,False,Neg,0,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,[H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2,2,33
2999,15321,15321,15650,15650,"Interactions with DRUGOTHER: DRUG1 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2) should NOT be administered to a patient who has received or is receiving a course of therapy with a DRUGOTHER such as DRUGOTHER.",Agonist/antagonist analgesics,buprenorphine,False,Neg,0,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O,3,10
3000,15323,15323,15652,15652,"Interactions with DRUGOTHER: DRUG1 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER) should NOT be administered to a patient who has received or is receiving a course of therapy with a DRUGOTHER such as DRUG2.",Agonist/antagonist analgesics,Levo-Dromoran,True,advise,1,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,[H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2,3,33
3001,15326,15326,15656,15656,"Interactions with DRUGOTHER: DRUGOTHER (eg, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2) should NOT be administered to a patient who has received or is receiving a course of therapy with a DRUGOTHER such as DRUGOTHER.",pentazocine,buprenorphine,False,Neg,0,C[C@H]1[C@H]2CC3=C([C@@]1(CCN2CC=C(C)C)C)C=C(C=C3)O,C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O,5,10
3002,15328,15328,15658,15658,"Interactions with DRUGOTHER: DRUGOTHER (eg, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER) should NOT be administered to a patient who has received or is receiving a course of therapy with a DRUGOTHER such as DRUG2.",pentazocine,Levo-Dromoran,True,advise,1,C[C@H]1[C@H]2CC3=C([C@@]1(CCN2CC=C(C)C)C)C=C(C=C3)O,[H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2,5,33
3003,15330,15330,15661,15661,"Interactions with DRUGOTHER: DRUGOTHER (eg, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER and DRUG2) should NOT be administered to a patient who has received or is receiving a course of therapy with a DRUGOTHER such as DRUGOTHER.",nalbuphine,buprenorphine,False,Neg,0,C1CC(C1)CN2CC[C@]34[C@@H]5[C@H](CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O)O,C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O,6,10
3004,15332,15332,15663,15663,"Interactions with DRUGOTHER: DRUGOTHER (eg, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER and DRUGOTHER) should NOT be administered to a patient who has received or is receiving a course of therapy with a DRUGOTHER such as DRUG2.",nalbuphine,Levo-Dromoran,True,advise,1,C1CC(C1)CN2CC[C@]34[C@@H]5[C@H](CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O)O,[H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2,6,33
3005,15333,15333,15665,15665,"Interactions with DRUGOTHER: DRUGOTHER (eg, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER and DRUG2) should NOT be administered to a patient who has received or is receiving a course of therapy with a DRUGOTHER such as DRUGOTHER.",butorphanol,buprenorphine,False,Neg,0,C1CC[C@]2([C@H]3CC4=C([C@]2(C1)CCN3CC5CCC5)C=C(C=C4)O)O,C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O,7,10
3006,15335,15335,15667,15667,"Interactions with DRUGOTHER: DRUGOTHER (eg, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER and DRUGOTHER) should NOT be administered to a patient who has received or is receiving a course of therapy with a DRUGOTHER such as DRUG2.",butorphanol,Levo-Dromoran,True,advise,1,C1CC[C@]2([C@H]3CC4=C([C@]2(C1)CCN3CC5CCC5)C=C(C=C4)O)O,[H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2,7,33
3007,15336,15336,15671,15671,"Interactions with DRUGOTHER: DRUGOTHER (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG1) should NOT be administered to a patient who has received or is receiving a course of therapy with a DRUG2 such as DRUGOTHER.",buprenorphine,pure agonist opioid analgesic,False,Neg,0,C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,10,30
3008,15338,15338,15673,15673,"Interactions with DRUGOTHER: DRUGOTHER (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER) should NOT be administered to a patient who has received or is receiving a course of therapy with a DRUG1 such as DRUG2.",pure agonist opioid analgesic,Levo-Dromoran,True,advise,1,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,[H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2,30,33
3009,15339,15339,15682,15682,"No Important Interactions To Date DRUGOTHER does not have clinically important pharmacokinetic interactions with DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER.",captopril,felodipine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,14,16
3010,15340,15340,15683,15683,"No Important Interactions To Date DRUGOTHER does not have clinically important pharmacokinetic interactions with DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER.",captopril,digoxin,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,14,17
3011,15341,15341,15684,15684,"No Important Interactions To Date DRUGOTHER does not have clinically important pharmacokinetic interactions with DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER.",captopril,warfarin,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,14,18
3012,15342,15342,15685,15685,"No Important Interactions To Date DRUGOTHER does not have clinically important pharmacokinetic interactions with DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER.",captopril,isosorbide mononitrate,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,[H][C@]1(O)CO[C@]2([H])[C@]([H])(O)CO[C@]12[H],14,19
3013,15343,15343,15686,15686,"No Important Interactions To Date DRUGOTHER does not have clinically important pharmacokinetic interactions with DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER.",captopril,carvedilol,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2,14,20
3014,15344,15344,15687,15687,"No Important Interactions To Date DRUGOTHER does not have clinically important pharmacokinetic interactions with DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER.",captopril,ethanol,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCO,14,21
3015,15345,15345,15688,15688,"No Important Interactions To Date DRUGOTHER does not have clinically important pharmacokinetic interactions with DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2.",captopril,itraconazole,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,14,23
3016,15382,15382,15730,15730,"Binding to Serum Proteins: The following agents may either inhibit DRUG1 binding to serum proteins or alter the concentrations of serum binding proteins: DRUGOTHER and related DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",levothyroxine sodium,furosemide,True,mechanism,4,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)[O-])N.[Na+],C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,10,33
3017,15389,15389,15737,15737,"Binding to Serum Proteins: The following agents may either inhibit DRUG1 binding to serum proteins or alter the concentrations of serum binding proteins: DRUGOTHER and related DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",levothyroxine sodium,phenytoin,True,mechanism,4,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)[O-])N.[Na+],C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,10,40
3018,15396,15396,15744,15744,"Binding to Serum Proteins: The following agents may either inhibit DRUGOTHER binding to serum proteins or alter the concentrations of serum binding proteins: DRUG1 and related DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",androgens,furosemide,False,Neg,0,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,23,33
3019,15403,15403,15751,15751,"Binding to Serum Proteins: The following agents may either inhibit DRUGOTHER binding to serum proteins or alter the concentrations of serum binding proteins: DRUG1 and related DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",androgens,phenytoin,False,Neg,0,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,23,40
3020,15409,15409,15757,15757,"Binding to Serum Proteins: The following agents may either inhibit DRUGOTHER binding to serum proteins or alter the concentrations of serum binding proteins: DRUGOTHER and related DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",clofibrate,furosemide,False,Neg,0,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,28,33
3021,15416,15416,15764,15764,"Binding to Serum Proteins: The following agents may either inhibit DRUGOTHER binding to serum proteins or alter the concentrations of serum binding proteins: DRUGOTHER and related DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",clofibrate,phenytoin,False,Neg,0,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,28,40
3022,15421,15421,15769,15769,"Binding to Serum Proteins: The following agents may either inhibit DRUGOTHER binding to serum proteins or alter the concentrations of serum binding proteins: DRUGOTHER and related DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 and DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",estrogens,furosemide,False,Neg,0,C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)OS(=O)(=O)[O-])[C@@H]1CCC2=O.[Na+],C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,29,33
3023,15428,15428,15776,15776,"Binding to Serum Proteins: The following agents may either inhibit DRUGOTHER binding to serum proteins or alter the concentrations of serum binding proteins: DRUGOTHER and related DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",estrogens,phenytoin,False,Neg,0,C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)OS(=O)(=O)[O-])[C@@H]1CCC2=O.[Na+],C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,29,40
3024,15432,15432,15780,15780,"Binding to Serum Proteins: The following agents may either inhibit DRUGOTHER binding to serum proteins or alter the concentrations of serum binding proteins: DRUGOTHER and related DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",estrogen-containing compounds,furosemide,False,Neg,0,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,31,33
3025,15439,15439,15787,15787,"Binding to Serum Proteins: The following agents may either inhibit DRUGOTHER binding to serum proteins or alter the concentrations of serum binding proteins: DRUGOTHER and related DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",estrogen-containing compounds,phenytoin,False,Neg,0,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,31,40
3026,15442,15442,15790,15790,"Binding to Serum Proteins: The following agents may either inhibit DRUGOTHER binding to serum proteins or alter the concentrations of serum binding proteins: DRUGOTHER and related DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",5-fluorouracil,furosemide,False,Neg,0,FC1=CNC(=O)NC1=O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,32,33
3027,15449,15449,15797,15797,"Binding to Serum Proteins: The following agents may either inhibit DRUGOTHER binding to serum proteins or alter the concentrations of serum binding proteins: DRUGOTHER and related DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",5-fluorouracil,phenytoin,False,Neg,0,FC1=CNC(=O)NC1=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,32,40
3028,15452,15452,15800,15800,"Binding to Serum Proteins: The following agents may either inhibit DRUGOTHER binding to serum proteins or alter the concentrations of serum binding proteins: DRUGOTHER and related DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",furosemide,glucocorticoids,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1,33,34
3029,15453,15453,15801,15801,"Binding to Serum Proteins: The following agents may either inhibit DRUGOTHER binding to serum proteins or alter the concentrations of serum binding proteins: DRUGOTHER and related DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",furosemide,meclofenamic acid,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1,33,35
3030,15454,15454,15802,15802,"Binding to Serum Proteins: The following agents may either inhibit DRUGOTHER binding to serum proteins or alter the concentrations of serum binding proteins: DRUGOTHER and related DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",furosemide,mefenamic acid,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1,33,36
3031,15455,15455,15803,15803,"Binding to Serum Proteins: The following agents may either inhibit DRUGOTHER binding to serum proteins or alter the concentrations of serum binding proteins: DRUGOTHER and related DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",furosemide,methadone,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,33,37
3032,15456,15456,15804,15804,"Binding to Serum Proteins: The following agents may either inhibit DRUGOTHER binding to serum proteins or alter the concentrations of serum binding proteins: DRUGOTHER and related DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",furosemide,perphenazine,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,33,38
3033,15457,15457,15805,15805,"Binding to Serum Proteins: The following agents may either inhibit DRUGOTHER binding to serum proteins or alter the concentrations of serum binding proteins: DRUGOTHER and related DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER.",furosemide,phenylbutazone,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,33,39
3034,15459,15459,15807,15807,"Binding to Serum Proteins: The following agents may either inhibit DRUGOTHER binding to serum proteins or alter the concentrations of serum binding proteins: DRUGOTHER and related DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER.",furosemide,salicylates,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1,33,41
3035,15460,15460,15808,15808,"Binding to Serum Proteins: The following agents may either inhibit DRUGOTHER binding to serum proteins or alter the concentrations of serum binding proteins: DRUGOTHER and related DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2.",furosemide,tamoxifen,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,33,42
3036,15466,15466,15814,15814,"Binding to Serum Proteins: The following agents may either inhibit DRUGOTHER binding to serum proteins or alter the concentrations of serum binding proteins: DRUGOTHER and related DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",glucocorticoids,phenytoin,False,Neg,0,COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,34,40
3037,15473,15473,15821,15821,"Binding to Serum Proteins: The following agents may either inhibit DRUGOTHER binding to serum proteins or alter the concentrations of serum binding proteins: DRUGOTHER and related DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",meclofenamic acid,phenytoin,False,Neg,0,CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,35,40
3038,15479,15479,15827,15827,"Binding to Serum Proteins: The following agents may either inhibit DRUGOTHER binding to serum proteins or alter the concentrations of serum binding proteins: DRUGOTHER and related DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",mefenamic acid,phenytoin,False,Neg,0,CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,36,40
3039,15484,15484,15832,15832,"Binding to Serum Proteins: The following agents may either inhibit DRUGOTHER binding to serum proteins or alter the concentrations of serum binding proteins: DRUGOTHER and related DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",methadone,phenytoin,False,Neg,0,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,37,40
3040,15488,15488,15836,15836,"Binding to Serum Proteins: The following agents may either inhibit DRUGOTHER binding to serum proteins or alter the concentrations of serum binding proteins: DRUGOTHER and related DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",perphenazine,phenytoin,False,Neg,0,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,38,40
3041,15491,15491,15839,15839,"Binding to Serum Proteins: The following agents may either inhibit DRUGOTHER binding to serum proteins or alter the concentrations of serum binding proteins: DRUGOTHER and related DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER.",phenylbutazone,phenytoin,False,Neg,0,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,39,40
3042,15494,15494,15842,15842,"Binding to Serum Proteins: The following agents may either inhibit DRUGOTHER binding to serum proteins or alter the concentrations of serum binding proteins: DRUGOTHER and related DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER.",phenytoin,salicylates,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1,40,41
3043,15495,15495,15843,15843,"Binding to Serum Proteins: The following agents may either inhibit DRUGOTHER binding to serum proteins or alter the concentrations of serum binding proteins: DRUGOTHER and related DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2.",phenytoin,tamoxifen,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,40,42
3044,15519,15519,15867,15867,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",aminoglutethimide,nitroprusside,False,Neg,0,CCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,30,69
3045,15521,15521,15869,15869,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",aminoglutethimide,phenytoin,False,Neg,0,CCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,30,71
3046,15525,15525,15873,15873,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",aminoglutethimide,sulfonamides,False,Neg,0,CCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,30,75
3047,15548,15548,15896,15896,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",p-aminosalicylic acid,nitroprusside,False,Neg,0,NC1=CC(O)=C(C=C1)C(O)=O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,31,69
3048,15550,15550,15898,15898,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",p-aminosalicylic acid,phenytoin,False,Neg,0,NC1=CC(O)=C(C=C1)C(O)=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,31,71
3049,15554,15554,15902,15902,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",p-aminosalicylic acid,sulfonamides,False,Neg,0,NC1=CC(O)=C(C=C1)C(O)=O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,31,75
3050,15576,15576,15924,15924,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",amiodarone,nitroprusside,False,Neg,0,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,32,69
3051,15578,15578,15926,15926,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",amiodarone,phenytoin,False,Neg,0,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,32,71
3052,15582,15582,15930,15930,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",amiodarone,sulfonamides,False,Neg,0,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,32,75
3053,15603,15603,15951,15951,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",androgens,nitroprusside,False,Neg,0,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,33,69
3054,15605,15605,15953,15953,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",androgens,phenytoin,False,Neg,0,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,33,71
3055,15609,15609,15957,15957,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",androgens,sulfonamides,False,Neg,0,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,33,75
3056,15629,15629,15977,15977,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",thiocyanate,nitroprusside,False,Neg,0,S=C=NCCC1=CC=CC=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,40,69
3057,15631,15631,15979,15979,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",thiocyanate,phenytoin,False,Neg,0,S=C=NCCC1=CC=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,40,71
3058,15635,15635,15983,15983,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",thiocyanate,sulfonamides,False,Neg,0,S=C=NCCC1=CC=CC=C1,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,40,75
3059,15654,15654,16002,16002,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",perchlorate,nitroprusside,False,Neg,0,[O-][Cl](=O)(=O)=O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,41,69
3060,15656,15656,16004,16004,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",perchlorate,phenytoin,False,Neg,0,[O-][Cl](=O)(=O)=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,41,71
3061,15660,15660,16008,16008,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",perchlorate,sulfonamides,False,Neg,0,[O-][Cl](=O)(=O)=O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,41,75
3062,15678,15678,16026,16026,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",pertechnetate,nitroprusside,False,Neg,0,O.O.O.O.[98Tc-],CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,42,69
3063,15680,15680,16028,16028,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",pertechnetate,phenytoin,False,Neg,0,O.O.O.O.[98Tc-],C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,42,71
3064,15684,15684,16032,16032,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",pertechnetate,sulfonamides,False,Neg,0,O.O.O.O.[98Tc-],CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,42,75
3065,15701,15701,16049,16049,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",b-adrenergic blocking agents,nitroprusside,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,44,69
3066,15703,15703,16051,16051,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",b-adrenergic blocking agents,phenytoin,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,44,71
3067,15707,15707,16055,16055,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",b-adrenergic blocking agents,sulfonamides,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,44,75
3068,15723,15723,16071,16071,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",carbamazepine,nitroprusside,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,45,69
3069,15725,15725,16073,16073,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",carbamazepine,phenytoin,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,45,71
3070,15729,15729,16077,16077,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",carbamazepine,sulfonamides,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,45,75
3071,15744,15744,16092,16092,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",chloral hydrate,nitroprusside,False,Neg,0,C(C(Cl)(Cl)Cl)(O)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,46,69
3072,15746,15746,16094,16094,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",chloral hydrate,phenytoin,False,Neg,0,C(C(Cl)(Cl)Cl)(O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,46,71
3073,15750,15750,16098,16098,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",chloral hydrate,sulfonamides,False,Neg,0,C(C(Cl)(Cl)Cl)(O)O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,46,75
3074,15764,15764,16112,16112,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",diazepam,nitroprusside,False,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,47,69
3075,15766,15766,16114,16114,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",diazepam,phenytoin,False,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,47,71
3076,15770,15770,16118,16118,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",diazepam,sulfonamides,False,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,47,75
3077,15783,15783,16131,16131,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 and DRUG1 agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",dopamine,nitroprusside,False,Neg,0,[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,48,69
3078,15785,15785,16133,16133,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 and DRUG1 agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",dopamine,phenytoin,False,Neg,0,[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,48,71
3079,15789,15789,16137,16137,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 and DRUG1 agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",dopamine,sulfonamides,False,Neg,0,[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,48,75
3080,15801,15801,16149,16149,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",dopamine agonists,nitroprusside,False,Neg,0,NCCC1=CC(O)=C(O)C=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,50,68
3081,15803,15803,16151,16151,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",dopamine agonists,phenytoin,False,Neg,0,NCCC1=CC(O)=C(O)C=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,50,70
3082,15807,15807,16155,16155,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",dopamine agonists,sulfonamides,False,Neg,0,NCCC1=CC(O)=C(O)C=C1,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,50,74
3083,15818,15818,16166,16166,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUG1, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",ethionamide,nitroprusside,False,Neg,0,CCC1=NC=CC(=C1)C(N)=S,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,52,69
3084,15820,15820,16168,16168,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUG1, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",ethionamide,phenytoin,False,Neg,0,CCC1=NC=CC(=C1)C(N)=S,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,52,71
3085,15824,15824,16172,16172,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUG1, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",ethionamide,sulfonamides,False,Neg,0,CCC1=NC=CC(=C1)C(N)=S,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,52,75
3086,15834,15834,16182,16182,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUG1, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",glucocorticoids,nitroprusside,False,Neg,0,COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,53,69
3087,15836,15836,16184,16184,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUG1, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",glucocorticoids,phenytoin,False,Neg,0,COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,53,71
3088,15840,15840,16188,16188,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUG1, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",glucocorticoids,sulfonamides,False,Neg,0,COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,53,75
3089,15849,15849,16197,16197,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUG1, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",heparin,nitroprusside,False,Neg,0,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,54,69
3090,15851,15851,16199,16199,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUG1, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",heparin,phenytoin,False,Neg,0,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,54,71
3091,15855,15855,16203,16203,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUG1, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",heparin,sulfonamides,False,Neg,0,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,54,75
3092,15863,15863,16211,16211,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUG1, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",insulin,nitroprusside,False,Neg,0,CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CN=CN2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,58,69
3093,15865,15865,16213,16213,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUG1, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",insulin,phenytoin,False,Neg,0,CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CN=CN2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,58,71
3094,15869,15869,16217,16217,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUG1, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",insulin,sulfonamides,False,Neg,0,CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CN=CN2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,58,75
3095,15876,15876,16224,16224,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",iodine-containing compounds,nitroprusside,False,Neg,0,[Na+].[I-],CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,62,69
3096,15878,15878,16226,16226,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",iodine-containing compounds,phenytoin,False,Neg,0,[Na+].[I-],C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,62,71
3097,15882,15882,16230,16230,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",iodine-containing compounds,sulfonamides,False,Neg,0,[Na+].[I-],CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,62,75
3098,15888,15888,16236,16236,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",levodopa,nitroprusside,False,Neg,0,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,63,69
3099,15890,15890,16238,16238,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",levodopa,phenytoin,False,Neg,0,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,63,71
3100,15894,15894,16242,16242,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",levodopa,sulfonamides,False,Neg,0,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,63,75
3101,15899,15899,16247,16247,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",lovastatin,nitroprusside,False,Neg,0,CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,64,69
3102,15901,15901,16249,16249,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",lovastatin,phenytoin,False,Neg,0,CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,64,71
3103,15905,15905,16253,16253,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",lovastatin,sulfonamides,False,Neg,0,CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,64,75
3104,15909,15909,16257,16257,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",6-mercaptopurine,nitroprusside,False,Neg,0,S=C1N=CNC2=C1NC=N2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,66,69
3105,15911,15911,16259,16259,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",6-mercaptopurine,phenytoin,False,Neg,0,S=C1N=CNC2=C1NC=N2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,66,71
3106,15915,15915,16263,16263,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",6-mercaptopurine,sulfonamides,False,Neg,0,S=C1N=CNC2=C1NC=N2,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,66,75
3107,15918,15918,16266,16266,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",metoclopramide,nitroprusside,False,Neg,0,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,67,69
3108,15920,15920,16268,16268,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",metoclopramide,phenytoin,False,Neg,0,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,67,71
3109,15924,15924,16272,16272,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",metoclopramide,sulfonamides,False,Neg,0,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,67,75
3110,15926,15926,16274,16274,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",mitotane,nitroprusside,False,Neg,0,C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,68,69
3111,15928,15928,16276,16276,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",mitotane,phenytoin,False,Neg,0,C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,68,71
3112,15932,15932,16280,16280,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",mitotane,sulfonamides,False,Neg,0,C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,68,75
3113,15934,15934,16282,16282,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",nitroprusside,phenobarbital,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,69,70
3114,15936,15936,16284,16284,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",nitroprusside,resorcinol,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,OC1=CC(O)=CC=C1,69,72
3115,15937,15937,16285,16285,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",nitroprusside,rifampin,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,69,73
3116,15938,15938,16286,16286,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER.",nitroprusside,somatostatin analogs,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O,69,74
3117,15940,15940,16288,16288,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER.",nitroprusside,sulfonylureas,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,NC(N)=O,69,76
3118,15941,15941,16289,16289,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",phenobarbital,phenytoin,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,70,71
3119,15945,15945,16293,16293,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",phenobarbital,sulfonamides,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,70,75
3120,15947,15947,16295,16295,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",phenytoin,resorcinol,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,OC1=CC(O)=CC=C1,71,72
3121,15948,15948,16296,16296,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",phenytoin,rifampin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,71,73
3122,15949,15949,16297,16297,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER.",phenytoin,somatostatin analogs,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O,71,74
3123,15951,15951,16299,16299,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER.",phenytoin,sulfonylureas,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NC(N)=O,71,76
3124,15954,15954,16302,16302,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",resorcinol,sulfonamides,False,Neg,0,OC1=CC(O)=CC=C1,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,72,75
3125,15957,15957,16305,16305,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",rifampin,sulfonamides,False,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,73,75
3126,15959,15959,16307,16307,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER.",somatostatin analogs,sulfonamides,False,Neg,0,C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,74,75
3127,15961,15961,16309,16309,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER.",sulfonamides,sulfonylureas,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,NC(N)=O,75,76
3128,15986,15986,16335,16335,"Therefore, DRUG1 has the potential for interaction with DRUG2 and DRUGOTHER.",linezolid,adrenergic,True,int,3,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,1,8
3129,15987,15987,16336,16336,"Therefore, DRUG1 has the potential for interaction with DRUGOTHER and DRUG2.",linezolid,serotonergic agents,True,int,3,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,1,10
3130,15989,15989,16338,16338,"DRUG1:Some individuals receiving DRUG2 may experience a reversible enhancement of the pressor response to indirect-acting DRUGOTHER, DRUGOTHER or DRUGOTHER.",Adrenergic Agents,ZYVOX,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1,0,3
3131,15991,15991,16340,16340,"DRUG1:Some individuals receiving DRUGOTHER may experience a reversible enhancement of the pressor response to indirect-acting DRUGOTHER, DRUG2 or DRUGOTHER.",Adrenergic Agents,vasopressor,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,0,16
3132,15993,15993,16342,16342,"DRUGOTHER:Some individuals receiving DRUG1 may experience a reversible enhancement of the pressor response to indirect-acting DRUG2, DRUGOTHER or DRUGOTHER.",ZYVOX,sympathomimetic agents,True,effect,2,CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,3,15
3133,15995,15995,16344,16344,"DRUGOTHER:Some individuals receiving DRUG1 may experience a reversible enhancement of the pressor response to indirect-acting DRUGOTHER, DRUGOTHER or DRUG2.",ZYVOX,dopaminergic agents,True,effect,2,CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1,NCCC1=CC(O)=C(O)C=C1,3,18
3134,15996,15996,16345,16345,"DRUGOTHER:Some individuals receiving DRUGOTHER may experience a reversible enhancement of the pressor response to indirect-acting DRUG1, DRUG2 or DRUGOTHER.",sympathomimetic agents,vasopressor,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,15,16
3135,15998,15998,16347,16347,"DRUGOTHER:Some individuals receiving DRUGOTHER may experience a reversible enhancement of the pressor response to indirect-acting DRUGOTHER, DRUG1 or DRUG2.",vasopressor,dopaminergic agents,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,NCCC1=CC(O)=C(O)C=C1,16,18
3136,16001,16001,16350,16350,"DRUG1: Co-administration of DRUG2 and DRUGOTHER was not associated with serotonin syndrome in Phase 1, 2 or 3 studies.",Serotonergic Agents,linezolid,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,0,3
3137,16003,16003,16352,16352,"DRUGOTHER: Co-administration of DRUG1 and DRUG2 was not associated with serotonin syndrome in Phase 1, 2 or 3 studies.",linezolid,serotonergic agents,False,Neg,0,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,3,5
3138,16004,16004,16353,16353,"Spontaneous reports of serotonin syndrome associated with co-administration of DRUG1 and DRUG2, including DRUGOTHER such as DRUGOTHER (DRUGOTHER), have been reported.",ZYVOX,serotonergic agents,True,effect,2,CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,9,11
3139,16005,16005,16354,16354,"Spontaneous reports of serotonin syndrome associated with co-administration of DRUG1 and DRUGOTHER, including DRUG2 such as DRUGOTHER (DRUGOTHER), have been reported.",ZYVOX,antidepressants,True,effect,2,CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,9,13
3140,16008,16008,16357,16357,"Spontaneous reports of serotonin syndrome associated with co-administration of DRUGOTHER and DRUG1, including DRUGOTHER such as DRUG2 (DRUGOTHER), have been reported.",serotonergic agents,selective serotonin reuptake inhibitors,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,NCCC1=CNC2=CC=C(O)C=C12,11,16
3141,16009,16009,16358,16358,"Spontaneous reports of serotonin syndrome associated with co-administration of DRUGOTHER and DRUGOTHER, including DRUG1 such as DRUG2 (DRUGOTHER), have been reported.",antidepressants,selective serotonin reuptake inhibitors,False,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,NCCC1=CNC2=CC=C(O)C=C12,13,16
3142,16010,16010,16359,16359,"Patients who are treated with DRUG1 and concomitant DRUG2 should be closely observed for signs and symptoms of serotonin syndrome (e.g., cognitive dysfunction, hyperpyrexia, hyperreflexia, incoordination).",ZYVOX,serotonergic agents,True,effect,2,CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,5,8
3143,16011,16011,16360,16360,If any signs or symptoms occur physicians should consider discontinuation of either one or both agents (DRUG1 or concomitant DRUG2).,ZYVOX,serotonergic agents,True,advise,1,CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,16,19
3144,16031,16031,16380,16380,DRUG1s: DRUG2 increases the adrenergic effect of catecholamines such as DRUGOTHER and norDRUGOTHER.,Vasopressor,Thyroxine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,0,1
3145,16032,16032,16381,16381,DRUG1s: DRUGOTHER increases the adrenergic effect of catecholamines such as DRUGOTHER and DRUG2.,Vasopressor,norepinephrine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C1=CC(=C(C=C1[C@H](CN)O)O)O,0,12
3146,16088,16088,16437,16437,DRUG1: DRUG2 may delay intestinal absorption of DRUGOTHER.,Ethosuximide,Amphetamines,False,Neg,0,CCC1(C)CC(=O)NC1=O,CC(N)CC1=CC=CC=C1,0,1
3147,16090,16090,16439,16439,DRUGOTHER: DRUG1 may delay intestinal absorption of DRUG2.,Amphetamines,ethosuximide,True,mechanism,4,CC(N)CC1=CC=CC=C1,CCC1(C)CC(=O)NC1=O,1,7
3148,16092,16092,16441,16441,"DRUG1: DRUG1 blocks dopamine receptors, thus inhibiting the central stimulant effects of DRUG2.",Haloperidol,amphetamines,False,Neg,0,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1,CC(N)CC1=CC=CC=C1,0,12
3149,16093,16093,16442,16442,"DRUG1: DRUG1 blocks dopamine receptors, thus inhibiting the central stimulant effects of DRUG2.",Haloperidol,amphetamines,True,effect,2,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1,CC(N)CC1=CC=CC=C1,0,12
3150,16097,16097,16446,16446,DRUG1: DRUG2 potentiate the analgesic effect of DRUGOTHER.,Meperidine,Amphetamines,False,Neg,0,CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1,CC(N)CC1=CC=CC=C1,0,1
3151,16099,16099,16448,16448,DRUGOTHER: DRUG1 potentiate the analgesic effect of DRUG2.,Amphetamines,meperidine,True,effect,2,CC(N)CC1=CC=CC=C1,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,1,7
3152,16107,16107,16458,16458,DRUG1: DRUG2 may delay intestinal absorption of DRUGOTHER;,Phenytoin,Amphetamines,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(N)CC1=CC=CC=C1,0,1
3153,16109,16109,16460,16460,DRUGOTHER: DRUG1 may delay intestinal absorption of DRUG2;,Amphetamines,phenytoin,True,mechanism,4,CC(N)CC1=CC=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,1,7
3154,16124,16124,16475,16475,"DRUG1: In some patients with compromised renal function who are being treated with DRUGOTHER, the co-administration of DRUG2 may result in a further deterioration of renal function.",Non-steroidal Anti-inflammatory Agents,lisinopril,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,0,17
3155,16125,16125,16476,16476,"DRUGOTHER: In some patients with compromised renal function who are being treated with DRUG1, the co-administration of DRUG2 may result in a further deterioration of renal function.",non-steroidal anti-inflammatory drugs,lisinopril,True,effect,2,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,13,17
3156,16136,16136,16487,16487,No clinically important pharmacokinetic interactions occurred when DRUG1 was used concomitantly with DRUGOTHER or DRUG2.,PRINIVIL,hydrochlorothiazide,False,Neg,0,NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,7,14
3157,16137,16137,16488,16488,No clinically important pharmacokinetic interactions occurred when DRUGOTHER was used concomitantly with DRUG1 or DRUG2.,propranolol,hydrochlorothiazide,False,Neg,0,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,12,14
3158,16138,16138,16489,16489,"Use of DRUG1 with DRUGOTHER (e.g., DRUG2, DRUGOTHER, or DRUGOTHER), DRUGOTHER supplements, or DRUGOTHER-containing salt substitutes may lead to significant increases in serum DRUGOTHER.",PRINIVIL,spironolactone,True,effect,2,NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,2,6
3159,16141,16141,16492,16492,"Use of DRUGOTHER with DRUGOTHER (e.g., DRUG1, DRUG2, or DRUGOTHER), DRUGOTHER supplements, or DRUGOTHER-containing salt substitutes may lead to significant increases in serum DRUGOTHER.",spironolactone,triamterene,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,6,7
3160,16142,16142,16493,16493,"Use of DRUGOTHER with DRUGOTHER (e.g., DRUG1, DRUGOTHER, or DRUG2), DRUGOTHER supplements, or DRUGOTHER-containing salt substitutes may lead to significant increases in serum DRUGOTHER.",spironolactone,amiloride,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N,6,9
3161,16146,16146,16497,16497,"DRUG1: In three pharmacokinetic studies including 46 normal, healthy subjects, DRUGOTHER clearance and concentration were not significantly altered by the addition of DRUG2.",Theophylline,lomefloxacin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O,0,22
3162,16147,16147,16498,16498,"DRUGOTHER: In three pharmacokinetic studies including 46 normal, healthy subjects, DRUG1 clearance and concentration were not significantly altered by the addition of DRUG2.",theophylline,lomefloxacin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O,10,22
3163,16148,16148,16499,16499,"In clinical studies where patients were on chronic DRUG1 therapy, DRUG2 had no measurable effect on the mean distribution of DRUG1 concentrations or the mean estimates of DRUG1 clearance.",theophylline,lomefloxacin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O,8,10
3164,16151,16151,16502,16502,"In clinical studies where patients were on chronic DRUG2 therapy, DRUG1 had no measurable effect on the mean distribution of DRUG2 concentrations or the mean estimates of DRUG2 clearance.",lomefloxacin,theophylline,False,Neg,0,CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,10,8
3165,16152,16152,16503,16503,"In clinical studies where patients were on chronic DRUG2 therapy, DRUG1 had no measurable effect on the mean distribution of DRUG2 concentrations or the mean estimates of DRUG2 clearance.",lomefloxacin,theophylline,False,Neg,0,CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,10,8
3166,16169,16169,16520,16520,"DRUG1: Two hundred mg of DRUGOTHER (equivalent to 1 to 3 cups of American coffee) was administered to 16 normal, healthy volunteers who had achieved steady-state blood concentrations of DRUG2 after being dosed at 400 mg qd.",Caffeine,lomefloxacin,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O,0,29
3167,16170,16170,16521,16521,"DRUGOTHER: Two hundred mg of DRUG1 (equivalent to 1 to 3 cups of American coffee) was administered to 16 normal, healthy volunteers who had achieved steady-state blood concentrations of DRUG2 after being dosed at 400 mg qd.",caffeine,lomefloxacin,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O,5,29
3168,16187,16187,16538,16538,"DRUG1: No significant differences were observed in mean DRUGOTHER AUC, C max , C min or T max (although C max increased by 11%) when extended DRUGOTHER sodium capsules (100 mg tid) were coadministered with DRUG2 (400 mg qd) for five days in 15 healthy males.",Phenytoin,lomefloxacin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O,0,35
3169,16189,16189,16540,16540,"DRUGOTHER: No significant differences were observed in mean DRUG1 AUC, C max , C min or T max (although C max increased by 11%) when extended DRUG1 sodium capsules (100 mg tid) were coadministered with DRUG2 (400 mg qd) for five days in 15 healthy males.",phenytoin,lomefloxacin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O,8,35
3170,16190,16190,16541,16541,"DRUGOTHER: No significant differences were observed in mean DRUGOTHER AUC, C max , C min or T max (although C max increased by 11%) when extended DRUG1 capsules (100 mg tid) were coadministered with DRUG2 (400 mg qd) for five days in 15 healthy males.",phenytoin sodium,lomefloxacin,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O,26,34
3171,16191,16191,16542,16542,DRUG1 is unlikely to have a significant effect on DRUG2 metabolism.,Lomefloxacin,phenytoin,False,Neg,0,CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,9
3172,16275,16275,16633,16633,"No significant drug-drug pharmacokinetic interactions have been found in interaction studies with DRUG1, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER.",hydrochlorothiazide,digoxin,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,12,13
3173,16276,16276,16634,16634,"No significant drug-drug pharmacokinetic interactions have been found in interaction studies with DRUG1, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER.",hydrochlorothiazide,warfarin,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,12,14
3174,16277,16277,16635,16635,"No significant drug-drug pharmacokinetic interactions have been found in interaction studies with DRUG1, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER.",hydrochlorothiazide,cimetidine,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,CC1=C(N=CN1)CSCCNC(=NC)NC#N,12,15
3175,16278,16278,16636,16636,"No significant drug-drug pharmacokinetic interactions have been found in interaction studies with DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2.",hydrochlorothiazide,phenobarbital,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,12,17
3176,16293,16293,16651,16651,"As with other drugs that block angiotensin II or its effects, concomitant use of DRUGOTHER (e.g., DRUG1, DRUG2, DRUGOTHER), DRUGOTHER supplements, or salt substitutes containing DRUGOTHER may lead to increases in serum DRUGOTHER.",spironolactone,triamterene,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,16,17
3177,16294,16294,16652,16652,"As with other drugs that block angiotensin II or its effects, concomitant use of DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUG2), DRUGOTHER supplements, or salt substitutes containing DRUGOTHER may lead to increases in serum DRUGOTHER.",spironolactone,amiloride,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N,16,18
3178,16333,16333,16691,16691,"Oral DRUG1: In pharmacokinetic studies of DRUGOTHER in hypercholesterolemic noninsulin dependent diabetic patients, there was no drug interaction with DRUG2 or with DRUGOTHER",Hypoglycemic Agents,glipizide,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,1,19
3179,16335,16335,16693,16693,"Oral DRUGOTHER: In pharmacokinetic studies of DRUGOTHER in hypercholesterolemic noninsulin dependent diabetic patients, there was no drug interaction with DRUG1 or with DRUG2",glipizide,chlorpropamide,False,Neg,0,CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl,19,22
3180,16364,16364,16722,16722,"During concomitant therapy of DRUG1 with DRUG2, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.",Ponstel,furosemide,True,advise,1,CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,4,6
3181,16411,16411,16770,16770,"In patients taking an DRUG1 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2), the concomitant use of DRUGOTHER may reduce seizure control by lowering the plasma levels of the DRUG1.",anticonvulsant,phenytoin,False,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,4,10
3182,16416,16416,16775,16775,"In patients taking an DRUGOTHER (eg, DRUG1, DRUGOTHER, DRUGOTHER or DRUG2), the concomitant use of DRUGOTHER may reduce seizure control by lowering the plasma levels of the DRUGOTHER.",valproic acid,phenytoin,False,Neg,0,CCCC(CCC)C(=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,6,10
3183,16420,16420,16779,16779,"In patients taking an DRUGOTHER (eg, DRUGOTHER, DRUG1, DRUGOTHER or DRUG2), the concomitant use of DRUGOTHER may reduce seizure control by lowering the plasma levels of the DRUGOTHER.",carbamazepine,phenytoin,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,7,10
3184,16423,16423,16782,16782,"In patients taking an DRUGOTHER (eg, DRUGOTHER, DRUGOTHER, DRUG1 or DRUG2), the concomitant use of DRUGOTHER may reduce seizure control by lowering the plasma levels of the DRUGOTHER.",phenobarbital,phenytoin,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,8,10
3185,16426,16426,16785,16785,"In patients taking an DRUGOTHER (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG1), the concomitant use of DRUG2 may reduce seizure control by lowering the plasma levels of the DRUGOTHER.",phenytoin,Mefloquine,True,effect,2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,OC(C1CCCCN1)C1=CC(=NC2=C1C=CC=C2C(F)(F)F)C(F)(F)F,10,15
3186,16427,16427,16786,16786,"In patients taking an DRUG2 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG1), the concomitant use of DRUGOTHER may reduce seizure control by lowering the plasma levels of the DRUG2.",phenytoin,anticonvulsant,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,10,4
3187,16447,16447,16829,16829,DRUG1-DRUG1 may decrease the absorption of DRUG2.,Orlistat,vitamin K,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CC1=C(C(=O)C2=CC=CC=C2C1=O)C/C=C(\C)/CCCC(C)CCCC(C)CCCC(C)C,0,6
3188,16448,16448,16830,16830,DRUG1-DRUG1 may decrease the absorption of DRUG2.,Orlistat,vitamin K,True,mechanism,4,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CC1=C(C(=O)C2=CC=CC=C2C1=O)C/C=C(\C)/CCCC(C)CCCC(C)CCCC(C)C,0,6
3189,16453,16453,16835,16835,"DRUGOTHER should be administered with caution to patients who are taking other DRUG1 or DRUG2, including DRUGOTHER, DRUGOTHER and DRUGOTHER, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).",psychoactive drugs,CNS depressants,False,Neg,0,OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,12,14
3190,16457,16457,16839,16839,"DRUGOTHER should be administered with caution to patients who are taking other DRUGOTHER or DRUG1, including DRUG2, DRUGOTHER and DRUGOTHER, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).",CNS depressants,alcohol,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCO,14,16
3191,16458,16458,16840,16840,"DRUGOTHER should be administered with caution to patients who are taking other DRUGOTHER or DRUG1, including DRUGOTHER, DRUG2 and DRUGOTHER, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).",CNS depressants,barbiturates,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O,14,17
3192,16459,16459,16841,16841,"DRUGOTHER should be administered with caution to patients who are taking other DRUGOTHER or DRUG1, including DRUGOTHER, DRUGOTHER and DRUG2, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).",CNS depressants,narcotic analgesics,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,14,19
3193,16468,16468,16850,16850,"DRUG1, a DRUG2, may antagonize the bactericidal effect of DRUGOTHER and concurrent use of these drugs should be avoided.",Tetracycline,bacteriostatic antibiotic,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,0,2
3194,16469,16469,16851,16851,"DRUG1, a DRUGOTHER, may antagonize the bactericidal effect of DRUG2 and concurrent use of these drugs should be avoided.",Tetracycline,penicillin,True,effect,2,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,0,9
3195,16471,16471,16853,16853,Elevated plasma levels of DRUG1 have been reported with concomitant DRUG2 use.,theophylline,quinolone,True,mechanism,4,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C(=O)C=CC2=CC=CC=C12,4,10
3196,16501,16501,16886,16886,"Because there is a theoretical basis that these effects may be additive, use of DRUG1-containing or DRUGOTHER (like dihydroDRUG1 or DRUG2) and DRUGOTHER within 24 hours is contraindicated.",ergotamine,methysergide,False,Neg,0,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C,14,20
3197,16502,16502,16888,16888,"Because there is a theoretical basis that these effects may be additive, use of DRUGOTHER-containing or DRUGOTHER (like DRUG1 or DRUG2) and DRUGOTHER within 24 hours is contraindicated.",dihydroergotamine,methysergide,False,Neg,0,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C,18,20
3198,16503,16503,16891,16891,"DRUG1 (DRUGOTHER) (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HTv agonists.",Selective serotonin reuptake inhibitors,fluoxetine,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,0,3
3199,16504,16504,16892,16892,"DRUG1 (DRUGOTHER) (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HTv agonists.",Selective serotonin reuptake inhibitors,fluvoxamine,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,0,4
3200,16505,16505,16893,16893,"DRUG1 (DRUGOTHER) (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HTv agonists.",Selective serotonin reuptake inhibitors,paroxetine,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,0,5
3201,16506,16506,16894,16894,"DRUG1 (DRUGOTHER) (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HTv agonists.",Selective serotonin reuptake inhibitors,sertraline,False,Neg,0,NCCC1=CNC2=CC=C(O)C=C12,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,0,6
3202,16529,16529,16917,16917,"In vitro displacement studies with highly protein-bound drugs such as DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER showed no influence on the extent of DRUGOTHER protein binding.",furosemide,propranolol,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,10,11
3203,16531,16531,16919,16919,"In vitro displacement studies with highly protein-bound drugs such as DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER showed no influence on the extent of DRUGOTHER protein binding.",furosemide,nicardipine,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1,10,13
3204,16533,16533,16921,16921,"In vitro displacement studies with highly protein-bound drugs such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER showed no influence on the extent of DRUGOTHER protein binding.",furosemide,glyburide,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,10,15
3205,16534,16534,16922,16922,"In vitro displacement studies with highly protein-bound drugs such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER showed no influence on the extent of DRUGOTHER protein binding.",furosemide,warfarin,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,10,16
3206,16536,16536,16924,16924,"In vitro displacement studies with highly protein-bound drugs such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER showed no influence on the extent of DRUGOTHER protein binding.",furosemide,acetylsalicylic acid,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC(=O)OC1=CC=CC=C1C(=O)O,10,18
3207,16537,16537,16925,16925,"In vitro displacement studies with highly protein-bound drugs such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER showed no influence on the extent of DRUGOTHER protein binding.",furosemide,tolbutamide,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,10,19
3208,16538,16538,16926,16926,"In vitro displacement studies with highly protein-bound drugs such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2 showed no influence on the extent of DRUGOTHER protein binding.",furosemide,metformin,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CN(C)C(=N)N=C(N)N,10,21
3209,16539,16539,16927,16927,"In vitro displacement studies with highly protein-bound drugs such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER showed no influence on the extent of DRUG2 protein binding.",furosemide,nateglinide,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,[H][C@](CC1=CC=CC=C1)(N=C(O)[C@@]1([H])CC[C@@]([H])(CC1)C(C)C)C(O)=O,10,29
3210,16540,16540,16928,16928,"In vitro displacement studies with highly protein-bound drugs such as DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER showed no influence on the extent of DRUGOTHER protein binding.",propranolol,captopril,False,Neg,0,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,11,12
3211,16542,16542,16930,16930,"In vitro displacement studies with highly protein-bound drugs such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER showed no influence on the extent of DRUGOTHER protein binding.",propranolol,pravastatin,False,Neg,0,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,11,14
3212,16545,16545,16933,16933,"In vitro displacement studies with highly protein-bound drugs such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER showed no influence on the extent of DRUGOTHER protein binding.",propranolol,phenytoin,False,Neg,0,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,11,17
3213,16550,16550,16938,16938,"In vitro displacement studies with highly protein-bound drugs such as DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER showed no influence on the extent of DRUGOTHER protein binding.",captopril,nicardipine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1,12,13
3214,16552,16552,16940,16940,"In vitro displacement studies with highly protein-bound drugs such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER showed no influence on the extent of DRUGOTHER protein binding.",captopril,glyburide,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,12,15
3215,16553,16553,16941,16941,"In vitro displacement studies with highly protein-bound drugs such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER showed no influence on the extent of DRUGOTHER protein binding.",captopril,warfarin,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,12,16
3216,16555,16555,16943,16943,"In vitro displacement studies with highly protein-bound drugs such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER showed no influence on the extent of DRUGOTHER protein binding.",captopril,acetylsalicylic acid,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(=O)OC1=CC=CC=C1C(=O)O,12,18
3217,16556,16556,16944,16944,"In vitro displacement studies with highly protein-bound drugs such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER showed no influence on the extent of DRUGOTHER protein binding.",captopril,tolbutamide,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,12,19
3218,16557,16557,16945,16945,"In vitro displacement studies with highly protein-bound drugs such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2 showed no influence on the extent of DRUGOTHER protein binding.",captopril,metformin,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN(C)C(=N)N=C(N)N,12,21
3219,16558,16558,16946,16946,"In vitro displacement studies with highly protein-bound drugs such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER showed no influence on the extent of DRUG2 protein binding.",captopril,nateglinide,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,[H][C@](CC1=CC=CC=C1)(N=C(O)[C@@]1([H])CC[C@@]([H])(CC1)C(C)C)C(O)=O,12,29
3220,16559,16559,16947,16947,"In vitro displacement studies with highly protein-bound drugs such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER showed no influence on the extent of DRUGOTHER protein binding.",nicardipine,pravastatin,False,Neg,0,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,13,14
3221,16562,16562,16950,16950,"In vitro displacement studies with highly protein-bound drugs such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER showed no influence on the extent of DRUGOTHER protein binding.",nicardipine,phenytoin,False,Neg,0,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,13,17
3222,16567,16567,16955,16955,"In vitro displacement studies with highly protein-bound drugs such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER showed no influence on the extent of DRUGOTHER protein binding.",pravastatin,glyburide,False,Neg,0,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,14,15
3223,16568,16568,16956,16956,"In vitro displacement studies with highly protein-bound drugs such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER showed no influence on the extent of DRUGOTHER protein binding.",pravastatin,warfarin,False,Neg,0,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,14,16
3224,16570,16570,16958,16958,"In vitro displacement studies with highly protein-bound drugs such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER showed no influence on the extent of DRUGOTHER protein binding.",pravastatin,acetylsalicylic acid,False,Neg,0,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,CC(=O)OC1=CC=CC=C1C(=O)O,14,18
3225,16571,16571,16959,16959,"In vitro displacement studies with highly protein-bound drugs such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER showed no influence on the extent of DRUGOTHER protein binding.",pravastatin,tolbutamide,False,Neg,0,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,14,19
3226,16572,16572,16960,16960,"In vitro displacement studies with highly protein-bound drugs such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2 showed no influence on the extent of DRUGOTHER protein binding.",pravastatin,metformin,False,Neg,0,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,CN(C)C(=N)N=C(N)N,14,21
3227,16573,16573,16961,16961,"In vitro displacement studies with highly protein-bound drugs such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER showed no influence on the extent of DRUG2 protein binding.",pravastatin,nateglinide,False,Neg,0,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,[H][C@](CC1=CC=CC=C1)(N=C(O)[C@@]1([H])CC[C@@]([H])(CC1)C(C)C)C(O)=O,14,29
3228,16575,16575,16963,16963,"In vitro displacement studies with highly protein-bound drugs such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER showed no influence on the extent of DRUGOTHER protein binding.",glyburide,phenytoin,False,Neg,0,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,15,17
3229,16580,16580,16968,16968,"In vitro displacement studies with highly protein-bound drugs such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER showed no influence on the extent of DRUGOTHER protein binding.",warfarin,phenytoin,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,16,17
3230,16585,16585,16973,16973,"In vitro displacement studies with highly protein-bound drugs such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER showed no influence on the extent of DRUGOTHER protein binding.",phenytoin,acetylsalicylic acid,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(=O)OC1=CC=CC=C1C(=O)O,17,18
3231,16586,16586,16974,16974,"In vitro displacement studies with highly protein-bound drugs such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER showed no influence on the extent of DRUGOTHER protein binding.",phenytoin,tolbutamide,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,17,19
3232,16587,16587,16975,16975,"In vitro displacement studies with highly protein-bound drugs such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2 showed no influence on the extent of DRUGOTHER protein binding.",phenytoin,metformin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN(C)C(=N)N=C(N)N,17,21
3233,16588,16588,16976,16976,"In vitro displacement studies with highly protein-bound drugs such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER showed no influence on the extent of DRUG2 protein binding.",phenytoin,nateglinide,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[H][C@](CC1=CC=CC=C1)(N=C(O)[C@@]1([H])CC[C@@]([H])(CC1)C(C)C)C(O)=O,17,29
3234,16599,16599,16987,16987,"Similarly, DRUG1 had no influence on the serum protein binding of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER in vitro .",nateglinide,phenytoin,False,Neg,0,[H][C@](CC1=CC=CC=C1)(N=C(O)[C@@]1([H])CC[C@@]([H])(CC1)C(C)C)C(O)=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,1,15
3235,16605,16605,16993,16993,"Similarly, DRUGOTHER had no influence on the serum protein binding of DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER in vitro .",propranolol,phenytoin,False,Neg,0,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,11,15
3236,16610,16610,16998,16998,"Similarly, DRUGOTHER had no influence on the serum protein binding of DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER in vitro .",glyburide,phenytoin,False,Neg,0,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,12,15
3237,16614,16614,17002,17002,"Similarly, DRUGOTHER had no influence on the serum protein binding of DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER in vitro .",nicardipine,phenytoin,False,Neg,0,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,13,15
3238,16617,16617,17005,17005,"Similarly, DRUGOTHER had no influence on the serum protein binding of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER in vitro .",warfarin,phenytoin,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,14,15
3239,16620,16620,17008,17008,"Similarly, DRUGOTHER had no influence on the serum protein binding of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER in vitro .",phenytoin,acetylsalicylic acid,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(=O)OC1=CC=CC=C1C(=O)O,15,16
3240,16621,16621,17009,17009,"Similarly, DRUGOTHER had no influence on the serum protein binding of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2 in vitro .",phenytoin,tolbutamide,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,15,18
3241,16633,16633,17021,17021,"Certain drugs including DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER may reduce the hypoglycemic action of DRUGOTHER and other oral DRUGOTHER.",thiazides,corticosteroids,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,3,4
3242,16634,16634,17022,17022,"Certain drugs including DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER may reduce the hypoglycemic action of DRUG2 and other oral DRUGOTHER.",thiazides,Starlix,True,effect,2,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,[H][C@](CC1=CC=CC=C1)(N=C(O)[C@@]1([H])CC[C@@]([H])(CC1)C(C)C)C(O)=O,3,14
3243,16755,16755,17144,17144,DRUG1: Coadministration of DRUGOTHER with DRUG2 resulted in a 152% increase in DRUGOTHER plasma AUC and very little change in DRUGOTHER plasma A.C.,Ritonavir,VIRACEPT,False,Neg,0,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C,0,5
3244,16756,16756,17145,17145,DRUG1: Coadministration of DRUGOTHER with DRUGOTHER resulted in a 152% increase in DRUG2 plasma AUC and very little change in DRUGOTHER plasma A.C.,Ritonavir,nelfinavir,False,Neg,0,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,0,12
3245,16758,16758,17147,17147,DRUGOTHER: Coadministration of DRUG1 with DRUG2 resulted in a 152% increase in DRUGOTHER plasma AUC and very little change in DRUG1 plasma A.C.,ritonavir,VIRACEPT,True,mechanism,4,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C,3,5
3246,16759,16759,17148,17148,DRUGOTHER: Coadministration of DRUG1 with DRUGOTHER resulted in a 152% increase in DRUG2 plasma AUC and very little change in DRUG1 plasma A.C.,ritonavir,nelfinavir,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,3,12
3247,16762,16762,17151,17151,DRUGOTHER: Coadministration of DRUG2 with DRUG1 resulted in a 152% increase in DRUGOTHER plasma AUC and very little change in DRUG2 plasma A.C.,VIRACEPT,ritonavir,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,5,3
3248,16763,16763,17152,17152,DRUGOTHER: Coadministration of DRUG2 with DRUGOTHER resulted in a 152% increase in DRUG1 plasma AUC and very little change in DRUG2 plasma A.C.,nelfinavir,ritonavir,False,Neg,0,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,12,3
3249,16766,16766,17155,17155,DRUG1: Coadministration of DRUGOTHER (using an experimental soft-gelatin capsule formulation of DRUGOTHER 1200mg) with DRUG2 resulted in an 18% increase in DRUGOTHER plasma AUC and a 4-fold increase in DRUGOTHER plasma A.C.,Saquinavir,VIRACEPT,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C,0,14
3250,16767,16767,17156,17156,DRUG1: Coadministration of DRUGOTHER (using an experimental soft-gelatin capsule formulation of DRUGOTHER 1200mg) with DRUGOTHER resulted in an 18% increase in DRUG2 plasma AUC and a 4-fold increase in DRUGOTHER plasma A.C.,Saquinavir,nelfinavir,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,0,21
3251,16770,16770,17159,17159,DRUGOTHER: Coadministration of DRUG1 (using an experimental soft-gelatin capsule formulation of DRUG1 1200mg) with DRUG2 resulted in an 18% increase in DRUGOTHER plasma AUC and a 4-fold increase in DRUG1 plasma A.C.,saquinavir,VIRACEPT,True,mechanism,4,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C,3,14
3252,16771,16771,17160,17160,DRUGOTHER: Coadministration of DRUG1 (using an experimental soft-gelatin capsule formulation of DRUG1 1200mg) with DRUGOTHER resulted in an 18% increase in DRUG2 plasma AUC and a 4-fold increase in DRUG1 plasma A.C.,saquinavir,nelfinavir,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,3,21
3253,16773,16773,17162,17162,DRUGOTHER: Coadministration of DRUG1 (using an experimental soft-gelatin capsule formulation of DRUG1 1200mg) with DRUG2 resulted in an 18% increase in DRUGOTHER plasma AUC and a 4-fold increase in DRUG1 plasma A.C.,saquinavir,VIRACEPT,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C,3,14
3254,16774,16774,17163,17163,DRUGOTHER: Coadministration of DRUG1 (using an experimental soft-gelatin capsule formulation of DRUG1 1200mg) with DRUGOTHER resulted in an 18% increase in DRUG2 plasma AUC and a 4-fold increase in DRUG1 plasma A.C.,saquinavir,nelfinavir,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,3,21
3255,16777,16777,17166,17166,DRUGOTHER: Coadministration of DRUG2 (using an experimental soft-gelatin capsule formulation of DRUG2 1200mg) with DRUG1 resulted in an 18% increase in DRUGOTHER plasma AUC and a 4-fold increase in DRUG2 plasma A.C.,VIRACEPT,saquinavir,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,14,3
3256,16778,16778,17167,17167,DRUGOTHER: Coadministration of DRUG2 (using an experimental soft-gelatin capsule formulation of DRUG2 1200mg) with DRUGOTHER resulted in an 18% increase in DRUG1 plasma AUC and a 4-fold increase in DRUG2 plasma A.C.,nelfinavir,saquinavir,False,Neg,0,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,21,3
3257,16819,16819,17215,17215,"The co-administration of DRUGOTHER with IV DRUGOTHER such as DRUG1, DRUG2, DRUGOTHER, or IV DRUGOTHER has not been evaluated (these drugs were not co-administered with DRUGOTHER in clinical trials).",nitroglycerin,nitroprusside,False,Neg,0,OCC(O)CO,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,9,10
3258,16821,16821,17217,17217,"The co-administration of DRUGOTHER with IV DRUGOTHER such as DRUGOTHER, DRUG1, DRUG2, or IV DRUGOTHER has not been evaluated (these drugs were not co-administered with DRUGOTHER in clinical trials).",nitroprusside,milrinone,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,[Mg++].[O-]C([O-])=O,10,11
3259,16822,16822,17220,17220,DRUGOTHER should not be administered concomitantly with potent DRUGOTHER such as DRUG1 and DRUG2 as the potential for ototoxicity is enhanced by the combination.,furosemide,ethacrynic acid,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl,11,13
3260,16831,16831,17229,17229,DRUG1/DRUG2,Lopinavir,Ritonavir,False,Neg,0,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,0,0
3261,16832,16832,17230,17230,A dose increase of DRUG1/DRUG2 to 533/133 mg twice daily with food isrecommended in combination with DRUGOTHER.,lopinavir,ritonavir,False,Neg,0,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,4,4
3262,16834,16834,17232,17232,A dose increase of DRUGOTHER/DRUG1 to 533/133 mg twice daily with food isrecommended in combination with DRUG2.,ritonavir,nevirapine,True,advise,1,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1,4,16
3263,16855,16855,17253,17253,"DRUG1, DRUGOTHER, DRUG2",Carbamazepine,ethosuximide,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CCC1(C)CC(=O)NC1=O,0,2
3264,16856,16856,17254,17254,"DRUGOTHER, DRUG1, DRUG2",clonazepam,ethosuximide,False,Neg,0,[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,CCC1(C)CC(=O)NC1=O,1,2
3265,16859,16859,17257,17257,"DRUG1, DRUGOTHER, DRUG2",Cyclosporin,sirolimus,False,Neg,0,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,0,2
3266,16860,16860,17258,17258,"DRUGOTHER, DRUG1, DRUG2",tacrolimus,sirolimus,False,Neg,0,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,1,2
3267,16891,16891,17289,17289,"When therapeutic concentrations of DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER were added to human plasma (in vitro), the plasma protein binding of DRUGOTHER was not altered.",furosemide,propranolol,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,4,5
3268,16892,16892,17290,17290,"When therapeutic concentrations of DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER were added to human plasma (in vitro), the plasma protein binding of DRUGOTHER was not altered.",furosemide,dipyridamole,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO,4,6
3269,16893,16893,17291,17291,"When therapeutic concentrations of DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER were added to human plasma (in vitro), the plasma protein binding of DRUGOTHER was not altered.",furosemide,warfarin,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,4,7
3270,16894,16894,17292,17292,"When therapeutic concentrations of DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER were added to human plasma (in vitro), the plasma protein binding of DRUGOTHER was not altered.",furosemide,quinidine,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,4,8
3271,16895,16895,17293,17293,"When therapeutic concentrations of DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2 were added to human plasma (in vitro), the plasma protein binding of DRUGOTHER was not altered.",furosemide,naproxen,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,4,10
3272,16896,16896,17294,17294,"When therapeutic concentrations of DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER were added to human plasma (in vitro), the plasma protein binding of DRUG2 was not altered.",furosemide,nicardipine HCl,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1,4,23
3273,16913,16913,17311,17311,"Physiological changes resulting from smoking cessation, with or without DRUG1 replacement, may alter the pharmacokinetics of certain concomitant medications, such as DRUGOTHER and DRUG2.",nicotine,theophylline,False,Neg,0,CN1CCC[C@H]1C2=CN=CC=C2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,9,23
3274,16914,16914,17312,17312,"Physiological changes resulting from smoking cessation, with or without DRUGOTHER replacement, may alter the pharmacokinetics of certain concomitant medications, such as DRUG1 and DRUG2.",tricyclic antidepressants,theophylline,False,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CN1C2=C(C(=O)N(C1=O)C)NC=N2,21,23
3275,16959,16959,17357,17357,"Consequently, drugs with a low therapeutic margin, such as DRUG1, DRUG2, and DRUGOTHER, could have a delayed elimination and increases in their serum half-life leading to a toxic level.",vitamin K antagonists,phenytoin,False,Neg,0,OC(=O)CCCCCCCC(O)=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,9,10
3276,16960,16960,17358,17358,"Consequently, drugs with a low therapeutic margin, such as DRUG1, DRUGOTHER, and DRUG2, could have a delayed elimination and increases in their serum half-life leading to a toxic level.",vitamin K antagonists,theophylline,False,Neg,0,OC(=O)CCCCCCCC(O)=O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,9,12
3277,16970,16970,17368,17368,Coadministration of DRUG1 with 40 mg DRUG2 tablets in epileptic patients lowered the DRUGOTHER plasma concentrations to undetectable levels.,phenytoin,SULAR,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OCC(C)C,2,6
3278,16971,16971,17369,17369,Coadministration of DRUG1 with 40 mg DRUGOTHER tablets in epileptic patients lowered the DRUG2 plasma concentrations to undetectable levels.,phenytoin,nisoldipine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OCC(C)C,2,13
3279,16973,16973,17371,17371,Coadministration of DRUG1 with DRUG2 or any known CYP3A4 inducer should be avoided and alternative DRUGOTHER therapy should be considered.,SULAR,phenytoin,True,advise,1,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OCC(C)C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,2,4
3280,16975,16975,17373,17373,Coadministration of DRUGOTHER with DRUG1 or any known CYP3A4 inducer should be avoided and alternative DRUG2 therapy should be considered.,phenytoin,antihypertensive,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,4,15
3281,17014,17014,17417,17417,"No interactions have been observed between DRUGOTHER and DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",theophylline,chlordiazepoxide,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1,8,9
3282,17015,17015,17418,17418,"No interactions have been observed between DRUGOTHER and DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",theophylline,lorazepam,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,8,10
3283,17017,17017,17420,17420,"No interactions have been observed between DRUGOTHER and DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",theophylline,warfarin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,8,14
3284,17019,17019,17422,17422,"No interactions have been observed between DRUGOTHER and DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",chlordiazepoxide,phenytoin,False,Neg,0,CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,9,12
3285,17021,17021,17424,17424,"No interactions have been observed between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER.",lorazepam,phenytoin,False,Neg,0,C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,10,12
3286,17023,17023,17426,17426,"No interactions have been observed between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2.",phenytoin,warfarin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,12,14
3287,17026,17026,17429,17429,"The effectiveness of DRUG1-only pills is reduced by hepatic enzyme-inducing drugs such as the DRUGOTHER DRUG2, DRUGOTHER, and DRUGOTHER, and the DRUGOTHER DRUGOTHER.",progestin,phenytoin,True,effect,2,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,3,15
3288,17030,17030,17433,17433,"The effectiveness of DRUGOTHER-only pills is reduced by hepatic enzyme-inducing drugs such as the DRUG1 DRUG2, DRUGOTHER, and DRUGOTHER, and the DRUGOTHER DRUGOTHER.",anticonvulsants,phenytoin,False,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,14,15
3289,17034,17034,17437,17437,"The effectiveness of DRUGOTHER-only pills is reduced by hepatic enzyme-inducing drugs such as the DRUGOTHER DRUG1, DRUG2, and DRUGOTHER, and the DRUGOTHER DRUGOTHER.",phenytoin,carbamazepine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,15,16
3290,17035,17035,17438,17438,"The effectiveness of DRUGOTHER-only pills is reduced by hepatic enzyme-inducing drugs such as the DRUGOTHER DRUG1, DRUGOTHER, and DRUG2, and the DRUGOTHER DRUGOTHER.",phenytoin,barbiturates,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O,15,18
3291,17036,17036,17439,17439,"The effectiveness of DRUGOTHER-only pills is reduced by hepatic enzyme-inducing drugs such as the DRUGOTHER DRUG1, DRUGOTHER, and DRUGOTHER, and the DRUGOTHER DRUG2.",phenytoin,rifampin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,15,22
3292,17040,17040,17443,17443,Elevated plasma levels of DRUG1 have been reported with concomitant DRUG2 use.,theophylline,quinolone,True,mechanism,4,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C(=O)C=CC2=CC=CC=C12,4,10
3293,17041,17041,17444,17444,There have been reports of DRUG1-related side effects in patients on concomitant therapy with DRUG2 and DRUG1.,theophylline,norfloxacin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C,5,14
3294,17043,17043,17446,17446,There have been reports of DRUG2-related side effects in patients on concomitant therapy with DRUG1 and DRUG2.,norfloxacin,theophylline,True,effect,2,[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C,CN1C2=C(C(=O)N(C1=O)C)NC=N2,14,5
3295,17076,17076,17479,17479,"A similar association, though less marked, has been suggested with DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly with DRUGOTHER and DRUGOTHER 72.",barbiturates,phenytoin sodium,False,Neg,0,CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,10,12
3296,17079,17079,17482,17482,"A similar association, though less marked, has been suggested with DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and possibly with DRUGOTHER and DRUGOTHER 72.",barbiturates,topiramate,False,Neg,0,CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,10,15
3297,17082,17082,17485,17485,"A similar association, though less marked, has been suggested with DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly with DRUGOTHER and DRUGOTHER 72.",phenylbutazone,phenytoin sodium,False,Neg,0,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,11,12
3298,17085,17085,17488,17488,"A similar association, though less marked, has been suggested with DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and possibly with DRUGOTHER and DRUGOTHER 72.",phenylbutazone,topiramate,False,Neg,0,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,11,15
3299,17088,17088,17491,17491,"A similar association, though less marked, has been suggested with DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and possibly with DRUGOTHER and DRUGOTHER 72.",phenytoin sodium,carbamazepine,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,12,13
3300,17089,17089,17492,17492,"A similar association, though less marked, has been suggested with DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and possibly with DRUGOTHER and DRUGOTHER 72.",phenytoin sodium,griseofulvin,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC,12,14
3301,17091,17091,17494,17494,"A similar association, though less marked, has been suggested with DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly with DRUG2 and DRUGOTHER 72.",phenytoin sodium,ampicillin,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C,12,19
3302,17092,17092,17495,17495,"A similar association, though less marked, has been suggested with DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly with DRUGOTHER and DRUG2 72.",phenytoin sodium,tetracyclines,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O,12,21
3303,17094,17094,17497,17497,"A similar association, though less marked, has been suggested with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and possibly with DRUGOTHER and DRUGOTHER 72.",carbamazepine,topiramate,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,13,15
3304,17097,17097,17500,17500,"A similar association, though less marked, has been suggested with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and possibly with DRUGOTHER and DRUGOTHER 72.",griseofulvin,topiramate,False,Neg,0,C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,14,15
3305,17100,17100,17503,17503,"A similar association, though less marked, has been suggested with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and possibly with DRUG2 and DRUGOTHER 72.",topiramate,ampicillin,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C,15,19
3306,17101,17101,17504,17504,"A similar association, though less marked, has been suggested with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and possibly with DRUGOTHER and DRUG2 72.",topiramate,tetracyclines,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O,15,21
3307,17115,17115,17518,17518,"Such individuals are referred to as  poor metabolizers  of drugs such as DRUG1, DRUG2, and the DRUGOTHER.",debrisoquin,dextromethorphan,False,Neg,0,NC(=N)N1CCC2=CC=CC=C2C1,[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C,14,15
3308,17117,17117,17520,17520,"Such individuals are referred to as  poor metabolizers  of drugs such as DRUGOTHER, DRUG1, and the DRUG2.",dextromethorphan,tricyclic antidepressants,False,Neg,0,[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,15,18
3309,17119,17119,17522,17522,"In addition, certain drugs that are metabolized by this isoenzyme, including many DRUG1 (tricyclic DRUG1, DRUG2, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions.",antidepressants,selective serotonin reuptake inhibitors,False,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,NCCC1=CNC2=CC=C(O)C=C12,12,15
3310,17120,17120,17523,17523,"In addition, certain drugs that are metabolized by this isoenzyme, including many DRUGOTHER (DRUG1, DRUG2, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions.",tricyclic antidepressants,selective serotonin reuptake inhibitors,False,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,NCCC1=CNC2=CC=C(O)C=C12,13,14
3311,17154,17154,17557,17557,"1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high DRUG1 doses In vivo, the plasma levels of DRUG2 increased by up to 40%, when DRUG1 was given at doses above 1200 mg/day.",Trileptal,phenytoin,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,19,27
3312,17156,17156,17559,17559,"1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high DRUG2 doses In vivo, the plasma levels of DRUG1 increased by up to 40%, when DRUG2 was given at doses above 1200 mg/day.",phenytoin,Trileptal,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,27,19
3313,17157,17157,17560,17560,"Therefore, when using doses of DRUG1 greater than 1200 mg/day during adjunctive therapy, a decrease in the dose of DRUG2 may be required.",Trileptal,phenytoin,True,advise,1,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,5,19
3314,17159,17159,17562,17562,"Strong inducers of cytochrome P450 enzymes (i.e. DRUG1, DRUG2 and DRUGOTHER) have been shown to decrease the plasma levels of DRUGOTHER (29-40%).",carbamazepine,phenytoin,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,7,8
3315,17161,17161,17564,17564,"Strong inducers of cytochrome P450 enzymes (i.e. DRUGOTHER, DRUG1 and DRUG2) have been shown to decrease the plasma levels of DRUGOTHER (29-40%).",phenytoin,phenobarbital,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,8,10
3316,17198,17198,17601,17601,"Potential interactions between DRUG1, a substrate of CYP3A4, and DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.",TAXOL,ritonavir,False,Neg,0,[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,3,10
3317,17199,17199,17602,17602,"Potential interactions between DRUG1, a substrate of CYP3A4, and DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.",TAXOL,saquinavir,False,Neg,0,[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,3,11
3318,17203,17203,17606,17606,"Potential interactions between DRUGOTHER, a substrate of CYP3A4, and DRUGOTHER (DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.",ritonavir,indinavir,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,10,12
3319,17204,17204,17607,17607,"Potential interactions between DRUGOTHER, a substrate of CYP3A4, and DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.",ritonavir,nelfinavir,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,10,14
3320,17205,17205,17608,17608,"Potential interactions between DRUGOTHER, a substrate of CYP3A4, and DRUGOTHER (DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.",saquinavir,indinavir,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,11,12
3321,17206,17206,17609,17609,"Potential interactions between DRUGOTHER, a substrate of CYP3A4, and DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.",saquinavir,nelfinavir,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,11,14
3322,17318,17318,17731,17731,"DRUG1 DRUG2 12.5, 25, and 50 mg administered once daily for 7 days increased plasma DRUGOTHER concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of DRUGOTHER.",Theophylline,VIOXX,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1,0,1
3323,17321,17321,17734,17734,"DRUGOTHER DRUG1 12.5, 25, and 50 mg administered once daily for 7 days increased plasma DRUG2 concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of DRUG2.",VIOXX,theophylline,True,mechanism,4,CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,1,15
3324,17322,17322,17735,17735,"DRUGOTHER DRUG1 12.5, 25, and 50 mg administered once daily for 7 days increased plasma DRUG2 concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of DRUG2.",VIOXX,theophylline,False,Neg,0,CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,1,15
3325,17324,17324,17737,17737,Adequate monitoring of DRUG1 plasma concentrations should be considered when therapy with DRUG2 is initiated or changed in patients receiving DRUG1.,theophylline,VIOXX,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1,3,12
3326,17326,17326,17739,17739,Adequate monitoring of DRUG2 plasma concentrations should be considered when therapy with DRUG1 is initiated or changed in patients receiving DRUG2.,VIOXX,theophylline,True,advise,1,CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,12,3
3327,17338,17338,17753,17753,"DRUGOTHER: DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER CONTRAINDICATED due to potential for serious and/or life-threatening reactions.",Amiodarone,bepridil,False,Neg,0,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,1,2
3328,17342,17342,17757,17757,"DRUGOTHER: DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER CONTRAINDICATED due to potential for serious and/or life-threatening reactions.",bepridil,flecainide,False,Neg,0,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,2,3
3329,17343,17343,17758,17758,"DRUGOTHER: DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER CONTRAINDICATED due to potential for serious and/or life-threatening reactions.",bepridil,propafenone,False,Neg,0,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O,2,4
3330,17344,17344,17759,17759,"DRUGOTHER: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2 CONTRAINDICATED due to potential for serious and/or life-threatening reactions.",bepridil,quinidine,False,Neg,0,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,2,5
3331,17351,17351,17766,17766,"DRUGOTHER: DRUG1, DRUG2, DRUGOTHER, methylDRUG2 CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute DRUGOTHER toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.",Dihydroergotamine,ergonovine,False,Neg,0,[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O,[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO,1,2
3332,17353,17353,17768,17768,"DRUGOTHER: DRUG1, DRUGOTHER, DRUGOTHER, DRUG2 CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute DRUGOTHER toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.",Dihydroergotamine,methylergonovine,False,Neg,0,[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O,[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO,1,4
3333,17354,17354,17770,17770,"DRUGOTHER: DihydroDRUG2, DRUG1, DRUG2, methylDRUG1 CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute DRUGOTHER toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.",ergonovine,ergotamine,False,Neg,0,[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C,2,1
3334,17356,17356,17773,17773,"DRUGOTHER: DihydroDRUG1, DRUGOTHER, DRUG1, DRUG2 CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute DRUGOTHER toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.",ergotamine,methylergonovine,False,Neg,0,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C,[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO,1,4
3335,17358,17358,17777,17777,DRUG1: DRUGOTHER CONTRAINDICATED since the coadministration of this product with DRUG2 in an DRUGOTHER regimen reduces the plasma concentrations of DRUG2.,Antimycobacterial Agents,saquinavir,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,0,10
3336,17360,17360,17779,17779,DRUG1: DRUGOTHER CONTRAINDICATED since the coadministration of this product with DRUG2 in an DRUGOTHER regimen reduces the plasma concentrations of DRUG2.,Antimycobacterial Agents,saquinavir,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,0,10
3337,17361,17361,17780,17780,DRUGOTHER: DRUG1 CONTRAINDICATED since the coadministration of this product with DRUG2 in an DRUGOTHER regimen reduces the plasma concentrations of DRUG2.,rifampin,saquinavir,False,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1,10
3338,17363,17363,17782,17782,DRUGOTHER: DRUG1 CONTRAINDICATED since the coadministration of this product with DRUG2 in an DRUGOTHER regimen reduces the plasma concentrations of DRUG2.,rifampin,saquinavir,False,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,1,10
3339,17364,17364,17783,17783,DRUGOTHER: DRUGOTHER CONTRAINDICATED since the coadministration of this product with DRUG1 in an DRUG2 regimen reduces the plasma concentrations of DRUG1.,saquinavir,antiretroviral,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O,10,13
3340,17366,17366,17785,17785,DRUGOTHER: DRUGOTHER CONTRAINDICATED since the coadministration of this product with DRUG2 in an DRUG1 regimen reduces the plasma concentrations of DRUG2.,antiretroviral,saquinavir,False,Neg,0,CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,13,10
3341,17387,17387,17806,17806,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, alDRUG2, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUGOTHER;",dapsone,fentanyl,False,Neg,0,NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,18,29
3342,17388,17388,17807,17807,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUGOTHER;",dapsone,alfentanyl,False,Neg,0,NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,18,30
3343,17391,17391,17810,17810,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, alDRUGOTHER, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUG2;",dapsone,saquinavir,True,mechanism,4,NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,18,42
3344,17400,17400,17819,17819,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, alDRUG2, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUGOTHER;",disopyramide,fentanyl,False,Neg,0,OC(=O)CCCCCCCC(O)=O,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,19,29
3345,17401,17401,17820,17820,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUGOTHER;",disopyramide,alfentanyl,False,Neg,0,OC(=O)CCCCCCCC(O)=O,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,19,30
3346,17404,17404,17823,17823,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, alDRUGOTHER, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUG2;",disopyramide,saquinavir,True,mechanism,4,OC(=O)CCCCCCCC(O)=O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,19,42
3347,17412,17412,17831,17831,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, alDRUG2, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUGOTHER;",quinine,fentanyl,False,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,20,29
3348,17413,17413,17832,17832,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUGOTHER;",quinine,alfentanyl,False,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,20,30
3349,17416,17416,17835,17835,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, alDRUGOTHER, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUG2;",quinine,saquinavir,True,mechanism,4,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,20,42
3350,17423,17423,17842,17842,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, alDRUG2, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUGOTHER;",amiodarone,fentanyl,False,Neg,0,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,21,29
3351,17424,17424,17843,17843,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUGOTHER;",amiodarone,alfentanyl,False,Neg,0,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,21,30
3352,17427,17427,17846,17846,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, alDRUGOTHER, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUG2;",amiodarone,saquinavir,True,mechanism,4,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,21,42
3353,17433,17433,17852,17852,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, alDRUG2, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUGOTHER;",quinidine,fentanyl,False,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,22,29
3354,17434,17434,17853,17853,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUGOTHER;",quinidine,alfentanyl,False,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,22,30
3355,17437,17437,17856,17856,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, alDRUGOTHER, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUG2;",quinidine,saquinavir,True,mechanism,4,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,22,42
3356,17442,17442,17861,17861,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, alDRUG2, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUGOTHER;",warfarin,fentanyl,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,23,29
3357,17443,17443,17862,17862,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUGOTHER;",warfarin,alfentanyl,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,23,30
3358,17446,17446,17865,17865,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, alDRUGOTHER, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUG2;",warfarin,saquinavir,True,mechanism,4,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,23,42
3359,17450,17450,17869,17869,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, alDRUG2, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUGOTHER;",tacrolimus,fentanyl,False,Neg,0,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,24,29
3360,17451,17451,17870,17870,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUGOTHER;",tacrolimus,alfentanyl,False,Neg,0,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,24,30
3361,17454,17454,17873,17873,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, alDRUGOTHER, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUG2;",tacrolimus,saquinavir,True,mechanism,4,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,24,42
3362,17457,17457,17876,17876,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, alDRUG2, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUGOTHER;",cyclosporine,fentanyl,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,25,29
3363,17458,17458,17877,17877,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUGOTHER;",cyclosporine,alfentanyl,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,25,30
3364,17461,17461,17880,17880,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, alDRUGOTHER, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUG2;",cyclosporine,saquinavir,True,mechanism,4,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,25,42
3365,17463,17463,17882,17882,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, alDRUG2, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUGOTHER;",pimozide,fentanyl,False,Neg,0,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,27,29
3366,17464,17464,17883,17883,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUGOTHER;",pimozide,alfentanyl,False,Neg,0,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,27,30
3367,17467,17467,17886,17886,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, alDRUGOTHER, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUG2;",pimozide,saquinavir,True,mechanism,4,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,27,42
3368,17468,17468,17887,17887,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, alDRUG2, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUGOTHER;",carbamazepine,fentanyl,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,28,29
3369,17469,17469,17888,17888,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUGOTHER;",carbamazepine,alfentanyl,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,28,30
3370,17472,17472,17891,17891,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, alDRUGOTHER, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUG2;",carbamazepine,saquinavir,True,mechanism,4,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,28,42
3371,17474,17474,17893,17893,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, alDRUG1, DRUG2, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUGOTHER;",fentanyl,alprazolam,False,Neg,0,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12,29,31
3372,17475,17475,17894,17894,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, alDRUG1, DRUGOTHER, and DRUG2) may have elevated plasma concentrations when coadministered with DRUGOTHER;",fentanyl,triazolam,False,Neg,0,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1,29,33
3373,17477,17477,17896,17896,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUGOTHER;",alfentanyl,alprazolam,False,Neg,0,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12,30,31
3374,17478,17478,17897,17897,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2) may have elevated plasma concentrations when coadministered with DRUGOTHER;",alfentanyl,triazolam,False,Neg,0,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1,30,33
3375,17481,17481,17900,17900,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, alDRUGOTHER, DRUG1, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUG2;",alprazolam,saquinavir,True,mechanism,4,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,31,42
3376,17482,17482,17901,17901,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, alDRUGOTHER, DRUGOTHER, and DRUG1) may have elevated plasma concentrations when coadministered with DRUG2;",triazolam,saquinavir,True,mechanism,4,O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,33,42
3377,17486,17486,17905,17905,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER) may result in decreased plasma levels of DRUGOTHER.",phenobarbital,phenytoin,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,10,11
3378,17489,17489,17908,17908,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER) may result in decreased plasma levels of DRUG2.",phenobarbital,saquinavir,True,mechanism,4,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,10,21
3379,17490,17490,17909,17909,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER) may result in decreased plasma levels of DRUGOTHER.",phenytoin,dexamethasone,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,11,12
3380,17491,17491,17910,17910,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2) may result in decreased plasma levels of DRUGOTHER.",phenytoin,carbamazepine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,11,13
3381,17494,17494,17913,17913,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER) may result in decreased plasma levels of DRUG2.",dexamethasone,saquinavir,True,mechanism,4,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,12,21
3382,17495,17495,17914,17914,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1) may result in decreased plasma levels of DRUG2.",carbamazepine,saquinavir,True,mechanism,4,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,13,21
3383,17497,17497,17917,17917,"- DRUGOTHER (DRUG1 [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",nandrolone,oxandrolone,False,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C,2,5
3384,17498,17498,17918,17918,"- DRUGOTHER (DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG2], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",nandrolone,Anavar,False,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)OC[C@]12C,2,7
3385,17504,17504,17924,17924,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",oxandrolone,oxymetholone,False,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)\C(C[C@]12C)=C/O,5,8
3386,17505,17505,17925,17925,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG2], DRUGOTHER [e.g., DRUGOTHER]) or",oxandrolone,Anadrol,False,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)\C(C[C@]12C)=C/O,5,10
3387,17506,17506,17926,17926,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER]) or",oxandrolone,stanozolol,False,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC3=NNC=C3C[C@]12C,5,11
3388,17507,17507,17927,17927,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG2]) or",oxandrolone,Winstrol,False,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC3=NNC=C3C[C@]12C,5,13
3389,17508,17508,17928,17928,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG1], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",Anavar,oxymetholone,False,Neg,0,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)OC[C@]12C,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)\C(C[C@]12C)=C/O,7,8
3390,17509,17509,17929,17929,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG1], DRUGOTHER [e.g., DRUG2], DRUGOTHER [e.g., DRUGOTHER]) or",Anavar,Anadrol,False,Neg,0,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)OC[C@]12C,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)\C(C[C@]12C)=C/O,7,10
3391,17510,17510,17930,17930,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG1], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER]) or",Anavar,stanozolol,False,Neg,0,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)OC[C@]12C,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC3=NNC=C3C[C@]12C,7,11
3392,17511,17511,17931,17931,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG1], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG2]) or",Anavar,Winstrol,False,Neg,0,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)OC[C@]12C,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC3=NNC=C3C[C@]12C,7,13
3393,17532,17532,17954,17954,"- DRUG1 (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG2], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",Phenothiazines,Prolixin,False,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,1,10
3394,17533,17533,17955,17955,"- DRUG1 (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",Phenothiazines,mesoridazine,False,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,CN1CCCCC1CCN1C2=C(SC3=C1C=C(C=C3)S(C)=O)C=CC=C2,1,11
3395,17543,17543,17965,17965,"- DRUG1 (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",Phenothiazines,thioridazine,False,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,1,26
3396,17554,17554,17976,17976,"- DRUGOTHER (DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG2], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",acetophenazine,Prolixin,False,Neg,0,CC(=O)C1=CC=C2SC3=C(C=CC=C3)N(CCCN3CCN(CCO)CC3)C2=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,2,10
3397,17555,17555,17977,17977,"- DRUGOTHER (DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",acetophenazine,mesoridazine,False,Neg,0,CC(=O)C1=CC=C2SC3=C(C=CC=C3)N(CCCN3CCN(CCO)CC3)C2=C1,CN1CCCCC1CCN1C2=C(SC3=C1C=C(C=C3)S(C)=O)C=CC=C2,2,11
3398,17565,17565,17987,17987,"- DRUGOTHER (DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",acetophenazine,thioridazine,False,Neg,0,CC(=O)C1=CC=C2SC3=C(C=CC=C3)N(CCCN3CCN(CCO)CC3)C2=C1,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,2,26
3399,17575,17575,17997,17997,"- DRUGOTHER (DRUGOTHER [e.g., DRUG1], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG2], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",Tindal,Prolixin,False,Neg,0,CC(=O)C1=CC=C2SC3=C(C=CC=C3)N(CCCN3CCN(CCO)CC3)C2=C1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,4,10
3400,17576,17576,17998,17998,"- DRUGOTHER (DRUGOTHER [e.g., DRUG1], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",Tindal,mesoridazine,False,Neg,0,CC(=O)C1=CC=C2SC3=C(C=CC=C3)N(CCCN3CCN(CCO)CC3)C2=C1,CN1CCCCC1CCN1C2=C(SC3=C1C=C(C=C3)S(C)=O)C=CC=C2,4,11
3401,17586,17586,18008,18008,"- DRUGOTHER (DRUGOTHER [e.g., DRUG1], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",Tindal,thioridazine,False,Neg,0,CC(=O)C1=CC=C2SC3=C(C=CC=C3)N(CCCN3CCN(CCO)CC3)C2=C1,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,4,26
3402,17595,17595,18017,18017,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG2], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",chlorpromazine,Prolixin,False,Neg,0,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,5,10
3403,17596,17596,18018,18018,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",chlorpromazine,mesoridazine,False,Neg,0,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CN1CCCCC1CCN1C2=C(SC3=C1C=C(C=C3)S(C)=O)C=CC=C2,5,11
3404,17606,17606,18028,18028,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",chlorpromazine,thioridazine,False,Neg,0,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,5,26
3405,17614,17614,18036,18036,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG1], DRUGOTHER [e.g., DRUG2], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",Thorazine,Prolixin,False,Neg,0,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,7,10
3406,17615,17615,18037,18037,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG1], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",Thorazine,mesoridazine,False,Neg,0,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2,CN1CCCCC1CCN1C2=C(SC3=C1C=C(C=C3)S(C)=O)C=CC=C2,7,11
3407,17625,17625,18047,18047,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG1], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",Thorazine,thioridazine,False,Neg,0,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,7,26
3408,17632,17632,18054,18054,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUG2], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",fluphenazine,Prolixin,False,Neg,0,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,8,10
3409,17633,17633,18055,18055,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",fluphenazine,mesoridazine,False,Neg,0,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,CN1CCCCC1CCN1C2=C(SC3=C1C=C(C=C3)S(C)=O)C=CC=C2,8,11
3410,17643,17643,18065,18065,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",fluphenazine,thioridazine,False,Neg,0,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,8,26
3411,17651,17651,18073,18073,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG1], DRUGOTHER [e.g., DRUG2], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",Prolixin,Serentil,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,10,13
3412,17652,17652,18074,18074,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG1], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",Prolixin,perphenazine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,10,14
3413,17653,17653,18075,18075,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG1], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG2], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",Prolixin,Trilafon,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1,10,16
3414,17654,17654,18076,18076,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG1], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",Prolixin,prochlorperazine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1,10,17
3415,17655,17655,18077,18077,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG1], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG2], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",Prolixin,Compazine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1,10,19
3416,17656,17656,18078,18078,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], chlorDRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG1], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",Prolixin,promazine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(C)=O,10,5
3417,17657,17657,18079,18079,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG1], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG2], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",Prolixin,Sparine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12,10,22
3418,17658,17658,18080,18080,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG1], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",Prolixin,promethazine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,10,23
3419,17659,17659,18081,18081,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG1], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG2], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",Prolixin,Phenergan,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,10,25
3420,17661,17661,18083,18083,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG1], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG2], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",Prolixin,Mellaril,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN(C)C1=CC=C(C=C1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12,10,28
3421,17662,17662,18084,18084,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG1], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",Prolixin,trifluoperazine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN1CCN(CCCN2C3=CC=CC=C3SC3=CC=CC=C23)CC1,10,29
3422,17663,17663,18085,18085,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG1], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG2], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",Prolixin,Stelazine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,10,31
3423,17664,17664,18086,18086,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG1], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",Prolixin,triflupromazine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F,10,32
3424,17665,17665,18087,18087,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG1], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUG2], DRUGOTHER [e.g., DRUGOTHER]) or",Prolixin,Vesprin,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F,10,34
3425,17666,17666,18088,18088,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG1], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER]) or",Prolixin,trimeprazine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12,10,35
3426,17667,17667,18089,18089,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUG2], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",mesoridazine,Serentil,False,Neg,0,CN1CCCCC1CCN1C2=C(SC3=C1C=C(C=C3)S(C)=O)C=CC=C2,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,11,13
3427,17668,17668,18090,18090,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",mesoridazine,perphenazine,False,Neg,0,CN1CCCCC1CCN1C2=C(SC3=C1C=C(C=C3)S(C)=O)C=CC=C2,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,11,14
3428,17669,17669,18091,18091,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG2], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",mesoridazine,Trilafon,False,Neg,0,CN1CCCCC1CCN1C2=C(SC3=C1C=C(C=C3)S(C)=O)C=CC=C2,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1,11,16
3429,17670,17670,18092,18092,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",mesoridazine,prochlorperazine,False,Neg,0,CN1CCCCC1CCN1C2=C(SC3=C1C=C(C=C3)S(C)=O)C=CC=C2,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1,11,17
3430,17671,17671,18093,18093,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG2], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",mesoridazine,Compazine,False,Neg,0,CN1CCCCC1CCN1C2=C(SC3=C1C=C(C=C3)S(C)=O)C=CC=C2,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1,11,19
3431,17672,17672,18094,18094,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], chlorDRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",mesoridazine,promazine,False,Neg,0,CN1CCCCC1CCN1C2=C(SC3=C1C=C(C=C3)S(C)=O)C=CC=C2,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(C)=O,11,5
3432,17673,17673,18095,18095,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG2], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",mesoridazine,Sparine,False,Neg,0,CN1CCCCC1CCN1C2=C(SC3=C1C=C(C=C3)S(C)=O)C=CC=C2,CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12,11,22
3433,17674,17674,18096,18096,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",mesoridazine,promethazine,False,Neg,0,CN1CCCCC1CCN1C2=C(SC3=C1C=C(C=C3)S(C)=O)C=CC=C2,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,11,23
3434,17675,17675,18097,18097,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG2], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",mesoridazine,Phenergan,False,Neg,0,CN1CCCCC1CCN1C2=C(SC3=C1C=C(C=C3)S(C)=O)C=CC=C2,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,11,25
3435,17677,17677,18099,18099,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG2], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",mesoridazine,Mellaril,False,Neg,0,CN1CCCCC1CCN1C2=C(SC3=C1C=C(C=C3)S(C)=O)C=CC=C2,CN(C)C1=CC=C(C=C1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12,11,28
3436,17678,17678,18100,18100,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",mesoridazine,trifluoperazine,False,Neg,0,CN1CCCCC1CCN1C2=C(SC3=C1C=C(C=C3)S(C)=O)C=CC=C2,CN1CCN(CCCN2C3=CC=CC=C3SC3=CC=CC=C23)CC1,11,29
3437,17679,17679,18101,18101,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG2], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",mesoridazine,Stelazine,False,Neg,0,CN1CCCCC1CCN1C2=C(SC3=C1C=C(C=C3)S(C)=O)C=CC=C2,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,11,31
3438,17680,17680,18102,18102,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",mesoridazine,triflupromazine,False,Neg,0,CN1CCCCC1CCN1C2=C(SC3=C1C=C(C=C3)S(C)=O)C=CC=C2,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F,11,32
3439,17681,17681,18103,18103,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUG2], DRUGOTHER [e.g., DRUGOTHER]) or",mesoridazine,Vesprin,False,Neg,0,CN1CCCCC1CCN1C2=C(SC3=C1C=C(C=C3)S(C)=O)C=CC=C2,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F,11,34
3440,17682,17682,18104,18104,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER]) or",mesoridazine,trimeprazine,False,Neg,0,CN1CCCCC1CCN1C2=C(SC3=C1C=C(C=C3)S(C)=O)C=CC=C2,CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12,11,35
3441,17691,17691,18113,18113,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG1], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",Serentil,thioridazine,False,Neg,0,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,13,26
3442,17705,17705,18127,18127,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",perphenazine,thioridazine,False,Neg,0,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,14,26
3443,17718,17718,18140,18140,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG1], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",Trilafon,thioridazine,False,Neg,0,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,16,26
3444,17730,17730,18152,18152,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",prochlorperazine,thioridazine,False,Neg,0,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,17,26
3445,17741,17741,18163,18163,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG1], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",Compazine,thioridazine,False,Neg,0,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,19,26
3446,17751,17751,18173,18173,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], chlorDRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",promazine,thioridazine,False,Neg,0,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(C)=O,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,5,26
3447,17760,17760,18182,18182,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG1], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",Sparine,thioridazine,False,Neg,0,CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,22,26
3448,17768,17768,18190,18190,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",promethazine,thioridazine,False,Neg,0,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,23,26
3449,17775,17775,18197,18197,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG1], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",Phenergan,thioridazine,False,Neg,0,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,25,26
3450,17782,17782,18204,18204,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUG2], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",thioridazine,Mellaril,False,Neg,0,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,CN(C)C1=CC=C(C=C1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12,26,28
3451,17783,17783,18205,18205,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",thioridazine,trifluoperazine,False,Neg,0,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,CN1CCN(CCCN2C3=CC=CC=C3SC3=CC=CC=C23)CC1,26,29
3452,17784,17784,18206,18206,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG2], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",thioridazine,Stelazine,False,Neg,0,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,26,31
3453,17785,17785,18207,18207,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",thioridazine,triflupromazine,False,Neg,0,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F,26,32
3454,17786,17786,18208,18208,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUG2], DRUGOTHER [e.g., DRUGOTHER]) or",thioridazine,Vesprin,False,Neg,0,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F,26,34
3455,17787,17787,18209,18209,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER]) or",thioridazine,trimeprazine,False,Neg,0,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12,26,35
3456,17809,17809,18232,18232," DRUG1 (e.g., DRUG2) or",Procainamide,Pronestyl,False,Neg,0,OC(=O)CCCCCCCC(O)=O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,1,3
3457,17836,17836,18259,18259," DRUG1 (e.g., DRUGOTHER) use of DRUGOTHER with DRUG2 may increase The chance of side effects affecting The liver and/or The side effects of DRUGOTHER",Phenytoin,sulfapyridine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NC1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1,1,8
3458,17839,17839,18262,18262," DRUGOTHER (e.g., DRUG1) use of DRUGOTHER with DRUG2 may increase The chance of side effects affecting The liver and/or The side effects of DRUGOTHER",Dilantin,sulfapyridine,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,NC1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1,3,8
3459,17841,17841,18264,18264," DRUGOTHER (e.g., DRUGOTHER) use of DRUG1 with DRUG2 may increase The chance of side effects affecting The liver and/or The side effects of DRUG1",phenytoin,sulfapyridine,True,effect,2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NC1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1,6,8
3460,17843,17843,18266,18266," DRUGOTHER (e.g., DRUGOTHER) use of DRUG2 with DRUG1 may increase The chance of side effects affecting The liver and/or The side effects of DRUG2",sulfapyridine,phenytoin,False,Neg,0,NC1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,8,6
3461,17844,17844,18267,18267,"DRUG1, DRUG2 and DRUGOTHER are ge nerally classified as enzyme inducers;",Phenytoin,phenobarbital,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,0,1
3462,17845,17845,18268,18268,"DRUG1, DRUGOTHER and DRUG2 are ge nerally classified as enzyme inducers;",Phenytoin,carbamazepine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,0,3
3463,17847,17847,18270,18270,DRUG1 and DRUG2 are not.,valproate,gabapentin,False,Neg,0,CCCC(CCC)C(=O)O,NCC1(CC(O)=O)CCCCC1,0,2
3464,17849,17849,18272,18272,Effects of DRUG1 on other Antiepilepsy Drugs (DRUGOTHER) : DRUG2: DRUGOTHER had no effect on the steady-state plasma concentrations of DRUGOTHER in patients with epilepsy.,GABITRIL,Phenytoin,False,Neg,0,CC1=C(SC=C1)C(=CCCN1CCC[C@H](C1)C(O)=O)C1=C(C)C=CS1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,2,9
3465,17851,17851,18274,18274,Effects of DRUG1 on other Antiepilepsy Drugs (DRUGOTHER) : DRUGOTHER: DRUGOTHER had no effect on the steady-state plasma concentrations of DRUG2 in patients with epilepsy.,GABITRIL,phenytoin,False,Neg,0,CC1=C(SC=C1)C(=CCCN1CCC[C@H](C1)C(O)=O)C1=C(C)C=CS1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,2,20
3466,17852,17852,18275,18275,Effects of DRUGOTHER on other Antiepilepsy Drugs (DRUGOTHER) : DRUG1: DRUG2 had no effect on the steady-state plasma concentrations of DRUGOTHER in patients with epilepsy.,Phenytoin,Tiagabine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F,9,10
3467,17854,17854,18277,18277,Effects of DRUGOTHER on other Antiepilepsy Drugs (DRUGOTHER) : DRUGOTHER: DRUG1 had no effect on the steady-state plasma concentrations of DRUG2 in patients with epilepsy.,Tiagabine,phenytoin,False,Neg,0,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,10,20
3468,17859,17859,18282,18282,DRUG1 or DRUG2 : No formal pharmacokinetic studies have been performed examining the addition of DRUGOTHER to regimens containing DRUGOTHER or DRUGOTHER.,Phenobarbital,Primidone,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,0,2
3469,17863,17863,18286,18286,DRUGOTHER or DRUG1 : No formal pharmacokinetic studies have been performed examining the addition of DRUG2 to regimens containing DRUGOTHER or DRUGOTHER.,Primidone,tiagabine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F,2,15
3470,17864,17864,18287,18287,DRUGOTHER or DRUG1 : No formal pharmacokinetic studies have been performed examining the addition of DRUGOTHER to regimens containing DRUG2 or DRUGOTHER.,Primidone,phenobarbital,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,2,19
3471,17865,17865,18288,18288,DRUGOTHER or DRUG1 : No formal pharmacokinetic studies have been performed examining the addition of DRUGOTHER to regimens containing DRUGOTHER or DRUG2.,Primidone,primidone,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,2,21
3472,17878,17878,18301,18301,DRUG1: Population pharmacokinetic analyses indicate that DRUG2 clearance is 60% greater in patients taking DRUGOTHER with or without other enzyme- inducing DRUGOTHER.,Phenytoin,tiagabine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F,0,6
3473,17880,17880,18303,18303,DRUGOTHER: Population pharmacokinetic analyses indicate that DRUG1 clearance is 60% greater in patients taking DRUG2 with or without other enzyme- inducing DRUGOTHER.,tiagabine,phenytoin,True,mechanism,4,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,6,14
3474,17881,17881,18304,18304,DRUG1 (DRUG2): Population pharmacokinetic analyses indicate that DRUGOTHER clearance is 60% greater in patients taking DRUGOTHER (DRUGOTHER) with or without other enzyme-inducing DRUGOTHER.,Phenobarbital,Primidone,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,0,1
3475,17885,17885,18308,18308,DRUGOTHER (DRUG1): Population pharmacokinetic analyses indicate that DRUG2 clearance is 60% greater in patients taking DRUGOTHER (DRUGOTHER) with or without other enzyme-inducing DRUGOTHER.,Primidone,tiagabine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F,1,7
3476,17886,17886,18309,18309,DRUGOTHER (DRUG1): Population pharmacokinetic analyses indicate that DRUGOTHER clearance is 60% greater in patients taking DRUG2 (DRUGOTHER) with or without other enzyme-inducing DRUGOTHER.,Primidone,phenobarbital,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,1,15
3477,17887,17887,18310,18310,DRUGOTHER (DRUG1): Population pharmacokinetic analyses indicate that DRUGOTHER clearance is 60% greater in patients taking DRUGOTHER (DRUG2) with or without other enzyme-inducing DRUGOTHER.,Primidone,primidone,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,1,16
3478,17911,17911,18334,18334,DRUG1: A single 10 mg dose of DRUG2 did not affect the pharmacokinetics of DRUGOTHER at steady state.,Theophylline,tiagabine,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F,0,7
3479,17913,17913,18336,18336,DRUGOTHER: A single 10 mg dose of DRUG1 did not affect the pharmacokinetics of DRUG2 at steady state.,tiagabine,theophylline,False,Neg,0,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F,CN1C2=C(C(=O)N(C1=O)C)NC=N2,7,14
3480,17962,17962,18385,18385,DRUG1 (DRUG2): Steady state plasma exposure (AUC) of DRUGOTHER (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of DRUGOTHER (a CYP 3A4 inducer).,Anticonvulsants,Phenytoin,False,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,1
3481,17964,17964,18387,18387,DRUG1 (DRUGOTHER): Steady state plasma exposure (AUC) of DRUGOTHER (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of DRUG2 (a CYP 3A4 inducer).,Anticonvulsants,phenytoin,False,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,31
3482,17965,17965,18388,18388,DRUGOTHER (DRUG1): Steady state plasma exposure (AUC) of DRUG2 (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of DRUGOTHER (a CYP 3A4 inducer).,Phenytoin,valdecoxib,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O,1,8
3483,17967,17967,18390,18390,DRUGOTHER (DRUGOTHER): Steady state plasma exposure (AUC) of DRUG1 (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of DRUG2 (a CYP 3A4 inducer).,valdecoxib,phenytoin,True,mechanism,4,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,8,31
3484,17968,17968,18391,18391,Patients already stabilized on DRUG1 should be closely monitored for loss of symptom control with DRUG2 coadministration.,valdecoxib,phenytoin,True,advise,1,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,4,15
3485,17969,17969,18392,18392,DRUG1 did not have a statistically significant effect on the pharmacokinetics of DRUG2 (a CYP 2C9 and CYP 2C19 substrate).,Valdecoxib,phenytoin,False,Neg,0,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,12
3486,17971,17971,18394,18394,"Coadministration with DRUG1 (40 mg BID for 7 days) resulted in a significant increase in DRUG2 plasma levels suggesting that, at these doses, DRUG1 is a weak inhibitor of 2D6.",valdecoxib,dextromethorphan,True,mechanism,4,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O,[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C,2,15
3487,17973,17973,18396,18396,"Coadministration with DRUG2 (40 mg BID for 7 days) resulted in a significant increase in DRUG1 plasma levels suggesting that, at these doses, DRUG2 is a weak inhibitor of 2D6.",dextromethorphan,valdecoxib,False,Neg,0,[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O,15,2
3488,17974,17974,18397,18397,Even so DRUG1 plasma concentrations in the presence of high doses of DRUG2 were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.,dextromethorphan,valdecoxib,True,mechanism,4,[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O,2,12
3489,18100,18100,18523,18523,DRUG1 (600 mg b.i.d.) co-administered with DRUG2 5 mg resulted in a 49-fold increase in DRUGOTHER AUC and a 13-fold increase in DRUGOTHER Cmax.,Ritonavir,Vardenafil,True,mechanism,4,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,0,6
3490,18101,18101,18524,18524,DRUG1 (600 mg b.i.d.) co-administered with DRUGOTHER 5 mg resulted in a 49-fold increase in DRUG2 AUC and a 13-fold increase in DRUG2 Cmax.,Ritonavir,vardenafil,False,Neg,0,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,0,15
3491,18102,18102,18525,18525,DRUG1 (600 mg b.i.d.) co-administered with DRUGOTHER 5 mg resulted in a 49-fold increase in DRUG2 AUC and a 13-fold increase in DRUG2 Cmax.,Ritonavir,vardenafil,False,Neg,0,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,0,15
3492,18106,18106,18529,18529,"The interaction is a consequence of blocking hepatic metabolism of DRUG1 by DRUG2, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.",vardenafil,ritonavir,True,mechanism,4,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,10,12
3493,18107,18107,18530,18530,DRUG1 significantly prolonged the half-life of DRUG2 to 26 hours.,Ritonavir,vardenafil,True,mechanism,4,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,0,6
3494,18108,18108,18531,18531,"Consequently, it is recommended not to exceed a single 2.5 mg DRUG1 dose in a 72-hour period when used in combination with DRUG2.",Vardenafil,ritonavir,True,advise,1,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,11,22
3495,18143,18143,18566,18566,"DRUGOTHER: When DRUG1 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of DRUG2, significant hypotension developed in a substantial number of subjects.",Vardenafil,terazosin,True,effect,2,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,2,23
3496,18144,18144,18567,18567,"With simultaneous dosing of DRUG1 10 mg and DRUG2 10 mg, 6 of 8 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.",Vardenafil,terazosin,True,effect,2,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,4,8
3497,18145,18145,18568,18568,"With simultaneous dosing of DRUG1 20 mg and DRUG2 10 mg, 2 of 9 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.",Vardenafil,terazosin,True,effect,2,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,4,8
3498,18146,18146,18569,18569,"When DRUG1 dosing was separated from DRUG2 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of DRUG1 experienced a decrease in standing systolic blood pressure below 85 mm Hg.",Vardenafil,terazosin,True,effect,2,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,1,6
3499,18148,18148,18571,18571,"When DRUG2 dosing was separated from DRUG1 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of DRUG2 experienced a decrease in standing systolic blood pressure below 85 mm Hg.",terazosin,Vardenafil,False,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,6,1
3500,18153,18153,18576,18576,"DRUG1 and DRUG2: Upon concomitant administration of 5 mg of DRUGOTHER with 600 mg BID DRUGOTHER, the Cmax and AUC of DRUGOTHER were reduced by approximately 20%.",Ritonavir,indinavir,False,Neg,0,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,0,2
3501,18154,18154,18577,18577,"DRUG1 and DRUGOTHER: Upon concomitant administration of 5 mg of DRUG2 with 600 mg BID DRUGOTHER, the Cmax and AUC of DRUGOTHER were reduced by approximately 20%.",Ritonavir,Vardenafil,False,Neg,0,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,0,10
3502,18158,18158,18581,18581,"DRUGOTHER and DRUG1: Upon concomitant administration of 5 mg of DRUGOTHER with 600 mg BID DRUG2, the Cmax and AUC of DRUG2 were reduced by approximately 20%.",indinavir,ritonavir,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,2,15
3503,18159,18159,18582,18582,"DRUGOTHER and DRUG1: Upon concomitant administration of 5 mg of DRUGOTHER with 600 mg BID DRUG2, the Cmax and AUC of DRUG2 were reduced by approximately 20%.",indinavir,ritonavir,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,2,15
3504,18160,18160,18583,18583,"DRUGOTHER and DRUGOTHER: Upon concomitant administration of 5 mg of DRUG1 with 600 mg BID DRUG2, the Cmax and AUC of DRUG2 were reduced by approximately 20%.",Vardenafil,ritonavir,True,mechanism,4,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,10,15
3505,18161,18161,18584,18584,"DRUGOTHER and DRUGOTHER: Upon concomitant administration of 5 mg of DRUG1 with 600 mg BID DRUG2, the Cmax and AUC of DRUG2 were reduced by approximately 20%.",Vardenafil,ritonavir,False,Neg,0,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,10,15
3506,18203,18203,18626,18626,"DRUG1: The combination of DRUG2, DRUGOTHER, and DRUGOTHER has been studied (as triple combination) in adults.",Saquinavir,HIVID,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,NC1=NC(=O)N(C=C1)[C@H]1CC[C@@H](CO)O1,0,4
3507,18205,18205,18628,18628,"DRUG1: The combination of DRUGOTHER, DRUGOTHER, and DRUG2 has been studied (as triple combination) in adults.",Saquinavir,ZDV,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O,0,7
3508,18206,18206,18629,18629,"DRUGOTHER: The combination of DRUG1, DRUG2, and DRUGOTHER has been studied (as triple combination) in adults.",HIVID,saquinavir,False,Neg,0,NC1=NC(=O)N(C=C1)[C@H]1CC[C@@H](CO)O1,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,4,5
3509,18208,18208,18631,18631,"DRUGOTHER: The combination of DRUGOTHER, DRUG1, and DRUG2 has been studied (as triple combination) in adults.",saquinavir,ZDV,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O,5,7
3510,18215,18215,18638,18638,"Drugs that have been associated with peripheral neuropathy include DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",antiretroviral nucleoside analogues,hydralazine,False,Neg,0,CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O,C1=CC=C2C(=C1)C=NN=C2NN,9,17
3511,18220,18220,18643,18643,"Drugs that have been associated with peripheral neuropathy include DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",antiretroviral nucleoside analogues,phenytoin,False,Neg,0,CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,9,22
3512,18228,18228,18651,18651,"Drugs that have been associated with peripheral neuropathy include DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",chloramphenicol,hydralazine,False,Neg,0,CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O,C1=CC=C2C(=C1)C=NN=C2NN,10,17
3513,18233,18233,18656,18656,"Drugs that have been associated with peripheral neuropathy include DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",chloramphenicol,phenytoin,False,Neg,0,CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,10,22
3514,18240,18240,18663,18663,"Drugs that have been associated with peripheral neuropathy include DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",cisplatin,hydralazine,False,Neg,0,N.N.Cl[Pt]Cl,C1=CC=C2C(=C1)C=NN=C2NN,11,17
3515,18245,18245,18668,18668,"Drugs that have been associated with peripheral neuropathy include DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",cisplatin,phenytoin,False,Neg,0,N.N.Cl[Pt]Cl,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,11,22
3516,18251,18251,18674,18674,"Drugs that have been associated with peripheral neuropathy include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",dapsone,hydralazine,False,Neg,0,NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1,C1=CC=C2C(=C1)C=NN=C2NN,12,17
3517,18256,18256,18679,18679,"Drugs that have been associated with peripheral neuropathy include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",dapsone,phenytoin,False,Neg,0,NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,12,22
3518,18261,18261,18684,18684,"Drugs that have been associated with peripheral neuropathy include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",disulfiram,hydralazine,False,Neg,0,CCN(CC)C(=S)SSC(=S)N(CC)CC,C1=CC=C2C(=C1)C=NN=C2NN,13,17
3519,18266,18266,18689,18689,"Drugs that have been associated with peripheral neuropathy include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",disulfiram,phenytoin,False,Neg,0,CCN(CC)C(=S)SSC(=S)N(CC)CC,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,13,22
3520,18270,18270,18693,18693,"Drugs that have been associated with peripheral neuropathy include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",ethionamide,hydralazine,False,Neg,0,CCC1=NC=CC(=C1)C(N)=S,C1=CC=C2C(=C1)C=NN=C2NN,14,17
3521,18275,18275,18698,18698,"Drugs that have been associated with peripheral neuropathy include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",ethionamide,phenytoin,False,Neg,0,CCC1=NC=CC(=C1)C(N)=S,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,14,22
3522,18278,18278,18701,18701,"Drugs that have been associated with peripheral neuropathy include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",glutethimide,hydralazine,False,Neg,0,CCC1(CCC(=O)NC1=O)C1=CC=CC=C1,C1=CC=C2C(=C1)C=NN=C2NN,15,17
3523,18283,18283,18706,18706,"Drugs that have been associated with peripheral neuropathy include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",glutethimide,phenytoin,False,Neg,0,CCC1(CCC(=O)NC1=O)C1=CC=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,15,22
3524,18286,18286,18709,18709,"Drugs that have been associated with peripheral neuropathy include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",hydralazine,iodoquinol,False,Neg,0,C1=CC=C2C(=C1)C=NN=C2NN,OC1=C2N=CC=CC2=C(I)C=C1I,17,18
3525,18287,18287,18710,18710,"Drugs that have been associated with peripheral neuropathy include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",hydralazine,isoniazid,False,Neg,0,C1=CC=C2C(=C1)C=NN=C2NN,CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O,17,19
3526,18288,18288,18711,18711,"Drugs that have been associated with peripheral neuropathy include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",hydralazine,metronidazole,False,Neg,0,C1=CC=C2C(=C1)C=NN=C2NN,CC1=NC=C(N1CCO)[N+](=O)[O-],17,20
3527,18289,18289,18712,18712,"Drugs that have been associated with peripheral neuropathy include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",hydralazine,nitrofurantoin,False,Neg,0,C1=CC=C2C(=C1)C=NN=C2NN,[O-][N+](=O)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O,17,21
3528,18291,18291,18714,18714,"Drugs that have been associated with peripheral neuropathy include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",hydralazine,ribavirin,False,Neg,0,C1=CC=C2C(=C1)C=NN=C2NN,C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N,17,23
3529,18292,18292,18715,18715,"Drugs that have been associated with peripheral neuropathy include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",hydralazine,vincristine,False,Neg,0,C1=CC=C2C(=C1)C=NN=C2NN,OC1=CC=CC2=C1C(=O)C1=C(C=CC=C1O)C2=O,17,25
3530,18296,18296,18719,18719,"Drugs that have been associated with peripheral neuropathy include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",iodoquinol,phenytoin,False,Neg,0,OC1=C2N=CC=CC2=C(I)C=C1I,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,18,22
3531,18301,18301,18724,18724,"Drugs that have been associated with peripheral neuropathy include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",isoniazid,phenytoin,False,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,19,22
3532,18305,18305,18728,18728,"Drugs that have been associated with peripheral neuropathy include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",metronidazole,phenytoin,False,Neg,0,CC1=NC=C(N1CCO)[N+](=O)[O-],C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,20,22
3533,18308,18308,18731,18731,"Drugs that have been associated with peripheral neuropathy include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER.",nitrofurantoin,phenytoin,False,Neg,0,[O-][N+](=O)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,21,22
3534,18311,18311,18734,18734,"Drugs that have been associated with peripheral neuropathy include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER.",phenytoin,ribavirin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N,22,23
3535,18312,18312,18735,18735,"Drugs that have been associated with peripheral neuropathy include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2.",phenytoin,vincristine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,OC1=CC=CC2=C1C(=O)C1=C(C=CC=C1O)C2=O,22,25
3536,18386,18386,18813,18813,DRUG1: Coadministration of single doses of DRUGOTHER 20 mg and DRUG2 50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.,Thioridazine,thioridazine,False,Neg,0,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,0,10
3537,18387,18387,18814,18814,DRUGOTHER: Coadministration of single doses of DRUG1 20 mg and DRUG2 50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.,Sonata,thioridazine,True,effect,2,CCN(C(C)=O)C1=CC=CC(=C1)C1=CC=NC2=C(C=NN12)C#N,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,6,10
3538,18409,18409,18836,18836,"An alternative non-CYP3A4 substrate DRUG1 may be considered in patients taking CYP3A4 inducers such as DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",hypnotic agent,phenytoin,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,4,16
3539,18412,18412,18839,18839,"An alternative non-CYP3A4 substrate DRUGOTHER may be considered in patients taking CYP3A4 inducers such as DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER.",rifampin,phenytoin,False,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,15,16
3540,18415,18415,18842,18842,"An alternative non-CYP3A4 substrate DRUGOTHER may be considered in patients taking CYP3A4 inducers such as DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER.",phenytoin,carbamazepine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,16,17
3541,18416,18416,18843,18843,"An alternative non-CYP3A4 substrate DRUGOTHER may be considered in patients taking CYP3A4 inducers such as DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2.",phenytoin,phenobarbital,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,16,19
3542,18594,18594,19044,19044,The effects of DRUG1 (DRUGOTHER) on DRUG2 (DRUGOTHER)-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. ,ruthenium red,"inositol 1,4,5-trisphosphate",False,Neg,0,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,O[C@@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](O)[C@@H]1OP(O)(O)=O,3,6
3543,18609,18609,19060,19060,"Concomitant DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER chemotherapy plus DRUGOTHER therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.",cyclophosphamide,doxorubicin,False,Neg,0,ClCCN(CCCl)P1(=O)NCCCO1,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,1,2
3544,18610,18610,19061,19061,"Concomitant DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER chemotherapy plus DRUGOTHER therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.",cyclophosphamide,vincristine,False,Neg,0,ClCCN(CCCl)P1(=O)NCCCO1,OC1=CC=CC2=C1C(=O)C1=C(C=CC=C1O)C2=O,1,3
3545,18611,18611,19062,19062,"Concomitant DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2 chemotherapy plus DRUGOTHER therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.",cyclophosphamide,prednisone,False,Neg,0,ClCCN(CCCl)P1(=O)NCCCO1,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,1,5
3546,18612,18612,19063,19063,"Concomitant DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER chemotherapy plus DRUG2 therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.",cyclophosphamide,highly active antiretroviral,False,Neg,0,ClCCN(CCCl)P1(=O)NCCCO1,CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O,1,8
3547,18619,18619,19070,19070,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER with DRUGOTHER plus DRUGOTHER) without receiving DRUGOTHER therapy. ",cyclophosphamide,doxorubicin,False,Neg,0,ClCCN(CCCl)P1(=O)NCCCO1,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,36,37
3548,18620,18620,19071,19071,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER with DRUG2 plus DRUGOTHER) without receiving DRUGOTHER therapy. ",cyclophosphamide,vincristine,False,Neg,0,ClCCN(CCCl)P1(=O)NCCCO1,OC1=CC=CC2=C1C(=O)C1=C(C=CC=C1O)C2=O,36,38
3549,18621,18621,19072,19072,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2 (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2 with DRUGOTHER plus DRUGOTHER) without receiving DRUGOTHER therapy. ",cyclophosphamide,prednisone,False,Neg,0,ClCCN(CCCl)P1(=O)NCCCO1,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,36,40
3550,18623,18623,19074,19074,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER with DRUGOTHER plus DRUGOTHER) without receiving DRUGOTHER therapy. ",cyclophosphamide,doxorubicin,False,Neg,0,ClCCN(CCCl)P1(=O)NCCCO1,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,36,37
3551,18624,18624,19075,19075,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER with DRUGOTHER plus DRUGOTHER) without receiving DRUGOTHER therapy. ",cyclophosphamide,teniposide,False,Neg,0,ClCCN(CCCl)P1(=O)NCCCO1,COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](C4=CC5=C(C=C24)OCO5)O[C@H]6[C@@H]([C@H]([C@H]7[C@H](O6)CO[C@H](O7)C8=CC=CS8)O)O,36,65
3552,18625,18625,19076,19076,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2 (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2 with DRUGOTHER plus DRUGOTHER) without receiving DRUGOTHER therapy. ",cyclophosphamide,prednisone,False,Neg,0,ClCCN(CCCl)P1(=O)NCCCO1,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,36,40
3553,18626,18626,19077,19077,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER with DRUG2 plus DRUGOTHER) without receiving DRUGOTHER therapy. ",cyclophosphamide,vincristine,False,Neg,0,ClCCN(CCCl)P1(=O)NCCCO1,OC1=CC=CC2=C1C(=O)C1=C(C=CC=C1O)C2=O,36,38
3554,18627,18627,19078,19078,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER with DRUGOTHER plus DRUGOTHER) without receiving DRUG2 therapy. ",cyclophosphamide,antiretroviral,False,Neg,0,ClCCN(CCCl)P1(=O)NCCCO1,CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O,36,74
3555,18630,18630,19081,19081,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUG2, DRUG1, DRUGOTHER, and DRUGOTHER (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUG2, DRUG1, DRUGOTHER, and DRUGOTHER with DRUGOTHER plus DRUGOTHER) without receiving DRUGOTHER therapy. ",doxorubicin,cyclophosphamide,False,Neg,0,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,ClCCN(CCCl)P1(=O)NCCCO1,37,36
3556,18637,18637,19088,19088,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUG2, DRUGOTHER, DRUG1, and DRUGOTHER (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER with DRUG1 plus DRUGOTHER) without receiving DRUGOTHER therapy. ",vincristine,cyclophosphamide,False,Neg,0,OC1=CC=CC2=C1C(=O)C1=C(C=CC=C1O)C2=O,ClCCN(CCCl)P1(=O)NCCCO1,38,36
3557,18643,18643,19094,19094,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUG2, DRUGOTHER, DRUGOTHER, and DRUG1 (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUG2, DRUGOTHER, DRUGOTHER, and DRUG1 with DRUGOTHER plus DRUGOTHER) without receiving DRUGOTHER therapy. ",prednisone,cyclophosphamide,False,Neg,0,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,ClCCN(CCCl)P1(=O)NCCCO1,40,36
3558,18649,18649,19100,19100,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER with DRUGOTHER plus DRUGOTHER) without receiving DRUGOTHER therapy. ",cyclophosphamide,doxorubicin,False,Neg,0,ClCCN(CCCl)P1(=O)NCCCO1,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,36,37
3559,18650,18650,19101,19101,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER with DRUGOTHER plus DRUGOTHER) without receiving DRUGOTHER therapy. ",cyclophosphamide,teniposide,False,Neg,0,ClCCN(CCCl)P1(=O)NCCCO1,COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](C4=CC5=C(C=C24)OCO5)O[C@H]6[C@@H]([C@H]([C@H]7[C@H](O6)CO[C@H](O7)C8=CC=CS8)O)O,36,65
3560,18651,18651,19102,19102,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2 (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2 with DRUGOTHER plus DRUGOTHER) without receiving DRUGOTHER therapy. ",cyclophosphamide,prednisone,False,Neg,0,ClCCN(CCCl)P1(=O)NCCCO1,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,36,40
3561,18652,18652,19103,19103,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER with DRUG2 plus DRUGOTHER) without receiving DRUGOTHER therapy. ",cyclophosphamide,vincristine,False,Neg,0,ClCCN(CCCl)P1(=O)NCCCO1,OC1=CC=CC2=C1C(=O)C1=C(C=CC=C1O)C2=O,36,38
3562,18653,18653,19104,19104,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER with DRUGOTHER plus DRUGOTHER) without receiving DRUG2 therapy. ",cyclophosphamide,antiretroviral,False,Neg,0,ClCCN(CCCl)P1(=O)NCCCO1,CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O,36,74
3563,18678,18678,19135,19135,"Activity of DRUGOTHER alone and in combination with DRUG1 and DRUG2 against Cryptosporidium parvum in cell culture.
",azithromycin,minocycline,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C,8,10
3564,18679,18679,19136,19136,The in vitro anti-cryptosporidial activity of DRUGOTHER alone and in combination with DRUG1 and DRUG2 was investigated. ,azithromycin,minocycline,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C,12,14
3565,18680,18680,19137,19137,"Moreover, its activity was enhanced when it was combined with either DRUG1 or DRUG2 with 90% parasite reduction at the highest concentration tested. ",azithromycin,minocycline,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C,11,13
3566,18681,18681,19138,19138,DRUGOTHER may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either DRUG1 or DRUG2.,azithromycin,minocycline,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C,15,17
3567,18686,18686,19143,19143,"Numerous drug interactions are possible with some DRUG1, such as DRUGOTHER and DRUG2, which affect hepatic microsomal enzyme systems. ",anticonvulsant agents,phenytoin,False,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,7,12
3568,18687,18687,19144,19144,"Numerous drug interactions are possible with some DRUGOTHER, such as DRUG1 and DRUG2, which affect hepatic microsomal enzyme systems. ",phenobarbitone,phenytoin,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,10,12
3569,18758,18758,19223,19223,"To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of DRUG1 (20mM), DRUGOTHER (100 or 150 mg. per 100 ml.), and DRUG2 (10 mM). ",arginine,theophylline,False,Neg,0,N[C@H](CCCNC(N)=N)C(O)=O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,33,44
3570,18759,18759,19224,19224,"To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of DRUGOTHER (20mM), DRUG1 (100 or 150 mg. per 100 ml.), and DRUG2 (10 mM). ",glucose,theophylline,False,Neg,0,[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C=O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,35,44
3571,18760,18760,19225,19225,"DRUG1, alone and in the presence of DRUG2, caused subnormal insulin release and less suppression of glucagon release in the diabectics than in the normals. ",Glucose,theophylline,False,Neg,0,[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C=O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,7
3572,18762,18762,19227,19227,"DRUG1, in the presence of DRUGOTHER and DRUG2, caused excessive glucagon release but nearly normal insulin release in the diabetics. ",Arginine,theophylline,False,Neg,0,N[C@H](CCCNC(N)=N)C(O)=O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,7
3573,18763,18763,19228,19228,"DRUGOTHER, in the presence of DRUG1 and DRUG2, caused excessive glucagon release but nearly normal insulin release in the diabetics. ",glucose,theophylline,False,Neg,0,[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C=O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,5,7
3574,18765,18765,19230,19230,"DRUG1, in the absence of DRUGOTHER or DRUG2, caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals. ",Arginine,theophylline,False,Neg,0,N[C@H](CCCNC(N)=N)C(O)=O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,7
3575,18766,18766,19231,19231,"DRUGOTHER, in the absence of DRUG1 or DRUG2, caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals. ",glucose,theophylline,False,Neg,0,[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C=O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,5,7
3576,18767,18767,19232,19232,"Further, these results confirm that the diabetic Chinese hamster's alpha and beta cells respond normally to DRUG1, but are relatively insensitive to DRUG2.",theophylline,glucose,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C=O,16,22
3577,18796,18796,19262,19262,"Pharmacokinetic interaction between single oral doses of DRUG1 and DRUG2 in healthy volunteers.
",diltiazem,sirolimus,True,mechanism,4,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,7,9
3578,18797,18797,19263,19263,"AIM AND BACKGROUND: The pharmacokinetic interaction between DRUG1, a DRUG2 metabolized by CYP3A4, and the DRUGOTHER DRUGOTHER was studied in 18 healthy subjects. ",sirolimus,macrolide immunosuppressant,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,7,9
3579,18798,18798,19264,19264,"AIM AND BACKGROUND: The pharmacokinetic interaction between DRUG1, a DRUGOTHER metabolized by CYP3A4, and the DRUGOTHER DRUG2 was studied in 18 healthy subjects. ",sirolimus,diltiazem,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,7,16
3580,18800,18800,19266,19266,"METHODS: Healthy subjects who were 20 to 43 years old participated in an open, three-period, randomized, crossover study of the pharmacokinetics of a single 10-mg oral dose of DRUG1, a single oral 120-mg dose of DRUG2, and the two drugs given together. ",sirolimus,diltiazem,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,28,35
3581,18801,18801,19267,19267,"RESULTS: The geometric mean (90% confidence interval) whole blood DRUG1 area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with DRUG2 coadministration, whereas the mean elimination half-life of DRUG1 decreased slightly, from 79 to 67 hours. ",sirolimus,diltiazem,True,mechanism,4,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,9,38
3582,18803,18803,19269,19269,"RESULTS: The geometric mean (90% confidence interval) whole blood DRUG2 area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with DRUG1 coadministration, whereas the mean elimination half-life of DRUG2 decreased slightly, from 79 to 67 hours. ",diltiazem,sirolimus,False,Neg,0,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,38,9
3583,18805,18805,19271,19271,"Apparent oral clearance and volume of distribution of DRUG1 decreased with 38% and 45%, respectively, when DRUG1 was given with DRUG2. ",sirolimus,diltiazem,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,8,20
3584,18806,18806,19272,19272,"Apparent oral clearance and volume of distribution of DRUG1 decreased with 38% and 45%, respectively, when DRUG1 was given with DRUG2. ",sirolimus,diltiazem,True,mechanism,4,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,8,20
3585,18809,18809,19275,19275,"The plasma maximum concentration and area under the plasma concentration-time curve of DRUG1, desacetylDRUG1, and desmethylDRUG1 were unchanged after coadministration of DRUG2, and no potentiation of the effects of DRUG1 on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. ",diltiazem,sirolimus,False,Neg,0,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,12,21
3586,18812,18812,19278,19278,"The plasma maximum concentration and area under the plasma concentration-time curve of DRUGOTHER, DRUG1, and desmethylDRUGOTHER were unchanged after coadministration of DRUG2, and no potentiation of the effects of DRUGOTHER on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. ",desacetyldiltiazem,sirolimus,False,Neg,0,COC1=CC=C(C=C1)[C@@H]1SC2=C(C=CC=C2)N(CCN(C)C)C(=O)[C@@H]1OC(C)=O,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,13,21
3587,18814,18814,19280,19280,"The plasma maximum concentration and area under the plasma concentration-time curve of DRUGOTHER, desacetylDRUGOTHER, and DRUG1 were unchanged after coadministration of DRUG2, and no potentiation of the effects of DRUGOTHER on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. ",desmethyldiltiazem,sirolimus,False,Neg,0,COC1=CC=C(C=C1)[C@@H]1SC2=C(C=CC=C2)N(CCN(C)C)C(=O)[C@@H]1OC(C)=O,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,15,21
3588,18816,18816,19282,19282,"The plasma maximum concentration and area under the plasma concentration-time curve of DRUG2, desacetylDRUG2, and desmethylDRUG2 were unchanged after coadministration of DRUG1, and no potentiation of the effects of DRUG2 on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. ",sirolimus,diltiazem,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,21,12
3589,18817,18817,19283,19283,"CONCLUSIONS: Single-dose DRUG1 coadministration leads to higher DRUG2 exposure, presumably by inhibition of the first-pass metabolism of DRUG2. ",diltiazem,sirolimus,True,mechanism,4,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,2,7
3590,18818,18818,19284,19284,"CONCLUSIONS: Single-dose DRUG1 coadministration leads to higher DRUG2 exposure, presumably by inhibition of the first-pass metabolism of DRUG2. ",diltiazem,sirolimus,False,Neg,0,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,2,7
3591,18820,18820,19286,19286,"Because of the pronounced intersubject variability in the extent of the DRUG1-DRUG2 interaction, whole blood DRUG1 concentrations should be monitored closely in patients treated with the two drugs.",sirolimus,diltiazem,True,advise,1,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,11,11
3592,18822,18822,19288,19288,"Because of the pronounced intersubject variability in the extent of the DRUG2-DRUG1 interaction, whole blood DRUG2 concentrations should be monitored closely in patients treated with the two drugs.",diltiazem,sirolimus,False,Neg,0,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,11,11
3593,18840,18840,19306,19306,"Longitudinal assessment of DRUG1 in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on DRUG2.
",everolimus,cyclosporine,False,Neg,0,[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,3,21
3594,18841,18841,19307,19307,"OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of DRUG1 and DRUG2 (INN, DRUGOTHER) when coadministered in de novo kidney allograft recipients during the first year after transplantation. ",everolimus,cyclosporine,False,Neg,0,[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,10,12
3595,18842,18842,19308,19308,"OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of DRUG1 and DRUGOTHER (INN, DRUG2) when coadministered in de novo kidney allograft recipients during the first year after transplantation. ",everolimus,ciclosporin,False,Neg,0,[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,10,14
3596,18844,18844,19310,19310,"METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive DRUG1 tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with DRUG2 and DRUGOTHER. ",everolimus,cyclosporine,False,Neg,0,[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,19,34
3597,18845,18845,19311,19311,"METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive DRUG1 tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with DRUGOTHER and DRUG2. ",everolimus,prednisone,False,Neg,0,[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,19,36
3598,18847,18847,19313,19313,"Blood sampling for the pharmacokinetics of DRUG1 and DRUG2 was performed on day 1, on weeks 1, 2, 3, and 4, and on months 2, 3, 6, 9, and 12. ",everolimus,cyclosporine,False,Neg,0,[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,6,8
3599,18848,18848,19314,19314,Potential differences in DRUG1 dosing and pharmacokinetics at different levels of DRUG2 exposure were assessed in the context of ANOVA. ,cyclosporine,everolimus,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC,3,11
3600,18849,18849,19315,19315,"DRUG1 doses, trough concentrations, and AUC exhibited similar temporal patterns during the course of the study regardless of the co-administered DRUG2 dose level (P = .13, .82, and .76, respectively). ",Cyclosporine,everolimus,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC,0,20
3601,18850,18850,19316,19316,For a 4-fold range of DRUG1 doses there were no differential effects on DRUG2 dosing or pharmacokinetics.,everolimus,cyclosporine,False,Neg,0,[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,5,13
3602,18866,18866,19332,19332,"The effects of concomitant DRUG1 administration on the steady-state pharmacokinetics of DRUG2.
",phenytoin,quetiapine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12,4,11
3603,18870,18870,19336,19336,"This study demonstrated that the potent cytochrome P450 enzyme-inducer DRUG1 did indeed have a marked effect on the metabolism of DRUG2, resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder. ",phenytoin,quetiapine,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12,9,20
3604,18873,18873,19339,19339,"DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER were added to pooled human serum at therapeutic concentrations. ",Acetaminophen,theophylline,False,Neg,0,CC(=O)NC1=CC=C(C=C1)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,4
3605,18876,18876,19342,19342,"DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER were added to pooled human serum at therapeutic concentrations. ",phenobarbital,theophylline,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,2,4
3606,18878,18878,19344,19344,"DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER were added to pooled human serum at therapeutic concentrations. ",quinidine,theophylline,False,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,3,4
3607,18880,18880,19346,19346,"DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2 were added to pooled human serum at therapeutic concentrations. ",theophylline,valproic acid,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CCCC(CCC)C(=O)O,4,6
3608,18882,18882,19348,19348,"DRUG1/DRUG2, DRUGOTHER/DRUGOTHER, DRUGOTHER/DRUG1, DRUGOTHER/DRUGOTHER, DRUGOTHER/DRUGOTHER, DRUG2/DRUG1, and DRUGOTHER/DRUGOTHER. ",acetaminophen,theophylline,False,Neg,0,CC(=O)NC1=CC=C(C=C1)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,0
3609,18889,18889,19355,19355,"DRUG1/DRUG2, DRUGOTHER/DRUGOTHER, DRUGOTHER/DRUG1, DRUGOTHER/DRUGOTHER, DRUGOTHER/DRUGOTHER, DRUG2/DRUG1, and DRUGOTHER/DRUGOTHER. ",acetaminophen,theophylline,False,Neg,0,CC(=O)NC1=CC=C(C=C1)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,0
3610,18893,18893,19359,19359,"DRUGOTHER/DRUG1, DRUGOTHER/DRUG2, DRUGOTHER/DRUGOTHER, DRUGOTHER/DRUGOTHER, DRUG2/DRUGOTHER, DRUG1/DRUGOTHER, and DRUGOTHER/DRUGOTHER. ",theophylline,quinidine,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,0,1
3611,18894,18894,19360,19360,"DRUGOTHER/DRUG1, DRUGOTHER/DRUGOTHER, DRUG2/DRUGOTHER, DRUG2/DRUGOTHER, DRUGOTHER/DRUGOTHER, DRUG1/DRUGOTHER, and DRUGOTHER/DRUG2. ",theophylline,phenobarbital,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,0,2
3612,18895,18895,19361,19361,"DRUG2/DRUG1, DRUGOTHER/DRUGOTHER, DRUGOTHER/DRUG2, DRUGOTHER/DRUGOTHER, DRUGOTHER/DRUGOTHER, DRUG1/DRUG2, and DRUGOTHER/DRUGOTHER. ",theophylline,acetaminophen,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC(=O)NC1=CC=C(C=C1)O,0,0
3613,18896,18896,19362,19362,"DRUGOTHER/DRUG1, DRUGOTHER/DRUGOTHER, DRUG2/DRUGOTHER, DRUG2/DRUGOTHER, DRUGOTHER/DRUGOTHER, DRUG1/DRUGOTHER, and DRUGOTHER/DRUG2. ",theophylline,phenobarbital,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,0,2
3614,18897,18897,19363,19363,"DRUGOTHER/DRUG1, DRUGOTHER/DRUGOTHER, DRUGOTHER/DRUGOTHER, DRUGOTHER/DRUG2, DRUGOTHER/DRUGOTHER, DRUG1/DRUGOTHER, and DRUG2/DRUGOTHER. ",theophylline,valproic acid,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CCCC(CCC)C(=O)O,0,3
3615,18898,18898,19364,19364,"DRUGOTHER/DRUG1, DRUGOTHER/DRUG2, DRUGOTHER/DRUGOTHER, DRUGOTHER/DRUGOTHER, DRUG2/DRUGOTHER, DRUG1/DRUGOTHER, and DRUGOTHER/DRUGOTHER. ",theophylline,quinidine,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,0,1
3616,18900,18900,19366,19366,"DRUG2/DRUG1, DRUGOTHER/DRUGOTHER, DRUGOTHER/DRUG2, DRUGOTHER/DRUGOTHER, DRUGOTHER/DRUGOTHER, DRUG1/DRUG2, and DRUGOTHER/DRUGOTHER. ",theophylline,acetaminophen,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC(=O)NC1=CC=C(C=C1)O,0,0
3617,18901,18901,19367,19367,"DRUGOTHER/DRUG1, DRUGOTHER/DRUGOTHER, DRUGOTHER/DRUGOTHER, DRUGOTHER/DRUG2, DRUGOTHER/DRUGOTHER, DRUG1/DRUGOTHER, and DRUG2/DRUGOTHER. ",theophylline,valproic acid,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CCCC(CCC)C(=O)O,0,3
3618,18902,18902,19368,19368,"DRUGOTHER/DRUG1, DRUGOTHER/DRUGOTHER, DRUG2/DRUGOTHER, DRUG2/DRUGOTHER, DRUGOTHER/DRUGOTHER, DRUG1/DRUGOTHER, and DRUGOTHER/DRUG2. ",theophylline,phenobarbital,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,0,2
3619,18908,18908,19374,19374,"DRUGOTHER/DRUG2, DRUGOTHER/DRUG1, DRUGOTHER/DRUGOTHER, DRUGOTHER/DRUGOTHER, DRUG1/DRUGOTHER, DRUG2/DRUGOTHER, and DRUGOTHER/DRUGOTHER. ",quinidine,theophylline,False,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,1,0
3620,18916,18916,19382,19382,"DRUGOTHER/DRUG2, DRUGOTHER/DRUGOTHER, DRUG1/DRUGOTHER, DRUG1/DRUGOTHER, DRUGOTHER/DRUGOTHER, DRUG2/DRUGOTHER, and DRUGOTHER/DRUG1. ",phenobarbital,theophylline,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,2,0
3621,18923,18923,19389,19389,"DRUG1/DRUG2, DRUGOTHER/DRUGOTHER, DRUGOTHER/DRUG1, DRUGOTHER/DRUGOTHER, DRUGOTHER/DRUGOTHER, DRUG2/DRUG1, and DRUGOTHER/DRUGOTHER. ",acetaminophen,theophylline,False,Neg,0,CC(=O)NC1=CC=C(C=C1)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,0
3622,18929,18929,19395,19395,"DRUGOTHER/DRUG2, DRUGOTHER/DRUGOTHER, DRUG1/DRUGOTHER, DRUG1/DRUGOTHER, DRUGOTHER/DRUGOTHER, DRUG2/DRUGOTHER, and DRUGOTHER/DRUG1. ",phenobarbital,theophylline,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,2,0
3623,18934,18934,19400,19400,"DRUGOTHER/DRUG2, DRUGOTHER/DRUGOTHER, DRUGOTHER/DRUGOTHER, DRUGOTHER/DRUG1, DRUGOTHER/DRUGOTHER, DRUG2/DRUGOTHER, and DRUG1/DRUGOTHER. ",valproic acid,theophylline,False,Neg,0,CCCC(CCC)C(=O)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,3,0
3624,18938,18938,19404,19404,"DRUGOTHER/DRUG2, DRUGOTHER/DRUG1, DRUGOTHER/DRUGOTHER, DRUGOTHER/DRUGOTHER, DRUG1/DRUGOTHER, DRUG2/DRUGOTHER, and DRUGOTHER/DRUGOTHER. ",quinidine,theophylline,False,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,1,0
3625,18942,18942,19408,19408,"DRUG2/DRUG1, DRUGOTHER/DRUGOTHER, DRUGOTHER/DRUG2, DRUGOTHER/DRUGOTHER, DRUGOTHER/DRUGOTHER, DRUG1/DRUG2, and DRUGOTHER/DRUGOTHER. ",theophylline,acetaminophen,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC(=O)NC1=CC=C(C=C1)O,0,0
3626,18943,18943,19409,19409,"DRUGOTHER/DRUG1, DRUGOTHER/DRUGOTHER, DRUGOTHER/DRUGOTHER, DRUGOTHER/DRUG2, DRUGOTHER/DRUGOTHER, DRUG1/DRUGOTHER, and DRUG2/DRUGOTHER. ",theophylline,valproic acid,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CCCC(CCC)C(=O)O,0,3
3627,18944,18944,19410,19410,"DRUGOTHER/DRUG1, DRUGOTHER/DRUGOTHER, DRUG2/DRUGOTHER, DRUG2/DRUGOTHER, DRUGOTHER/DRUGOTHER, DRUG1/DRUGOTHER, and DRUGOTHER/DRUG2. ",theophylline,phenobarbital,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,0,2
3628,18949,18949,19415,19415,"Similarly dialyzed were DRUG1, DRUGOTHER, and DRUG2, both alone at therapeutic concentrations in serum and with DRUGOTHER at three different concentrations in serum. ",phenobarbital,theophylline,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,3,6
3629,18951,18951,19417,19417,"Similarly dialyzed were DRUGOTHER, DRUG1, and DRUG2, both alone at therapeutic concentrations in serum and with DRUGOTHER at three different concentrations in serum. ",quinidine,theophylline,False,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,4,6
3630,18953,18953,19419,19419,"Similarly dialyzed were DRUGOTHER, DRUGOTHER, and DRUG1, both alone at therapeutic concentrations in serum and with DRUG2 at three different concentrations in serum. ",theophylline,ethanol,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CCO,6,16
3631,18954,18954,19420,19420,"DRUG1 diminished the binding of DRUG2 to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L. ",Acetaminophen,theophylline,True,mechanism,4,CC(=O)NC1=CC=C(C=C1)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,5
3632,18955,18955,19421,19421,"DRUG1 decreased the binding of DRUG2 by a net change of 6.8% (percentage increase in FDF, 8.8%) at 277.5 micromol/L; ",Theophylline,acetaminophen,True,mechanism,4,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC(=O)NC1=CC=C(C=C1)O,0,5
3633,18957,18957,19423,19423,"Coingestion of DRUG1 with DRUG2, DRUGOTHER with DRUG1, and DRUGOTHER with DRUGOTHER at high to toxic concentrations decreases the binding of the target drug. ",acetaminophen,theophylline,True,effect,2,CC(=O)NC1=CC=C(C=C1)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,2,4
3634,18962,18962,19428,19428,"Coingestion of DRUGOTHER with DRUG1, DRUG2 with DRUGOTHER, and DRUGOTHER with DRUG2 at high to toxic concentrations decreases the binding of the target drug. ",theophylline,phenobarbital,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,4,5
3635,18963,18963,19429,19429,"Coingestion of DRUG2 with DRUG1, DRUGOTHER with DRUG2, and DRUGOTHER with DRUGOTHER at high to toxic concentrations decreases the binding of the target drug. ",theophylline,acetaminophen,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC(=O)NC1=CC=C(C=C1)O,4,2
3636,18964,18964,19430,19430,"Coingestion of DRUGOTHER with DRUG1, DRUGOTHER with DRUGOTHER, and DRUG2 with DRUGOTHER at high to toxic concentrations decreases the binding of the target drug. ",theophylline,valproic acid,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CCCC(CCC)C(=O)O,4,9
3637,18965,18965,19431,19431,"Coingestion of DRUGOTHER with DRUG1, DRUG2 with DRUGOTHER, and DRUGOTHER with DRUG2 at high to toxic concentrations decreases the binding of the target drug. ",theophylline,phenobarbital,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,4,5
3638,18972,18972,19438,19438,"The serum concentration of DRUG1 increased dramatically from 16.6 to 49.1 microg/mL when DRUG2 was coadministered, although the daily dosage of DRUG1 and other DRUGOTHER had not changed. ",phenytoin,fluvoxamine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,4,13
3639,18974,18974,19440,19440,"The serum concentration of DRUG1 increased dramatically from 16.6 to 49.1 microg/mL when DRUGOTHER was coadministered, although the daily dosage of DRUG1 and other DRUG2 had not changed. ",phenytoin,drugs,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=C(N(N=C1C(=O)NN1CCCCC1)C1=C(Cl)C=C(Cl)C=C1)C1=CC=C(Cl)C=C1,4,24
3640,18975,18975,19441,19441,"The serum concentration of DRUG2 increased dramatically from 16.6 to 49.1 microg/mL when DRUG1 was coadministered, although the daily dosage of DRUG2 and other DRUGOTHER had not changed. ",fluvoxamine,phenytoin,False,Neg,0,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,13,4
3641,18977,18977,19443,19443,"The serum concentration of DRUG1 increased dramatically from 16.6 to 49.1 microg/mL when DRUGOTHER was coadministered, although the daily dosage of DRUG1 and other DRUG2 had not changed. ",phenytoin,drugs,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=C(N(N=C1C(=O)NN1CCCCC1)C1=C(Cl)C=C(Cl)C=C1)C1=CC=C(Cl)C=C1,4,24
3642,18979,18979,19445,19445,"Here we show that a combination of DRUG1 or 3,7-dihydroxyflavone with DRUG2 may be used to sensitize resistant strains of Enterococcus faecalis and Enterococcus faecium to the level of DRUG2-sensitive strains. ",galangin,vancomycin,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,7,11
3643,19077,19077,19548,19548,"In large, well controlled trials in patients with schizophrenia or related psychoses, DRUG1 5 to 20 mg/day was significantly superior to DRUG2 5 to 20 mg/day in overall improvements in psychopathology rating scales and in the treatment of depressive and negative symptoms, and was comparable in effects on positive psychotic symptoms. ",olanzapine,haloperidol,False,Neg,0,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,12,21
3644,19078,19078,19549,19549,The 1-year risk of relapse (rehospitalisation) was significantly lower with DRUG1 than with DRUG2 treatment. ,olanzapine,haloperidol,False,Neg,0,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,10,13
3645,19087,19087,19558,19558,"Improvements in general cognitive function seen with DRUG1 treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either DRUGOTHER or DRUG2. ",olanzapine,haloperidol,False,Neg,0,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,7,29
3646,19088,19088,19559,19559,"Improvements in general cognitive function seen with DRUGOTHER treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either DRUG1 or DRUG2. ",risperidone,haloperidol,False,Neg,0,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,27,29
3647,19091,19091,19562,19562,DRUG1 is associated with significantly fewer extrapyramidal symptoms than DRUG2 and DRUGOTHER. ,Olanzapine,haloperidol,False,Neg,0,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,0,9
3648,19093,19093,19564,19564,DRUGOTHER is associated with significantly fewer extrapyramidal symptoms than DRUG1 and DRUG2. ,haloperidol,risperidone,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,9,11
3649,19097,19097,19568,19568,"In comparison with DRUG1, the adverse events reported significantly more frequently with DRUG2 in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with DRUGOTHER, only bodyweight gain occurred significantly more frequently with DRUG2. ",haloperidol,olanzapine,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12,3,12
3650,19098,19098,19569,19569,"In comparison with DRUG1, the adverse events reported significantly more frequently with DRUGOTHER in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with DRUG2, only bodyweight gain occurred significantly more frequently with DRUGOTHER. ",haloperidol,risperidone,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,3,31
3651,19099,19099,19570,19570,"In comparison with DRUG1, the adverse events reported significantly more frequently with DRUG2 in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with DRUGOTHER, only bodyweight gain occurred significantly more frequently with DRUG2. ",haloperidol,olanzapine,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12,3,12
3652,19103,19103,19574,19574,"Pharmacoeconomic analyses indicate that DRUG1 does not significantly increase, and may even decrease, the overall direct treatment costs of schizophrenia, compared with DRUG2. ",olanzapine,haloperidol,False,Neg,0,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,4,22
3653,19105,19105,19576,19576,"DRUG1 treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than DRUG2, and to broadly the same extent as DRUGOTHER. ",Olanzapine,haloperidol,False,Neg,0,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,0,18
3654,19107,19107,19578,19578,"DRUGOTHER treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than DRUG1, and to broadly the same extent as DRUG2. ",haloperidol,risperidone,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,18,26
3655,19108,19108,19579,19579,"CONCLUSIONS: DRUG1 demonstrated superior antipsychotic efficacy compared with DRUG2 in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia. ",Olanzapine,haloperidol,False,Neg,0,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,1,8
3656,19109,19109,19580,19580,The reduced risk of adverse events and therapeutic superiority compared with DRUG1 and DRUG2 in the treatment of negative and depressive symptoms support the choice of DRUGOTHER as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.,haloperidol,risperidone,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,11,13
3657,19110,19110,19581,19581,The reduced risk of adverse events and therapeutic superiority compared with DRUG1 and DRUGOTHER in the treatment of negative and depressive symptoms support the choice of DRUG2 as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.,haloperidol,olanzapine,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12,11,26
3658,19143,19143,19614,19614,"RESULTS: DRUG1 has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, DRUG2 [DRUGOTHER]). ",Sildenafil,selective serotonin reuptake inhibitors,False,Neg,0,CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1,NCCC1=CNC2=CC=C(O)C=C12,1,24
3659,19147,19147,19622,19622,"The effects of DRUG1 and of DRUG2 anesthesia on DRUGOTHER tolerance in dogs.
",ketamine,Innovar,False,Neg,0,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,3,6
3660,19149,19149,19624,19624,"The effects of DRUGOTHER and of DRUG1 anesthesia on DRUG2 tolerance in dogs.
",Innovar,digitalis,False,Neg,0,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,6,9
3661,19155,19155,19630,19630,"In a comparison of DRUG1 tolerance in dogs anesthetized with DRUGOTHER, DRUG2 Vet, or DRUGOTHER, the dosage of DRUGOTHER needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGOTHER, with DRUGOTHER or DRUG2 than with DRUGOTHER. ",digitalis,Innovar,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,4,11
3662,19161,19161,19636,19636,"In a comparison of DRUGOTHER tolerance in dogs anesthetized with DRUG1, DRUG2 Vet, or DRUGOTHER, the dosage of DRUGOTHER needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGOTHER, with DRUG1 or DRUG2 than with DRUGOTHER. ",ketamine,Innovar,False,Neg,0,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,10,11
3663,19166,19166,19641,19641,"In a comparison of DRUGOTHER tolerance in dogs anesthetized with DRUGOTHER, DRUG2 Vet, or DRUG1, the dosage of DRUGOTHER needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGOTHER, with DRUGOTHER or DRUG2 than with DRUG1. ",pentobarbital,Innovar,False,Neg,0,CCC1(CC)C(=O)NC(=O)NC1=O,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,14,11
3664,19170,19170,19645,19645,"In a comparison of DRUGOTHER tolerance in dogs anesthetized with DRUGOTHER, DRUG2 Vet, or DRUGOTHER, the dosage of DRUG1 needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUG1, with DRUGOTHER or DRUG2 than with DRUGOTHER. ",ouabain,Innovar,False,Neg,0,[H][C@@]12CC[C@]3(O)C[C@H](C[C@@H](O)[C@]3(CO)[C@@]1([H])[C@H](O)C[C@]1(C)[C@H](CC[C@]21O)C1=CC(=O)OC1)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,18,11
3665,19173,19173,19648,19648,"In a comparison of DRUGOTHER tolerance in dogs anesthetized with DRUGOTHER, DRUG2 Vet, or DRUGOTHER, the dosage of DRUG1 needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUG1, with DRUGOTHER or DRUG2 than with DRUGOTHER. ",ouabain,Innovar,False,Neg,0,[H][C@@]12CC[C@]3(O)C[C@H](C[C@@H](O)[C@]3(CO)[C@@]1([H])[C@H](O)C[C@]1(C)[C@H](CC[C@]21O)C1=CC(=O)OC1)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,18,11
3666,19175,19175,19650,19650,"In a comparison of DRUGOTHER tolerance in dogs anesthetized with DRUG1, DRUG2 Vet, or DRUGOTHER, the dosage of DRUGOTHER needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGOTHER, with DRUG1 or DRUG2 than with DRUGOTHER. ",ketamine,Innovar,False,Neg,0,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,10,11
3667,19177,19177,19652,19652,"In a comparison of DRUGOTHER tolerance in dogs anesthetized with DRUGOTHER, DRUG1 Vet, or DRUG2, the dosage of DRUGOTHER needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGOTHER, with DRUGOTHER or DRUG1 than with DRUG2. ",Innovar,pentobarbital,False,Neg,0,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,CCC1(CC)C(=O)NC(=O)NC1=O,11,14
3668,19178,19178,19653,19653,"Ventricular tachycardia induced by DRUG1 was generally converted to sinus rhythm following administration of DRUG2, DRUGOTHER, or DRUGOTHER but not after administration of DRUGOTHER alone or after DRUGOTHER.",ouabain,Innovar,True,effect,2,[H][C@@]12CC[C@]3(O)C[C@H](C[C@@H](O)[C@]3(CO)[C@@]1([H])[C@H](O)C[C@]1(C)[C@H](CC[C@]21O)C1=CC(=O)OC1)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,4,14
3669,19183,19183,19658,19658,"Ventricular tachycardia induced by DRUGOTHER was generally converted to sinus rhythm following administration of DRUG1, DRUG2, or DRUGOTHER but not after administration of DRUGOTHER alone or after DRUGOTHER.",Innovar,ketamine,False,Neg,0,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,14,15
3670,19184,19184,19659,19659,"Ventricular tachycardia induced by DRUGOTHER was generally converted to sinus rhythm following administration of DRUG1, DRUGOTHER, or DRUG2 but not after administration of DRUGOTHER alone or after DRUGOTHER.",Innovar,droperidol,False,Neg,0,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F,14,17
3671,19185,19185,19660,19660,"Ventricular tachycardia induced by DRUGOTHER was generally converted to sinus rhythm following administration of DRUG1, DRUGOTHER, or DRUGOTHER but not after administration of DRUG2 alone or after DRUGOTHER.",Innovar,fentayl,False,Neg,0,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,14,23
3672,19186,19186,19661,19661,"Ventricular tachycardia induced by DRUGOTHER was generally converted to sinus rhythm following administration of DRUG1, DRUGOTHER, or DRUGOTHER but not after administration of DRUGOTHER alone or after DRUG2.",Innovar,pentobarbital,False,Neg,0,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,CCC1(CC)C(=O)NC(=O)NC1=O,14,27
3673,19210,19210,19695,19695,"DRUG1 works differently from the DRUGOTHER currently available, and except for increased lipid levels, the adverse reaction profile of DRUGOTHER does not appear to overlap to any great extent with that associated with DRUG2 or DRUGOTHER. ",Sirolimus,cyclosporine,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,0,33
3674,19211,19211,19696,19696,"DRUG1 works differently from the DRUGOTHER currently available, and except for increased lipid levels, the adverse reaction profile of DRUGOTHER does not appear to overlap to any great extent with that associated with DRUGOTHER or DRUG2. ",Sirolimus,tacrolimus,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,0,35
3675,19213,19213,19698,19698,"DRUGOTHER works differently from the DRUG1 currently available, and except for increased lipid levels, the adverse reaction profile of DRUGOTHER does not appear to overlap to any great extent with that associated with DRUG2 or DRUGOTHER. ",immunosuppressants,cyclosporine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,5,33
3676,19214,19214,19699,19699,"DRUGOTHER works differently from the DRUG1 currently available, and except for increased lipid levels, the adverse reaction profile of DRUGOTHER does not appear to overlap to any great extent with that associated with DRUGOTHER or DRUG2. ",immunosuppressants,tacrolimus,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,5,35
3677,19215,19215,19700,19700,"DRUGOTHER works differently from the DRUGOTHER currently available, and except for increased lipid levels, the adverse reaction profile of DRUG1 does not appear to overlap to any great extent with that associated with DRUG2 or DRUGOTHER. ",sirolimus,cyclosporine,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,19,33
3678,19216,19216,19701,19701,"DRUGOTHER works differently from the DRUGOTHER currently available, and except for increased lipid levels, the adverse reaction profile of DRUG1 does not appear to overlap to any great extent with that associated with DRUGOTHER or DRUG2. ",sirolimus,tacrolimus,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,19,35
3679,19218,19218,19703,19703,"While additional research is needed, the initial clinical data in kidney recipients suggest that DRUG1, in combination with DRUG2 or DRUGOTHER, might have the potential to reduce the frequency of rejection episodes, permit reductions in DRUG2 or DRUGOTHER dosage, and permit steroid withdrawal (Kelly, 1999).",sirolimus,cyclosporine,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,14,18
3680,19219,19219,19704,19704,"While additional research is needed, the initial clinical data in kidney recipients suggest that DRUG1, in combination with DRUGOTHER or DRUG2, might have the potential to reduce the frequency of rejection episodes, permit reductions in DRUGOTHER or DRUG2 dosage, and permit steroid withdrawal (Kelly, 1999).",sirolimus,tacrolimus,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,14,20
3681,19220,19220,19705,19705,"While additional research is needed, the initial clinical data in kidney recipients suggest that DRUG1, in combination with DRUG2 or DRUGOTHER, might have the potential to reduce the frequency of rejection episodes, permit reductions in DRUG2 or DRUGOTHER dosage, and permit steroid withdrawal (Kelly, 1999).",sirolimus,cyclosporine,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,14,18
3682,19221,19221,19706,19706,"While additional research is needed, the initial clinical data in kidney recipients suggest that DRUG1, in combination with DRUGOTHER or DRUG2, might have the potential to reduce the frequency of rejection episodes, permit reductions in DRUGOTHER or DRUG2 dosage, and permit steroid withdrawal (Kelly, 1999).",sirolimus,tacrolimus,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,14,20
3683,19234,19234,19719,19719,"It is structurally distinct from the other currently available DRUGOTHER (DRUG1, DRUGOTHER, and DRUG2), leading to unique biopharmaceutical properties relative to the other agents of this class. ",lovastatin,pravastatin,False,Neg,0,CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,10,13
3684,19235,19235,19720,19720,"It is structurally distinct from the other currently available DRUGOTHER (DRUGOTHER, DRUG1, and DRUG2), leading to unique biopharmaceutical properties relative to the other agents of this class. ",simvastatin,pravastatin,False,Neg,0,CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,11,13
3685,19281,19281,19777,19777,"[Stimulation by DRUGOTHER--an analog of the octapeptide cholecystokinin--of DRUGOTHER binding after the long-term administration of DRUGOTHER] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUG1 (0.25 mg/kg) and DRUG2 (0.25 mg/kg) resulted in the reduced interaction between DRUGOTHER and low affinity binding sites for DRUGOTHER in subcortical structures, whereas DRUGOTHER binding with high affinity binding sites for DRUGOTHER increased both in the frontal cortex and subcortical structures of the forebrain. ",haloperidol,pyreneperone,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,36,40
3686,19282,19282,19778,19778,"[Stimulation by DRUGOTHER--an analog of the octapeptide cholecystokinin--of DRUGOTHER binding after the long-term administration of DRUGOTHER] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUG1 (0.25 mg/kg) and DRUGOTHER (0.25 mg/kg) resulted in the reduced interaction between DRUGOTHER and low affinity binding sites for DRUG2 in subcortical structures, whereas DRUGOTHER binding with high affinity binding sites for DRUG2 increased both in the frontal cortex and subcortical structures of the forebrain. ",haloperidol,apomorphine,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23,36,56
3687,19283,19283,19779,19779,"[Stimulation by DRUGOTHER--an analog of the octapeptide cholecystokinin--of DRUGOTHER binding after the long-term administration of DRUGOTHER] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUG1 (0.25 mg/kg) and DRUGOTHER (0.25 mg/kg) resulted in the reduced interaction between DRUGOTHER and low affinity binding sites for DRUG2 in subcortical structures, whereas DRUGOTHER binding with high affinity binding sites for DRUG2 increased both in the frontal cortex and subcortical structures of the forebrain. ",haloperidol,apomorphine,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23,36,56
3688,19322,19322,19818,19818,"Neurochemical and functional consequences following DRUG1 (DRUG2) and DRUGOTHER.
","1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine",MPTP,False,Neg,0,OCC(O)CO,CN1CCC(=CC1)C2=CC=CC=C2,5,6
3689,19324,19324,19820,19820,"Neurochemical and functional consequences following DRUGOTHER (DRUG1) and DRUG2.
",MPTP,methamphetamine,False,Neg,0,CN1CCC(=CC1)C2=CC=CC=C2,CC(N)CC1=CC=CC=C1,6,8
3690,19325,19325,19821,19821,The neurochemical and functional consequences following DRUG1 administration to the rat were evaluated and compared to similar effects following DRUG2 administration. ,MPTP,methamphetamine,False,Neg,0,CN1CCC(=CC1)C2=CC=CC=C2,CC(N)CC1=CC=CC=C1,6,19
3691,19326,19326,19822,19822,It was observed that DRUG1 induced long lasting depletions of striatal dopamine concentrations and this neurotoxic effect could be prevented by DRUG2 pretreatment. ,MPTP,pargyline,True,effect,2,CN1CCC(=CC1)C2=CC=CC=C2,CN(CC#C)CC1=CC=CC=C1,4,21
3692,19327,19327,19823,19823,The DRUG1-induced neuronal damage produced a tolerance to the disruptive effects of DRUG2 and a supersensitivity to the disruptive effects of DRUGOTHER in rats responding in a schedule controlled paradigm. ,MPTP,amphetamine,True,effect,2,CN1CCC(=CC1)C2=CC=CC=C2,CC(CC1=CC=CC=C1)N,1,12
3693,19328,19328,19824,19824,The DRUG1-induced neuronal damage produced a tolerance to the disruptive effects of DRUGOTHER and a supersensitivity to the disruptive effects of DRUG2 in rats responding in a schedule controlled paradigm. ,MPTP,apomorphine,True,effect,2,CN1CCC(=CC1)C2=CC=CC=C2,[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23,1,21
3694,19330,19330,19826,19826,"DRUGOTHER, like DRUG1, produced depletions of striatal dopamine but these actions were potentiated by DRUG2 pretreatment. ",MPTP,pargyline,False,Neg,0,CN1CCC(=CC1)C2=CC=CC=C2,CN(CC#C)CC1=CC=CC=C1,2,14
3695,19378,19378,19874,19874,"DRUG1 protects mouse tumour and normal tissues from the toxicity of oral DRUG2.
",Misonidazole,CCNU,True,effect,2,COCC(O)CN1C=CN=C1[N+]([O-])=O,ClCCN(N=O)C(=O)NC1CCCCC1,0,12
3696,19379,19379,19875,19875,"Because the DRUG1 DRUG2 is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral DRUG2, either alone or in combination with the chemosensitizer DRUGOTHER. ",nitrosourea,CCNU,False,Neg,0,NC(N)=O,ClCCN(N=O)C(=O)NC1CCCCC1,2,3
3697,19380,19380,19876,19876,"Because the DRUG1 DRUG2 is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral DRUG2, either alone or in combination with the chemosensitizer DRUGOTHER. ",nitrosourea,CCNU,False,Neg,0,NC(N)=O,ClCCN(N=O)C(=O)NC1CCCCC1,2,3
3698,19383,19383,19879,19879,"Because the DRUGOTHER DRUG1 is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral DRUG1, either alone or in combination with the chemosensitizer DRUG2. ",CCNU,misonidazole,False,Neg,0,ClCCN(N=O)C(=O)NC1CCCCC1,COCC(O)CN1C=CN=C1[N+]([O-])=O,3,39
3699,19384,19384,19880,19880,"Because the DRUGOTHER DRUG1 is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral DRUG1, either alone or in combination with the chemosensitizer DRUG2. ",CCNU,misonidazole,False,Neg,0,ClCCN(N=O)C(=O)NC1CCCCC1,COCC(O)CN1C=CN=C1[N+]([O-])=O,3,39
3700,19385,19385,19881,19881,DRUG1 reduced the antitumour activity of oral DRUG2 by dose modifying factors (DMF) of 0.58-0.71. ,Misonidazole,CCNU,True,effect,2,COCC(O)CN1C=CN=C1[N+]([O-])=O,ClCCN(N=O)C(=O)NC1CCCCC1,0,7
3701,19386,19386,19882,19882,DRUG1 has a complex effect on oral DRUG2 pharmacokinetics. ,Misonidazole,CCNU,True,mechanism,4,COCC(O)CN1C=CN=C1[N+]([O-])=O,ClCCN(N=O)C(=O)NC1CCCCC1,0,7
3702,19387,19387,19883,19883,We propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral DRUG1 cytotoxicity by DRUG2. ,CCNU,misonidazole,True,mechanism,4,ClCCN(N=O)C(=O)NC1CCCCC1,COCC(O)CN1C=CN=C1[N+]([O-])=O,15,18
3703,19394,19394,19891,19891,"DRUG1 reduced or eliminated the increases in FI responding produced by intermediate doses of either DRUGOTHER or DRUG2 in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of DRUG2 or either stereoisomer of DRUGOTHER. ",Haloperidol,PCP,True,effect,2,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1,[H][C@]1(O)O[C@]([H])(COP(O)(=O)CP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)[C@@]([H])(O)[C@@]1([H])O,0,17
3704,19395,19395,19892,19892,Increased hepatotoxicity of DRUG1 by concomitant administration of DRUG2 in the rat.,acetaminophen,caffeine,True,effect,2,CC(=O)NC1=CC=C(C=C1)O,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,3,8
3705,19396,19396,19893,19893,"Since DRUG1 is frequently co-administered with DRUG2, it is of clinical interest to study the effect of DRUG1 on the hepatotoxicity of DRUG2. ",caffeine,acetaminophen,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC(=O)NC1=CC=C(C=C1)O,1,6
3706,19398,19398,19895,19895,"Since DRUG1 is frequently co-administered with DRUG2, it is of clinical interest to study the effect of DRUG1 on the hepatotoxicity of DRUG2. ",caffeine,acetaminophen,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC(=O)NC1=CC=C(C=C1)O,1,6
3707,19399,19399,19896,19896,"Since DRUG2 is frequently co-administered with DRUG1, it is of clinical interest to study the effect of DRUG2 on the hepatotoxicity of DRUG1. ",acetaminophen,caffeine,False,Neg,0,CC(=O)NC1=CC=C(C=C1)O,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,6,1
3708,19401,19401,19898,19898,"Since DRUG1 is frequently co-administered with DRUG2, it is of clinical interest to study the effect of DRUG1 on the hepatotoxicity of DRUG2. ",caffeine,acetaminophen,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC(=O)NC1=CC=C(C=C1)O,1,6
3709,19402,19402,19899,19899,Careful observations on hepatotoxicity are suggested when DRUG1 is prescribed with DRUG2.,acetaminophen,caffeine,True,effect,2,CC(=O)NC1=CC=C(C=C1)O,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,7,11
3710,19468,19468,19974,19974,"DRUG1 (5 mg/kg, s.c.) completely antagonized the inhibitory effect of DRUGOTHER and partly antagonized the effect of DRUG2. ",N-methyllevallorphan,morphine,True,effect,2,[H][C@@]12CCCC[C@@]11CCN(CC=C)[C@@H]2CC2=C1C=C(O)C=C2,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,0,17
3711,19476,19476,19983,19983,"This article looks at five commonly used DRUG1 in turn (DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. ",immunosuppressive drugs,corticosteroids,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,7,10
3712,19477,19477,19984,19984,"This article looks at five commonly used DRUG1 in turn (DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. ",immunosuppressive drugs,cyclosporin,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,7,11
3713,19478,19478,19985,19985,"This article looks at five commonly used DRUG1 in turn (DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. ",immunosuppressive drugs,azathioprine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],7,12
3714,19479,19479,19986,19986,"This article looks at five commonly used DRUG1 in turn (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. ",immunosuppressive drugs,methotrexate,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,7,13
3715,19484,19484,19991,19991,"This article looks at five commonly used DRUGOTHER in turn (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. ",corticosteroids,cyclophosphamide,False,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,ClCCN(CCCl)P1(=O)NCCCO1,10,14
3716,19487,19487,19994,19994,"This article looks at five commonly used DRUGOTHER in turn (DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. ",cyclosporin,cyclophosphamide,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,ClCCN(CCCl)P1(=O)NCCCO1,11,14
3717,19489,19489,19996,19996,"This article looks at five commonly used DRUGOTHER in turn (DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. ",azathioprine,cyclophosphamide,False,Neg,0,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],ClCCN(CCCl)P1(=O)NCCCO1,12,14
3718,19490,19490,19997,19997,"This article looks at five commonly used DRUGOTHER in turn (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. ",methotrexate,cyclophosphamide,False,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,ClCCN(CCCl)P1(=O)NCCCO1,13,14
3719,19507,19507,20017,20017,"The anxiogenic effects of DRUG1 were reduced by pretreatment with DRUGOTHER, an A2-selective agonist, but not by DRUG2 (DRUGOTHER), an A1-selective agonist. ",theophylline,N6-cyclopentyladenosine,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1,4,17
3720,19569,19569,20091,20091,"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUG1 was co-administered with DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",ezetimibe,pravastatin,False,Neg,0,C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,9,15
3721,19573,19573,20095,20095,"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUGOTHER was co-administered with DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",atorvastatin,pravastatin,False,Neg,0,CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,13,15
3722,19576,19576,20098,20098,"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUGOTHER was co-administered with DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, or DRUGOTHER. ",simvastatin,pravastatin,False,Neg,0,CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,14,15
3723,19579,19579,20101,20101,"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUGOTHER was co-administered with DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, or DRUGOTHER. ",pravastatin,lovastatin,False,Neg,0,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,15,16
3724,19580,19580,20102,20102,"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUGOTHER was co-administered with DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, or DRUG2. ",pravastatin,fluvastatin,False,Neg,0,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@H](C[C@H](CC(=O)O)O)O)C3=CC=C(C=C3)F,15,18
3725,19591,19591,20113,20113,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Phenytoin,Cyclosporine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,11,12
3726,19592,19592,20114,20114,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Phenytoin,Rifampin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,11,13
3727,19594,19594,20116,20116,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Phenytoin,Terfenadine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,11,15
3728,19595,19595,20117,20117,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Phenytoin,Cisapride,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,11,16
3729,19596,19596,20118,20118,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Phenytoin,Astemizole,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,11,17
3730,19597,19597,20119,20119,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Phenytoin,Rifabutin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,11,18
3731,19598,19598,20120,20120,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Phenytoin,Tacrolimus,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,11,19
3732,19599,19599,20121,20121,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral DRUGOTHER; ",Phenytoin,DIFLUCAN,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,11,34
3733,19600,19600,20122,20122,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUG2; ",Phenytoin,hypoglycemic agents,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,11,37
3734,19602,19602,20124,20124,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Cyclosporine,Theophylline,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CN1C2=C(C(=O)N(C1=O)C)NC=N2,12,14
3735,19610,19610,20132,20132,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Rifampin,Theophylline,False,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CN1C2=C(C(=O)N(C1=O)C)NC=N2,13,14
3736,19618,19618,20140,20140,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Theophylline,Terfenadine,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,14,15
3737,19619,19619,20141,20141,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Theophylline,Cisapride,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,14,16
3738,19620,19620,20142,20142,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Theophylline,Astemizole,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,14,17
3739,19621,19621,20143,20143,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Theophylline,Rifabutin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,14,18
3740,19622,19622,20144,20144,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Theophylline,Tacrolimus,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,14,19
3741,19623,19623,20145,20145,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral DRUGOTHER; ",Theophylline,DIFLUCAN,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,14,34
3742,19624,19624,20146,20146,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUG2; ",Theophylline,hypoglycemic agents,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,14,37
3743,19649,19649,20171,20171,"DRUG1 reduces the metabolism of DRUGOTHER, DRUGOTHER, and DRUG2 and increases the plasma concentration of these agents. ",DIFLUCAN,glipizide,True,mechanism,4,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,0,8
3744,19651,19651,20173,20173,"DRUGOTHER reduces the metabolism of DRUG1, DRUGOTHER, and DRUG2 and increases the plasma concentration of these agents. ",tolbutamide,glipizide,False,Neg,0,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,5,8
3745,19652,19652,20174,20174,"DRUGOTHER reduces the metabolism of DRUGOTHER, DRUG1, and DRUG2 and increases the plasma concentration of these agents. ",glyburide,glipizide,False,Neg,0,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,6,8
3746,19657,19657,20179,20179,DRUG1: DRUG2 increases the plasma concentrations of DRUGOTHER. ,Phenytoin,DIFLUCAN,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,0,1
3747,19659,19659,20181,20181,DRUGOTHER: DRUG1 increases the plasma concentrations of DRUG2. ,DIFLUCAN,phenytoin,True,mechanism,4,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,1,7
3748,19660,19660,20182,20182,Careful monitoring of DRUG1 concentrations in patients receiving DRUG2 and DRUG1 is recommended. ,phenytoin,DIFLUCAN,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,3,8
3749,19662,19662,20184,20184,Careful monitoring of DRUG2 concentrations in patients receiving DRUG1 and DRUG2 is recommended. ,DIFLUCAN,phenytoin,True,advise,1,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,8,3
3750,19673,19673,20195,20195,DRUG1: DRUG2 increases the serum concentrations of DRUGOTHER. ,Theophylline,DIFLUCAN,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,0,1
3751,19675,19675,20197,20197,DRUGOTHER: DRUG1 increases the serum concentrations of DRUG2. ,DIFLUCAN,theophylline,True,mechanism,4,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,1,7
3752,19676,19676,20198,20198,Careful monitoring of serum DRUG1 concentrations in patients receiving DRUG2 and DRUG1 is recommended. ,theophylline,DIFLUCAN,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,4,9
3753,19678,19678,20200,20200,Careful monitoring of serum DRUG2 concentrations in patients receiving DRUG1 and DRUG2 is recommended. ,DIFLUCAN,theophylline,True,advise,1,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,9,4
3754,19768,19768,20290,20290,DRUG1 may reduce the effects of DRUG2 (DRUGOTHER). ,Mazindol,guanethidine,True,effect,2,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,C1CCCN(CCC1)CCN=C(N)N,0,6
3755,19769,19769,20291,20291,DRUG1 may reduce the effects of DRUGOTHER (DRUG2). ,Mazindol,Ismelin,True,effect,2,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,C1CCCN(CCC1)CCN=C(N)N,0,7
3756,19775,19775,20297,20297,"Before taking this medication, tell your doctor if you are taking a DRUG1 such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",tricyclic antidepressant,doxepin,False,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,12,19
3757,19776,19776,20298,20298,"Before taking this medication, tell your doctor if you are taking a DRUG1 such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",tricyclic antidepressant,Sinequan,False,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,12,20
3758,19790,19790,20312,20312,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",amitriptyline,doxepin,False,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,15,19
3759,19791,19791,20313,20313,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",amitriptyline,Sinequan,False,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,15,20
3760,19804,19804,20326,20326,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Elavil,doxepin,False,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,16,19
3761,19805,19805,20327,20327,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Elavil,Sinequan,False,Neg,0,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,16,20
3762,19817,19817,20339,20339,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",amoxapine,doxepin,False,Neg,0,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,17,19
3763,19818,19818,20340,20340,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",amoxapine,Sinequan,False,Neg,0,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,17,20
3764,19829,19829,20351,20351,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Asendin,doxepin,False,Neg,0,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,18,19
3765,19830,19830,20352,20352,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Asendin,Sinequan,False,Neg,0,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,18,20
3766,19842,19842,20364,20364,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",doxepin,nortriptyline,False,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,19,21
3767,19843,19843,20365,20365,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",doxepin,Pamelor,False,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,19,22
3768,19844,19844,20366,20366,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",doxepin,imipramine,False,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,19,23
3769,19845,19845,20367,20367,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",doxepin,Tofranil,False,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,19,24
3770,19846,19846,20368,20368,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",doxepin,clomipramine,False,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,19,25
3771,19847,19847,20369,20369,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",doxepin,Anafranil,False,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.Cl,19,26
3772,19848,19848,20370,20370,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",doxepin,protriptyline,False,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,19,27
3773,19849,19849,20371,20371,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER). ",doxepin,Vivactil,False,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,19,28
3774,19850,19850,20372,20372,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER). ",doxepin,desipramine,False,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,19,30
3775,19851,19851,20373,20373,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2). ",doxepin,Norpramin,False,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,19,31
3776,19852,19852,20374,20374,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Sinequan,nortriptyline,False,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,20,21
3777,19853,19853,20375,20375,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Sinequan,Pamelor,False,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,20,22
3778,19854,19854,20376,20376,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Sinequan,imipramine,False,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,20,23
3779,19855,19855,20377,20377,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Sinequan,Tofranil,False,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,20,24
3780,19856,19856,20378,20378,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Sinequan,clomipramine,False,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,20,25
3781,19857,19857,20379,20379,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Sinequan,Anafranil,False,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.Cl,20,26
3782,19858,19858,20380,20380,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",Sinequan,protriptyline,False,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,20,27
3783,19859,19859,20381,20381,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER). ",Sinequan,Vivactil,False,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,20,28
3784,19860,19860,20382,20382,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER). ",Sinequan,desipramine,False,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,20,30
3785,19861,19861,20383,20383,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2). ",Sinequan,Norpramin,False,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,20,31
3786,19907,19907,20432,20432,Patients receiving DRUG1 and DRUG2 generally should not be treated with DRUGOTHER.  ,antibiotics,sulfonamides,False,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,2,4
3787,19916,19916,20449,20449,"DRUG1 may interact with the following drugs: DRUG2 and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",Melatonin,aspirin,True,int,3,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)OC1=CC=CC=C1C(=O)O,0,7
3788,19918,19918,20451,20451,"DRUG1 may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUG2 (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",Melatonin,fluvoxamine,True,int,3,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,0,15
3789,19921,19921,20454,20454,"DRUG1 may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUG2 (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",Melatonin,fluoxetine,True,int,3,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,0,29
3790,19922,19922,20455,20455,"DRUG1 may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUGOTHER with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",Melatonin,progestin,True,int,3,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,0,36
3791,19924,19924,20457,20457,"DRUG1 may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUGOTHER with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",Melatonin,progestin,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,0,36
3792,19925,19925,20458,20458,"DRUG1 may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",Melatonin,corticosteroids,True,int,3,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,0,66
3793,19927,19927,20460,20460,"DRUG1 may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",Melatonin,corticosteroids,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,0,66
3794,19928,19928,20461,20461,"DRUG1 may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",Melatonin,corticosteroids,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,0,66
3795,19929,19929,20462,20462,"DRUGOTHER may interact with the following drugs: DRUG1 and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",aspirin,melatonin,False,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,7,13
3796,19931,19931,20464,20464,"DRUGOTHER may interact with the following drugs: DRUG1 and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",aspirin,melatonin,False,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,7,13
3797,19932,19932,20465,20465,"DRUGOTHER may interact with the following drugs: DRUG1 and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",aspirin,melatonin,False,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,7,13
3798,19935,19935,20468,20468,"DRUGOTHER may interact with the following drugs: DRUG1 and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",aspirin,melatonin,False,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,7,13
3799,19938,19938,20471,20471,"DRUGOTHER may interact with the following drugs: DRUG1 and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",aspirin,melatonin,False,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,7,13
3800,19941,19941,20474,20474,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUG2 (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,fluvoxamine,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,13,15
3801,19944,19944,20477,20477,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUG2 (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,fluoxetine,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,13,29
3802,19945,19945,20478,20478,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,progestin,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,13,36
3803,19947,19947,20480,20480,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,progestin,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,13,36
3804,19948,19948,20481,20481,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",melatonin,corticosteroids,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,13,66
3805,19950,19950,20483,20483,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",melatonin,corticosteroids,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,13,66
3806,19951,19951,20484,20484,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",melatonin,corticosteroids,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,13,66
3807,19952,19952,20485,20485,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUG1 (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",fluvoxamine,melatonin,False,Neg,0,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,15,13
3808,19953,19953,20486,20486,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUG1 (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",fluvoxamine,melatonin,False,Neg,0,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,15,13
3809,19956,19956,20489,20489,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUG1 (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",fluvoxamine,melatonin,False,Neg,0,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,15,13
3810,19959,19959,20492,20492,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUG1 (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",fluvoxamine,melatonin,False,Neg,0,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,15,13
3811,19963,19963,20496,20496,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUG2 (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,fluoxetine,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,13,29
3812,19964,19964,20497,20497,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,progestin,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,13,36
3813,19966,19966,20499,20499,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,progestin,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,13,36
3814,19967,19967,20500,20500,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",melatonin,corticosteroids,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,13,66
3815,19969,19969,20502,20502,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",melatonin,corticosteroids,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,13,66
3816,19970,19970,20503,20503,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",melatonin,corticosteroids,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,13,66
3817,19971,19971,20504,20504,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUG2 (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,fluoxetine,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,13,29
3818,19972,19972,20505,20505,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,progestin,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,13,36
3819,19974,19974,20507,20507,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,progestin,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,13,36
3820,19975,19975,20508,20508,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",melatonin,corticosteroids,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,13,66
3821,19977,19977,20510,20510,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",melatonin,corticosteroids,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,13,66
3822,19978,19978,20511,20511,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",melatonin,corticosteroids,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,13,66
3823,19980,19980,20513,20513,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUG1 (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",fluoxetine,melatonin,False,Neg,0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,29,13
3824,19983,19983,20516,20516,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUG1 (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",fluoxetine,melatonin,False,Neg,0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,29,13
3825,19986,19986,20519,20519,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG1 (coadministration of DRUG2 with DRUG1 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",progestin,melatonin,False,Neg,0,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,36,13
3826,19989,19989,20522,20522,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG1 (coadministration of DRUG2 with DRUG1 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",progestin,melatonin,False,Neg,0,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,36,13
3827,19992,19992,20525,20525,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,progestin,True,effect,2,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,13,36
3828,19993,19993,20526,20526,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",melatonin,corticosteroids,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,13,66
3829,19995,19995,20528,20528,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",melatonin,corticosteroids,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,13,66
3830,19996,19996,20529,20529,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",melatonin,corticosteroids,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,13,66
3831,19998,19998,20531,20531,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG1 (coadministration of DRUG2 with DRUG1 can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",progestin,melatonin,False,Neg,0,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,36,13
3832,20001,20001,20534,20534,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG1 (coadministration of DRUG2 and DRUG1 may interfere with the efficacy of the DRUG1).",corticosteroids,melatonin,False,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,66,13
3833,20004,20004,20537,20537,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",melatonin,corticosteroids,True,effect,2,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,13,66
3834,20005,20005,20538,20538,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",melatonin,corticosteroids,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,13,66
3835,20008,20008,20541,20541,DRUG1: Concomitant administration of DRUGOTHER (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of DRUG2. ,Aspirin,meloxicam,False,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,0,21
3836,20009,20009,20542,20542,DRUGOTHER: Concomitant administration of DRUG1 (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of DRUG2. ,aspirin,meloxicam,True,mechanism,4,CC(=O)OC1=CC=CC=C1C(=O)O,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,4,21
3837,20010,20010,20543,20543,"however, as with other DRUGOTHER, concomitant administration of DRUG1 and DRUG2 is not generally recommended because of the potential for increased adverse effects. ",meloxicam,aspirin,True,advise,1,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,CC(=O)OC1=CC=CC=C1C(=O)O,8,10
3838,20011,20011,20544,20544,"Concomitant administration of low-dose DRUG1 with DRUG2 may result in an increased rate of GI ulceration or other complications, compared to use of DRUG2 alone. ",aspirin,MOBIC,True,effect,2,CC(=O)OC1=CC=CC=C1C(=O)O,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,4,6
3839,20012,20012,20545,20545,"Concomitant administration of low-dose DRUG1 with DRUG2 may result in an increased rate of GI ulceration or other complications, compared to use of DRUG2 alone. ",aspirin,MOBIC,False,Neg,0,CC(=O)OC1=CC=CC=C1C(=O)O,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,4,6
3840,20014,20014,20547,20547,DRUG1 is not a substitute for DRUG2 for cardiovascular prophylaxis. ,MOBIC,aspirin,False,Neg,0,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,CC(=O)OC1=CC=CC=C1C(=O)O,0,6
3841,20016,20016,20549,20549,DRUG1: Pretreatment for four days with DRUGOTHER significantly increased the clearance of DRUG2 by 50%. ,Cholestyramine,meloxicam,False,Neg,0,CCC1=CC=C(C=C1)C(C)CCC2=CC=C(C=C2)[N+](C)(C)C,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,0,12
3842,20017,20017,20550,20550,DRUGOTHER: Pretreatment for four days with DRUG1 significantly increased the clearance of DRUG2 by 50%. ,cholestyramine,meloxicam,True,mechanism,4,CCC1=CC=C(C=C1)C(C)CCC2=CC=C(C=C2)[N+](C)(C)C,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,6,12
3843,20019,20019,20552,20552,DRUG1: Concomitant administration of 200 mg DRUGOTHER QID did not alter the single-dose pharmacokinetics of 30 mg DRUG2. ,Cimetidine,meloxicam,False,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,0,17
3844,20020,20020,20553,20553,DRUGOTHER: Concomitant administration of 200 mg DRUG1 QID did not alter the single-dose pharmacokinetics of 30 mg DRUG2. ,cimetidine,meloxicam,False,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,6,17
3845,20021,20021,20554,20554,DRUG1: DRUG2 15 mg once daily for 7 days did not alter the plasma concentration profile of DRUGOTHER after b-acetylDRUGOTHER administration for 7 days at clinical doses. ,Digoxin,Meloxicam,False,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,0,1
3846,20023,20023,20556,20556,DRUGOTHER: DRUG1 15 mg once daily for 7 days did not alter the plasma concentration profile of DRUG2 after b-acetylDRUG2 administration for 7 days at clinical doses. ,Meloxicam,digoxin,False,Neg,0,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,1,17
3847,20024,20024,20557,20557,In vitro testing found no protein binding drug interaction between DRUG1 and DRUG2. ,digoxin,meloxicam,False,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,10,12
3848,20029,20029,20562,20562,DRUG1: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of DRUG2 on the pharmacokinetics of DRUGOTHER taken once weekly. ,Methotrexate,meloxicam,False,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,0,16
3849,20031,20031,20564,20564,DRUGOTHER: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of DRUG1 on the pharmacokinetics of DRUG2 taken once weekly. ,meloxicam,methotrexate,False,Neg,0,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,16,21
3850,20032,20032,20565,20565,DRUG1 did not have a significant effect on the pharmacokinetics of single doses of DRUG2. ,Meloxicam,methotrexate,False,Neg,0,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,0,14
3851,20033,20033,20566,20566,"In vitro, DRUG1 did not displace DRUG2 from its human serum binding sites. ",methotrexate,meloxicam,False,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,2,6
3852,20034,20034,20567,20567,"DRUG1: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing DRUG2 therapy in patients receiving DRUGOTHER or similar agents, since these patients are at an increased risk of bleeding. ",Warfarin,MOBIC,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,0,16
3853,20036,20036,20569,20569,"DRUGOTHER: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing DRUG1 therapy in patients receiving DRUG2 or similar agents, since these patients are at an increased risk of bleeding. ",MOBIC,warfarin,True,advise,1,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,16,21
3854,20037,20037,20570,20570,The effect of DRUG1 on the anticoagulant effect of DRUG2 was studied in a group of healthy subjects receiving daily doses of DRUG2 that produced an INR (International Normalized Ratio) between 1.2 and 1.8. ,meloxicam,warfarin,False,Neg,0,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,3,9
3855,20038,20038,20571,20571,The effect of DRUG1 on the anticoagulant effect of DRUG2 was studied in a group of healthy subjects receiving daily doses of DRUG2 that produced an INR (International Normalized Ratio) between 1.2 and 1.8. ,meloxicam,warfarin,False,Neg,0,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,3,9
3856,20040,20040,20573,20573,"In these subjects, DRUG1 did not alter DRUG2 pharmacokinetics and the average anticoagulant effect of DRUG2 as determined by prothrombin time. ",meloxicam,warfarin,False,Neg,0,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,3,7
3857,20041,20041,20574,20574,"In these subjects, DRUG1 did not alter DRUG2 pharmacokinetics and the average anticoagulant effect of DRUG2 as determined by prothrombin time. ",meloxicam,warfarin,False,Neg,0,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,3,7
3858,20043,20043,20576,20576,Caution should be used when administering DRUG1 with DRUG2 since patients on DRUG2 may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.,MOBIC,warfarin,True,advise,1,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,6,8
3859,20044,20044,20577,20577,Caution should be used when administering DRUG1 with DRUG2 since patients on DRUG2 may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.,MOBIC,warfarin,False,Neg,0,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,6,8
3860,20056,20056,20589,20589,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG2), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",amantadine,meperidine,False,Neg,0,C1C2CC3CC1CC(C2)(C3)N,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,12,24
3861,20066,20066,20599,20599,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG2), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",quinidine,meperidine,False,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,15,24
3862,20075,20075,20608,20608,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG2), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",antihistamines,meperidine,False,Neg,0,NCCC1=CNC=N1,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,16,24
3863,20083,20083,20616,20616,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG2), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",phenothiazines,meperidine,False,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,19,24
3864,20090,20090,20623,20623,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER (e.g., DRUG2), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",benzodiazepines,meperidine,False,Neg,0,N1N=CC=CC2=CC=CC=C12,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,20,24
3865,20096,20096,20629,20629,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER (e.g., DRUG2), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",MAO inhibitors,meperidine,False,Neg,0,CN(CC#C)CC1=CC=CC=C1,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,21,24
3866,20101,20101,20634,20634,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1 (e.g., DRUG2), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",narcotic analgesics,meperidine,False,Neg,0,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,22,24
3867,20106,20106,20639,20639,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUG2 and DRUGOTHER, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",meperidine,nitrates,False,Neg,0,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,[N+](=O)([O-])[O-],24,25
3868,20107,20107,20640,20640,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER and DRUG2, DRUGOTHER, DRUGOTHER, and other drugs having anticholinergic activity. ",meperidine,nitrites,False,Neg,0,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,N(=O)[O-],24,27
3869,20108,20108,20641,20641,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER and DRUGOTHER, DRUG2, DRUGOTHER, and other drugs having anticholinergic activity. ",meperidine,sympathomimetic agents,False,Neg,0,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,24,28
3870,20109,20109,20642,20642,"The following agents may increase certain actions or side effects of DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG2, and other drugs having anticholinergic activity. ",meperidine,tricyclic antidepressants,False,Neg,0,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,24,29
3871,20116,20116,20649,20649,"Interaction with Other DRUGOTHER: DRUG1 SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUG2). ",MEPERIDINE,ALCOHOL,True,advise,1,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,CCO,4,36
3872,20125,20125,20658,20658,"DRUG1 may also affect the effects of other drugs, which include some DRUGOTHER, DRUGOTHER, certain heart medicines, birth control pills, DRUGOTHER, DRUG2 and DRUGOTHER Please note that DRUG1 may interact with other drugs that are not listed here.",Mephenytoin,furosemide,True,effect,2,CCC1(C(=O)N(C(=O)N1)C)C2=CC=CC=C2,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,0,21
3873,20126,20126,20659,20659,"DRUG1 may also affect the effects of other drugs, which include some DRUGOTHER, DRUGOTHER, certain heart medicines, birth control pills, DRUGOTHER, DRUGOTHER and DRUG2 Please note that DRUG1 may interact with other drugs that are not listed here.",Mephenytoin,theophylline,True,effect,2,CCC1(C(=O)N(C(=O)N1)C)C2=CC=CC=C2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,23
3874,20128,20128,20661,20661,"DRUGOTHER may also affect the effects of other drugs, which include some DRUGOTHER, DRUG1, certain heart medicines, birth control pills, DRUGOTHER, DRUG2 and DRUGOTHER Please note that DRUGOTHER may interact with other drugs that are not listed here.",warfarin,furosemide,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,13,21
3875,20129,20129,20662,20662,"DRUGOTHER may also affect the effects of other drugs, which include some DRUGOTHER, DRUG1, certain heart medicines, birth control pills, DRUGOTHER, DRUGOTHER and DRUG2 Please note that DRUGOTHER may interact with other drugs that are not listed here.",warfarin,theophylline,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,13,23
3876,20132,20132,20665,20665,"DRUG2 may also affect the effects of other drugs, which include some DRUGOTHER, DRUGOTHER, certain heart medicines, birth control pills, DRUGOTHER, DRUG1 and DRUGOTHER Please note that DRUG2 may interact with other drugs that are not listed here.",furosemide,Mephenytoin,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CCC1(C(=O)N(C(=O)N1)C)C2=CC=CC=C2,21,0
3877,20133,20133,20666,20666,"DRUG2 may also affect the effects of other drugs, which include some DRUGOTHER, DRUGOTHER, certain heart medicines, birth control pills, DRUGOTHER, DRUGOTHER and DRUG1 Please note that DRUG2 may interact with other drugs that are not listed here.",theophylline,Mephenytoin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CCC1(C(=O)N(C(=O)N1)C)C2=CC=CC=C2,23,0
3878,20138,20138,20681,20681,"DRUGOTHER may enhance the effects of DRUG1, DRUGOTHER and other DRUG2.",alcohol,CNS depressants,False,Neg,0,CCO,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,6,10
3879,20152,20152,20698,20698,DRUG1 and/or stimulantes of the DRUG2/DRUGOTHER type may counteract the specific actions of DRUGOTHER. ,Caffeine,ephedrine,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC,0,5
3880,20153,20153,20699,20699,DRUG1 and/or stimulantes of the DRUGOTHER/DRUG2 type may counteract the specific actions of DRUGOTHER. ,Caffeine,amphetamine,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC(CC1=CC=CC=C1)N,0,5
3881,20154,20154,20700,20700,DRUG1 and/or stimulantes of the DRUGOTHER/DRUGOTHER type may counteract the specific actions of DRUG2. ,Caffeine,levomepromazine,True,effect,2,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C,0,13
3882,20159,20159,20705,20705,"Since DRUGOTHER (DRUG1) may interact with concurrently administered DRUGOTHER, periodic serum level determinations of these drugs may be necessary (eg DRUG1 may increase the plasma concentrations of DRUG2 and DRUGOTHER).",methsuximide,phenytoin,False,Neg,0,CC1(CC(=O)N(C1=O)C)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,2,27
3883,20161,20161,20707,20707,"Since DRUGOTHER (DRUG1) may interact with concurrently administered DRUGOTHER, periodic serum level determinations of these drugs may be necessary (eg DRUG1 may increase the plasma concentrations of DRUG2 and DRUGOTHER).",methsuximide,phenytoin,True,mechanism,4,CC1(CC(=O)N(C1=O)C)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,2,27
3884,20163,20163,20709,20709,"Since DRUGOTHER (DRUGOTHER) may interact with concurrently administered DRUGOTHER, periodic serum level determinations of these drugs may be necessary (eg DRUGOTHER may increase the plasma concentrations of DRUG1 and DRUG2).",phenytoin,phenobarbital,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,27,29
3885,20164,20164,20710,20710,DRUG1 may decrease arterial responsiveness to DRUG2. ,Thiazides,norepinephrine,True,effect,2,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,C1=CC(=C(C=C1[C@H](CN)O)O)O,0,6
3886,20165,20165,20711,20711,DRUG1 may add to or potentiate the action of other DRUG2. ,Thiazides,antihypertensive drugs,True,effect,2,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,0,10
3887,20188,20188,20734,20734,"Examples of some of the more potent CYP 3A4 inhibitors include DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",macrolide antibiotics,ritonavir,False,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,11,21
3888,20198,20198,20744,20744,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",erythromycin,ritonavir,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,13,21
3889,20207,20207,20753,20753,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",troleandomycin,ritonavir,False,Neg,0,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,14,21
3890,20215,20215,20761,20761,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1), HIV protease or DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",clarithromycin,ritonavir,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,15,21
3891,20223,20223,20769,20769,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUG1, DRUG2, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",ritonavir,indinavir,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,21,22
3892,20224,20224,20770,20770,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUG2, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",ritonavir,nelfinavir,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,21,23
3893,20225,20225,20771,20771,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUG2) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",ritonavir,delavirdine,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C,21,24
3894,20226,20226,20772,20772,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUG2 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",ritonavir,azole antifungals,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,OC(=O)CCCCCCCCC=C,21,26
3895,20227,20227,20773,20773,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER). ",ritonavir,ketoconazole,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,21,28
3896,20228,20228,20774,20774,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER). ",ritonavir,itraconazole,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,21,29
3897,20229,20229,20775,20775,"Examples of some of the more potent CYP 3A4 inhibitors include DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2). ",ritonavir,voriconazole,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,21,30
3898,20252,20252,20798,20798,"Less potent inhibitors include DRUG1, DRUGOTHER, DRUG2, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",saquinavir,fluconazole,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,4,6
3899,20253,20253,20799,20799,"Less potent inhibitors include DRUG1, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",saquinavir,fluoxetine,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,4,9
3900,20254,20254,20800,20800,"Less potent inhibitors include DRUG1, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",saquinavir,fluvoxamine,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,4,10
3901,20255,20255,20801,20801,"Less potent inhibitors include DRUG1, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",saquinavir,zileuton,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,4,11
3902,20256,20256,20802,20802,"Less potent inhibitors include DRUG1, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",saquinavir,clotrimazole,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,4,13
3903,20257,20257,20803,20803,"Less potent inhibitors include DRUGOTHER, DRUG1, DRUG2, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",nefazodone,fluconazole,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,5,6
3904,20258,20258,20804,20804,"Less potent inhibitors include DRUGOTHER, DRUG1, DRUGOTHER, grapefruit juice, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",nefazodone,fluoxetine,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,5,9
3905,20259,20259,20805,20805,"Less potent inhibitors include DRUGOTHER, DRUG1, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",nefazodone,fluvoxamine,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,5,10
3906,20260,20260,20806,20806,"Less potent inhibitors include DRUGOTHER, DRUG1, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",nefazodone,zileuton,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,5,11
3907,20261,20261,20807,20807,"Less potent inhibitors include DRUGOTHER, DRUG1, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",nefazodone,clotrimazole,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,5,13
3908,20273,20273,20819,20819,Caution should be exercised when DRUG1    (DRUGOTHER) is used concurrently with other DRUGOTHER or DRUG2.,Methergine,ergot alkaloids,True,advise,1,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,5,17
3909,20274,20274,20820,20820,Caution should be exercised when DRUGOTHER    (DRUG1) is used concurrently with other DRUGOTHER or DRUG2.,methylergonovine maleate,ergot alkaloids,False,Neg,0,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C.C(=C\C(=O)O)\C(=O)O,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,9,17
3910,20275,20275,20821,20821,DRUG1 may decrease the hypotensive effect of DRUG2. ,Ritalin,guanethidine,True,effect,2,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,C1CCCN(CCC1)CCN=C(N)N,0,7
3911,20278,20278,20824,20824,"Human pharmacologic studies have shown that DRUG1 may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",Ritalin,diphenylhydantoin,True,mechanism,4,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,6,15
3912,20285,20285,20831,20831,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUG1 (DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",anticonvulsants,diphenylhydantoin,False,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,13,15
3913,20291,20291,20837,20837,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUG1, DRUG2, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",phenobarbital,diphenylhydantoin,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,14,15
3914,20297,20297,20843,20843,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUG1, DRUG2), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",diphenylhydantoin,primidone,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,15,16
3915,20298,20298,20844,20844,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER), DRUG2, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",diphenylhydantoin,phenylbutazone,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,15,17
3916,20299,20299,20845,20845,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER). ",diphenylhydantoin,imipramine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,15,20
3917,20300,20300,20846,20846,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER). ",diphenylhydantoin,clomipramine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,15,21
3918,20301,20301,20847,20847,"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2). ",diphenylhydantoin,desipramine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,15,22
3919,20315,20315,20861,20861,"Drugs that induce hepatic enzymes such as DRUG1, DRUG2, and DRUGOTHER may increase the clearance of DRUGOTHER and may require increased in DRUGOTHER dose to achieve the desired response. ",phenobarbital,phenytoin,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,7,8
3920,20319,20319,20865,20865,"Drugs that induce hepatic enzymes such as DRUGOTHER, DRUG1, and DRUG2 may increase the clearance of DRUGOTHER and may require increased in DRUGOTHER dose to achieve the desired response. ",phenytoin,rifampin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,8,10
3921,20320,20320,20866,20866,"Drugs that induce hepatic enzymes such as DRUGOTHER, DRUG1, and DRUGOTHER may increase the clearance of DRUG2 and may require increased in DRUG2 dose to achieve the desired response. ",phenytoin,methylprednisolone,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,8,16
3922,20321,20321,20867,20867,"Drugs that induce hepatic enzymes such as DRUGOTHER, DRUG1, and DRUGOTHER may increase the clearance of DRUG2 and may require increased in DRUG2 dose to achieve the desired response. ",phenytoin,methylprednisolone,True,advise,1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,8,16
3923,20336,20336,20882,20882,"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",Methscopolamine,linezolid,True,int,3,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,0,10
3924,20354,20354,20900,20900,"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",antidepressants,linezolid,False,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,4,10
3925,20371,20371,20917,20917,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",MAO inhibitors,linezolid,False,Neg,0,CN(CC#C)CC1=CC=CC=C1,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,7,10
3926,20387,20387,20933,20933,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",phenelzine,linezolid,False,Neg,0,C1=CC=C(C=C1)CCNN,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,9,10
3927,20403,20403,20949,20949,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",linezolid,tranylcypromine,False,Neg,0,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,C1[C@H]([C@@H]1N)C2=CC=CC=C2,10,11
3928,20404,20404,20950,20950,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",linezolid,isocarboxazid,False,Neg,0,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,10,12
3929,20405,20405,20951,20951,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",linezolid,selegiline,False,Neg,0,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,C[C@H](CC1=CC=CC=C1)N(C)CC#C,10,13
3930,20406,20406,20952,20952,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",linezolid,furazolidone,False,Neg,0,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],10,14
3931,20407,20407,20953,20953,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",linezolid,quinidine,False,Neg,0,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,10,15
3932,20408,20408,20954,20954,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",linezolid,amantadine,False,Neg,0,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,C1C2CC3CC1CC(C2)(C3)N,10,16
3933,20409,20409,20955,20955,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",linezolid,antihistamines,False,Neg,0,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,NCCC1=CNC=N1,10,17
3934,20410,20410,20956,20956,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG2), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",linezolid,diphenhydramine,False,Neg,0,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,10,19
3935,20411,20411,20957,20957,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG2, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",linezolid,anticholinergics,False,Neg,0,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,C[N+](C)(C)CCO,10,21
3936,20412,20412,20958,20958,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUG2 supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",linezolid,potassium chloride,False,Neg,0,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,[Cl-].[K+],10,22
3937,20413,20413,20959,20959,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",linezolid,kaolin,False,Neg,0,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O,10,27
3938,20414,20414,20960,20960,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",linezolid,pectin,False,Neg,0,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,[C@@H]1([C@H]([C@H](O[C@H]([C@@H]1O)O)C(=O)O)O)O,10,27
3939,20415,20415,20961,20961,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",linezolid,phenothiazines,False,Neg,0,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,N1C2=CC=CC=C2SC2=CC=CC=C12,10,28
3940,20416,20416,20962,20962,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",linezolid,chlorpromazine,False,Neg,0,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,10,30
3941,20417,20417,20963,20963,"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",linezolid,promethazine,False,Neg,0,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,10,31
3942,20523,20523,21070,21070,DRUG1 may reverse the analgesic activity of DRUG2. ,Methysergide,narcotic analgesics,True,effect,2,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,0,7
3943,20524,20524,21071,21071,"Concurrent use with DRUGOTHER including DRUG1, DRUG2, and DRUGOTHER (e.g. smoking) may result in enhanced vasoconstriction.",ergot alkaloids,sumatriptan,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,5,6
3944,20526,20526,21073,21073,"Concurrent use with DRUGOTHER including DRUGOTHER, DRUG1, and DRUG2 (e.g. smoking) may result in enhanced vasoconstriction.",sumatriptan,nicotine,False,Neg,0,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,CN1CCC[C@H]1C2=CN=CC=C2,6,8
3945,20533,20533,21080,21080,"Absorption of drugs from the stomach may be diminished (e.g., DRUG1) by DRUGOTHER, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER). ",digoxin,tetracycline,False,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,10,31
3946,20538,20538,21085,21085,"Absorption of drugs from the stomach may be diminished (e.g., DRUGOTHER) by DRUG1, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER). ",metoclopramide,tetracycline,False,Neg,0,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,12,31
3947,20542,20542,21089,21089,"Absorption of drugs from the stomach may be diminished (e.g., DRUGOTHER) by DRUGOTHER, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER). ",acetaminophen,tetracycline,False,Neg,0,CC(=O)NC1=CC=C(C=C1)O,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,30,31
3948,20546,20546,21093,21093,"Absorption of drugs from the stomach may be diminished (e.g., DRUGOTHER) by DRUGOTHER, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER). ",tetracycline,levodopa,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O,31,32
3949,20547,20547,21094,21094,"Absorption of drugs from the stomach may be diminished (e.g., DRUGOTHER) by DRUGOTHER, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER). ",tetracycline,ethanol,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CCO,31,33
3950,20548,20548,21095,21095,"Absorption of drugs from the stomach may be diminished (e.g., DRUGOTHER) by DRUGOTHER, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2). ",tetracycline,cyclosporine,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,31,34
3951,20553,20553,21100,21100,DRUG1: DRUG2 and probably other DRUGOTHER given concomitantly with DRUGOTHER can cause unusually large or prolonged losses of fluid and electrolytes. ,Diuretics,Furosemide,False,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,0,1
3952,20564,20564,21121,21121,Caution should be observed in administering DRUG1 to patients receiving DRUGOTHER or DRUG2 because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. ,DEMSER,haloperidol,True,advise,1,C[C@](CC1=CC=C(C=C1)O)(C(=O)O)N,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,6,12
3953,20565,20565,21122,21122,Caution should be observed in administering DRUGOTHER to patients receiving DRUG1 or DRUG2 because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. ,phenothiazines,haloperidol,False,Neg,0,N1C2=CC=CC=C2SC2=CC=CC=C12,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,10,12
3954,20567,20567,21124,21124,Concurrent use of DRUG1 with DRUGOTHER or other DRUG2 can increase their sedative effects.,DEMSER,CNS depressants,True,effect,2,C[C@](CC1=CC=C(C=C1)O)(C(=O)O)N,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,3,8
3955,20568,20568,21125,21125,Concurrent use of DRUGOTHER with DRUG1 or other DRUG2 can increase their sedative effects.,alcohol,CNS depressants,False,Neg,0,CCO,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,5,8
3956,20578,20578,21135,21135,"When DRUG1 or other hepatic enzyme inducers such as DRUG2 and DRUGOTHER have been taken concurrently with DRUGOTHER   , lowered DRUGOTHER    plasma levels have been reported. ",phenytoin,rifampin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,1,9
3957,20579,20579,21136,21136,"When DRUG1 or other hepatic enzyme inducers such as DRUGOTHER and DRUG2 have been taken concurrently with DRUGOTHER   , lowered DRUGOTHER    plasma levels have been reported. ",phenytoin,phenobarbital,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,1,11
3958,20580,20580,21137,21137,"When DRUG1 or other hepatic enzyme inducers such as DRUGOTHER and DRUGOTHER have been taken concurrently with DRUG2   , lowered DRUG2    plasma levels have been reported. ",phenytoin,Mexitil,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=C(C(=CC=C1)C)OCC(C)N,1,17
3959,20581,20581,21138,21138,"When DRUG1 or other hepatic enzyme inducers such as DRUGOTHER and DRUGOTHER have been taken concurrently with DRUG2   , lowered DRUG2    plasma levels have been reported. ",phenytoin,Mexitil,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=C(C(=CC=C1)C)OCC(C)N,1,17
3960,20604,20604,21161,21161,Concurrent use of DRUG1    and DRUG2 may lead to increased plasma DRUG2 levels. ,Mexitil,theophylline,True,mechanism,4,CC1=C(C(=CC=C1)C)OCC(C)N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,3,8
3961,20605,20605,21162,21162,Concurrent use of DRUG1    and DRUG2 may lead to increased plasma DRUG2 levels. ,Mexitil,theophylline,False,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,3,8
3962,20607,20607,21164,21164,"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUG2 plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUGOTHER are to be used concurrently, DRUGOTHER blood levels should be monitored, particularly when the DRUG1    dose is changed. ",Mexitil,Theophylline,False,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,16,20
3963,20611,20611,21168,21168,"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",Mexitil,theophylline,False,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,16,42
3964,20612,20612,21169,21169,"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",Mexitil,theophylline,False,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,16,42
3965,20614,20614,21171,21171,"This increase was observed at the first test point which was the second day after starting DRUG2   . DRUG1 plasma levels returned to pre-DRUG2    values within 48 hours after discontinuing DRUG2   . If DRUG2 and DRUGOTHER are to be used concurrently, DRUGOTHER blood levels should be monitored, particularly when the DRUG2    dose is changed. ",Theophylline,Mexitil,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1=C(C(=CC=C1)C)OCC(C)N,20,16
3966,20615,20615,21172,21172,"This increase was observed at the first test point which was the second day after starting DRUG2   . DRUG1 plasma levels returned to pre-DRUG2    values within 48 hours after discontinuing DRUG2   . If DRUG2 and DRUGOTHER are to be used concurrently, DRUGOTHER blood levels should be monitored, particularly when the DRUG2    dose is changed. ",Theophylline,Mexitil,True,mechanism,4,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1=C(C(=CC=C1)C)OCC(C)N,20,16
3967,20616,20616,21173,21173,"This increase was observed at the first test point which was the second day after starting DRUG2   . DRUG1 plasma levels returned to pre-DRUG2    values within 48 hours after discontinuing DRUG2   . If DRUG2 and DRUGOTHER are to be used concurrently, DRUGOTHER blood levels should be monitored, particularly when the DRUG2    dose is changed. ",Theophylline,Mexitil,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1=C(C(=CC=C1)C)OCC(C)N,20,16
3968,20619,20619,21176,21176,"This increase was observed at the first test point which was the second day after starting DRUG2   . DRUG1 plasma levels returned to pre-DRUG2    values within 48 hours after discontinuing DRUG2   . If DRUG2 and DRUGOTHER are to be used concurrently, DRUGOTHER blood levels should be monitored, particularly when the DRUG2    dose is changed. ",Theophylline,Mexitil,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1=C(C(=CC=C1)C)OCC(C)N,20,16
3969,20622,20622,21179,21179,"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",Mexitil,theophylline,False,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,16,42
3970,20623,20623,21180,21180,"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",Mexitil,theophylline,False,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,16,42
3971,20626,20626,21183,21183,"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",Mexitil,theophylline,False,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,16,42
3972,20627,20627,21184,21184,"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",Mexitil,theophylline,False,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,16,42
3973,20629,20629,21186,21186,"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",Mexitil,theophylline,True,advise,1,CC1=C(C(=CC=C1)C)OCC(C)N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,16,42
3974,20630,20630,21187,21187,"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",Mexitil,theophylline,False,Neg,0,CC1=C(C(=CC=C1)C)OCC(C)N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,16,42
3975,20633,20633,21190,21190,"This increase was observed at the first test point which was the second day after starting DRUG2   . DRUGOTHER plasma levels returned to pre-DRUG2    values within 48 hours after discontinuing DRUG2   . If DRUG2 and DRUG1 are to be used concurrently, DRUG1 blood levels should be monitored, particularly when the DRUG2    dose is changed. ",theophylline,Mexitil,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1=C(C(=CC=C1)C)OCC(C)N,42,16
3976,20634,20634,21191,21191,"This increase was observed at the first test point which was the second day after starting DRUG2   . DRUGOTHER plasma levels returned to pre-DRUG2    values within 48 hours after discontinuing DRUG2   . If DRUG2 and DRUG1 are to be used concurrently, DRUG1 blood levels should be monitored, particularly when the DRUG2    dose is changed. ",theophylline,Mexitil,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1=C(C(=CC=C1)C)OCC(C)N,42,16
3977,20635,20635,21192,21192,"Additionally, in one controlled study in five normal subjects and seven patients, the clearance of DRUG1 was decreased 50% following the administration of DRUG2   .",caffeine,Mexitil,True,mechanism,4,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC1=C(C(=CC=C1)C)OCC(C)N,15,23
3978,20649,20649,21211,21211,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",mycophenolate mofetil,sirolimus,False,Neg,0,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,22,26
3979,20652,20652,21214,21214,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",mycophenolate mofetil,ritonavir,False,Neg,0,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,22,29
3980,20656,20656,21218,21218,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",cyclosporine,sirolimus,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,23,26
3981,20659,20659,21221,21221,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",cyclosporine,ritonavir,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,23,29
3982,20662,20662,21224,21224,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",tacrolimus,sirolimus,False,Neg,0,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,24,26
3983,20665,20665,21227,21227,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",tacrolimus,ritonavir,False,Neg,0,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,24,29
3984,20667,20667,21229,21229,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",prednisolone,sirolimus,False,Neg,0,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,25,26
3985,20670,20670,21232,21232,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",prednisolone,ritonavir,False,Neg,0,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,25,29
3986,20672,20672,21234,21234,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",sirolimus,nifedipine,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,26,27
3987,20673,20673,21235,21235,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",sirolimus,fluconazole,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,26,28
3988,20675,20675,21237,21237,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",sirolimus,rifampin,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,26,31
3989,20677,20677,21239,21239,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER. ",nifedipine,ritonavir,False,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,27,29
3990,20679,20679,21241,21241,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER. ",fluconazole,ritonavir,False,Neg,0,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,28,29
3991,20681,20681,21243,21243,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2. ",ritonavir,rifampin,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,29,31
3992,20697,20697,21259,21259,DRUG1 AUC was increased by 21% with no effect on Cmax in the presence of steady-state DRUG2 compared with DRUGOTHER alone. ,Sirolimus,MYCAMINE,True,mechanism,4,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)[C@@H](CC(=O)N)O)C)O)O)O,0,16
3993,20699,20699,21261,21261,DRUGOTHER AUC was increased by 21% with no effect on Cmax in the presence of steady-state DRUG1 compared with DRUG2 alone. ,MYCAMINE,sirolimus,False,Neg,0,CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)[C@@H](CC(=O)N)O)C)O)O)O,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,16,19
3994,20703,20703,21265,21265,Patients receiving DRUG1 or DRUG2 in combination with DRUGOTHER should be monitored for DRUG1 or DRUG2 toxicity and DRUG1 or DRUG2 dosage should be reduced if necessary. ,sirolimus,nifedipine,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,2,4
3995,20704,20704,21266,21266,Patients receiving DRUG1 or DRUGOTHER in combination with DRUG2 should be monitored for DRUG1 or DRUGOTHER toxicity and DRUG1 or DRUGOTHER dosage should be reduced if necessary. ,sirolimus,MYCAMINE,True,advise,1,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)[C@@H](CC(=O)N)O)C)O)O)O,2,8
3996,20706,20706,21268,21268,Patients receiving DRUG1 or DRUG2 in combination with DRUGOTHER should be monitored for DRUG1 or DRUG2 toxicity and DRUG1 or DRUG2 dosage should be reduced if necessary. ,sirolimus,nifedipine,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,2,4
3997,20708,20708,21270,21270,Patients receiving DRUG1 or DRUG2 in combination with DRUGOTHER should be monitored for DRUG1 or DRUG2 toxicity and DRUG1 or DRUG2 dosage should be reduced if necessary. ,sirolimus,nifedipine,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,2,4
3998,20710,20710,21272,21272,Patients receiving DRUG2 or DRUG1 in combination with DRUGOTHER should be monitored for DRUG2 or DRUG1 toxicity and DRUG2 or DRUG1 dosage should be reduced if necessary. ,nifedipine,sirolimus,False,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,4,2
3999,20712,20712,21274,21274,Patients receiving DRUG2 or DRUG1 in combination with DRUGOTHER should be monitored for DRUG2 or DRUG1 toxicity and DRUG2 or DRUG1 dosage should be reduced if necessary. ,nifedipine,sirolimus,False,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,4,2
4000,20714,20714,21276,21276,Patients receiving DRUG2 or DRUGOTHER in combination with DRUG1 should be monitored for DRUG2 or DRUGOTHER toxicity and DRUG2 or DRUGOTHER dosage should be reduced if necessary. ,MYCAMINE,sirolimus,False,Neg,0,CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)[C@@H](CC(=O)N)O)C)O)O)O,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,8,2
4001,20716,20716,21278,21278,Patients receiving DRUG2 or DRUGOTHER in combination with DRUG1 should be monitored for DRUG2 or DRUGOTHER toxicity and DRUG2 or DRUGOTHER dosage should be reduced if necessary. ,MYCAMINE,sirolimus,False,Neg,0,CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)[C@@H](CC(=O)N)O)C)O)O)O,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,8,2
4002,20718,20718,21280,21280,Patients receiving DRUG1 or DRUG2 in combination with DRUGOTHER should be monitored for DRUG1 or DRUG2 toxicity and DRUG1 or DRUG2 dosage should be reduced if necessary. ,sirolimus,nifedipine,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,2,4
4003,20720,20720,21282,21282,Patients receiving DRUG1 or DRUG2 in combination with DRUGOTHER should be monitored for DRUG1 or DRUG2 toxicity and DRUG1 or DRUG2 dosage should be reduced if necessary. ,sirolimus,nifedipine,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,2,4
4004,20721,20721,21283,21283,Patients receiving DRUG2 or DRUG1 in combination with DRUGOTHER should be monitored for DRUG2 or DRUG1 toxicity and DRUG2 or DRUG1 dosage should be reduced if necessary. ,nifedipine,sirolimus,False,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,4,2
4005,20723,20723,21285,21285,Patients receiving DRUG1 or DRUG2 in combination with DRUGOTHER should be monitored for DRUG1 or DRUG2 toxicity and DRUG1 or DRUG2 dosage should be reduced if necessary. ,sirolimus,nifedipine,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,2,4
4006,20746,20746,21308,21308,"Although not studied, the potent cytochrome P450 3A4 inhibitors DRUG1 and DRUG2 may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of DRUGOTHER. ",ritonavir,nelfinavir,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,9,11
4007,20747,20747,21309,21309,"Although not studied, the potent cytochrome P450 3A4 inhibitors DRUG1 and DRUGOTHER may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of DRUG2. ",ritonavir,midazolam,True,mechanism,4,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,9,29
4008,20750,20750,21312,21312,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as DRUG1, DRUGOTHER, and DRUG2, induce metabolism and caused a markedly decreased C max and AUC of oral DRUGOTHER in adult studies. ",rifampin,phenytoin,False,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,9,12
4009,20752,20752,21314,21314,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as DRUGOTHER, DRUG1, and DRUG2, induce metabolism and caused a markedly decreased C max and AUC of oral DRUGOTHER in adult studies. ",carbamazepine,phenytoin,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,10,12
4010,20754,20754,21316,21316,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as DRUGOTHER, DRUGOTHER, and DRUG1, induce metabolism and caused a markedly decreased C max and AUC of oral DRUG2 in adult studies. ",phenytoin,midazolam,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,12,26
4011,20755,20755,21317,21317,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUG1, DRUG2 and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",morphine,meperidine,False,Neg,0,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,21,22
4012,20756,20756,21318,21318,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUG1, DRUGOTHER and DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",morphine,fentanyl,False,Neg,0,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,21,24
4013,20763,20763,21325,21325,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUG1 and DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",meperidine,propofol,False,Neg,0,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,CC(C)C1=C(C(=CC=C1)C(C)C)O,22,25
4014,20764,20764,21326,21326,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUG1 and DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",meperidine,ketamine,False,Neg,0,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,22,26
4015,20765,20765,21327,21327,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUG1 and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER. ",meperidine,nitrous oxide,False,Neg,0,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,[N-]=[N+]=O,22,27
4016,20766,20766,21328,21328,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUG1 and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER. ",meperidine,secobarbital,False,Neg,0,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,CCCC(C)C1(C(=O)NC(=O)NC1=O)CC=C,22,28
4017,20767,20767,21329,21329,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUG1 and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2. ",meperidine,droperidol,False,Neg,0,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F,22,30
4018,20768,20768,21330,21330,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUG1), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",fentanyl,propofol,False,Neg,0,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CC(C)C1=C(C(=CC=C1)C(C)C)O,24,25
4019,20769,20769,21331,21331,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUG1), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",fentanyl,ketamine,False,Neg,0,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,24,26
4020,20770,20770,21332,21332,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUG1), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER. ",fentanyl,nitrous oxide,False,Neg,0,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,[N-]=[N+]=O,24,27
4021,20771,20771,21333,21333,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER. ",fentanyl,secobarbital,False,Neg,0,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CCCC(C)C1(C(=O)NC(=O)NC1=O)CC=C,24,28
4022,20772,20772,21334,21334,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2. ",fentanyl,droperidol,False,Neg,0,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F,24,30
4023,20816,20816,21383,21383,"DRUG1. DRUGOTHER, such as DRUGOTHER, DRUG2, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",ProAmatine,terazosin,False,Neg,0,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,0,5
4024,20827,20827,21394,21394,"DRUGOTHER. DRUGOTHER, such as DRUG1, DRUG2, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",prazosin,terazosin,False,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,4,5
4025,20838,20838,21405,21405,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUG1, and DRUG2, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",terazosin,doxazosin,False,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC,5,7
4026,20839,20839,21406,21406,"DRUG2. DRUGOTHER, such as DRUGOTHER, DRUG1, and DRUGOTHER, can antagonize the effects of DRUG2. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",terazosin,ProAmatine,True,effect,2,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,5,0
4027,20840,20840,21407,21407,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUG1, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG2 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",terazosin,desglymidodrine,False,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,COC1=CC(=C(C=C1)OC)C(CN)O,5,34
4028,20841,20841,21408,21408,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUG1, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",terazosin,metformin,False,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,CN(C)C(=N)N=C(N)N,5,56
4029,20842,20842,21409,21409,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUG1, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",terazosin,cimetidine,False,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,CC1=C(N=CN1)CSCCNC(=NC)NC#N,5,57
4030,20843,20843,21410,21410,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUG1, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",terazosin,ranitidine,False,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,5,58
4031,20844,20844,21411,21411,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUG1, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",terazosin,procainamide,False,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,5,59
4032,20845,20845,21412,21412,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUG1, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",terazosin,triamterene,False,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,5,60
4033,20846,20846,21413,21413,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUG1, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",terazosin,flecainide,False,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,5,61
4034,20847,20847,21414,21414,"DRUGOTHER. DRUGOTHER, such as DRUGOTHER, DRUG1, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",terazosin,quinidine,False,Neg,0,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,5,63
4035,20904,20904,21471,21471,"John   s Wort, and certain DRUG1 (DRUG2, DRUGOTHER, DRUGOTHER) may induce DRUGOTHER metabolism (lowering serum levels of DRUGOTHER). ",anticonvulsants,phenytoin,False,Neg,0,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,7,8
4036,20909,20909,21476,21476,"John   s Wort, and certain DRUGOTHER (DRUG1, DRUG2, DRUGOTHER) may induce DRUGOTHER metabolism (lowering serum levels of DRUGOTHER). ",phenytoin,phenobarbital,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,8,9
4037,20910,20910,21477,21477,"John   s Wort, and certain DRUGOTHER (DRUG1, DRUGOTHER, DRUG2) may induce DRUGOTHER metabolism (lowering serum levels of DRUGOTHER). ",phenytoin,carbamazepine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,8,10
4038,20911,20911,21478,21478,"John   s Wort, and certain DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER) may induce DRUG2 metabolism (lowering serum levels of DRUG2). ",phenytoin,mifepristone,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O,8,13
4039,20912,20912,21479,21479,"John   s Wort, and certain DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER) may induce DRUG2 metabolism (lowering serum levels of DRUG2). ",phenytoin,mifepristone,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O,8,13
4040,20923,20923,21490,21490,The concurrent use of DRUG1 and DRUG2 has been reported to result in fatal renal toxicity. ,tetracycline,methoxyflurane,True,effect,2,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,COC(C(Cl)Cl)(F)F,4,6
4041,21026,21026,21596,21596,"The neuromuscular blocking effect of DRUG1 may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUGOTHER, DRUGOTHER, or certain DRUGOTHER) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUG2 or DRUGOTHER. ",MIVACRON,phenytoin,False,Neg,0,C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-],C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,5,50
4042,21030,21030,21600,21600,"The neuromuscular blocking effect of DRUGOTHER may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUG1, DRUGOTHER, or certain DRUGOTHER) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUG2 or DRUGOTHER. ",contraceptives,phenytoin,False,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,20,50
4043,21033,21033,21603,21603,"The neuromuscular blocking effect of DRUGOTHER may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUGOTHER, DRUG1, or certain DRUGOTHER) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUG2 or DRUGOTHER. ",glucocorticoids,phenytoin,False,Neg,0,COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,21,50
4044,21035,21035,21605,21605,"The neuromuscular blocking effect of DRUGOTHER may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUGOTHER, DRUGOTHER, or certain DRUG1) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUG2 or DRUGOTHER. ",monoamine oxidase inhibitors,phenytoin,False,Neg,0,OC(=O)CCCCCCCC(O)=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,24,50
4045,21037,21037,21607,21607,"The neuromuscular blocking effect of DRUGOTHER may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUGOTHER, DRUGOTHER, or certain DRUGOTHER) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUG1 or DRUG2. ",phenytoin,carbamazepine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,50,52
4046,21038,21038,21608,21608,"While the effects of chronic DRUG1 or DRUG2 therapy on the action of DRUGOTHER are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. ",phenytoin,carbamazepine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,5,7
4047,21039,21039,21609,21609,"While the effects of chronic DRUG1 or DRUGOTHER therapy on the action of DRUG2 are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. ",phenytoin,MIVACRON,True,effect,2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-],5,13
4048,21041,21041,21611,21611,Some drug interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG2 or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,corticosteroids,phenytoin,False,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,10,30
4049,21052,21052,21622,21622,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUG2 - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,phenytoin,carbamazepine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,30,32
4050,21053,21053,21623,21623,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUGOTHER - certain DRUG2 given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,phenytoin,antibiotics,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,30,35
4051,21054,21054,21624,21624,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUGOTHER - certain DRUGOTHER given by injection - DRUG2 - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,phenytoin,cisplatin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,N.N.Cl[Pt]Cl,30,40
4052,21055,21055,21625,21625,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUG2 - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,phenytoin,edrophonium,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC[N+](C)(C)C1=CC(=CC=C1)O,30,42
4053,21056,21056,21626,21626,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUG2 - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,phenytoin,neostigmine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C,30,44
4054,21057,21057,21627,21627,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUG2 or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,phenytoin,polymyxin B,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC1=O)CCN)CC2=CC=CC=C2)CC(C)C)CCN)CCN)[C@@H](C)O,30,46
4055,21058,21058,21628,21628,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,phenytoin,anesthetics,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCOC(=O)C1=CC=C(N)C=C1,30,51
4056,21059,21059,21629,21629,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUG2 - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,phenytoin,procaine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,30,54
4057,21060,21060,21630,21630,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,phenytoin,anesthetics,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCOC(=O)C1=CC=C(N)C=C1,30,51
4058,21061,21061,21631,21631,Some drug interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUG2 or other DRUGOTHER,phenytoin,succinylcholine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,30,59
4059,21107,21107,21678,21678,"Use of DRUGOTHER (DRUG1, DRUG2, DRUGOTHER) or DRUGOTHER supplements concomitantly with DRUGOTHER can increase the risk of hyperkalemia. ",spironolactone,triamterene,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,3,4
4060,21108,21108,21679,21679,"Use of DRUGOTHER (DRUG1, DRUGOTHER, DRUG2) or DRUGOTHER supplements concomitantly with DRUGOTHER can increase the risk of hyperkalemia. ",spironolactone,amiloride,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N,3,5
4061,21111,21111,21685,21685,"Other Agents: No clinically important pharmacokinetic interactions occurred when DRUGOTHER    was administered concomitantly with DRUG1, DRUG2, or DRUGOTHER. ",hydrochlorothiazide,digoxin,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,17,18
4062,21112,21112,21686,21686,"Other Agents: No clinically important pharmacokinetic interactions occurred when DRUGOTHER    was administered concomitantly with DRUG1, DRUGOTHER, or DRUG2. ",hydrochlorothiazide,cimetidine,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,CC1=C(N=CN1)CSCCNC(=NC)NC#N,17,20
4063,21117,21117,21695,21695,DRUG1 at a Dose of 10 mg Once Daily Dosed to Pharmacokinetic Steady State  - did not cause clinically significant changes in the kinetics of a single intravenous dose of DRUG2 (predominantly a cytochrome P450 1A2 substrate). ,Montelukast,theophylline,False,Neg,0,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,31
4064,21134,21134,21712,21712,"In drug-interaction studies, the recommended clinical dose of DRUG1 did not have clinically important effects on the pharmacokinetics of the following drugs: DRUG2, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",montelukast,theophylline,False,Neg,0,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,8,22
4065,21143,21143,21721,21721,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUG1, DRUG2, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",theophylline,prednisone,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,22,23
4066,21144,21144,21722,21722,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUG1, DRUGOTHER, DRUG2, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",theophylline,prednisolone,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,22,24
4067,21145,21145,21723,21723,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUG1, DRUGOTHER, DRUGOTHER, oral DRUG2 (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",theophylline,contraceptives,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,22,26
4068,21146,21146,21724,21724,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUG1, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUG2 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",theophylline,norethindrone,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,22,27
4069,21147,21147,21725,21725,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUG1, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUG2 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",theophylline,ethinyl estradiol,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,22,29
4070,21148,21148,21726,21726,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUG1, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUG2, DRUGOTHER, and DRUGOTHER. ",theophylline,terfenadine,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,22,32
4071,21149,21149,21727,21727,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUG1, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUG2, and DRUGOTHER. ",theophylline,digoxin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,22,33
4072,21150,21150,21728,21728,"In drug-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following drugs: DRUG1, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUG2. ",theophylline,warfarin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,22,35
4073,21188,21188,21766,21766,"Use with Other DRUGOTHER: The depressant effects of DRUG1 are potentiated by the presence of other DRUG2 such as DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",morphine,CNS depressants,True,effect,2,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,8,16
4074,21190,21190,21768,21768,"Use with Other DRUGOTHER: The depressant effects of DRUGOTHER are potentiated by the presence of other DRUG1 such as DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",CNS depressants,alcohol,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCO,16,19
4075,21193,21193,21771,21771,"Interaction with DRUGOTHER: DRUGOTHER (i.e., DRUG1, DRUGOTHER, DRUGOTHER, or DRUG2) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUGOTHER. ",pentazocine,buprenorphine,False,Neg,0,C[C@H]1[C@H]2CC3=C([C@@]1(CCN2CC=C(C)C)C)C=C(C=C3)O,C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O,5,9
4076,21195,21195,21773,21773,"Interaction with DRUGOTHER: DRUGOTHER (i.e., DRUGOTHER, DRUG1, DRUGOTHER, or DRUG2) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUGOTHER. ",nalbuphine,buprenorphine,False,Neg,0,C1CC(C1)CN2CC[C@]34[C@@H]5[C@H](CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O)O,C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O,6,9
4077,21196,21196,21774,21774,"Interaction with DRUGOTHER: DRUGOTHER (i.e., DRUGOTHER, DRUGOTHER, DRUG1, or DRUG2) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUGOTHER. ",butorphanol,buprenorphine,False,Neg,0,C1CC[C@]2([C@H]3CC4=C([C@]2(C1)CCN3CC5CCC5)C=C(C=C4)O)O,C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O,7,9
4078,21234,21234,21815,21815,"DRUG1, DRUG2, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUGOTHER, DRUGOTHER, and DRUGOTHER), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",Phenytoin,Carbamazepine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,0,1
4079,21235,21235,21816,21816,"DRUG1, DRUGOTHER, and DRUG2: In patients treated with potent inducers of CYP3A4 (i.e., DRUGOTHER, DRUGOTHER, and DRUGOTHER), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",Phenytoin,Rifampicin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,0,3
4080,21237,21237,21818,21818,"DRUG1, DRUGOTHER, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUGOTHER, DRUG2, and DRUGOTHER), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",Phenytoin,carbamazepine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,0,14
4081,21238,21238,21819,21819,"DRUG1, DRUGOTHER, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUGOTHER, DRUGOTHER, and DRUG2), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",Phenytoin,rifampicin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,0,16
4082,21239,21239,21820,21820,"DRUG1, DRUGOTHER, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUGOTHER, DRUGOTHER, and DRUGOTHER), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",Phenytoin,ondansetron,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,0,20
4083,21240,21240,21821,21821,"DRUG1, DRUGOTHER, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUGOTHER, DRUGOTHER, and DRUGOTHER), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",Phenytoin,ondansetron,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,0,20
4084,21242,21242,21823,21823,"DRUGOTHER, DRUG1, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUG2, DRUGOTHER, and DRUGOTHER), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",Carbamazepine,phenytoin,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,1,13
4085,21247,21247,21828,21828,"DRUGOTHER, DRUGOTHER, and DRUG1: In patients treated with potent inducers of CYP3A4 (i.e., DRUG2, DRUGOTHER, and DRUGOTHER), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",Rifampicin,phenytoin,False,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,3,13
4086,21252,21252,21833,21833,"DRUGOTHER, DRUGOTHER, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUG1, DRUG2, and DRUGOTHER), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",phenytoin,carbamazepine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,13,14
4087,21253,21253,21834,21834,"DRUGOTHER, DRUGOTHER, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUG1, DRUGOTHER, and DRUG2), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",phenytoin,rifampicin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,13,16
4088,21254,21254,21835,21835,"DRUGOTHER, DRUGOTHER, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUG1, DRUGOTHER, and DRUGOTHER), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",phenytoin,ondansetron,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,13,20
4089,21255,21255,21836,21836,"DRUGOTHER, DRUGOTHER, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUG1, DRUGOTHER, and DRUGOTHER), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",phenytoin,ondansetron,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,13,20
4090,21291,21291,21873,21873,"DRUG1: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUG2 and 40 grams of DRUGOTHER (e.g., approximately 3 glasses of wine) did not result in alteration of DRUGOTHER pharmacokinetics, DRUGOTHER pharmacodynamics (fecal fat excretion), or systemic exposure to DRUGOTHER. ",Alcohol,XENICAL,False,Neg,0,CCO,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,12
4091,21294,21294,21876,21876,"DRUG1: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUGOTHER and 40 grams of DRUGOTHER (e.g., approximately 3 glasses of wine) did not result in alteration of DRUGOTHER pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",Alcohol,orlistat,False,Neg,0,CCO,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,32
4092,21295,21295,21877,21877,"DRUG1: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUGOTHER and 40 grams of DRUGOTHER (e.g., approximately 3 glasses of wine) did not result in alteration of DRUGOTHER pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",Alcohol,orlistat,False,Neg,0,CCO,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,32
4093,21296,21296,21878,21878,"DRUGOTHER: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUG1 and 40 grams of DRUG2 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG2 pharmacokinetics, DRUGOTHER pharmacodynamics (fecal fat excretion), or systemic exposure to DRUGOTHER. ",XENICAL,alcohol,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CCO,12,17
4094,21297,21297,21879,21879,"DRUGOTHER: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUG1 and 40 grams of DRUG2 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG2 pharmacokinetics, DRUGOTHER pharmacodynamics (fecal fat excretion), or systemic exposure to DRUGOTHER. ",XENICAL,alcohol,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CCO,12,17
4095,21301,21301,21883,21883,"DRUGOTHER: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUGOTHER and 40 grams of DRUG1 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG1 pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",alcohol,orlistat,False,Neg,0,CCO,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,17,32
4096,21302,21302,21884,21884,"DRUGOTHER: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUGOTHER and 40 grams of DRUG1 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG1 pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",alcohol,orlistat,False,Neg,0,CCO,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,17,32
4097,21303,21303,21885,21885,"DRUGOTHER: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUGOTHER and 40 grams of DRUG1 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG1 pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",alcohol,orlistat,False,Neg,0,CCO,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,17,32
4098,21304,21304,21886,21886,"DRUGOTHER: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUGOTHER and 40 grams of DRUG1 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG1 pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",alcohol,orlistat,False,Neg,0,CCO,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,17,32
4099,21306,21306,21888,21888,DRUG1: Preliminary data from a DRUG2 and DRUGOTHER drug interaction study indicate a reduction in DRUGOTHER plasma levels when DRUG2 was coadministered with DRUGOTHER. ,Cyclosporine,XENICAL,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,5
4100,21309,21309,21891,21891,DRUG1: Preliminary data from a DRUG2 and DRUGOTHER drug interaction study indicate a reduction in DRUGOTHER plasma levels when DRUG2 was coadministered with DRUGOTHER. ,Cyclosporine,XENICAL,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,5
4101,21311,21311,21893,21893,DRUGOTHER: Preliminary data from a DRUG1 and DRUG2 drug interaction study indicate a reduction in DRUG2 plasma levels when DRUG1 was coadministered with DRUG2. ,XENICAL,cyclosporine,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,5,7
4102,21312,21312,21894,21894,DRUGOTHER: Preliminary data from a DRUG1 and DRUG2 drug interaction study indicate a reduction in DRUG2 plasma levels when DRUG1 was coadministered with DRUG2. ,XENICAL,cyclosporine,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,5,7
4103,21314,21314,21896,21896,DRUGOTHER: Preliminary data from a DRUG1 and DRUG2 drug interaction study indicate a reduction in DRUG2 plasma levels when DRUG1 was coadministered with DRUG2. ,XENICAL,cyclosporine,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,5,7
4104,21316,21316,21898,21898,DRUGOTHER: Preliminary data from a DRUG2 and DRUG1 drug interaction study indicate a reduction in DRUG1 plasma levels when DRUG2 was coadministered with DRUG1. ,cyclosporine,XENICAL,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,7,5
4105,21318,21318,21900,21900,DRUGOTHER: Preliminary data from a DRUG2 and DRUG1 drug interaction study indicate a reduction in DRUG1 plasma levels when DRUG2 was coadministered with DRUG1. ,cyclosporine,XENICAL,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,7,5
4106,21320,21320,21902,21902,DRUGOTHER: Preliminary data from a DRUG1 and DRUG2 drug interaction study indicate a reduction in DRUG2 plasma levels when DRUG1 was coadministered with DRUG2. ,XENICAL,cyclosporine,True,mechanism,4,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,5,7
4107,21321,21321,21903,21903,"DRUG1: In 12 normal-weight subjects receiving DRUG2 120 mg three times a day for 6 days, DRUG2 did not alter the pharmacokinetics of a single dose of DRUGOTHER. ",Digoxin,XENICAL,False,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,6
4108,21322,21322,21904,21904,"DRUG1: In 12 normal-weight subjects receiving DRUG2 120 mg three times a day for 6 days, DRUG2 did not alter the pharmacokinetics of a single dose of DRUGOTHER. ",Digoxin,XENICAL,False,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,6
4109,21325,21325,21907,21907,"DRUGOTHER: In 12 normal-weight subjects receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not alter the pharmacokinetics of a single dose of DRUG2. ",XENICAL,digoxin,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,6,27
4110,21326,21326,21908,21908,"DRUGOTHER: In 12 normal-weight subjects receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not alter the pharmacokinetics of a single dose of DRUG2. ",XENICAL,digoxin,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,6,27
4111,21327,21327,21911,21911,"The effect of DRUG1 on the absorption of supplemental DRUG2, DRUGOTHER, and nutritionally-derived DRUGOTHER is not known at this time. ",orlistat,vitamin D,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,OC(=O)CCCCCCCC(O)=O,3,9
4112,21328,21328,21912,21912,"The effect of DRUG1 on the absorption of supplemental DRUGOTHER, DRUG2, and nutritionally-derived DRUGOTHER is not known at this time. ",orlistat,vitamin A,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/CO)/C)/C,3,10
4113,21329,21329,21913,21913,"The effect of DRUG1 on the absorption of supplemental DRUGOTHER, DRUGOTHER, and nutritionally-derived DRUG2 is not known at this time. ",orlistat,vitamin K,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CC1=C(C(=O)C2=CC=CC=C2C1=O)C/C=C(\C)/CCCC(C)CCCC(C)CCCC(C)C,3,13
4114,21333,21333,21917,21917,"DRUG1: In 12 normal-weight subjects receiving DRUG2 80 mg three times a day for 5 days, DRUG2 did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of DRUGOTHER. ",Glyburide,orlistat,False,Neg,0,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,6
4115,21334,21334,21918,21918,"DRUG1: In 12 normal-weight subjects receiving DRUG2 80 mg three times a day for 5 days, DRUG2 did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of DRUGOTHER. ",Glyburide,orlistat,False,Neg,0,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,6
4116,21337,21337,21921,21921,"DRUGOTHER: In 12 normal-weight subjects receiving DRUG1 80 mg three times a day for 5 days, DRUG1 did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of DRUG2. ",orlistat,glyburide,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,6,27
4117,21338,21338,21922,21922,"DRUGOTHER: In 12 normal-weight subjects receiving DRUG1 80 mg three times a day for 5 days, DRUG1 did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of DRUG2. ",orlistat,glyburide,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,6,27
4118,21339,21339,21923,21923,"DRUG1 (extended-release tablets): In 17 normal-weight subjects receiving DRUG2 120 mg three times a day for 6 days, DRUG2 did not alter the bioavailability of DRUGOTHER (extended-release tablets). ",Nifedipine,XENICAL,False,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,8
4119,21340,21340,21924,21924,"DRUG1 (extended-release tablets): In 17 normal-weight subjects receiving DRUG2 120 mg three times a day for 6 days, DRUG2 did not alter the bioavailability of DRUGOTHER (extended-release tablets). ",Nifedipine,XENICAL,False,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,8
4120,21343,21343,21927,21927,"DRUGOTHER (extended-release tablets): In 17 normal-weight subjects receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not alter the bioavailability of DRUG2 (extended-release tablets). ",XENICAL,nifedipine,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,8,25
4121,21344,21344,21928,21928,"DRUGOTHER (extended-release tablets): In 17 normal-weight subjects receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not alter the bioavailability of DRUG2 (extended-release tablets). ",XENICAL,nifedipine,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,8,25
4122,21345,21345,21929,21929,"Oral DRUGOTHER: In 20 normal-weight female subjects, the treatment of DRUG1 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral DRUG2. ",XENICAL,contraceptives,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,10,30
4123,21358,21358,21942,21942,"DRUG1: In 12 normal-weight subjects, administration of DRUG2 120 mg three times a day for 16 days did not result in any change in either DRUGOTHER pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). ",Warfarin,XENICAL,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,7
4124,21360,21360,21944,21944,"DRUGOTHER: In 12 normal-weight subjects, administration of DRUG1 120 mg three times a day for 16 days did not result in any change in either DRUG2 pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). ",XENICAL,warfarin,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,7,25
4125,21362,21362,21946,21946,"Therefore, as DRUG1 absorption may be decreased with DRUG2, patients on chronic stable doses of DRUGOTHER who are prescribed DRUG2 should be monitored closely for changes in coagulation parameters.",vitamin K,XENICAL,True,mechanism,4,CC1=C(C(=O)C2=CC=CC=C2C1=O)C/C=C(\C)/CCCC(C)CCCC(C)CCCC(C)C,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,2,8
4126,21364,21364,21948,21948,"Therefore, as DRUG1 absorption may be decreased with DRUG2, patients on chronic stable doses of DRUGOTHER who are prescribed DRUG2 should be monitored closely for changes in coagulation parameters.",vitamin K,XENICAL,False,Neg,0,CC1=C(C(=O)C2=CC=CC=C2C1=O)C/C=C(\C)/CCCC(C)CCCC(C)CCCC(C)C,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,2,8
4127,21365,21365,21949,21949,"Therefore, as DRUGOTHER absorption may be decreased with DRUG1, patients on chronic stable doses of DRUG2 who are prescribed DRUG1 should be monitored closely for changes in coagulation parameters.",XENICAL,warfarin,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,8,15
4128,21367,21367,21951,21951,"Therefore, as DRUGOTHER absorption may be decreased with DRUG2, patients on chronic stable doses of DRUG1 who are prescribed DRUG2 should be monitored closely for changes in coagulation parameters.",warfarin,XENICAL,True,advise,1,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,15,8
4129,21368,21368,21952,21952,"DRUG1, a bacteriostatic DRUGOTHER, may antagonize the bactericidal effect of DRUG2 and concurrent use of these drugs should be avoided.",Tetracycline,penicillin,True,effect,2,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,0,10
4130,21369,21369,21953,21953,"DRUG1: A multidose study of DRUG2, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with DRUGOTHER, resulted in a mean increase in S-DRUGOTHER half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-DRUGOTHER half-life and AUC were also detected. ",Warfarin,oxandrolone,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C,0,5
4131,21373,21373,21957,21957,"DRUGOTHER: A multidose study of DRUG1, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with DRUG2, resulted in a mean increase in S-DRUG2 half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-DRUG2 half-life and AUC were also detected. ",oxandrolone,warfarin,True,mechanism,4,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,5,20
4132,21374,21374,21958,21958,"DRUGOTHER: A multidose study of DRUG1, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with DRUGOTHER, resulted in a mean increase in DRUG2 half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-DRUGOTHER half-life and AUC were also detected. ",oxandrolone,S-warfarin,False,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C,CC(=O)C[C@@H](C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,5,27
4133,21375,21375,21959,21959,"DRUGOTHER: A multidose study of DRUG1, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with DRUGOTHER, resulted in a mean increase in S-DRUGOTHER half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in DRUG2 half-life and AUC were also detected. ",oxandrolone,R-warfarin,False,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C,CC(=O)C[C@H](C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,5,44
4134,21380,21380,21964,21964,"When DRUG1 therapy is initiated in a patient already receiving treatment with DRUG2, the INR or prothrombin time (PT) should be monitored closely and the dose of DRUG2 adjusted as necessary until a stable target INR or PT has been achieved. ",oxandrolone,warfarin,True,advise,1,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,1,12
4135,21381,21381,21965,21965,"When DRUG1 therapy is initiated in a patient already receiving treatment with DRUG2, the INR or prothrombin time (PT) should be monitored closely and the dose of DRUG2 adjusted as necessary until a stable target INR or PT has been achieved. ",oxandrolone,warfarin,False,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,1,12
4136,21383,21383,21967,21967,"Furthermore, in patients receiving both drugs, careful monitoring of the INR or PT, and adjustment of the DRUG1 dosage if indicated are recommended when the DRUG2 dose is changed or discontinued. ",warfarin,oxandrolone,True,advise,1,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C,17,25
4137,21384,21384,21968,21968,Oral DRUG1 DRUG2 may inhibit the metabolism of oral DRUG1. ,hypoglycemic agents,Oxandrolone,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C,1,2
4138,21386,21386,21970,21970,Oral DRUG2 DRUG1 may inhibit the metabolism of oral DRUG2. ,Oxandrolone,hypoglycemic agents,True,mechanism,4,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,2,1
4139,21427,21427,22011,22011,The CNS depressant effects of DRUG1 may be additive with that of other DRUG2..,oxycodone hydrochloride,CNS depressants,True,effect,2,CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O.Cl,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,5,13
4140,21460,21460,22044,22044,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,cisapride,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,22,23
4141,21461,21461,22045,22045,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,antipyrine,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1=CC(=O)N(N1C)C2=CC=CC=C2,22,24
4142,21463,21463,22047,22047,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,carbamazepine,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,22,26
4143,21464,21464,22048,22048,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 (and its active metabolite, desmethylDRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,diazepam,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,22,27
4144,21465,21465,22049,22049,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,desmethyldiazepam,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,22,32
4145,21466,21466,22050,22050,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,diclofenac,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,22,33
4146,21467,21467,22051,22051,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,naproxen,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,22,34
4147,21468,21468,22052,22052,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,piroxicam,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,22,35
4148,21469,21469,22053,22053,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,digoxin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,22,36
4149,21470,21470,22054,22054,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,ethanol,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CCO,22,37
4150,21471,21471,22055,22055,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,glyburide,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,22,38
4151,21472,21472,22056,22056,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG2 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,contraceptive,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,22,41
4152,21473,21473,22057,22057,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG2/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,levonorgestrel,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,22,42
4153,21474,21474,22058,22058,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,ethinyl estradiol,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,22,42
4154,21475,21475,22059,22059,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,metoprolol,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,22,43
4155,21476,21476,22060,22060,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,nifedipine,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,22,44
4156,21478,21478,22062,22062,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,warfarin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,22,46
4157,21479,21479,22063,22063,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,midazolam,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,22,47
4158,21480,21480,22064,22064,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",theophylline,clarithromycin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,22,48
4159,21481,21481,22065,22065,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",theophylline,metronidazole,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1=NC=C(N1CCO)[N+](=O)[O-],22,49
4160,21482,21482,22066,22066,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",theophylline,amoxicillin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,22,51
4161,21484,21484,22068,22068,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",cisapride,caffeine,False,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,23,25
4162,21499,21499,22083,22083,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",cisapride,phenytoin,False,Neg,0,CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,23,45
4163,21505,21505,22089,22089,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",antipyrine,caffeine,False,Neg,0,CC1=CC(=O)N(N1C)C2=CC=CC=C2,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,24,25
4164,21520,21520,22104,22104,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",antipyrine,phenytoin,False,Neg,0,CC1=CC(=O)N(N1C)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,24,45
4165,21526,21526,22110,22110,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,carbamazepine,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,25,26
4166,21527,21527,22111,22111,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2 (and its active metabolite, desmethylDRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,diazepam,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,25,27
4167,21528,21528,22112,22112,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,desmethyldiazepam,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,25,32
4168,21529,21529,22113,22113,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,diclofenac,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,25,33
4169,21530,21530,22114,22114,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,naproxen,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,25,34
4170,21531,21531,22115,22115,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,piroxicam,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,25,35
4171,21532,21532,22116,22116,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,digoxin,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,25,36
4172,21533,21533,22117,22117,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,ethanol,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CCO,25,37
4173,21534,21534,22118,22118,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,glyburide,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,25,38
4174,21535,21535,22119,22119,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG2 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,contraceptive,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,25,41
4175,21536,21536,22120,22120,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG2/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,levonorgestrel,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,25,42
4176,21537,21537,22121,22121,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,ethinyl estradiol,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,25,42
4177,21538,21538,22122,22122,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,metoprolol,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,25,43
4178,21539,21539,22123,22123,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,nifedipine,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,25,44
4179,21541,21541,22125,22125,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,warfarin,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,25,46
4180,21542,21542,22126,22126,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,midazolam,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,25,47
4181,21543,21543,22127,22127,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",caffeine,clarithromycin,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,25,48
4182,21544,21544,22128,22128,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",caffeine,metronidazole,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC1=NC=C(N1CCO)[N+](=O)[O-],25,49
4183,21545,21545,22129,22129,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",caffeine,amoxicillin,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,25,51
4184,21559,21559,22143,22143,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",carbamazepine,phenytoin,False,Neg,0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,26,45
4185,21577,21577,22161,22161,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, desmethylDRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",diazepam,phenytoin,False,Neg,0,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,27,45
4186,21594,21594,22178,22178,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",desmethyldiazepam,phenytoin,False,Neg,0,C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,32,45
4187,21610,21610,22194,22194,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",diclofenac,phenytoin,False,Neg,0,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,33,45
4188,21625,21625,22209,22209,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",naproxen,phenytoin,False,Neg,0,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,34,45
4189,21639,21639,22223,22223,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",piroxicam,phenytoin,False,Neg,0,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,35,45
4190,21652,21652,22236,22236,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",digoxin,phenytoin,False,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,36,45
4191,21664,21664,22248,22248,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",ethanol,phenytoin,False,Neg,0,CCO,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,37,45
4192,21675,21675,22259,22259,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",glyburide,phenytoin,False,Neg,0,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,38,45
4193,21685,21685,22269,22269,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG1 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",contraceptive,phenytoin,False,Neg,0,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,41,45
4194,21694,21694,22278,22278,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG1/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",levonorgestrel,phenytoin,False,Neg,0,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,42,45
4195,21702,21702,22286,22286,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUG1), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",ethinyl estradiol,phenytoin,False,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,42,45
4196,21709,21709,22293,22293,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",metoprolol,phenytoin,False,Neg,0,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,43,45
4197,21715,21715,22299,22299,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",nifedipine,phenytoin,False,Neg,0,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,44,45
4198,21721,21721,22305,22305,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",phenytoin,warfarin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,45,46
4199,21722,21722,22306,22306,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",phenytoin,midazolam,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,45,47
4200,21723,21723,22307,22307,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",phenytoin,clarithromycin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,45,48
4201,21724,21724,22308,22308,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",phenytoin,metronidazole,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1=NC=C(N1CCO)[N+](=O)[O-],45,49
4202,21725,21725,22309,22309,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",phenytoin,amoxicillin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,45,51
4203,21750,21750,22337,22337,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,nefazodone,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,8,58
4204,21752,21752,22339,22339,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,ritonavir,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,8,60
4205,21753,21753,22340,22340,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",ketoconazole,saquinavir,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,8,61
4206,21754,21754,22341,22341,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",ketoconazole,telithromycin,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,8,62
4207,21764,21764,22351,22351,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,nefazodone,False,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,11,58
4208,21766,21766,22353,22353,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,ritonavir,False,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,11,60
4209,21767,21767,22354,22354,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",paricalcitol,saquinavir,False,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,11,61
4210,21768,21768,22355,22355,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",paricalcitol,telithromycin,False,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,11,62
4211,21777,21777,22364,22364,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,nefazodone,False,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,11,58
4212,21779,21779,22366,22366,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,ritonavir,False,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,11,60
4213,21780,21780,22367,22367,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",paricalcitol,saquinavir,False,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,11,61
4214,21781,21781,22368,22368,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",paricalcitol,telithromycin,False,Neg,0,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,11,62
4215,21789,21789,22376,22376,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,nefazodone,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,8,58
4216,21791,21791,22378,22378,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,ritonavir,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,8,60
4217,21792,21792,22379,22379,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",ketoconazole,saquinavir,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,8,61
4218,21793,21793,22380,22380,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",ketoconazole,telithromycin,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,8,62
4219,21800,21800,22387,22387,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,nefazodone,True,advise,1,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,11,58
4220,21802,21802,22389,22389,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",paricalcitol,ritonavir,True,advise,1,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,11,60
4221,21803,21803,22390,22390,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",paricalcitol,saquinavir,True,advise,1,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,11,61
4222,21804,21804,22391,22391,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",paricalcitol,telithromycin,True,advise,1,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,11,62
4223,21810,21810,22397,22397,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,nefazodone,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,8,58
4224,21812,21812,22399,22399,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",ketoconazole,ritonavir,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,8,60
4225,21813,21813,22400,22400,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",ketoconazole,saquinavir,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,8,61
4226,21814,21814,22401,22401,"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",ketoconazole,telithromycin,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,8,62
4227,21819,21819,22406,22406,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",atazanavir,nefazodone,False,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,54,58
4228,21821,21821,22408,22408,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",atazanavir,ritonavir,False,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,54,60
4229,21822,21822,22409,22409,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",atazanavir,saquinavir,False,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,54,61
4230,21823,21823,22410,22410,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",atazanavir,telithromycin,False,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,54,62
4231,21827,21827,22414,22414,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",clarithromycin,nefazodone,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,55,58
4232,21829,21829,22416,22416,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",clarithromycin,ritonavir,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,55,60
4233,21830,21830,22417,22417,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",clarithromycin,saquinavir,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,55,61
4234,21831,21831,22418,22418,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",clarithromycin,telithromycin,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,55,62
4235,21834,21834,22421,22421,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",indinavir,nefazodone,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,56,58
4236,21836,21836,22423,22423,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",indinavir,ritonavir,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,56,60
4237,21837,21837,22424,22424,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",indinavir,saquinavir,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,56,61
4238,21838,21838,22425,22425,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",indinavir,telithromycin,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,56,62
4239,21840,21840,22427,22427,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",itraconazole,nefazodone,False,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,57,58
4240,21842,21842,22429,22429,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",itraconazole,ritonavir,False,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,57,60
4241,21843,21843,22430,22430,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",itraconazole,saquinavir,False,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,57,61
4242,21844,21844,22431,22431,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",itraconazole,telithromycin,False,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,57,62
4243,21846,21846,22433,22433,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",nefazodone,nelfinavir,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,58,59
4244,21850,21850,22437,22437,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2. ",nefazodone,voriconazole,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,58,64
4245,21851,21851,22438,22438,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",nelfinavir,ritonavir,False,Neg,0,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,59,60
4246,21852,21852,22439,22439,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",nelfinavir,saquinavir,False,Neg,0,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,59,61
4247,21853,21853,22440,22440,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",nelfinavir,telithromycin,False,Neg,0,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,59,62
4248,21857,21857,22444,22444,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER or DRUG2. ",ritonavir,voriconazole,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,60,64
4249,21859,21859,22446,22446,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER or DRUG2. ",saquinavir,voriconazole,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,61,64
4250,21860,21860,22447,22447,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 or DRUG2. ",telithromycin,voriconazole,False,Neg,0,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,62,64
4251,21866,21866,22461,22461,"Concurrent administration of DRUGOTHER (e.g., DRUG1, DRUG2) may diminish the bactericidal effects of DRUGOTHER by slowing the rate of bacterial growth. ",erythromycin,tetracycline,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,5,6
4252,21868,21868,22463,22463,"Concurrent administration of DRUGOTHER (e.g., DRUGOTHER, DRUG1) may diminish the bactericidal effects of DRUG2 by slowing the rate of bacterial growth. ",tetracycline,penicillins,True,effect,2,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,6,13
4253,21882,21882,22477,22477,"DRUG1 has been used concurrently with DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER, without observed problems. ",TRENTAL,antihypertensive drugs,False,Neg,0,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,0,6
4254,21883,21883,22478,22478,"DRUG1 has been used concurrently with DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER, without observed problems. ",TRENTAL,digitalis,False,Neg,0,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,0,8
4255,21884,21884,22479,22479,"DRUG1 has been used concurrently with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER, without observed problems. ",TRENTAL,diuretics,False,Neg,0,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,0,9
4256,21885,21885,22480,22480,"DRUG1 has been used concurrently with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER, without observed problems. ",TRENTAL,antidiabetic agents,False,Neg,0,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,0,10
4257,21893,21893,22488,22488,"DRUGOTHER, such as the DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER ) or DRUGOTHER, ordinarily should not be administered concurrently with DRUG2 (a DRUGOTHER); ",phenothiazines,Permax,True,advise,1,N1C2=CC=CC=C2SC2=CC=CC=C12,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC,5,18
4258,21894,21894,22489,22489,"DRUGOTHER, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER ) or DRUG1, ordinarily should not be administered concurrently with DRUG2 (a DRUGOTHER); ",metoclopramide,Permax,True,advise,1,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC,10,18
4259,21903,21903,22498,22498,"Use of DRUGOTHER (DRUG1, DRUG2, DRUGOTHER and others), DRUGOTHER supplements or other drugs capable of increasing serum DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER and others) can increase the risk of hyperkalemia. ",spironolactone,amiloride,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N,3,4
4260,21904,21904,22499,22499,"Use of DRUGOTHER (DRUG1, DRUGOTHER, DRUG2 and others), DRUGOTHER supplements or other drugs capable of increasing serum DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER and others) can increase the risk of hyperkalemia. ",spironolactone,triamterene,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,3,5
4261,21905,21905,22500,22500,"Use of DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER and others), DRUGOTHER supplements or other drugs capable of increasing serum DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER and others) can increase the risk of hyperkalemia. ",spironolactone,indomethacin,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,3,18
4262,21906,21906,22501,22501,"Use of DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER and others), DRUGOTHER supplements or other drugs capable of increasing serum DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER and others) can increase the risk of hyperkalemia. ",spironolactone,heparin,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,3,19
4263,21907,21907,22502,22502,"Use of DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER and others), DRUGOTHER supplements or other drugs capable of increasing serum DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2 and others) can increase the risk of hyperkalemia. ",spironolactone,cyclosporine,False,Neg,0,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,3,20
4264,22009,22009,22605,22605,"DRUG1 has been used with a variety of DRUG2, including DRUGOTHER, DRUGOTHER, and DRUGOTHER without unexpected adverse interactions. ",Pindolol,antihypertensive agents,False,Neg,0,CC(C)NCC(COC1=CC=CC2=C1C=CN2)O,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,0,8
4265,22013,22013,22609,22609,"DRUGOTHER has been used with a variety of DRUG1, including DRUG2, DRUGOTHER, and DRUGOTHER without unexpected adverse interactions. ",antihypertensive agents,hydrochlorothiazide,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,8,10
4266,22014,22014,22610,22610,"DRUGOTHER has been used with a variety of DRUG1, including DRUGOTHER, DRUG2, and DRUGOTHER without unexpected adverse interactions. ",antihypertensive agents,hydralazine,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,C1=CC=C2C(=C1)C=NN=C2NN,8,11
4267,22015,22015,22611,22611,"DRUGOTHER has been used with a variety of DRUG1, including DRUGOTHER, DRUGOTHER, and DRUG2 without unexpected adverse interactions. ",antihypertensive agents,guanethidine,False,Neg,0,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,C1CCCN(CCC1)CCN=C(N)N,8,13
4268,22040,22040,22636,22636,"DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER should be avoided in patients with organophosphate poisoning.",morphine,theophylline,False,Neg,0,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,1
4269,22044,22044,22640,22640,"DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER should be avoided in patients with organophosphate poisoning.",theophylline,aminophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,1,2
4270,22045,22045,22641,22641,"DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER should be avoided in patients with organophosphate poisoning.",theophylline,succinylcholine,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,1,3
4271,22046,22046,22642,22642,"DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER should be avoided in patients with organophosphate poisoning.",theophylline,reserpine,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,1,4
4272,22082,22082,22678,22678,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",cimetidine,hydrochlorothiazide,False,Neg,0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,23,52
4273,22094,22094,22690,22690,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",ranitidine,hydrochlorothiazide,False,Neg,0,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,24,52
4274,22105,22105,22701,22701,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",diltiazem,hydrochlorothiazide,False,Neg,0,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,25,52
4275,22115,22115,22711,22711,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",triamterene,hydrochlorothiazide,False,Neg,0,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,26,52
4276,22124,22124,22720,22720,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",verapamil,hydrochlorothiazide,False,Neg,0,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,27,52
4277,22132,22132,22728,22728,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",quinidine,hydrochlorothiazide,False,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,28,52
4278,22139,22139,22735,22735,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",quinine,hydrochlorothiazide,False,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,30,52
4279,22144,22144,22740,22740,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",cephalosporins,hydrochlorothiazide,False,Neg,0,CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CCC[C@H](C(=O)O)N)SC1)C(=O)O,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,49,52
4280,22148,22148,22744,22744,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",penicillins,hydrochlorothiazide,False,Neg,0,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,50,52
4281,22151,22151,22747,22747,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",indomethacin,hydrochlorothiazide,False,Neg,0,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,51,52
4282,22154,22154,22750,22750,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2) are likely to have little effect on the oral clearance of DRUGOTHER. ",hydrochlorothiazide,chlorpropamide,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl,52,54
4283,22155,22155,22751,22751,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",hydrochlorothiazide,pramipexole,True,mechanism,4,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,52,36
4284,22170,22170,22767,22767,"Drugs that induce hepatic enzymes such as DRUG1, DRUG2 and DRUGOTHER may increase the clearance of DRUGOTHER and may require increases in DRUGOTHER dose to achieve the desired response. ",phenobarbital,phenytoin,False,Neg,0,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,7,8
4285,22174,22174,22771,22771,"Drugs that induce hepatic enzymes such as DRUGOTHER, DRUG1 and DRUG2 may increase the clearance of DRUGOTHER and may require increases in DRUGOTHER dose to achieve the desired response. ",phenytoin,rifampin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,8,10
4286,22175,22175,22772,22772,"Drugs that induce hepatic enzymes such as DRUGOTHER, DRUG1 and DRUGOTHER may increase the clearance of DRUG2 and may require increases in DRUGOTHER dose to achieve the desired response. ",phenytoin,corticosteroids,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,8,16
4287,22176,22176,22773,22773,"Drugs that induce hepatic enzymes such as DRUGOTHER, DRUG1 and DRUGOTHER may increase the clearance of DRUG2s and may require increases in DRUG2 dose to achieve the desired response. ",phenytoin,corticosteroid,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,8,16
4288,22195,22195,22795,22795,DRUG1: Concurrent use of DRUG2 and DRUGOTHER may result in a reduction of the antibacterial action of the DRUGOTHER. ,Sulfonamides,procaine hydrochloride,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N.Cl,0,4
4289,22197,22197,22797,22797,DRUGOTHER: Concurrent use of DRUG1 and DRUG2 may result in a reduction of the antibacterial action of the DRUGOTHER. ,procaine hydrochloride,sulfonamides,True,effect,2,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N.Cl,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,4,6
4290,22215,22215,22815,22815,Antihypertensive effects of DRUG1 and related compounds may be counteracted when DRUG2 are used concomitantly. ,guanethidine,phenothiazines,True,effect,2,C1CCCN(CCC1)CCN=C(N)N,N1C2=CC=CC=C2SC2=CC=CC=C12,3,11
4291,22218,22218,22818,22818,"The induction dose requirements of DRUG1 Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with DRUGOTHER (eg, DRUGOTHER, DRUG2, and DRUGOTHER, etc.) ",DIPRIVAN,meperidine,True,effect,2,CC(C)C1=C(C(=CC=C1)C(C)C)O,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,5,23
4292,22219,22219,22819,22819,"The induction dose requirements of DRUG1 Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with DRUGOTHER (eg, DRUGOTHER, DRUGOTHER, and DRUG2, etc.) ",DIPRIVAN,fentanyl,True,effect,2,CC(C)C1=C(C(=CC=C1)C(C)C)O,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,5,25
4293,22220,22220,22820,22820,"The induction dose requirements of DRUGOTHER Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with DRUGOTHER (eg, DRUG1, DRUG2, and DRUGOTHER, etc.) ",morphine,meperidine,False,Neg,0,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,22,23
4294,22221,22221,22821,22821,"The induction dose requirements of DRUGOTHER Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with DRUGOTHER (eg, DRUG1, DRUGOTHER, and DRUG2, etc.) ",morphine,fentanyl,False,Neg,0,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,22,25
4295,22239,22239,22839,22839,"The CNS-depressant effect of DRUG1 is additive with that of other DRUG2, including DRUGOTHER. ",propoxyphene,CNS depressants,True,effect,2,CCC(=O)O[C@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@H](C)CN(C)C,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,4,11
4296,22241,22241,22841,22841,"The CNS-depressant effect of DRUGOTHER is additive with that of other DRUG1, including DRUG2. ",CNS depressants,alcohol,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCO,11,13
4297,22252,22252,22852,22852,"DRUG1 may be used with DRUG2, DRUGOTHER and other DRUGOTHER, and with other DRUGOTHER. ",Pyrimethamine,sulfonamides,False,Neg,0,CCC1=C(C(=NC(=N1)N)N)C2=CC=C(C=C2)Cl,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,0,5
4298,22255,22255,22855,22855,"DRUGOTHER may be used with DRUG1, DRUG2 and other DRUGOTHER, and with other DRUGOTHER. ",sulfonamides,quinine,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,5,6
4299,22256,22256,22856,22856,"DRUGOTHER may be used with DRUG1, DRUGOTHER and other DRUGOTHER, and with other DRUG2. ",sulfonamides,antibiotics,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,5,13
4300,22270,22270,22871,22871,"In vitro, DRUG1 did not affect the binding of DRUGOTHER, DRUG2, or DRUGOTHER. ",raloxifene,phenytoin,False,Neg,0,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,2,10
4301,22272,22272,22873,22873,"In vitro, DRUGOTHER did not affect the binding of DRUG1, DRUG2, or DRUGOTHER. ",warfarin,phenytoin,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,9,10
4302,22274,22274,22875,22875,"In vitro, DRUGOTHER did not affect the binding of DRUGOTHER, DRUG1, or DRUG2. ",phenytoin,tamoxifen,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,10,12
4303,22307,22307,22912,22912,"In addition to bleeding associated with DRUG1 and DRUGOTHER, drugs that alter platelet function (such as DRUGOTHER, DRUGOTHER, and DRUGOTHER) may increase the risk of bleeding if administered prior to or after DRUG2    therapy.",heparin,Retavase,True,effect,2,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,C1CC(CCC1CN)C(=O)O,6,32
4304,22310,22310,22915,22915,"In addition to bleeding associated with DRUGOTHER and DRUG1, drugs that alter platelet function (such as DRUGOTHER, DRUGOTHER, and DRUGOTHER) may increase the risk of bleeding if administered prior to or after DRUG2    therapy.",vitamin K antagonists,Retavase,True,effect,2,OC(=O)CCCCCCCC(O)=O,C1CC(CCC1CN)C(=O)O,8,32
4305,22312,22312,22917,22917,Interactions for DRUG1 (DRUGOTHER):  DRUG2 - impairs the intestinal absorption of DRUGOTHER,Vitamin B2,Alcohol,False,Neg,0,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](CO)O)O)O,CCO,2,5
4306,22314,22314,22919,22919,Interactions for DRUGOTHER (DRUG1):  DRUG2 - impairs the intestinal absorption of DRUGOTHER,Riboflavin,Alcohol,False,Neg,0,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](CO)O)O)O,CCO,3,5
4307,22316,22316,22921,22921,Interactions for DRUGOTHER (DRUGOTHER):  DRUG1 - impairs the intestinal absorption of DRUG2,Alcohol,riboflavin,True,mechanism,4,CCO,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](CO)O)O)O,5,12
4308,22317,22317,22922,22922,DRUG1 - concurrent use decreases gastrointestinal absorption of DRUG2; ,Probenecid,riboflavin,True,mechanism,4,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](CO)O)O)O,0,8
4309,22318,22318,22923,22923,requirements for DRUG1 may be increased in patients receiving DRUG2.,riboflavin,probenecid,True,effect,2,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](CO)O)O)O,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,2,9
4310,22378,22378,22991,22991,Possible interactions with drugs known to be metabolized by CYP1A2 via competitive inhibition such as DRUG1 and DRUG2 may also occur. ,theophylline,imipramine,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,15,17
4311,22410,22410,23030,23030,"DRUG1 competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",Salicylate,phenytoin,True,mechanism,4,C1=CC=C(C(=C1)C(=O)O)[O-],C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,16
4312,22419,22419,23039,23039,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",penicillin,phenytoin,False,Neg,0,CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,12,16
4313,22427,22427,23047,23047,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",thiopental,phenytoin,False,Neg,0,CCCC(C)C1(C(=O)NC(=S)NC1=O)CC,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,13,16
4314,22434,22434,23054,23054,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",thyroxine,phenytoin,False,Neg,0,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)O)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,14,16
4315,22440,22440,23060,23060,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",triiodothyronine,phenytoin,False,Neg,0,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@@H](C(=O)O)N)I)I)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,15,16
4316,22446,22446,23066,23066,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",phenytoin,sulfinpyrazone,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4,16,17
4317,22447,22447,23067,23067,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",phenytoin,naproxen,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,16,18
4318,22448,22448,23068,23068,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and possibly DRUGOTHER. ",phenytoin,warfarin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,16,19
4319,22449,22449,23069,23069,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and possibly DRUGOTHER. ",phenytoin,methotrexate,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,16,20
4320,22450,22450,23070,23070,"DRUGOTHER competes with a number of drugs for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUG2. ",phenytoin,corticosteroids,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,16,23
4321,22467,22467,23092,23092,"DRUGOTHER may decrease the effectiveness of oral DRUG1, certain DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",contraceptives,theophylline,False,Neg,0,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,CN1C2=C(C(=O)N(C1=O)C)NC=N2,7,11
4322,22470,22470,23095,23095,"DRUGOTHER may decrease the effectiveness of oral DRUGOTHER, certain DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",antibiotics,theophylline,False,Neg,0,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,9,11
4323,22472,22472,23097,23097,"DRUGOTHER may decrease the effectiveness of oral DRUGOTHER, certain DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",quinidine,theophylline,False,Neg,0,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,10,11
4324,22474,22474,23099,23099,"DRUGOTHER may decrease the effectiveness of oral DRUGOTHER, certain DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER.",theophylline,corticosteroids,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,11,12
4325,22475,22475,23100,23100,"The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of DRUG1 and DRUG2. ",selegiline,meperidine,True,effect,2,C[C@H](CC1=CC=CC=C1)N(C)CC#C,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,21,23
4326,22477,22477,23102,23102,Severe toxicity has also been reported in patients receiving the combination of DRUG1 and DRUGOTHER and DRUG2 and DRUGOTHER. ,tricyclic antidepressants,selective serotonin reuptake inhibitors,False,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,NCCC1=CNC2=CC=C(O)C=C12,12,16
4327,22479,22479,23104,23104,Severe toxicity has also been reported in patients receiving the combination of DRUGOTHER and DRUG1 and DRUG2 and DRUG1. ,ELDEPRYL,selective serotonin reuptake inhibitors,False,Neg,0,C[C@H](CC1=CC=CC=C1)N(C)CC#C,NCCC1=CNC2=CC=C(O)C=C12,14,16
4328,22481,22481,23106,23106,Severe toxicity has also been reported in patients receiving the combination of DRUGOTHER and DRUG2 and DRUG1 and DRUG2. ,selective serotonin reuptake inhibitors,ELDEPRYL,True,effect,2,NCCC1=CNC2=CC=C(O)C=C12,C[C@H](CC1=CC=CC=C1)N(C)CC#C,16,14
4329,22490,22490,23118,23118,"Patients with Congenital or Acquired QT Prolongation In a study of the effect of DRUG1 on the QT interval in 76 healthy women, the QT prolonging effect appeared less with DRUG1 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of DRUG1 30 mg did not appear as large as that of the positive control DRUG2 at its therapeutic dose. ",solifenacin,moxifloxacin,False,Neg,0,C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5,COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O,14,61
4330,22492,22492,23120,23120,"Patients with Congenital or Acquired QT Prolongation In a study of the effect of DRUG1 on the QT interval in 76 healthy women, the QT prolonging effect appeared less with DRUG1 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of DRUG1 30 mg did not appear as large as that of the positive control DRUG2 at its therapeutic dose. ",solifenacin,moxifloxacin,False,Neg,0,C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5,COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O,14,61
4331,22493,22493,23121,23121,"Patients with Congenital or Acquired QT Prolongation In a study of the effect of DRUG1 on the QT interval in 76 healthy women, the QT prolonging effect appeared less with DRUG1 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of DRUG1 30 mg did not appear as large as that of the positive control DRUG2 at its therapeutic dose. ",solifenacin,moxifloxacin,False,Neg,0,C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5,COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O,14,61
4332,22504,22504,23135,23135,The concurrent use of DRUG1 and DRUG2 has been reported in one case to result in reduced DRUG1 cytotoxicity.    ,streptozocin,phenytoin,True,effect,2,CN(C(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1O)CO)O)O)N=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,4,6
4333,22506,22506,23137,23137,The concurrent use of DRUG2 and DRUG1 has been reported in one case to result in reduced DRUG2 cytotoxicity.    ,phenytoin,streptozocin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN(C(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1O)CO)O)O)N=O,6,4
4334,22507,22507,23139,23139,"It may also interact with DRUG1 (increased thrombocytopenia), DRUG2 (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",thiazides,cyclosporine,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,5,8
4335,22508,22508,23140,23140,"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUG2 (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",thiazides,warfarin,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,5,15
4336,22509,22509,23141,23141,"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",thiazides,methotrexate,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,5,19
4337,22510,22510,23142,23142,"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",thiazides,methotrexate,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,5,19
4338,22516,22516,23148,23148,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",cyclosporine,phenytoin,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,8,25
4339,22517,22517,23149,23149,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",cyclosporine,phenytoin,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,8,25
4340,22520,22520,23152,23152,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUG1 (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",warfarin,phenytoin,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,15,25
4341,22521,22521,23153,23153,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUG1 (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",warfarin,phenytoin,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,15,25
4342,22523,22523,23155,23155,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",methotrexate,phenytoin,False,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,19,25
4343,22524,22524,23156,23156,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",methotrexate,phenytoin,False,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,19,25
4344,22525,22525,23157,23157,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",methotrexate,phenytoin,False,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,19,25
4345,22526,22526,23158,23158,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",methotrexate,phenytoin,False,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,19,25
4346,22528,22528,23160,23160,"In elderly patients concurrently receiving certain DRUG1, primarily DRUG2, an increased incidence of thrombopenia with purpura has been reported. ",diuretics,thiazides,False,Neg,0,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,6,8
4347,22532,22532,23164,23164,DRUG1 may inhibit the hepatic metabolism of DRUG2. ,Sulfamethoxazole,phenytoin,True,mechanism,4,CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,7
4348,22533,22533,23165,23165,"At a 1.6-g dose, DRUG1 produced a slight but significant increase in the half-life of DRUG2 but did not produce a corresponding decrease in the metabolic clearance rate. ",sulfamethoxazole,phenytoin,True,mechanism,4,CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,4,15
4349,22534,22534,23166,23166,"DRUG1 can also displace DRUG2 from plasma protein-binding sites, thus increasing free DRUG2 concentrations. ",Sulfonamides,methotrexate,True,mechanism,4,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,0,4
4350,22535,22535,23167,23167,"DRUG1 can also displace DRUG2 from plasma protein-binding sites, thus increasing free DRUG2 concentrations. ",Sulfonamides,methotrexate,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,0,4
4351,22543,22543,23175,23175,"It may also interact with DRUG1 (increased thrombocytopenia), DRUG2 (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",thiazides,cyclosporine,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,5,8
4352,22544,22544,23176,23176,"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUG2 (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",thiazides,warfarin,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,5,15
4353,22545,22545,23177,23177,"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",thiazides,methotrexate,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,5,19
4354,22546,22546,23178,23178,"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",thiazides,methotrexate,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,5,19
4355,22552,22552,23184,23184,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",cyclosporine,phenytoin,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,8,25
4356,22553,22553,23185,23185,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",cyclosporine,phenytoin,False,Neg,0,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,8,25
4357,22556,22556,23188,23188,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUG1 (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",warfarin,phenytoin,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,15,25
4358,22557,22557,23189,23189,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUG1 (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",warfarin,phenytoin,False,Neg,0,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,15,25
4359,22559,22559,23191,23191,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",methotrexate,phenytoin,False,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,19,25
4360,22560,22560,23192,23192,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",methotrexate,phenytoin,False,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,19,25
4361,22561,22561,23193,23193,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",methotrexate,phenytoin,False,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,19,25
4362,22562,22562,23194,23194,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",methotrexate,phenytoin,False,Neg,0,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,19,25
4363,22565,22565,23197,23197,"Because there is a theoretical basis that these effects may be additive, use of DRUG1-containing or DRUGOTHER (like dihydroDRUG1 or DRUG2) and DRUGOTHER within 24 hours of each other should be avoided. ",ergotamine,methysergide,False,Neg,0,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C,14,20
4364,22566,22566,23198,23198,"Because there is a theoretical basis that these effects may be additive, use of DRUG1-containing or DRUGOTHER (like dihydroDRUG1 or DRUGOTHER) and DRUG2 within 24 hours of each other should be avoided. ",ergotamine,sumatriptan,True,advise,1,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,14,22
4365,22567,22567,23199,23199,"Because there is a theoretical basis that these effects may be additive, use of DRUGOTHER-containing or DRUGOTHER (like DRUG1 or DRUG2) and DRUGOTHER within 24 hours of each other should be avoided. ",dihydroergotamine,methysergide,False,Neg,0,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C,18,20
4366,22568,22568,23200,23200,"Because there is a theoretical basis that these effects may be additive, use of DRUGOTHER-containing or DRUGOTHER (like DRUG1 or DRUGOTHER) and DRUG2 within 24 hours of each other should be avoided. ",dihydroergotamine,sumatriptan,True,advise,1,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,18,22
4367,22570,22570,23202,23202,"Therefore, the use of DRUG1 tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",sumatriptan succinate,fluoxetine,False,Neg,0,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C.C(CC(=O)O)C(=O)O,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,4,16
4368,22571,22571,23203,23203,"Therefore, the use of DRUG1 tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",sumatriptan succinate,fluvoxamine,False,Neg,0,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C.C(CC(=O)O)C(=O)O,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,4,17
4369,22572,22572,23204,23204,"Therefore, the use of DRUG1 tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",sumatriptan succinate,paroxetine,False,Neg,0,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C.C(CC(=O)O)C(=O)O,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,4,18
4370,22573,22573,23205,23205,"Therefore, the use of DRUG1 tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",sumatriptan succinate,sertraline,False,Neg,0,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C.C(CC(=O)O)C(=O)O,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,4,19
4371,22578,22578,23210,23210,"Therefore, the use of DRUG2 succinate tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2. ",fluoxetine,sumatriptan,True,effect,2,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,17,4
4372,22581,22581,23213,23213,"Therefore, the use of DRUG2 succinate tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2. ",fluvoxamine,sumatriptan,True,effect,2,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,18,4
4373,22583,22583,23215,23215,"Therefore, the use of DRUG2 succinate tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2. ",paroxetine,sumatriptan,True,effect,2,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,19,4
4374,22584,22584,23216,23216,"Therefore, the use of DRUG2 succinate tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2. ",sertraline,sumatriptan,True,effect,2,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,20,4
4375,22590,22590,23222,23222,"Co-administration of DRUG1 with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",SUTENT,nefazodone,True,mechanism,4,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,2,16
4376,22592,22592,23224,23224,"Co-administration of DRUG1 with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",SUTENT,ritonavir,True,mechanism,4,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,2,18
4377,22593,22593,23225,23225,"Co-administration of DRUG1 with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",SUTENT,saquinavir,True,mechanism,4,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,2,19
4378,22594,22594,23226,23226,"Co-administration of DRUG1 with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increases DRUGOTHER concentrations. ",SUTENT,telithromycin,True,mechanism,4,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,2,20
4379,22600,22600,23232,23232,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",ketoconazole,nefazodone,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,11,16
4380,22602,22602,23234,23234,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",ketoconazole,ritonavir,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,11,18
4381,22603,22603,23235,23235,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",ketoconazole,saquinavir,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,11,19
4382,22604,22604,23236,23236,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increases DRUGOTHER concentrations. ",ketoconazole,telithromycin,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,11,20
4383,22609,22609,23241,23241,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",itraconazole,nefazodone,False,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,12,16
4384,22611,22611,23243,23243,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",itraconazole,ritonavir,False,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,12,18
4385,22612,22612,23244,23244,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",itraconazole,saquinavir,False,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,12,19
4386,22613,22613,23245,23245,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increases DRUGOTHER concentrations. ",itraconazole,telithromycin,False,Neg,0,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,12,20
4387,22617,22617,23249,23249,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",clarithromycin,nefazodone,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,13,16
4388,22619,22619,23251,23251,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",clarithromycin,ritonavir,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,13,18
4389,22620,22620,23252,23252,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",clarithromycin,saquinavir,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,13,19
4390,22621,22621,23253,23253,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increases DRUGOTHER concentrations. ",clarithromycin,telithromycin,False,Neg,0,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,13,20
4391,22624,22624,23256,23256,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",atazanavir,nefazodone,False,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,14,16
4392,22626,22626,23258,23258,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",atazanavir,ritonavir,False,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,14,18
4393,22627,22627,23259,23259,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",atazanavir,saquinavir,False,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,14,19
4394,22628,22628,23260,23260,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increases DRUGOTHER concentrations. ",atazanavir,telithromycin,False,Neg,0,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,14,20
4395,22630,22630,23262,23262,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",indinavir,nefazodone,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,15,16
4396,22632,22632,23264,23264,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",indinavir,ritonavir,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,15,18
4397,22633,22633,23265,23265,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",indinavir,saquinavir,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,15,19
4398,22634,22634,23266,23266,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increases DRUGOTHER concentrations. ",indinavir,telithromycin,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,15,20
4399,22636,22636,23268,23268,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",nefazodone,nelfinavir,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,16,17
4400,22640,22640,23272,23272,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUG2 concentrations. ",nefazodone,sunitinib,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,16,24
4401,22641,22641,23273,23273,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",nelfinavir,ritonavir,False,Neg,0,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,17,18
4402,22642,22642,23274,23274,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",nelfinavir,saquinavir,False,Neg,0,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,17,19
4403,22643,22643,23275,23275,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increases DRUGOTHER concentrations. ",nelfinavir,telithromycin,False,Neg,0,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,17,20
4404,22647,22647,23279,23279,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUG2 concentrations. ",ritonavir,sunitinib,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,18,24
4405,22649,22649,23281,23281,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER) may increases DRUG2 concentrations. ",saquinavir,sunitinib,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,19,24
4406,22650,22650,23282,23282,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER) may increases DRUG2 concentrations. ",telithromycin,sunitinib,False,Neg,0,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,20,24
4407,22652,22652,23284,23284,"Co-administration of DRUG1 with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",SUTENT,phenytoin,True,mechanism,4,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,2,11
4408,22659,22659,23291,23291,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",dexamethasone,phenytoin,False,Neg,0,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,10,11
4409,22666,22666,23298,23298,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",phenytoin,carbamazepine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,11,12
4410,22667,22667,23299,23299,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",phenytoin,rifampin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,11,13
4411,22668,22668,23300,23300,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",phenytoin,rifabutin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,11,14
4412,22669,22669,23301,23301,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",phenytoin,rifapentin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C6CCCC6)/C,11,15
4413,22670,22670,23302,23302,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, St. Johns Wort) may decrease DRUGOTHER concentrations. ",phenytoin,phenobarbital,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,11,16
4414,22671,22671,23303,23303,"Co-administration of DRUGOTHER with inducers of the CYP3A4 family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUG2 concentrations. ",phenytoin,sunitinib,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,11,22
4415,22723,22723,23364,23364,"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as DRUG1,    -blockers, DRUG2 (DRUGOTHER), and DRUGOTHER, if they have a narrow therapeutic window. ",tricyclic antidepressants,selective serotonin reuptake inhibitors,False,Neg,0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,NCCC1=CNC2=CC=C(O)C=C12,15,20
4416,22727,22727,23368,23368,DRUG1 decreases the clearance of DRUG2 by 19%. ,Terbinafine,caffeine,True,mechanism,4,CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,0,5
4417,22812,22812,23461,23461,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUG1: Concomitant use of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or certain herbal supplements such as St. ",Hormonal Contraceptives,phenytoin,False,Neg,0,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,8,18
4418,22818,22818,23467,23467,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or certain herbal supplements such as St. ",griseofulvin,phenytoin,False,Neg,0,C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,13,18
4419,22823,22823,23472,23472,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or certain herbal supplements such as St. ",modafinil,phenytoin,False,Neg,0,C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,14,18
4420,22827,22827,23476,23476,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or certain herbal supplements such as St. ",penicillins,phenytoin,False,Neg,0,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,15,18
4421,22830,22830,23479,23479,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, or certain herbal supplements such as St. ",rifampin,phenytoin,False,Neg,0,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,16,18
4422,22832,22832,23481,23481,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, or certain herbal supplements such as St. ",rifabutin,phenytoin,False,Neg,0,C[C@H]1/C=C/C=C(\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,17,18
4423,22834,22834,23483,23483,"Important Non-DRUGOTHER Drug Interactions Drugs That Interfere with DRUGOTHER: Concomitant use of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, or certain herbal supplements such as St. ",phenytoin,carbamazepine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,18,19
4424,22838,22838,23488,23488,"DRUG1 are capable of potentiating DRUG2 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, etc.) ",Phenothiazines,CNS depressants,True,effect,2,N1C2=CC=CC=C2SC2=CC=CC=C12,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,0,5
4425,22841,22841,23491,23491,"DRUGOTHER are capable of potentiating DRUG1 (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, etc.) ",CNS depressants,anesthetics,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCOC(=O)C1=CC=C(N)C=C1,5,8
4426,22842,22842,23492,23492,"DRUGOTHER are capable of potentiating DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, etc.) ",CNS depressants,alcohol,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCO,5,10
4427,22853,22853,23506,23506,Prothrombin time or other suitable anticoagulation test should be monitored if DRUG1 is administered with DRUG2.   ,tigecycline,warfarin,True,advise,1,CC(C)(C)NCC(=O)NC1=CC(=C2C[C@H]3C[C@H]4[C@@H](C(=O)C(=C([C@]4(C(=O)C3=C(C2=C1O)O)O)O)C(=O)N)N(C)C)N(C)C,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,11,15
4428,22881,22881,23543,23543,"DRUG1 should not be administered concomitantly with DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER.",TOBI,furosemide,True,advise,1,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H](C[C@@H]([C@H](O3)CN)O)N)N,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,0,8
4429,22884,22884,23546,23546,"DRUGOTHER should not be administered concomitantly with DRUG1, DRUG2, DRUGOTHER, or DRUGOTHER.",ethacrynic acid,furosemide,False,Neg,0,CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,7,8
4430,22887,22887,23549,23549,"DRUGOTHER should not be administered concomitantly with DRUGOTHER, DRUG1, DRUG2, or DRUGOTHER.",furosemide,urea,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C(=O)(N)N,8,9
4431,22888,22888,23550,23550,"DRUGOTHER should not be administered concomitantly with DRUGOTHER, DRUG1, DRUGOTHER, or DRUG2.",furosemide,mannitol,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C([C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O,8,11
4432,22992,22992,23662,23662,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER). ",Sanctura,vancomycin,False,Neg,0,C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O.[Cl-],C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,13,40
4433,22999,22999,23669,23669,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER). ",Sanctura,vancomycin,True,mechanism,4,C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O.[Cl-],C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,13,40
4434,23005,23005,23675,23675,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER). ",digoxin,vancomycin,False,Neg,0,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,36,40
4435,23010,23010,23680,23680,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER). ",procainamide,vancomycin,False,Neg,0,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,37,40
4436,23014,23014,23684,23684,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER). ",pancuronium,vancomycin,False,Neg,0,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1[N+]4(CCCCC4)C)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,38,40
4437,23017,23017,23687,23687,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER and DRUGOTHER). ",morphine,vancomycin,False,Neg,0,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,39,40
4438,23020,23020,23690,23690,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2 and DRUGOTHER). ",vancomycin,metformin,False,Neg,0,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,CN(C)C(=N)N=C(N)N,40,41
4439,23021,23021,23691,23691,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER and DRUG2). ",vancomycin,tenofovir,False,Neg,0,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,C[C@H](CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O,40,43
4440,23024,23024,23694,23694,Concomitant administration of DRUG1 and DRUG2 has been associated with erythema and histamine-like flushing and anaphylactoid reactions. ,vancomycin,anesthetic agents,True,effect,2,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,CCOC(=O)C1=CC=C(N)C=C1,3,5
4441,23036,23036,23711,23711,"In 1984, Drs Rimmer and Richens at the University of Wales reported that administering DRUG1 with DRUG2 lowered the serum DRUG2 concentration in patients with treatment-resistant epilepsy. ",vigabatrin,phenytoin,True,mechanism,4,C=CC(CCC(=O)O)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,14,16
4442,23037,23037,23712,23712,"In 1984, Drs Rimmer and Richens at the University of Wales reported that administering DRUG1 with DRUG2 lowered the serum DRUG2 concentration in patients with treatment-resistant epilepsy. ",vigabatrin,phenytoin,False,Neg,0,C=CC(CCC(=O)O)N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,14,16
4443,23050,23050,23726,23726,"Effect of DRUG1-mediated CYP3A4 inhibition on clinical pharmacokinetics of DRUG2 (DRUGOTHER), an orally active DRUGOTHER.
",ketoconazole,panobinostat,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO,2,9
4444,23051,23051,23727,23727,"Effect of DRUG1-mediated CYP3A4 inhibition on clinical pharmacokinetics of DRUGOTHER (DRUG2), an orally active DRUGOTHER.
",ketoconazole,LBH589,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO,2,10
4445,23053,23053,23732,23732,"This study evaluated the effect of a potent CYP3A inhibitor, DRUG1, on the pharmacokinetics and safety of DRUG2.",ketoconazole,panobinostat,False,Neg,0,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO,10,17
4446,23054,23054,23733,23733,"On day 8, a single DRUG1 dose was co-administered with DRUG2. ",panobinostat,ketoconazole,False,Neg,0,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,5,10
4447,23055,23055,23734,23734,"In the presence of DRUG1, there was 1.6- and 1.8-fold increase in C (max) and AUC of DRUG2, respectively. ",ketoconazole,panobinostat,True,mechanism,4,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO,4,17
4448,23058,23058,23737,23737,DRUG1 and DRUG2 are DRUGOTHER used in treating urinary and respiratory tract infections. ,Moxifloxacin,lomefloxacin,False,Neg,0,COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O,CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O,0,2
4449,23059,23059,23738,23738,"Being DRUG1 and lomefloxacin DRUGOTHER the interaction study of was carried out with DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",moxifloxacin,sucralfate,False,Neg,0,COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al].O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Al],1,13
4450,23060,23060,23739,23739,"Being DRUG1 and lomefloxacin DRUGOTHER the interaction study of was carried out with DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER. ",moxifloxacin,erythromycin,False,Neg,0,COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,1,15
4451,23062,23062,23741,23741,The response of DRUG1 and DRUG2 after interaction with co-administered drugs at different conditions and temperature were noted using a Shimadzu HPLC system with PDA detector. ,moxifloxacin,lomefloxacin,False,Neg,0,COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O,CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O,3,5
4452,23063,23063,23742,23742,DRUG1 and DRUG2 reacts faster with DRUGOTHER and DRUGOTHER in acidic media whereas with DRUGOTHER in basic media and DRUGOTHER in neutral media. ,Moxifloxacin,Lomefloxacin,False,Neg,0,COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O,CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O,0,2
4453,23064,23064,23743,23743,DRUG1 and DRUGOTHER reacts faster with DRUG2 and DRUGOTHER in acidic media whereas with DRUGOTHER in basic media and DRUGOTHER in neutral media. ,Moxifloxacin,sucralfate,True,mechanism,4,COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al].O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Al],0,6
4454,23065,23065,23744,23744,DRUG1 and DRUGOTHER reacts faster with DRUGOTHER and DRUGOTHER in acidic media whereas with DRUG2 in basic media and DRUGOTHER in neutral media. ,Moxifloxacin,erythromycin,True,mechanism,4,COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,0,14
4455,23191,23191,23884,23884,"In vitro activity of DRUG1 combined with DRUG2 against clinical isolates of DRUGOTHER-resistant Staphylococcus aureus.
",minocycline,fosfomycin,False,Neg,0,CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C,C[C@H]1[C@H](O1)P(=O)(O)O,4,7
4456,23192,23192,23887,23887,This study aimed to evaluate the in vitro activity of DRUG1 combined with DRUG2 against isolates of DRUGOTHER-resistant Staphylococcus aureus (MRSA). ,minocycline,fosfomycin,False,Neg,0,CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C,C[C@H]1[C@H](O1)P(=O)(O)O,10,13
4457,23193,23193,23890,23890,The susceptibility results for DRUG1 and DRUG2 were interpreted according to the most relevant criteria. ,minocycline,fosfomycin,False,Neg,0,CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C,C[C@H]1[C@H](O1)P(=O)(O)O,4,6
4458,23194,23194,23891,23891,The combination of DRUG1 and DRUG2 can be synergistic against MRSA. ,minocycline,fosfomycin,True,effect,2,CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C,C[C@H]1[C@H](O1)P(=O)(O)O,3,5
4459,23228,23228,23929,23929,"The role of p27(Kip1) in DRUG1-enhanced DRUG2 cytotoxicity in human ovarian cancer cells.
",dasatinib,paclitaxel,True,effect,2,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,5,6
4460,23229,23229,23930,23930,"The effect of DRUG1, an inhibitor of Src and Abl kinases, on DRUG2 sensitivity was measured in ovarian cancer cells and HEY xenografts. ",dasatinib,paclitaxel,False,Neg,0,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,3,12
4461,23230,23230,23931,23931,"The roles of p27(Kip1), Bcl-2, and Cdk1 in apoptosis induced by DRUG1 and DRUG2 were assessed using a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, siRNA knockdown of gene expression, transfection with Bcl-2 and Cdk1 expression vectors, and flow cytometry. ",dasatinib,paclitaxel,False,Neg,0,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,11,13
4462,23231,23231,23932,23932,HEY cells treated with DRUG1 plus DRUG2 formed fewer colonies than did cells treated with either agent alone. ,dasatinib,paclitaxel,True,effect,2,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,4,6
4463,23232,23232,23933,23933,"Treatment of HEY xenograft-bearing mice with DRUG1 plus DRUG2 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUG1 + DRUG2 vs DRUG2: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",dasatinib,paclitaxel,True,effect,2,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,6,8
4464,23234,23234,23935,23935,"Treatment of HEY xenograft-bearing mice with DRUG1 plus DRUG2 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUG1 + DRUG2 vs DRUG2: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",dasatinib,paclitaxel,False,Neg,0,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,6,8
4465,23235,23235,23936,23936,"Treatment of HEY xenograft-bearing mice with DRUG1 plus DRUG2 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUG1 + DRUG2 vs DRUG2: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",dasatinib,paclitaxel,False,Neg,0,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,6,8
4466,23236,23236,23937,23937,"Treatment of HEY xenograft-bearing mice with DRUG2 plus DRUG1 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUG2 + DRUG1 vs DRUG1: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",paclitaxel,dasatinib,False,Neg,0,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,8,6
4467,23239,23239,23940,23940,"Treatment of HEY xenograft-bearing mice with DRUG1 plus DRUG2 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUG1 + DRUG2 vs DRUG2: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",dasatinib,paclitaxel,False,Neg,0,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,6,8
4468,23240,23240,23941,23941,"Treatment of HEY xenograft-bearing mice with DRUG1 plus DRUG2 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUG1 + DRUG2 vs DRUG2: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",dasatinib,paclitaxel,False,Neg,0,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,6,8
4469,23242,23242,23943,23943,DRUG1 + DRUG2 vs. ,dasatinib,paclitaxel,False,Neg,0,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,0,2
4470,23243,23243,23944,23944,"The siRNA knockdown of p27(Kip1) decreased DRUG1- and DRUG2-induced apoptosis compared with a negative control siRNA (sub-G1 fraction, control siRNA vs. p27(Kip1) siRNA: 42.5% vs. 20.1%, difference = 22.4%, 95% CI = 20.1% to 24.7%, P = .017). ",dasatinib,paclitaxel,False,Neg,0,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,6,8
4471,23244,23244,23945,23945,Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that DRUG1-mediated induction of p27(Kip1) enhanced DRUG2-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression. ,dasatinib,paclitaxel,True,effect,2,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,13,18
4472,23245,23245,23946,23946,Inhibition of Src family and Abl kinases with either siRNAs or DRUG1 enhances DRUG2 sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.,dasatinib,paclitaxel,True,effect,2,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,11,13
4473,23246,23246,23947,23947,"Phase I trial of DRUG1 and DRUG2 in patients with relapsed multiple myeloma: evidence for DRUG1-DRUG2 interaction via P-glycoprotein.
",lenalidomide,CCI-779,False,Neg,0,C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OC(=O)C(C)(CO)CO)C)/C)O)OC)C)C)/C)OC,4,6
4474,23248,23248,23949,23949,"Phase I trial of DRUG1 and DRUG2 in patients with relapsed multiple myeloma: evidence for DRUG1-DRUG2 interaction via P-glycoprotein.
",lenalidomide,CCI-779,False,Neg,0,C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OC(=O)C(C)(CO)CO)C)/C)O)OC)C)C)/C)OC,4,6
4475,23249,23249,23950,23950,"Phase I trial of DRUG2 and DRUG1 in patients with relapsed multiple myeloma: evidence for DRUG2-DRUG1 interaction via P-glycoprotein.
",CCI-779,lenalidomide,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OC(=O)C(C)(CO)CO)C)/C)O)OC)C)C)/C)OC,C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N,6,4
4476,23251,23251,23952,23952,"Phase I trial of DRUG1 and DRUG2 in patients with relapsed multiple myeloma: evidence for DRUG1-DRUG2 interaction via P-glycoprotein.
",lenalidomide,CCI-779,False,Neg,0,C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OC(=O)C(C)(CO)CO)C)/C)O)OC)C)C)/C)OC,4,6
4477,23252,23252,23953,23953,The preclinical combination of DRUG1 with the mTOR inhibitor DRUG2 has displayed synergy in vitro and represents a novel combination in MM.,lenalidomide,CCI-779,True,effect,2,C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OC(=O)C(C)(CO)CO)C)/C)O)OC)C)C)/C)OC,4,9
